<SEC-DOCUMENT>0000320017-22-000102.txt : 20221110
<SEC-HEADER>0000320017-22-000102.hdr.sgml : 20221110
<ACCEPTANCE-DATETIME>20221110161258
ACCESSION NUMBER:		0000320017-22-000102
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		67
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221110
DATE AS OF CHANGE:		20221110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LISATA THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0000320017
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		IRS NUMBER:				222343568
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33650
		FILM NUMBER:		221377309

	BUSINESS ADDRESS:	
		STREET 1:		110 ALLEN ROAD
		STREET 2:		SECOND FLOOR
		CITY:			BASKING RIDGE
		STATE:			NJ
		ZIP:			07920
		BUSINESS PHONE:		908-229-2590

	MAIL ADDRESS:	
		STREET 1:		110 ALLEN ROAD
		STREET 2:		SECOND FLOOR
		CITY:			BASKING RIDGE
		STATE:			NJ
		ZIP:			07920

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CALADRIUS BIOSCIENCES, INC.
		DATE OF NAME CHANGE:	20170808

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Caladrius Biosciences, Inc.
		DATE OF NAME CHANGE:	20150608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NeoStem, Inc.
		DATE OF NAME CHANGE:	20060906
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>clbs-20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:f426f7a3-6c2d-403e-bcce-1884a6ad721b,g:3088fff3-3c71-4b75-95a2-34e3a251fb1c,d:e1084e3f1fc74e21b06ddcc16cf4ec69--><html xmlns:clbs="http://www.caladrius.com/20220930" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2021-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>clbs-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80L2ZyYWc6OTY1NDY4YTZjODkyNDE5OGIxNjgwZWU5MWM4MjJhNGIvdGFibGU6YmY0ZDVjMGJhZGRjNDI2ODlhYjI2MWU4OGJiODZjZmIvdGFibGVyYW5nZTpiZjRkNWMwYmFkZGM0MjY4OWFiMjYxZTg4YmI4NmNmYl8zLTEtMS0xLTIyODU4_0b15f89b-1bf2-45b4-b62d-5e61066db333">0000320017</ix:nonNumeric><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80L2ZyYWc6OTY1NDY4YTZjODkyNDE5OGIxNjgwZWU5MWM4MjJhNGIvdGFibGU6YmY0ZDVjMGJhZGRjNDI2ODlhYjI2MWU4OGJiODZjZmIvdGFibGVyYW5nZTpiZjRkNWMwYmFkZGM0MjY4OWFiMjYxZTg4YmI4NmNmYl80LTEtMS0xLTIyODU4_b9f937d4-8b02-43bf-b454-a5429e614d5e">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80L2ZyYWc6OTY1NDY4YTZjODkyNDE5OGIxNjgwZWU5MWM4MjJhNGIvdGFibGU6YmY0ZDVjMGJhZGRjNDI2ODlhYjI2MWU4OGJiODZjZmIvdGFibGVyYW5nZTpiZjRkNWMwYmFkZGM0MjY4OWFiMjYxZTg4YmI4NmNmYl81LTEtMS0xLTIyODU4_6f725780-8d1a-4fdf-8908-a02de0567e5b">2022</ix:nonNumeric><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80L2ZyYWc6OTY1NDY4YTZjODkyNDE5OGIxNjgwZWU5MWM4MjJhNGIvdGFibGU6YmY0ZDVjMGJhZGRjNDI2ODlhYjI2MWU4OGJiODZjZmIvdGFibGVyYW5nZTpiZjRkNWMwYmFkZGM0MjY4OWFiMjYxZTg4YmI4NmNmYl82LTEtMS0xLTIyODU4_4c608d57-6d1a-4662-bdb1-c1615a88afb4">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80L2ZyYWc6OTY1NDY4YTZjODkyNDE5OGIxNjgwZWU5MWM4MjJhNGIvdGFibGU6YmY0ZDVjMGJhZGRjNDI2ODlhYjI2MWU4OGJiODZjZmIvdGFibGVyYW5nZTpiZjRkNWMwYmFkZGM0MjY4OWFiMjYxZTg4YmI4NmNmYl83LTEtMS0xLTIyODU4_7559117f-7be9-41ad-9bd0-7cf772163a86">false</ix:nonNumeric><ix:nonNumeric contextRef="ib97be91eba48467897085df19e17a272_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfMi0wLTEtMS0yMjg1OA_188c2eed-0925-44f8-bfd8-8dc48bf41cee">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfMi0wLTEtMS0yMjg1OA_cda64072-7450-44a6-a48d-ee2b330b6907">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNi0wLTEtMS0yMjg1OA_466bdee9-6b20-428a-b677-b820ae3ba607">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ib97be91eba48467897085df19e17a272_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNi0wLTEtMS0yMjg1OA_62800bd1-bc30-473e-aedd-b0b3d9f06907">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ib97be91eba48467897085df19e17a272_I20211231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNy0wLTEtMS0yMjg1OA_ceb1d506-32b0-442d-b209-59921ea40600">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNy0wLTEtMS0yMjg1OA_f9192e00-f937-46b7-9c41-0640551a459c">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i961120305be6447cb05c316b019232b0_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNDg3Mw_6c617069-871e-4bcc-ac83-10a9da649366">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="clbs-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3f379b9aca34c4c99fad8b18e07b126_I20221110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ib97be91eba48467897085df19e17a272_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5c2e6f4066b47fbb0c62e47d1a34e30_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86d263da61bd426cb7086a17123228f7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17ae6b2b209f4867bbb33069c004b3aa_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id86020b0b46045dc893b03e2966eb75c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i029fe570e6734389a205caae3c3445a0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03285eb13bc340e3a8a2ff34047b4093_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07070a35a7c74213a020599cb2deffb7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c69daf49eff4222a69cd10c77c98604_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9d9e85847ab4fcf9aac296f60571be8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69110a58290f48db984963c9b07024c0_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b905b12169646dea54aa6e1e067b6f0_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d228b1f84b744de88a126fa2a54dd15_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebd096734b704a05b20e0d2a7a46f6f4_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cec8b5ec5914024a14b5f754a3d6ddf_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9801b9ed9e24c90b66bf7dc589a24f2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i944ba198ef814601b1dc3e189a2d15b9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5163c19edf884a309a10703ede9fbc6c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i853118dfc75844fb9a23dfa0374528cd_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c936e2b28ea43c7b0b9af4a69e00249_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b81c7260bd84f378acc80251b158b2a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ec4c587d4a3466ab448abb94ba9f29d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3c09e4703ba40298dd79e85417cdb61_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d30a645527f4337a60c7da8f18e85ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7eef7cc26c004a4c908e6fe160d201d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i686c5d52741f40f5a71ed6e2545ec05b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4050b9a1a6ec412b8853f688ad35a4fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fa893b6dc4a4a698cf4f78caf023478_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7779b193bfe449bbd568049e6084cc7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d1ccf571c4245369c9de32e62b102ee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63f9702a0ee94ee3a2adeeac786c1860_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie19069eadb3a4525bd0e3c209f26c6fc_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29f228f551d04b7d9d199959a37d10b2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1e85bf072d8481caf42f6d9beb8f4e6_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9485a0db274745a69f25443e8b178239_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab2f266a4d614842a787f8e85ec8abfd_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8fa07dd822c4c8db0ca288934287b7d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16004a445bd449db8e2738b544722065_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i038ee7bc9a294a179161a5703da8dba9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57d6d03e551b49a8a244e5310fc9c806_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bd86cb6ffe24ae9af1b0bf46c620e7f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec685200531f473bab6967cb468862fb_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0251e8a199d84ca68ff8b0e1aa8255ce_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedd0d04163e74945bb220b2e853c3e5e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia59e32a50e1444c697ba1a65e5e48334_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0d534735e7c4b63b3bf26d250ca8b2b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadddb49f7b264fa48f4b8133ef8e3991_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81f77055e79c4a769aa1eeb70f3e5de2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc9fdc2eadc94b589888a37676c11ae9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f9539108c6c4e1ba0d051b1aabb567a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d2b62b865bd4041b0251301f7f51424_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i872ef751a6a241769e47a7626414f412_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee65085e733d41a19e4143446eff7b7c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33afa975dd374f46b8ea96b4c0471c87_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2242481d947422a87b50a693e117608_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57e94f040b084f7b9def7834d945a4c7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9d73cec2ab1421e98d1f86d5a3b506a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic87a4ec489bc4ec0bf3f93cc71f5e063_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74b1319645614dceb3e4fce1f773ff25_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i848e51e03eed447c935cb2899345a1ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26cf58fb84e74ac694d839db83461838_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib450656958d64dd7809ab86b82185cce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3e5d05a52e7442a8b64eb445899cdf0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85b4ca140e7d4f318fdd15f0a5cfb26c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8a27c130df24312b50441271af5f833_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fad62fd3c3b4c7083f34c136706b9ab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5443afa6b3c4665b9c1eae0dbd038e1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83e78453949e4f5fb203beb11be8a1dc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a6f0161fc68498fb65a78febe096c25_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0a6fa60498746079ad9eb4134e0a7c0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07a0bb3234e14e0fbc6b7bce9f23f88a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86917d398d3247a6b5578480b5333d60_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3698298d7aba49a9af19841d1ba110c1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59aeca5b7a5446ed90ba736d79d9d4f4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">clbs:CENDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac286da95e1c493abbddee71f1aac890_I20220914"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">clbs:CENDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia46e584dcd2741798d67f30f0cfd9c15_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">clbs:CENDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d567e0b72224eb89e01194dfcc635c5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i098bf094035d44e2af451fa66daf6448_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57b538ea7c44400bad5071a7a6c98c1d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie90154aebcd24967a0f809ea3f40f699_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd0667d730324d439adcd5260c8be67a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2502dcdd9a7b46ccb98d0960950fb9ae_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie80e4088fafa43969d532971e7a875dc_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09c4e12405dd4187a733724a3dd4b1c8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33f0a817fe2049da85aa3551a5c905e4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e0d719ce9044ab281734908fb138fe4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i422414ad4ec143fe9c83f80484b18850_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i972cd99d76534d3cb8f6e561e629dc10_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i161cdf72d862420686200bfdd753f6d7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifccd968d78a3473898c3258429a71f76_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48063441de8a46dc974334dbf9a3a293_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7348558529cf46d2959b0b4229242404_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a76766f174f4c3b84f09f885f2170c6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib35c54c2e1b14397ae34101068f8d0a3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f89ef4342fe4c27b982bc991aff78d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2404060e56d462683781d6a6eb5e03e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03006f5a9605427eb1a8f9b1e13d1902_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aa7a96703004d078dc7feb5458b2718_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="office"><xbrli:measure>clbs:office</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i7128331c98ad445b8fb23487460be1ba_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:LincolnParkAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic92d752f756145678f3d08b54d87d88e_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:LincolnParkAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5748a0eb61f64415a43f6fd83aab5103_I20210604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f7b301665c749bf9b60eccd141f1949_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafd0678032f1403699288c6ead8540b2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib889d615bc824253bdc29e6be132de5e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i307650e93d90403dbe9bbce2cef38283_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i961120305be6447cb05c316b019232b0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9c9001c970d4ccd8a77b7e8f997ca0c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85d58dcae34e4ef8875042573be0b9be_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0800b6bb894400cb3122c7e867ed365_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34bf47839bf14111b1a9f241df421e60_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01ce7704d3fe44b2b990f2b244335218_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i837f26cb6fd94ea2be192be38846f7d4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cdf12952bfe4ee58d1c62f6fc6b922f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddf5f8d32bb9415e8e2d387027b79ab6_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia363623f86d0452f826ddd27e9bd14ef_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i750cd69f59fa41ab8d1716b4af6483aa_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie55321c2f35248728ece5383ad81d1ab_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i018aef0ebc684655bb91626b836264c8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bdf4a4104384257bd274663a65297cc_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb6073bf55444dc9adf45d6bd29a32bd_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb50bb2a566f4b72a4ec8baa84a38a44_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83d716d023604513b9d5e44c712a5656_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if68b9c4980394919b2d4601761b01f4d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31c432312f38454b845861eb8d0891a5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b434d8601de4e05b998640da3d91bcc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02b1d9ded41146128c64adca8ae00256_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93a7f18008c44e9997baaba9c4bcc603_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic221f3b9f147476abbbaa83788e46406_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68d905e37c484eff8d11dc6b86a7e0f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i579b018c55b04e3c984da0273c1ef442_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if463b298d932482a86bb1787b18f2ed0_D20220222-20220222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-22</xbrli:startDate><xbrli:endDate>2022-02-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54c1f41cac654131b84226d73d9d67db_I20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:SanfordBurnhamPrebysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i155f1b104580445ca4ca140a0f0d9e28_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:SanfordBurnhamPrebysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fd21aa0eb7e469692c04143d4a0aaa5_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:SanfordBurnhamPrebysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i568bd639252d47638984e18f0836cd66_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:SanfordBurnhamPrebysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7a582d9c51846c999a8aae8d00b9b3f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:SanfordBurnhamPrebysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0f3bab25f7348bdbffea94e657798a0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:UniversityOfCaliforniaAtSanDiegoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1424658bffc4343bd5497ca9d561930_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:UniversityOfCaliforniaAtSanDiegoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa3e87e793164479a26fb0338f9209f6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:UniversityOfCaliforniaAtSanDiegoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb7b6c7937914fcea021631924808998_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0050d762a7e64fa192ac048bca1f9775_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib023bcf774d145f5834f6ee5051da753_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2362238e05b541a487b62ee42291726f_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic23e1c2433b54fffa2ed10e25463b457_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:QiluMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab8db93a425c431683da42085f6e40e9_D20220914-20220914"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:QiluMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-14</xbrli:startDate><xbrli:endDate>2022-09-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00de76018f10443a96daffcfc7a36a9f_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:QiluMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51afcddd58ef4d74a4eecfadef3991a2_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000320017</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:QiluMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FORM <ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGV4dHJlZ2lvbjoxNmJjYTZmMGFlZTQ0MmY2YTMyMWQ3MDAzNmQ0YmRjN18yMDI0_01e078f8-76b4-43ee-b765-c3770199fc9d">10-Q</ix:nonNumeric></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.533%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6MGFkODEzZDI1NWVhNGZiZjljMTYxYzk1ZjVlNmI5NjcvdGFibGVyYW5nZTowYWQ4MTNkMjU1ZWE0ZmJmOWMxNjFjOTVmNWU2Yjk2N18wLTAtMS0xLTIyODU4_f55f067e-c78a-42e6-9970-54140eda70d0">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Quarterly Period Ended <ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGV4dHJlZ2lvbjoxNmJjYTZmMGFlZTQ0MmY2YTMyMWQ3MDAzNmQ0YmRjN181NDk3NTU4MTQxMTc0_eabc1e54-e77d-4123-8ea7-da3484ac54eb">September 30, 2022</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6MjM4YjJkZGE3Njc1NGUzODhiN2ZmYTJhZTA5NTEzZDkvdGFibGVyYW5nZToyMzhiMmRkYTc2NzU0ZTM4OGI3ZmZhMmFlMDk1MTNkOV8wLTAtMS0xLTIyODU4_b8c58660-e962-4a48-ae24-8bd27c119447">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Transition Period from __________________&#160;&#160;&#160;to _________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number <ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGV4dHJlZ2lvbjoxNmJjYTZmMGFlZTQ0MmY2YTMyMWQ3MDAzNmQ0YmRjN18yMDI1_276b6a86-70c1-4028-9205-36d776179463">001-33650</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGV4dHJlZ2lvbjoxNmJjYTZmMGFlZTQ0MmY2YTMyMWQ3MDAzNmQ0YmRjN18yMDI2_fc1e5521-ba54-4ef0-80f7-2ee5bb79dd2a">LISATA THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6NTkxMzVlZWVhYmUxNDM1MjkzOTM0ZmYwZDU3YmU0YzYvdGFibGVyYW5nZTo1OTEzNWVlZWFiZTE0MzUyOTM5MzRmZjBkNTdiZTRjNl8wLTAtMS0xLTIyODU4_5af43b55-c3d8-45f1-a82b-6caebbd9e052">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6NTkxMzVlZWVhYmUxNDM1MjkzOTM0ZmYwZDU3YmU0YzYvdGFibGVyYW5nZTo1OTEzNWVlZWFiZTE0MzUyOTM5MzRmZjBkNTdiZTRjNl8wLTEtMS0xLTIyODU4_b7a90460-89d7-4a96-b4fc-ebde1208a87a">22-2343568</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6NTkxMzVlZWVhYmUxNDM1MjkzOTM0ZmYwZDU3YmU0YzYvdGFibGVyYW5nZTo1OTEzNWVlZWFiZTE0MzUyOTM5MzRmZjBkNTdiZTRjNl8zLTAtMS0xLTIyODU4L3RleHRyZWdpb246ZDg4OTlkMDc4NGFjNGM0YWIxMjc4ZmNkMGU1ZGRjZDlfNA_64d55451-d388-4b7a-9c25-ca0ea3845d86">110 Allen Road, 2nd Floor</ix:nonNumeric>, <ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6NTkxMzVlZWVhYmUxNDM1MjkzOTM0ZmYwZDU3YmU0YzYvdGFibGVyYW5nZTo1OTEzNWVlZWFiZTE0MzUyOTM5MzRmZjBkNTdiZTRjNl8zLTAtMS0xLTIyODU4L3RleHRyZWdpb246ZDg4OTlkMDc4NGFjNGM0YWIxMjc4ZmNkMGU1ZGRjZDlfOA_b228ba69-7690-4413-b31d-3e8d6fed453c">Basking Ridge</ix:nonNumeric>, <ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6NTkxMzVlZWVhYmUxNDM1MjkzOTM0ZmYwZDU3YmU0YzYvdGFibGVyYW5nZTo1OTEzNWVlZWFiZTE0MzUyOTM5MzRmZjBkNTdiZTRjNl8zLTAtMS0xLTIyODU4L3RleHRyZWdpb246ZDg4OTlkMDc4NGFjNGM0YWIxMjc4ZmNkMGU1ZGRjZDlfMTI_4560da38-2fe6-4dce-aac0-3c34b6373122">New Jersey</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6NTkxMzVlZWVhYmUxNDM1MjkzOTM0ZmYwZDU3YmU0YzYvdGFibGVyYW5nZTo1OTEzNWVlZWFiZTE0MzUyOTM5MzRmZjBkNTdiZTRjNl8zLTEtMS0xLTIyODU4_829933df-3355-40d1-b96c-00926129aaef">07920</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(zip code)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGV4dHJlZ2lvbjoxNmJjYTZmMGFlZTQ0MmY2YTMyMWQ3MDAzNmQ0YmRjN18yMDI3_4197accc-9f19-4412-9a40-0fd962179d87">908</ix:nonNumeric>-<ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGV4dHJlZ2lvbjoxNmJjYTZmMGFlZTQ0MmY2YTMyMWQ3MDAzNmQ0YmRjN18yMDMy_1127eb25-a27c-433c-8631-c4690ec64f83">842-0100</ix:nonNumeric></span></div><div style="text-align:center"><span style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:EntityInformationFormerLegalOrRegisteredName" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGV4dHJlZ2lvbjoxNmJjYTZmMGFlZTQ0MmY2YTMyMWQ3MDAzNmQ0YmRjN18yNzQ4Nzc5MDcxNzEz_b0c1a4b3-12df-4f6a-b88d-c59759ddaf43">Caladrius Biosciences, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report) <br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:34.255%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.817%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.628%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6ZDQyNDZiZjU4ZWMyNDM1NDlhYjBhOTU0YzBjNjRhNjcvdGFibGVyYW5nZTpkNDI0NmJmNThlYzI0MzU0OWFiMGE5NTRjMGM2NGE2N18yLTAtMS0xLTIyODU4_68eeda75-6045-4b3d-9afe-a5467a71c58d">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6ZDQyNDZiZjU4ZWMyNDM1NDlhYjBhOTU0YzBjNjRhNjcvdGFibGVyYW5nZTpkNDI0NmJmNThlYzI0MzU0OWFiMGE5NTRjMGM2NGE2N18yLTEtMS0xLTIyODU4_d5b811f2-0294-446d-90a0-bd3a54d33d2d">LSTA</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The <ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6ZDQyNDZiZjU4ZWMyNDM1NDlhYjBhOTU0YzBjNjRhNjcvdGFibGVyYW5nZTpkNDI0NmJmNThlYzI0MzU0OWFiMGE5NTRjMGM2NGE2N18yLTItMS0xLTIyODU4L3RleHRyZWdpb246OWVkOTI2ZTQwYTE4NDQ1YWE0OTQ3NDk5YzgwZTdmNTFfOA_816653f5-16c9-4523-b29d-6e6bee61e15a">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGV4dHJlZ2lvbjoxNmJjYTZmMGFlZTQ0MmY2YTMyMWQ3MDAzNmQ0YmRjN18yMDI4_8cffe7f6-5cc1-4792-8ccc-41a3237cb0de">Yes</ix:nonNumeric> &#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No &#9744;</span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGV4dHJlZ2lvbjoxNmJjYTZmMGFlZTQ0MmY2YTMyMWQ3MDAzNmQ0YmRjN18yMDI5_1a504af2-65b5-4331-87f2-4b419c31173d">Yes</ix:nonNumeric> &#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No &#9744;</span></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6NDE3OGJkOTJlNDg1NDhmNmJhMTE2MmQzZTY3OWM0ZWEvdGFibGVyYW5nZTo0MTc4YmQ5MmU0ODU0OGY2YmExMTYyZDNlNjc5YzRlYV8xLTAtMS0xLTIyODU4_ec1a82f4-7ffb-4731-af80-e36cf0e861ce">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6NDE3OGJkOTJlNDg1NDhmNmJhMTE2MmQzZTY3OWM0ZWEvdGFibGVyYW5nZTo0MTc4YmQ5MmU0ODU0OGY2YmExMTYyZDNlNjc5YzRlYV8xLTQtMS0xLTIyODU4_7bbee5da-850e-4a33-9e46-9ddd49e31172">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6NDE3OGJkOTJlNDg1NDhmNmJhMTE2MmQzZTY3OWM0ZWEvdGFibGVyYW5nZTo0MTc4YmQ5MmU0ODU0OGY2YmExMTYyZDNlNjc5YzRlYV8yLTQtMS0xLTIyODU4_7bfba1eb-148f-4905-996b-25b0ee7dc00a">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;&#9744;</span></div><div style="text-indent:20.16pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#9744;&#160;&#160;&#160;&#160;&#160;No&#160;<ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGV4dHJlZ2lvbjoxNmJjYTZmMGFlZTQ0MmY2YTMyMWQ3MDAzNmQ0YmRjN18yMDMx_3219b9e6-c6ec-4a01-aea8-89e8a80739eb">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:3.3pt;padding-right:2.25pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:331.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Class</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of November 10, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $0.001 par value per share</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3f379b9aca34c4c99fad8b18e07b126_I20221110" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6YjczY2RmZTBjNDc4NDljNGE0NzhmN2Q3MDZmNjkyNTMvdGFibGVyYW5nZTpiNzNjZGZlMGM0Nzg0OWM0YTQ3OGY3ZDcwNmY2OTI1M18xLTEtMS0xLTIyODU4_8b515f62-2391-4ae6-b796-635fe59ddc9c">7,859,684</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">shares</span></td></tr></table></div><div style="padding-right:2.25pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:3.3pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><div style="margin-bottom:3.3pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This quarterly report (this &#8220;Quarterly Report&#8221;) contains &#8220;forward-looking&#8221; statements within the meaning of the Private Securities Litigation Reform Act of 1995, as well as historical information. When used in this Quarterly Report, statements that are not statements of current or historical fact may be deemed to be forward-looking statements, including, without limitation, all statements related to any expectations of revenues, expenses, cash flows, earnings or losses from operations, cash required to maintain current and planned operations, capital or other financial items; any statements of the plans, strategies and objectives of management for future operations; any plans or expectations with respect to product research, development and commercialization, including regulatory approvals; any other statements of expectations, plans, intentions or beliefs; and any statements of assumptions underlying any of the foregoing. Without limiting the foregoing, the words &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;forecast,&#8221; &#8220;outlook,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;likely,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;target&#8221; or similar expressions or other variations or comparable terminology are intended to identify such forward-looking statements, although some forward-looking statements are expressed differently. We remind readers that forward-looking statements are merely predictions and therefore inherently subject to uncertainties and other factors and involve known and unknown risks that could cause the actual results, performance, levels of activity or our achievements or industry results, to be materially different from any future results, performance, levels of activity or our achievements or industry results expressed or implied by such forward-looking statements. Factors that could cause our actual results to differ materially from anticipated results expressed or implied by forward-looking statements include, among others:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our ability to obtain sufficient capital or strategic business arrangements to fund our operations and expansion plans, including meeting our financial obligations under various licensing and other strategic arrangements, the funding of our clinical trials for product candidates, and the commercialization of the relevant technology;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to build and maintain the management and human resources infrastructure necessary to support the growth of our business;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether a relevant market is established for our products and services and our ability to capture a meaningful share of this market;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">scientific, regulatory and medical developments beyond our control;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain, as applicable, appropriate governmental licenses, accreditations or certifications or to comply with healthcare laws and regulations or any other adverse effect or limitations caused by government regulation of our business;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether any of our current or future patent applications result in issued patents, the scope of those patents and our ability to obtain and maintain other rights to technology required or desirable for the conduct of our business,&#160;and our ability to commercialize products without infringing upon the claims of third-party patents;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether any potential strategic or financial benefits of various licensing agreements will be realized;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the long-term success of our recently completed merger with Cend Therapeutics, Inc. (&#8220;Cend&#8221;), including the ongoing integration of Cend&#8217;s operations and the advancement of their development programs;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our development activities; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to complete our other planned clinical trials (or initiate other trials) in accordance with our estimated timelines due to delays associated with enrolling patients due to the novelty of the treatment, the size of the patient population, competition with other clinical trials for similar subjects and the need of patients to meet the inclusion criteria of the trial or otherwise; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which the COVID-19 pandemic and/or its long-term effects may impact, directly or indirectly, our business, including our clinical trials and financial condition; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain the listing of our common stock on The Nasdaq Capital Market; and </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors discussed in &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 22, 2022 (our &#8220;2021 Form 10-K&#8221;), in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2022 and June 30, 2022 and in Exhibit 99.2 to our Amendment No. 1 to Current Report on Form 8-K/A filed on October 4, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The factors discussed herein, including those risks described in &#8220;Item 1A. Risk Factors&#8221; and elsewhere in our 2021 Form 10-K and in our other periodic filings with the SEC, which are available for review at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> could cause actual results and developments to be materially different from those expressed or implied by such statements. All forward-looking statements attributable to us are expressly qualified in their entirety by these and other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they were made. Except as required by law, we undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.</span></div><div style="margin-bottom:3.3pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><div style="margin-bottom:3.3pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:3.3pt;margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART I- FINANCIAL INFORMATION</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Page No.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_10">Financial Statements:</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_13">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_16">Consolidated Balance Sheets at </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_16">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_16"> 30, 2022 (unaudited) and December 31, 2021</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_16">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_19">Consolidated Statements of Operations for the three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_19">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_19"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_16">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_19"> 30, 2022 and 2021 (unaudited)</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_19">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_22">Consolidated Statements of Comprehensive Loss for the three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_22">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_22"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_16">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_22"> 30, 2022 and 2021 (unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_22">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_25">Consolidated Statements of Equity for the three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_25">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_25"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_16">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_25"> 30, 2022 and 2021 (unaudited) </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_25">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_28">Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_28">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_28"> months ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_16">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_28"> 30, 2022 and 2021 (unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_28">10</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Notes to Unaudited Consolidated Financial Statements</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_31">11</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 2.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_73">26</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 3.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_85">35</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 4.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Controls and Procedures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_88">35</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">PART II- OTHER INFORMATION</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Legal Proceedings</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_94">37</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 1A.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Risk Factors</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_97">37</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 2.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_100">37</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 3.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Defaults Upon Senior Securities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_103">37</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 4.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Mine Safety Disclosures</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_106">37</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 5.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Information</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_109">37</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Item 6.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exhibits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_112">37</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Signatures</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:none" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_115">38</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4 </span></div></div></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_13"></div><div><span><br/></span></div><div><span><br/></span></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands, except share data)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:72.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.951%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMi0xLTEtMS0yMjg1OA_fcbd2f33-975f-486a-9d90-4f51e1e70150">31,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMi0zLTEtMS0yMjg1OA_3c05dd56-01f8-40c8-81d6-488e94253f06">24,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMy0xLTEtMS0yMjg1OA_8976e59f-ba0b-4345-80cd-99af97db261f">44,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMy0zLTEtMS0yMjg1OA_c64479fc-7512-46bd-85fb-4879a9e03745">70,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfNC0xLTEtMS0yMjg1OA_38fe226a-caaf-4cb0-b961-56122eb25dd5">1,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfNC0zLTEtMS0yMjg1OA_0be02dc8-6ae7-4369-affc-e30c5037b495">1,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfNS0xLTEtMS0yMjg1OA_1e4130eb-e060-4857-b848-c47743dd3595">77,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfNS0zLTEtMS0yMjg1OA_09655d58-05fe-405e-9ccf-586807651ad9">96,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfNi0xLTEtMS0yMjg1OA_46cd8623-5951-4d7c-a530-7397ba5c9cf9">299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfNi0zLTEtMS0yMjg1OA_e27bb1f1-08dd-421d-98eb-ece6fb290c7d">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired license - intangible</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfOC0xLTEtMS0yNTY3Mg_a4ee7f66-6276-46c7-9e18-768827138ae3">352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfOC0zLTEtMS0yNTY3Mg_4bea6d7b-62af-45a2-93e6-4f89b4766b0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfOC0xLTEtMS0yMjg1OA_892a7f75-0548-4a56-81b8-75d9e0412d87">588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfOC0zLTEtMS0yMjg1OA_af16f550-079b-4ed0-86e7-096e59b4d262">764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfOS0xLTEtMS0yMjg1OA_c214d88f-ddf3-4104-979a-e74bf084f6e4">78,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfOS0zLTEtMS0yMjg1OA_5ea6d810-e12d-4d3c-ad8c-2b7b6beca541">97,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMTMtMS0xLTEtMjI4NTg_8381d992-9f44-4153-a559-79dc3eca57c3">974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMTMtMy0xLTEtMjI4NTg_ad8c4c85-eb6f-4f07-92ec-98aa71aee6bd">1,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMTQtMS0xLTEtMjI4NTg_595f4bf2-6e24-4dbf-8f6c-f5e3b8db3c69">5,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMTQtMy0xLTEtMjI4NTg_59c0659d-17ec-4380-a530-b10124209ad7">2,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMTUtMS0xLTEtMjI4NTg_9d76990e-bb6f-4490-bb6c-e9ba9e24ba24">6,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMTUtMy0xLTEtMjI4NTg_86831fec-30f8-4493-8263-87cca941b4c1">4,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMTYtMS0xLTEtMjI4NTg_cb9655e0-5964-4fd5-8c6b-6e41189eb8d8">367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMTYtMy0xLTEtMjI4NTg_2bebce60-95a9-4af7-8270-23a65c784385">485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMTctMS0xLTEtMjI4NTg_65ce0363-954b-403b-b54d-bc35304fba7f">6,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMTctMy0xLTEtMjI4NTg_3ed9d16c-be4f-439e-a507-f73173296ae5">5,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Commitments and Contingencies (Note 13)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMTgtMS0xLTEtMjI4NTg_d72fb535-c0e7-4559-b62c-15683e90c43e"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMTgtMy0xLTEtMjI4NTg_651aa9b2-0e1b-4163-bcac-4d1fb2ea8b9d"></ix:nonFraction></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stockholders' Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, authorized, <ix:nonFraction unitRef="shares" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjEtMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjoyYTE5MjcxNjFmNWY0N2JlODQ4YmIxY2RkZjMwYjBkNl8zNA_5ec8f056-984e-4957-ab98-e42540316f9e"><ix:nonFraction unitRef="shares" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjEtMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjoyYTE5MjcxNjFmNWY0N2JlODQ4YmIxY2RkZjMwYjBkNl8zNA_d1fc4e60-8f3e-4875-8347-7691e38fe504">20,000,000</ix:nonFraction></ix:nonFraction> shares Series B convertible redeemable preferred stock</span></div><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">liquidation value, <ix:nonFraction unitRef="shares" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="INF" name="clbs:PreferredStockLiquidationPreferenceShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjEtMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjoyYTE5MjcxNjFmNWY0N2JlODQ4YmIxY2RkZjMwYjBkNl8xMTE_63d232f6-8022-48a2-8ab6-52b7a2a4187e"><ix:nonFraction unitRef="shares" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="INF" name="clbs:PreferredStockLiquidationPreferenceShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjEtMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjoyYTE5MjcxNjFmNWY0N2JlODQ4YmIxY2RkZjMwYjBkNl8xMTE_f959406c-06f8-41cd-a63d-2af99b1d728c">0.000067</ix:nonFraction></ix:nonFraction> share of common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjEtMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjoyYTE5MjcxNjFmNWY0N2JlODQ4YmIxY2RkZjMwYjBkNl8xMzc_a729fead-d39f-4d26-baab-7455eef9750d"><ix:nonFraction unitRef="usdPerShare" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjEtMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjoyYTE5MjcxNjFmNWY0N2JlODQ4YmIxY2RkZjMwYjBkNl8xMzc_cf298571-b826-44c2-b789-33202e59b5a9">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="INF" name="clbs:PreferredStockSharesDesignated" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjEtMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjoyYTE5MjcxNjFmNWY0N2JlODQ4YmIxY2RkZjMwYjBkNl8xNTE_6b741403-bef2-4f27-89ce-456588d48b61"><ix:nonFraction unitRef="shares" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="INF" name="clbs:PreferredStockSharesDesignated" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjEtMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjoyYTE5MjcxNjFmNWY0N2JlODQ4YmIxY2RkZjMwYjBkNl8xNTE_c25a3df1-16f2-401c-b12a-5eb2023efe45">825,000</ix:nonFraction></ix:nonFraction> shares designated; </span></div><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">issued and outstanding, <ix:nonFraction unitRef="shares" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjEtMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjoyYTE5MjcxNjFmNWY0N2JlODQ4YmIxY2RkZjMwYjBkNl8xOTc_678624b7-6cf4-4ab8-b7d9-dbd59ce42a9f"><ix:nonFraction unitRef="shares" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjEtMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjoyYTE5MjcxNjFmNWY0N2JlODQ4YmIxY2RkZjMwYjBkNl8xOTc_776d44ad-a154-46bf-8791-50cb314cd389"><ix:nonFraction unitRef="shares" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjEtMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjoyYTE5MjcxNjFmNWY0N2JlODQ4YmIxY2RkZjMwYjBkNl8xOTc_bf6125ad-f3fa-4d3c-ac0a-d68194e8fc6b"><ix:nonFraction unitRef="shares" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjEtMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjoyYTE5MjcxNjFmNWY0N2JlODQ4YmIxY2RkZjMwYjBkNl8xOTc_ef55544b-3169-4431-ae0f-b31849c371da">10,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares at September 30, 2022 and December 31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjEtMS0xLTEtMjI4NTg_903fec47-f670-4bc0-a2af-5fa28e6e4c5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjEtMy0xLTEtMjI4NTg_8daca816-520d-4237-a0e6-bf5f7fe9dd6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjItMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjpmOTBiNTkzYmFmNGE0MjU3Yjg3NzEwYmM4OTg4NTI4OV8xOA_24dd4b41-f4a9-49a5-9e64-dbe7c48bac65"><ix:nonFraction unitRef="usdPerShare" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjItMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjpmOTBiNTkzYmFmNGE0MjU3Yjg3NzEwYmM4OTg4NTI4OV8xOA_4248d274-5ed8-4049-8163-9683ccab88bb">0.001</ix:nonFraction></ix:nonFraction> par value, authorized <ix:nonFraction unitRef="shares" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjItMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjpmOTBiNTkzYmFmNGE0MjU3Yjg3NzEwYmM4OTg4NTI4OV80Mw_6e124651-ec79-4468-a72c-ba973f8ab0e6"><ix:nonFraction unitRef="shares" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjItMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjpmOTBiNTkzYmFmNGE0MjU3Yjg3NzEwYmM4OTg4NTI4OV80Mw_72aa93b3-19d5-494b-a342-a8ea67ae4394">33,333,333</ix:nonFraction></ix:nonFraction> shares; issued <ix:nonFraction unitRef="shares" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjItMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjpmOTBiNTkzYmFmNGE0MjU3Yjg3NzEwYmM4OTg4NTI4OV82MQ_1cad9fdc-a295-4518-aca7-49385ecade87">7,863,340</ix:nonFraction></span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">and <ix:nonFraction unitRef="shares" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjItMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjpmOTBiNTkzYmFmNGE0MjU3Yjg3NzEwYmM4OTg4NTI4OV82OA_1bf1eeca-0cbc-426e-9f85-6195c97afb15">3,986,719</ix:nonFraction> shares at September 30, 2022 and December 31, 2021, respectively; and </span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">outstanding, <ix:nonFraction unitRef="shares" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjItMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjpmOTBiNTkzYmFmNGE0MjU3Yjg3NzEwYmM4OTg4NTI4OV8xNTA_ec6c3696-3c34-4b8f-a486-54d70495fa9c">7,862,602</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjItMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjpmOTBiNTkzYmFmNGE0MjU3Yjg3NzEwYmM4OTg4NTI4OV8xNTc_763ed42e-5c9a-486c-92c8-c4bddd6d2924">3,985,981</ix:nonFraction> shares at September 30, 2022 and December 31, 2021, </span></div><div style="padding-left:27pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjItMS0xLTEtMjI4NTg_d67e402c-d43e-4792-86d2-83fbf36b7fe1">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjItMy0xLTEtMjI4NTg_60fbf5fc-c878-4a53-8cc1-aec66e3dcfb0">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjMtMS0xLTEtMjI4NTg_316bf048-45b2-4f5c-8be6-4f5cf39eafc4">574,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjMtMy0xLTEtMjI4NTg_efce5a8b-c24f-4c4c-b460-2c591306a9ed">546,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock, at cost; <ix:nonFraction unitRef="shares" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjQtMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjpkNjFlZGE5ZGU4MDQ0MTA3YWFkZDQ4ZjRmZTc2Yjc4Nl8yOQ_3e222d38-9a30-4b3b-8c81-b2fba11cd13e"><ix:nonFraction unitRef="shares" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="INF" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjQtMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjpkNjFlZGE5ZGU4MDQ0MTA3YWFkZDQ4ZjRmZTc2Yjc4Nl8yOQ_6c46ddad-bff4-42c3-bba2-cca610365d12">738</ix:nonFraction></ix:nonFraction> shares at September 30, 2022 and December 31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:TreasuryStockCommonValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjQtMS0xLTEtMjI4NTg_851f1614-b38f-4d8a-8dee-a8351b5096e4">708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:TreasuryStockCommonValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjQtMy0xLTEtMjI4NTg_435038cd-df69-4169-a4d6-6bb5a8d0b27e">708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjUtMS0xLTEtMjI4NTg_a36b5c32-582b-4fea-a1d2-cdef07d4b694">501,251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjUtMy0xLTEtMjI4NTg_2e996b12-2308-4539-ad13-113b1bdeddb8">453,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjYtMS0xLTEtMjI4NTg_6a413d38-85b9-4d3a-8068-3e8c6f8526a0">90</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjYtMy0xLTEtMjI4NTg_bc8ef4fa-e189-4890-9158-59b9a34fc398">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Lisata Therapeutics, Inc. stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjctMS0xLTEtMjI4NTg_6328a608-34fb-474a-abf6-a86974206e03">72,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjctMy0xLTEtMjI4NTg_05d84807-ea83-4148-b48c-af08b7310a60">92,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" sign="-" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjgtMS0xLTEtMjI4NTg_0773bbc8-5bbc-4da7-b44b-dd5cc8491aa8">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" sign="-" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjgtMy0xLTEtMjI4NTg_5a3978b2-8e16-4eb1-b878-44f89d2c6a12">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjktMS0xLTEtMjI4NTg_838ff811-8ea7-4d6b-9d4c-757a87a76437">71,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjktMy0xLTEtMjI4NTg_38dd1a13-4528-4c5d-88f4-95fc4b5ecc32">92,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities, non-controlling interests and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMzAtMS0xLTEtMjI4NTg_913868ee-a901-40c5-beae-a5cbc174634c">78,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMzAtMy0xLTEtMjI4NTg_4f135996-9823-4cac-b00c-6372b6789277">97,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><div style="text-align:center"><span><br/></span></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands, except per share data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"><tr><td style="width:1.0%"></td><td style="width:58.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMy0xLTEtMS0yMjg1OA_83d04f7b-df16-42d0-b061-11d7c41543b1">3,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMy0zLTEtMS0yMjg1OA_3e4e121e-ae67-40bd-91fe-6e0e0bdfa6c1">4,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMy01LTEtMS0yMjg1OA_8f8b3e4e-1591-427d-977f-65aa4059640c">9,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMy03LTEtMS0yMjg1OA_4a86c6ac-9ec0-4a9e-9672-11dec8481096">13,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNC0xLTEtMS0yNTcxNw_39fc7f31-cbdd-490d-bfe4-af538f100cd7">30,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNC0zLTEtMS0yNTcxNw_bf15ad9b-7632-4241-8825-4f4bce6224a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNC01LTEtMS0yNTcxNw_b3bcbebb-c70b-46a5-aaa1-814d7d584daf">30,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNC03LTEtMS0yNTcxNw_0b6c6cd2-b27a-4e8d-826b-c1bb202bb1bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNC0xLTEtMS0yMjg1OA_aa82c80d-d834-410c-a05e-f84c236e1db7">3,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNC0zLTEtMS0yMjg1OA_1318c6da-391f-4ba9-9e16-3939e88f1203">2,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNC01LTEtMS0yMjg1OA_5c4906f3-80d5-41dd-9f72-ea4ec4a7140c">10,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNC03LTEtMS0yMjg1OA_f7d555bc-1c81-4b6a-a1fb-e651a0ef9d68">8,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNS0xLTEtMS0yMjg1OA_4ad99122-6669-44d7-bd4a-f33b361c5316">37,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNS0zLTEtMS0yMjg1OA_6a3f028c-9fa3-4f86-8ca3-61cc36aebb6d">6,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNS01LTEtMS0yMjg1OA_f02b791a-fef9-4ec4-91c0-2f0dc4c53b3f">51,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNS03LTEtMS0yMjg1OA_1f967702-ef53-4dc5-8091-38e55e1c3bd7">22,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNy0xLTEtMS0yMjg1OA_852b5f2e-87b1-4cf6-9aec-dcf687ddfe13">37,720</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNy0zLTEtMS0yMjg1OA_4069e2b6-1d9d-4bd4-a184-1c169a5582cf">6,968</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNy01LTEtMS0yMjg1OA_807fed68-2de6-49a7-a577-c3ebb0e293b3">51,061</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNy03LTEtMS0yMjg1OA_7401306d-1a3d-4cfb-b94d-9252d112221e">22,201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTAtMS0xLTEtMjI4NTg_a08f3ffd-4d54-44a5-8f88-3ab5b113b40f">337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTAtMy0xLTEtMjI4NTg_77bc159e-10b1-4fee-ba7b-46b0729ee523">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTAtNS0xLTEtMjI4NTg_3457b61d-0882-4ee5-8d8b-53088a6923db">496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTAtNy0xLTEtMjI4NTg_1b670033-c78e-4cd0-9913-cdd493eeae15">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTEtMS0xLTEtMjI4NTg_b7f84ee1-657a-4c05-bc5d-e41bb93d9d21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTEtMy0xLTEtMjI4NTg_80bee637-7fe8-45a8-859f-98a75c43d5fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTEtNS0xLTEtMjI4NTg_8867e619-3b81-450b-ba64-7e295a1e0946">149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTEtNy0xLTEtMjI4NTg_14ac4da1-2835-45c5-9a49-ae7204417815">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTItMS0xLTEtMjI4NTg_8dc9db37-5def-421b-b51d-718e26d41365">337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTItMy0xLTEtMjI4NTg_b8615b8d-c1d2-4ea7-8037-655dbd313072">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTItNS0xLTEtMjI4NTg_3e1ae8ef-bf3a-425c-bd8b-50c8245d4b20">347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTItNy0xLTEtMjI4NTg_4aef3511-5815-4089-a507-ee5a5027a40e">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net loss before benefit from income taxes and noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTQtMS0xLTEtMjI4NTg_cd390cda-a1f5-4600-9f44-f515b5a6e332">37,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTQtMy0xLTEtMjI4NTg_17146ed3-1bd4-4e63-a9b1-1f2b7c617f9a">6,927</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTQtNS0xLTEtMjI4NTg_c11507ff-84ae-4d89-8470-34c29ed0df3c">50,714</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTQtNy0xLTEtMjI4NTg_b585ff59-2f54-425d-b93a-7d0440e88614">22,180</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTUtMS0xLTEtMjI4NTg_83cb84bb-f2d2-4de4-8e47-184f61ff80c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTUtMy0xLTEtMjI4NTg_a55d9400-59ce-49c5-9810-e4a40252a8be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTUtNS0xLTEtMjI4NTg_ac0025f1-4ca1-454b-afde-d58cd1972d6b">2,479</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTUtNy0xLTEtMjI4NTg_21b21305-0585-48f2-bba3-2ebca2690477">1,508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Lisata Therapeutics, Inc. common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTgtMS0xLTEtMjI4NTg_99664396-70b1-46f7-b61c-13512fdf5f5a">37,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTgtMy0xLTEtMjI4NTg_9fb460b4-3e96-451b-b479-7109c2288e76">6,927</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTgtNS0xLTEtMjI4NTg_544efbd5-bb74-4116-bce0-683bcbaee335">48,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTgtNy0xLTEtMjI4NTg_9a560e89-dcf4-4cd4-a3f4-18beb24fe5e7">20,672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basic and diluted loss per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lisata Therapeutics, Inc. common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjItMS0xLTEtMjI4NTg_3c00c754-a4aa-4693-a74c-abf43d2a1cbb"><ix:nonFraction unitRef="usdPerShare" contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjItMS0xLTEtMjI4NTg_9f66202f-9cea-4939-8c15-b460e5ec47a3">7.88</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjItMy0xLTEtMjI4NTg_327bbc0c-8d60-4e53-82fc-6d7d1b0e96e5"><ix:nonFraction unitRef="usdPerShare" contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjItMy0xLTEtMjI4NTg_40748671-82ec-4684-af0b-66beda6a0f0d">1.74</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjItNS0xLTEtMjI4NTg_3db279b4-3208-4435-8f1b-dec6cf0cedfc"><ix:nonFraction unitRef="usdPerShare" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjItNS0xLTEtMjI4NTg_7cc146e9-09d9-46a6-8c7a-dc69e8cc024d">11.28</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjItNy0xLTEtMjI4NTg_15235622-9d54-4071-beda-d92e807929d6"><ix:nonFraction unitRef="usdPerShare" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjItNy0xLTEtMjI4NTg_475ee68b-45fb-4562-b6de-9e0c97acc405">5.76</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average common shares outstanding</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic and diluted shares</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjUtMS0xLTEtMjI4NTg_916137b8-937b-4e1e-9b57-3905217ea913"><ix:nonFraction unitRef="shares" contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjUtMS0xLTEtMjI4NTg_b4012e4e-8705-4c69-ae39-e11bfeb4af09">4,747</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjUtMy0xLTEtMjI4NTg_8ba6df43-736c-4be4-a879-de3fc25f1bb2"><ix:nonFraction unitRef="shares" contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjUtMy0xLTEtMjI4NTg_c8790877-1dbf-422b-beb4-21921901617a">3,974</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjUtNS0xLTEtMjI4NTg_7fdf6efc-5004-4f5b-8ca8-b8ad8a42eacc"><ix:nonFraction unitRef="shares" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjUtNS0xLTEtMjI4NTg_ccbb88a2-31e7-4cd0-b9eb-e46585b05519">4,276</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjUtNy0xLTEtMjI4NTg_4f167adb-6dd4-44c8-8deb-78870e0ad8ab"><ix:nonFraction unitRef="shares" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjUtNy0xLTEtMjI4NTg_adf36ad4-d258-41bd-850c-06bc66eab2a2">3,587</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6 </span></div></div></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"></td><td style="width:56.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfMi0xLTEtMS0yMjg1OA_658f2293-3478-496a-829b-1050e71b4456">37,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfMi0zLTEtMS0yMjg1OA_8b41def3-04f4-4ab3-ac39-dd0b269c4c47">6,927</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfMi01LTEtMS0yMjg1OA_f2318eb9-4a70-4705-91e4-c97ce551822a">48,235</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfMi03LTEtMS0yMjg1OA_8112ca4a-6c62-4f13-8043-86d0ff8eb543">20,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available for sale securities - net unrealized gain (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfNS0xLTEtMS0yMjg1OA_f0397538-58cb-4e98-bc17-18d208e320f5">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfNS0zLTEtMS0yMjg1OA_96db2c0c-92de-42e5-b5bb-5f8b3a978954">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfNS01LTEtMS0yMjg1OA_e1998432-5b38-4a11-b185-586aaf02aaf6">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfNS03LTEtMS0yMjg1OA_944a5136-db96-4b7e-b87b-3007f7625be4">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative translation adjustment arising during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfNi0xLTEtMS0yNTc1Nw_624eb1e8-fd56-45a7-859f-d2d529d66a25">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfNi0zLTEtMS0yNTc1Nw_397e5d59-7571-4463-9197-c4e408d02719">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfNi01LTEtMS0yNTc1Nw_f0e83d22-6c35-4327-9eb8-090e23cd3e2c">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfNi03LTEtMS0yNTk3NA_183d1cba-1007-45a4-b183-4dda241aa129">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfNi0xLTEtMS0yMjg1OA_c3aedb94-b0fc-4e93-9ec5-7b6dd045f4b6">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfNi0zLTEtMS0yMjg1OA_9d9b0e65-a989-4ea0-98ff-1e63d9e18f5b">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfNi01LTEtMS0yMjg1OA_f61f24e0-97df-49dd-a132-2f67368089fc">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfNi03LTEtMS0yMjg1OA_5041678b-5757-4f40-b626-b74c1aeaf182">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss attributable to Lisata Therapeutics, Inc. common</span><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">stockholders</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfMTItMS0xLTEtMjI4NTg_2cfeeb8f-e9fb-4f7c-b41f-778188badcfd">37,403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfMTItMy0xLTEtMjI4NTg_52eb00f3-0fae-4534-a359-3b23d0bcfd66">6,974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfMTItNS0xLTEtMjI4NTg_bcd194a2-dfd9-41e2-a810-9c1ef2cbb1d5">48,255</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfMTItNy0xLTEtMjI4NTg_0bc13504-2dd8-4d2e-a4bd-4d5b6be21631">20,723</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7 </span></div></div></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.817%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.832%"></td><td style="width:0.1%"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series B Convertible<br/>Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Lisata Therapeutics,<br/>Inc.<br/>Stockholders'<br/>Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest in<br/>Subsidiary</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia5c2e6f4066b47fbb0c62e47d1a34e30_I20220630" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMi0xLTEtMS0yMjg1OA_1fd54ff4-5489-412d-9b90-ff2a9c3a51ca"><ix:nonFraction unitRef="shares" contextRef="ia5c2e6f4066b47fbb0c62e47d1a34e30_I20220630" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMi0xLTEtMS0yMjg1OA_585fe28b-52c9-42f3-aaec-aaaaa25f043e"><ix:nonFraction unitRef="shares" contextRef="ia5c2e6f4066b47fbb0c62e47d1a34e30_I20220630" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMi0xLTEtMS0yMjg1OA_a9629bf9-0a8b-45db-be18-87e9b84fdc18">&#8212;</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5c2e6f4066b47fbb0c62e47d1a34e30_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMi0zLTEtMS0yMjg1OA_976ab462-ec6c-48d0-8d77-06a65f579a3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86d263da61bd426cb7086a17123228f7_I20220630" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMi01LTEtMS0yMjg1OA_0d97ad07-d0f8-46bf-a870-a8accc628647">4,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86d263da61bd426cb7086a17123228f7_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMi03LTEtMS0yMjg1OA_ce04d74d-1e95-4b81-91ee-fd15dbd917a9">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17ae6b2b209f4867bbb33069c004b3aa_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMi05LTEtMS0yMjg1OA_220a777c-9c1a-49f5-8faa-e3ed5e7db7be">547,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id86020b0b46045dc893b03e2966eb75c_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMi0xMS0xLTEtMjI4NTg_07752db1-a296-460b-b89d-e7a119ee9de1">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i029fe570e6734389a205caae3c3445a0_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMi0xMy0xLTEtMjI4NTg_f9d84907-6b7a-436b-b17d-b15e82ca83e9">463,868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03285eb13bc340e3a8a2ff34047b4093_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMi0xNS0xLTEtMjI4NTg_2da00b92-de90-4231-b032-85fde0dc7e01">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07070a35a7c74213a020599cb2deffb7_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMi0xNy0xLTEtMjI4NTg_d517e113-d607-4a83-963c-3c9086f7dcf8">82,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c69daf49eff4222a69cd10c77c98604_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMi0xOS0xLTEtMjI4NTg_33e199bb-9985-44a5-8c4a-08fdd23be4c3">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d9e85847ab4fcf9aac296f60571be8_I20220630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMi0yMS0xLTEtMjI4NTg_408ade25-6a72-47e0-b650-7052346cc03d">82,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69110a58290f48db984963c9b07024c0_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMy0xMy0xLTEtMjI4NTg_3993ceb3-4cde-46e9-8cd8-244a9b82f19c">37,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b905b12169646dea54aa6e1e067b6f0_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMy0xNy0xLTEtMjI4NTg_8090696a-657e-4125-a5ca-1054483553a8">37,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMy0yMS0xLTEtMjI4NTg_c4c258a3-f324-460d-9f71-40ee0b37e52c">37,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6d228b1f84b744de88a126fa2a54dd15_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfNS01LTEtMS0yMjg1OA_0823e33d-db6b-4c16-b53f-52ec8c985614">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd096734b704a05b20e0d2a7a46f6f4_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfNS05LTEtMS0yMjg1OA_f7484aa3-4340-44bf-b02a-52b1b63f048f">940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b905b12169646dea54aa6e1e067b6f0_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfNS0xNy0xLTEtMjI4NTg_2efac6ec-0f20-46cb-8279-544475309619">939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfNS0yMS0xLTEtMjI4NTg_01b0449f-4e8b-4332-818b-fc5caaabc8b0">939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with merger</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6d228b1f84b744de88a126fa2a54dd15_D20220701-20220930" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfOS01LTEtMS0yNjE3Ng_fe7368b1-a874-4e9b-b391-4506a438e779">3,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d228b1f84b744de88a126fa2a54dd15_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfOS03LTEtMS0yNjE3Ng_1bd66d3f-91dd-4594-9335-747d1a09824e">4</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebd096734b704a05b20e0d2a7a46f6f4_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTAtOS0xLTEtMjU1NDE_65d97fca-9413-4d19-9439-b1866d803184">26,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b905b12169646dea54aa6e1e067b6f0_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTAtMTctMS0xLTI1NTM2_e51ed6f0-f4bd-4f4d-b688-c056b09b4945">26,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTAtMjEtMS0xLTI1NTM2_33087518-7ab9-4a05-bef3-efdfcd3cd557">26,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cec8b5ec5914024a14b5f754a3d6ddf_D20220701-20220930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTItMTEtMS0xLTI1NTQx_5b47337e-5730-49bc-a485-3ae47a2650d3">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b905b12169646dea54aa6e1e067b6f0_D20220701-20220930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTItMTctMS0xLTI1NTM2_cbe2691b-2d00-43b5-92dd-04086e74b3a1">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTItMjEtMS0xLTI1NTM2_20c40406-2e46-45fc-a171-e1415c66d4fe">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1cec8b5ec5914024a14b5f754a3d6ddf_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTEtMTEtMS0xLTI3NTU5_e511d19b-417c-4601-ae0d-8f732dc0771f">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTEtMTctMS0xLTI3NTU5_5eaf2722-4520-410c-9bab-13d6f8d7e009">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTEtMjEtMS0xLTI3NTU5_036d7c63-87a5-42ee-b117-6931ca3f9387">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9801b9ed9e24c90b66bf7dc589a24f2_I20220930" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfOS0xLTEtMS0yMjg1OA_dd8a8779-c5a9-473f-83b5-e5a5cb2eaf36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9801b9ed9e24c90b66bf7dc589a24f2_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfOS0zLTEtMS0yMjg1OA_5d6e864e-b02b-4594-adb1-3956e1eaeb31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i944ba198ef814601b1dc3e189a2d15b9_I20220930" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfOS01LTEtMS0yMjg1OA_2bc0981c-aec1-481f-9c07-ae1140d56cb2">7,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i944ba198ef814601b1dc3e189a2d15b9_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfOS03LTEtMS0yMjg1OA_ec05452c-994e-4126-ae16-cf81feff68b0">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5163c19edf884a309a10703ede9fbc6c_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfOS05LTEtMS0yMjg1OA_d7e388ee-f017-46d7-a698-86e12b866a9d">574,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i853118dfc75844fb9a23dfa0374528cd_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfOS0xMS0xLTEtMjI4NTg_a921c7b0-124d-4a95-91f5-1bc0cd138cd6">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c936e2b28ea43c7b0b9af4a69e00249_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfOS0xMy0xLTEtMjI4NTg_1b36074e-c8a3-43bc-85c4-6dcd577bdbb5">501,251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b81c7260bd84f378acc80251b158b2a_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfOS0xNS0xLTEtMjI4NTg_2217b371-04f4-4ca0-83ae-e5a64733bb71">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ec4c587d4a3466ab448abb94ba9f29d_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfOS0xNy0xLTEtMjI4NTg_9b325ab8-a08d-4dfb-9061-b0326cdeb407">72,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3c09e4703ba40298dd79e85417cdb61_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfOS0xOS0xLTEtMjI4NTg_684d9c54-5913-437f-9f70-b74767efcaf5">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfOS0yMS0xLTEtMjI4NTg_372a5efb-5cf7-459c-99cd-8441ad3ebe33">71,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series B Convertible<br/>Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Lisata Therapeutics,<br/>Inc.<br/>Stockholders'<br/>Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest in<br/>Subsidiary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d30a645527f4337a60c7da8f18e85ae_I20211231" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTMtMS0xLTEtMjI4NTg_aa878e7e-fbc5-4cb9-bc29-5541973de815">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d30a645527f4337a60c7da8f18e85ae_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTMtMy0xLTEtMjI4NTg_6397f74f-82f9-472a-83d4-aadc40bc15e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7eef7cc26c004a4c908e6fe160d201d1_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTMtNS0xLTEtMjI4NTg_0358b2ce-b039-49cc-82ed-f96a4f27ba76">3,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eef7cc26c004a4c908e6fe160d201d1_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTMtNy0xLTEtMjI4NTg_fc960858-e938-4d26-8999-032c53592c9f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i686c5d52741f40f5a71ed6e2545ec05b_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTMtOS0xLTEtMjI4NTg_079ab309-cc51-4c76-9b1d-e80d099fa11e">546,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4050b9a1a6ec412b8853f688ad35a4fd_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTMtMTEtMS0xLTIyODU4_8833e898-df4d-4f8a-9519-a964868b18ca">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fa893b6dc4a4a698cf4f78caf023478_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTMtMTMtMS0xLTIyODU4_7eb7efe3-21b2-46fc-9402-79345e0fc9a0">453,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7779b193bfe449bbd568049e6084cc7_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTMtMTUtMS0xLTIyODU4_e5a397f3-2093-488a-af34-892edc0e7f32">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d1ccf571c4245369c9de32e62b102ee_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTMtMTctMS0xLTIyODU4_6eed1f10-0c4b-4103-b374-f5deff793c3c">92,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63f9702a0ee94ee3a2adeeac786c1860_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTMtMTktMS0xLTIyODU4_5ec14768-ff6f-48c3-a408-a8a24c48ecc1">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTMtMjEtMS0xLTIyODU4_8ca926cd-ba60-4858-8d6c-a2789d9932f3">92,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie19069eadb3a4525bd0e3c209f26c6fc_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTUtMTMtMS0xLTIyODU4_2b62ec51-9635-4c02-9a7a-fdc200b3b506">48,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29f228f551d04b7d9d199959a37d10b2_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTUtMTctMS0xLTIyODU4_2f0ed9e2-525f-4f4b-b145-f365744d1f4c">48,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTUtMjEtMS0xLTIyODU4_e18fd70a-2683-4f32-96ee-d7f8a5339aad">48,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie1e85bf072d8481caf42f6d9beb8f4e6_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTctNS0xLTEtMjI4NTg_ffd00571-aa19-407c-9856-6264ea799026">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1e85bf072d8481caf42f6d9beb8f4e6_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTctNy0xLTEtMjI4NTg_f5aef239-bf32-45fc-b890-bd62587616c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9485a0db274745a69f25443e8b178239_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTctOS0xLTEtMjI4NTg_d5359c2b-aa84-4550-82e1-81ba3b5a21fe">1,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f228f551d04b7d9d199959a37d10b2_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTctMTctMS0xLTIyODU4_72c7ecdf-02a3-4b26-8ba9-3f323068ddf0">1,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTctMjEtMS0xLTIyODU4_b0800809-d062-4502-8dc5-fd9f4117e5ec">1,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from issuances of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie1e85bf072d8481caf42f6d9beb8f4e6_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTgtNS0xLTEtMjI4NTg_07e69ff1-ff3f-40b7-bff1-ff35973f7cfc">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9485a0db274745a69f25443e8b178239_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTgtOS0xLTEtMjI4NTg_d5e94e8c-cdce-4d58-ad96-44a5e8bf6f31">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f228f551d04b7d9d199959a37d10b2_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTgtMTctMS0xLTIyODU4_3bf496a2-c658-43f3-968e-8005ac7e803d">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTgtMjEtMS0xLTIyODU4_da440d21-b349-432e-9320-e92675efb04b">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with merger</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie1e85bf072d8481caf42f6d9beb8f4e6_D20220101-20220930" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjMtNS0xLTEtMjYyMDU_3102fabe-b22a-43a8-a0b9-55a8eb9b6e05">3,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1e85bf072d8481caf42f6d9beb8f4e6_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjMtNy0xLTEtMjYyMDU_0fcff799-d7c1-4e99-b864-7a92fafe0008">4</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9485a0db274745a69f25443e8b178239_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjMtOS0xLTEtMjYyMDU_07f13f86-c164-4afe-888d-c25d1f33b88f">26,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f228f551d04b7d9d199959a37d10b2_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjYtMTctMS0xLTI1NTYz_0484f77f-19b1-4b5f-a507-e6220d0a0486"><ix:nonFraction unitRef="usd" contextRef="i29f228f551d04b7d9d199959a37d10b2_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjYtMTctMS0xLTI1NTYz_52a3741c-9a9f-44e8-b6a8-ff4ae71f78fe">26,098</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjYtMjEtMS0xLTI1NTcy_48dbfb0d-4906-4ffb-beb6-3b4a1076b4f1">26,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab2f266a4d614842a787f8e85ec8abfd_D20220101-20220930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjgtMTEtMS0xLTI1NTYz_ce2ac3d5-2024-4017-b6b3-683d6275d9bb">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f228f551d04b7d9d199959a37d10b2_D20220101-20220930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjgtMTctMS0xLTI1NTYz_a2342957-0274-4262-a9b7-457526dbbba0">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjgtMjEtMS0xLTI1NTcy_fb31a95d-7e0a-4a27-a200-96803806c371">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab2f266a4d614842a787f8e85ec8abfd_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjUtMTEtMS0xLTI3NTg1_00e2631e-37bc-4f91-9589-1d79504e22c6">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjUtMTctMS0xLTI3NTg1_5c63aec5-76e6-4bd2-b240-fe8bb178ad48">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjUtMjEtMS0xLTI3NTg1_44bd9fec-2d07-44b8-99b1-be4639eb4d9b">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9801b9ed9e24c90b66bf7dc589a24f2_I20220930" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjEtMS0xLTEtMjI4NTg_cdb5378a-6a18-4707-b2eb-aafb08f15e14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9801b9ed9e24c90b66bf7dc589a24f2_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjEtMy0xLTEtMjI4NTg_e9347d2c-1161-4f88-bafe-3ef03fa27fa2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i944ba198ef814601b1dc3e189a2d15b9_I20220930" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjEtNS0xLTEtMjI4NTg_737eebdb-0e3f-4c8d-a7b4-a3874a0ef1c8">7,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i944ba198ef814601b1dc3e189a2d15b9_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjEtNy0xLTEtMjI4NTg_1cf1f71e-c597-451f-89ce-b61321334a3f">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5163c19edf884a309a10703ede9fbc6c_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjEtOS0xLTEtMjI4NTg_3138934d-a075-44ce-832b-9456e9424227">574,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i853118dfc75844fb9a23dfa0374528cd_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjEtMTEtMS0xLTIyODU4_e9e53df6-0497-41bb-b861-97149d91a9c7">90</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c936e2b28ea43c7b0b9af4a69e00249_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjEtMTMtMS0xLTIyODU4_7f2d0d43-aa8b-43ef-8504-b6b923e78b21">501,251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b81c7260bd84f378acc80251b158b2a_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjEtMTUtMS0xLTIyODU4_7676f774-6fb0-420f-8031-c15b6b68191c">708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ec4c587d4a3466ab448abb94ba9f29d_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjEtMTctMS0xLTIyODU4_ef398382-21fa-47c8-bf22-e56f351cc7da">72,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3c09e4703ba40298dd79e85417cdb61_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjEtMTktMS0xLTIyODU4_6bd2cc61-7fa0-4cc7-9405-eea116a00bfe">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjEtMjEtMS0xLTIyODU4_f2416230-4551-4b6d-984b-a44d20cd71df">71,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.458%"><tr><td style="width:1.0%"></td><td style="width:22.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.843%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.884%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.320%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.870%"></td><td style="width:0.1%"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series B Convertible<br/>Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Lisata Therapeutics,<br/>Inc.<br/>Stockholders'<br/>Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest in<br/>Subsidiary</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie8fa07dd822c4c8db0ca288934287b7d_I20210630" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMi0xLTEtMS0yMjg1OA_94f9e7df-45db-40da-a5cf-49ca8229bea1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8fa07dd822c4c8db0ca288934287b7d_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMi0zLTEtMS0yMjg1OA_9b15572d-19c2-4130-8053-e5259caf6e4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16004a445bd449db8e2738b544722065_I20210630" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMi01LTEtMS0yMjg1OA_3c88c480-ddf9-4e6a-b08b-e7ddb82f2744">3,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16004a445bd449db8e2738b544722065_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMi03LTEtMS0yMjg1OA_dc7c914b-d210-4bf3-9b06-0cf6cf7d70f8">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i038ee7bc9a294a179161a5703da8dba9_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMi05LTEtMS0yMjg1OA_f2704af1-02e7-436a-85a6-9ea26e9f8a0e">544,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d6d03e551b49a8a244e5310fc9c806_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMi0xMS0xLTEtMjI4NTg_5f2bb70f-08ca-4bb0-be60-f8c0f4b68055">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd86cb6ffe24ae9af1b0bf46c620e7f_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMi0xMy0xLTEtMjI4NTg_976a123f-af21-419d-ac31-3b27c64a6812">439,295</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec685200531f473bab6967cb468862fb_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMi0xNS0xLTEtMjI4NTg_4ee8a726-c49d-45d9-8620-b0475f2b360f">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0251e8a199d84ca68ff8b0e1aa8255ce_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMi0xNy0xLTEtMjI4NTg_5b9a40ad-264b-4b49-8058-bdfffdcaf470">104,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedd0d04163e74945bb220b2e853c3e5e_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMi0xOS0xLTEtMjI4NTg_f6acf282-d556-4a91-a92b-f087fa4cfba7">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia59e32a50e1444c697ba1a65e5e48334_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMi0yMS0xLTEtMjI4NTg_f9ac0724-9b9e-4fb4-985b-c4bf7b30b31e">104,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0d534735e7c4b63b3bf26d250ca8b2b_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMy0xMy0xLTEtMjI4NTg_73f7b72a-6c16-4bd4-8526-2da80cb4b53e">6,927</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iadddb49f7b264fa48f4b8133ef8e3991_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMy0xNy0xLTEtMjI4NTg_ff31e612-aa55-4ceb-95be-ed33a84b8c35">6,927</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMy0yMS0xLTEtMjI4NTg_e6a6e65d-ae2b-42d5-9dfd-cc50382ddaf4">6,927</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i81f77055e79c4a769aa1eeb70f3e5de2_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfNS01LTEtMS0yMjg1OA_bec44a67-5212-4b00-8ab4-d3736d0252f4">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc9fdc2eadc94b589888a37676c11ae9_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfNS05LTEtMS0yMjg1OA_b85b2cb2-1cb5-4ae9-9d29-ad12bca1efa9">708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadddb49f7b264fa48f4b8133ef8e3991_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfNS0xNy0xLTEtMjI4NTg_2ff58c40-a53d-4736-95e9-ddc8356c7a2b">708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfNS0yMS0xLTEtMjI4NTg_a7881ff7-ef44-47e5-b94c-383b078c06bf">708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f9539108c6c4e1ba0d051b1aabb567a_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS0xMS0xLTEtMjc2MTM_95cdb4b4-6fe2-4930-831f-10ee63400fcb">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iadddb49f7b264fa48f4b8133ef8e3991_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS0xNy0xLTEtMjc2MTM_4bac063e-db3e-43ea-96b4-4196f271cea4">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS0yMS0xLTEtMjc2MTM_25d70de0-9c36-4700-b285-c3f909435503">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d2b62b865bd4041b0251301f7f51424_I20210930" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS0xLTEtMS0yMjg1OA_52f8eef2-8f8f-47af-8fbf-87ff1e4deaf0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d2b62b865bd4041b0251301f7f51424_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS0zLTEtMS0yMjg1OA_0e6b1bf1-142d-423c-bebc-9ec00ecc1260">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i872ef751a6a241769e47a7626414f412_I20210930" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS01LTEtMS0yMjg1OA_7ec64f7a-c926-4d16-b543-3c29efa82529">3,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872ef751a6a241769e47a7626414f412_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS03LTEtMS0yMjg1OA_b20aa0a0-3a58-429b-ab32-d4c193794afb">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee65085e733d41a19e4143446eff7b7c_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS05LTEtMS0yMjg1OA_fcbd2d8c-9d90-4761-bf3e-53870b1492bf">545,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33afa975dd374f46b8ea96b4c0471c87_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS0xMS0xLTEtMjI4NTg_978d45f7-9e96-40d3-a06a-16984997881c">64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2242481d947422a87b50a693e117608_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS0xMy0xLTEtMjI4NTg_468b22a4-9989-4dbd-9d08-332401fa62e8">446,222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57e94f040b084f7b9def7834d945a4c7_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS0xNS0xLTEtMjI4NTg_21141e7a-731f-4cce-a627-337dd4f784d7"><ix:nonFraction unitRef="usd" contextRef="i57e94f040b084f7b9def7834d945a4c7_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS0xNS0xLTEtMjI4NTg_8808068a-7fef-4b55-bbc1-4063497d5d49">708</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d73cec2ab1421e98d1f86d5a3b506a_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS0xNy0xLTEtMjI4NTg_b7089ac1-1a09-499f-b9a3-9c7bdf467a45">98,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic87a4ec489bc4ec0bf3f93cc71f5e063_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS0xOS0xLTEtMjI4NTg_30ae9603-3d1f-4a3b-8d63-355e758deaa6">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74b1319645614dceb3e4fce1f773ff25_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS0yMS0xLTEtMjI4NTg_19e6a4b1-82b4-4d4b-94d3-3f838d916aa9">98,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:39pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series B Convertible<br/>Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Lisata Therapeutics,<br/>Inc.<br/>Stockholders'<br/>Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest in<br/>Subsidiary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i848e51e03eed447c935cb2899345a1ff_I20201231" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTMtMS0xLTEtMjI4NTg_999525f4-1ff7-43cd-8c16-c3bf0e99fa48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i848e51e03eed447c935cb2899345a1ff_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTMtMy0xLTEtMjI4NTg_c6fd1bae-cd03-4d2a-823f-fa96acdc35b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i26cf58fb84e74ac694d839db83461838_I20201231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTMtNS0xLTEtMjI4NTg_fa002cc7-6adc-4b9d-81b7-3bce15dc0572">1,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26cf58fb84e74ac694d839db83461838_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTMtNy0xLTEtMjI4NTg_73fa3bd2-7d0e-460b-a300-18d1e6313368">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib450656958d64dd7809ab86b82185cce_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTMtOS0xLTEtMjI4NTg_0f1c1cbb-dbf7-4684-8f5f-29d81c548d2b">458,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3e5d05a52e7442a8b64eb445899cdf0_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTMtMTEtMS0xLTIyODU4_8dd0f77f-1bf9-4313-9a76-bf7671dacbdf">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85b4ca140e7d4f318fdd15f0a5cfb26c_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTMtMTMtMS0xLTIyODU4_1db113de-ae55-4aeb-9b57-cc34e1cc9612">425,550</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib8a27c130df24312b50441271af5f833_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTMtMTUtMS0xLTIyODU4_29d1eae2-1a8b-4645-bbbb-eb70637f7a77">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fad62fd3c3b4c7083f34c136706b9ab_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTMtMTctMS0xLTIyODU4_a4acc085-9694-4b96-a104-b346db0d8d9b">32,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5443afa6b3c4665b9c1eae0dbd038e1_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTMtMTktMS0xLTIyODU4_c9405939-1e5f-4e13-9ab1-331230b617a3">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83e78453949e4f5fb203beb11be8a1dc_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTMtMjEtMS0xLTIyODU4_9ec94b5b-64ff-42c7-bb92-41d716fd70c5">32,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a6f0161fc68498fb65a78febe096c25_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTUtMTMtMS0xLTIyODU4_2efab64e-5758-4b77-9747-32665d59be63">20,672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0a6fa60498746079ad9eb4134e0a7c0_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTUtMTctMS0xLTIyODU4_05d33702-601b-4de3-a7c2-e43a932b2c1c">20,672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTUtMjEtMS0xLTIyODU4_e85d5f30-950d-46a4-916b-c57a9eb93ce8">20,672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07a0bb3234e14e0fbc6b7bce9f23f88a_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTctNS0xLTEtMjI4NTg_17d146f9-7145-4ba0-9b92-52f541b3c491">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86917d398d3247a6b5578480b5333d60_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTctOS0xLTEtMjI4NTg_f4891042-b4d9-4dd6-88cf-f8540372516b">1,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0a6fa60498746079ad9eb4134e0a7c0_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTctMTctMS0xLTIyODU4_84bab397-7784-407d-a061-fee20a39d19f">1,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTctMjEtMS0xLTIyODU4_35a9e0d8-a1b9-4ced-a852-0dcc51d4cbd6">1,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from issuances of common stock and warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07a0bb3234e14e0fbc6b7bce9f23f88a_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTgtNS0xLTEtMjI4NTg_78975ee3-ab08-4651-b602-24883b1e43a4">2,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07a0bb3234e14e0fbc6b7bce9f23f88a_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTgtNy0xLTEtMjI4NTg_0e761f3a-6f40-478a-bf2d-c54964855b63">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86917d398d3247a6b5578480b5333d60_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTgtOS0xLTEtMjI4NTg_8accac95-d149-4f0a-9691-0e3efdaff72b">85,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0a6fa60498746079ad9eb4134e0a7c0_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTgtMTctMS0xLTIyODU4_e9643d95-5e84-41df-a988-5489f45b8156">85,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTgtMjEtMS0xLTIyODU4_c0c82757-dfa0-409c-933b-3f2a6e1f3d21">85,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86917d398d3247a6b5578480b5333d60_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTktOS0xLTEtMjI4NTg_d3bc8ff2-dbc0-4e2a-99d6-44b15b8ae6b0">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0a6fa60498746079ad9eb4134e0a7c0_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTktMTctMS0xLTIyODU4_c6ab49d4-4d48-4d25-9303-f3ee4b635060">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTktMjEtMS0xLTIyODU4_fad0402f-771e-42a9-8a22-67e69514ee2c">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3698298d7aba49a9af19841d1ba110c1_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMjEtMTEtMS0xLTI3NjIz_427197bd-a714-474b-9847-7f42d816c282">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0a6fa60498746079ad9eb4134e0a7c0_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMjEtMTctMS0xLTI3NjIz_dea36293-4bdd-44ec-9172-4c4311248726">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMjEtMjEtMS0xLTI3NjIz_ecd72f3f-7954-4cdc-ad8d-04c7d03e5d54">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d2b62b865bd4041b0251301f7f51424_I20210930" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMjEtMS0xLTEtMjI4NTg_2c59fcc1-a89d-43ee-8bff-3d7a7dd90b50">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d2b62b865bd4041b0251301f7f51424_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMjEtMy0xLTEtMjI4NTg_153a63d4-3f31-4fe9-9598-97a1af0a2a22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i872ef751a6a241769e47a7626414f412_I20210930" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMjEtNS0xLTEtMjI4NTg_8cf55cf2-f7a3-4d48-a186-28cc96dc61ca">3,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872ef751a6a241769e47a7626414f412_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMjEtNy0xLTEtMjI4NTg_a894efd8-b458-4fe3-980e-9bdaa072ebad">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee65085e733d41a19e4143446eff7b7c_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMjEtOS0xLTEtMjI4NTg_1d5d7225-7f81-425c-b0a1-664a63efb05c">545,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33afa975dd374f46b8ea96b4c0471c87_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMjEtMTEtMS0xLTIyODU4_e93aaeaf-0867-47af-a97a-7b4a9e263f85">64</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2242481d947422a87b50a693e117608_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMjEtMTMtMS0xLTIyODU4_ce3df694-b5b1-4bbe-aadb-0d4111403273">446,222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57e94f040b084f7b9def7834d945a4c7_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMjEtMTUtMS0xLTIyODU4_f1787862-8598-4b30-9503-e3f335f8d448">708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d73cec2ab1421e98d1f86d5a3b506a_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMjEtMTctMS0xLTIyODU4_43b8fcc6-ff63-490e-8be5-0aac115e1d9c">98,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic87a4ec489bc4ec0bf3f93cc71f5e063_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMjEtMTktMS0xLTIyODU4_eae0e136-3fdb-4c9e-b1a7-e068e8d2d43d">254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74b1319645614dceb3e4fce1f773ff25_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMjEtMjEtMS0xLTIyODU4_36986143-4f86-415d-9060-b37b120e2163">98,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9 </span></div></div></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(In thousands)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.600%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMy0xLTEtMS0yMjg1OA_4faa62ac-0c13-49a1-95d1-1bda6fbb3ddd">48,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMy0zLTEtMS0yMjg1OA_5cfaa974-115d-4be7-a398-61e7d577761a">20,672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfNS0xLTEtMS0yMjg1OA_4c5f89d1-e73d-4b23-8dfc-12698ac5564f">2,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfNS0zLTEtMS0yMjg1OA_c3de061b-3a1f-4b3b-b76e-304e6137307f">1,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfNi0xLTEtMS0yMjg1OA_f728d8d9-ba6f-480e-affd-5c1478ac1473">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfNi0zLTEtMS0yMjg1OA_195f14aa-e758-43e1-acae-9bcc9abf3ba2">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In process research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfOS0xLTEtMS0yNTQwNg_9180f76a-3429-495f-8936-0d68e23a494a">30,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfOS0zLTEtMS0yNTQxNA_5ece3386-c0da-4dcc-95c5-e4e371c313b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfOS0xLTEtMS0yMjg1OA_539cf581-b792-4fbf-9f89-9608248190bd">893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfOS0zLTEtMS0yMjg1OA_d1d11fdd-5aae-4a12-b77d-2bf473f6dba6">1,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTEtMS0xLTEtMjI4NTg_8539d966-8b68-462f-a7c6-fc04b63fc9a4">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTEtMy0xLTEtMjI4NTg_3e96fc3d-b7b9-4550-a620-f0ecfb55ed33">1,199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTItMS0xLTEtMjI4NTg_4191adfe-9919-4f9e-ab20-cd5a6e1d80d5">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTItMy0xLTEtMjI4NTg_7cb45f32-557e-40c3-bdae-ef803ad920f4">252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued liabilities and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" sign="-" name="clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTMtMS0xLTEtMjI4NTg_d43c8c51-a341-4040-ab92-c9854ed45888">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTMtMy0xLTEtMjI4NTg_68af70c2-f985-4ebc-b55b-da140f869ddf">367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTQtMS0xLTEtMjI4NTg_264d2c83-bc15-4bbd-b21b-a8126f3933d9">14,702</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTQtMy0xLTEtMjI4NTg_594c9e47-5025-45d1-a02e-109426af8ebb">17,641</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTYtMS0xLTEtMjI4NTg_ec6625a1-771e-4661-ae91-d831f6a3a483">68,481</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTYtMy0xLTEtMjI4NTg_6961ea4f-83b2-439b-a5d5-93ea6d1f6b25">137,329</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sale of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTctMS0xLTEtMjI4NTg_3eb5dab2-0ba2-4a35-a410-0f83584b0095">93,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTctMy0xLTEtMjI4NTg_0f238869-4c67-497f-9590-ca1b5831ed81">66,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset acquisition costs, net of cash acquired related to merger with Cend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTktMS0xLTEtMjU0MzQ_a69a96d9-27df-4460-880d-c544b94960c1">3,320</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTktMy0xLTEtMjU0NTE_b8225435-5fd5-47c4-845d-c0add9e7f0e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTgtMS0xLTEtMjI4NTg_999177c2-9871-4253-b3d6-80997a7eca70">259</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTgtMy0xLTEtMjI4NTg_9f4a4b38-afd2-403f-8987-2f55f276a5a3">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjAtMS0xLTEtMjI4NTg_bd86958c-21fe-4f3e-83d4-789d7479322b">21,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjAtMy0xLTEtMjI4NTg_b6119e2c-d608-45ab-a89d-a38a29ce2b21">71,354</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercise of options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjItMS0xLTEtMjI4NTg_76363b53-d4ab-468f-bf96-e10a798bf745">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjItMy0xLTEtMjI4NTg_33cef3e9-3922-46f7-a1f3-30c2188dd59e">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax withholding payments on net share settlement equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjMtMS0xLTEtMjI4NTg_bb2a09a1-780a-4948-9579-e2a4781fff03">267</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjMtMy0xLTEtMjI4NTg_084f9568-ceb7-47a7-a187-35fb525717b4">248</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net proceeds from issuance of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjQtMS0xLTEtMjI4NTg_af58d4ea-da5a-4b1c-9145-2efcab3c9e75">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjQtMy0xLTEtMjI4NTg_0fcc2e66-3007-4bdd-996b-aba088a8f674">85,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjYtMS0xLTEtMjI4NTg_d1334bcd-49cf-4672-8f85-ef9a7e547378">238</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjYtMy0xLTEtMjI4NTg_2979077e-fe51-425f-a41b-615b25368fc4">85,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Effect of exchange rate changes on cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMzAtMS0xLTEtMjYxMzA_b2605385-cdac-4874-9714-90d6d8722dfe">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMzAtMy0xLTEtMjYxMzA_34260be4-fc4d-4559-89a1-afaf03d2c6f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjctMS0xLTEtMjI4NTg_b6247137-cf8b-4652-8f12-7c920e30c67b">6,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjctMy0xLTEtMjI4NTg_2b3bc528-8557-49c5-96b7-d6d147f27a3e">3,740</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjgtMS0xLTEtMjI4NTg_defe284b-8a72-468e-855f-f5864a37a874">24,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83e78453949e4f5fb203beb11be8a1dc_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjgtMy0xLTEtMjI4NTg_f1850d41-2e46-40ce-8e12-dc0c47dbc1ab">16,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjktMS0xLTEtMjI4NTg_dfa08e33-f91e-4d87-abcc-3b4b85ced83f">31,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74b1319645614dceb3e4fce1f773ff25_I20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjktMy0xLTEtMjI4NTg_45279e3f-62e0-4684-a2bc-192f9922da4f">12,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of noncash investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock in connection with merger</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMzYtMS0xLTEtMjc2NDY_67b84b9d-54b5-4380-93ec-e80e9249a0d7">23,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMzYtMy0xLTEtMjc2NDY_c2e60fe4-53f4-445b-801f-890cefaa638b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incremental fair value of Cend's fully vested stock options assumed</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" name="us-gaap:LiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMzctMS0xLTEtMjc2NDY_8f858d62-6301-41b1-9b58-f62608bba82f">2,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="us-gaap:LiabilitiesAssumed1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMzctMy0xLTEtMjc2NDY_6e567bf3-327c-44be-a5c0-bcb1e85ce085">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 </span></div></div></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC. AND SUBSIDIARIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_34"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 1&#160;&#8211; <ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="clbs:BusinessTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8zNC9mcmFnOjBkYzk4ZTljODdlZDQ0OTNhNTk1NjVkNjc2YjJlZmQ3L3RleHRyZWdpb246MGRjOThlOWM4N2VkNDQ5M2E1OTU2NWQ2NzZiMmVmZDdfMTk4MTQ_be48859e-7e1e-4b9b-b386-fc226fe9231d" continuedAt="i00a39f7f2f70414086039ba20bea7377" escape="true">The Business</ix:nonNumeric></span></div><ix:continuation id="i00a39f7f2f70414086039ba20bea7377" continuedAt="i937c20d5b73e4c5f8f18ba7511107938"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lisata Therapeutics, Inc. (together with its subsidiaries, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Lisata&#8221; or the &#8220;Company&#8221;) is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Lisata&#8217;s lead investigational product candidate, LSTA1 (formerly known as CEND-1), is designed to activate a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment (&#8220;TME&#8221;), making tumors more susceptible to immunotherapies. LSTA1 has demonstrated favorable safety, tolerability, and activity to date in completed and ongoing clinical trials to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. Lisata and its collaborators have also amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics. Lisata is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively. In addition, Lisata also has clinical development programs based on its autologous CD34+ cell therapy technology platform.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience across a variety of therapeutic categories and at all stages of development from preclinical through to product registration and launch. Its goal is to develop and commercialize products that address important unmet medical needs based on a broad and versatile portfolio of candidates. The Company&#8217;s current product candidates include: </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">LSTA1, the subject of phase 1b/2a and 2b clinical studies being conducted globally in a variety of solid tumor types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a variety of anti-cancer regimens;</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (LSTA16 formerly CLBS16), the subject of both a completed positive Phase 2a study (ESCaPE-CMD) and follow on Phase 2b study (FREEDOM Trial) in the United States for the treatment of coronary microvascular dysfunction (&#8220;CMD&#8221;); </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (LSTA12 formerly CLBS12), recipient of SAKIGAKE designation, pursuant to which early conditional approval in Japan for the treatment of critical limb ischemia (&#8220;CLI&#8221;) and Buerger&#8217;s disease is being sought based on the current results of a clinical trial executed in Japan. HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was the recipient of orphan drug designation in March 2021 from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for Buerger's disease; and</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">LSTA201 (formerly CLBS201), the subject of a study designed to assess the safety and efficacy of CD34+ cell therapy as a regenerative treatment for patients with chronic kidney disease related to type 2 diabetes (diabetic kidney disease or &#8220;DKD&#8221;).</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merger with Cend Therapeutics, Inc. and Name Change</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2022, the Company, then operating as Caladrius Biosciences, Inc. (&#8220;Caladrius"), completed its acquisition of Cend Therapeutics, Inc. (&#8220;Cend&#8221;), a Delaware corporation (the &#8220;Merger&#8221;), in accordance with the terms of the Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), dated as of April 26, 2022, by and among Caladrius, Cend and CS Cedar Merger Sub, Inc. (&#8220;Merger Sub&#8221;).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms set forth in the Merger Agreement and effective September 15, 2022 (the &#8220;Effective Time&#8221;): (i) Merger Sub merged with and into Cend, with Cend surviving as a wholly owned subsidiary of Caladrius, (ii) Caladrius changed its name to Lisata Therapeutics, Inc. in connection with and immediately following to the Effective Time, and (iii) Caladrius effected a 1:15 reverse stock split of its common stock (&#8220;Reverse Stock Split&#8221;) prior to the Effective Time. At the Effective Time, each share of Cend's common stock outstanding immediately prior to the Effective Time was converted into the right to receive shares of Lisata&#8217;s common stock based on an exchange ratio of 0.5338 (the &#8220;Exchange Ratio&#8221;), after taking into account the Reverse Stock Split. In connection with the Merger close, the Company issued an aggregate of 3,772,768 shares of common stock, based on the Exchange Ratio, to holders of Cend, in exchange for all of the Cend capital stock outstanding immediately prior to the closing of the Merger.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><ix:continuation id="i937c20d5b73e4c5f8f18ba7511107938" continuedAt="i9a7283f5186744c1b1cfd456fdd8aa4a"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Merger Agreement, Lisata assumed all of the outstanding and unexercised options to purchase shares of Cend capital stock under the 2016 Equity Incentive Plan (the &#8220;Cend Plan&#8221;), and, in connection with the Merger, such options were converted into options to purchase shares of Lisata&#8217;s common stock based on the Exchange Ratio. At the closing of the Merger at the Effective Time, the Company assumed Cend's stock options to purchase an aggregate of 1,227,776 shares of the Company's common stock. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caladrius was considered to be the accounting acquirer based on the terms of the Merger Agreement and certain factors including: (i) Caladrius owned approximately 52% of the Company's outstanding shares of common stock immediately following the close of the Merger; (ii) although both entities contributed to the new management team of Lisata, the Caladrius team has more individuals on the management team and will hold the CEO, CMO and other senior management roles; (iii) Caladrius paid a premium to acquire Cend&#8217;s assets; and (iv) Caladrius was significantly larger than Cend regarding total assets, operations, and research and development activities. The Merger was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (&#8220;IPR&amp;D&#8221;). Cend&#8217;s assets (except for cash and working capital) were measured and recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated with IPR&amp;D with no alternative future use being expensed as reported in the consolidated statement of operations. The prior reported operating results prior to the Merger close are those of Caladrius alone.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coronavirus Considerations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In December 2019, a novel strain of coronavirus (SARS-CoV-2), which causes COVID-19, was reported to have surfaced in China. In March 2020, the World Health Organization declared the outbreak of COVID-19 to be a pandemic, and the world's economies began to experience pronounced effects. Despite the FDA approval of multiple COVID-19 vaccines in late 2020, there remains uncertainty around the extent and duration of disruption and any future related financial impact cannot reasonably be estimated at this time. In response to the COVID-19 pandemic, the Company implemented a universal work from home policy as well as stringent social distancing and other hygiene policies for employees when they must be in the office. The Company's clinical study of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan experienced significant delays in enrollment due to the States of Emergency in effect in Japan for most of 2020, 2021, and 2022 covering Tokyo and other regions in response to an increased number of COVID-19 infections. With the Company's expectation that COVID-19 in Japan will continue to impact negatively clinical site operations and enrollment of patients in the HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical trial, it elected to suspend trial enrollment, seek a development partner and consult with the Japanese regulatory authorities regarding the submission of patient data already accrued. Caladrius' phase 2b FREEDOM Trial of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. has also experienced delays in enrolling patients as a result of COVID-19. While early enrollment proceeded to plan with the first patient treated in January 2021, the impact of the COVID-19 pandemic contributed to a general slowing of enrollment, including supply chain disruptions affecting the availability of qualified catheters used in the diagnosis of CMD and/or administration of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as with a contrast agent typically used in many catheter laboratories. In May 2022, the Company announced that enrollment in the FREEDOM Trial had been suspended and that it intended to conduct an interim analysis of the data from not less than the first 20 patients enrolled using the 6-month follow-up data to evaluate the efficacy and safety of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in subjects with CMD. Following the analysis of results of the FREEDOM Trial subjects completing 6-month follow-up along with Key Opinion Leaders&#8217; input, the Company&#8217;s board of directors determined that execution of a redesigned FREEDOM-like trial would be the appropriate next step, but the cost of such a trial would be prohibitively expensive to undergo without a strategic partner. Accordingly, the Company&#8217;s board of directors concluded that XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> development will only be continued if a strategic partner that can contribute the necessary capital for a redesigned trial is identified and secured. There can be no assurance that we will be able to identify such a partner and enter into an agreement with such partner on acceptable terms or at all.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 14, 2022, in connection with the Merger, the Company implemented the Reverse Stock Split, as authorized at the annual meeting of stockholders on September 13, 2022. The Reverse Stock Split became effective on September 14, 2022 at 5:00 pm and the Company's common stock began trading on The Nasdaq Capital Market on a post-split basis at the open of business on September 15, 2022. As of September 14, 2022, every fifteen shares of the Company&#8217;s issued and outstanding common stock (and such shares held in treasury) were automatically converted into one share of common stock, without any change in the par value per share. In addition, proportionate adjustments were made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options, stock appreciation rights, convertible notes and warrants to purchase shares of common stock, the number of shares issuable upon the vesting of all restricted stock awards, and the number of shares of common stock reserved for issuance pursuant to the Company&#8217;s equity incentive compensation plans. Any stockholder who would otherwise be entitled to a fractional share of common stock created as a result of the Reverse Stock Split received a cash payment equal to the product of such resulting fractional interest in one share of common stock multiplied by the closing trading price of the common stock on September 15, 2022. The Reverse Stock Split was effectuated in order to </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><ix:continuation id="i9a7283f5186744c1b1cfd456fdd8aa4a"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase the per share trading price of our common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods presented to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from &#8220;common stock&#8221; to &#8220;additional paid-in capital&#8221; in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.</span></div><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8zNC9mcmFnOjBkYzk4ZTljODdlZDQ0OTNhNTk1NjVkNjc2YjJlZmQ3L3RleHRyZWdpb246MGRjOThlOWM4N2VkNDQ5M2E1OTU2NWQ2NzZiMmVmZDdfMTk4MjQ_3c02d9e3-0f73-4e32-aaff-20fc67fb422f" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of September&#160;30, 2022, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2021 and 2020 included in our 2021 Form 10-K. Operating results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8zNC9mcmFnOjBkYzk4ZTljODdlZDQ0OTNhNTk1NjVkNjc2YjJlZmQ3L3RleHRyZWdpb246MGRjOThlOWM4N2VkNDQ5M2E1OTU2NWQ2NzZiMmVmZDdfMTk4MjU_0d0aa015-3f18-485a-8ad9-cf1f703b9935" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values and the valuation of the Merger which was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (&#8220;IPR&amp;D&#8221;). Accordingly, actual results could differ from those estimates and assumptions.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8zNC9mcmFnOjBkYzk4ZTljODdlZDQ0OTNhNTk1NjVkNjc2YjJlZmQ3L3RleHRyZWdpb246MGRjOThlOWM4N2VkNDQ5M2E1OTU2NWQ2NzZiMmVmZDdfMTk4MTg_b155d972-7f1c-4683-8516-a13836ab3d99" continuedAt="ia9b2aef69bd84d42918b833dc4ca8f96" escape="true">Principles of Consolidation</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia9b2aef69bd84d42918b833dc4ca8f96">The Consolidated Financial Statements include the accounts of Lisata and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation</ix:continuation>.</span></div><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8zNC9mcmFnOjBkYzk4ZTljODdlZDQ0OTNhNTk1NjVkNjc2YjJlZmQ3L3RleHRyZWdpb246MGRjOThlOWM4N2VkNDQ5M2E1OTU2NWQ2NzZiMmVmZDdfNTQ5NzU1ODIzMTExMg_640b54c7-f05a-4eb3-9cdc-93e4d8107aee" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Remeasurement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is the U.S. Dollar. The functional currency of DrugCendR Australia PTY Ltd. which is a foreign subsidiary of the Company is the Australian Dollar. The assets and liabilities of DrugCendR Australia PTY Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_37"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 2 &#8211; <ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8zNy9mcmFnOjIyMTc1Zjg5MDIwMjQwZTU5NTQxNGY2MjAxMTgyNzg5L3RleHRyZWdpb246MjIxNzVmODkwMjAyNDBlNTk1NDE0ZjYyMDExODI3ODlfMzE4OQ_93612445-82c8-4d07-b092-b7efacccadab" continuedAt="ib7c8a83b7e124df8896fc662ad3cbcfb" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ib7c8a83b7e124df8896fc662ad3cbcfb" continuedAt="ica872bf2f255429d9469dfa5e95f06f5"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased. </span></div><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8zNy9mcmFnOjIyMTc1Zjg5MDIwMjQwZTU5NTQxNGY2MjAxMTgyNzg5L3RleHRyZWdpb246MjIxNzVmODkwMjAyNDBlNTk1NDE0ZjYyMDExODI3ODlfNTQ5NzU1ODE2OTk2MA_405f593e-08b7-4bb3-998b-688f3a8bda69" continuedAt="i9856cd057bda4a2480b48c121bfe5c2e" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and Australia.  Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><ix:continuation id="ica872bf2f255429d9469dfa5e95f06f5" continuedAt="i024d8345d27d4964828fce0f85118082"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9856cd057bda4a2480b48c121bfe5c2e">of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</ix:continuation></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property and equipment are as follows:</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of lease</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment and intangibles. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company&#8217;s restricted stock and restricted stock units is based on the closing market price of the Company&#8217;s common stock on the date of grant. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><ix:continuation id="i024d8345d27d4964828fce0f85118082" continuedAt="i9992e291ccc04950acbba1d74329bfa2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (&#8220;R&amp;D&#8221;) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further drive the Company&#8217;s initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company&#8217;s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.</span></div><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8zNy9mcmFnOjIyMTc1Zjg5MDIwMjQwZTU5NTQxNGY2MjAxMTgyNzg5L3RleHRyZWdpb246MjIxNzVmODkwMjAyNDBlNTk1NDE0ZjYyMDExODI3ODlfMzE5Mw_3052cc8d-b8fd-4ae5-8532-2975832f2e6f" continuedAt="i87e764dc39874726a496191de17e9619" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-process Research and Development Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#8220;business&#8221; as defined under GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Asset</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible asset consists of a single asset, Cend&#8217;s license agreement with Qilu Pharmaceutical, Co., Ltd. (&#8220;Qilu&#8221;) acquired in the Merger, with a value of $0.4&#160;million. The intangible asset is stated at fair value and is amortized using the straight-line method over its estimated useful life of 5 years. Amortization expense was $3 thousand for the three and nine months ended September&#160;30, 2022. The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable.  The projected amortization expense is $71 thousand per year for the next five years. </span></div><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8zNy9mcmFnOjIyMTc1Zjg5MDIwMjQwZTU5NTQxNGY2MjAxMTgyNzg5L3RleHRyZWdpb246MjIxNzVmODkwMjAyNDBlNTk1NDE0ZjYyMDExODI3ODlfNTQ5NzU1ODE2OTk1OA_1803c03d-2c2c-4890-98f7-f59b4de49359" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. There was no revenue recognized for the three and nine months ended September&#160;30, 2022.</span></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><ix:continuation id="i9992e291ccc04950acbba1d74329bfa2"><ix:continuation id="i87e764dc39874726a496191de17e9619"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestones</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company&#8217;s collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company&#8217;s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.</span></div></ix:continuation></ix:continuation><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_981"></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 3 &#8211; <ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90ZXh0cmVnaW9uOjk4MmNjYWFmYjM2YzQ3NzNhN2VkZmMwZmY5OGFmODMwXzU0OTc1NTgxNDg4OA_b47298c4-1400-40a1-8631-b07879810521" continuedAt="i2bf865b36bb344efbd7816c3a294bfb0" escape="true">Merger</ix:nonNumeric></span></div><ix:continuation id="i2bf865b36bb344efbd7816c3a294bfb0"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger was accounted for as an asset acquisition as substantially all of the fair value was concentrated in IPR&amp;D. Cend&#8217;s assets (except for cash and working capital) were measured and recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated with IPR&amp;D being expensed. The fair value of total consideration was $<ix:nonFraction unitRef="usd" contextRef="i59aeca5b7a5446ed90ba736d79d9d4f4_I20220930" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90ZXh0cmVnaW9uOjk4MmNjYWFmYjM2YzQ3NzNhN2VkZmMwZmY5OGFmODMwXzU0OTc1NTgxNDAwNzE_24f5955e-4161-49fc-9c11-fd413ed30282">36.1</ix:nonFraction>&#160;million. The following table is a summary of the purchase price calculation (in thousands except per share data).</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of common shares of the combined company owned by Cend stockholders</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iac286da95e1c493abbddee71f1aac890_I20220914" decimals="0" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90YWJsZTplYjE5N2UzMDIwYzY0MjQ1OTY5YzM5NjFjYzdkNjc1OS90YWJsZXJhbmdlOmViMTk3ZTMwMjBjNjQyNDU5NjljMzk2MWNjN2Q2NzU5XzMtMS0xLTEtMjc0Mzk_a3a5ee75-71e2-4b51-acf5-253444d56d98">3,772,768</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multiplied by the fair value per share of Lisata common stock on September 15, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i59aeca5b7a5446ed90ba736d79d9d4f4_I20220930" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90YWJsZTplYjE5N2UzMDIwYzY0MjQ1OTY5YzM5NjFjYzdkNjc1OS90YWJsZXJhbmdlOmViMTk3ZTMwMjBjNjQyNDU5NjljMzk2MWNjN2Q2NzU5XzQtMS0xLTEtMjc0Mzk_15e7a7e9-7597-4899-a329-28ab5e6e00cf">6.25</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i59aeca5b7a5446ed90ba736d79d9d4f4_I20220930" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90YWJsZTplYjE5N2UzMDIwYzY0MjQ1OTY5YzM5NjFjYzdkNjc1OS90YWJsZXJhbmdlOmViMTk3ZTMwMjBjNjQyNDU5NjljMzk2MWNjN2Q2NzU5XzUtMS0xLTEtMjc0Mzk_2a2ab5d1-8cca-4df6-bdba-0d1a099c9d25">23,580</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of Lisata's cost method investment in Cend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59aeca5b7a5446ed90ba736d79d9d4f4_I20220930" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90YWJsZTplYjE5N2UzMDIwYzY0MjQ1OTY5YzM5NjFjYzdkNjc1OS90YWJsZXJhbmdlOmViMTk3ZTMwMjBjNjQyNDU5NjljMzk2MWNjN2Q2NzU5XzYtMS0xLTEtMjc0Mzk_7a886845-af74-48ef-ac53-d7273a65dbf2">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental fair value of Cend's fully vested stock options</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia46e584dcd2741798d67f30f0cfd9c15_D20220101-20220930" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90YWJsZTplYjE5N2UzMDIwYzY0MjQ1OTY5YzM5NjFjYzdkNjc1OS90YWJsZXJhbmdlOmViMTk3ZTMwMjBjNjQyNDU5NjljMzk2MWNjN2Q2NzU5XzgtMS0xLTEtMjc0NjQ_9cead5d8-48f8-481b-8767-e2709c8b27bb">2,136</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lisata transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia46e584dcd2741798d67f30f0cfd9c15_D20220101-20220930" decimals="-3" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90YWJsZTplYjE5N2UzMDIwYzY0MjQ1OTY5YzM5NjFjYzdkNjc1OS90YWJsZXJhbmdlOmViMTk3ZTMwMjBjNjQyNDU5NjljMzk2MWNjN2Q2NzU5XzktMS0xLTEtMjc0NjQ_9c85344e-44f1-43de-b174-087781a8de46">382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price</span></td><td colspan="3" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i59aeca5b7a5446ed90ba736d79d9d4f4_I20220930" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90YWJsZTplYjE5N2UzMDIwYzY0MjQ1OTY5YzM5NjFjYzdkNjc1OS90YWJsZXJhbmdlOmViMTk3ZTMwMjBjNjQyNDU5NjljMzk2MWNjN2Q2NzU5XzEwLTEtMS0xLTI3NDY0_1230beba-7f21-4045-937d-b237bd7c62ea"><ix:nonFraction unitRef="usd" contextRef="i59aeca5b7a5446ed90ba736d79d9d4f4_I20220930" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90YWJsZTplYjE5N2UzMDIwYzY0MjQ1OTY5YzM5NjFjYzdkNjc1OS90YWJsZXJhbmdlOmViMTk3ZTMwMjBjNjQyNDU5NjljMzk2MWNjN2Q2NzU5XzEwLTEtMS0xLTI3NDY0_1778e641-0bff-4e2e-af78-0e709a7f374e">36,098</ix:nonFraction></ix:nonFraction></span></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The allocation of the purchase price was as follows (amounts in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i59aeca5b7a5446ed90ba736d79d9d4f4_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90YWJsZTozZTA4MDNjYzlkNTA0ODIzOGQ3YmIyM2I3ZWE3ZGI2ZS90YWJsZXJhbmdlOjNlMDgwM2NjOWQ1MDQ4MjM4ZDdiYjIzYjdlYTdkYjZlXzQtMS0xLTEtMjc1MTc_72155266-1df6-4bed-870a-0c30b8cca54d">7,062</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net working capital (excluding cash)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59aeca5b7a5446ed90ba736d79d9d4f4_I20220930" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90YWJsZTozZTA4MDNjYzlkNTA0ODIzOGQ3YmIyM2I3ZWE3ZGI2ZS90YWJsZXJhbmdlOjNlMDgwM2NjOWQ1MDQ4MjM4ZDdiYjIzYjdlYTdkYjZlXzUtMS0xLTEtMjc1MTc_035112c0-13d2-4b1a-a354-e5215791c996">1,690</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59aeca5b7a5446ed90ba736d79d9d4f4_I20220930" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90YWJsZTozZTA4MDNjYzlkNTA0ODIzOGQ3YmIyM2I3ZWE3ZGI2ZS90YWJsZXJhbmdlOjNlMDgwM2NjOWQ1MDQ4MjM4ZDdiYjIzYjdlYTdkYjZlXzYtMS0xLTEtMjc1MTc_b065ff63-0d33-4614-b3bb-f1e202748cf6">22</ix:nonFraction>)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59aeca5b7a5446ed90ba736d79d9d4f4_I20220930" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90YWJsZTozZTA4MDNjYzlkNTA0ODIzOGQ3YmIyM2I3ZWE3ZGI2ZS90YWJsZXJhbmdlOjNlMDgwM2NjOWQ1MDQ4MjM4ZDdiYjIzYjdlYTdkYjZlXzctMS0xLTEtMjc1MTc_4f91341f-abd2-4074-9564-06e6ee9ac85b">30,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia46e584dcd2741798d67f30f0cfd9c15_D20220101-20220930" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90YWJsZTozZTA4MDNjYzlkNTA0ODIzOGQ3YmIyM2I3ZWE3ZGI2ZS90YWJsZXJhbmdlOjNlMDgwM2NjOWQ1MDQ4MjM4ZDdiYjIzYjdlYTdkYjZlXzgtMS0xLTEtMjc1MTc_b6f3881a-3ec6-4384-8a0c-16d0d0eb5f96">355</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i59aeca5b7a5446ed90ba736d79d9d4f4_I20220930" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90YWJsZTozZTA4MDNjYzlkNTA0ODIzOGQ3YmIyM2I3ZWE3ZGI2ZS90YWJsZXJhbmdlOjNlMDgwM2NjOWQ1MDQ4MjM4ZDdiYjIzYjdlYTdkYjZlXzEwLTEtMS0xLTI3NTE3_815f70ec-d9b7-40ec-80df-8b918d383564">36,098</ix:nonFraction></span></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16 </span></div></div></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 4 &#8211; <ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RleHRyZWdpb246Zjc3NmYzODJlZDFlNDJiMGFlMDFkZmQxMzk2OWExNDFfNjI3_b9310997-34d5-4069-9b4e-8000afb27bd5" continuedAt="i2aaa34d9a0ab49cd89ccb20353ace295" escape="true">Available-for-Sale-Securities</ix:nonNumeric></span></div><ix:continuation id="i2aaa34d9a0ab49cd89ccb20353ace295"><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RleHRyZWdpb246Zjc3NmYzODJlZDFlNDJiMGFlMDFkZmQxMzk2OWExNDFfNjIy_2326b578-26ff-4681-ad03-f84d4575b756" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"><tr><td style="width:1.0pt"></td><td style="width:94.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d567e0b72224eb89e01194dfcc635c5_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfMy0xLTEtMS0yMjg1OA_fb2d3c18-c5f0-4764-b2ec-9c5a3d7c452d">39,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d567e0b72224eb89e01194dfcc635c5_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfMy0zLTEtMS0yMjg1OA_8a11404a-3651-47f1-a3b0-5c264eddf081">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d567e0b72224eb89e01194dfcc635c5_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfMy01LTEtMS0yMjg1OA_691b78ba-8a4d-4cba-a50e-1983ae42118c">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d567e0b72224eb89e01194dfcc635c5_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfMy03LTEtMS0yMjg1OA_b88c15c4-51ab-4a5e-8777-153d3da0782a">39,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i098bf094035d44e2af451fa66daf6448_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfMy05LTEtMS0yMjg1OA_b72d7775-92cb-4331-92be-f1a6f8e2ea34">53,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i098bf094035d44e2af451fa66daf6448_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfMy0xMS0xLTEtMjI4NTg_da9b98e5-9a65-402b-abd5-08a55f91563e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i098bf094035d44e2af451fa66daf6448_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfMy0xMy0xLTEtMjI4NTg_8a232ffe-49dc-436d-a6de-c6a9341e084c">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i098bf094035d44e2af451fa66daf6448_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfMy0xNS0xLTEtMjI4NTg_6ab77659-2bc4-4192-9b38-1d39bf9ef65b">53,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57b538ea7c44400bad5071a7a6c98c1d_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNC0xLTEtMS0yMjg1OA_fdc01db1-a8c2-432d-9290-8624d6031bc3">14,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57b538ea7c44400bad5071a7a6c98c1d_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNC0zLTEtMS0yMjg1OA_adb045d1-0b1b-43af-ad4c-38595ca4a9e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57b538ea7c44400bad5071a7a6c98c1d_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNC01LTEtMS0yMjg1OA_29b2eab7-1443-4ce4-b6f2-0b2369f3f76b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57b538ea7c44400bad5071a7a6c98c1d_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNC03LTEtMS0yMjg1OA_fbd79627-f2a9-461c-a715-f59be6251204">14,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie90154aebcd24967a0f809ea3f40f699_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNC05LTEtMS0yMjg1OA_2227036a-f80e-409b-adbe-8a454c5c4ef8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie90154aebcd24967a0f809ea3f40f699_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNC0xMS0xLTEtMjI4NTg_50b3188b-109b-4779-a429-36bb53b63613">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie90154aebcd24967a0f809ea3f40f699_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNC0xMy0xLTEtMjI4NTg_194a19e3-cdc9-4b40-a23e-56f8a0367650">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie90154aebcd24967a0f809ea3f40f699_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNC0xNS0xLTEtMjI4NTg_c34b6e32-8378-48eb-8331-2692cc760fee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd0667d730324d439adcd5260c8be67a_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNS0xLTEtMS0yMjg1OA_83272426-4dd2-4bcc-a820-797f25c6df74">13,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd0667d730324d439adcd5260c8be67a_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNS0zLTEtMS0yMjg1OA_2957e992-7848-4bac-944d-1624beab8038">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd0667d730324d439adcd5260c8be67a_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNS01LTEtMS0yMjg1OA_0414a021-41a4-4eae-9a6d-2904f0cdffb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd0667d730324d439adcd5260c8be67a_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNS03LTEtMS0yMjg1OA_72d16e6c-dd93-483f-9eae-5892b24f6f7a">13,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2502dcdd9a7b46ccb98d0960950fb9ae_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNS05LTEtMS0yMjg1OA_fa9651fb-3d62-40ed-962a-496fceabc068">18,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2502dcdd9a7b46ccb98d0960950fb9ae_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNS0xMS0xLTEtMjI4NTg_658c507d-6fa9-453b-9939-0d71843c54f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2502dcdd9a7b46ccb98d0960950fb9ae_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNS0xMy0xLTEtMjI4NTg_b307b1aa-cf0a-4656-9d50-cf254cd7b2f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2502dcdd9a7b46ccb98d0960950fb9ae_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNS0xNS0xLTEtMjI4NTg_6d032aa5-0fc9-437e-b77f-f55e1b6f78ca">18,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie80e4088fafa43969d532971e7a875dc_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNi0xLTEtMS0yMjg1OA_47ecdde0-a70a-4e2c-b339-2aaeb5860b41">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie80e4088fafa43969d532971e7a875dc_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNi0zLTEtMS0yMjg1OA_8a3b70bb-b456-40a6-82a6-3571cb5f7b19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie80e4088fafa43969d532971e7a875dc_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNi01LTEtMS0yMjg1OA_c7c67a1e-0eca-47bd-83b4-89d2899b37b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie80e4088fafa43969d532971e7a875dc_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNi03LTEtMS0yMjg1OA_d84f2667-dfb7-4222-858a-020140d63636">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09c4e12405dd4187a733724a3dd4b1c8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNi05LTEtMS0yMjg1OA_1f8a490e-5a00-4304-8696-d7db0a060b0f">20,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09c4e12405dd4187a733724a3dd4b1c8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNi0xMS0xLTEtMjI4NTg_68ff3676-23f9-4178-950f-b43d39474026">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09c4e12405dd4187a733724a3dd4b1c8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNi0xMy0xLTEtMjI4NTg_fcafe892-9632-40aa-b88c-9a92f43c26af">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09c4e12405dd4187a733724a3dd4b1c8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNi0xNS0xLTEtMjI4NTg_164daa83-9331-4d9f-a393-e23d2dff55ad">20,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfOC0xLTEtMS0yMjg1OA_73d6b041-66e0-4d85-b7ac-357563a4d868">67,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfOC0zLTEtMS0yMjg1OA_cb7948da-97b0-4e6e-aca3-8b16a09ab398">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfOC01LTEtMS0yMjg1OA_fae0bf85-e1b8-4e3b-84b3-9c139434c7d5">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfOC03LTEtMS0yMjg1OA_daceb9cf-fe6a-405e-af18-0e2582422aa7">67,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfOC05LTEtMS0yMjg1OA_88b10d43-1818-4ceb-a92c-0f1fbb5e4a63">91,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfOC0xMS0xLTEtMjI4NTg_d5a0622a-2682-4205-9bbc-97a56779ee69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfOC0xMy0xLTEtMjI4NTg_32f3a154-2243-4e40-a2f4-bd1c9b126411">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfOC0xNS0xLTEtMjI4NTg_3149e09f-812a-45ca-a982-8f5a02a04ee4">91,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RleHRyZWdpb246Zjc3NmYzODJlZDFlNDJiMGFlMDFkZmQxMzk2OWExNDFfNjM1_9b79947a-dfc1-489d-86cb-baebf4ffcd55" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:360.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOjA0NDMwN2VhNTc4MTRkMGE5MzBhYTVlODg3ZWMzNDYwL3RhYmxlcmFuZ2U6MDQ0MzA3ZWE1NzgxNGQwYTkzMGFhNWU4ODdlYzM0NjBfMS0xLTEtMS0yMjg1OA_a00ae2c6-19e6-4f11-8baa-10b5935c6f0b">23,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOjA0NDMwN2VhNTc4MTRkMGE5MzBhYTVlODg3ZWMzNDYwL3RhYmxlcmFuZ2U6MDQ0MzA3ZWE1NzgxNGQwYTkzMGFhNWU4ODdlYzM0NjBfMS0zLTEtMS0yMjg1OA_5828d859-d03f-440f-9f65-f56be3740316">21,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOjA0NDMwN2VhNTc4MTRkMGE5MzBhYTVlODg3ZWMzNDYwL3RhYmxlcmFuZ2U6MDQ0MzA3ZWE1NzgxNGQwYTkzMGFhNWU4ODdlYzM0NjBfMi0xLTEtMS0yMjg1OA_7930ccde-a133-42d2-b3e4-ca71474301bc">44,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOjA0NDMwN2VhNTc4MTRkMGE5MzBhYTVlODg3ZWMzNDYwL3RhYmxlcmFuZ2U6MDQ0MzA3ZWE1NzgxNGQwYTkzMGFhNWU4ODdlYzM0NjBfMi0zLTEtMS0yMjg1OA_63ac805b-34b5-4179-ae96-653b1c32d134">70,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOjA0NDMwN2VhNTc4MTRkMGE5MzBhYTVlODg3ZWMzNDYwL3RhYmxlcmFuZ2U6MDQ0MzA3ZWE1NzgxNGQwYTkzMGFhNWU4ODdlYzM0NjBfMy0xLTEtMS0yMjg1OA_62e36d16-daf4-4c24-ab0b-acde4b44c730">67,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOjA0NDMwN2VhNTc4MTRkMGE5MzBhYTVlODg3ZWMzNDYwL3RhYmxlcmFuZ2U6MDQ0MzA3ZWE1NzgxNGQwYTkzMGFhNWU4ODdlYzM0NjBfMy0zLTEtMS0yMjg1OA_6eea9530-c081-43ea-95dd-d6300ac4aaad">91,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RleHRyZWdpb246Zjc3NmYzODJlZDFlNDJiMGFlMDFkZmQxMzk2OWExNDFfNjM4_bc682c15-af83-4dfd-9357-2c6c6ce68e69" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:361.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:70.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOjg4NGUxZmNmYTkzNjRmZTc5MmViZDg4NDdhOWMyZTdjL3RhYmxlcmFuZ2U6ODg0ZTFmY2ZhOTM2NGZlNzkyZWJkODg0N2E5YzJlN2NfMi0xLTEtMS0yMjg1OA_3ff8b98a-baa9-467f-b380-b6f80a3cc6df">67,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOjg4NGUxZmNmYTkzNjRmZTc5MmViZDg4NDdhOWMyZTdjL3RhYmxlcmFuZ2U6ODg0ZTFmY2ZhOTM2NGZlNzkyZWJkODg0N2E5YzJlN2NfMi0zLTEtMS0yMjg1OA_64cccf75-87fb-47c2-8e35-a1018b68b235">67,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOjg4NGUxZmNmYTkzNjRmZTc5MmViZDg4NDdhOWMyZTdjL3RhYmxlcmFuZ2U6ODg0ZTFmY2ZhOTM2NGZlNzkyZWJkODg0N2E5YzJlN2NfMy0xLTEtMS0yMjg1OA_d4755ce3-c136-4e7d-9c9f-78f5a4a6fa3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOjg4NGUxZmNmYTkzNjRmZTc5MmViZDg4NDdhOWMyZTdjL3RhYmxlcmFuZ2U6ODg0ZTFmY2ZhOTM2NGZlNzkyZWJkODg0N2E5YzJlN2NfMy0zLTEtMS0yMjg1OA_1cc9ec1e-1da0-4798-b2da-b1c0be805d32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOjg4NGUxZmNmYTkzNjRmZTc5MmViZDg4NDdhOWMyZTdjL3RhYmxlcmFuZ2U6ODg0ZTFmY2ZhOTM2NGZlNzkyZWJkODg0N2E5YzJlN2NfNC0xLTEtMS0yMjg1OA_ad02eddc-e693-41b0-a73b-3a4a5bca3278">67,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOjg4NGUxZmNmYTkzNjRmZTc5MmViZDg4NDdhOWMyZTdjL3RhYmxlcmFuZ2U6ODg0ZTFmY2ZhOTM2NGZlNzkyZWJkODg0N2E5YzJlN2NfNC0zLTEtMS0yMjg1OA_570128eb-7470-45a6-80ee-91a9ede7438e">67,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_46"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 5 &#8211; <ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80Ni9mcmFnOmNhYTNmODFmNDZmZTQ1MzNhNGQyM2Y4MjNhM2VjMjAwL3RleHRyZWdpb246Y2FhM2Y4MWY0NmZlNDUzM2E0ZDIzZjgyM2EzZWMyMDBfMzE5_1658d64b-c3fe-4f71-b624-73f3c09011c7" continuedAt="ibd2ac8b8acca49e3b634add4e545d0a7" escape="true">Income (Loss) Per Share</ix:nonNumeric></span></div><ix:continuation id="ibd2ac8b8acca49e3b634add4e545d0a7"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September&#160;30, 2022 and 2021, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive. <ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80Ni9mcmFnOmNhYTNmODFmNDZmZTQ1MzNhNGQyM2Y4MjNhM2VjMjAwL3RleHRyZWdpb246Y2FhM2Y4MWY0NmZlNDUzM2E0ZDIzZjgyM2EzZWMyMDBfMzM2_d66f018f-fa7b-435f-87d8-d92439ff7419" continuedAt="ice8e196e7a38412baa8661f6f5d7f2d0" escape="true">At September&#160;30, 2022 and 2021, the Company excluded the following potentially dilutive securities (in thousands):</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="ice8e196e7a38412baa8661f6f5d7f2d0"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33f0a817fe2049da85aa3551a5c905e4_D20220101-20220930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80Ni9mcmFnOmNhYTNmODFmNDZmZTQ1MzNhNGQyM2Y4MjNhM2VjMjAwL3RhYmxlOmQzY2NmNjg3YzVkNDRlYWNhY2QwOTAxMzBmMmM2ZWRlL3RhYmxlcmFuZ2U6ZDNjY2Y2ODdjNWQ0NGVhY2FjZDA5MDEzMGYyYzZlZGVfMi0xLTEtMS0yMjg1OA_96458680-f7e2-4469-8d99-80741c257f8b">1,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e0d719ce9044ab281734908fb138fe4_D20210101-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80Ni9mcmFnOmNhYTNmODFmNDZmZTQ1MzNhNGQyM2Y4MjNhM2VjMjAwL3RhYmxlOmQzY2NmNjg3YzVkNDRlYWNhY2QwOTAxMzBmMmM2ZWRlL3RhYmxlcmFuZ2U6ZDNjY2Y2ODdjNWQ0NGVhY2FjZDA5MDEzMGYyYzZlZGVfMi0zLTEtMS0yMjg1OA_266c3528-a23f-4fbc-afa7-a89c0b07f31a">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i422414ad4ec143fe9c83f80484b18850_D20220101-20220930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80Ni9mcmFnOmNhYTNmODFmNDZmZTQ1MzNhNGQyM2Y4MjNhM2VjMjAwL3RhYmxlOmQzY2NmNjg3YzVkNDRlYWNhY2QwOTAxMzBmMmM2ZWRlL3RhYmxlcmFuZ2U6ZDNjY2Y2ODdjNWQ0NGVhY2FjZDA5MDEzMGYyYzZlZGVfMy0xLTEtMS0yMjg1OA_d9198294-c5d2-47f7-bca2-fc47c0060c64">1,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i972cd99d76534d3cb8f6e561e629dc10_D20210101-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80Ni9mcmFnOmNhYTNmODFmNDZmZTQ1MzNhNGQyM2Y4MjNhM2VjMjAwL3RhYmxlOmQzY2NmNjg3YzVkNDRlYWNhY2QwOTAxMzBmMmM2ZWRlL3RhYmxlcmFuZ2U6ZDNjY2Y2ODdjNWQ0NGVhY2FjZDA5MDEzMGYyYzZlZGVfMy0zLTEtMS0yMjg1OA_e3840494-4af1-41d4-84e2-47db2954202e">1,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i161cdf72d862420686200bfdd753f6d7_D20220101-20220930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80Ni9mcmFnOmNhYTNmODFmNDZmZTQ1MzNhNGQyM2Y4MjNhM2VjMjAwL3RhYmxlOmQzY2NmNjg3YzVkNDRlYWNhY2QwOTAxMzBmMmM2ZWRlL3RhYmxlcmFuZ2U6ZDNjY2Y2ODdjNWQ0NGVhY2FjZDA5MDEzMGYyYzZlZGVfNS0xLTEtMS0yMjg1OA_ac7a416e-5325-41c3-926e-456a2deb5c23">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifccd968d78a3473898c3258429a71f76_D20210101-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80Ni9mcmFnOmNhYTNmODFmNDZmZTQ1MzNhNGQyM2Y4MjNhM2VjMjAwL3RhYmxlOmQzY2NmNjg3YzVkNDRlYWNhY2QwOTAxMzBmMmM2ZWRlL3RhYmxlcmFuZ2U6ZDNjY2Y2ODdjNWQ0NGVhY2FjZDA5MDEzMGYyYzZlZGVfNS0zLTEtMS0yMjg1OA_facb7368-f9d5-4124-9fbd-30cfa686efb0">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_49"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 6 &#8211; <ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RleHRyZWdpb246NTM0ZWJlNjRlOTk0NDBkMTg5YmU5ZjNjOWY3YmYyMjVfMTQ3MA_34fd32b0-baf4-40e5-a59d-a2acff74627b" continuedAt="ibf6b0f0a485d48ecb77a613afed3137f" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="ibf6b0f0a485d48ecb77a613afed3137f" continuedAt="i0539131031bd49b289a22b99e7e6b620"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><ix:continuation id="i0539131031bd49b289a22b99e7e6b620"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.</span></div><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RleHRyZWdpb246NTM0ZWJlNjRlOTk0NDBkMTg5YmU5ZjNjOWY3YmYyMjVfMTQ3Mw_ee024a13-6685-4c41-bef5-a525fb20b0a0" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth by level within the fair value hierarchy the Company's financial assets that were accounted for at fair value on a recurring basis as of September&#160;30, 2022 and December&#160;31, 2021 (in thousands).</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:116.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities - available for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48063441de8a46dc974334dbf9a3a293_I20220930" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfMy0yLTEtMS0yMjg1OA_321471fc-bad3-4cd6-8d4f-493b5564d258">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7348558529cf46d2959b0b4229242404_I20220930" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfMy00LTEtMS0yMjg1OA_0b2de1b0-e477-46a2-bb95-7c8cf630c168">44,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a76766f174f4c3b84f09f885f2170c6_I20220930" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfMy02LTEtMS0yMjg1OA_c8edbe3a-6aa8-4f1e-8846-998c8f1227e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib35c54c2e1b14397ae34101068f8d0a3_I20220930" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfMy04LTEtMS0yMjg1OA_8110c7ad-222f-4f8c-b567-07a2e7561c56">44,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f89ef4342fe4c27b982bc991aff78d8_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfMy0xMC0xLTEtMjI4NTg_b450b90e-b9d8-43c7-af42-ec51d4056e7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2404060e56d462683781d6a6eb5e03e_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfMy0xMi0xLTEtMjI4NTg_4411763e-cd00-4d8e-ba60-cbe4428bbc34">70,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03006f5a9605427eb1a8f9b1e13d1902_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfMy0xNC0xLTEtMjI4NTg_26187e07-cf87-42d9-a17b-2cadde6bac7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aa7a96703004d078dc7feb5458b2718_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfMy0xNi0xLTEtMjI4NTg_b686d104-b0e4-478c-8dca-5bd4f5351bad">70,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48063441de8a46dc974334dbf9a3a293_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfNS0yLTEtMS0yMjg1OA_c3c9b8ad-902d-40af-9f0a-60541a04660e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7348558529cf46d2959b0b4229242404_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfNS00LTEtMS0yMjg1OA_d593f6db-5fd4-4353-b508-673212ecd7b3">44,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a76766f174f4c3b84f09f885f2170c6_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfNS02LTEtMS0yMjg1OA_54980177-d5f6-4956-afe0-2117ef9f5247">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib35c54c2e1b14397ae34101068f8d0a3_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfNS04LTEtMS0yMjg1OA_92aba935-71fa-436a-85c4-b6da7ad73bbc">44,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f89ef4342fe4c27b982bc991aff78d8_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfNS0xMC0xLTEtMjI4NTg_f8407896-c207-453f-b297-c98bbb1000c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2404060e56d462683781d6a6eb5e03e_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfNS0xMi0xLTEtMjI4NTg_0e159fbb-b961-45d0-b84a-33c9e48dea68">70,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03006f5a9605427eb1a8f9b1e13d1902_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfNS0xNC0xLTEtMjI4NTg_71b295f0-759a-45b5-bf50-c6cf5b896f6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aa7a96703004d078dc7feb5458b2718_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfNS0xNi0xLTEtMjI4NTg_a96cf3d8-fbb2-4e0b-b321-04e17b1b0012">70,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_52"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 7&#160;&#8211;&#160;<ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81Mi9mcmFnOjc3NWQ4YzBmOTE4OTRlYWRhYjlhYWM1YjY1YzJjM2I2L3RleHRyZWdpb246Nzc1ZDhjMGY5MTg5NGVhZGFiOWFhYzViNjVjMmMzYjZfMTA4_0990548a-c4f1-4f65-8f60-7995cb087f8e" continuedAt="id1a0e7dbb5de4ec4bea5e3336d380386" escape="true">Accrued Liabilities</ix:nonNumeric></span></div><ix:continuation id="id1a0e7dbb5de4ec4bea5e3336d380386"><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81Mi9mcmFnOjc3NWQ4YzBmOTE4OTRlYWRhYjlhYWM1YjY1YzJjM2I2L3RleHRyZWdpb246Nzc1ZDhjMGY5MTg5NGVhZGFiOWFhYzViNjVjMmMzYjZfMTA2_0c0b8d26-6d15-439c-85e1-3e902535816a" escape="true"><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of September&#160;30, 2022 and December&#160;31, 2021 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"><tr><td style="width:1.0pt"></td><td style="width:313.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, employee benefits and related taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81Mi9mcmFnOjc3NWQ4YzBmOTE4OTRlYWRhYjlhYWM1YjY1YzJjM2I2L3RhYmxlOjAwM2IzNjkwNTNjYjQzOGI5NmZjOWQ4MGJlYzNkMmIxL3RhYmxlcmFuZ2U6MDAzYjM2OTA1M2NiNDM4Yjk2ZmM5ZDgwYmVjM2QyYjFfMS0xLTEtMS0yMjg1OA_b3cc5ce4-6e7f-403f-822d-5cc3095d87c1">2,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81Mi9mcmFnOjc3NWQ4YzBmOTE4OTRlYWRhYjlhYWM1YjY1YzJjM2I2L3RhYmxlOjAwM2IzNjkwNTNjYjQzOGI5NmZjOWQ4MGJlYzNkMmIxL3RhYmxlcmFuZ2U6MDAzYjM2OTA1M2NiNDM4Yjk2ZmM5ZDgwYmVjM2QyYjFfMS0zLTEtMS0yMjg1OA_8a66de97-22d5-4e5f-9f88-49b3872a9a8b">2,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities &#8212; current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81Mi9mcmFnOjc3NWQ4YzBmOTE4OTRlYWRhYjlhYWM1YjY1YzJjM2I2L3RhYmxlOjAwM2IzNjkwNTNjYjQzOGI5NmZjOWQ4MGJlYzNkMmIxL3RhYmxlcmFuZ2U6MDAzYjM2OTA1M2NiNDM4Yjk2ZmM5ZDgwYmVjM2QyYjFfMi0xLTEtMS0yMjg1OA_74764e98-7adb-43c5-b82e-4e07588f1229">203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81Mi9mcmFnOjc3NWQ4YzBmOTE4OTRlYWRhYjlhYWM1YjY1YzJjM2I2L3RhYmxlOjAwM2IzNjkwNTNjYjQzOGI5NmZjOWQ4MGJlYzNkMmIxL3RhYmxlcmFuZ2U6MDAzYjM2OTA1M2NiNDM4Yjk2ZmM5ZDgwYmVjM2QyYjFfMi0zLTEtMS0yMjg1OA_de35edb9-cca5-4b32-9601-91507ca71ff9">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and R&amp;D related liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="clbs:ClinicalAndRDRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81Mi9mcmFnOjc3NWQ4YzBmOTE4OTRlYWRhYjlhYWM1YjY1YzJjM2I2L3RhYmxlOjAwM2IzNjkwNTNjYjQzOGI5NmZjOWQ4MGJlYzNkMmIxL3RhYmxlcmFuZ2U6MDAzYjM2OTA1M2NiNDM4Yjk2ZmM5ZDgwYmVjM2QyYjFfNC0xLTEtMS0yOTI0Nw_caf584c2-fb8a-419d-a98a-946ef5807a5f">2,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="clbs:ClinicalAndRDRelatedLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81Mi9mcmFnOjc3NWQ4YzBmOTE4OTRlYWRhYjlhYWM1YjY1YzJjM2I2L3RhYmxlOjAwM2IzNjkwNTNjYjQzOGI5NmZjOWQ4MGJlYzNkMmIxL3RhYmxlcmFuZ2U6MDAzYjM2OTA1M2NiNDM4Yjk2ZmM5ZDgwYmVjM2QyYjFfNC0zLTEtMS0yOTI0Nw_cb1bbea9-f563-4211-b1a2-bc563865cb5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81Mi9mcmFnOjc3NWQ4YzBmOTE4OTRlYWRhYjlhYWM1YjY1YzJjM2I2L3RhYmxlOjAwM2IzNjkwNTNjYjQzOGI5NmZjOWQ4MGJlYzNkMmIxL3RhYmxlcmFuZ2U6MDAzYjM2OTA1M2NiNDM4Yjk2ZmM5ZDgwYmVjM2QyYjFfNC0xLTEtMS0yMjg1OA_5f4246ee-c14f-4263-a246-e641db45fd7b">729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81Mi9mcmFnOjc3NWQ4YzBmOTE4OTRlYWRhYjlhYWM1YjY1YzJjM2I2L3RhYmxlOjAwM2IzNjkwNTNjYjQzOGI5NmZjOWQ4MGJlYzNkMmIxL3RhYmxlcmFuZ2U6MDAzYjM2OTA1M2NiNDM4Yjk2ZmM5ZDgwYmVjM2QyYjFfNC0zLTEtMS0yMjg1OA_7fb49a96-04b9-43d0-8c47-a5a864e00b17">326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81Mi9mcmFnOjc3NWQ4YzBmOTE4OTRlYWRhYjlhYWM1YjY1YzJjM2I2L3RhYmxlOjAwM2IzNjkwNTNjYjQzOGI5NmZjOWQ4MGJlYzNkMmIxL3RhYmxlcmFuZ2U6MDAzYjM2OTA1M2NiNDM4Yjk2ZmM5ZDgwYmVjM2QyYjFfNS0xLTEtMS0yMjg1OA_e4617342-2362-4eb9-93b1-7b9ea2a5ff61">5,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81Mi9mcmFnOjc3NWQ4YzBmOTE4OTRlYWRhYjlhYWM1YjY1YzJjM2I2L3RhYmxlOjAwM2IzNjkwNTNjYjQzOGI5NmZjOWQ4MGJlYzNkMmIxL3RhYmxlcmFuZ2U6MDAzYjM2OTA1M2NiNDM4Yjk2ZmM5ZDgwYmVjM2QyYjFfNS0zLTEtMS0yMjg1OA_7eea2ee0-81ef-4f58-a51a-d1b9e0ba9f5c">2,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_55"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 8&#160;&#8211;&#160;<ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RleHRyZWdpb246NmY4MzE5YmExYjIwNGI3YWIzNWY5NWJhYjE1ODQ5MTZfMTE3Mw_44214626-81cb-4c81-ad82-b5459fb0996b" continuedAt="iff9edd4afa114c90992f502c83f58583" escape="true">Operating Leases</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iff9edd4afa114c90992f502c83f58583" continuedAt="i5ed7587064bf4d25831a436d065cb672">The Company has operating leases for <ix:nonFraction unitRef="office" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="INF" name="clbs:NumberOfOfficesUnderOperatingLeases" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RleHRyZWdpb246NmY4MzE5YmExYjIwNGI3YWIzNWY5NWJhYjE1ODQ5MTZfNjg_f6e666ca-34fe-4ae9-900f-4360c658944c">two</ix:nonFraction> offices with terms that expire in 2023 and 2025, respectively. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. Each of the Company's leases includes options for the Company to extend the lease term and/or sub-lease space in whole or in part.</ix:continuation></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><ix:continuation id="i5ed7587064bf4d25831a436d065cb672"><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RleHRyZWdpb246NmY4MzE5YmExYjIwNGI3YWIzNWY5NWJhYjE1ODQ5MTZfMTE2OQ_3885cd80-9893-41e0-b6a3-0cbc8685ffab" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:325.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of Use Assets:</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfMi0wLTEtMS0yMjg1OA_188c2eed-0925-44f8-bfd8-8dc48bf41cee"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfMi0wLTEtMS0yMjg1OA_cda64072-7450-44a6-a48d-ee2b330b6907">Other assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfMi0xLTEtMS0yMjg1OA_8618a7ce-3cb2-40ff-a9df-c38536c62579">548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfMi0zLTEtMS0yMjg1OA_1477247d-293d-4143-bf2f-7a77e3a3d68a">724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Right-of-Use Asset</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfMy0xLTEtMS0yMjg1OA_e071524f-012d-4a79-8d61-7125155a838a">548</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfMy0zLTEtMS0yMjg1OA_59f48ac5-92f6-4d26-a785-dae4a7de2d9c">724</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNi0wLTEtMS0yMjg1OA_466bdee9-6b20-428a-b677-b820ae3ba607"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNi0wLTEtMS0yMjg1OA_62800bd1-bc30-473e-aedd-b0b3d9f06907">Accrued liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNi0xLTEtMS0yMjg1OA_c1b7d532-7036-4e80-8487-bd6d37a95244">203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNi0zLTEtMS0yMjg1OA_05fd999a-67e5-42be-ae59-b76b211cf417">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNy0wLTEtMS0yMjg1OA_ceb1d506-32b0-442d-b209-59921ea40600"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNy0wLTEtMS0yMjg1OA_f9192e00-f937-46b7-9c41-0640551a459c">Other long-term liabilities</span></span></span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNy0xLTEtMS0yMjg1OA_e847a94a-8491-4808-ad49-71a5f522ed83">345</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNy0zLTEtMS0yMjg1OA_921fae82-f15a-41b1-bd08-f9d223d896ec">485</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Lease Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfOC0xLTEtMS0yMjg1OA_010f4aa7-cc81-43d7-8053-babdf63e4755">548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfOC0zLTEtMS0yMjg1OA_931ad48c-cb4e-48df-ac62-70c580ef43c2">714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the weighted average remaining lease term for our operating leases was <ix:nonNumeric contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RleHRyZWdpb246NmY4MzE5YmExYjIwNGI3YWIzNWY5NWJhYjE1ODQ5MTZfOTky_86c53463-7ab3-4c28-83d0-ed860f873e84">1.8</ix:nonNumeric> years, and the weighted average discount rate for our operating leases was <ix:nonFraction unitRef="number" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="5" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RleHRyZWdpb246NmY4MzE5YmExYjIwNGI3YWIzNWY5NWJhYjE1ODQ5MTZfMTA2NA_aaddf0f0-0da5-46c9-b64d-fae4879bba45">9.625</ix:nonFraction>%. <ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RleHRyZWdpb246NmY4MzE5YmExYjIwNGI3YWIzNWY5NWJhYjE1ODQ5MTZfMTE3MA_ebbf77ec-375e-4c3a-886d-8087463b7184" continuedAt="iad989ce6a7d945f98107a47ea9d14b0f" escape="true">Future minimum lease payments under the lease agreements as of September&#160;30, 2022 were as follows (in thousands):</ix:nonNumeric></span></div><div style="text-align:center"><ix:continuation id="iad989ce6a7d945f98107a47ea9d14b0f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:448.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjQwY2I5MDA2NWFmYjRhNjg4OTdiYTdmMGFjYWRlNjJjL3RhYmxlcmFuZ2U6NDBjYjkwMDY1YWZiNGE2ODg5N2JhN2YwYWNhZGU2MmNfMy0xLTEtMS0yMjg1OA_a32edbd6-e1fc-473a-906b-f3d5a015e1d6">75</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjQwY2I5MDA2NWFmYjRhNjg4OTdiYTdmMGFjYWRlNjJjL3RhYmxlcmFuZ2U6NDBjYjkwMDY1YWZiNGE2ODg5N2JhN2YwYWNhZGU2MmNfNC0xLTEtMS0yMjg1OA_a815a78d-4f3d-4694-926f-73b1a2d9723a">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjQwY2I5MDA2NWFmYjRhNjg4OTdiYTdmMGFjYWRlNjJjL3RhYmxlcmFuZ2U6NDBjYjkwMDY1YWZiNGE2ODg5N2JhN2YwYWNhZGU2MmNfNS0xLTEtMS0yMjg1OA_b1fffc04-419a-4e9e-ae96-6388c49831ae">190</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjQwY2I5MDA2NWFmYjRhNjg4OTdiYTdmMGFjYWRlNjJjL3RhYmxlcmFuZ2U6NDBjYjkwMDY1YWZiNGE2ODg5N2JhN2YwYWNhZGU2MmNfNi0xLTEtMS0yMjg1OA_a188f76e-f727-4922-8f3c-f30f2dccb268">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjQwY2I5MDA2NWFmYjRhNjg4OTdiYTdmMGFjYWRlNjJjL3RhYmxlcmFuZ2U6NDBjYjkwMDY1YWZiNGE2ODg5N2JhN2YwYWNhZGU2MmNfNy0xLTEtMS0yMjg1OA_3fc95408-4c14-40bd-967b-730cd604143e">625</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjQwY2I5MDA2NWFmYjRhNjg4OTdiYTdmMGFjYWRlNjJjL3RhYmxlcmFuZ2U6NDBjYjkwMDY1YWZiNGE2ODg5N2JhN2YwYWNhZGU2MmNfOC0xLTEtMS0yMjg1OA_0c390648-2246-48e3-95f1-1f50094705b4">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjQwY2I5MDA2NWFmYjRhNjg4OTdiYTdmMGFjYWRlNjJjL3RhYmxlcmFuZ2U6NDBjYjkwMDY1YWZiNGE2ODg5N2JhN2YwYWNhZGU2MmNfOS0xLTEtMS0yMjg1OA_964416bc-0a8e-46e2-9f33-b16420bc1c2e">548</ix:nonFraction>&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_58"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 9 &#8211; <ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNTQ1NQ_5fc84d0c-8e88-4872-90f2-fc40c9ad57a8" continuedAt="i0bc6570f4a804c2691f4e32048d3e492" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="i0bc6570f4a804c2691f4e32048d3e492" continuedAt="iae9a841ba6544dc4bb5e360481bf85cf"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 14, 2022, in connection with the merger, we implemented the Reverse Stock Split, as described in Note 1. All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods presented to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from &#8220;common stock&#8221; to &#8220;additional paid-in capital&#8221; in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Issuances</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March&#160;2019, the Company and Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) entered into a purchase agreement (the &#8220;Purchase Agreement&#8221;) and a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;), pursuant to which the Company has the right to sell to Lincoln Park shares of the Company&#8217;s common stock having an aggregate value of up to $<ix:nonFraction unitRef="usd" contextRef="i7128331c98ad445b8fb23487460be1ba_I20190930" decimals="-5" name="clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNDI2_dcc91888-8956-4189-910c-ec546458b139">26.0</ix:nonFraction> million, subject to certain limitations and conditions set forth in the Purchase Agreement (the &#8220;Offering&#8221;). As consideration for entering into the Purchase Agreement, the Company issued to Lincoln Park an additional <ix:nonFraction unitRef="shares" contextRef="ic92d752f756145678f3d08b54d87d88e_D20190301-20190331" decimals="INF" name="clbs:StockIssuedDuringPeriodSharesIssuedAsConsideration" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNjM4_bd30dc61-5002-4f60-8f69-eba860b3d32b">181,510</ix:nonFraction> shares of common stock as commitment shares.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Purchase Agreement, Lincoln Park purchased <ix:nonFraction unitRef="shares" contextRef="ic92d752f756145678f3d08b54d87d88e_D20190301-20190331" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNzQ1_1c1b3646-1993-40cf-a97e-035b5bd15216">250,000</ix:nonFraction> shares of common stock, at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7128331c98ad445b8fb23487460be1ba_I20190930" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNzg2_cb92ed88-408f-4940-b9d7-2c3870c29a48">4.00</ix:nonFraction> per share, for a total gross purchase price of $<ix:nonFraction unitRef="usd" contextRef="ic92d752f756145678f3d08b54d87d88e_D20190301-20190331" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfODM2_050c50dd-ac7f-46dd-9209-d54e560b22c2">1.0</ix:nonFraction> million (the &#8220;Initial Purchase&#8221;) upon commencement. Thereafter, as often as every business day from and after one business day following the date of the Initial Purchase and over the <ix:nonNumeric contextRef="ic92d752f756145678f3d08b54d87d88e_D20190301-20190331" name="clbs:TermOfAgreement" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfMTAxNA_d5b504a0-4c53-425e-8318-d46233e10c78">36</ix:nonNumeric>-month term of the Purchase Agreement, the Company has the right, from time to time, at its sole discretion and subject to certain conditions, to direct Lincoln Park to purchase up to <ix:nonFraction unitRef="shares" contextRef="i7128331c98ad445b8fb23487460be1ba_I20190930" decimals="INF" name="clbs:SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfMTE5OQ_0bacc891-7cf6-4a71-81a6-c820d66deab9">100,000</ix:nonFraction> shares of common stock, with such amount increasing as the closing sale price of the common stock increases; provided Lincoln Park&#8217;s obligation under any single such purchase will not exceed $<ix:nonFraction unitRef="usd" contextRef="i7128331c98ad445b8fb23487460be1ba_I20190930" decimals="-5" name="clbs:SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfMTM5Mw_d020bb79-c52d-4965-ab11-5b08373eca26">2.5</ix:nonFraction> million, unless the Company and Lincoln Park mutually agree to increase the maximum amount of such single purchase (each, a &#8220;Regular Purchase&#8221;).&#160;If the Company directs Lincoln Park to purchase the maximum number of shares of common stock it then may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations in the Purchase Agreement, the Company may direct Lincoln Park in an &#8220;accelerated purchase&#8221; to purchase an additional amount </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><ix:continuation id="iae9a841ba6544dc4bb5e360481bf85cf" continuedAt="i1251c1fbc7e8421f9ab32abb75fd167b"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of common stock that may not exceed the lesser of (i)&#160;<ix:nonFraction unitRef="number" contextRef="i7128331c98ad445b8fb23487460be1ba_I20190930" decimals="2" name="clbs:SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfMTkzOA_a646cc86-0459-40ac-8beb-46d270bdd977">300</ix:nonFraction>% the number of shares purchased pursuant to the corresponding Regular Purchase or (ii)&#160;<ix:nonFraction unitRef="number" contextRef="i7128331c98ad445b8fb23487460be1ba_I20190930" decimals="2" name="clbs:SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfMjAyNw_1990c02f-50f3-4b2a-bcd4-e9a830283c1e">30</ix:nonFraction>% of the total number of shares of the Company&#8217;s common stock traded during a specified period on the applicable purchase date as set forth in the Purchase Agreement. Under certain circumstances and in accordance with the Purchase Agreement, the Company may direct Lincoln Park to purchase shares in multiple accelerated purchases on the same trading day.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company controls the timing and amount of any sales of its common stock to Lincoln Park.&#160;There is no upper limit on the price per share that Lincoln Park must pay for its common stock under the Purchase Agreement, but in no event will shares be sold to Lincoln Park on a day the closing price is less than the floor price specified in the Purchase Agreement. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the purchase agreement if it would result in Lincoln Park beneficially owning more than <ix:nonFraction unitRef="number" contextRef="i7128331c98ad445b8fb23487460be1ba_I20190930" decimals="4" name="clbs:RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfMjkyNw_f4cd5ac6-c9b5-4f31-af45-9c5f315b0b2a">9.99</ix:nonFraction>% of its common stock.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Purchase Agreement does not limit the Company&#8217;s ability to raise capital from other sources at the Company&#8217;s sole discretion, except that (subject to certain exceptions) the Company may not enter into any Variable Rate Transaction (as defined in the Purchase Agreement, including the issuance of any floating conversion rate or variable priced equity-like securities) during the <ix:nonNumeric contextRef="ic92d752f756145678f3d08b54d87d88e_D20190301-20190331" name="clbs:TermOfAgreement" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfMzMzNA_d5b504a0-4c53-425e-8318-d46233e10c78">36</ix:nonNumeric> months after the date of the Purchase Agreement. The Company has the right to terminate the Purchase Agreement at any time, at no cost to the Company.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company had not made any sales of common stock to Lincoln Park under the Purchase Agreement other than the Initial Purchase. The agreement expired on April 1, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">At The Market Offering Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC, as sales agent, in connection with an &#8220;at the market offering&#8221; under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i5748a0eb61f64415a43f6fd83aab5103_I20210604" decimals="-5" name="clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNDAwNg_35ef4269-f791-40d5-a663-b669bd9bd749">50.0</ix:nonFraction>&#160;million.  During the nine months ended September&#160;30, 2022 and since inception, the Company has <ix:nonFraction unitRef="shares" contextRef="i4f7b301665c749bf9b60eccd141f1949_D20220101-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNDA2NA_e9f40945-f113-44ec-9da6-845fb84f0af7">no</ix:nonFraction>t issued any shares under the ATM Agreement. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger close, the Company issued an aggregate of 3,772,768 shares of common stock, based on the Exchange Ratio, to holders of Cend, in exchange for all of the Cend capital stock outstanding immediately prior to the closing of the Merger. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><ix:continuation id="i1251c1fbc7e8421f9ab32abb75fd167b" continuedAt="ie16a51a29b284ba0b2ae3fc3061db689"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Warrants</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger and after giving effect to the Reverse Stock Split, the Company assumed 1,227,776 options outstanding from Cend. The options granted from the Cend Plan are exercisable at various dates as determined upon grant and will expire no more than ten years from their original date of grant. The Cend Plan stock options generally vest over a four-year term. <ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNTQzNw_f3adf315-7fac-45d2-9673-92d5f2c0d3ab" continuedAt="ia00194e04d5d40769bf9bab703d0a570" escape="true">The following table summarizes the activity for stock options and warrants for the nine months ended September&#160;30, 2022:</ix:nonNumeric></span></div><div style="text-align:center"><ix:continuation id="ia00194e04d5d40769bf9bab703d0a570"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMi0yLTEtMS0yMjg1OA_4b15dbee-c2c8-41e2-bd99-35d2e4ac7d39">142,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMi00LTEtMS0yMjg1OA_b07c9239-b388-43f4-8204-5f04b4e29722">84.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iafd0678032f1403699288c6ead8540b2_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMi02LTEtMS0yMjg1OA_ce3e0407-63c6-4d21-8a04-a2c07e871e6e">7.97</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMi04LTEtMS0yMjg1OA_0981da9a-2767-40cb-b7b1-a42a0f9bbb8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="INF" name="clbs:CommonStockWarrantsShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMi0xMC0xLTEtMjI4NTg_121e8515-42be-405b-85cc-750ab76dd772">1,423,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMi0xMi0xLTEtMjI4NTg_d5ac3e1e-dd4f-454f-a692-0d07318bca53">42.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iafd0678032f1403699288c6ead8540b2_D20210101-20211231" name="clbs:WeightedAverageRemainingContractualTermwarrantoutstanding" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMi0xNC0xLTEtMjI4NTg_e32beeb9-bd61-48c5-8f1d-6105f29de027">4.37</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-3" name="clbs:AggregateIntrinsicValueWarrantsOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMi0xNi0xLTEtMjI4NTg_8385816a-eb3e-4ed7-8302-b9ff1d4596f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfNS0yLTEtMS0yMjg1OA_58848d4f-3466-4978-b6ed-c4c78f8299d7">37,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfNS00LTEtMS0yMjg1OA_b0195f7e-2a00-482c-8e8a-8833a764eaa6">13.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="INF" name="clbs:WarrantsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfNS0xMC0xLTEtMjI4NTg_8f601099-4dbc-44c5-9583-e7ff87d461e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfNS0xMi0xLTEtMjI4NTg_2ae7184d-e557-4661-81d1-0de3b093eddb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assumed through merger</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,227,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfNi0yLTEtMS0yMjg1OA_577e9608-b394-454e-9f89-17a40db1f1e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfNi00LTEtMS0yMjg1OA_8c4cd91d-1f0c-4f9e-bb03-b57d8009f76c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="INF" name="clbs:WarrantsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfNi0xMC0xLTEtMjI4NTg_539597f6-6990-4de3-991c-2c28c8d78065">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfNi0xMi0xLTEtMjI4NTg_2c527801-a2c3-4ce4-bda4-f22072099fa2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfNy0yLTEtMS0yMjg1OA_22d344ea-a5db-44db-be8c-144715d2adb4">2,910</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfNy00LTEtMS0yMjg1OA_de210cef-5da0-4418-b907-1aed42c497aa">19.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="INF" name="clbs:WarrantsCanceled" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfNy0xMC0xLTEtMjI4NTg_1ec9d46a-404a-4941-87a0-f9e746ea8158">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsCanceled" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfNy0xMi0xLTEtMjI4NTg_05ddfcb6-4049-4d10-8299-2129ddf11976">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfOC0yLTEtMS0yMjg1OA_bf513154-00c9-4268-bcac-f2d8bb542fe6">5,388</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfOC00LTEtMS0yMjg1OA_465bcc78-c099-4d32-86a2-f424d442bbd9">352.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="INF" name="clbs:WarrantsExpired" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfOC0xMC0xLTEtMjI4NTg_1a0548ee-2462-4522-a7ad-eb3000da929c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsExpired" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfOC0xMi0xLTEtMjI4NTg_499070e7-3bf7-4d76-89b8-4c9360ae2a86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfOS0yLTEtMS0yMjg1OA_5561c9c1-1300-4cfc-b72a-5ca0845e7fec">1,398,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfOS00LTEtMS0yMjg1OA_e0d20a29-2432-43f4-9c6a-42f28d5bf9a4">10.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfOS02LTEtMS0yMjg1OA_69a16e6f-7760-4e8f-9e1d-c4fe02d0f534">7.30</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfOS04LTEtMS0yMjg1OA_8d352182-538c-458b-a2e1-fbbcb09c0946">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="INF" name="clbs:CommonStockWarrantsShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfOS0xMC0xLTEtMjI4NTg_f59fab96-2497-4fd5-8722-e6bc7e528f35">1,423,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfOS0xMi0xLTEtMjI4NTg_ec8504f1-c191-4c63-8763-f66d85dbe029">42.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="clbs:WeightedAverageRemainingContractualTermwarrantoutstanding" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfOS0xNC0xLTEtMjI4NTg_6bb5772a-96ba-4514-868e-5bcb3518a190">3.63</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="clbs:AggregateIntrinsicValueWarrantsOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfOS0xNi0xLTEtMjI4NTg_32a06bf1-0098-4ae9-aa24-4bfb0764b465">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at September 30, 2022<br/>&#160;or expected to vest in the future</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTAtMi0xLTEtMjI4NTg_7e2ea44e-9c56-4b79-a3ed-92e2780d9caa">1,396,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTAtNC0xLTEtMjI4NTg_16329620-82eb-4afa-b899-d75ee91e84f2">10.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTAtNi0xLTEtMjI4NTg_17156f2e-bc3d-4844-b088-9d5f1bd133a1">7.30</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTAtOC0xLTEtMjI4NTg_95a69dd8-f3f9-4cbb-905a-f241148b711f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="INF" name="clbs:Sharesvestedandexpectedtovest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTAtMTAtMS0xLTIyODU4_0ba70e5d-2a84-4e94-9730-06cf5000b69d">1,423,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTAtMTItMS0xLTIyODU4_a6a8f7f0-3f08-48da-a203-793ce071beb6">42.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="clbs:WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTAtMTQtMS0xLTIyODU4_22ba8c14-f52e-45e9-bcfe-46091d7db16e">3.63</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="clbs:AggregateIntrinsicValueWarrantsvestedandexpectedtovest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTAtMTYtMS0xLTIyODU4_4d5861c8-4467-4cb5-ab6c-4ca26ec3a545">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTEtMi0xLTEtMjI4NTg_da2811a2-b36c-48ec-8bfb-99e81652b849">1,110,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTEtNC0xLTEtMjI4NTg_de0d6e59-f097-4fcb-b72a-f305fa5a72fd">11.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="clbs:OptionsVestedweightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTEtNi0xLTEtMjI4NTg_a942b037-acd9-42ea-9982-5ac5ce66313c">6.97</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTEtOC0xLTEtMjI4NTg_2485c9a8-fdf9-4462-96e7-927475850270">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="INF" name="clbs:WarrantsVested" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTEtMTAtMS0xLTIyODU4_faa8189a-a0f4-47ae-94f3-d49ff20a1fb4">1,423,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="2" name="clbs:WeightedAverageExercisePriceWarrantsExercisable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTEtMTItMS0xLTIyODU4_527cd8ac-6047-481a-bcea-50b76e4e25f8">42.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="clbs:WeightedAverageRemainingContractualTermwarrantsvested" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTEtMTQtMS0xLTIyODU4_df3d396b-fda3-48c6-9c00-5729a0cca3da">3.63</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930" decimals="-3" name="clbs:AggregateIntrinsicValueWarrantsvested" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTEtMTYtMS0xLTIyODU4_edd693d8-6a60-42de-ab51-fec7c957d137">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNTQ0Mw_038141bf-9894-4687-bf18-874a6f61e0c0" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022 and 2021, the Company issued restricted stock for services as follows ($ in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"><tr><td style="width:1.0pt"></td><td style="width:322.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:4.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib889d615bc824253bdc29e6be132de5e_D20220101-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmFlMjRhMTIyOTBlYzRlNDdiMGY0Zjg0YjUzOGRjOGExL3RhYmxlcmFuZ2U6YWUyNGExMjI5MGVjNGU0N2IwZjRmODRiNTM4ZGM4YTFfMi0yLTEtMS0yMjg1OA_b11f6cd4-52f7-40f6-bb7a-abb2729abdc7">70,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i307650e93d90403dbe9bbce2cef38283_D20210101-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmFlMjRhMTIyOTBlYzRlNDdiMGY0Zjg0YjUzOGRjOGExL3RhYmxlcmFuZ2U6YWUyNGExMjI5MGVjNGU0N2IwZjRmODRiNTM4ZGM4YTFfMi00LTEtMS0yMjg1OA_bd2681f5-b8e1-4035-a8fd-e56b504d6010">40,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib889d615bc824253bdc29e6be132de5e_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmFlMjRhMTIyOTBlYzRlNDdiMGY0Zjg0YjUzOGRjOGExL3RhYmxlcmFuZ2U6YWUyNGExMjI5MGVjNGU0N2IwZjRmODRiNTM4ZGM4YTFfMy0yLTEtMS0yMjg1OA_141ccde7-2756-4f6c-bc6e-14a939997363">973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i307650e93d90403dbe9bbce2cef38283_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmFlMjRhMTIyOTBlYzRlNDdiMGY0Zjg0YjUzOGRjOGExL3RhYmxlcmFuZ2U6YWUyNGExMjI5MGVjNGU0N2IwZjRmODRiNTM4ZGM4YTFfMy00LTEtMS0yMjg1OA_9c376dae-b569-4048-9da8-f4be40890d3e">878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vesting terms of restricted stock issuances are generally between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNDg3Mw_6c617069-871e-4bcc-ac83-10a9da649366">one</span> and <ix:nonNumeric contextRef="id9c9001c970d4ccd8a77b7e8f997ca0c_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNDg3OQ_b5b5178b-dced-4384-89e6-c2720bce1e27">four years</ix:nonNumeric>.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNTQ0Ng_bc0c5bad-c81d-451d-b7cf-234350d57585" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022 and 2021, the Company issued restricted stock units for services as follows ($ in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"><tr><td style="width:1.0pt"></td><td style="width:343.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock units issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i85d58dcae34e4ef8875042573be0b9be_D20220101-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOjc5ZDg1YTE3ZjZhNDRmYzFhYjIzZGJiOWVlOTUxYzU2L3RhYmxlcmFuZ2U6NzlkODVhMTdmNmE0NGZjMWFiMjNkYmI5ZWU5NTFjNTZfMi0xLTEtMS0yMjg1OA_814af3af-41d8-454e-8c66-fc08c9907c94">111,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib0800b6bb894400cb3122c7e867ed365_D20210101-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOjc5ZDg1YTE3ZjZhNDRmYzFhYjIzZGJiOWVlOTUxYzU2L3RhYmxlcmFuZ2U6NzlkODVhMTdmNmE0NGZjMWFiMjNkYmI5ZWU5NTFjNTZfMi0zLTEtMS0yMjg1OA_77e3914d-e3a6-45f0-abdb-10427e0aad5b">30,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock units issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85d58dcae34e4ef8875042573be0b9be_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOjc5ZDg1YTE3ZjZhNDRmYzFhYjIzZGJiOWVlOTUxYzU2L3RhYmxlcmFuZ2U6NzlkODVhMTdmNmE0NGZjMWFiMjNkYmI5ZWU5NTFjNTZfMy0xLTEtMS0yMjg1OA_cf44c526-41b5-4821-9e0e-f153e3826719">1,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0800b6bb894400cb3122c7e867ed365_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOjc5ZDg1YTE3ZjZhNDRmYzFhYjIzZGJiOWVlOTUxYzU2L3RhYmxlcmFuZ2U6NzlkODVhMTdmNmE0NGZjMWFiMjNkYmI5ZWU5NTFjNTZfMy0zLTEtMS0yMjg1OA_04d28f48-def0-44d0-8f33-453c11f8bd32">729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie16a51a29b284ba0b2ae3fc3061db689">The weighted average estimated fair value of restricted stock issued for services in the nine months ended September&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ib889d615bc824253bdc29e6be132de5e_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNTE0Mw_c7a9c3ea-7796-4042-b73c-1913098a5d3d">12.46</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i307650e93d90403dbe9bbce2cef38283_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNTE1MA_d16a1307-957f-437e-adff-01e884c8ce29">23.85</ix:nonFraction> per share, respectively. The fair value of the restricted stock units was determined using the Company&#8217;s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally <ix:nonNumeric contextRef="i85d58dcae34e4ef8875042573be0b9be_D20220101-20220930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNTM3MA_147986da-179b-4876-9be3-2e37ec92fa89">one year</ix:nonNumeric>, or upon the achievement of performance-based milestones.</ix:continuation> </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_64"></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 10 &#8211; <ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RleHRyZWdpb246OGMyNTFlYzUyMmIxNGI5NmJiZTRmMDVlMDkxNTU5YzVfMTEzMw_bf029629-c732-41fb-8723-910091ba97ce" continuedAt="id39f46390c1c4676b2d71c46d1897cb0" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="id39f46390c1c4676b2d71c46d1897cb0"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize share-based compensation in the form of stock options, restricted stock, and restricted stock units.&#160;<ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RleHRyZWdpb246OGMyNTFlYzUyMmIxNGI5NmJiZTRmMDVlMDkxNTU5YzVfMTEzNg_799a332c-d66a-43c9-8a1e-86825c4e4cb0" continuedAt="id6846b6166be47d7b8463ff3ab86ac5a" escape="true">The following table summarizes the components of share-based compensation expense for the three and nine months ended September&#160;30, 2022 and 2021 (in thousands):</ix:nonNumeric></span></div><div style="text-align:center;text-indent:18pt"><ix:continuation id="id6846b6166be47d7b8463ff3ab86ac5a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:44.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34bf47839bf14111b1a9f241df421e60_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjM3NjA4YmYwODIyZDQ1MGU4ZTM4MWQxODBkYmNhM2FhL3RhYmxlcmFuZ2U6Mzc2MDhiZjA4MjJkNDUwZThlMzgxZDE4MGRiY2EzYWFfMi0xLTEtMS0yMjg1OA_d28989e1-1665-4cc2-ae1c-2069b4f6db60">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01ce7704d3fe44b2b990f2b244335218_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjM3NjA4YmYwODIyZDQ1MGU4ZTM4MWQxODBkYmNhM2FhL3RhYmxlcmFuZ2U6Mzc2MDhiZjA4MjJkNDUwZThlMzgxZDE4MGRiY2EzYWFfMi0zLTEtMS0yMjg1OA_46b257be-a0b9-4fd5-b7ea-aa9d57a81501">523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i837f26cb6fd94ea2be192be38846f7d4_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjM3NjA4YmYwODIyZDQ1MGU4ZTM4MWQxODBkYmNhM2FhL3RhYmxlcmFuZ2U6Mzc2MDhiZjA4MjJkNDUwZThlMzgxZDE4MGRiY2EzYWFfMi01LTEtMS0yMjg1OA_5ce95f9d-9997-4eaa-9e93-ffcafb0a5318">631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cdf12952bfe4ee58d1c62f6fc6b922f_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjM3NjA4YmYwODIyZDQ1MGU4ZTM4MWQxODBkYmNhM2FhL3RhYmxlcmFuZ2U6Mzc2MDhiZjA4MjJkNDUwZThlMzgxZDE4MGRiY2EzYWFfMi03LTEtMS0yMjg1OA_c7185105-cb60-4244-83b1-9c1153f40f15">643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddf5f8d32bb9415e8e2d387027b79ab6_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjM3NjA4YmYwODIyZDQ1MGU4ZTM4MWQxODBkYmNhM2FhL3RhYmxlcmFuZ2U6Mzc2MDhiZjA4MjJkNDUwZThlMzgxZDE4MGRiY2EzYWFfMy0xLTEtMS0yMjg1OA_410620fe-dd34-4f26-afe4-6c71d47d5ce5">769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia363623f86d0452f826ddd27e9bd14ef_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjM3NjA4YmYwODIyZDQ1MGU4ZTM4MWQxODBkYmNhM2FhL3RhYmxlcmFuZ2U6Mzc2MDhiZjA4MjJkNDUwZThlMzgxZDE4MGRiY2EzYWFfMy0zLTEtMS0yMjg1OA_2d097404-beaa-49f2-a95d-360e00545308">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i750cd69f59fa41ab8d1716b4af6483aa_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjM3NjA4YmYwODIyZDQ1MGU4ZTM4MWQxODBkYmNhM2FhL3RhYmxlcmFuZ2U6Mzc2MDhiZjA4MjJkNDUwZThlMzgxZDE4MGRiY2EzYWFfMy01LTEtMS0yMjg1OA_74d4ab29-8844-492c-be75-4755a3c3268f">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie55321c2f35248728ece5383ad81d1ab_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjM3NjA4YmYwODIyZDQ1MGU4ZTM4MWQxODBkYmNhM2FhL3RhYmxlcmFuZ2U6Mzc2MDhiZjA4MjJkNDUwZThlMzgxZDE4MGRiY2EzYWFfMy03LTEtMS0yMjg1OA_236e67ba-6f1e-418c-9e87-76758524c712">996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjM3NjA4YmYwODIyZDQ1MGU4ZTM4MWQxODBkYmNhM2FhL3RhYmxlcmFuZ2U6Mzc2MDhiZjA4MjJkNDUwZThlMzgxZDE4MGRiY2EzYWFfNC0xLTEtMS0yMjg1OA_2ac51f51-b004-45d0-bff7-bbe5bd45f70d">1,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjM3NjA4YmYwODIyZDQ1MGU4ZTM4MWQxODBkYmNhM2FhL3RhYmxlcmFuZ2U6Mzc2MDhiZjA4MjJkNDUwZThlMzgxZDE4MGRiY2EzYWFfNC0zLTEtMS0yMjg1OA_79817a8a-2901-44d8-aca1-513866bb9a38">773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjM3NjA4YmYwODIyZDQ1MGU4ZTM4MWQxODBkYmNhM2FhL3RhYmxlcmFuZ2U6Mzc2MDhiZjA4MjJkNDUwZThlMzgxZDE4MGRiY2EzYWFfNC01LTEtMS0yMjg1OA_0ec64807-fcd1-41a9-bf33-920513d3e2ba">2,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjM3NjA4YmYwODIyZDQ1MGU4ZTM4MWQxODBkYmNhM2FhL3RhYmxlcmFuZ2U6Mzc2MDhiZjA4MjJkNDUwZThlMzgxZDE4MGRiY2EzYWFfNC03LTEtMS0yMjg1OA_d90e31ae-d8d9-44ad-a7e9-302d9fdc8532">1,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></ix:continuation></div><div style="text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RleHRyZWdpb246OGMyNTFlYzUyMmIxNGI5NmJiZTRmMDVlMDkxNTU5YzVfMTE0Mw_b0810825-a773-4879-a06b-beb3a7190ecb" escape="true"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost related to non-vested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at September&#160;30, 2022 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized compensation cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i018aef0ebc684655bb91626b836264c8_I20220930" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOmYxMjJjOThhMGRhMTRhYjA4MGJkZjJkYzI3NmZhYjQ2L3RhYmxlcmFuZ2U6ZjEyMmM5OGEwZGExNGFiMDgwYmRmMmRjMjc2ZmFiNDZfMS0xLTEtMS0yMjg1OA_5aecbf00-25c2-447f-ab58-db4ca33f82c4">1,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bdf4a4104384257bd274663a65297cc_I20220930" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOmYxMjJjOThhMGRhMTRhYjA4MGJkZjJkYzI3NmZhYjQ2L3RhYmxlcmFuZ2U6ZjEyMmM5OGEwZGExNGFiMDgwYmRmMmRjMjc2ZmFiNDZfMS0zLTEtMS0yMjg1OA_f206298a-ea05-4aac-8db7-b5705a011299">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb6073bf55444dc9adf45d6bd29a32bd_I20220930" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOmYxMjJjOThhMGRhMTRhYjA4MGJkZjJkYzI3NmZhYjQ2L3RhYmxlcmFuZ2U6ZjEyMmM5OGEwZGExNGFiMDgwYmRmMmRjMjc2ZmFiNDZfMS01LTEtMS0yMjg1OA_1d845f6f-a4cb-46c2-bc7e-bf4601f70daa">722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted-average period in years of compensation cost to be recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifb50bb2a566f4b72a4ec8baa84a38a44_D20220101-20220930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOmYxMjJjOThhMGRhMTRhYjA4MGJkZjJkYzI3NmZhYjQ2L3RhYmxlcmFuZ2U6ZjEyMmM5OGEwZGExNGFiMDgwYmRmMmRjMjc2ZmFiNDZfMi0xLTEtMS0yMjg1OA_c9509799-d45e-4416-b268-9bbc5fcbaed1">1.66</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i85d58dcae34e4ef8875042573be0b9be_D20220101-20220930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOmYxMjJjOThhMGRhMTRhYjA4MGJkZjJkYzI3NmZhYjQ2L3RhYmxlcmFuZ2U6ZjEyMmM5OGEwZGExNGFiMDgwYmRmMmRjMjc2ZmFiNDZfMi0zLTEtMS0yMjg1OA_9ae274e4-a134-43e9-bee6-e0594701b653">2.16</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib889d615bc824253bdc29e6be132de5e_D20220101-20220930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOmYxMjJjOThhMGRhMTRhYjA4MGJkZjJkYzI3NmZhYjQ2L3RhYmxlcmFuZ2U6ZjEyMmM5OGEwZGExNGFiMDgwYmRmMmRjMjc2ZmFiNDZfMi01LTEtMS0yMjg1OA_798d9c9e-7cc7-49da-b1cf-035c19d72609">1.83</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RleHRyZWdpb246OGMyNTFlYzUyMmIxNGI5NmJiZTRmMDVlMDkxNTU5YzVfMTE0NQ_2dca7413-c43d-4cf5-8f86-2d002c360499" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the nine months ended September&#160;30, 2022 and 2021 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:378.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.75pt"></td><td style="width:1.0pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb50bb2a566f4b72a4ec8baa84a38a44_D20220101-20220930" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjZkZWIwYzc2ZjMwNzQ1NzQ5NjBjOGNiZjFjZDQ2YWMyL3RhYmxlcmFuZ2U6NmRlYjBjNzZmMzA3NDU3NDk2MGM4Y2JmMWNkNDZhYzJfMy0xLTEtMS0yMjg1OA_928e9b9e-0fe3-4149-84a5-8d1fa8dcd9df">853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d716d023604513b9d5e44c712a5656_D20210101-20210930" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjZkZWIwYzc2ZjMwNzQ1NzQ5NjBjOGNiZjFjZDQ2YWMyL3RhYmxlcmFuZ2U6NmRlYjBjNzZmMzA3NDU3NDk2MGM4Y2JmMWNkNDZhYzJfMy0zLTEtMS0yMjg1OA_69f3a100-d366-4689-a780-97a6c3eba375">757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average estimated fair value of shares granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifb50bb2a566f4b72a4ec8baa84a38a44_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjZkZWIwYzc2ZjMwNzQ1NzQ5NjBjOGNiZjFjZDQ2YWMyL3RhYmxlcmFuZ2U6NmRlYjBjNzZmMzA3NDU3NDk2MGM4Y2JmMWNkNDZhYzJfNC0xLTEtMS0yMjg1OA_76396df9-a13e-477a-8459-6db6f87a5777">1.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i83d716d023604513b9d5e44c712a5656_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjZkZWIwYzc2ZjMwNzQ1NzQ5NjBjOGNiZjFjZDQ2YWMyL3RhYmxlcmFuZ2U6NmRlYjBjNzZmMzA3NDU3NDk2MGM4Y2JmMWNkNDZhYzJfNC0zLTEtMS0yMjg1OA_92bf0cb0-fb51-4bd4-873a-1de34121a7e2">13.59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation Assumptions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options and warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company&#8217;s common stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_67"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 11 &#8211; <ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfNDI2OA_c4e71926-bc9a-49c1-9c91-2e6ea3093c8c" continuedAt="i4fdca29f122f40658ea76db973a43d88" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i4fdca29f122f40658ea76db973a43d88" continuedAt="i26b62a18009e46389ba674b7e95f9227"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (&#8220;NOLs&#8221;), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.  Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="if68b9c4980394919b2d4601761b01f4d_I20211231" decimals="-3" name="clbs:OperatingLossCarryforwardsBeforeWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfNTQw_4dc79b93-2130-419f-a227-b34d66dab4d3">281</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i31c432312f38454b845861eb8d0891a5_I20201231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfNTQ3_62244b91-bff7-4005-a27b-c3a95a60e3da">264</ix:nonFraction>&#160;million, respectively, of federal NOLs available to offset future taxable income expiring from 2030 through 2036.&#160;The Company performed an analysis and determined that it had an ownership change of greater than 50% over a 3-year testing period on January 25, 2021.  As a result, $<ix:nonFraction unitRef="usd" contextRef="if68b9c4980394919b2d4601761b01f4d_I20211231" decimals="-6" name="clbs:OperatingLossCarryforwardsSetToExpireWrittenDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfODIy_b293a518-9e51-478b-8bef-2919c9e0ff9a">169</ix:nonFraction>&#160;million of the $<ix:nonFraction unitRef="usd" contextRef="if68b9c4980394919b2d4601761b01f4d_I20211231" decimals="-6" name="clbs:OperatingLossCarryforwardsBeforeWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfODMy_f49e955b-c6d2-4896-8590-98028bc0409a">281</ix:nonFraction>&#160;million of federal NOLs will expire unutilized.  The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $<ix:nonFraction unitRef="usd" contextRef="if68b9c4980394919b2d4601761b01f4d_I20211231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfMTAwMA_ea156777-c158-4352-a361-b18751790a82">112</ix:nonFraction>&#160;million of remaining federal NOL.  The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on January 25, 2021 will be subject to an annual limitation of $173 thousand under Internal Revenue Code Section 382, while losses incurred after January 25, 2021 will not be subject to limitations. The Company may be able to utilize additional NOLs of approximately $<ix:nonFraction unitRef="usd" contextRef="ib97be91eba48467897085df19e17a272_I20211231" decimals="-5" name="clbs:OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfMTQ4NA_5bf07f1c-65e5-449a-8a66-72f523d3dc4b">1.1</ix:nonFraction>&#160;million per year for the first five years after this ownership change as a result of the application of the Net Unrealized Built-in Gain rules.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><ix:continuation id="i26b62a18009e46389ba674b7e95f9227"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the Company had state NOLs available in New Jersey of $<ix:nonFraction unitRef="usd" contextRef="i1b434d8601de4e05b998640da3d91bcc_I20211231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfMTY5NQ_c0a47c9c-85c3-4a9b-ae73-cb403806776c">97</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i02b1d9ded41146128c64adca8ae00256_I20201231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfMTcwMg_90d14897-e168-43a3-ba34-da499bd2b8a1">99</ix:nonFraction>&#160;million, respectively, California of $<ix:nonFraction unitRef="usd" contextRef="i93a7f18008c44e9997baaba9c4bcc603_I20211231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfMTczNA_62788509-81ed-4e69-9e9a-4ec930554f9e">70</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ic221f3b9f147476abbbaa83788e46406_I20201231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfMTc0MQ_c9b7f507-08f7-4722-a167-c7c56cf6c29d">70</ix:nonFraction>&#160;million, respectively, and New York City of $<ix:nonFraction unitRef="usd" contextRef="i68d905e37c484eff8d11dc6b86a7e0f6_I20211231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfMTc4MA_1abcb5ce-5a76-4da1-a779-11362b006c3a">13</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i579b018c55b04e3c984da0273c1ef442_I20201231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfMTc4Nw_9737ae57-9cff-485d-b657-1ca58fb94d01">13</ix:nonFraction>&#160;million, respectively, to offset future taxable income expiring from 2031 through 2041. In accordance with Section 382 of the Internal Revenue code, the usage of the Company&#8217;s NOLs would be limited given the change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the FASB&#8217;s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with uncertain tax positions as a component of income tax expense.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For years prior to 2018, the federal statute of limitations is closed for assessing tax. The Company&#8217;s state tax returns remain open to examination for a period of three to four years from date of filing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company received preliminary approval from the New Jersey Economic Development Authority (&#8220;NJEDA&#8221;) to participate in the Technology Business Tax Certificate Transfer Program (the &#8220;Program&#8221;). The Program permits qualified companies to sell a percentage of their New Jersey net operating losses (&#8220;NJ NOLs&#8221;) to unrelated profitable corporations. On February 22, 2022, the Company received final approval from NJEDA to sell $<ix:nonFraction unitRef="usd" contextRef="if463b298d932482a86bb1787b18f2ed0_D20220222-20220222" decimals="-5" name="clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfMzg5OQ_251bab9a-c782-4b3d-997c-14b66ccf5a7c">2.5</ix:nonFraction>&#160;million of its NJ NOLs related tax benefits (&#8220;NJ NOL Tax Benefits&#8221;), which was subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="if463b298d932482a86bb1787b18f2ed0_D20220222-20220222" decimals="-5" name="clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfNDA3MA_56bafe88-386b-492f-9dcf-7bf60890e7a8">2.3</ix:nonFraction>&#160;million. The gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="if463b298d932482a86bb1787b18f2ed0_D20220222-20220222" decimals="-5" name="clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfNDA5Ng_5282f25a-5f71-454b-8f26-1730b261c001">2.5</ix:nonFraction>&#160;million have been recorded as a benefit from income taxes and the loss on sale of NJ NOLs of $<ix:nonFraction unitRef="usd" contextRef="if463b298d932482a86bb1787b18f2ed0_D20220222-20220222" decimals="-5" name="clbs:LossOnSaleOfNetOperatingLosses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfNDE4NA_fde4034e-2013-4603-a33e-3bfa0e38a2ab">0.1</ix:nonFraction>&#160;million recorded in other income (expense) in the consolidated financial statements.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the merger with Cend Therapeutics, Inc. (&#8220;Cend&#8221;) on September 15, 2022, federal and state NOLs of Cend may be subject to certain annual limitations under the ownership change rules of Section 382 of the IRC. As of December 31, 2021, Cend had state and foreign NOLs of approximately $4.3 million and $1.3 million, respectively. The state NOLs will begin to expire in 2036 unless previously utilized. The foreign NOLs will carry forward indefinitely.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, Cend had state research credit carryforwards of approximately $48 thousand that will carry forward indefinitely.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_1062"></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 12 &#8211; <ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="clbs:ResearchAndDevelopmentTaxIncentiveTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDYyL2ZyYWc6ZmM4MGE5Mjk4ODYxNGEwNmIyYTJkMjEyYjM2YzRhNGEvdGV4dHJlZ2lvbjpmYzgwYTkyOTg4NjE0YTA2YjJhMmQyMTJiMzZjNGE0YV81NDk3NTU4MTM5NzM0_0ad0953f-6a2d-44c1-9f35-c9cd99850311" continuedAt="i084da96dcb524a5b8c988e21a08d908c" escape="true">Australia Research and Development Tax Incentive</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i084da96dcb524a5b8c988e21a08d908c">The Company&#8217;s Australian subsidiary, which conducts core research and development activities, is eligible to receive a <ix:nonFraction unitRef="number" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDYyL2ZyYWc6ZmM4MGE5Mjk4ODYxNGEwNmIyYTJkMjEyYjM2YzRhNGEvdGV4dHJlZ2lvbjpmYzgwYTkyOTg4NjE0YTA2YjJhMmQyMTJiMzZjNGE0YV81NDk3NTU4MTM5NzM2_c7ea679a-62e7-4ca2-b8d4-0a463fb27518">43.5</ix:nonFraction>% refundable tax incentive for qualified research and development activities. As of the nine months ended September&#160;30, 2022, $<ix:nonFraction unitRef="usd" contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCredits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDYyL2ZyYWc6ZmM4MGE5Mjk4ODYxNGEwNmIyYTJkMjEyYjM2YzRhNGEvdGV4dHJlZ2lvbjpmYzgwYTkyOTg4NjE0YTA2YjJhMmQyMTJiMzZjNGE0YV81NDk3NTU4MTM5NzQz_1e329347-26f4-499b-93a2-db3b96ec35c5">0.4</ix:nonFraction>&#160;million was recorded as an income tax incentive receivable in the consolidated balance sheets, as the Company determined that the expenses met the eligibility criteria and the amounts claimed are expected to be received shortly after the related tax returns are filed.</ix:continuation></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_70"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 13 &#8211; <ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV83MC9mcmFnOjljNjBkMTM0Nzg4MTQ1ZjNhNzNkY2M1MmZjM2U5OTg2L3RleHRyZWdpb246OWM2MGQxMzQ3ODgxNDVmM2E3M2RjYzUyZmMzZTk5ODZfNDM3_e5153877-baaa-4f98-9b7b-fa8e83ef7497" continuedAt="i3b79a29a52684552b164f8511b299d8d" escape="true">Contingencies</ix:nonNumeric></span></div><ix:continuation id="i3b79a29a52684552b164f8511b299d8d" continuedAt="ife6ee253c0a24cf0803465c29938b096"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, Cend received a written threat of litigation on behalf of a Chinese entity called Lingmed Limited (&#8220;Lingmed&#8221;) claiming Lingmed was entitled to a success fee based on Cend&#8217;s Collaboration and License Agreement with Qilu Pharmaceuticals. Cend responded by denying that Lingmed is entitled to a success fee under the terms of their agreement. In May 2022, Cend was served with a complaint filed by Lingmed in the San Diego County Superior Court, alleging claims for breach of contract, fraud and declaratory relief. Cend&#8217;s response to the complaint was filed on June 6, 2022. Lingmed filed an </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ife6ee253c0a24cf0803465c29938b096">answer to Cend&#8217;s response on July 11, 2022. The court held a case management conference on October 7, 2022, which resulted in a continuance until December 16, 2022.</ix:continuation></span></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_1014"></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 14 &#8211; <ix:nonNumeric contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5NTE3_7a66f858-fc06-42c5-be40-cf44de2d5123" continuedAt="i68a3648150dc4841a6595be844ab365f" escape="true">License Agreements</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><ix:continuation id="i68a3648150dc4841a6595be844ab365f" continuedAt="ie24ca60d1f2a430e86f16c11156d665b"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanford Burnham Prebys</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (&#8220;SBP&#8221;) under which Cend was granted an exclusive, worldwide, royalty-bearing license to certain patent rights and know-how controlled by SBP related to the development of CEND-1. At the time the license agreement was entered into, Cend&#8217;s founding shareholder, now a Lisata board member, was an executive at SBP. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of <ix:nonFraction unitRef="shares" contextRef="i54c1f41cac654131b84226d73d9d67db_I20151231" decimals="INF" name="clbs:SharesIssuedUnderLicenseAgreement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5MjY4_99350bf7-8db6-4d9b-a961-ffc239b97f5f">382,030</ix:nonFraction> shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $<ix:nonFraction unitRef="usd" contextRef="i54c1f41cac654131b84226d73d9d67db_I20151231" decimals="-3" name="clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5Mjc3_83e74a55-ca27-4459-b0b4-e1c9ebbda608">10,000</ix:nonFraction> increasing to $<ix:nonFraction unitRef="usd" contextRef="i54c1f41cac654131b84226d73d9d67db_I20151231" decimals="-3" name="clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5Mjg5_589db692-3496-4a2c-afdf-09233bf08976">20,000</ix:nonFraction> on year seven of the agreement. The Company could also be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $<ix:nonFraction unitRef="usd" contextRef="i54c1f41cac654131b84226d73d9d67db_I20151231" decimals="-5" name="clbs:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5MzAx_a38a8596-88fd-4019-8d0e-49772cc84de8">10.6</ix:nonFraction>&#160;million. The Company has also agreed to pay SBP royalties of <ix:nonFraction unitRef="number" contextRef="i54c1f41cac654131b84226d73d9d67db_I20151231" decimals="INF" name="clbs:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5MzE2_781c8402-2c77-459f-9f00-e2290e2d4383">4</ix:nonFraction>% of net sales of products sold by the Company, or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP <ix:nonFraction unitRef="usd" contextRef="i54c1f41cac654131b84226d73d9d67db_I20151231" decimals="INF" name="clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5MzIw_ef1fce96-2845-433c-a275-6e43d915ee35">25</ix:nonFraction>% of any sublicensing income. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Cend entered into a license agreement with SBP under which Cend was granted an exclusive, royalty-bearing license to certain patent rights and know-how controlled by SBP. The agreement provides Cend with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. The Company is required to pay an annual license maintenance fee of $<ix:nonFraction unitRef="usd" contextRef="i155f1b104580445ca4ca140a0f0d9e28_I20211031" decimals="-3" name="clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5MzI1_f832a56b-0ced-4126-a343-723df6820865">20,000</ix:nonFraction>, increasing to $<ix:nonFraction unitRef="usd" contextRef="i155f1b104580445ca4ca140a0f0d9e28_I20211031" decimals="-3" name="clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5MzM3_f93597fa-a1ce-4595-8754-ee5424eb3c8c">30,000</ix:nonFraction> on year four of the agreement. Further, the Company could be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $<ix:nonFraction unitRef="usd" contextRef="i155f1b104580445ca4ca140a0f0d9e28_I20211031" decimals="-5" name="clbs:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5MzQ5_abe0b9d0-6469-4e1f-b90c-179aa2a0699a">23.2</ix:nonFraction>&#160;million. The Company is obligated to pay SBP royalties of <ix:nonFraction unitRef="number" contextRef="i155f1b104580445ca4ca140a0f0d9e28_I20211031" decimals="INF" name="clbs:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5MzY0_0d9aa64f-940e-4bf2-a9ec-9164e86c4e7f">4</ix:nonFraction>% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP varying sublicense fees, ranging from <ix:nonFraction unitRef="usd" contextRef="i3fd21aa0eb7e469692c04143d4a0aaa5_I20211031" decimals="INF" name="clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5MzY4_dd1c7096-0295-4815-bc8d-a827442090f4">10</ix:nonFraction>% to <ix:nonFraction unitRef="usd" contextRef="i568bd639252d47638984e18f0836cd66_I20211031" decimals="INF" name="clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5Mzcz_69e68bc9-7f7e-47dd-b771-a23afabfcb5a">25</ix:nonFraction>%, dependent on when the related milestones are reached. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreements will expire upon the later of (i) the final abandonment of all pending patent applications within the licensed patents or (ii) the expiration of the last to expire patent within the licensed patents. The agreements may be terminated in their entirety by the Company at any time by giving SBP sixty days&#8217; prior written notice. The agreements may be terminated in their entirety by SBP if the Company, at any time, defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice. The agreements may be terminated in their entirety by SBP or the Company (i) in the event of an uncured material breach by the other party, or (ii) in the event the other party (a) files for, or is involuntarily petitioned with, bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation), (b) makes an assignment of all or substantially all of its assets for the benefit of creditors, or (c) has a receiver or trustee is appointed and is unable to secure a dismissal, stay or other suspension of such proceedings within thirty days. Upon termination of the agreements for any reason, all rights and obligations of the Company with respect to the patents and patent applications shall terminate and revert to SBP.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SBP owned <ix:nonFraction unitRef="shares" contextRef="ie7a582d9c51846c999a8aae8d00b9b3f_I20211231" decimals="INF" name="clbs:SharesHeldByThirdParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5Mzc4_a4fbb587-6c41-45ff-a44d-9d3a8831ff32">382,030</ix:nonFraction> shares of the Company&#8217;s common stock as of September 30, 2022 and is a related party. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">University of California at San Diego</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, Cend entered into a license agreement with the University of California at San Diego (&#8220;UCSD&#8221;) under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of nano-particles to modulate immune response. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell and otherwise exploit the patent rights. The Company could be required to make milestone payments to UCSD upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $<ix:nonFraction unitRef="usd" contextRef="ie0f3bab25f7348bdbffea94e657798a0_I20210331" decimals="-5" name="clbs:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5Mzk2_19a7bd05-6f9b-4de5-90dd-487b90c0b22f">1.2</ix:nonFraction>&#160;million. The Company has also agreed to pay UCSD royalties of <ix:nonFraction unitRef="number" contextRef="ie0f3bab25f7348bdbffea94e657798a0_I20210331" decimals="INF" name="clbs:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5NDEw_4f85a8bf-7159-4c6a-9cb3-8f7b1499e4eb">1.5</ix:nonFraction>% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company agreed to pay UCSD varying sublicense fees, ranging from <ix:nonFraction unitRef="usd" contextRef="if1424658bffc4343bd5497ca9d561930_I20210331" decimals="INF" name="clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5NDE2_63c0d9c6-0473-4174-a272-eec7f1937c05">10</ix:nonFraction>% to <ix:nonFraction unitRef="usd" contextRef="ifa3e87e793164479a26fb0338f9209f6_I20210331" decimals="INF" name="clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5NDIx_975761c4-4a3c-4c51-80b9-641c83e2daa5">20</ix:nonFraction>%, dependent on when the related milestones are reached. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the expiration of the longest-lived patent rights. The agreement may be terminated in its entirety by the Company at any time by giving UCSD ninety days&#8217; prior written notice. The agreement may be terminated in its entirety by UCSD if the Company, at any time, (i) fails to perform or violates any term of the agreement and fails to cure the default within sixty days. Upon termination of the agreement for any reason, UCSD may terminate a sublicensee but will allow </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><ix:continuation id="ie24ca60d1f2a430e86f16c11156d665b" continuedAt="iefd829cdda524324bb11fe33a5acc31d"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company to assign any sublicenses to UCSD provided a) that the sublicensee is in good standing upon termination of the agreement with the Company; and b) the sublicensee is not currently involved in litigation as an adverse party to UCSD.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Massachusetts Institute of Technology</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Cend entered into a license agreement with the Massachusetts Institute of Technology ("MIT") under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of tissue specific delivery of interfering RNA. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. The Company is required to pay an annual license maintenance fee of $<ix:nonFraction unitRef="usd" contextRef="ieb7b6c7937914fcea021631924808998_I20211031" decimals="-3" name="clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5NDI2_c2062c96-6337-4d2f-85da-7358e6aa8145">20,000</ix:nonFraction>, increasing to $<ix:nonFraction unitRef="usd" contextRef="ieb7b6c7937914fcea021631924808998_I20211031" decimals="-3" name="clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5NDM1_24495cfd-b731-443c-b048-ed2475f15482">25,000</ix:nonFraction> for year two and three of the agreement, increasing to $<ix:nonFraction unitRef="usd" contextRef="ieb7b6c7937914fcea021631924808998_I20211031" decimals="-3" name="clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5NTM2_ffba508d-558e-4a12-8331-006fa9eca697">50,000</ix:nonFraction> on year four of the agreement and thereafter until the first commercial sale, and increasing to $<ix:nonFraction unitRef="usd" contextRef="i0050d762a7e64fa192ac048bca1f9775_I20211031" decimals="-3" name="clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5NDYy_2c047468-3818-4bad-a95d-e910f60b75d7">150,000</ix:nonFraction> each year of the agreement after the first sale. Further, the Company could be required to make milestone payments to MIT upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $<ix:nonFraction unitRef="usd" contextRef="ieb7b6c7937914fcea021631924808998_I20211031" decimals="-5" name="clbs:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5NDc1_9c5fd571-afd9-4c87-bf4d-598671d617f3">5.0</ix:nonFraction>&#160;million. The Company has also agreed to pay MIT royalties of <ix:nonFraction unitRef="number" contextRef="ieb7b6c7937914fcea021631924808998_I20211031" decimals="INF" name="clbs:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5NDg5_8168a6e4-ece2-40ee-aa86-f73dd392eec4">2</ix:nonFraction>% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay MIT varying sublicense fees, ranging from <ix:nonFraction unitRef="usd" contextRef="ib023bcf774d145f5834f6ee5051da753_I20211031" decimals="INF" name="clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5NDkz_3f2ba4c1-36c5-4c1b-b90d-fc28dfe35497">3</ix:nonFraction>% to <ix:nonFraction unitRef="usd" contextRef="i2362238e05b541a487b62ee42291726f_I20211031" decimals="INF" name="clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5NTIz_263ebaf1-d3e1-46b2-a4bb-517fb9470a8b">20</ix:nonFraction>%, dependent on when the related milestones are reached. In connection with the close of the Merger,, the Company was required to pay MIT a change of control fee of $<ix:nonFraction unitRef="usd" contextRef="ieb7b6c7937914fcea021631924808998_I20211031" decimals="-5" name="clbs:CollaborativeArrangementRightsAndObligationsChangeOfControlFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5NTAy_3da26bb5-07d5-4e33-bb7a-3dc5feaa52c5">0.3</ix:nonFraction>&#160;million, which is included in accrued liabilities within the condensed consolidated balance sheets as of September 30, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the expiration or abandonment of all valid claims. The agreement may be terminated in its entirety by the Company at any time by giving MIT six months prior written notice. The agreement may be terminated in its entirety by MIT if the Company, at any time, (i) defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice, or (ii) commits a material breach of its obligations under the agreement (aside from item (i)) and fails to cure that breach within sixty days after receipt of written notice. Upon termination of the agreement for any reason, the rights and licenses granted to the Company shall terminate and revert to MIT. Upon termination of the agreement for any reason, MIT may terminate a sublicensee but will allow the Company to assign any sublicenses to MIT provided that the sublicensee is in good standing upon termination of the agreement with the Company.</span></div></ix:continuation><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_1038"></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Note 15 &#8211; <ix:continuation id="iefd829cdda524324bb11fe33a5acc31d" continuedAt="i3b9d26e5b04a46ceabbda1651d96fd04">Research Collaboration and License Agreement</ix:continuation></span></div><ix:continuation id="i3b9d26e5b04a46ceabbda1651d96fd04"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusive License and Collaboration Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Cend entered into an Exclusive License and Collaboration Agreement (the &#8220;Qilu Agreement&#8221;) in which Cend granted an exclusive license to Qilu for the development and commercialization of CEND-1 in the Territory (defined as the Greater Area of China including China, Macau, Hong Kong, and Taiwan). Under the terms of the agreement, Qilu is solely responsible for the development of CEND-1 in its Territory. In consideration for the license, Qilu made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ic23e1c2433b54fffa2ed10e25463b457_I20210228" decimals="-6" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDM4L2ZyYWc6MTg4OGEwOGI5Nzg4NGU4OTk4MzQxN2FmYzIyMjA4YWMvdGV4dHJlZ2lvbjoxODg4YTA4Yjk3ODg0ZTg5OTgzNDE3YWZjMjIyMDhhY181NDk3NTU4MTUwOTMy_17d81b93-7f32-4b28-b904-f2d566781a1e">10</ix:nonFraction>&#160;million to Cend, which was recognized as revenue by Cend prior to the Merger. In addition, Cend received and recognized as revenue a $<ix:nonFraction unitRef="usd" contextRef="iab8db93a425c431683da42085f6e40e9_D20220914-20220914" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDM4L2ZyYWc6MTg4OGEwOGI5Nzg4NGU4OTk4MzQxN2FmYzIyMjA4YWMvdGV4dHJlZ2lvbjoxODg4YTA4Yjk3ODg0ZTg5OTgzNDE3YWZjMjIyMDhhY181NDk3NTU4MTUwOTkz_68476783-a538-417a-bfa7-896b4f732367">5</ix:nonFraction>&#160;million development milestone prior to the Merger. The Company is eligible to receive additional developmental and commercial milestone payments up to $<ix:nonFraction unitRef="usd" contextRef="i00de76018f10443a96daffcfc7a36a9f_I20210228" decimals="-6" name="clbs:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDM4L2ZyYWc6MTg4OGEwOGI5Nzg4NGU4OTk4MzQxN2FmYzIyMjA4YWMvdGV4dHJlZ2lvbjoxODg4YTA4Yjk3ODg0ZTg5OTgzNDE3YWZjMjIyMDhhY181NDk3NTU4MTUwOTQ1_b2a2f9be-fd5b-4da5-b9ef-ca623a5164d4">100</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i51afcddd58ef4d74a4eecfadef3991a2_I20210228" decimals="-6" name="clbs:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDM4L2ZyYWc6MTg4OGEwOGI5Nzg4NGU4OTk4MzQxN2FmYzIyMjA4YWMvdGV4dHJlZ2lvbjoxODg4YTA4Yjk3ODg0ZTg5OTgzNDE3YWZjMjIyMDhhY181NDk3NTU4MTUwOTU5_367ffe3f-ea87-4576-a690-fa8bf01d6e14">125</ix:nonFraction>&#160;million, respectively, tiered royalties on net sales ranging from <ix:nonFraction unitRef="number" contextRef="i00de76018f10443a96daffcfc7a36a9f_I20210228" decimals="INF" name="clbs:RevenuePerformanceObligationPercentageOfNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDM4L2ZyYWc6MTg4OGEwOGI5Nzg4NGU4OTk4MzQxN2FmYzIyMjA4YWMvdGV4dHJlZ2lvbjoxODg4YTA4Yjk3ODg0ZTg5OTgzNDE3YWZjMjIyMDhhY181NDk3NTU4MTUwOTgz_4401b3b1-0c77-4353-9634-31a4909fd9a2">10</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i51afcddd58ef4d74a4eecfadef3991a2_I20210228" decimals="INF" name="clbs:RevenuePerformanceObligationPercentageOfNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDM4L2ZyYWc6MTg4OGEwOGI5Nzg4NGU4OTk4MzQxN2FmYzIyMjA4YWMvdGV4dHJlZ2lvbjoxODg4YTA4Yjk3ODg0ZTg5OTgzNDE3YWZjMjIyMDhhY181NDk3NTU4MTUwOTg4_c5eec827-54d1-42d2-9d8b-c31f68edbc99">15</ix:nonFraction>%, and tiered sublicensing revenues ranging from <ix:nonFraction unitRef="number" contextRef="i00de76018f10443a96daffcfc7a36a9f_I20210228" decimals="INF" name="clbs:RevenuePerformanceObligationPercentageOfSublicensingRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDM4L2ZyYWc6MTg4OGEwOGI5Nzg4NGU4OTk4MzQxN2FmYzIyMjA4YWMvdGV4dHJlZ2lvbjoxODg4YTA4Yjk3ODg0ZTg5OTgzNDE3YWZjMjIyMDhhY181NDk3NTU4MTUwOTcz_271c4c48-ed1a-42e7-ad09-826eec0589ac">12</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i51afcddd58ef4d74a4eecfadef3991a2_I20210228" decimals="INF" name="clbs:RevenuePerformanceObligationPercentageOfSublicensingRevenues" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDM4L2ZyYWc6MTg4OGEwOGI5Nzg4NGU4OTk4MzQxN2FmYzIyMjA4YWMvdGV4dHJlZ2lvbjoxODg4YTA4Yjk3ODg0ZTg5OTgzNDE3YWZjMjIyMDhhY181NDk3NTU4MTUwOTc4_0d422acf-0445-4a68-b757-5f28aa0138c1">35</ix:nonFraction>%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated early, the Qilu Agreement will continue in effect until the expiration of all Qilu payment obligations. Either party may terminate the Qilu Agreement if an undisputed material breach by the other party is not cured within a defined period of time, or upon notice for insolvency-related events of the other party that are not discharged within a defined time period. Qilu may terminate the Qilu Agreement in its entirety, at any time with at least sixty days written notice. All right and obligations of Qilu with respect to such licensed patents and patent applications would terminate.</span></div></ix:continuation><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25 </span></div></div></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; herein and under &#8220;Risk Factors&#8221; in our 2021 Form 10-K. The following discussion should be read in conjunction with our consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report and in our 2021 Form 10-K.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Lisata&#8217;s lead investigational product candidate, LSTA1 (formerly known as CEND-1), is designed to activate a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment (&#8220;TME&#8221;), making tumors more susceptible to immunotherapies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LSTA1 has demonstrated favorable safety, tolerability, and activity to date in completed and ongoing clinical trials to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. Lisata and its collaborators have also amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics. We are exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively. In addition, Lisata also has clinical development programs based on its autologous CD34+ cell therapy technology platform.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience across a variety of therapeutic categories and at all stages of development from preclinical through to product registration and launch. Our goal is to develop and commercialize products that address important unmet medical needs based on a broad and versatile portfolio of candidates. Our current product candidates include: </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">LSTA1, the subject of phase 1b/2a and 2b clinical studies being conducted globally in a variety of solid tumor types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a variety of anti-cancer regimens;</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (LSTA16 formerly CLBS16), the subject of both a completed positive Phase 2a study (ESCaPE-CMD) and follow on Phase 2b study (FREEDOM Trial) in the United States for the treatment of coronary microvascular dysfunction (&#8220;CMD&#8221;); </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (LSTA12 formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (&#8220;CLI&#8221;) and Buerger&#8217;s disease is being sought based on the current results of a clinical trial executed in Japan. CLBS12 was the recipient of orphan drug designation in March 2021 from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for Buerger's disease; and </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">LSTA201 (formerly CLBS201), the subject of a study designed to assess the safety and efficacy of CD34+ cell therapy as a regenerative treatment for patients with chronic kidney disease related to type 2 diabetes (diabetic kidney disease or &#8220;DKD&#8221;). </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Targeted Solid Tumor Penetration via CendR Active Transport</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many solid tumor cancers, including pancreatic ductal adenocarcinoma (&#8220;PDAC&#8221;), gastric cancers and many other solid tumor cancers are surrounded by dense fibrotic tissue, or stroma. This limits the efficacy of current chemotherapies for these cancers. Emerging immunotherapy treatments, including checkpoint inhibitors, adoptive cell therapies such as chimeric antigen receptor T (&#8220;CAR-T&#8221;) cells, as well as nucleic acid-based therapies, such as short interfering RNA (&#8220;siRNA&#8221;), antisense oligonucleotides (&#8220;ASO&#8221;), and messenger RNAs (&#8220;mRNAs&#8221;) face particular challenges in penetrating solid tumors. Many tumors also exhibit an immunosuppressive tumor microenvironment (&#8220;TME&#8221;), which suppresses patients&#8217; immune systems&#8217; ability to fight their cancer and can limit effectiveness of immunotherapies. These factors negatively impact the ability of many therapeutic agents and immunotherapies to effectively treat these cancers.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To address the tumor stroma&#8217;s role as a primary impediment to effective treatment, Lisata&#8217;s approach is to activate the C-end rule (&#8220;CendR&#8221;) natural transport system that normally brings nutrients into a tissue under emergency situations such as an injury.  Cancers highjack this system to promote their own growth.  Lisata&#8217;s lead investigational drug, LSTA1 (a specific internalizing R-G-D or iRGD peptide) activates this transport system in a tumor-specific manner (Sugahara, Science, 2010). </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This results in tumors taking up systemically administered anticancer drugs as if they were nutrients. As a result, more drug accumulates in the tumor than would accumulate without LSTA1, while normal tissues are not affected. Moreover, the drugs penetrate tumor cells farther away from blood vessels with LSTA1 than without. The overall result is enhanced anticancer activity without an increase in side effects. Anticancer drugs can be coupled/tethered or conjugated to LSTA1 or other CendR peptides in Lisata&#8217;s portfolio, but can be also simply given together with LSTA1. Lisata believes that the co-administration option is an advantage because it is not necessary to create a new chemical entity with its attendant development and regulatory hurdles, providing a potentially faster-to-clinic and potentially faster-to-market product opportunity for a range of solid tumor cancers and for co-administration with a range of therapies.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical progress with other approaches to address delivery to highly fibrotic tumors, such as PEGylated hyaluronidase and hedgehog inhibitors, has been limited by toxicity and side effects. LSTA1 has demonstrated favorable safety/tolerability and activity in clinical trials to enhance delivery of standard-of-care chemotherapy for PDAC. Lisata and its collaborators have also amassed non-clinical data demonstrating enhanced delivery of a range of emerging anticancer therapies, including immunotherapies, and RNA-based therapeutics. LSTA1&#8217;s cancer-targeted delivery may enable such emerging treatment modalities to potentially more effectively treat a range of solid tumors.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LSTA1 as a treatment for solid tumor cancers in combination with other anti-cancer agents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LSTA1 is an investigational drug that actuates the CendR active transport mechanism while also having the potential to modify the TME and make it less immunosuppresive. It is targeted to tumor vasculature by its affinity for alpha-v, beta-3 and beta-5 integrins that are selectively expressed in tumor vasculature, but not healthy tissue vasculature. LSTA1 is a specific cyclic internalizing RGD (&#8220;iRGD&#8221;) peptide that, once bound to these integrins, is cleaved by proteases expressed in tumors to release a peptide fragment, called a CendR fragment, which binds to a second receptor, called neuropilin-1, to activate a novel uptake pathway that allows anticancer drugs to more selectively penetrate solid tumors. The ability of LSTA1 and iRGD peptides to modify the TME to enhance delivery and efficacy of co-administered drugs has been demonstrated in models of a range of solid tumors with the results from Lisata, collaborators and research groups around the world having been the subject of over 200 scientific publications.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to clinical development, LSTA1 is the subject of a completed Phase 1b clinical trial of 31 first-line metastatic pancreatic ductal adenocarcinoma patients, of which 29 were evaluable. Results from the trial showed that the safety profile of the LSTA1 combination regimen was similar to standard of care (&#8220;SoC&#8221;) alone with LSTA1 being well-tolerated with no-dose limiting toxicities. An Objective Response Rate (&#8220;ORR&#8221;) of fifty nine percent was observed, including a rare complete response, which compares favorably to the twenty three percent ORR observed in the &#8220;MPACT&#8221; clinical trial that served as the basis for approval of nab-paclitaxel for use in combination with gemcitabine for the treatment of first line, metastatic pancreatic ductal adenocarcinoma. A Disease Control Rate (&#8220;DCR&#8221;); (partial and complete responses plus stable disease) of over seventy nine percent was observed in comparison to a DCR of forty eight percent observed in the MPACT trial. Reduction in the level of circulating tumor biomarker CA19-1 was observed in ninety six percent of patients versus sixty one percent in the MPACT trial. Importantly, median progression-free survival and median overall survival of nearly ten months and over thirteen months was observed, respectively, vs. less than six months and less than nine months, respectively, in the MPACT trial. These results have been published in The Lancet Gastroenterology and Hepatology (Dean, et al. 2022).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, LSTA1 is the subject of multiple ongoing and planned clinical trials being conducted globally in a variety of solid tumor types and in combination with several chemotherapy and immunotherapy anti-cancer regimens. The following diagram summarizes these studies.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:36pt"><img src="clbs-20220930_g1.jpg" alt="clbs-20220930_g1.jpg" style="height:371px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ischemic Repair (CD34+ Cell Technology)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CD34+ cell was discovered as a result of the deliberate search for a cell capable of stimulating the development and/or repair of blood vessels. All tissues in the body maintain their function by replacing cells over time. In addition to the maintenance function, the body must also be capable of building new blood vessels after injury. A CD34+ cell is an endothelial progenitor cell that has the ability to stimulate new blood vessel formation at the level of the microvasculature. No other native cell discovered to date has demonstrated this same capability.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary cell technology using autologous (a patient&#8217;s own naturally occurring) CD34+ cells has led to the development of therapeutic product candidates designed to address diseases and conditions caused by ischemia. Ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted or reduced. Through the administration of CD34+ cells, we seek to promote the development and formation of new microvasculature and thereby increase blood flow to the impacted area. We believe that a number of conditions caused by underlying ischemic injury can be improved through our CD34+ cell technology, including, but not limited to, Buerger's disease, CLI, CMD, and DKD.</span></div><div style="margin-bottom:8pt;padding-left:1.44pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for Treatment of Coronary Microvascular Dysfunction</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, with the assistance of a $1.9&#160;million grant from the National Institutes of Health (Award Number R44HL135889), we initiated our program for XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of CMD, a disease that afflicts as many as 1.6 million patients in the United States alone, with no current targeted treatment options. That study, the ESCaPE-CMD Trial, was a Phase 2a proof-of-concept, open label study that enrolled patients at the Mayo Clinic in Rochester, MN and Cedars-Sinai Medical Center in Los Angeles, CA. Those data showed a positive therapeutic effect with a statistically significant improvement in angina frequency, coronary flow reserve, Canadian Cardiovascular Society Angina Class and Seattle Angina Questionnaire scores, as well as an acceptable safety profile. The full data set from that study was presented at the SCAI 2020 Scientific Sessions Virtual Conference on May 14, 2020 by Dr. Timothy Henry, FACC, of the Christ Hospital in Cincinnati, Ohio.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In December 2020, we commenced enrollment in our Phase 2b FREEDOM Trial of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a double-blind, randomized, placebo-controlled clinical trial designed to further evaluate the efficacy and safety of intracoronary artery delivery of autologous CD34+ cells in subjects with Coronary Microvascular Dysfunction (CMD) and without obstructive coronary artery disease and was expected to complete enrollment in approximately 12 months. While early enrollment proceeded to plan with the first patient treated in January 2021, the COVID-19 pandemic resulted in insurmountable enrollment rate challenges and population heterogenicity. As a result, in May 2022, we announced that enrollment in the FREEDOM Trial had been suspended and that we intended to conduct an interim analysis of the data from not less than the first 20 patients enrolled using the 6-month follow-up data to evaluate the efficacy and safety of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in subjects with CMD. Following the analysis of results of the FREEDOM Trial subjects completing 6-month follow-up along with Key Opinion Leaders&#8217; input, our board of directors determined that execution of a redesigned FREEDOM-like trial would be the appropriate next step, but the cost of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such a trial would be prohibitively expensive to undergo without a strategic partner. Accordingly, our board of directors concluded that XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> development will only be continued if a strategic partner that can contribute the necessary capital for a redesigned trial is identified and secured. There can be no assurance that we will be able to identify such a partner and enter into an agreement with such partner on acceptable terms or at all.</span></div><div style="margin-bottom:8pt;padding-left:0.72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> for Treatment of Critical Limb Ischemia</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our randomized, open-label, registration-eligible study of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan for the treatment of CLI and Buerger's disease has, to date, demonstrated positive trends in both safety and efficacy. The HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> study's enrollment, however, has been significantly curtailed by the COVID-19 pandemic's impact in Japan, including the States of Emergency in Japan that have persisted for much of 2020, 2021, and 2022. Due to the significant and continued operational and financial burden incurred as a result of these COVID-19 delays, coupled with the unpredictability of the timing of site enrollment re-initiation, we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">suspended further enrollment in the fourth quarter of 2021. Following study suspension, we completed all protocol-defined patient observations and are preparing the clinical study report. HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is now in the pre-consultation phase of the registration process with the Pharmaceuticals and Medical Devices Agency (&#8220;PMDA&#8221;) in Japan.  Data from the follow-up of all patients completed in the registration-eligible clinical trial in Japan has been compiled and are being reviewed by the PMDA after which the PMDA is expected to provide important perspective to be considered in preparation for the formal consultation meetings which precede the Japanese new drug application. If successful in the pre-consultation process, we expect formal clinical consultation to occur by mid-year 2023.  In the meantime, we are focusing our efforts on consummating a partnership for the product in Japan. Such a partnership may become the basis for the completion of development and registration of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan.  This may include the completion of enrollment of the four remaining no-option CLI subjects stipulated in the original protocol, if necessary, and/or exploration of submitting the existing data to Japan's PMDA under Japan's regenerative medicine regulations, which allow for conditional approval of innovative regenerative medicine products. Despite receipt of orphan designation from the FDA in March 2021 in the United States for LSTA12 as a potential treatment for Buerger's disease, based on a response from the FDA in October 2021 regarding a development plan for U.S. registration, we have decided not to pursue U.S. development in Buerger's disease at this time.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LSTA201 for Treatment of Diabetic Kidney Disease</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progressive kidney failure is associated with attrition of the microcirculation of the kidney. Pre-clinical studies in kidney disease and injury models have demonstrated that protection or replenishment of the microcirculation results in improved kidney function. Based on these observations, we have elected to move forward with a Phase 1b, open-label, proof-of-concept trial evaluating LSTA201 dosed via intra-renal artery injections in subjects with DKD. This protocol includes six subjects in total with the first two subjects sequentially dosed and followed for a two-week safety observation period. Clearance by an independent Data Safety Monitoring Board (&#8220;DSMB&#8221;) overseeing the study then permitted the treatment of the next four patients, with all patients being followed for safety and therapeutic effect. A read-out of data will occur after the six-month follow-up visit for all patients. A key criterion for continued development of LSTA201 will be our ability to demonstrate a therapeutic effect that will make it competitive in the field of DKD treatment, i.e., kidney function regeneration, as indicated by increased glomerular filtration rate. The Company treated the first patient in the LSTA201 proof-of-concept study in April 2022 and completed treatment for all six subjects during the third quarter of 2022. Top-line data is anticipated from all subjects in the first quarter of 2023. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Out-licensing Opportunities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our broad intellectual property portfolio of assets includes notable programs available for out-licensing in order to augment or continue their clinical development. Our current long-term strategy focuses on advancing our therapies through development with the ultimate objective of obtaining market authorizations and entering commercialization, either alone or with partners, to provide treatment options to patients suffering from life-threatening medical conditions. We believe that we are well-positioned to realize potentially meaningful value increases within our own proprietary pipeline if we are successful in advancing our product candidates to their next significant development milestones.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merger with Cend Therapeutics, Inc. and Name Change</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2022, the Company, then operating as Caladrius Biosciences, Inc. (&#8220;Caladrius"), completed its acquisition of Cend Therapeutics, Inc. (&#8220;Cend&#8221;), a Delaware corporation (the &#8220;Merger&#8221;), in accordance with the terms of the Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), dated as of April 26, 2022, by and among Caladrius, Cend and CS Cedar Merger Sub, Inc. (&#8220;Merger Sub&#8221;).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms set forth in the Merger Agreement and effective September 15, 2022 (the &#8220;Effective Time&#8221;): (i) Merger Sub merged with and into Cend, with Cend surviving as a wholly owned subsidiary of Caladrius, (ii) Caladrius changed its name to Lisata Therapeutics, Inc. in connection with and immediately following to the Effective Time, and (iii) Caladrius </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effected a 1:15 reverse stock split of its common stock (&#8220;Reverse Stock Split&#8221;) prior to the Effective Time. At the Effective Time, each share of Cend's common stock outstanding immediately prior to the Effective Time was converted into the right to receive shares of Lisata&#8217;s common stock based on an exchange ratio of 0.5338 (the &#8220;Exchange Ratio&#8221;), after taking into account the Reverse Stock Split. In connection with the Merger close, the Company issued an aggregate of 3,772,768 shares of common stock, based on the Exchange Ratio, to holders of Cend, in exchange for all of the Cend capital stock outstanding immediately prior to the closing of the Merger.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Merger Agreement, we assumed all of the outstanding and unexercised options to purchase shares of Cend capital stock under the 2016 Equity Incentive Plan (the &#8220;Cend Plan&#8221;), and, in connection with the Merger, such options were converted into options to purchase shares of Lisata&#8217;s common stock based on the Exchange Ratio. At the closing of the Merger at the Effective Time, we assumed Cend's stock options to purchase an aggregate of 1,227,776 shares of the Company's common stock. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caladrius was considered to be the accounting acquirer based on the terms of the Merger Agreement and certain factors including: (i) Caladrius owned approximately 52% of the Company's outstanding shares of common stock immediately following the close of the Merger; (ii) although both entities contributed to the new management team of Lisata, the Caladrius team has more individuals on the management team and will hold the CEO, CMO and other senior management roles; (iii) Caladrius paid a premium to acquire Cend&#8217;s assets; and (iv) Caladrius was significantly larger than Cend regarding total assets, operations, and research and development activities. The Merger was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (&#8220;IPR&amp;D&#8221;). Cend&#8217;s assets (except for cash and working capital) were measured and recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated with IPR&amp;D with no alternative future use being expensed. The prior reported operating results prior to the Merger close are those of Caladrius.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of the COVID-19 Pandemic</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to present substantial public health and economic challenges around the world, and to date has led to the implementation of various responses, including government-imposed quarantines, stay-at-home orders, travel restrictions, mandated business closures and other public health safety measures.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to closely monitor the impact of the COVID-19 pandemic on all aspects of our business, including how it has and will continue to impact our operations and the operations of our suppliers, vendors and business partners, and may take further precautionary and preemptive actions as may be required by federal, state or local authorities. In addition, we have taken steps to minimize the current environment&#8217;s impact on our business and strategy, including devising contingency plans and securing additional resources from third party service providers. For the safety of our employees and families, we implemented a universal work from home policy as well as stringent social distancing and other hygiene policies for employees when they must be in the office. Our clinical study of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan experienced significant delays in enrollment due to the States of Emergency in effect in Japan for most of 2020, 2021, and 2022 covering Tokyo and other regions in response to an increased number of COVID-19 infections. With our expectation that COVID-19 in Japan would continue to impact negatively enrollment of patients in the HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical trial, we elected to suspend trial enrollment, seek a development partner and consult with the Japanese regulatory authorities regarding the submission of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patient data already accrued. In addition, our phase 2b trial of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States has also experienced delays in enrolling patients as a result of COVID-19, as described above. In May 2022, we announced that enrollment in the FREEDOM Trial had been suspended and that we intend to conduct an interim analysis of the data from not less than the first 20 patients enrolled using the 6-month follow-up data to evaluate the efficacy and safety of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in subjects with CMD. Following the analysis of results of the FREEDOM Trial subjects completing 6-month follow-up along with Key Opinion Leaders&#8217; input, the Company&#8217;s board of directors determined that execution of a redesigned FREEDOM-like trial would be the appropriate next step, but the cost of such a trial would be prohibitively expensive to undergo without a strategic partner. Accordingly, the Company&#8217;s board of directors concluded that XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> development will only be continued if a strategic partner that can contribute the necessary capital for a redesigned trial is identified and secured. There can be no assurance that we will be able to identify such a partner and enter into an agreement with such partner on acceptable terms or at all.<br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond its impact on our development pipeline described above, the extent to which COVID-19 ultimately impacts our business, results of operations and financial condition will depend on future developments, which remain highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, the emergence of new variants, new information that may emerge concerning the severity of COVID-19 or the effectiveness of actions taken to contain COVID-19 or treat its impact, including vaccination campaigns, among others. If we or any of the third parties with whom we engage, however, were to experience any additional shutdowns or other prolonged business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially or negatively affected, which could have a material adverse impact on our business, financial condition and results of operations. It is possible that our clinical development timelines could </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">continue to be negatively affected by COVID-19, which could materially and adversely affect our business, financial condition and results of operations. See &#8220;Risk Factors&#8221; in our 2021 Form 10-K for additional discussion of the potential adverse impact of the COVID-19 pandemic on our business, financial condition and results of operations.</span></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_76"></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September&#160;30, 2022 Compared to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September&#160;30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended September&#160;30, 2022 and September&#160;30, 2021:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.789%"><tr><td style="width:1.0%"></td><td style="width:51.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(745)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;In-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,720&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,968&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,752&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37,720)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,752)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37,383)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,927)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,456)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, net losses were $37.4 million for the three months ended September&#160;30, 2022, compared to $6.9 million for the three months ended September&#160;30, 2021. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September&#160;30, 2022, operating expenses totaled $37.7 million compared to $7.0 million for the three months ended September&#160;30, 2021, representing an increase of 441.3%. Excluding the in-process research and development expense of $30.4&#160;million relating to the Merger, operating expenses increased by $0.4&#160;million, or 5.2% compared to the three months ended September&#160;30, 2021 . Operating expenses comprised the following:&#160;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and development expenses were approximately $3.4&#160;million for the three months ended September&#160;30, 2022, compared to $4.1 million for the three months ended September&#160;30, 2021, representing a decrease of $0.7&#160;million or 18.1%. This was primarily due to a decrease in expenses associated with our XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Phase 2b study (the FREEDOM Trial) as a result of the suspension in enrollment which commenced in the second quarter of 2022 and study close out activities in the third quarter of 2022, a decrease in expenses associated with HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan related to study close out costs partially offset by the addition of Chemistry, Manufacturing, and Controls (&#8220;CMC&#8221;) activities for LSTA1 and enrollment activities for Australasian Gastrointestinal Trials Group (&#8220;AGITG&#8221;) ASCEND study. Research and development in both periods related to:</span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.25pt">expenses associated with our XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Phase 2b study (the FREEDOM Trial); </span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">expenses associated with our registration-eligible study for HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in critical limb ischemia in Japan as well as corresponding regulatory discussions support expenses; </span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">expenses associated with the preparation of our filing of an Investigational New Drug Application (&#8220;IND&#8221;), as well as study execution expenses for the clinical study of LSTA201 for treatment of DKD, A Phase 1b, open-label, proof-of-concept trial which includes six subjects in total;</span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">expenses associated with the addition of CMC activities for LSTA1, enrollment activities for the LSTA1 Phase 2b ASCEND study and preparatory activities associated with the design of a planned LSTA1 proof-of-concept basket trial in various solid tumors and in combination with the corresponding standards of care. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expenses were approximately $3.9 million for the three months ended September&#160;30, 2022, compared to $2.8 million for the three months ended September&#160;30, 2021, representing an increase of 39.0%. This increase was primarily due to an increase in equity expense as a result of performance stock unit vesting, Merger option assumption expense and departing board member restricted stock unit vesting in addition to an increase in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses associated with our annual stockholder meeting. Our general and administrative expenses focus on general corporate-related activities.  </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, to minimize our use of cash, we have used a variety of equity and equity-linked instruments to compensate employees, consultants and other service providers. The use of these instruments has resulted in charges to the results of operations, which have been significant in the past.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income is comprised of investment income on cash, cash equivalents and marketable securities.</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September&#160;30, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compared to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September&#160;30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the nine months ended September&#160;30, 2022 and September&#160;30, 2021:</span></div><div style="margin-bottom:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.643%"><tr><td style="width:1.0%"></td><td style="width:52.932%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.258%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,632)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;In-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,061&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,201&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,860&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51,061)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,201)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28,860)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,479)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,235)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,672)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27,563)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, net losses were $48.2 million for the nine months ended September&#160;30, 2022, compared to $20.7 million for the nine months ended September&#160;30, 2021.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September&#160;30, 2022, operating expenses totaled $51.1 million compared to $22.2 million for the nine months ended September&#160;30, 2021, representing an increase of 130.0%. Excluding the one-off in-process research and development expense of $30.4&#160;million, operating expenses decreased by $1.5&#160;million or 6.9% compared to the nine months ended September&#160;30, 2021. Operating expenses comprised the following:&#160;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and development expenses were approximately $9.9&#160;million for the nine months ended September&#160;30, 2022, compared to $13.5 million for the nine months ended September&#160;30, 2021, representing a decrease of $3.6&#160;million or 26.8%. This was primarily due to a decrease in expenses associated with our XOWNA&#174; Phase 2b study (the FREEDOM Trial) as a result of the suspension in enrollment which commenced in the second quarter of 2022 and study close out activities in the third quarter of 2022, a decrease in expenses associated with HONEDRA&#174; in Japan related to study close out costs and one off recruiting expenses and interim CMO consulting expenses in the prior year partially offset by the addition of CMC activities for LSTA1 and enrollment activities for AGITG ASCEND study. Research and development in both periods related to:</span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.25pt">expenses associated with our XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Phase 2b study (the FREEDOM Trial); </span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">expenses associated with our registration-eligible study for HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in critical limb ischemia in Japan as well as corresponding regulatory discussions support expenses; </span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">expenses associated with the preparation of our filing of an Investigational New Drug Application (&#8220;IND&#8221;), as well as study execution expenses for the clinical study of LSTA201 for treatment of DKD, a Phase 1b, open-label, proof-of-concept trial which includes six subjects in total;</span></div><div style="margin-bottom:8pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">expenses associated with the addition of CMC activities for LSTA1, enrollment activities for the LSTA1 Phase 2b ASCEND study and preparatory activities associated with the design of a planned LSTA1 proof-of-concept basket trial in various solid tumors and in combination with the corresponding standards of care.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expenses were approximately $10.8 million for the nine months ended September&#160;30, 2022, compared to $8.7 million for the nine months ended September&#160;30, 2021, representing an increase of 24.0%. This was primarily due to a one-time increase in fees associated with the review of potential strategic transactions and Merger related costs, an increase in equity expense as a result of performance stock unit vesting, Merger option assumption expense and departing board member restricted stock unit vesting in addition to an increase in expenses associated with our annual stockholder meeting. Our general and administrative expenses focus on general corporate-related activities.  </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, to minimize our use of cash, we have used a variety of equity and equity-linked instruments to compensate employees, consultants and other service providers. The use of these instruments has resulted in charges to the results of operations, which have been significant in the past.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income (expense) is comprised of investment income on cash, cash equivalents and marketable securities and a loss on sale related to the sale of our NJ NOLs.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Tax Benefit</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we received final approval from the New Jersey Economic Development Authority (&#8220;NJEDA&#8221;) under the Technology Business Tax Certificate Transfer Program (&#8220;Program&#8221;) to sell a percentage of our NJ NOLs, which were subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $2.3 million. The $2.5 million of our NJ NOL Tax Benefits have been recorded as a benefit from income taxes and the loss on sale of $0.1 million recorded in other income (expense).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33 </span></div></div></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Analysis of Liquidity and Capital Resources</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022, we had cash, cash equivalents and marketable securities of approximately $75.5 million, working capital of approximately $70.9 million, and stockholders&#8217; equity of approximately $72.0 million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022, we met our immediate cash requirements through existing cash balances.  Additionally, we used equity and equity-linked instruments to pay for services and compensation. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in or provided by, operating, investing and financing activities were as follows (in thousands):&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:66.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,702)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,641)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,354)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Operating Activities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in operating activities during the nine months ended September&#160;30, 2022 was $14.7 million, which is comprised of (i) our net loss of $48.2 million, adjusted for non-cash expenses totaling $33.5&#160;million (which includes adjustments for equity-based compensation, depreciation and amortization, in process research and development expenses, and amortization/accretion of marketable securities), and (ii) changes in operating assets and liabilities providing approximately $0.1 million.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in operating activities during the nine months ended September&#160;30, 2021 was $17.6 million, which is comprised of (i) our net loss of $20.7 million, adjusted for non-cash expenses totaling $3.6 million (which includes adjustments for equity-based compensation, depreciation and amortization, and amortization/accretion of marketable securities) and (ii) changes in operating assets and liabilities using approximately $0.6 million.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Investing Activities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash provided by investing activities during the nine months ended September&#160;30, 2022 totaled $21.8 million and was primarily due to net sales of marketable securities (net of purchases of marketable securities) partially offset by the asset acquisition costs, net of cash acquired related to the Merger with Cend.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in investing activities during the nine months ended September&#160;30, 2021 totaled $71.4 million and was primarily due to net purchases of marketable securities (net of sales of marketable securities).</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Financing Activities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash used in financing activities during the nine months ended September&#160;30, 2022 totaled $0.2 million, consisted primarily of tax withholding-related payments on net share settlement equity awards to employees. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash provided by financing activities during the nine months ended September&#160;30, 2021 totaled $85.3 million, primarily consisted of (i) net proceeds of $23.1 million through the issuance of common shares and warrants in our January 2021 private placement, (ii) net proceeds of $1.8 million in connection with warrant exercises, (iii) net proceeds of $60.6 million through the issuance of common shares and warrants in both of our February 2021 registered direct offerings, which was partially offset by tax withholding-related payments on net share settlement equity awards to employees. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Requirements Outlook</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To meet our short and long-term liquidity needs, we expect to use existing cash balances and a variety of other means. Other sources of liquidity could include additional potential issuances of debt or equity securities in public or private financings, partnerships and/or collaborations and/or sale of assets. Our history of operating losses and liquidity challenges may make it difficult for us to raise capital on acceptable terms or at all. The demand for the equity and debt of pharmaceutical companies like ours is dependent upon many factors, including the general state of the financial markets. During times of extreme market volatility, capital may not be available on favorable terms, if at all. Our inability to obtain such additional capital could materially and adversely affect our business operations. We will also continue to seek, as appropriate, grants for scientific and clinical studies from various governmental agencies and foundations, and other sources of non-dilutive funding. We believe that our cash on hand will enable us to fund operating expenses for at least the next 12 months following the issuance of our financial statements. Our future capital requirements are difficult to forecast and will depend on many factors </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including the timing and nature of any other strategic transactions that we undertake; and our ability to establish and maintain collaboration partnerships, in-license/out-license or other similar arrangements and the financial terms of such agreements.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2021, we entered into an At The Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC as sales agent, in connection with an &#8220;at the market offering&#8221; under which we from time to time may offer and sell shares of our common stock, having an aggregate offering price of up to $50.0&#160;million. As of September&#160;30, 2022, we had not issued any shares under the ATM Agreement. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to seek capital through a number of means, there can be no assurance that additional financing will be available on acceptable terms, if at all, and our negotiating position in capital generating efforts may worsen as existing resources are used. Additional equity financing may be dilutive to our stockholders; debt financing, if available, may involve significant cash payment obligations and covenants that restrict our ability to operate as a business; our stock price may not reach levels necessary to induce option or warrant exercises; and asset sales may not be possible on terms we consider acceptable. If we are unable to access capital necessary to meet our long-term liquidity needs, we may have to delay the expansion of our business or raise funds on terms that we currently consider unfavorable. <br/></span></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_82"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that our operations are seasonal in nature.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our critical accounting policies and estimates during the three and nine months ended September&#160;30, 2022, compared to those reported in our 2021 Form 10-K with the exception of the valuation of the Merger which was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (&#8220;IPR&amp;D&#8221;).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_85"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.<br/></span></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_88"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)&#160;&#160;Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosure controls and procedures are the controls and other procedures we have designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports that we file under the Exchange Act is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well-designed and operated, can provide only reasonable assurance of achieving the desired control objectives. Due to the inherent limitations of control systems, not all misstatements may be detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. Controls and procedures can only provide reasonable, not absolute, assurance that the above objectives have been met.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, we carried out an evaluation, with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective, at the reasonable assurance level, in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms and is accumulated and communicated to management, including the principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35 </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)&#160;&#160;Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the internal control over financial reporting in conjunction with the Merger, there were no changes in our internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15, that occurred during our last quarter to which this Quarterly Report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36 </span></div></div></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_94"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than as disclosed in &#8220;Note 13 &#8211; Contingencies&#8221; set forth in the Notes to Unaudited Consolidated Financial Statements, which are included herein, there are no material changes to the disclosures previously reported in our 2021 Form 10-K.<br/></span></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_97"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the risk factors previously reported in our 2021 Form 10-K, in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2022 and June 30, 2022 and in Exhibit 99.2 to our Amendment No. 1 to Current Report on Form 8-K/A filed on October 4, 2022. See the risk factors set forth in our 2021 Annual Report on Form 10-K under the caption &#8220;Item 1 A - Risk Factors.&#8221;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify"><span><br/></span></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_100"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_103"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span><br/></span></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_106"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span><br/></span></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_109"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. OTHER INFORMATION</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_112"></div><div style="-sec-extract:summary;margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Exhibit Index appearing immediately after the signature page to this Form 10-Q is incorporated herein by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37 </span></div></div></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><div style="margin-bottom:8pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LISATA THERAPEUTICS, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 10, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> /s/ David J. Mazzo, PhD      </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name: David J. Mazzo, PhD      </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title:   Chief Executive Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer, Principal Financial Officer </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and Principal Accounting Officer)</span></div></td></tr></table></div><div style="margin-bottom:3.3pt;padding-left:6.75pt;padding-right:2.25pt;text-align:justify;text-indent:15.75pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38 </span></div></div></div><div id="ie1084e3f1fc74e21b06ddcc16cf4ec69_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie1084e3f1fc74e21b06ddcc16cf4ec69_7">Index</a></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LISATA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:522.00pt"><tr><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:13.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:461.50pt"></td><td style="width:1.0pt"></td></tr><tr style="height:32pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001722000031/ex21-mergeragreement10pf.htm">2.1</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agreement and Plan of Merger and Reorganization, dated April 26, 2022, among Caladrius Biosciences, Inc., CS Cedar Merger Sub, Inc., and Cend Therapeutics, Inc. (filed as Exhibit 2.1 to the Company's Current Report on Form 8-K, filed with the SEC on April 27, 2022).</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001722000031/exhibit22-supportagreeme.htm">2.2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Support Agreement, by and between Caladrius Biosciences, Inc. and certain securityholders of Cend Therapeutics, Inc. (filed as Exhibit 2.2 to the Company's Current Report on Form 8-K, filed with the SEC on April 27, 2022).</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001722000031/exhibit23-supportagreeme.htm">2.3</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Support Agreement, by and between Cend Therapeutics, Inc. and certain securityholders of Caladrius Biosciences, Inc. (filed as Exhibit 2.3 to the Company's Current Report on Form 8-K, filed with the SEC on April 27, 2022).</span></td></tr><tr style="height:32pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001722000031/exhibit24-lockxupagreeme.htm">2.4</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Lock-Up Agreement, by and between Caladrius Biosciences, Inc. and certain securityholders of Caladrius Biosciences, Inc. and Cend Therapeutics, Inc. (filed as Exhibit 2.4 to the Company's Current Report on Form 8-K, filed with the SEC on April 27, 2022).</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000114036122033411/brhc10041800_ex3-1.htm">3.1</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of Amendment (Reverse Stock Split) to the Amended and Restated Certificate of Incorporation, dated September 14, 2022 (filed as Exhibit 3.1 to the Company's Current Report on Form 8-K, filed with the SEC on September 15, 2022).</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000114036122033411/brhc10041800_ex3-2.htm">3.2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of Amendment (Name Change) to the Amended and Restated Certificate of Incorporation, dated September 15, 2022 (filed as Exhibit 3.2 of the Company's Current Report on Form 8-K, filed with the SEC on September 15, 2022).</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000032001722000031/exhibit101-stockpurchase.htm">10.1</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Series D Preferred Stock Purchase Agreement, dated April 26, 2022, among Caladrius Biosciences, Inc. and Cend Therapeutics, Inc. (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K, filed with the SEC on April 27, 2022).</span></div></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/320017/000032001722000031/exhibit102-collaboration.htm">10.2</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration Agreement, dated April 26, 2022, between Caladrius Biosciences, Inc. and Cend Therapeutics, Inc. (filed as Exhibit 10.2 to the Company's Current Report on Form 8-K, filed with the SEC on April 27, 2022).</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000114036122033411/brhc10041800_ex10-1.htm">10.3</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employment Agreement, dated as of September 15, 2022, by and between the Company and David Slack (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K, filed with the SEC on September 15, 2022).</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000114036122033411/brhc10041800_ex10-2.htm">10.4</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Indemnification Agreement between the Company and each of its directors and officers (filed as Exhibit 10.2 to the Company's Current Report on Form 8-K, filed with the SEC on September 15, 2022).</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/320017/000114036122037387/brhc10042829_ex99-1.htm">10.5</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cend 2016 Equity Incentive Plan, including all amendments thereto (filed as Exhibit 99.1 to the Company's Registration Statement on Form S-8, filed with the SEC on October 17, 2022).</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="clbs-ex311_20220930xq3.htm">31.1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification of Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></td></tr><tr style="height:27pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="clbs-ex32_20220930q3.htm">32</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification of Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_______________</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:522.00pt"><tr><td style="width:1.0pt"></td><td style="width:16.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:502.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contract or compensatory plans or arrangements.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">             </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39 </span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>clbs-ex311_20220930xq3.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1d3cf720180142e08083507f284c1ceb_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS UNDER SECTION 302</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David J. Mazzo, PhD, certify that&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Lisata Therapeutics, Inc.&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by&#160;this report based on such evaluation&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;I have disclosed, based on my most recent evaluation of internal control over financial reporting to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;10, 2022 </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; David J. Mazzo, PhD&#160;&#160;&#160;&#160;       </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; David J. Mazzo, PhD</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; Chief Executive Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>3
<FILENAME>clbs-ex32_20220930q3.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib038d4ffdf8547a8b026f7bb46a613e6_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Lisata Therapeutics, Inc. (the &#8220;Company&#8221;) for the quarter ended September&#160;30, 2022 filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, David J. Mazzo, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge that&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 as amended&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition of the Company as of the dates presented and the results of operations of the Company for the periods presented.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58;&#160;&#160;November&#160;10, 2022 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:54.834%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.966%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; David J. Mazzo, PhD     </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David J. Mazzo, PhD</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>clbs-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:f426f7a3-6c2d-403e-bcce-1884a6ad721b,g:3088fff3-3c71-4b75-95a2-34e3a251fb1c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:clbs="http://www.caladrius.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.caladrius.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="clbs-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="clbs-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="clbs-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="clbs-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.caladrius.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.caladrius.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParentheticals" roleURI="http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofOperations">
        <link:definition>0000004 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>0000005 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquity" roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofEquity">
        <link:definition>0000006 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheBusiness" roleURI="http://www.caladrius.com/role/TheBusiness">
        <link:definition>0000008 - Disclosure - The Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Merger" roleURI="http://www.caladrius.com/role/Merger">
        <link:definition>0000010 - Disclosure - Merger</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecurities" roleURI="http://www.caladrius.com/role/AvailableforSaleSecurities">
        <link:definition>0000011 - Disclosure - Available-for-Sale-Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeLossPerShare" roleURI="http://www.caladrius.com/role/IncomeLossPerShare">
        <link:definition>0000012 - Disclosure - Income (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.caladrius.com/role/FairValueMeasurements">
        <link:definition>0000013 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilities" roleURI="http://www.caladrius.com/role/AccruedLiabilities">
        <link:definition>0000014 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeases" roleURI="http://www.caladrius.com/role/OperatingLeases">
        <link:definition>0000015 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.caladrius.com/role/StockholdersEquity">
        <link:definition>0000016 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.caladrius.com/role/ShareBasedCompensation">
        <link:definition>0000017 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.caladrius.com/role/IncomeTaxes">
        <link:definition>0000018 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AustraliaResearchandDevelopmentTaxIncentive" roleURI="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive">
        <link:definition>0000019 - Disclosure - Australia Research and Development Tax Incentive</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.caladrius.com/role/Contingencies">
        <link:definition>0000020 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreements" roleURI="http://www.caladrius.com/role/LicenseAgreements">
        <link:definition>0000021 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreement" roleURI="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement">
        <link:definition>0000022 - Disclosure - Research Collaboration and License Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000023 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerTables" roleURI="http://www.caladrius.com/role/MergerTables">
        <link:definition>0000024 - Disclosure - Merger (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesTables" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesTables">
        <link:definition>0000025 - Disclosure - Available-for-Sale-Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeLossPerShareTables" roleURI="http://www.caladrius.com/role/IncomeLossPerShareTables">
        <link:definition>0000026 - Disclosure - Income (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.caladrius.com/role/FairValueMeasurementsTables">
        <link:definition>0000027 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesTables" roleURI="http://www.caladrius.com/role/AccruedLiabilitiesTables">
        <link:definition>0000028 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesTables" roleURI="http://www.caladrius.com/role/OperatingLeasesTables">
        <link:definition>0000029 - Disclosure - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.caladrius.com/role/StockholdersEquityTables">
        <link:definition>0000030 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.caladrius.com/role/ShareBasedCompensationTables">
        <link:definition>0000031 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>0000032 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MergerDetails" roleURI="http://www.caladrius.com/role/MergerDetails">
        <link:definition>0000033 - Disclosure - Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails">
        <link:definition>0000034 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails">
        <link:definition>0000035 - Disclosure - Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails">
        <link:definition>0000036 - Disclosure - Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeLossPerShareDetails" roleURI="http://www.caladrius.com/role/IncomeLossPerShareDetails">
        <link:definition>0000037 - Disclosure - Income (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.caladrius.com/role/FairValueMeasurementsDetails">
        <link:definition>0000038 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesDetails" roleURI="http://www.caladrius.com/role/AccruedLiabilitiesDetails">
        <link:definition>0000039 - Disclosure - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesNarrativeDetails" roleURI="http://www.caladrius.com/role/OperatingLeasesNarrativeDetails">
        <link:definition>0000040 - Disclosure - Operating Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesBalanceSheetPresentationDetails" roleURI="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails">
        <link:definition>0000041 - Disclosure - Operating Leases - Balance Sheet Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesFutureMinimumLeasePaymentsDetails" roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails">
        <link:definition>0000042 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesFutureMinimumLeasePaymentsDetails_1" roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1">
        <link:definition>0000042 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityEquityIssuancesDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails">
        <link:definition>0000043 - Disclosure - Stockholders' Equity - Equity Issuances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockOptionsandWarrantsDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails">
        <link:definition>0000044 - Disclosure - Stockholders' Equity - Stock Options and Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" roleURI="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails">
        <link:definition>0000045 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails">
        <link:definition>0000046 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationCompensationCostNotYetRecognizedDetails" roleURI="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails">
        <link:definition>0000047 - Disclosure - Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" roleURI="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails">
        <link:definition>0000048 - Disclosure - Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.caladrius.com/role/IncomeTaxesDetails">
        <link:definition>0000049 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails_1" roleURI="http://www.caladrius.com/role/IncomeTaxesDetails_1">
        <link:definition>0000050 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsDetails" roleURI="http://www.caladrius.com/role/LicenseAgreementsDetails">
        <link:definition>0000051 - Disclosure - License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementDetails" roleURI="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails">
        <link:definition>0000052 - Disclosure - Research Collaboration and License Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" abstract="false" name="ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_AggregateIntrinsicValueWarrantsOutstanding" abstract="false" name="AggregateIntrinsicValueWarrantsOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_OptionsVestedweightedAverageRemainingContractualTerm" abstract="false" name="OptionsVestedweightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsGranted" abstract="false" name="WeightedAverageExercisePriceWarrantsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees" abstract="false" name="CollaborativeArrangementRightsAndObligationsSublicensingFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_TermOfAgreement" abstract="false" name="TermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale" abstract="false" name="CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_WarrantsVested" abstract="false" name="WarrantsVested" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_ClinicalAndRDRelatedLiabilities" abstract="false" name="ClinicalAndRDRelatedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_AtTheMarketOfferingAgreementMember" abstract="true" name="AtTheMarketOfferingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsExercisable" abstract="false" name="WeightedAverageExercisePriceWarrantsExercisable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" abstract="false" name="CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" abstract="false" name="CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_OperatingLossCarryforwardsSetToExpireWrittenDown" abstract="false" name="OperatingLossCarryforwardsSetToExpireWrittenDown" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsCanceled" abstract="false" name="WeightedAverageExercisePriceWarrantsCanceled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" abstract="false" name="SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues" abstract="false" name="RevenuePerformanceObligationPercentageOfSublicensingRevenues" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="clbs_WarrantsWeightedAverageExercisePriceRollForward" abstract="true" name="WarrantsWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" abstract="false" name="WeightedAverageRemainingContractualTermwarrantoutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" abstract="false" name="ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_OperatingLossCarryforwardsBeforeWriteDown" abstract="false" name="OperatingLossCarryforwardsBeforeWriteDown" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" abstract="false" name="SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" abstract="false" name="SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree" abstract="false" name="CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_SharesHeldByThirdParty" abstract="false" name="SharesHeldByThirdParty" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_CommonStockWarrantsShares" abstract="false" name="CommonStockWarrantsShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_OperatingLeaseRightOfUseAssetAbstract" abstract="true" name="OperatingLeaseRightOfUseAssetAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="clbs_WarrantsExercised" abstract="false" name="WarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" abstract="false" name="CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee" abstract="false" name="CollaborativeArrangementRightsAndObligationsChangeOfControlFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_WeightedAverageRemainingContractualTermwarrantsvested" abstract="false" name="WeightedAverageRemainingContractualTermwarrantsvested" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="clbs_BusinessTextBlock" abstract="false" name="BusinessTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" abstract="false" name="RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="clbs_SanfordBurnhamPrebysMember" abstract="true" name="SanfordBurnhamPrebysMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_LossOnSaleOfNetOperatingLosses" abstract="false" name="LossOnSaleOfNetOperatingLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" abstract="false" name="LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="clbs_CENDMember" abstract="true" name="CENDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_LincolnParkAgreementMember" abstract="true" name="LincolnParkAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsExercised" abstract="false" name="WeightedAverageExercisePriceWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_WarrantsOtherDisclosuresAbstract" abstract="true" name="WarrantsOtherDisclosuresAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="clbs_UniversityOfCaliforniaAtSanDiegoMember" abstract="true" name="UniversityOfCaliforniaAtSanDiegoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" abstract="false" name="SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_AggregateIntrinsicValueWarrantsvested" abstract="false" name="AggregateIntrinsicValueWarrantsvested" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" abstract="false" name="SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_WarrantsCanceled" abstract="false" name="WarrantsCanceled" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_WarrantsGranted" abstract="false" name="WarrantsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_PreferredStockLiquidationPreferenceShare" abstract="false" name="PreferredStockLiquidationPreferenceShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_ResearchAndDevelopmentTaxIncentiveTextBlock" abstract="false" name="ResearchAndDevelopmentTaxIncentiveTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="clbs_PreferredStockSharesDesignated" abstract="false" name="PreferredStockSharesDesignated" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" abstract="false" name="AggregateIntrinsicValueWarrantsvestedandexpectedtovest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_MassachusettsInstituteOfTechnologyMember" abstract="true" name="MassachusettsInstituteOfTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain" abstract="false" name="OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_QiluMember" abstract="true" name="QiluMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="clbs_WarrantsExpired" abstract="false" name="WarrantsExpired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_RevenuePerformanceObligationPercentageOfNetSale" abstract="false" name="RevenuePerformanceObligationPercentageOfNetSale" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsExpired" abstract="false" name="WeightedAverageExercisePriceWarrantsExpired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" abstract="false" name="WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" abstract="false" name="IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration" abstract="false" name="StockIssuedDuringPeriodSharesIssuedAsConsideration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_WeightedAverageExercisePriceWarrantsOutstanding" abstract="false" name="WeightedAverageExercisePriceWarrantsOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" abstract="false" name="WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" abstract="false" name="CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="clbs_SharesIssuedUnderLicenseAgreement" abstract="false" name="SharesIssuedUnderLicenseAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="clbs_NumberOfOfficesUnderOperatingLeases" abstract="false" name="NumberOfOfficesUnderOperatingLeases" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="clbs_Sharesvestedandexpectedtovest" abstract="false" name="Sharesvestedandexpectedtovest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>5
<FILENAME>clbs-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:f426f7a3-6c2d-403e-bcce-1884a6ad721b,g:3088fff3-3c71-4b75-95a2-34e3a251fb1c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="clbs-20220930.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8917da6b-5c80-4c6a-b088-7490902303bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_58a973da-4571-4614-b378-19904a722e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8917da6b-5c80-4c6a-b088-7490902303bf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_58a973da-4571-4614-b378-19904a722e0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_6e261bfa-680c-4168-b488-0596f83290c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8917da6b-5c80-4c6a-b088-7490902303bf" xlink:to="loc_us-gaap_MarketableSecurities_6e261bfa-680c-4168-b488-0596f83290c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6bc35b0f-f678-42c4-a926-31c23865dc70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8917da6b-5c80-4c6a-b088-7490902303bf" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6bc35b0f-f678-42c4-a926-31c23865dc70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d13fd5b2-73b4-4677-9a6d-0a3068b01544" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d6c2903d-2dce-441e-99a8-fdd46d47fe95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d13fd5b2-73b4-4677-9a6d-0a3068b01544" xlink:to="loc_us-gaap_AccountsPayableCurrent_d6c2903d-2dce-441e-99a8-fdd46d47fe95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_77e8761c-f84b-48bf-9057-35c8a3a2e0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d13fd5b2-73b4-4677-9a6d-0a3068b01544" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_77e8761c-f84b-48bf-9057-35c8a3a2e0ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_59bdc5f3-0ce6-4261-939e-649d4ed7ecd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_61ff4dd5-9f82-4596-afcc-866ef57039f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_59bdc5f3-0ce6-4261-939e-649d4ed7ecd9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_61ff4dd5-9f82-4596-afcc-866ef57039f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_47040916-9610-4e0c-8ffe-80cb131aa2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_59bdc5f3-0ce6-4261-939e-649d4ed7ecd9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_47040916-9610-4e0c-8ffe-80cb131aa2f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a5d2e083-3b1d-4982-9f47-e4c26e7c359e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_59bdc5f3-0ce6-4261-939e-649d4ed7ecd9" xlink:to="loc_us-gaap_Liabilities_a5d2e083-3b1d-4982-9f47-e4c26e7c359e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_060c242c-6b6c-4ad2-b971-16f3f3af9925" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_7ca42aba-c80b-4e14-8fe9-aa136f033795" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_060c242c-6b6c-4ad2-b971-16f3f3af9925" xlink:to="loc_us-gaap_PreferredStockValue_7ca42aba-c80b-4e14-8fe9-aa136f033795" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_40cb922b-0cff-475b-9cfc-e28a49d069f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_060c242c-6b6c-4ad2-b971-16f3f3af9925" xlink:to="loc_us-gaap_CommonStockValue_40cb922b-0cff-475b-9cfc-e28a49d069f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_069a38bf-42aa-41c5-ae11-a076ad884979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_060c242c-6b6c-4ad2-b971-16f3f3af9925" xlink:to="loc_us-gaap_AdditionalPaidInCapital_069a38bf-42aa-41c5-ae11-a076ad884979" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_2c9ab5c5-92e1-4476-ab80-3801ec4809b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_060c242c-6b6c-4ad2-b971-16f3f3af9925" xlink:to="loc_us-gaap_TreasuryStockCommonValue_2c9ab5c5-92e1-4476-ab80-3801ec4809b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b6416017-88c2-4e8e-9ef2-e2f686626ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_060c242c-6b6c-4ad2-b971-16f3f3af9925" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b6416017-88c2-4e8e-9ef2-e2f686626ba7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c98927fd-867d-4047-93c5-24825a04f8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_060c242c-6b6c-4ad2-b971-16f3f3af9925" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c98927fd-867d-4047-93c5-24825a04f8ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1f5fedab-832b-4d4f-b1b7-7597805618ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bda04b22-fdc3-4217-9b56-34d706150057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1f5fedab-832b-4d4f-b1b7-7597805618ae" xlink:to="loc_us-gaap_StockholdersEquity_bda04b22-fdc3-4217-9b56-34d706150057" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_c694d54f-ec4b-412f-9013-d8398490015e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1f5fedab-832b-4d4f-b1b7-7597805618ae" xlink:to="loc_us-gaap_MinorityInterest_c694d54f-ec4b-412f-9013-d8398490015e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9b289157-c81a-4728-8d29-af8a32630ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b6fab0d4-7a55-45ea-8a7e-0a611093c5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9b289157-c81a-4728-8d29-af8a32630ef9" xlink:to="loc_us-gaap_LiabilitiesCurrent_b6fab0d4-7a55-45ea-8a7e-0a611093c5a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_99268118-82da-48c4-9ceb-7a2dc1326525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9b289157-c81a-4728-8d29-af8a32630ef9" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_99268118-82da-48c4-9ceb-7a2dc1326525" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1c98cd32-60b6-4eb1-81cf-b14077814d78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_edc31e01-a529-4fec-b690-e87917d47d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1c98cd32-60b6-4eb1-81cf-b14077814d78" xlink:to="loc_us-gaap_AssetsCurrent_edc31e01-a529-4fec-b690-e87917d47d0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0265980c-be4e-4061-b1a3-d096a7caa66c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1c98cd32-60b6-4eb1-81cf-b14077814d78" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_0265980c-be4e-4061-b1a3-d096a7caa66c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_570a40d6-0767-4679-a193-e90882a52607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1c98cd32-60b6-4eb1-81cf-b14077814d78" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_570a40d6-0767-4679-a193-e90882a52607" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b2a2ece8-801a-4e29-93cb-73cbd40d5b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_1c98cd32-60b6-4eb1-81cf-b14077814d78" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b2a2ece8-801a-4e29-93cb-73cbd40d5b25" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="clbs-20220930.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_76235542-6f09-4572-bc16-fc49e273e553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_a03cfc8f-43da-4cbf-8bf0-039989813692" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_76235542-6f09-4572-bc16-fc49e273e553" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_a03cfc8f-43da-4cbf-8bf0-039989813692" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_560a168f-214f-4a27-9817-e088e89b9006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_76235542-6f09-4572-bc16-fc49e273e553" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_560a168f-214f-4a27-9817-e088e89b9006" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_447bb9a8-90b9-423f-b71c-be6a680cb388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_76235542-6f09-4572-bc16-fc49e273e553" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_447bb9a8-90b9-423f-b71c-be6a680cb388" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a87623ca-1e24-4027-830c-cd8026587c09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4bc95a13-234b-4ef1-9e53-97203a00cdc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a87623ca-1e24-4027-830c-cd8026587c09" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4bc95a13-234b-4ef1-9e53-97203a00cdc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1f195c91-6ede-419e-ab3f-87c75b21d297" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a87623ca-1e24-4027-830c-cd8026587c09" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1f195c91-6ede-419e-ab3f-87c75b21d297" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e6774447-1c25-45db-b1f0-9fdc1f01ed72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_32c8644a-594b-4199-913a-8b7480727828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e6774447-1c25-45db-b1f0-9fdc1f01ed72" xlink:to="loc_us-gaap_OperatingIncomeLoss_32c8644a-594b-4199-913a-8b7480727828" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_be33ad9a-5ecf-413f-b462-706c2f163e38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e6774447-1c25-45db-b1f0-9fdc1f01ed72" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_be33ad9a-5ecf-413f-b462-706c2f163e38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9c810a2b-fd12-48ef-b5b9-5221167905ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_61a335e2-6ca9-4733-8183-222f1e7c8c52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9c810a2b-fd12-48ef-b5b9-5221167905ac" xlink:to="loc_us-gaap_InvestmentIncomeNet_61a335e2-6ca9-4733-8183-222f1e7c8c52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_00a89406-8aa2-42ed-9c55-89807e6e2f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9c810a2b-fd12-48ef-b5b9-5221167905ac" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_00a89406-8aa2-42ed-9c55-89807e6e2f2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ae021290-e248-4b62-84dd-ca4b0b7618b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_25694096-30f7-41f1-b3f9-4ff92d9f2c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ae021290-e248-4b62-84dd-ca4b0b7618b8" xlink:to="loc_us-gaap_OperatingExpenses_25694096-30f7-41f1-b3f9-4ff92d9f2c7a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="clbs-20220930.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_16924737-c294-4ebd-84f9-b1d4c00a850b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_fdb9713c-5fc0-4a86-a705-f6cb9ace6add" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_16924737-c294-4ebd-84f9-b1d4c00a850b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_fdb9713c-5fc0-4a86-a705-f6cb9ace6add" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ed0de3ee-3922-4da6-87ef-335a745beb50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_16924737-c294-4ebd-84f9-b1d4c00a850b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ed0de3ee-3922-4da6-87ef-335a745beb50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5b657ed0-bd6b-4f41-b615-417e156f6572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3dde2932-5c29-49f5-b075-8cb9b392389e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5b657ed0-bd6b-4f41-b615-417e156f6572" xlink:to="loc_us-gaap_ProfitLoss_3dde2932-5c29-49f5-b075-8cb9b392389e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_29142166-65ab-4272-817d-9cf9516e60c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5b657ed0-bd6b-4f41-b615-417e156f6572" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_29142166-65ab-4272-817d-9cf9516e60c7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="clbs-20220930.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_89c2790f-34af-4ac2-a752-10fe10bfa179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_e681e62c-24ed-40c2-8a5b-c3dcc2277f00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_89c2790f-34af-4ac2-a752-10fe10bfa179" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_e681e62c-24ed-40c2-8a5b-c3dcc2277f00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_4649fe00-cbd4-45a0-934e-76fc1f72e4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_89c2790f-34af-4ac2-a752-10fe10bfa179" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_4649fe00-cbd4-45a0-934e-76fc1f72e4fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_79c3dc5c-9633-40d4-94e3-55ed455096e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_89c2790f-34af-4ac2-a752-10fe10bfa179" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_79c3dc5c-9633-40d4-94e3-55ed455096e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3a638f7e-7c38-4498-bb55-d7c0b29fe697" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_89c2790f-34af-4ac2-a752-10fe10bfa179" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3a638f7e-7c38-4498-bb55-d7c0b29fe697" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24a20683-f0bc-4531-bd8b-076608a2f320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_8e2fe04b-17f9-47f1-843f-6c303f803108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24a20683-f0bc-4531-bd8b-076608a2f320" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_8e2fe04b-17f9-47f1-843f-6c303f803108" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a5c44565-c919-4272-8086-865f1e4dbfe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24a20683-f0bc-4531-bd8b-076608a2f320" xlink:to="loc_us-gaap_ProfitLoss_a5c44565-c919-4272-8086-865f1e4dbfe7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8797dba1-311c-40cb-9161-b74d7986ea77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24a20683-f0bc-4531-bd8b-076608a2f320" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8797dba1-311c-40cb-9161-b74d7986ea77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_e2699d5a-605b-4265-850a-a582d7d025bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24a20683-f0bc-4531-bd8b-076608a2f320" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_e2699d5a-605b-4265-850a-a582d7d025bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_47daf845-9d80-44d2-8ca8-5d6823273b30" xlink:href="clbs-20220930.xsd#clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24a20683-f0bc-4531-bd8b-076608a2f320" xlink:to="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_47daf845-9d80-44d2-8ca8-5d6823273b30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4edcd37c-0dd7-4ab3-a9a8-dc951ec23563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24a20683-f0bc-4531-bd8b-076608a2f320" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4edcd37c-0dd7-4ab3-a9a8-dc951ec23563" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_54392a38-26b1-4e7e-a576-57e28de099e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24a20683-f0bc-4531-bd8b-076608a2f320" xlink:to="loc_us-gaap_DepreciationAndAmortization_54392a38-26b1-4e7e-a576-57e28de099e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1f85a3dd-7059-4e54-a232-328a5486bfd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24a20683-f0bc-4531-bd8b-076608a2f320" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1f85a3dd-7059-4e54-a232-328a5486bfd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c68c78cc-cafc-47a5-b29f-b574744f4324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ed9e9816-260f-4f4c-bf93-2119f8460db1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c68c78cc-cafc-47a5-b29f-b574744f4324" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ed9e9816-260f-4f4c-bf93-2119f8460db1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4c6ff5a-62b7-479c-b667-73086bff5235" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c68c78cc-cafc-47a5-b29f-b574744f4324" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4c6ff5a-62b7-479c-b667-73086bff5235" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_72cd0b9c-c39f-477b-99e5-2c41f430bee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c68c78cc-cafc-47a5-b29f-b574744f4324" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_72cd0b9c-c39f-477b-99e5-2c41f430bee2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_27674cb2-43f1-4f47-9470-3cab412ed420" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c68c78cc-cafc-47a5-b29f-b574744f4324" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_27674cb2-43f1-4f47-9470-3cab412ed420" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c930f84b-2924-4fea-8f60-b3ac544d535a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_4362d179-18b0-4753-9527-257cafb0190f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c930f84b-2924-4fea-8f60-b3ac544d535a" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_4362d179-18b0-4753-9527-257cafb0190f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7c617558-c60c-4eb4-88b0-4be26d3ad149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c930f84b-2924-4fea-8f60-b3ac544d535a" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7c617558-c60c-4eb4-88b0-4be26d3ad149" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_338afc33-3e9b-47c3-9bef-7fb16b25e60b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c930f84b-2924-4fea-8f60-b3ac544d535a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_338afc33-3e9b-47c3-9bef-7fb16b25e60b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_24e0da21-4371-4c33-8272-3d814360192c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9c01c6c0-5dc4-4ea5-9ac7-61a417b005e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_24e0da21-4371-4c33-8272-3d814360192c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9c01c6c0-5dc4-4ea5-9ac7-61a417b005e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4e128a20-5baa-4907-bc9d-8d062b9f63ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_24e0da21-4371-4c33-8272-3d814360192c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4e128a20-5baa-4907-bc9d-8d062b9f63ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a0fe4d3d-35df-4f6b-81e0-8cf968cd3d68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_24e0da21-4371-4c33-8272-3d814360192c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a0fe4d3d-35df-4f6b-81e0-8cf968cd3d68" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_e6940b4e-58e5-4b23-ba1a-9d20a5e67c92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_08d2fecb-3d6f-4c22-bd28-fe170f5968a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_e6940b4e-58e5-4b23-ba1a-9d20a5e67c92" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_08d2fecb-3d6f-4c22-bd28-fe170f5968a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_43e9e7d7-ec21-46fb-851d-4a1a06ac5b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_e6940b4e-58e5-4b23-ba1a-9d20a5e67c92" xlink:to="loc_us-gaap_MarketableSecurities_43e9e7d7-ec21-46fb-851d-4a1a06ac5b4d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_94cca783-b149-45d7-b356-f8db066559d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_cdf9156b-4d93-4124-b104-c838aaca48ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_94cca783-b149-45d7-b356-f8db066559d3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_cdf9156b-4d93-4124-b104-c838aaca48ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_1decd6d3-1b6e-4317-84ea-3e9241c38219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_94cca783-b149-45d7-b356-f8db066559d3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_1decd6d3-1b6e-4317-84ea-3e9241c38219" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_35d4f688-1118-44a2-9bcf-84347884ac81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_f3dd635f-3c61-4c97-ac33-635621d25dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_35d4f688-1118-44a2-9bcf-84347884ac81" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_f3dd635f-3c61-4c97-ac33-635621d25dd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_88303805-f3d2-4c7b-8232-ae396a2e492c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_35d4f688-1118-44a2-9bcf-84347884ac81" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_88303805-f3d2-4c7b-8232-ae396a2e492c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_14d5f6d8-8fe1-47eb-b994-a414ade66e41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_6128ad7f-9cfd-43d3-adec-8039c60974f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_14d5f6d8-8fe1-47eb-b994-a414ade66e41" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_6128ad7f-9cfd-43d3-adec-8039c60974f2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#AccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d72fbbe9-ba3e-45c3-b983-27feb795a0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_bf370aad-6995-4e50-88e2-e01f063d6a44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_d72fbbe9-ba3e-45c3-b983-27feb795a0eb" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_bf370aad-6995-4e50-88e2-e01f063d6a44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2b4de2a9-e754-418d-ab5b-b5c78bb3a5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_d72fbbe9-ba3e-45c3-b983-27feb795a0eb" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2b4de2a9-e754-418d-ab5b-b5c78bb3a5e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ClinicalAndRDRelatedLiabilities_e53bba25-c690-412f-b7d2-81c5817be002" xlink:href="clbs-20220930.xsd#clbs_ClinicalAndRDRelatedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_d72fbbe9-ba3e-45c3-b983-27feb795a0eb" xlink:to="loc_clbs_ClinicalAndRDRelatedLiabilities_e53bba25-c690-412f-b7d2-81c5817be002" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_954d8431-7959-43c0-bddb-bcd6bcc668dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_d72fbbe9-ba3e-45c3-b983-27feb795a0eb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_954d8431-7959-43c0-bddb-bcd6bcc668dc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#OperatingLeasesBalanceSheetPresentationDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bdb49d75-6ec9-49b7-a466-f0f56776e020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_07409614-3868-4b87-88ee-10dc6c1be0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_bdb49d75-6ec9-49b7-a466-f0f56776e020" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_07409614-3868-4b87-88ee-10dc6c1be0a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f85c6229-c9a1-4ea0-aea0-bce9013bcc6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_bdb49d75-6ec9-49b7-a466-f0f56776e020" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f85c6229-c9a1-4ea0-aea0-bce9013bcc6b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#OperatingLeasesFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_584e2da0-c810-4a9b-a785-734be6edb27a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d4dbf4c4-7781-4d06-9155-902015e30e47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_584e2da0-c810-4a9b-a785-734be6edb27a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d4dbf4c4-7781-4d06-9155-902015e30e47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_12a4a301-6618-40a9-a5bb-4e9e0b46a188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_584e2da0-c810-4a9b-a785-734be6edb27a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_12a4a301-6618-40a9-a5bb-4e9e0b46a188" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_34eea19b-c459-4fb2-a3d9-618d2dc3b9d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_584e2da0-c810-4a9b-a785-734be6edb27a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_34eea19b-c459-4fb2-a3d9-618d2dc3b9d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dd01aef2-f560-4f4d-9155-be029adcd633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_584e2da0-c810-4a9b-a785-734be6edb27a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dd01aef2-f560-4f4d-9155-be029adcd633" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="clbs-20220930.xsd#OperatingLeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cca20c2a-691a-4c52-9a34-5b392f638f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5088dcfa-b0cc-4934-b3ee-8865262d143c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cca20c2a-691a-4c52-9a34-5b392f638f1a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5088dcfa-b0cc-4934-b3ee-8865262d143c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d6555f37-e3f7-4f7d-904c-57fb9a1adc4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cca20c2a-691a-4c52-9a34-5b392f638f1a" xlink:to="loc_us-gaap_OperatingLeaseLiability_d6555f37-e3f7-4f7d-904c-57fb9a1adc4f" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>clbs-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:f426f7a3-6c2d-403e-bcce-1884a6ad721b,g:3088fff3-3c71-4b75-95a2-34e3a251fb1c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="clbs-20220930.xsd#ConsolidatedStatementsofEquity"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofEquity" xlink:type="extended" id="i975f7d1bcdc74605afb93f643c1f9c55_ConsolidatedStatementsofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a2b1417f-50fb-46f8-9602-ed7732c1859c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a2b1417f-50fb-46f8-9602-ed7732c1859c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_504699d4-78d6-41f1-8a86-8686eea0da01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_504699d4-78d6-41f1-8a86-8686eea0da01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0ef0b07f-6f3f-43f3-8b5c-6fa6f2704280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0ef0b07f-6f3f-43f3-8b5c-6fa6f2704280" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_19f62736-2a66-4542-929e-71b1b0155f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_19f62736-2a66-4542-929e-71b1b0155f9d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ee7c9cc3-067f-4c29-a6d4-83d9944c5f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_ProfitLoss_ee7c9cc3-067f-4c29-a6d4-83d9944c5f8a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3e9f7033-4199-4078-a742-8f98f7a3eafd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3e9f7033-4199-4078-a742-8f98f7a3eafd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_881a5128-2ee4-4e5a-b567-e81626c62b07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_881a5128-2ee4-4e5a-b567-e81626c62b07" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_85a864e5-11b5-499b-a2aa-e2eeee6f164e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_85a864e5-11b5-499b-a2aa-e2eeee6f164e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_8979e3c9-e53f-42ad-8a70-fa7991f4e849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_8979e3c9-e53f-42ad-8a70-fa7991f4e849" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_10ea759c-ac17-4f7d-b97f-a2b18e6faf58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_10ea759c-ac17-4f7d-b97f-a2b18e6faf58" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_89c8d7d5-e5bc-4a19-96b1-4be78669f0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_89c8d7d5-e5bc-4a19-96b1-4be78669f0ca" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d688f3ee-ee70-4261-ba91-51fa94a14240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d688f3ee-ee70-4261-ba91-51fa94a14240" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6bd3230a-ff34-4610-8f0c-8e1746d6ca85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6bd3230a-ff34-4610-8f0c-8e1746d6ca85" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_f0cd7305-708b-42ee-9a72-85952e8de062" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_f0cd7305-708b-42ee-9a72-85952e8de062" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_c61e0fe3-83c3-45f5-ab27-254d319bcf00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_678a485c-4c1c-4d9b-a91d-773b9de866ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f3d01b73-c3c1-4600-9f07-31f4480603e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ed38b24e-3f29-46b8-aa75-1b25db9b1cec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a2b1417f-50fb-46f8-9602-ed7732c1859c" xlink:to="loc_us-gaap_StatementTable_ed38b24e-3f29-46b8-aa75-1b25db9b1cec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f5192c26-79fe-492f-b032-26e5dbafc16f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ed38b24e-3f29-46b8-aa75-1b25db9b1cec" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f5192c26-79fe-492f-b032-26e5dbafc16f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f5192c26-79fe-492f-b032-26e5dbafc16f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f5192c26-79fe-492f-b032-26e5dbafc16f" xlink:to="loc_us-gaap_EquityComponentDomain_f5192c26-79fe-492f-b032-26e5dbafc16f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_774d31d5-551c-46ea-9eb8-e7a3b6467b56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f5192c26-79fe-492f-b032-26e5dbafc16f" xlink:to="loc_us-gaap_EquityComponentDomain_774d31d5-551c-46ea-9eb8-e7a3b6467b56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_81daa712-538a-4de5-9c76-c852c6806bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_774d31d5-551c-46ea-9eb8-e7a3b6467b56" xlink:to="loc_us-gaap_ParentMember_81daa712-538a-4de5-9c76-c852c6806bfd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_8b431cd1-6d3b-4a7b-8b6c-0be9a9b01e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_81daa712-538a-4de5-9c76-c852c6806bfd" xlink:to="loc_us-gaap_PreferredStockMember_8b431cd1-6d3b-4a7b-8b6c-0be9a9b01e6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8778d165-c4f2-47f8-b82d-a31372c68d34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_81daa712-538a-4de5-9c76-c852c6806bfd" xlink:to="loc_us-gaap_CommonStockMember_8778d165-c4f2-47f8-b82d-a31372c68d34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6106d6cb-fcf2-48d5-bea6-a598f821d461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_81daa712-538a-4de5-9c76-c852c6806bfd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6106d6cb-fcf2-48d5-bea6-a598f821d461" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_eb4bd6e4-0b58-4506-b1a9-aa71e8a3c0de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_81daa712-538a-4de5-9c76-c852c6806bfd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_eb4bd6e4-0b58-4506-b1a9-aa71e8a3c0de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_729b713f-cd40-4714-b89e-4b569ac85153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_81daa712-538a-4de5-9c76-c852c6806bfd" xlink:to="loc_us-gaap_RetainedEarningsMember_729b713f-cd40-4714-b89e-4b569ac85153" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_0d4288ff-a274-473d-938d-e6c58fa44148" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_81daa712-538a-4de5-9c76-c852c6806bfd" xlink:to="loc_us-gaap_TreasuryStockCommonMember_0d4288ff-a274-473d-938d-e6c58fa44148" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_df59b299-64f0-462a-8686-22fe1cfcbea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_774d31d5-551c-46ea-9eb8-e7a3b6467b56" xlink:to="loc_us-gaap_NoncontrollingInterestMember_df59b299-64f0-462a-8686-22fe1cfcbea9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/MergerDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#MergerDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/MergerDetails" xlink:type="extended" id="if7d369941bc04d9ca165e24921b394d0_MergerDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2a1a9f54-34d4-4d6c-8297-d6424786322b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_37767f24-3d52-4234-92da-da58999c7ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a1a9f54-34d4-4d6c-8297-d6424786322b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_37767f24-3d52-4234-92da-da58999c7ec3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_cbf7262a-13b7-4fae-97f0-561026825050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a1a9f54-34d4-4d6c-8297-d6424786322b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_cbf7262a-13b7-4fae-97f0-561026825050" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_6ab575a7-0645-4f13-9813-5c8a2b8cd800" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a1a9f54-34d4-4d6c-8297-d6424786322b" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_6ab575a7-0645-4f13-9813-5c8a2b8cd800" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_569608ee-578b-4ac6-b2e5-76aac8364f23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a1a9f54-34d4-4d6c-8297-d6424786322b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_569608ee-578b-4ac6-b2e5-76aac8364f23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_f9c31ce4-4819-4c0c-a889-cdc7a9faeb05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a1a9f54-34d4-4d6c-8297-d6424786322b" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_f9c31ce4-4819-4c0c-a889-cdc7a9faeb05" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_bba7ed40-7ae9-4126-b376-b1adb9ec792a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a1a9f54-34d4-4d6c-8297-d6424786322b" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_bba7ed40-7ae9-4126-b376-b1adb9ec792a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f5b06c86-e109-4e18-9c86-2ef1a67dd3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a1a9f54-34d4-4d6c-8297-d6424786322b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f5b06c86-e109-4e18-9c86-2ef1a67dd3e7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_226cd145-314e-4a2b-93bd-9628adc89d67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a1a9f54-34d4-4d6c-8297-d6424786322b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_226cd145-314e-4a2b-93bd-9628adc89d67" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_77c39d6b-90d7-42c7-96f9-d79ad7d6e9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a1a9f54-34d4-4d6c-8297-d6424786322b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_77c39d6b-90d7-42c7-96f9-d79ad7d6e9ab" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_76db6815-75c1-44fa-942f-26c45b507fec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a1a9f54-34d4-4d6c-8297-d6424786322b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_76db6815-75c1-44fa-942f-26c45b507fec" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_4e84284f-bf7e-465f-b8c8-3cf4e58932aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a1a9f54-34d4-4d6c-8297-d6424786322b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_4e84284f-bf7e-465f-b8c8-3cf4e58932aa" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_5287a92e-5e8c-4c80-8191-d65070df4515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a1a9f54-34d4-4d6c-8297-d6424786322b" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_5287a92e-5e8c-4c80-8191-d65070df4515" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d91ef587-2cbe-4ebf-9c8a-e6d3a49b10ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a1a9f54-34d4-4d6c-8297-d6424786322b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d91ef587-2cbe-4ebf-9c8a-e6d3a49b10ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_debf43d4-2598-4aea-b70b-5f169f27f49b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d91ef587-2cbe-4ebf-9c8a-e6d3a49b10ce" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_debf43d4-2598-4aea-b70b-5f169f27f49b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_debf43d4-2598-4aea-b70b-5f169f27f49b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_debf43d4-2598-4aea-b70b-5f169f27f49b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_debf43d4-2598-4aea-b70b-5f169f27f49b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_51b9daae-e408-4909-bfe8-16fa60d60c16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_debf43d4-2598-4aea-b70b-5f169f27f49b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_51b9daae-e408-4909-bfe8-16fa60d60c16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CENDMember_78425297-31d2-4722-a6d3-02906dc64ca6" xlink:href="clbs-20220930.xsd#clbs_CENDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_51b9daae-e408-4909-bfe8-16fa60d60c16" xlink:to="loc_clbs_CENDMember_78425297-31d2-4722-a6d3-02906dc64ca6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="extended" id="i80465460c57441d198a8edb1dfcdedd8_AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09ce94c7-301e-42b1-8cd6-22eaa0de4987" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ea0fa003-d171-4fea-81a9-26e238e0bf37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09ce94c7-301e-42b1-8cd6-22eaa0de4987" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ea0fa003-d171-4fea-81a9-26e238e0bf37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_715034bd-d8dc-43cd-bd1c-87cc760cda28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09ce94c7-301e-42b1-8cd6-22eaa0de4987" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_715034bd-d8dc-43cd-bd1c-87cc760cda28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e3c39538-145b-4cd0-af77-b2d17cf0e12e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09ce94c7-301e-42b1-8cd6-22eaa0de4987" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e3c39538-145b-4cd0-af77-b2d17cf0e12e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_eb89e91f-81e7-4500-981c-76e906cd84ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09ce94c7-301e-42b1-8cd6-22eaa0de4987" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_eb89e91f-81e7-4500-981c-76e906cd84ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_81077c76-d0a0-4fa6-a4a7-b21747ef94bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09ce94c7-301e-42b1-8cd6-22eaa0de4987" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_81077c76-d0a0-4fa6-a4a7-b21747ef94bb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ac8cba9f-253e-4c2c-b2ae-14a050ea9c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_81077c76-d0a0-4fa6-a4a7-b21747ef94bb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ac8cba9f-253e-4c2c-b2ae-14a050ea9c0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac8cba9f-253e-4c2c-b2ae-14a050ea9c0b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ac8cba9f-253e-4c2c-b2ae-14a050ea9c0b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ac8cba9f-253e-4c2c-b2ae-14a050ea9c0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1578c09-fb89-46a5-8704-7062d0d4d7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ac8cba9f-253e-4c2c-b2ae-14a050ea9c0b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1578c09-fb89-46a5-8704-7062d0d4d7d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7dd45993-1b57-4c01-bb42-a6417f5d5a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1578c09-fb89-46a5-8704-7062d0d4d7d5" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7dd45993-1b57-4c01-bb42-a6417f5d5a3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_03d0e584-eec8-4a1d-8e31-036230403b46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1578c09-fb89-46a5-8704-7062d0d4d7d5" xlink:to="loc_us-gaap_CommercialPaperMember_03d0e584-eec8-4a1d-8e31-036230403b46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_1cf3adb6-a387-4035-8696-81369453e1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1578c09-fb89-46a5-8704-7062d0d4d7d5" xlink:to="loc_us-gaap_MoneyMarketFundsMember_1cf3adb6-a387-4035-8696-81369453e1d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_d6aaa58a-c5f5-4236-9500-7ad1f736af3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1578c09-fb89-46a5-8704-7062d0d4d7d5" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_d6aaa58a-c5f5-4236-9500-7ad1f736af3b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#IncomeLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="extended" id="i987128692df94a71908e71155a205587_IncomeLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_72e53427-cf5b-4a91-9847-a4373c66e54e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6f326294-fc49-451e-917c-00c0316587c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_72e53427-cf5b-4a91-9847-a4373c66e54e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6f326294-fc49-451e-917c-00c0316587c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_374107f7-7ede-4c8b-9652-7bf3d5351cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_72e53427-cf5b-4a91-9847-a4373c66e54e" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_374107f7-7ede-4c8b-9652-7bf3d5351cd6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c348ce25-c31c-431e-9707-ce649408872d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_374107f7-7ede-4c8b-9652-7bf3d5351cd6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c348ce25-c31c-431e-9707-ce649408872d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c348ce25-c31c-431e-9707-ce649408872d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c348ce25-c31c-431e-9707-ce649408872d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c348ce25-c31c-431e-9707-ce649408872d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_90ac4a50-ffea-4dfb-bb75-9e0df0355c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c348ce25-c31c-431e-9707-ce649408872d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_90ac4a50-ffea-4dfb-bb75-9e0df0355c55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bf9815bf-f6b6-4fe0-8928-195bc945b8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_90ac4a50-ffea-4dfb-bb75-9e0df0355c55" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bf9815bf-f6b6-4fe0-8928-195bc945b8a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_aa78ba37-d046-4899-9bf5-40c28bc1fdc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_90ac4a50-ffea-4dfb-bb75-9e0df0355c55" xlink:to="loc_us-gaap_WarrantMember_aa78ba37-d046-4899-9bf5-40c28bc1fdc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_dd954462-a0ed-4e0b-9302-d59a4b766701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_90ac4a50-ffea-4dfb-bb75-9e0df0355c55" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_dd954462-a0ed-4e0b-9302-d59a4b766701" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="ic97a2f42ae40497190b27b1933530ad7_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e103f22-6caa-41c6-8ca7-2d27d6424559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_a9477511-483a-4e6e-bbb2-48ed381ca90e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e103f22-6caa-41c6-8ca7-2d27d6424559" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_a9477511-483a-4e6e-bbb2-48ed381ca90e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_643064e8-99c2-4dce-a11d-b974e0514f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e103f22-6caa-41c6-8ca7-2d27d6424559" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_643064e8-99c2-4dce-a11d-b974e0514f9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e9da809b-565e-4bf0-b760-cf8ea8102b01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e103f22-6caa-41c6-8ca7-2d27d6424559" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e9da809b-565e-4bf0-b760-cf8ea8102b01" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ef0a553f-1ade-423e-935f-657e4d4e8b50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e9da809b-565e-4bf0-b760-cf8ea8102b01" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ef0a553f-1ade-423e-935f-657e4d4e8b50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ef0a553f-1ade-423e-935f-657e4d4e8b50_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ef0a553f-1ade-423e-935f-657e4d4e8b50" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ef0a553f-1ade-423e-935f-657e4d4e8b50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d66cf894-4cf7-421d-9855-180211530892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ef0a553f-1ade-423e-935f-657e4d4e8b50" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d66cf894-4cf7-421d-9855-180211530892" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a3a65c4f-f385-46ae-bb04-91a33406ef1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d66cf894-4cf7-421d-9855-180211530892" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a3a65c4f-f385-46ae-bb04-91a33406ef1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e10e1481-5364-4eee-ae8c-699ff20c4eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d66cf894-4cf7-421d-9855-180211530892" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e10e1481-5364-4eee-ae8c-699ff20c4eda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ab763314-3da5-4105-a081-c40dc3b8317d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d66cf894-4cf7-421d-9855-180211530892" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ab763314-3da5-4105-a081-c40dc3b8317d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0f616251-fd7d-47c0-9f10-03d0309518a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e9da809b-565e-4bf0-b760-cf8ea8102b01" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0f616251-fd7d-47c0-9f10-03d0309518a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0f616251-fd7d-47c0-9f10-03d0309518a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0f616251-fd7d-47c0-9f10-03d0309518a7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0f616251-fd7d-47c0-9f10-03d0309518a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_daad7c68-8185-47e0-82c0-3da9131a68de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0f616251-fd7d-47c0-9f10-03d0309518a7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_daad7c68-8185-47e0-82c0-3da9131a68de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_06be331c-6743-4917-a14e-c5266e663f41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_daad7c68-8185-47e0-82c0-3da9131a68de" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_06be331c-6743-4917-a14e-c5266e663f41" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#StockholdersEquityEquityIssuancesDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="extended" id="ie69709a058be4902ad71c59dc5d476c6_StockholdersEquityEquityIssuancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_c0022643-e109-468b-a739-98d96aebcaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_d210fc94-d7ab-4cd5-bdcb-a840da5b4b77" xlink:href="clbs-20220930.xsd#clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c0022643-e109-468b-a739-98d96aebcaa4" xlink:to="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_d210fc94-d7ab-4cd5-bdcb-a840da5b4b77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration_78db4902-c0b9-4a90-b84f-104ceb27ea54" xlink:href="clbs-20220930.xsd#clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c0022643-e109-468b-a739-98d96aebcaa4" xlink:to="loc_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration_78db4902-c0b9-4a90-b84f-104ceb27ea54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b15920e0-7c94-4d7f-86e5-df001c93b1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c0022643-e109-468b-a739-98d96aebcaa4" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b15920e0-7c94-4d7f-86e5-df001c93b1f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_aa5c0307-b708-4901-b3ef-bbfd532400cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c0022643-e109-468b-a739-98d96aebcaa4" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_aa5c0307-b708-4901-b3ef-bbfd532400cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_892d9456-5903-495e-8969-c7a14a764026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c0022643-e109-468b-a739-98d96aebcaa4" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_892d9456-5903-495e-8969-c7a14a764026" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_TermOfAgreement_4971d903-3916-449e-a0e8-a777fee612af" xlink:href="clbs-20220930.xsd#clbs_TermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c0022643-e109-468b-a739-98d96aebcaa4" xlink:to="loc_clbs_TermOfAgreement_4971d903-3916-449e-a0e8-a777fee612af" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase_6238060b-a551-482f-8ca7-ce2f8c8b0715" xlink:href="clbs-20220930.xsd#clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c0022643-e109-468b-a739-98d96aebcaa4" xlink:to="loc_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase_6238060b-a551-482f-8ca7-ce2f8c8b0715" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase_21ab5990-92a0-44c8-ae9a-565eb6097a2b" xlink:href="clbs-20220930.xsd#clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c0022643-e109-468b-a739-98d96aebcaa4" xlink:to="loc_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase_21ab5990-92a0-44c8-ae9a-565eb6097a2b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase_93853087-4cf5-4f96-9382-80fc03b8bf14" xlink:href="clbs-20220930.xsd#clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c0022643-e109-468b-a739-98d96aebcaa4" xlink:to="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase_93853087-4cf5-4f96-9382-80fc03b8bf14" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod_74e7274c-f538-4ddf-b36d-eb9fd5318902" xlink:href="clbs-20220930.xsd#clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c0022643-e109-468b-a739-98d96aebcaa4" xlink:to="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod_74e7274c-f538-4ddf-b36d-eb9fd5318902" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty_26f6b112-974f-4712-a27d-1648c06785ed" xlink:href="clbs-20220930.xsd#clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c0022643-e109-468b-a739-98d96aebcaa4" xlink:to="loc_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty_26f6b112-974f-4712-a27d-1648c06785ed" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8057e362-0842-4e41-86ac-06f870d4be3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c0022643-e109-468b-a739-98d96aebcaa4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8057e362-0842-4e41-86ac-06f870d4be3e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0672dc72-85b0-4a3d-b0aa-220842c6b546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_c0022643-e109-468b-a739-98d96aebcaa4" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0672dc72-85b0-4a3d-b0aa-220842c6b546" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_90322b94-0444-463b-908d-6ec02c21e473" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0672dc72-85b0-4a3d-b0aa-220842c6b546" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_90322b94-0444-463b-908d-6ec02c21e473" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_90322b94-0444-463b-908d-6ec02c21e473_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_90322b94-0444-463b-908d-6ec02c21e473" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_90322b94-0444-463b-908d-6ec02c21e473_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8b51b17c-0c79-4a3a-b103-8b3c2199d264" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_90322b94-0444-463b-908d-6ec02c21e473" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8b51b17c-0c79-4a3a-b103-8b3c2199d264" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LincolnParkAgreementMember_be2b5dad-03f9-4a2e-b2a0-f8199e25c53a" xlink:href="clbs-20220930.xsd#clbs_LincolnParkAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8b51b17c-0c79-4a3a-b103-8b3c2199d264" xlink:to="loc_clbs_LincolnParkAgreementMember_be2b5dad-03f9-4a2e-b2a0-f8199e25c53a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AtTheMarketOfferingAgreementMember_e2d1a89d-e4be-4b17-a88e-f03ad2ab3bdd" xlink:href="clbs-20220930.xsd#clbs_AtTheMarketOfferingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8b51b17c-0c79-4a3a-b103-8b3c2199d264" xlink:to="loc_clbs_AtTheMarketOfferingAgreementMember_e2d1a89d-e4be-4b17-a88e-f03ad2ab3bdd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="extended" id="i712fe45b3d534d88aacb5031d29c5e4f_StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70a2c20e-dbfa-41aa-bad6-3c4406f0dcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_27e553cf-ffd8-4a0d-9f7a-116fd3d4a861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70a2c20e-dbfa-41aa-bad6-3c4406f0dcb8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_27e553cf-ffd8-4a0d-9f7a-116fd3d4a861" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_ab460a68-b398-4edd-a68e-4b557170dda3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70a2c20e-dbfa-41aa-bad6-3c4406f0dcb8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_ab460a68-b398-4edd-a68e-4b557170dda3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b44332b9-ced3-4610-8863-c5e3759b848f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70a2c20e-dbfa-41aa-bad6-3c4406f0dcb8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b44332b9-ced3-4610-8863-c5e3759b848f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2dc33fdd-59b9-40a0-9d73-f0a0c5188782" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70a2c20e-dbfa-41aa-bad6-3c4406f0dcb8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2dc33fdd-59b9-40a0-9d73-f0a0c5188782" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c773da29-cb6c-47ca-9efd-cdd909b6e102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70a2c20e-dbfa-41aa-bad6-3c4406f0dcb8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c773da29-cb6c-47ca-9efd-cdd909b6e102" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_96fc2e2d-f7d1-4ead-a7cd-2c7fa05f18ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c773da29-cb6c-47ca-9efd-cdd909b6e102" xlink:to="loc_us-gaap_AwardTypeAxis_96fc2e2d-f7d1-4ead-a7cd-2c7fa05f18ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96fc2e2d-f7d1-4ead-a7cd-2c7fa05f18ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_96fc2e2d-f7d1-4ead-a7cd-2c7fa05f18ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96fc2e2d-f7d1-4ead-a7cd-2c7fa05f18ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc4f8fbc-b976-4ff4-9eb5-73a18b49af23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_96fc2e2d-f7d1-4ead-a7cd-2c7fa05f18ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc4f8fbc-b976-4ff4-9eb5-73a18b49af23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_92061513-6b48-463b-bf74-4340d1db1026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc4f8fbc-b976-4ff4-9eb5-73a18b49af23" xlink:to="loc_us-gaap_RestrictedStockMember_92061513-6b48-463b-bf74-4340d1db1026" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_fc9402fe-8365-4d26-8b49-fadf99150a91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc4f8fbc-b976-4ff4-9eb5-73a18b49af23" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_fc9402fe-8365-4d26-8b49-fadf99150a91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f3d7644a-a3f0-43f8-b9b7-8a5e45d0c83c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c773da29-cb6c-47ca-9efd-cdd909b6e102" xlink:to="loc_srt_RangeAxis_f3d7644a-a3f0-43f8-b9b7-8a5e45d0c83c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f3d7644a-a3f0-43f8-b9b7-8a5e45d0c83c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f3d7644a-a3f0-43f8-b9b7-8a5e45d0c83c" xlink:to="loc_srt_RangeMember_f3d7644a-a3f0-43f8-b9b7-8a5e45d0c83c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_32828330-a45c-411b-b63d-1c348df29574" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f3d7644a-a3f0-43f8-b9b7-8a5e45d0c83c" xlink:to="loc_srt_RangeMember_32828330-a45c-411b-b63d-1c348df29574" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ee53f08a-f113-46cc-9e47-e4e1fc44dc27" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_32828330-a45c-411b-b63d-1c348df29574" xlink:to="loc_srt_MinimumMember_ee53f08a-f113-46cc-9e47-e4e1fc44dc27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7ab21871-ba0c-4d52-9f37-a4c2b1f2d59a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_32828330-a45c-411b-b63d-1c348df29574" xlink:to="loc_srt_MaximumMember_7ab21871-ba0c-4d52-9f37-a4c2b1f2d59a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#ShareBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" id="i8fe55b6cbdee4290b0af7367c5c1c71e_ShareBasedCompensationShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e688834-28ae-440c-8300-b49ee857c154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d8befb0c-fda0-4065-8780-70a5e15ba703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e688834-28ae-440c-8300-b49ee857c154" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d8befb0c-fda0-4065-8780-70a5e15ba703" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_466c67a0-000f-4241-a181-ae91c941e70f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e688834-28ae-440c-8300-b49ee857c154" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_466c67a0-000f-4241-a181-ae91c941e70f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2035eaa8-b79a-4ef9-ae13-1952f37d9b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_466c67a0-000f-4241-a181-ae91c941e70f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2035eaa8-b79a-4ef9-ae13-1952f37d9b7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2035eaa8-b79a-4ef9-ae13-1952f37d9b7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2035eaa8-b79a-4ef9-ae13-1952f37d9b7d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2035eaa8-b79a-4ef9-ae13-1952f37d9b7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ec8a8101-e36a-4d02-9984-928a65bf1c95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2035eaa8-b79a-4ef9-ae13-1952f37d9b7d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ec8a8101-e36a-4d02-9984-928a65bf1c95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b181faf9-c0a6-4390-846e-f2ec027b9ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ec8a8101-e36a-4d02-9984-928a65bf1c95" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b181faf9-c0a6-4390-846e-f2ec027b9ed8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d4c14366-089e-43f2-b722-438acf3e5915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ec8a8101-e36a-4d02-9984-928a65bf1c95" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d4c14366-089e-43f2-b722-438acf3e5915" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bd03e317-8c2e-422a-b4b2-d57b7ef49d76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ec8a8101-e36a-4d02-9984-928a65bf1c95" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bd03e317-8c2e-422a-b4b2-d57b7ef49d76" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#ShareBasedCompensationCompensationCostNotYetRecognizedDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="extended" id="i0b1e63f4153e409ab9aab0341a1171bb_ShareBasedCompensationCompensationCostNotYetRecognizedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49b05ba9-3177-47d6-aa63-9d9181b30849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_26384413-e9a9-4eae-892e-1a13c43394dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49b05ba9-3177-47d6-aa63-9d9181b30849" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_26384413-e9a9-4eae-892e-1a13c43394dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b4ea9860-89eb-43fd-bbb2-600237c9abcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49b05ba9-3177-47d6-aa63-9d9181b30849" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b4ea9860-89eb-43fd-bbb2-600237c9abcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ef0e0a93-3b5e-44cc-9175-d51d0c33faeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49b05ba9-3177-47d6-aa63-9d9181b30849" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ef0e0a93-3b5e-44cc-9175-d51d0c33faeb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_164f74b1-bfb1-4059-b90b-bf83ad899c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ef0e0a93-3b5e-44cc-9175-d51d0c33faeb" xlink:to="loc_us-gaap_AwardTypeAxis_164f74b1-bfb1-4059-b90b-bf83ad899c4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_164f74b1-bfb1-4059-b90b-bf83ad899c4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_164f74b1-bfb1-4059-b90b-bf83ad899c4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_164f74b1-bfb1-4059-b90b-bf83ad899c4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ac21732-c2b3-429b-8bdd-7d4876d61949" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_164f74b1-bfb1-4059-b90b-bf83ad899c4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ac21732-c2b3-429b-8bdd-7d4876d61949" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_012ad819-af63-4502-a3f0-6d2de262a403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ac21732-c2b3-429b-8bdd-7d4876d61949" xlink:to="loc_us-gaap_EmployeeStockOptionMember_012ad819-af63-4502-a3f0-6d2de262a403" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c6284346-6df5-422b-8ea5-262b9bfbdaaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ac21732-c2b3-429b-8bdd-7d4876d61949" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c6284346-6df5-422b-8ea5-262b9bfbdaaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_952fbcda-a191-4bd1-96da-a072e4c5a4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ac21732-c2b3-429b-8bdd-7d4876d61949" xlink:to="loc_us-gaap_RestrictedStockMember_952fbcda-a191-4bd1-96da-a072e4c5a4a3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="extended" id="i2cf847f23c5948eabbcb10c42ec9bd57_ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_297ece5f-751c-4d49-8a7d-c48e4578ff7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_a5ce7637-4d2b-4e90-b551-557face077ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_297ece5f-751c-4d49-8a7d-c48e4578ff7d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_a5ce7637-4d2b-4e90-b551-557face077ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7e18c063-fee7-421a-b545-ac5ed267286f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_297ece5f-751c-4d49-8a7d-c48e4578ff7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7e18c063-fee7-421a-b545-ac5ed267286f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a88a5af-d2a1-49ad-b310-307a49a1a94f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_297ece5f-751c-4d49-8a7d-c48e4578ff7d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a88a5af-d2a1-49ad-b310-307a49a1a94f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dd9dfb3f-ea07-4f69-815a-c94e8efe70e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a88a5af-d2a1-49ad-b310-307a49a1a94f" xlink:to="loc_us-gaap_AwardTypeAxis_dd9dfb3f-ea07-4f69-815a-c94e8efe70e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd9dfb3f-ea07-4f69-815a-c94e8efe70e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_dd9dfb3f-ea07-4f69-815a-c94e8efe70e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dd9dfb3f-ea07-4f69-815a-c94e8efe70e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c68c6eae-40e4-41d0-ab9c-d90be692b944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_dd9dfb3f-ea07-4f69-815a-c94e8efe70e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c68c6eae-40e4-41d0-ab9c-d90be692b944" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f1ae34c8-34aa-4c6b-97fb-32edd12f46d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c68c6eae-40e4-41d0-ab9c-d90be692b944" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f1ae34c8-34aa-4c6b-97fb-32edd12f46d5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/IncomeTaxesDetails" xlink:type="extended" id="if5b02ad30c2d4fd09ef8a2d78035af14_IncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_cffaf573-590b-4560-9183-246833c2c834" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsBeforeWriteDown_fa9beb84-b14c-48f0-898f-8e3bb7fa2a87" xlink:href="clbs-20220930.xsd#clbs_OperatingLossCarryforwardsBeforeWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cffaf573-590b-4560-9183-246833c2c834" xlink:to="loc_clbs_OperatingLossCarryforwardsBeforeWriteDown_fa9beb84-b14c-48f0-898f-8e3bb7fa2a87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_7a34244c-f072-411c-a7ef-49806dbacf82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cffaf573-590b-4560-9183-246833c2c834" xlink:to="loc_us-gaap_OperatingLossCarryforwards_7a34244c-f072-411c-a7ef-49806dbacf82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown_764e3cf5-eff7-4d5c-a538-dfa74ab915a2" xlink:href="clbs-20220930.xsd#clbs_OperatingLossCarryforwardsSetToExpireWrittenDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cffaf573-590b-4560-9183-246833c2c834" xlink:to="loc_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown_764e3cf5-eff7-4d5c-a538-dfa74ab915a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain_01508086-0eb5-44e1-a886-6981ef8aab1b" xlink:href="clbs-20220930.xsd#clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cffaf573-590b-4560-9183-246833c2c834" xlink:to="loc_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain_01508086-0eb5-44e1-a886-6981ef8aab1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_df27af04-26cf-4475-8f90-c7b7e2a10ea8" xlink:href="clbs-20220930.xsd#clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cffaf573-590b-4560-9183-246833c2c834" xlink:to="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_df27af04-26cf-4475-8f90-c7b7e2a10ea8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram_4486f7c7-10df-4f4b-834b-c42423f3d44b" xlink:href="clbs-20220930.xsd#clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cffaf573-590b-4560-9183-246833c2c834" xlink:to="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram_4486f7c7-10df-4f4b-834b-c42423f3d44b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LossOnSaleOfNetOperatingLosses_d4f573ac-c10c-4a49-92d1-18fe965df6c2" xlink:href="clbs-20220930.xsd#clbs_LossOnSaleOfNetOperatingLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cffaf573-590b-4560-9183-246833c2c834" xlink:to="loc_clbs_LossOnSaleOfNetOperatingLosses_d4f573ac-c10c-4a49-92d1-18fe965df6c2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_6fb6d61d-c3b4-462e-bb33-c18f87b3ddfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cffaf573-590b-4560-9183-246833c2c834" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_6fb6d61d-c3b4-462e-bb33-c18f87b3ddfc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_229a0d7b-576f-4e4c-9ae2-9139f15ba51c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_6fb6d61d-c3b4-462e-bb33-c18f87b3ddfc" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_229a0d7b-576f-4e4c-9ae2-9139f15ba51c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_229a0d7b-576f-4e4c-9ae2-9139f15ba51c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_229a0d7b-576f-4e4c-9ae2-9139f15ba51c" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_229a0d7b-576f-4e4c-9ae2-9139f15ba51c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_585a1a7f-78fb-49c8-8aed-7a6da5b044dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_229a0d7b-576f-4e4c-9ae2-9139f15ba51c" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_585a1a7f-78fb-49c8-8aed-7a6da5b044dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_f82bffa0-1b18-434b-8e39-b16539b60d76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_585a1a7f-78fb-49c8-8aed-7a6da5b044dd" xlink:to="loc_us-gaap_DomesticCountryMember_f82bffa0-1b18-434b-8e39-b16539b60d76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_e781228e-35b1-46fa-b915-fd008b715c52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_585a1a7f-78fb-49c8-8aed-7a6da5b044dd" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_e781228e-35b1-46fa-b915-fd008b715c52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_cb46e1dd-7af3-4373-9920-6332000d099d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_6fb6d61d-c3b4-462e-bb33-c18f87b3ddfc" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_cb46e1dd-7af3-4373-9920-6332000d099d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_cb46e1dd-7af3-4373-9920-6332000d099d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_cb46e1dd-7af3-4373-9920-6332000d099d" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_cb46e1dd-7af3-4373-9920-6332000d099d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_e36f3063-8b31-40ca-adc4-0015b52d376f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_cb46e1dd-7af3-4373-9920-6332000d099d" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_e36f3063-8b31-40ca-adc4-0015b52d376f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember_c1494801-524b-4d05-8d94-7a213ea8217d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_e36f3063-8b31-40ca-adc4-0015b52d376f" xlink:to="loc_us-gaap_NewJerseyDivisionOfTaxationMember_c1494801-524b-4d05-8d94-7a213ea8217d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_71f6e704-def2-461e-a0d6-38e6cf27a94c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_e36f3063-8b31-40ca-adc4-0015b52d376f" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_71f6e704-def2-461e-a0d6-38e6cf27a94c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_bcf603db-3936-4eb3-befc-d975ef098a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_e36f3063-8b31-40ca-adc4-0015b52d376f" xlink:to="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_bcf603db-3936-4eb3-befc-d975ef098a2c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/LicenseAgreementsDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#LicenseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/LicenseAgreementsDetails" xlink:type="extended" id="idc85d37382024ee1b202b6936df35839_LicenseAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f39c5b1b-7239-40ff-a95f-506bc0e1fe79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SharesIssuedUnderLicenseAgreement_6ca1c98a-4b4e-4adc-bacd-e390fd0c6fdd" xlink:href="clbs-20220930.xsd#clbs_SharesIssuedUnderLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f39c5b1b-7239-40ff-a95f-506bc0e1fe79" xlink:to="loc_clbs_SharesIssuedUnderLicenseAgreement_6ca1c98a-4b4e-4adc-bacd-e390fd0c6fdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_2afdaabb-e677-4bbe-a85c-8cbd3be3f402" xlink:href="clbs-20220930.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f39c5b1b-7239-40ff-a95f-506bc0e1fe79" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_2afdaabb-e677-4bbe-a85c-8cbd3be3f402" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_a18292f0-7b6d-4262-9f2a-8080189d607b" xlink:href="clbs-20220930.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f39c5b1b-7239-40ff-a95f-506bc0e1fe79" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_a18292f0-7b6d-4262-9f2a-8080189d607b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_f050d5d8-a283-47e7-a2a4-fec47777c205" xlink:href="clbs-20220930.xsd#clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f39c5b1b-7239-40ff-a95f-506bc0e1fe79" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_f050d5d8-a283-47e7-a2a4-fec47777c205" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_d71990b9-1ab6-4899-9f38-29cd5086695a" xlink:href="clbs-20220930.xsd#clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f39c5b1b-7239-40ff-a95f-506bc0e1fe79" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_d71990b9-1ab6-4899-9f38-29cd5086695a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees_a7ba3c35-8fcf-4232-b673-e3b449d10d97" xlink:href="clbs-20220930.xsd#clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f39c5b1b-7239-40ff-a95f-506bc0e1fe79" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees_a7ba3c35-8fcf-4232-b673-e3b449d10d97" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour_65864b27-0aac-4218-99e7-a50bd865aa9c" xlink:href="clbs-20220930.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f39c5b1b-7239-40ff-a95f-506bc0e1fe79" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour_65864b27-0aac-4218-99e7-a50bd865aa9c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SharesHeldByThirdParty_25f79673-1740-4924-9965-a2563e2ae531" xlink:href="clbs-20220930.xsd#clbs_SharesHeldByThirdParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f39c5b1b-7239-40ff-a95f-506bc0e1fe79" xlink:to="loc_clbs_SharesHeldByThirdParty_25f79673-1740-4924-9965-a2563e2ae531" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree_d41483d6-8cec-4b74-98e5-912e8abf8361" xlink:href="clbs-20220930.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f39c5b1b-7239-40ff-a95f-506bc0e1fe79" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree_d41483d6-8cec-4b74-98e5-912e8abf8361" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale_753e46f0-6217-4b9d-a5fb-674e6a5b43a3" xlink:href="clbs-20220930.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f39c5b1b-7239-40ff-a95f-506bc0e1fe79" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale_753e46f0-6217-4b9d-a5fb-674e6a5b43a3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee_32d162e7-e2be-4c38-94ce-26bde92f7979" xlink:href="clbs-20220930.xsd#clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f39c5b1b-7239-40ff-a95f-506bc0e1fe79" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee_32d162e7-e2be-4c38-94ce-26bde92f7979" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a5a8c940-3ea7-40c5-8354-ae690de955b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f39c5b1b-7239-40ff-a95f-506bc0e1fe79" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a5a8c940-3ea7-40c5-8354-ae690de955b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4f6d4dda-fed2-4c76-b86f-11735320244a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a5a8c940-3ea7-40c5-8354-ae690de955b7" xlink:to="loc_srt_CounterpartyNameAxis_4f6d4dda-fed2-4c76-b86f-11735320244a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f6d4dda-fed2-4c76-b86f-11735320244a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4f6d4dda-fed2-4c76-b86f-11735320244a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f6d4dda-fed2-4c76-b86f-11735320244a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6fbecc32-00b2-4147-aa9a-6fe9a5ad1fc3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4f6d4dda-fed2-4c76-b86f-11735320244a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6fbecc32-00b2-4147-aa9a-6fe9a5ad1fc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SanfordBurnhamPrebysMember_a92da334-bb4f-4714-b81f-bc8a8e68394c" xlink:href="clbs-20220930.xsd#clbs_SanfordBurnhamPrebysMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6fbecc32-00b2-4147-aa9a-6fe9a5ad1fc3" xlink:to="loc_clbs_SanfordBurnhamPrebysMember_a92da334-bb4f-4714-b81f-bc8a8e68394c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_UniversityOfCaliforniaAtSanDiegoMember_843a4bb6-0567-402b-a8ac-49f3be565462" xlink:href="clbs-20220930.xsd#clbs_UniversityOfCaliforniaAtSanDiegoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6fbecc32-00b2-4147-aa9a-6fe9a5ad1fc3" xlink:to="loc_clbs_UniversityOfCaliforniaAtSanDiegoMember_843a4bb6-0567-402b-a8ac-49f3be565462" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MassachusettsInstituteOfTechnologyMember_0c3074c8-5073-47b8-abfc-ebae36dc0ba7" xlink:href="clbs-20220930.xsd#clbs_MassachusettsInstituteOfTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6fbecc32-00b2-4147-aa9a-6fe9a5ad1fc3" xlink:to="loc_clbs_MassachusettsInstituteOfTechnologyMember_0c3074c8-5073-47b8-abfc-ebae36dc0ba7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f24c85ee-1a46-43c2-b32c-edb2244d0ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a5a8c940-3ea7-40c5-8354-ae690de955b7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f24c85ee-1a46-43c2-b32c-edb2244d0ed6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f24c85ee-1a46-43c2-b32c-edb2244d0ed6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f24c85ee-1a46-43c2-b32c-edb2244d0ed6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f24c85ee-1a46-43c2-b32c-edb2244d0ed6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_92f0487d-f98c-4243-af16-44ae4be12dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f24c85ee-1a46-43c2-b32c-edb2244d0ed6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_92f0487d-f98c-4243-af16-44ae4be12dcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_cca6b84a-7ce6-4005-ae27-c050eaf9b111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_92f0487d-f98c-4243-af16-44ae4be12dcb" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_cca6b84a-7ce6-4005-ae27-c050eaf9b111" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ff9dc1c1-4a6b-43be-8479-91a5d9f015dc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a5a8c940-3ea7-40c5-8354-ae690de955b7" xlink:to="loc_srt_RangeAxis_ff9dc1c1-4a6b-43be-8479-91a5d9f015dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ff9dc1c1-4a6b-43be-8479-91a5d9f015dc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ff9dc1c1-4a6b-43be-8479-91a5d9f015dc" xlink:to="loc_srt_RangeMember_ff9dc1c1-4a6b-43be-8479-91a5d9f015dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_deecb026-9dd6-4419-8595-860f28462eda" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ff9dc1c1-4a6b-43be-8479-91a5d9f015dc" xlink:to="loc_srt_RangeMember_deecb026-9dd6-4419-8595-860f28462eda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4eaabeb9-f8c8-48d2-8591-68b28baf27ea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_deecb026-9dd6-4419-8595-860f28462eda" xlink:to="loc_srt_MinimumMember_4eaabeb9-f8c8-48d2-8591-68b28baf27ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d183e8b8-945d-4245-b851-25cc0c27ef6b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_deecb026-9dd6-4419-8595-860f28462eda" xlink:to="loc_srt_MaximumMember_d183e8b8-945d-4245-b851-25cc0c27ef6b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#ResearchCollaborationandLicenseAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" xlink:type="extended" id="idd389e0246824d2484b16511c2bc8d41_ResearchCollaborationandLicenseAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08d7cf8d-016f-417c-819e-0d852daff2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_fe4295ee-fd22-453f-a89f-43befb3cf494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08d7cf8d-016f-417c-819e-0d852daff2b8" xlink:to="loc_us-gaap_ContractWithCustomerLiability_fe4295ee-fd22-453f-a89f-43befb3cf494" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_18dc9fc9-6db3-4331-b94e-ef1c7d1214e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08d7cf8d-016f-417c-819e-0d852daff2b8" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_18dc9fc9-6db3-4331-b94e-ef1c7d1214e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount_56fcfb4a-0c62-4728-8deb-35faefc238d7" xlink:href="clbs-20220930.xsd#clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08d7cf8d-016f-417c-819e-0d852daff2b8" xlink:to="loc_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount_56fcfb4a-0c62-4728-8deb-35faefc238d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RevenuePerformanceObligationPercentageOfNetSale_434cb8ab-ba4e-4454-86d1-6de2183b9096" xlink:href="clbs-20220930.xsd#clbs_RevenuePerformanceObligationPercentageOfNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08d7cf8d-016f-417c-819e-0d852daff2b8" xlink:to="loc_clbs_RevenuePerformanceObligationPercentageOfNetSale_434cb8ab-ba4e-4454-86d1-6de2183b9096" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues_8ec9d5d6-495b-4063-bb3c-c347a12f1b8d" xlink:href="clbs-20220930.xsd#clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08d7cf8d-016f-417c-819e-0d852daff2b8" xlink:to="loc_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues_8ec9d5d6-495b-4063-bb3c-c347a12f1b8d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6d2a1ef7-8882-4869-a31e-e6c2c8b25b69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08d7cf8d-016f-417c-819e-0d852daff2b8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6d2a1ef7-8882-4869-a31e-e6c2c8b25b69" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2bf5a267-43a9-46e7-9039-792d5051a2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6d2a1ef7-8882-4869-a31e-e6c2c8b25b69" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2bf5a267-43a9-46e7-9039-792d5051a2bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2bf5a267-43a9-46e7-9039-792d5051a2bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2bf5a267-43a9-46e7-9039-792d5051a2bd" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2bf5a267-43a9-46e7-9039-792d5051a2bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3db976c5-a4dd-4e03-bf9c-0d4b388cbc74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2bf5a267-43a9-46e7-9039-792d5051a2bd" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3db976c5-a4dd-4e03-bf9c-0d4b388cbc74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_75c54cad-2953-421b-8c7c-9d6dbffbdea4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6d2a1ef7-8882-4869-a31e-e6c2c8b25b69" xlink:to="loc_srt_CounterpartyNameAxis_75c54cad-2953-421b-8c7c-9d6dbffbdea4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_75c54cad-2953-421b-8c7c-9d6dbffbdea4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_75c54cad-2953-421b-8c7c-9d6dbffbdea4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_75c54cad-2953-421b-8c7c-9d6dbffbdea4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b76d4eb5-9c91-409c-9225-b3480327cbdd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_75c54cad-2953-421b-8c7c-9d6dbffbdea4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b76d4eb5-9c91-409c-9225-b3480327cbdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_QiluMember_23d5b9ff-702f-4cd6-8c5d-7b727983243a" xlink:href="clbs-20220930.xsd#clbs_QiluMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b76d4eb5-9c91-409c-9225-b3480327cbdd" xlink:to="loc_clbs_QiluMember_23d5b9ff-702f-4cd6-8c5d-7b727983243a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cca51727-cf40-4cb0-a205-31e05d8c88cc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6d2a1ef7-8882-4869-a31e-e6c2c8b25b69" xlink:to="loc_srt_ProductOrServiceAxis_cca51727-cf40-4cb0-a205-31e05d8c88cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cca51727-cf40-4cb0-a205-31e05d8c88cc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_cca51727-cf40-4cb0-a205-31e05d8c88cc" xlink:to="loc_srt_ProductsAndServicesDomain_cca51727-cf40-4cb0-a205-31e05d8c88cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_830cc939-d62e-4373-879f-7d246183f7b4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_cca51727-cf40-4cb0-a205-31e05d8c88cc" xlink:to="loc_srt_ProductsAndServicesDomain_830cc939-d62e-4373-879f-7d246183f7b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_ab035b77-d1da-4104-a287-4eb9e312dd7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_830cc939-d62e-4373-879f-7d246183f7b4" xlink:to="loc_us-gaap_LicenseMember_ab035b77-d1da-4104-a287-4eb9e312dd7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_55f07164-1a80-4192-89dc-65bdf98b3637" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6d2a1ef7-8882-4869-a31e-e6c2c8b25b69" xlink:to="loc_srt_RangeAxis_55f07164-1a80-4192-89dc-65bdf98b3637" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_55f07164-1a80-4192-89dc-65bdf98b3637_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_55f07164-1a80-4192-89dc-65bdf98b3637" xlink:to="loc_srt_RangeMember_55f07164-1a80-4192-89dc-65bdf98b3637_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_76d6792b-2cf0-4c0c-a4b4-60191d120a22" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_55f07164-1a80-4192-89dc-65bdf98b3637" xlink:to="loc_srt_RangeMember_76d6792b-2cf0-4c0c-a4b4-60191d120a22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_70815e9f-382d-4864-80b5-21bf90757938" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_76d6792b-2cf0-4c0c-a4b4-60191d120a22" xlink:to="loc_srt_MinimumMember_70815e9f-382d-4864-80b5-21bf90757938" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_351efdde-0b56-48cd-87af-1597d073c697" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_76d6792b-2cf0-4c0c-a4b4-60191d120a22" xlink:to="loc_srt_MaximumMember_351efdde-0b56-48cd-87af-1597d073c697" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>clbs-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:f426f7a3-6c2d-403e-bcce-1884a6ad721b,g:3088fff3-3c71-4b75-95a2-34e3a251fb1c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b905c7ea-200b-4682-9fdf-6e93d8227195_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_401a90a3-5794-4639-986d-c4ca3f621f44_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Lisata Therapeutics, Inc. common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_fa61e780-e409-4d35-acc1-f88004c9c8d8_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_247576cb-53c0-4459-92e4-a3f43ad5c19e_periodStartLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_d25fe8c2-b67a-44d9-b702-8e5e715d434f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_b66e6b03-cfe3-4297-9563-9261a7f0d227_periodEndLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_b0ea997e-329c-4216-88a4-7979d8b4a159_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries, employee benefits and related taxes</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_3daea2cd-93dd-4930-a917-d3d7ed556551_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_Sharesvestedandexpectedtovest_40aeec7c-83c1-4890-aab3-5daf9925cdc2_terseLabel_en-US" xlink:label="lab_clbs_Sharesvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_clbs_Sharesvestedandexpectedtovest_label_en-US" xlink:label="lab_clbs_Sharesvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">shares, vested and expected to vest</link:label>
    <link:label id="lab_clbs_Sharesvestedandexpectedtovest_documentation_en-US" xlink:label="lab_clbs_Sharesvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">shares, vested and expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_Sharesvestedandexpectedtovest" xlink:href="clbs-20220930.xsd#clbs_Sharesvestedandexpectedtovest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_Sharesvestedandexpectedtovest" xlink:to="lab_clbs_Sharesvestedandexpectedtovest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_a45b9ed8-7180-4c11-b62d-763d7a9332c5_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_c322cf86-38bb-40ff-b9e0-9a3cc0020dd0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_7b010513-b0da-4f45-8ae6-22f82c372f0b_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f96da74d-d330-42c3-9036-1a01a9e117b4_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_21193928-e00b-4f58-9fbf-3092447f3baf_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_e07ac3d0-2ace-4a70-bff3-07f6e5438aad_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term for operating leases (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_963de742-d7d5-44e7-95cf-13a9e473c6b9_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Remeasurement</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_c98333b3-ffb2-45f1-8d10-0d37fafbe51e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b545a79d-b227-431a-8191-5cb3e0b10efc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_215be7e6-1841-4dce-8fff-3403905cdace_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_ae4d3b00-edff-4009-8ab1-62cdb21956c4_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable_9bbdac5e-6271-4e11-ac68-2c13f496db61_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercisable</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:href="clbs-20220930.xsd#clbs_WeightedAverageExercisePriceWarrantsExercisable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsExercisable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4c0e3d3a-b0b2-4df8-96c5-0a635bf6ca19_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_29f0c6b4-2878-44e8-8cd9-fb402d7830e2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate for operating leases (percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c70dfebe-d4bb-417c-b2f3-4fef2fd50e2b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_42bf82fd-fdac-4267-b7a0-e7631b861798_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase_a160424c-7444-4a67-897c-dbcabc6d69fe_terseLabel_en-US" xlink:label="lab_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares allowable to direct for Regular Purchase (in shares)</link:label>
    <link:label id="lab_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase_label_en-US" xlink:label="lab_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Amount Per Agreement, Allowable To Direct Counterparty To Purchase, Regular Purchase</link:label>
    <link:label id="lab_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase_documentation_en-US" xlink:label="lab_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Amount Per Agreement, Allowable To Direct Counterparty To Purchase, Regular Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" xlink:href="clbs-20220930.xsd#clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" xlink:to="lab_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_7e70d3d3-2936-4a7e-88a0-87e0dd7ed419_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bda80497-4691-4949-b1c7-c247fc2e0f1a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average estimated fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_5c80b746-95cb-457b-8a02-ce3595f0a4f3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_469b37b1-e276-49e3-bf8f-8a265d75e8ae_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale securities - net unrealized gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_5254c4f6-66f3-4bc9-af40-a6cd984bd025_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_efd96497-f33b-44d2-86ae-5620d69ce0f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_33d4c7ac-fa63-46cc-a42f-1369c005c60e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_52a50ae8-5896-4dd8-87b7-91c132585b5c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_5d20d0dd-9ef8-4a2e-a384-b9a2daf5da7f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase_86bf3b84-264a-448c-ab46-086a44a3c088_terseLabel_en-US" xlink:label="lab_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum obligation per directed purchase transaction for Regular Purchase</link:label>
    <link:label id="lab_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase_label_en-US" xlink:label="lab_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Amount Per Agreement Per Transaction For Direct Counterparty Purchase, Regular Purchase</link:label>
    <link:label id="lab_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase_documentation_en-US" xlink:label="lab_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Amount Per Agreement Per Transaction For Direct Counterparty Purchase, Regular Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" xlink:href="clbs-20220930.xsd#clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" xlink:to="lab_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees_77340c56-3ec2-4d65-a29b-d0b83f6b9223_terseLabel_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublicensing fee</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees_label_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sublicensing Fees</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees_documentation_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Sublicensing Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:href="clbs-20220930.xsd#clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:to="lab_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_41aebb47-4707-4011-9654-990f66f07298_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Weighted Average Contractual Term and Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_a90f32a2-7597-4112-a6f1-9d7970fb95e7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from contract</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_b980e39e-f3a3-491c-a27d-ebbe712f09d9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_5be5353f-c862-4759-9f0a-7b70cf75d4db_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_5383fdec-6109-4656-b8ca-27a1cfd9b939_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_eb1205fa-89c2-4649-8b9a-ac68cdc3786b_terseLabel_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal debt securities</link:label>
    <link:label id="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember_label_en-US" xlink:label="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US States and Political Subdivisions Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:to="lab_us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_87a7066f-7b95-499f-8a3b-29bf4d37532d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_619c257e-5f06-4ccf-87c3-a82c2e1816dc_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Vested And Expected To Vest</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Vested And Expected To Vest</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Vested And Expected To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:href="clbs-20220930.xsd#clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_fdbe5b7f-c4c2-4cc6-80f4-f0238b9f9670_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_63495b3a-b684-461a-b7a5-e66969ca62b3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.000067 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at September 30, 2022 and December 31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_798c570b-c9e6-4d5e-a2fd-cb5e077d1da8_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding_00c065d0-3116-42ca-a46d-3152969ca6b2_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding_label_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term warrant outstanding</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding_documentation_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term warrant outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:href="clbs-20220930.xsd#clbs_WeightedAverageRemainingContractualTermwarrantoutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:to="lab_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_aff40436-8707-42ca-a628-f3fd3f5a1a5e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, Beginning of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ec4c2e94-09e7-4866-8d4e-a861575c606e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, End of Period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_ba752979-f9a0-4054-958b-cce0bc68899e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_479ff272-e8ca-4826-ad8e-861349947fc9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_71dbbb66-4cea-4a24-9f47-a86ca47056d0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_eb47d0c7-a378-4268-be11-68eb2b366292_terseLabel_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual license maintenance fee</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_label_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_documentation_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:href="clbs-20220930.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:to="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2f51a95d-b44c-48cb-9401-50e469116190_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e0dee644-d72b-44ce-be81-080524e16bf7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_5d25151e-76c4-4ac1-ba50-82ea4780648b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_83ed4783-1783-4fb5-a11e-f4279e45abb8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_09dfc3b0-24ff-4bba-b336-d0fb720af874_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b7fcffd2-7807-426b-8869-c8d47cea0650_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caladrius Biosciences, Inc. common stockholders - basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d6ed5e59-339d-46f9-9425-8fe4036871a7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee_ba0cced9-f8d9-44fd-a742-57a83baf099a_terseLabel_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change of control fee</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee_label_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Change of Control Fee</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee_documentation_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Change of Control Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee" xlink:href="clbs-20220930.xsd#clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee" xlink:to="lab_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b17324fe-571e-4959-947c-8412d24aabd8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e50bfbe-1b6a-4bdd-8f72-5a6c757309d9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_4d74337b-00eb-44d5-8677-a7a884f52e8a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_dafcb04c-d0d9-4fc3-b46d-40ec30ae03df_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_577c7918-0f65-47e3-93ca-4f40e1fc4575_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_4a691ead-2753-4736-a753-f624cc0a888c_terseLabel_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_label_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_documentation_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:href="clbs-20220930.xsd#clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:to="lab_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase_481d3f44-1d2a-4f01-a48f-04f4ff39a518_terseLabel_en-US" xlink:label="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum shares allowed in Accelerated Purchase as percent of shares In Regular Purchase (percent)</link:label>
    <link:label id="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase_label_en-US" xlink:label="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares In Regular Purchase</link:label>
    <link:label id="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase_documentation_en-US" xlink:label="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares In Regular Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" xlink:href="clbs-20220930.xsd#clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" xlink:to="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_ef4b2526-901e-4311-8aa1-536ec5138944_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_05dcc828-9a99-45cf-ba2c-7e5df68a026a_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_970fe6aa-713a-443f-8363-bedca3e2c79d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9846467d-f9dc-4fad-ae8a-8dcf34942668_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_22048865-7c7b-4b56-93d2-7a6058730682_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_fb87350e-445c-4394-9014-4f4e2ba5df05_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_c5823cc7-6e9a-46d9-85d9-1470016f1e77_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_27df9dca-8be1-4f2e-8513-5f6a267d689d_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SharesHeldByThirdParty_6b10082f-299c-4fd7-8870-fee40c018841_terseLabel_en-US" xlink:label="lab_clbs_SharesHeldByThirdParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares held by third party</link:label>
    <link:label id="lab_clbs_SharesHeldByThirdParty_label_en-US" xlink:label="lab_clbs_SharesHeldByThirdParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Held by Third Party</link:label>
    <link:label id="lab_clbs_SharesHeldByThirdParty_documentation_en-US" xlink:label="lab_clbs_SharesHeldByThirdParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Held by Third Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SharesHeldByThirdParty" xlink:href="clbs-20220930.xsd#clbs_SharesHeldByThirdParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SharesHeldByThirdParty" xlink:to="lab_clbs_SharesHeldByThirdParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_8a0f1523-86fc-4369-8dc3-d1f09a4566c0_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_7572e55e-1f20-430e-928c-abae75eedbed_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, non-controlling interests and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_034e4bb5-ddf1-454e-9986-53ae7203cdd1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_30ad7afd-ba39-4727-beec-726f05307036_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_2f865098-fef7-46f5-8715-b2c33f037322_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_f902a0c6-5b8f-48f2-8e59-c9fc97e1f754_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_72b782a5-8290-4ae3-9931-63b65173c858_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a67588b9-29ff-4bd2-81fc-3c8aec0d30c2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsGranted_55be3901-8e61-4cd8-a0b7-a6fc1035d303_terseLabel_en-US" xlink:label="lab_clbs_WarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Granted (in shares)</link:label>
    <link:label id="lab_clbs_WarrantsGranted_label_en-US" xlink:label="lab_clbs_WarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Granted</link:label>
    <link:label id="lab_clbs_WarrantsGranted_documentation_en-US" xlink:label="lab_clbs_WarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsGranted" xlink:href="clbs-20220930.xsd#clbs_WarrantsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsGranted" xlink:to="lab_clbs_WarrantsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_ee7dc8ef-50aa-4a87-b394-a591c67a509a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_07474bd5-2a25-4b6c-ae11-a2ecd066fbe7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_20d14619-3d0a-485e-b13a-f9710f5db851_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding_f429de31-2bab-4baf-80b4-08c5e2760083_periodStartLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Outstanding, Beginning of Period (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding_267e6c6f-948a-456e-9ef9-af9baca4538b_periodEndLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Outstanding, End of Period (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:href="clbs-20220930.xsd#clbs_WeightedAverageExercisePriceWarrantsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_2d9f1e76-bec9-43b1-aba0-729297af79a1_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research tax credit rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_f0fff72f-2213-4f08-9567-23f57af1a306_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from option exercises</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_1f960402-5bd6-4959-9613-a92848ed124c_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fc2ee969-e15a-4c07-b708-2125d7feb40f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_195d3e5c-7d10-454f-8c26-4bb5ec2fb624_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain_cb67decd-5a16-4238-a19e-9f5332e1a971_terseLabel_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Possible additional NOLs for five years resulting from Net Unrealized Built-in Gain rules</link:label>
    <link:label id="lab_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain_label_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Annual Available, Five Years, Net Unrealized Built In Gain</link:label>
    <link:label id="lab_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain_documentation_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Annual Available, Five Years, Net Unrealized Built In Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain" xlink:href="clbs-20220930.xsd#clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain" xlink:to="lab_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_91b215d3-3e8e-4bd0-8763-17991dbce4c6_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_ed2d8519-8b12-49fd-98ef-339af7b54c7d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_64005249-7b32-4469-b6b0-3cdbf9a93ecd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_79ac4fd7-09b3-4c49-a512-5c5c9db86f61_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f9b3696e-f1f6-430f-b920-1bf524946485_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d75200a6-f3a7-4630-951b-895972ffd8dc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_OperatingLeaseRightOfUseAssetAbstract_774ccd51-0228-468a-857c-71915d49dfbb_terseLabel_en-US" xlink:label="lab_clbs_OperatingLeaseRightOfUseAssetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of Use Assets:</link:label>
    <link:label id="lab_clbs_OperatingLeaseRightOfUseAssetAbstract_label_en-US" xlink:label="lab_clbs_OperatingLeaseRightOfUseAssetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset [Abstract]</link:label>
    <link:label id="lab_clbs_OperatingLeaseRightOfUseAssetAbstract_documentation_en-US" xlink:label="lab_clbs_OperatingLeaseRightOfUseAssetAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLeaseRightOfUseAssetAbstract" xlink:href="clbs-20220930.xsd#clbs_OperatingLeaseRightOfUseAssetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_OperatingLeaseRightOfUseAssetAbstract" xlink:to="lab_clbs_OperatingLeaseRightOfUseAssetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_43536832-a0ed-40bd-9221-e8dfc2326113_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with merger</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_fccaed13-b7eb-4491-b1f6-50432afbbbf7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuances of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_844bdd96-c549-48a5-ac20-3216bd4e5982_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_31159c7b-fb38-48fa-b407-6f80b6bfca28_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_label_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_documentation_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:href="clbs-20220930.xsd#clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:to="lab_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d3adacb4-4900-4417-80d1-4dcc3ea70d54_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_d92f4db4-c939-4f2f-87c5-4a03005b7f9b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_a8f13702-bb36-42f4-9f53-cb4b00e4c66b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4c979ee1-1ebd-4257-8adc-fe8f03e13068_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1f22e58f-f809-46f7-b12e-7c1499c9343e_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock and warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_09a93efa-a61d-49b1-be62-e26975fc75c0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_a9dc5ce1-a04b-4c0d-8357-b02095d96d45_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale-Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_3d729151-8e23-4359-b642-0d38c56b882c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_b9c2103b-6c0f-443c-adae-99c40b1aca43_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_f07cf026-f396-403e-895d-ef2c13a34909_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_7a717b0d-0cf4-4f28-a089-4c9ad84d7f0a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, authorized 33,333,333 shares; issued 7,863,340 and 3,986,719 shares at September 30, 2022 and December 31, 2021, respectively; and outstanding, 7,862,602 and 3,985,981 shares at September 30, 2022 and December 31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_05c5ec42-0546-4204-9beb-1f5c9727f49a_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_657dc318-7ff5-4226-bb93-52ae8b2791ac_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected weighted-average period in years of compensation cost to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_fee4c3a1-b599-443a-9002-7543129e5dde_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e3df2d5c-43e0-4449-84bd-239675cce630_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_60566b00-1ef6-4690-95b8-1550fae7cf74_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (Note 13)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_32f72386-948e-4a11-b237-e3114ed62011_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_96716179-cfe8-4da0-8e04-d8bc58179fbc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding_a75f36fe-e5fa-48b7-af97-e01674d5ccf2_terseLabel_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding_label_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants Outstanding</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding_documentation_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:href="clbs-20220930.xsd#clbs_AggregateIntrinsicValueWarrantsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:to="lab_clbs_AggregateIntrinsicValueWarrantsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_efb78f7b-1e37-42ca-81bb-07904e7ee538_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration_39f54960-335b-402d-b1b1-1f9852c258ed_terseLabel_en-US" xlink:label="lab_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment shares issued as consideration per agreement (in shares)</link:label>
    <link:label id="lab_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration_label_en-US" xlink:label="lab_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued As Consideration</link:label>
    <link:label id="lab_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration_documentation_en-US" xlink:label="lab_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued As Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration" xlink:href="clbs-20220930.xsd#clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration" xlink:to="lab_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_90903104-c788-48c9-9538-56f29ab9e83e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_38a98bf6-24a6-418e-bcac-c7b6f4a5bf7a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_70412f1a-a8fd-4ae4-941c-e1bf219392c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Share-based Compensation Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_a642788a-27b1-481e-a0ed-ad5b92fb6e40_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_82e83cc5-b279-490b-9a1e-e54c5ec40ed1_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AtTheMarketOfferingAgreementMember_e1baac64-3ab3-4dff-b261-28f7c06b6018_terseLabel_en-US" xlink:label="lab_clbs_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Agreement</link:label>
    <link:label id="lab_clbs_AtTheMarketOfferingAgreementMember_label_en-US" xlink:label="lab_clbs_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering Agreement [Member]</link:label>
    <link:label id="lab_clbs_AtTheMarketOfferingAgreementMember_documentation_en-US" xlink:label="lab_clbs_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AtTheMarketOfferingAgreementMember" xlink:href="clbs-20220930.xsd#clbs_AtTheMarketOfferingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AtTheMarketOfferingAgreementMember" xlink:to="lab_clbs_AtTheMarketOfferingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_dfcc6d13-275d-4d5c-85d9-5d292bb4e107_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_514c2099-8e07-498f-bfb9-af677818cae5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Amounts representing interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewJerseyDivisionOfTaxationMember_cad3ab62-e9b0-41cb-82d2-6919ebce5f71_terseLabel_en-US" xlink:label="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey</link:label>
    <link:label id="lab_us-gaap_NewJerseyDivisionOfTaxationMember_label_en-US" xlink:label="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey Division of Taxation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:to="lab_us-gaap_NewJerseyDivisionOfTaxationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_c70e9d6e-b633-4491-92c4-640c30acb1bc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_959f8d1a-cf31-4704-8554-28ed011ac547_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross price for stock transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CommonStockWarrantsShares_9ed4a7c6-c7ac-42b0-9d3b-0fc898c771ab_periodStartLabel_en-US" xlink:label="lab_clbs_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Outstanding, Beginning of Period (in shares)</link:label>
    <link:label id="lab_clbs_CommonStockWarrantsShares_0d4328a0-7c2a-4b42-aac2-421c7e3dccfd_periodEndLabel_en-US" xlink:label="lab_clbs_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Outstanding, End of Period (in shares)</link:label>
    <link:label id="lab_clbs_CommonStockWarrantsShares_label_en-US" xlink:label="lab_clbs_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants, Shares</link:label>
    <link:label id="lab_clbs_CommonStockWarrantsShares_documentation_en-US" xlink:label="lab_clbs_CommonStockWarrantsShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CommonStockWarrantsShares" xlink:href="clbs-20220930.xsd#clbs_CommonStockWarrantsShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CommonStockWarrantsShares" xlink:to="lab_clbs_CommonStockWarrantsShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_789dfb9b-cbf9-4730-8618-61ee75e09723_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_bfaff95b-d403-4364-8d07-44b4f8c82832_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_faf28d40-d9d3-4da5-8a1a-3f645f09ede4_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_2a193d15-55c2-4ae0-a90a-5e9575db68e7_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_a001e334-c4e1-45f7-858c-d9656a30af07_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_7dfaced6-3bd8-4e03-99b3-e4e7a5b822da_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Greater than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_3164d58f-a0cb-462f-8984-cb2f91705ce9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_04da3cb5-613d-478b-b31e-cabfa9796c25_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_18e59180-7d02-4581-87a2-2a45d5ac3211_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_f0256484-f3e9-4f49-a982-a0c29d84ed60_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_6b9a7227-1873-47e5-8338-0535067c9072_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_b2889f0d-da54-4172-b6de-e626b6228473_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_93f750a0-52cb-4d5d-a608-e3b5f1fe6367_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour_a6b98e68-2288-4813-a577-e9e196c35b5f_terseLabel_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual license maintenance fee, year four</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour_label_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Four</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour_documentation_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" xlink:href="clbs-20220930.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" xlink:to="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_47b24480-2129-4cb8-b39c-85651dad1abe_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_854759fd-4418-468f-858c-cb3fb480861f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities &#8212; current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_2bfd13b3-d428-4b3c-ab3d-d1f9af0590a9_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a1e3a7f5-818c-434e-8e93-0deddbe4bd0a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e4143cee-c3e1-44c8-86ba-2d1cfed63d6d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_776389ec-5059-47cb-8caa-6df93937c009_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_16839eae-5711-4f69-808c-d472339e99e5_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration and License Agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_45459834-c703-480a-a2b5-f05232c8e712_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_bcf9107f-fea7-4305-b6c1-fb3ffa3147f7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_06ac1481-08bf-4115-8cfe-98070c9fe061_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsOtherDisclosuresAbstract_8d363ed5-6127-4688-8cd2-2aeb8e560a03_terseLabel_en-US" xlink:label="lab_clbs_WarrantsOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Weighted Average Contractual Term and Intrinsic Value</link:label>
    <link:label id="lab_clbs_WarrantsOtherDisclosuresAbstract_label_en-US" xlink:label="lab_clbs_WarrantsOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Other Disclosures [Abstract]</link:label>
    <link:label id="lab_clbs_WarrantsOtherDisclosuresAbstract_documentation_en-US" xlink:label="lab_clbs_WarrantsOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Other Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsOtherDisclosuresAbstract" xlink:href="clbs-20220930.xsd#clbs_WarrantsOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsOtherDisclosuresAbstract" xlink:to="lab_clbs_WarrantsOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_82d88579-7dce-46a2-972c-529ed0b9db60_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9f949e10-c69d-42ee-a389-83859fa4373e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_29f46e03-edea-419a-a9d1-aa459a9bb8e9_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_NumberOfOfficesUnderOperatingLeases_e2380730-52fd-474b-a79d-ae5126e63eda_terseLabel_en-US" xlink:label="lab_clbs_NumberOfOfficesUnderOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of offices under operating leases</link:label>
    <link:label id="lab_clbs_NumberOfOfficesUnderOperatingLeases_label_en-US" xlink:label="lab_clbs_NumberOfOfficesUnderOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Offices Under Operating Leases</link:label>
    <link:label id="lab_clbs_NumberOfOfficesUnderOperatingLeases_documentation_en-US" xlink:label="lab_clbs_NumberOfOfficesUnderOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Offices Under Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_NumberOfOfficesUnderOperatingLeases" xlink:href="clbs-20220930.xsd#clbs_NumberOfOfficesUnderOperatingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_NumberOfOfficesUnderOperatingLeases" xlink:to="lab_clbs_NumberOfOfficesUnderOperatingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_629f670b-a651-4796-9d65-87018a7ec804_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current, balance sheet line item</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_b09cb412-d203-4796-af8e-539edd0782a8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_4f2c2cef-7e70-485b-9026-96943e2079fd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with merger</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_ad5f6718-fa76-4da0-aac9-9f30f6feae79_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Cend Therapeutics</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6513fad8-a8c2-4610-8569-60a0c277eec4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_PreferredStockSharesDesignated_c2efe153-9808-4b30-882b-1123a7d6b55a_terseLabel_en-US" xlink:label="lab_clbs_PreferredStockSharesDesignated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated</link:label>
    <link:label id="lab_clbs_PreferredStockSharesDesignated_label_en-US" xlink:label="lab_clbs_PreferredStockSharesDesignated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated</link:label>
    <link:label id="lab_clbs_PreferredStockSharesDesignated_documentation_en-US" xlink:label="lab_clbs_PreferredStockSharesDesignated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares designated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PreferredStockSharesDesignated" xlink:href="clbs-20220930.xsd#clbs_PreferredStockSharesDesignated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_PreferredStockSharesDesignated" xlink:to="lab_clbs_PreferredStockSharesDesignated" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_cf16245f-d43f-4a63-bc72-aa22cd97cfea_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cbcae31b-4451-416c-a7c6-b00f92ec12ce_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_c1538f34-fbff-45bf-99de-49c6f8585837_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_11bbd935-e2c9-472a-9efa-b2c7d81cac05_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_ec153e33-2df8-4cc2-ab7b-7a91a6591005_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2dca5d70-6ac3-4359-b1c4-824ada4e81c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_343e6761-9b84-4369-af8b-38884de35bf9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_61b64777-bfa2-4821-8566-2817ba04b876_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_a0681e5b-36f0-43a4-80dc-8f848e5f25e4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d2681dc1-3cfd-407c-8701-cbc2bb0998ae_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_09534ecd-f28b-479d-b6f4-4bfaa57c2fbf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Lease Payments Under Lease Agreements</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_ea9e61ae-e775-47fc-bcbb-c292d9515ae0_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Lisata Therapeutics, Inc. stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_99eadc55-b542-4ca5-b408-757947d3d1cc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_6e645573-10d4-4ce1-8869-35004458c6e2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_d1f6df0c-5cd2-4e9f-a740-d4138588c0f4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_06ab8cb9-d8c5-426a-8830-d9dbe01e3fd7_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f97e1127-a8ef-4adf-a1ae-938be23b9515_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SharesIssuedUnderLicenseAgreement_d1955e63-53ca-4552-9fe0-751730416d2c_terseLabel_en-US" xlink:label="lab_clbs_SharesIssuedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under license agreement</link:label>
    <link:label id="lab_clbs_SharesIssuedUnderLicenseAgreement_label_en-US" xlink:label="lab_clbs_SharesIssuedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Under License Agreement</link:label>
    <link:label id="lab_clbs_SharesIssuedUnderLicenseAgreement_documentation_en-US" xlink:label="lab_clbs_SharesIssuedUnderLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued Under License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SharesIssuedUnderLicenseAgreement" xlink:href="clbs-20220930.xsd#clbs_SharesIssuedUnderLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SharesIssuedUnderLicenseAgreement" xlink:to="lab_clbs_SharesIssuedUnderLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_2e2c9eae-b79a-4bdf-8ecc-ff85e192f231_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_65c5a6aa-6afb-46af-8a39-a1d96f3a159e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c3b2e222-7999-4653-9f6c-a62e33bff04a_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of noncash investing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_b7437dd0-36a0-40ff-ae29-b0d2f144f61b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_d2e16e07-cb8a-4943-8b17-dcd1ecd551c5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Greater than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_4bf6e834-35d3-4580-baa9-8d2dba1f0d32_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Risks</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_8585f9ac-be7e-4b32-b088-d2a1e66c541f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_ad3d514f-3dce-4ec8-963a-013a7937ab10_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_796d6187-f9d1-4b79-9619-415c8c38bfbd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_55e73f17-336d-4abe-a06a-49ff754ebf46_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_c8bfe6f0-bcbf-4133-8919-e75eea9fc125_terseLabel_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual license maintenance fee, year seven</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_label_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_documentation_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:href="clbs-20220930.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:to="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_03581cbb-7616-43e1-9b9d-57f7fb456b76_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_be04dbfb-f8dc-4257-985b-65a3c270ff99_terseLabel_en-US" xlink:label="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of NOLs, gross</link:label>
    <link:label id="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_label_en-US" xlink:label="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross</link:label>
    <link:label id="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_documentation_en-US" xlink:label="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:href="clbs-20220930.xsd#clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:to="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_c7b598ec-c6a4-4aff-8b29-36fa31725341_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2339352e-53d8-4caf-94cd-bb26b87bca06_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram_f21426cb-bd7e-4ce6-a231-3382e7f0294a_terseLabel_en-US" xlink:label="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from sale of NOLs</link:label>
    <link:label id="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram_label_en-US" xlink:label="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Net Operating Losses, NJEDA Program</link:label>
    <link:label id="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram_documentation_en-US" xlink:label="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Net Operating Losses, NJEDA Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" xlink:href="clbs-20220930.xsd#clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" xlink:to="lab_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercised_6d238230-a044-4bcf-bd47-10122e432b0a_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Exercised (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercised_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercised</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExercised_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:href="clbs-20220930.xsd#clbs_WeightedAverageExercisePriceWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_0c32b288-e7d6-45dd-a6cc-9e0c3db50a3b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_d573721c-86b5-4109-a103-307c21143290_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_fc34103e-4cf7-4787-9600-8f8d6a1b72e7_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_0775fe63-c03c-45aa-be75-81204e971f46_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_26baf5ef-030f-423e-9f47-9c6ebd3efd2e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_fe248aa1-eb89-40ae-9e55-4a5756ad9381_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_OptionsVestedweightedAverageRemainingContractualTerm_f4fb2491-ae50-437f-81c7-e369883e0c78_terseLabel_en-US" xlink:label="lab_clbs_OptionsVestedweightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_clbs_OptionsVestedweightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_clbs_OptionsVestedweightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested, weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_clbs_OptionsVestedweightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_clbs_OptionsVestedweightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested, weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OptionsVestedweightedAverageRemainingContractualTerm" xlink:href="clbs-20220930.xsd#clbs_OptionsVestedweightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_OptionsVestedweightedAverageRemainingContractualTerm" xlink:to="lab_clbs_OptionsVestedweightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsExpired_46f2850a-b31c-49b0-bc58-44b468ac4f0a_negatedTerseLabel_en-US" xlink:label="lab_clbs_WarrantsExpired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expired (in shares)</link:label>
    <link:label id="lab_clbs_WarrantsExpired_label_en-US" xlink:label="lab_clbs_WarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expired</link:label>
    <link:label id="lab_clbs_WarrantsExpired_documentation_en-US" xlink:label="lab_clbs_WarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsExpired" xlink:href="clbs-20220930.xsd#clbs_WarrantsExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsExpired" xlink:to="lab_clbs_WarrantsExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsExercised_4e365db2-58c2-43b0-b289-e0af879e48ef_negatedTerseLabel_en-US" xlink:label="lab_clbs_WarrantsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Exercised (in shares)</link:label>
    <link:label id="lab_clbs_WarrantsExercised_label_en-US" xlink:label="lab_clbs_WarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercised</link:label>
    <link:label id="lab_clbs_WarrantsExercised_documentation_en-US" xlink:label="lab_clbs_WarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsExercised" xlink:href="clbs-20220930.xsd#clbs_WarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsExercised" xlink:to="lab_clbs_WarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_ee4042cd-10a3-412a-b31f-35ecafcf7263_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_d7c1272d-430b-4995-a1ae-9c642292a701_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_982fff77-fd73-4aa9-81cc-b6246199ebd8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9c5a64f1-8608-432f-98a2-c8d3f03a2aac_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eb33a1de-3e82-4db2-bf5e-893ef2dae764_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e84a357a-a952-4938-bb3e-4cc6050880e0_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f92a8a52-308c-4b6e-b324-75c4898f877b_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_274eb05a-4475-449d-9228-24df292e8378_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_62c94dbc-122a-4b83-9ec0-5f872216ae22_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_219f95ba-3e1c-44c6-8678-aeb84031a830_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_cda9602d-b582-4f2f-a0f8-bc4ef7715d39_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_17926d45-1bd0-4e6b-82f7-c95d7353f2c2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_4f529a86-30d4-4169-b1f2-e0e5922da50f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_48489973-8d75-4bc7-90cb-5a5f5552e40d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_bd80d510-a24c-44b6-bb5d-ed4fffb1d2d1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Name of Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f2192779-4d53-4cd7-abc1-7dc81efb50b9_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_dbb4c57c-414a-435c-9c7a-cecee4c12b08_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_8e94937d-544c-46a5-8534-67cd14669b25_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_535bf769-1574-4578-a96c-2799cbbf28c8_terseLabel_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties, net of sales</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_label_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_documentation_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:href="clbs-20220930.xsd#clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:to="lab_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6d78eb34-68ca-4818-bdbd-ccf535e26ecc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6c34f286-79d8-44be-a6b5-c55d746a3874_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_bb8d1530-f1e6-4948-9136-a1c63388ef02_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_5e996d38-262b-4190-a2f3-2b3970fc4a97_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_d7c701a5-0591-4663-8984-4ee08f78b958_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_05babc40-7fa1-4d9a-b07e-446d14bf277a_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsVested_593f7f1b-8a87-4ba4-b151-d94afd25da0c_terseLabel_en-US" xlink:label="lab_clbs_WarrantsVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested (in shares)</link:label>
    <link:label id="lab_clbs_WarrantsVested_label_en-US" xlink:label="lab_clbs_WarrantsVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested</link:label>
    <link:label id="lab_clbs_WarrantsVested_documentation_en-US" xlink:label="lab_clbs_WarrantsVested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsVested" xlink:href="clbs-20220930.xsd#clbs_WarrantsVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsVested" xlink:to="lab_clbs_WarrantsVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_328117ee-a5b5-4613-bc7a-9ae0d6e85cbc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_13cb86b6-80ff-4722-b1b3-67d404846dce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average estimated fair value of shares granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_b2435342-7e4c-4d00-bc7f-b13baafe7f8d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7034e758-cfeb-47b4-975f-4b7122036bb2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_BusinessTextBlock_27980eea-bc3a-43a7-b265-8c2be624de2b_terseLabel_en-US" xlink:label="lab_clbs_BusinessTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Business</link:label>
    <link:label id="lab_clbs_BusinessTextBlock_label_en-US" xlink:label="lab_clbs_BusinessTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Business [Text Block]</link:label>
    <link:label id="lab_clbs_BusinessTextBlock_documentation_en-US" xlink:label="lab_clbs_BusinessTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Business [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_BusinessTextBlock" xlink:href="clbs-20220930.xsd#clbs_BusinessTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_BusinessTextBlock" xlink:to="lab_clbs_BusinessTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_97050562-e522-4727-82f2-4a5eacaf7e42_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_24d09cc2-7c10-4c1c-9f8f-43c163f811f3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty_092476da-4183-49d6-8832-cda93f51f8ce_terseLabel_en-US" xlink:label="lab_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum beneficial ownership allowable per agreement (percent)</link:label>
    <link:label id="lab_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty_label_en-US" xlink:label="lab_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Rights Agreement, Maximum Beneficial Ownership Allowable For Counterparty</link:label>
    <link:label id="lab_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty_documentation_en-US" xlink:label="lab_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registration Rights Agreement, Maximum Beneficial Ownership Allowable For Counterparty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" xlink:href="clbs-20220930.xsd#clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" xlink:to="lab_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_f195be31-82fa-474e-8f66-03469d2031a7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_7d2c9fc4-c11d-4303-8139-e7cc23b35d54_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested_8b3f8ec6-6a65-43ad-93f2-a6773443deef_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested_label_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">weighted Average Remaining Contractual Term, warrants vested</link:label>
    <link:label id="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested_documentation_en-US" xlink:label="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">weighted Average Remaining Contractual Term, warrants vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:href="clbs-20220930.xsd#clbs_WeightedAverageRemainingContractualTermwarrantsvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:to="lab_clbs_WeightedAverageRemainingContractualTermwarrantsvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_3cf93141-4fa6-4580-8bdf-ecc9cf975d7b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in connection with Merger (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_811b18fc-fd6b-47bb-ab56-5c8c8eb1c327_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_90604348-f02e-4509-af1a-fdb0b637e194_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_9ec53773-28b0-4743-8271-d9edbf31623d_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_b0c26a46-0b9f-46b9-b580-f178ea1ae659_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_523c925a-bcfd-4ed0-bbcc-bf7e9488da3b_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d8f6f324-8d6a-4940-b54f-1d6f40b8e144_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_94fa2f53-1523-40cc-9d26-0d4dfdd0f452_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_6a0f1f64-228d-4118-9553-3a0dfaa35caf_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Compensation Cost Related to Nonvested Awards</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_7ae91dde-c230-4900-9c38-d2737b29e7c4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_eb9db5a1-f8af-42ac-95f5-4bee6794d65f_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before benefit from income taxes and noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_47fb0c95-cf83-4450-a18f-1af3dc36d9c5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3c6f54e3-d85c-4277-b040-73367aede7bc_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_70277dbb-b4e4-435a-a443-4aeee684ba89_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8b35e0d2-a721-48af-a14e-eb666a3ef961_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_14314f7e-1dba-4b80-9f70-0231e34bba71_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b89bef89-eee4-4701-afeb-a7a494e0687f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Share-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_UniversityOfCaliforniaAtSanDiegoMember_30d5bdb2-89b0-4e2c-a185-263a6cc426b8_terseLabel_en-US" xlink:label="lab_clbs_UniversityOfCaliforniaAtSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of California at San Diego</link:label>
    <link:label id="lab_clbs_UniversityOfCaliforniaAtSanDiegoMember_label_en-US" xlink:label="lab_clbs_UniversityOfCaliforniaAtSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of California at San Diego [Member]</link:label>
    <link:label id="lab_clbs_UniversityOfCaliforniaAtSanDiegoMember_documentation_en-US" xlink:label="lab_clbs_UniversityOfCaliforniaAtSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of California at San Diego</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_UniversityOfCaliforniaAtSanDiegoMember" xlink:href="clbs-20220930.xsd#clbs_UniversityOfCaliforniaAtSanDiegoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_UniversityOfCaliforniaAtSanDiegoMember" xlink:to="lab_clbs_UniversityOfCaliforniaAtSanDiegoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CENDMember_32569a61-67d5-42fd-8977-2541446efc63_terseLabel_en-US" xlink:label="lab_clbs_CENDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CEND</link:label>
    <link:label id="lab_clbs_CENDMember_label_en-US" xlink:label="lab_clbs_CENDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CEND [Member]</link:label>
    <link:label id="lab_clbs_CENDMember_documentation_en-US" xlink:label="lab_clbs_CENDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CEND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CENDMember" xlink:href="clbs-20220930.xsd#clbs_CENDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CENDMember" xlink:to="lab_clbs_CENDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_8e18d463-0d7b-4670-9e8a-2fe564ffb897_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_3b1974cf-3dd5-4f62-8a87-0c9468f8883c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_006ad638-9624-4a5c-9235-5d95080e1999_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_67e78ad7-e61a-43ed-8ffc-cb51a50f5fa6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_13f78c30-3b03-43f4-bb5e-3f06a2d5fb7b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_79a7ed88-e4e1-46f3-bf5f-f66fe24a52ac_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_27fa7080-f20f-40d6-b1ec-d407c20974d7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_18621329-bac5-409a-a44b-ee920e3f32ac_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- Controlling Interest in Subsidiary</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExpired_c22f6335-ba69-4123-b948-af0538116093_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expired (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExpired_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Expired</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsExpired_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:href="clbs-20220930.xsd#clbs_WeightedAverageExercisePriceWarrantsExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_0125f5cf-46ef-4f6d-928c-20cf56f2c6c7_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_TermOfAgreement_ded79830-340d-415d-84c9-9c136a0fc17a_terseLabel_en-US" xlink:label="lab_clbs_TermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of agreement (in months)</link:label>
    <link:label id="lab_clbs_TermOfAgreement_label_en-US" xlink:label="lab_clbs_TermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Of Agreement</link:label>
    <link:label id="lab_clbs_TermOfAgreement_documentation_en-US" xlink:label="lab_clbs_TermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Of Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_TermOfAgreement" xlink:href="clbs-20220930.xsd#clbs_TermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_TermOfAgreement" xlink:to="lab_clbs_TermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_243b51e0-c08a-470b-ad3b-4d6070270b34_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsCanceled_fb4b8fcb-a7fe-441c-97cf-a2d588632fc2_negatedLabel_en-US" xlink:label="lab_clbs_WarrantsCanceled" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Forfeited (in shares)</link:label>
    <link:label id="lab_clbs_WarrantsCanceled_label_en-US" xlink:label="lab_clbs_WarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Canceled</link:label>
    <link:label id="lab_clbs_WarrantsCanceled_documentation_en-US" xlink:label="lab_clbs_WarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Canceled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsCanceled" xlink:href="clbs-20220930.xsd#clbs_WarrantsCanceled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsCanceled" xlink:to="lab_clbs_WarrantsCanceled" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_16952529-de88-478e-9a67-69206f2dac4f_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues_a5930199-2353-4d77-9f1d-3610ed5b35cf_terseLabel_en-US" xlink:label="lab_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of sublicensing revenues</link:label>
    <link:label id="lab_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues_label_en-US" xlink:label="lab_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Percentage of Sublicensing Revenues</link:label>
    <link:label id="lab_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues_documentation_en-US" xlink:label="lab_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Percentage of Sublicensing Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:href="clbs-20220930.xsd#clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:to="lab_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_498e3e1f-7ebc-413f-8f36-3b47bf8a2ba6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3133420b-a326-4638-9a01-1b39f31032b1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_5cef4a01-45b3-4ad7-b86c-ae0f88b83c1a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_RevenuePerformanceObligationPercentageOfNetSale_a505721a-b9dc-4515-abee-6be35cca96d3_terseLabel_en-US" xlink:label="lab_clbs_RevenuePerformanceObligationPercentageOfNetSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net sale</link:label>
    <link:label id="lab_clbs_RevenuePerformanceObligationPercentageOfNetSale_label_en-US" xlink:label="lab_clbs_RevenuePerformanceObligationPercentageOfNetSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Percentage of Net Sale</link:label>
    <link:label id="lab_clbs_RevenuePerformanceObligationPercentageOfNetSale_documentation_en-US" xlink:label="lab_clbs_RevenuePerformanceObligationPercentageOfNetSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Percentage of Net Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RevenuePerformanceObligationPercentageOfNetSale" xlink:href="clbs-20220930.xsd#clbs_RevenuePerformanceObligationPercentageOfNetSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_RevenuePerformanceObligationPercentageOfNetSale" xlink:to="lab_clbs_RevenuePerformanceObligationPercentageOfNetSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_aa41a473-2bfa-4dc8-a6d0-0e6f2f23387e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_96315c7f-f061-4b7e-baf8-3e667e58328a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_ffc17802-8168-4cc6-886f-d99e3e330945_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Caladrius Biosciences, Inc. common stockholders - diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_055f8e97-4bf1-46f2-826d-10d454228d8c_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_4bee0fc6-427a-4b06-97ab-e37caa2419ae_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price of shares sold (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_b2053adc-af2f-49c5-b128-40cf4de4752d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_1cd8456e-cb1a-484c-8090-d019f7b551df_terseLabel_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger</link:label>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_224b3e5d-7c97-4f20-9f18-120221fe4cd1_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Lisata Therapeutics, Inc. common stockholders</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_3bb8431f-7381-4116-8371-dc41f0da8058_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationFormerLegalOrRegisteredName_c81372b4-6f7e-4776-834e-31b9066c6753_terseLabel_en-US" xlink:label="lab_dei_EntityInformationFormerLegalOrRegisteredName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information, Former Legal or Registered Name</link:label>
    <link:label id="lab_dei_EntityInformationFormerLegalOrRegisteredName_label_en-US" xlink:label="lab_dei_EntityInformationFormerLegalOrRegisteredName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information, Former Legal or Registered Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationFormerLegalOrRegisteredName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInformationFormerLegalOrRegisteredName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="lab_dei_EntityInformationFormerLegalOrRegisteredName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_36086c99-6a8a-4ea7-beef-0154002e8a9c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6487bb80-5f0b-43fd-81c8-0b3226570271_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d06df5b3-696d-4e08-8607-9dd45e7bd318_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting terms (years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_83f21521-98df-4fab-81b0-81b614d2467e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount_7574b3bf-8888-487e-9afb-99be241b648b_terseLabel_en-US" xlink:label="lab_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable consideration amounts, milestones</link:label>
    <link:label id="lab_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount_label_en-US" xlink:label="lab_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:label id="lab_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount_documentation_en-US" xlink:label="lab_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:href="clbs-20220930.xsd#clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:to="lab_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_2f86626f-e807-4d1e-8347-a14664fae159_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_f724d1bc-3f82-4cc8-8054-1cb600bc4306_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_cad42114-7361-4245-8e25-834aca5fc3fa_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_58df5bb8-e4df-41a1-8d5d-2ffa8dbb9646_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Lisata Therapeutics, Inc. Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_f153ee6e-5f49-49bf-94e8-b05b7ee417df_terseLabel_en-US" xlink:label="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate offering amount authorized per agreement</link:label>
    <link:label id="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_label_en-US" xlink:label="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement</link:label>
    <link:label id="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_documentation_en-US" xlink:label="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:href="clbs-20220930.xsd#clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:to="lab_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree_28e922d2-e200-4c06-b769-43a69d948865_terseLabel_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual license maintenance fee, years two and three</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree_label_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Two and Three</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree_documentation_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Two and Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree" xlink:href="clbs-20220930.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree" xlink:to="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_91f94a4d-16d0-4761-a673-25631fcea83f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3b6db397-ee70-4481-94d4-1cb3de13621b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_97407055-2e3c-450c-b2e7-a2707e652255_terseLabel_en-US" xlink:label="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued liabilities and other liabilities</link:label>
    <link:label id="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_label_en-US" xlink:label="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities</link:label>
    <link:label id="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_documentation_en-US" xlink:label="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:href="clbs-20220930.xsd#clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:to="lab_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_359ec871-dfb5-4011-a96b-3c40862bcc54_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_53dadb3c-0373-4e28-b25f-2cae2f72326e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_93912ac7-c38f-461f-855b-045f0cae1f5f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_23ae9e1f-6dad-4df7-8233-de8cbac9a73f_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_0f445a1b-0dea-41ce-922a-c6e390b6d189_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental fair value of Cend's fully vested stock options assumed</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1" xlink:to="lab_us-gaap_LiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown_2c7af98e-05e0-4d5f-9ae1-10b40e00f8d4_terseLabel_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write down of NOLs set to expire unutilized</link:label>
    <link:label id="lab_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown_label_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Set To Expire, Written Down</link:label>
    <link:label id="lab_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown_documentation_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Set To Expire, Written Down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown" xlink:href="clbs-20220930.xsd#clbs_OperatingLossCarryforwardsSetToExpireWrittenDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown" xlink:to="lab_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_OperatingLossCarryforwardsBeforeWriteDown_c4ed6f7b-2758-40bd-83bf-369bb0595fb3_terseLabel_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsBeforeWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards, prior to write down</link:label>
    <link:label id="lab_clbs_OperatingLossCarryforwardsBeforeWriteDown_label_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsBeforeWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Before Write Down</link:label>
    <link:label id="lab_clbs_OperatingLossCarryforwardsBeforeWriteDown_documentation_en-US" xlink:label="lab_clbs_OperatingLossCarryforwardsBeforeWriteDown" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Before Write Down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsBeforeWriteDown" xlink:href="clbs-20220930.xsd#clbs_OperatingLossCarryforwardsBeforeWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_OperatingLossCarryforwardsBeforeWriteDown" xlink:to="lab_clbs_OperatingLossCarryforwardsBeforeWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward_cfdf374f-c6ca-4500-b02d-5566144ccc9a_terseLabel_en-US" xlink:label="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Weighted Average Exercise Price</link:label>
    <link:label id="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:href="clbs-20220930.xsd#clbs_WarrantsWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:to="lab_clbs_WarrantsWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_34564c76-dc3a-4cbf-91a1-b974e5d0b177_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_34dbaff5-1fa3-44cd-8887-ac3db724fe3c_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d9cd47e3-7131-46f7-afcf-ebe0127cc70d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3bf3a2b6-8a01-4013-bbcc-c763032308ad_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_956b41a2-b8b4-4e10-a2c5-47bae63648b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options, Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_b797b549-ff1f-40c9-84a8-73db85ca80c1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale_b4fb4813-9275-4002-a8fa-e084914d36f4_terseLabel_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual license maintenance fee, after first sale</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale_label_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee After First Sale</link:label>
    <link:label id="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale_documentation_en-US" xlink:label="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee After First Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale" xlink:href="clbs-20220930.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale" xlink:to="lab_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_e512c3fe-3440-4ac5-845d-63df256239d0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_abc4da26-9639-41b0-924e-35af3a21f70d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities - available for sale</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_980b99d3-b85a-434b-8caa-73589cef830a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_ccc68c4f-bb26-4e17-a94d-3e7c1bc2a401_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_7fee9285-f17d-4f45-8d22-e3f6bd2f3995_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_09376de6-8d66-4202-a2c5-abe685aa3c35_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_db910c2f-ea3b-4c11-b994-3b3da7a55d5b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_06cdf036-ce30-4d37-9ac4-5da2794e39a7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_LincolnParkAgreementMember_7f703d50-b808-464e-ae05-49bf03ff9404_terseLabel_en-US" xlink:label="lab_clbs_LincolnParkAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincoln Park Agreement</link:label>
    <link:label id="lab_clbs_LincolnParkAgreementMember_label_en-US" xlink:label="lab_clbs_LincolnParkAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincoln Park Agreement [Member]</link:label>
    <link:label id="lab_clbs_LincolnParkAgreementMember_documentation_en-US" xlink:label="lab_clbs_LincolnParkAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lincoln Park Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LincolnParkAgreementMember" xlink:href="clbs-20220930.xsd#clbs_LincolnParkAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_LincolnParkAgreementMember" xlink:to="lab_clbs_LincolnParkAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_6fbfd5a2-5ea0-4741-a282-decd94e472c5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_3407d584-9eef-4c17-b85d-96189a6c5b4a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a03c4d2f-ec78-478d-be62-9e0bcca12b58_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_dea723f5-b7a3-41c2-9d34-6ccda102dcc6_terseLabel_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_label_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants vested and expected to vest</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_documentation_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants vested and expected to vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:href="clbs-20220930.xsd#clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:to="lab_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled_45441abd-1464-4334-8e75-455904c5fdfc_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Canceled</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Canceled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:href="clbs-20220930.xsd#clbs_WeightedAverageExercisePriceWarrantsCanceled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsCanceled" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsGranted_b838a721-65a9-4f51-86f0-b472313aa6a7_terseLabel_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Granted (in dollars per share)</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsGranted_label_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Granted</link:label>
    <link:label id="lab_clbs_WeightedAverageExercisePriceWarrantsGranted_documentation_en-US" xlink:label="lab_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:href="clbs-20220930.xsd#clbs_WeightedAverageExercisePriceWarrantsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:to="lab_clbs_WeightedAverageExercisePriceWarrantsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_aff8dc15-2489-4fae-8767-1e03217ec365_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SanfordBurnhamPrebysMember_d0e0746d-cb6e-4fcf-8bc1-890171f5b79e_terseLabel_en-US" xlink:label="lab_clbs_SanfordBurnhamPrebysMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanford Burnham Prebys</link:label>
    <link:label id="lab_clbs_SanfordBurnhamPrebysMember_label_en-US" xlink:label="lab_clbs_SanfordBurnhamPrebysMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanford Burnham Prebys [Member]</link:label>
    <link:label id="lab_clbs_SanfordBurnhamPrebysMember_documentation_en-US" xlink:label="lab_clbs_SanfordBurnhamPrebysMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanford Burnham Prebys</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SanfordBurnhamPrebysMember" xlink:href="clbs-20220930.xsd#clbs_SanfordBurnhamPrebysMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SanfordBurnhamPrebysMember" xlink:to="lab_clbs_SanfordBurnhamPrebysMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_f4a77853-872e-4fa6-b845-bbba2f5474af_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities:</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_66013b08-8032-436f-a686-193e26fc59f5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost; 738 shares at September 30, 2022 and December 31, 2021</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ca98de15-22af-4d2e-8b98-eda96b570601_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding. Beginning of Period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f7c73c98-5918-4318-9328-c8a384240f92_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Outstanding, End of Period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_529ca366-790f-4dee-a35e-b684bfa183d5_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_06f44240-aa97-455f-be13-65a46a4af273_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, noncurrent, balance sheet line item</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_ClinicalAndRDRelatedLiabilities_a2ec9f13-473d-4205-9b1b-2644bd6c97bf_terseLabel_en-US" xlink:label="lab_clbs_ClinicalAndRDRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical and R&amp;D related liabilities</link:label>
    <link:label id="lab_clbs_ClinicalAndRDRelatedLiabilities_label_en-US" xlink:label="lab_clbs_ClinicalAndRDRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical and R&amp;D Related Liabilities</link:label>
    <link:label id="lab_clbs_ClinicalAndRDRelatedLiabilities_documentation_en-US" xlink:label="lab_clbs_ClinicalAndRDRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical and R&amp;D Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ClinicalAndRDRelatedLiabilities" xlink:href="clbs-20220930.xsd#clbs_ClinicalAndRDRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_ClinicalAndRDRelatedLiabilities" xlink:to="lab_clbs_ClinicalAndRDRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_MassachusettsInstituteOfTechnologyMember_c179e821-7019-41c6-9532-bfe1b70d84c8_terseLabel_en-US" xlink:label="lab_clbs_MassachusettsInstituteOfTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Massachusetts Institute of Technology</link:label>
    <link:label id="lab_clbs_MassachusettsInstituteOfTechnologyMember_label_en-US" xlink:label="lab_clbs_MassachusettsInstituteOfTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Massachusetts Institute of Technology [Member]</link:label>
    <link:label id="lab_clbs_MassachusettsInstituteOfTechnologyMember_documentation_en-US" xlink:label="lab_clbs_MassachusettsInstituteOfTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Massachusetts Institute of Technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MassachusettsInstituteOfTechnologyMember" xlink:href="clbs-20220930.xsd#clbs_MassachusettsInstituteOfTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_MassachusettsInstituteOfTechnologyMember" xlink:to="lab_clbs_MassachusettsInstituteOfTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_1607b4f8-a4cf-4a47-a691-a22aa183055c_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvested_ba572421-2f0c-41d3-a66c-f86d5ff88131_terseLabel_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Vested, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvested_label_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants vested</link:label>
    <link:label id="lab_clbs_AggregateIntrinsicValueWarrantsvested_documentation_en-US" xlink:label="lab_clbs_AggregateIntrinsicValueWarrantsvested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Warrants vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsvested" xlink:href="clbs-20220930.xsd#clbs_AggregateIntrinsicValueWarrantsvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_AggregateIntrinsicValueWarrantsvested" xlink:to="lab_clbs_AggregateIntrinsicValueWarrantsvested" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_e7965069-4094-4adc-8cb9-4add2960d4c6_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_cf28ddea-0619-4f55-ab2a-4de51027e0ae_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_dc9e4379-5201-49cd-a6ea-a64ecf543166_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_e813c5ef-4314-4cce-868c-a1c020dda6f4_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_7d5c3c7a-685e-47aa-b019-a0cf9eff97c9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_4cdc5148-4ffa-4ac6-9f39-458821be0594_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_38563dd4-1b62-4bab-83d6-34a1fa5a8835_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d67eda61-0d0d-4a79-82fd-ca37320545fc_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2a01ff7d-6b12-4989-b3ef-b67a4ee49efb_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_bca5d0dc-a192-4e3a-8d75-66b43ed21d86_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_704183cf-edd7-44dd-b39c-0de5b275fdb9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ef2b5a9d-fd8c-46fb-aece-3c5dadf7fe6c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_12a90364-871f-454f-9a5c-59be82718677_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_339fe040-10d3-4dc8-a9d1-2d0c12ae6259_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_676e969c-9426-40fe-bfe3-e50f1912e15a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_879aa479-3fe2-4afb-9d29-835a4677ea48_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c51bb788-c1b1-4c1f-a532-83e307d4b207_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_99a6033f-db3f-475b-a1e2-a451ce48e97f_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_d5ddbafa-bb4a-46a4-bafa-529e67a3a011_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_ed3acf4d-0a59-4e82-a75a-9d09b99dc5e0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_d74f5021-2d6c-403b-a8b5-327a92c787b8_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_a4871d16-f219-4876-8d1b-21ee9bfe581d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option and Warrants Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_184aa41d-c06c-4381-919e-d971ea9aeb4f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0ba22ffd-bf99-47cb-98de-856602c7f957_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_e75bce51-aad5-453f-99be-a62f64a6947e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_58abde2c-e7a4-4165-a242-a29177b9c5a0_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_4e847894-dc3e-4d81-9820-8bd357429ea6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod_78a0c94d-085a-41e4-af2c-a6705b759f59_terseLabel_en-US" xlink:label="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum shares allowed in Accelerated Purchase as percent of shares traded during specified period (percent)</link:label>
    <link:label id="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod_label_en-US" xlink:label="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares Of Stock Traded During Specified Period</link:label>
    <link:label id="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod_documentation_en-US" xlink:label="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares Of Stock Traded During Specified Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" xlink:href="clbs-20220930.xsd#clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" xlink:to="lab_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_96d0467c-64c1-43c2-ad1c-62646bd51b0c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_28b53f57-93e7-46f3-a708-213e0e7a8cea_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_25006cc7-d03c-439f-82b1-5914659f0fde_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d436b80-760b-4c22-a83e-d2178bd16aca_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_PreferredStockLiquidationPreferenceShare_52b5e684-ee40-499b-93a3-83d16f254eb9_terseLabel_en-US" xlink:label="lab_clbs_PreferredStockLiquidationPreferenceShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, liquidation value</link:label>
    <link:label id="lab_clbs_PreferredStockLiquidationPreferenceShare_label_en-US" xlink:label="lab_clbs_PreferredStockLiquidationPreferenceShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Liquidation Preference, Share</link:label>
    <link:label id="lab_clbs_PreferredStockLiquidationPreferenceShare_documentation_en-US" xlink:label="lab_clbs_PreferredStockLiquidationPreferenceShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Liquidation Preference, Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PreferredStockLiquidationPreferenceShare" xlink:href="clbs-20220930.xsd#clbs_PreferredStockLiquidationPreferenceShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_PreferredStockLiquidationPreferenceShare" xlink:to="lab_clbs_PreferredStockLiquidationPreferenceShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_48906c59-030f-48d6-83c5-7b6368d9f194_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_48f94a11-46ab-4a4b-ade2-fc76730e70c8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_44e97c41-4bb7-4d05-841f-ac98e8e0f363_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_6c5048ce-bd35-49e9-9283-6d07dddbb75e_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_365e73dc-de18-4410-a022-a765a8bfd28d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_ResearchAndDevelopmentTaxIncentiveTextBlock_4fa5f7dd-0d7b-4d18-9a29-e3b04b982617_terseLabel_en-US" xlink:label="lab_clbs_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australia Research and Development Tax Incentive</link:label>
    <link:label id="lab_clbs_ResearchAndDevelopmentTaxIncentiveTextBlock_label_en-US" xlink:label="lab_clbs_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Tax Incentive [Text Block]</link:label>
    <link:label id="lab_clbs_ResearchAndDevelopmentTaxIncentiveTextBlock_documentation_en-US" xlink:label="lab_clbs_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Tax Incentive</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:href="clbs-20220930.xsd#clbs_ResearchAndDevelopmentTaxIncentiveTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:to="lab_clbs_ResearchAndDevelopmentTaxIncentiveTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_0025287d-148b-4d63-9914-c0554700cddc_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_998d7528-92ed-44be-9c34-d6f43a91e27d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax withholding payments on net share settlement equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_974752b0-9cb3-4edc-a618-a3b24f2f46bc_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_877fe247-3d84-4a8e-91d3-a39eb2840383_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_ea82d179-77af-4b1c-9843-6d87f9a7ce66_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_c064d951-575c-424e-98e2-cf8253ed3f90_terseLabel_en-US" xlink:label="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York</link:label>
    <link:label id="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_label_en-US" xlink:label="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York State Division of Taxation and Finance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:to="lab_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_fa2a05c9-56e0-420d-9e63-5cb9aac564ae_terseLabel_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California</link:label>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_label_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Franchise Tax Board [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:to="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_61be89c7-f21f-4b1b-b2db-d65539a09673_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_454f991f-1dfc-4309-a933-07ee8488622e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_39580b8d-f00c-46fa-bb7b-c9d8e0730bba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_27346560-c6b1-47fc-b1f6-c2cedb8b0c0e_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_11fb268b-612a-48f9-bc26-1c9b22cfa142_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_6a9807b3-a19f-4a6c-86cf-9de8d3cb4781_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_b5e003fc-1f54-46c9-afd6-85d22b6d268a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_606ce711-3ed2-4769-bf12-fe880a8e4806_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_QiluMember_18f6e9b0-c4f2-4a56-acd7-63fd2f7dbb98_terseLabel_en-US" xlink:label="lab_clbs_QiluMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu</link:label>
    <link:label id="lab_clbs_QiluMember_label_en-US" xlink:label="lab_clbs_QiluMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu [Member]</link:label>
    <link:label id="lab_clbs_QiluMember_documentation_en-US" xlink:label="lab_clbs_QiluMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_QiluMember" xlink:href="clbs-20220930.xsd#clbs_QiluMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_QiluMember" xlink:to="lab_clbs_QiluMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_5e569cfb-b1b5-40fd-8a08-54d51d5b1c8a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, balance sheet line item</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_b176cf12-d26c-49ac-9436-01090c8e88b6_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_bd0dee57-c2e5-4d47-b0df-0110eb49ad21_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_a191268a-3f72-42e6-9ae1-ffa4f57beb60_terseLabel_en-US" xlink:label="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet</link:label>
    <link:label id="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_label_en-US" xlink:label="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]</link:label>
    <link:label id="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_documentation_en-US" xlink:label="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:href="clbs-20220930.xsd#clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:to="lab_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_a843defa-9b8f-43ff-bc66-32aa8c0e6c19_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research tax credit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_19bac394-59bc-439c-8743-d47e3b99d594_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_clbs_LossOnSaleOfNetOperatingLosses_941971ca-ec4b-4316-9f62-29094187722c_terseLabel_en-US" xlink:label="lab_clbs_LossOnSaleOfNetOperatingLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on sale of NOLs</link:label>
    <link:label id="lab_clbs_LossOnSaleOfNetOperatingLosses_label_en-US" xlink:label="lab_clbs_LossOnSaleOfNetOperatingLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss On Sale Of Net Operating Losses</link:label>
    <link:label id="lab_clbs_LossOnSaleOfNetOperatingLosses_documentation_en-US" xlink:label="lab_clbs_LossOnSaleOfNetOperatingLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss On Sale Of Net Operating Losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LossOnSaleOfNetOperatingLosses" xlink:href="clbs-20220930.xsd#clbs_LossOnSaleOfNetOperatingLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_clbs_LossOnSaleOfNetOperatingLosses" xlink:to="lab_clbs_LossOnSaleOfNetOperatingLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4ce67c68-61f4-41c3-86d2-279976981126_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_af02bd21-36cd-4458-974a-04eedb599a79_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested and expected to vest, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>clbs-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:f426f7a3-6c2d-403e-bcce-1884a6ad721b,g:3088fff3-3c71-4b75-95a2-34e3a251fb1c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.caladrius.com/role/Cover" xlink:type="simple" xlink:href="clbs-20220930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_315037c0-6aa4-4d51-b1ed-b4a2319c4e0c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_DocumentType_315037c0-6aa4-4d51-b1ed-b4a2319c4e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_456c9e85-0178-4ca1-bea4-870750812259" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_DocumentQuarterlyReport_456c9e85-0178-4ca1-bea4-870750812259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_eb4740b1-ee30-4ea9-a55f-e638608837bb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_DocumentPeriodEndDate_eb4740b1-ee30-4ea9-a55f-e638608837bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_303aebd9-2ed4-4c65-928e-cb88c078e27b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_DocumentTransitionReport_303aebd9-2ed4-4c65-928e-cb88c078e27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d38d4a4a-a1ad-4c3b-981a-f7519a9995e2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_EntityFileNumber_d38d4a4a-a1ad-4c3b-981a-f7519a9995e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_bf480930-4bff-4caf-ae27-c2858e345566" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_EntityRegistrantName_bf480930-4bff-4caf-ae27-c2858e345566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3ba7734e-ca34-4c20-821b-7237e4fb5deb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3ba7734e-ca34-4c20-821b-7237e4fb5deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_956688ac-b382-4cb6-adfd-f0d22830d8b0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_EntityTaxIdentificationNumber_956688ac-b382-4cb6-adfd-f0d22830d8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b977a5fd-6051-421b-a95e-c93c8df10c64" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_EntityAddressAddressLine1_b977a5fd-6051-421b-a95e-c93c8df10c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_6e59e235-d39d-4832-98f7-ec859b1980f4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_EntityAddressCityOrTown_6e59e235-d39d-4832-98f7-ec859b1980f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e6c39544-d929-414f-9a2d-8a1fe34573c7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_EntityAddressStateOrProvince_e6c39544-d929-414f-9a2d-8a1fe34573c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_02141e2f-ae62-4d0d-9aaa-18bf618864de" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_EntityAddressPostalZipCode_02141e2f-ae62-4d0d-9aaa-18bf618864de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_91b927f7-1210-4197-aa48-c25dd926d687" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_CityAreaCode_91b927f7-1210-4197-aa48-c25dd926d687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_97713baf-9600-493f-b8a9-a2387017ea96" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_LocalPhoneNumber_97713baf-9600-493f-b8a9-a2387017ea96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationFormerLegalOrRegisteredName_c254e7ad-3c48-4da8-bb3d-eee9860d7a46" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInformationFormerLegalOrRegisteredName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_EntityInformationFormerLegalOrRegisteredName_c254e7ad-3c48-4da8-bb3d-eee9860d7a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_74dfc9c8-acc5-4c00-ac04-a68f5ba0f88e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_Security12bTitle_74dfc9c8-acc5-4c00-ac04-a68f5ba0f88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e89bd3a0-20c8-4b3e-b547-d34f98243b26" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_TradingSymbol_e89bd3a0-20c8-4b3e-b547-d34f98243b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_729ed6bf-569f-471a-b585-1c92b094e25a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_SecurityExchangeName_729ed6bf-569f-471a-b585-1c92b094e25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_ccfb9a49-b8dc-4c53-8a48-be9e654ff15d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_EntityCurrentReportingStatus_ccfb9a49-b8dc-4c53-8a48-be9e654ff15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_596781f9-0756-4169-8d38-baa57ff2eb5f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_EntityInteractiveDataCurrent_596781f9-0756-4169-8d38-baa57ff2eb5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_7cadb4ed-f116-4b6e-897f-5b2153438c84" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_EntityFilerCategory_7cadb4ed-f116-4b6e-897f-5b2153438c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_9500dfc1-b343-49a6-9ff4-e0aa369e037d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_EntitySmallBusiness_9500dfc1-b343-49a6-9ff4-e0aa369e037d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b6eff2ec-4c8d-4881-b340-9983cd307cf0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_EntityEmergingGrowthCompany_b6eff2ec-4c8d-4881-b340-9983cd307cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_7512f781-ee7a-4131-8b57-030db3e76c88" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_EntityShellCompany_7512f781-ee7a-4131-8b57-030db3e76c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_26170cce-afd1-4739-beb2-a58f32f7a1b0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_EntityCentralIndexKey_26170cce-afd1-4739-beb2-a58f32f7a1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_76bb734b-763c-4b97-bd98-459a111ad39e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_CurrentFiscalYearEndDate_76bb734b-763c-4b97-bd98-459a111ad39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_cfce93f5-3bf8-4dc0-a1cc-00ddc7b6193d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_DocumentFiscalYearFocus_cfce93f5-3bf8-4dc0-a1cc-00ddc7b6193d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_eed1d27b-dd92-4f13-a757-a4f9837d1007" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_DocumentFiscalPeriodFocus_eed1d27b-dd92-4f13-a757-a4f9837d1007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f0f0d08f-c6d0-4453-9e70-6f430612f8ff" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_AmendmentFlag_f0f0d08f-c6d0-4453-9e70-6f430612f8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_14db4f5a-bbf5-46aa-b9c4-8457987d46a9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3dc08fb8-ca09-42db-a0c9-a9c50d3e54a9" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_14db4f5a-bbf5-46aa-b9c4-8457987d46a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="clbs-20220930.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_10cb7dbc-4212-4132-8529-62ef202e7a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_29a15ace-ca2e-421f-abfa-cf5b8a6bfbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_10cb7dbc-4212-4132-8529-62ef202e7a1d" xlink:to="loc_us-gaap_AssetsAbstract_29a15ace-ca2e-421f-abfa-cf5b8a6bfbaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32abc4e3-1256-49a1-8169-ecc15431690e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_29a15ace-ca2e-421f-abfa-cf5b8a6bfbaf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32abc4e3-1256-49a1-8169-ecc15431690e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_aead7959-9d82-4feb-8584-4274783cb384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_29a15ace-ca2e-421f-abfa-cf5b8a6bfbaf" xlink:to="loc_us-gaap_MarketableSecurities_aead7959-9d82-4feb-8584-4274783cb384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_954e62eb-0d60-44d2-8805-e67cd3f4930e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_29a15ace-ca2e-421f-abfa-cf5b8a6bfbaf" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_954e62eb-0d60-44d2-8805-e67cd3f4930e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f7e4c16a-334c-4267-a282-5c165ac8155f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_29a15ace-ca2e-421f-abfa-cf5b8a6bfbaf" xlink:to="loc_us-gaap_AssetsCurrent_f7e4c16a-334c-4267-a282-5c165ac8155f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c03b34e6-b207-46e8-b558-25fab4046bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_29a15ace-ca2e-421f-abfa-cf5b8a6bfbaf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c03b34e6-b207-46e8-b558-25fab4046bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fa9d8890-25d6-4290-9698-d1eb48dfa6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_29a15ace-ca2e-421f-abfa-cf5b8a6bfbaf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fa9d8890-25d6-4290-9698-d1eb48dfa6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_02df797f-a13f-4444-a247-09ca91effd2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_29a15ace-ca2e-421f-abfa-cf5b8a6bfbaf" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_02df797f-a13f-4444-a247-09ca91effd2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_638e6a72-6fb3-42e2-b668-6db3a6c566d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_29a15ace-ca2e-421f-abfa-cf5b8a6bfbaf" xlink:to="loc_us-gaap_Assets_638e6a72-6fb3-42e2-b668-6db3a6c566d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c8aab1c1-8791-4e09-95d1-ead34f309320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_10cb7dbc-4212-4132-8529-62ef202e7a1d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c8aab1c1-8791-4e09-95d1-ead34f309320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_c3860a8e-aaad-4389-9308-db3e473688d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c8aab1c1-8791-4e09-95d1-ead34f309320" xlink:to="loc_us-gaap_LiabilitiesAbstract_c3860a8e-aaad-4389-9308-db3e473688d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9e23e952-8d87-4578-b3cd-639e9fa99eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_c3860a8e-aaad-4389-9308-db3e473688d0" xlink:to="loc_us-gaap_AccountsPayableCurrent_9e23e952-8d87-4578-b3cd-639e9fa99eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c0c0a543-9854-4d2a-9bfa-c24a862caf0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_c3860a8e-aaad-4389-9308-db3e473688d0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c0c0a543-9854-4d2a-9bfa-c24a862caf0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_eec1485c-a0d5-4f61-aee3-e46728ac4bab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_c3860a8e-aaad-4389-9308-db3e473688d0" xlink:to="loc_us-gaap_LiabilitiesCurrent_eec1485c-a0d5-4f61-aee3-e46728ac4bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3da193fb-a96b-4eac-a562-1df9ae8ee484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_c3860a8e-aaad-4389-9308-db3e473688d0" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3da193fb-a96b-4eac-a562-1df9ae8ee484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_43e3f207-9209-4a23-a23c-f7bcca53c690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_c3860a8e-aaad-4389-9308-db3e473688d0" xlink:to="loc_us-gaap_Liabilities_43e3f207-9209-4a23-a23c-f7bcca53c690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_5dbc5efe-3505-4eb1-a84b-23f7f2d51fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c8aab1c1-8791-4e09-95d1-ead34f309320" xlink:to="loc_us-gaap_CommitmentsAndContingencies_5dbc5efe-3505-4eb1-a84b-23f7f2d51fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_42454dcf-1c47-4a37-b5af-12efb695c4c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c8aab1c1-8791-4e09-95d1-ead34f309320" xlink:to="loc_us-gaap_StockholdersEquityAbstract_42454dcf-1c47-4a37-b5af-12efb695c4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ec53cf93-f29c-4bbf-bd85-4efaf0808419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_42454dcf-1c47-4a37-b5af-12efb695c4c1" xlink:to="loc_us-gaap_PreferredStockValue_ec53cf93-f29c-4bbf-bd85-4efaf0808419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_dd8472ff-87e8-4167-91ad-5f698b915fba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_42454dcf-1c47-4a37-b5af-12efb695c4c1" xlink:to="loc_us-gaap_CommonStockValue_dd8472ff-87e8-4167-91ad-5f698b915fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1465489d-d4ca-4948-ac86-3bea5cf71c79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_42454dcf-1c47-4a37-b5af-12efb695c4c1" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1465489d-d4ca-4948-ac86-3bea5cf71c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_c2e27572-847f-4077-abd3-ed9e3a14d1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_42454dcf-1c47-4a37-b5af-12efb695c4c1" xlink:to="loc_us-gaap_TreasuryStockCommonValue_c2e27572-847f-4077-abd3-ed9e3a14d1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_793e8858-49cf-466e-b5ab-cab8ab2d3b56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_42454dcf-1c47-4a37-b5af-12efb695c4c1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_793e8858-49cf-466e-b5ab-cab8ab2d3b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5946d345-f632-43d1-8ae3-304df6204f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_42454dcf-1c47-4a37-b5af-12efb695c4c1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5946d345-f632-43d1-8ae3-304df6204f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d511be2b-d333-41ef-86d5-c2989311e871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_42454dcf-1c47-4a37-b5af-12efb695c4c1" xlink:to="loc_us-gaap_StockholdersEquity_d511be2b-d333-41ef-86d5-c2989311e871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_94475dd2-64d4-40b1-a34d-2e8635bd13ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_42454dcf-1c47-4a37-b5af-12efb695c4c1" xlink:to="loc_us-gaap_MinorityInterest_94475dd2-64d4-40b1-a34d-2e8635bd13ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_42db8698-9c31-4c08-9111-1d6370705e89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_42454dcf-1c47-4a37-b5af-12efb695c4c1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_42db8698-9c31-4c08-9111-1d6370705e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d66c9a6d-67c6-4c69-9408-e0f92cc121dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c8aab1c1-8791-4e09-95d1-ead34f309320" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d66c9a6d-67c6-4c69-9408-e0f92cc121dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="simple" xlink:href="clbs-20220930.xsd#ConsolidatedBalanceSheetsParentheticals"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_72caed3d-729e-42ac-b322-7553e085678e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_c8331193-d0ee-4587-a209-82d53fba52fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72caed3d-729e-42ac-b322-7553e085678e" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_c8331193-d0ee-4587-a209-82d53fba52fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PreferredStockLiquidationPreferenceShare_83efdf57-0514-48c4-8c6a-e215ef447b27" xlink:href="clbs-20220930.xsd#clbs_PreferredStockLiquidationPreferenceShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72caed3d-729e-42ac-b322-7553e085678e" xlink:to="loc_clbs_PreferredStockLiquidationPreferenceShare_83efdf57-0514-48c4-8c6a-e215ef447b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_cd2db35c-a480-480e-895f-3f7c49c44029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72caed3d-729e-42ac-b322-7553e085678e" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_cd2db35c-a480-480e-895f-3f7c49c44029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_PreferredStockSharesDesignated_156f53bb-8a03-41ed-bcf9-613c4828ded2" xlink:href="clbs-20220930.xsd#clbs_PreferredStockSharesDesignated"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72caed3d-729e-42ac-b322-7553e085678e" xlink:to="loc_clbs_PreferredStockSharesDesignated_156f53bb-8a03-41ed-bcf9-613c4828ded2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_d46cee72-0ffe-46c6-87ab-a229d606c70f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72caed3d-729e-42ac-b322-7553e085678e" xlink:to="loc_us-gaap_PreferredStockSharesIssued_d46cee72-0ffe-46c6-87ab-a229d606c70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_36ebc287-9285-4560-b308-12ad0bfe8912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72caed3d-729e-42ac-b322-7553e085678e" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_36ebc287-9285-4560-b308-12ad0bfe8912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a87b69a3-af4e-44b9-b79b-f36dd79c6536" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72caed3d-729e-42ac-b322-7553e085678e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a87b69a3-af4e-44b9-b79b-f36dd79c6536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_bba340ed-d243-4d32-bcdf-075088739872" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72caed3d-729e-42ac-b322-7553e085678e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_bba340ed-d243-4d32-bcdf-075088739872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_67268199-62e2-496e-a958-65c1252de9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72caed3d-729e-42ac-b322-7553e085678e" xlink:to="loc_us-gaap_CommonStockSharesIssued_67268199-62e2-496e-a958-65c1252de9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3d8eb108-3a60-48af-b5e2-39aa69bc217a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72caed3d-729e-42ac-b322-7553e085678e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3d8eb108-3a60-48af-b5e2-39aa69bc217a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_0f3e3a45-c8d9-431d-9957-fe13c7de4a98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_72caed3d-729e-42ac-b322-7553e085678e" xlink:to="loc_us-gaap_TreasuryStockCommonShares_0f3e3a45-c8d9-431d-9957-fe13c7de4a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="clbs-20220930.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_2b46a127-0337-4a27-b50e-c0bc9d1036f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_0aaa9bb9-6a99-4917-8335-f8ff138399ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b46a127-0337-4a27-b50e-c0bc9d1036f4" xlink:to="loc_us-gaap_OperatingExpensesAbstract_0aaa9bb9-6a99-4917-8335-f8ff138399ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e1b13c74-a963-4c2e-bade-78f87743715e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0aaa9bb9-6a99-4917-8335-f8ff138399ed" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e1b13c74-a963-4c2e-bade-78f87743715e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_9e4d6afb-f629-484a-8a99-f1fc35b98d77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0aaa9bb9-6a99-4917-8335-f8ff138399ed" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_9e4d6afb-f629-484a-8a99-f1fc35b98d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ea29d935-7db6-4fab-bdfb-81d472c9e316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0aaa9bb9-6a99-4917-8335-f8ff138399ed" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ea29d935-7db6-4fab-bdfb-81d472c9e316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8519c343-6d6f-4e09-b243-e2dabfe2cebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0aaa9bb9-6a99-4917-8335-f8ff138399ed" xlink:to="loc_us-gaap_OperatingExpenses_8519c343-6d6f-4e09-b243-e2dabfe2cebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1dced6fc-6995-4e28-805e-1827ea93138c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b46a127-0337-4a27-b50e-c0bc9d1036f4" xlink:to="loc_us-gaap_OperatingIncomeLoss_1dced6fc-6995-4e28-805e-1827ea93138c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0e349b22-0f5c-45e7-9bb8-fd4c4010b893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b46a127-0337-4a27-b50e-c0bc9d1036f4" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0e349b22-0f5c-45e7-9bb8-fd4c4010b893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_b1a686e4-31aa-403d-8786-73dd8d65504c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0e349b22-0f5c-45e7-9bb8-fd4c4010b893" xlink:to="loc_us-gaap_InvestmentIncomeNet_b1a686e4-31aa-403d-8786-73dd8d65504c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d29e3ff0-aaa3-4582-9b03-44e0c671ca22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0e349b22-0f5c-45e7-9bb8-fd4c4010b893" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d29e3ff0-aaa3-4582-9b03-44e0c671ca22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_07e51ba9-bd3a-42ca-8ec3-d4940615e4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0e349b22-0f5c-45e7-9bb8-fd4c4010b893" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_07e51ba9-bd3a-42ca-8ec3-d4940615e4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e331f516-4672-448b-bf69-052e777aaf12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b46a127-0337-4a27-b50e-c0bc9d1036f4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e331f516-4672-448b-bf69-052e777aaf12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_29e66d0c-439a-4f62-88cd-66f9cdbb3ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b46a127-0337-4a27-b50e-c0bc9d1036f4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_29e66d0c-439a-4f62-88cd-66f9cdbb3ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b6d9814a-d90e-4fbe-a5e0-9ae0136e7d05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b46a127-0337-4a27-b50e-c0bc9d1036f4" xlink:to="loc_us-gaap_NetIncomeLoss_b6d9814a-d90e-4fbe-a5e0-9ae0136e7d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1d9c51f9-c303-42f7-894a-6177e3c7d1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b46a127-0337-4a27-b50e-c0bc9d1036f4" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1d9c51f9-c303-42f7-894a-6177e3c7d1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_de630426-0e00-42af-ad4b-0ec91bb3520a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1d9c51f9-c303-42f7-894a-6177e3c7d1cf" xlink:to="loc_us-gaap_EarningsPerShareBasic_de630426-0e00-42af-ad4b-0ec91bb3520a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_41c1e094-08ef-4412-aa88-d8bfd81a2a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1d9c51f9-c303-42f7-894a-6177e3c7d1cf" xlink:to="loc_us-gaap_EarningsPerShareDiluted_41c1e094-08ef-4412-aa88-d8bfd81a2a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d51d5c3c-5d8e-468f-b00a-81b5ace2340a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b46a127-0337-4a27-b50e-c0bc9d1036f4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d51d5c3c-5d8e-468f-b00a-81b5ace2340a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a5d9a84f-2bd8-4a3f-abd3-f42da66a9362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d51d5c3c-5d8e-468f-b00a-81b5ace2340a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a5d9a84f-2bd8-4a3f-abd3-f42da66a9362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a57e2c2a-acd7-456e-b291-632da64f3725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_d51d5c3c-5d8e-468f-b00a-81b5ace2340a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a57e2c2a-acd7-456e-b291-632da64f3725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="clbs-20220930.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e3630379-fc4c-46ff-a350-e70c76c49ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5bd09ac9-2e8f-47fb-a851-53ea03921a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e3630379-fc4c-46ff-a350-e70c76c49ad8" xlink:to="loc_us-gaap_ProfitLoss_5bd09ac9-2e8f-47fb-a851-53ea03921a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ef539a3d-6b16-4060-8853-2d51d351abc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e3630379-fc4c-46ff-a350-e70c76c49ad8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ef539a3d-6b16-4060-8853-2d51d351abc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2cc69cb4-d39e-4209-bf76-8a618e0189f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e3630379-fc4c-46ff-a350-e70c76c49ad8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2cc69cb4-d39e-4209-bf76-8a618e0189f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5f0b0daf-9b7a-485a-821d-26520832e4d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e3630379-fc4c-46ff-a350-e70c76c49ad8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5f0b0daf-9b7a-485a-821d-26520832e4d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f38c112d-d529-483b-8159-9820b4951459" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e3630379-fc4c-46ff-a350-e70c76c49ad8" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_f38c112d-d529-483b-8159-9820b4951459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="clbs-20220930.xsd#ConsolidatedStatementsofEquity"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_2ca94cbe-6c3c-4799-8efc-e1cf69084368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ed38b24e-3f29-46b8-aa75-1b25db9b1cec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_2ca94cbe-6c3c-4799-8efc-e1cf69084368" xlink:to="loc_us-gaap_StatementTable_ed38b24e-3f29-46b8-aa75-1b25db9b1cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f5192c26-79fe-492f-b032-26e5dbafc16f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ed38b24e-3f29-46b8-aa75-1b25db9b1cec" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f5192c26-79fe-492f-b032-26e5dbafc16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_774d31d5-551c-46ea-9eb8-e7a3b6467b56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f5192c26-79fe-492f-b032-26e5dbafc16f" xlink:to="loc_us-gaap_EquityComponentDomain_774d31d5-551c-46ea-9eb8-e7a3b6467b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_81daa712-538a-4de5-9c76-c852c6806bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_774d31d5-551c-46ea-9eb8-e7a3b6467b56" xlink:to="loc_us-gaap_ParentMember_81daa712-538a-4de5-9c76-c852c6806bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_8b431cd1-6d3b-4a7b-8b6c-0be9a9b01e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_81daa712-538a-4de5-9c76-c852c6806bfd" xlink:to="loc_us-gaap_PreferredStockMember_8b431cd1-6d3b-4a7b-8b6c-0be9a9b01e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8778d165-c4f2-47f8-b82d-a31372c68d34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_81daa712-538a-4de5-9c76-c852c6806bfd" xlink:to="loc_us-gaap_CommonStockMember_8778d165-c4f2-47f8-b82d-a31372c68d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6106d6cb-fcf2-48d5-bea6-a598f821d461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_81daa712-538a-4de5-9c76-c852c6806bfd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6106d6cb-fcf2-48d5-bea6-a598f821d461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_eb4bd6e4-0b58-4506-b1a9-aa71e8a3c0de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_81daa712-538a-4de5-9c76-c852c6806bfd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_eb4bd6e4-0b58-4506-b1a9-aa71e8a3c0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_729b713f-cd40-4714-b89e-4b569ac85153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_81daa712-538a-4de5-9c76-c852c6806bfd" xlink:to="loc_us-gaap_RetainedEarningsMember_729b713f-cd40-4714-b89e-4b569ac85153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_0d4288ff-a274-473d-938d-e6c58fa44148" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_81daa712-538a-4de5-9c76-c852c6806bfd" xlink:to="loc_us-gaap_TreasuryStockCommonMember_0d4288ff-a274-473d-938d-e6c58fa44148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_df59b299-64f0-462a-8686-22fe1cfcbea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_774d31d5-551c-46ea-9eb8-e7a3b6467b56" xlink:to="loc_us-gaap_NoncontrollingInterestMember_df59b299-64f0-462a-8686-22fe1cfcbea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a2b1417f-50fb-46f8-9602-ed7732c1859c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ed38b24e-3f29-46b8-aa75-1b25db9b1cec" xlink:to="loc_us-gaap_StatementLineItems_a2b1417f-50fb-46f8-9602-ed7732c1859c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a2b1417f-50fb-46f8-9602-ed7732c1859c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_504699d4-78d6-41f1-8a86-8686eea0da01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_504699d4-78d6-41f1-8a86-8686eea0da01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0ef0b07f-6f3f-43f3-8b5c-6fa6f2704280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0ef0b07f-6f3f-43f3-8b5c-6fa6f2704280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_19f62736-2a66-4542-929e-71b1b0155f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_19f62736-2a66-4542-929e-71b1b0155f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ee7c9cc3-067f-4c29-a6d4-83d9944c5f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_ProfitLoss_ee7c9cc3-067f-4c29-a6d4-83d9944c5f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3e9f7033-4199-4078-a742-8f98f7a3eafd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3e9f7033-4199-4078-a742-8f98f7a3eafd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_881a5128-2ee4-4e5a-b567-e81626c62b07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_881a5128-2ee4-4e5a-b567-e81626c62b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_85a864e5-11b5-499b-a2aa-e2eeee6f164e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_85a864e5-11b5-499b-a2aa-e2eeee6f164e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_8979e3c9-e53f-42ad-8a70-fa7991f4e849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_8979e3c9-e53f-42ad-8a70-fa7991f4e849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_10ea759c-ac17-4f7d-b97f-a2b18e6faf58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_10ea759c-ac17-4f7d-b97f-a2b18e6faf58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_89c8d7d5-e5bc-4a19-96b1-4be78669f0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_89c8d7d5-e5bc-4a19-96b1-4be78669f0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d688f3ee-ee70-4261-ba91-51fa94a14240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d688f3ee-ee70-4261-ba91-51fa94a14240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6bd3230a-ff34-4610-8f0c-8e1746d6ca85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_6bd3230a-ff34-4610-8f0c-8e1746d6ca85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_f0cd7305-708b-42ee-9a72-85952e8de062" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_f0cd7305-708b-42ee-9a72-85952e8de062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_c61e0fe3-83c3-45f5-ab27-254d319bcf00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_c61e0fe3-83c3-45f5-ab27-254d319bcf00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_678a485c-4c1c-4d9b-a91d-773b9de866ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_678a485c-4c1c-4d9b-a91d-773b9de866ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f3d01b73-c3c1-4600-9f07-31f4480603e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_daada38c-f176-4df4-b279-1c10e482fa08" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f3d01b73-c3c1-4600-9f07-31f4480603e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="clbs-20220930.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_c8ba7d46-729e-4075-aaec-5b3de59fc561" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1c75fbbf-1a59-4aa8-b9d3-26f53fc0e76c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c8ba7d46-729e-4075-aaec-5b3de59fc561" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1c75fbbf-1a59-4aa8-b9d3-26f53fc0e76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_22ba0943-602d-42fc-adfe-2f95831781ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1c75fbbf-1a59-4aa8-b9d3-26f53fc0e76c" xlink:to="loc_us-gaap_ProfitLoss_22ba0943-602d-42fc-adfe-2f95831781ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_137dd3b8-a1fd-4cf1-8899-96ee9fcfd75b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1c75fbbf-1a59-4aa8-b9d3-26f53fc0e76c" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_137dd3b8-a1fd-4cf1-8899-96ee9fcfd75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_131696d9-ab25-4364-9bc8-3d18b2e02e53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_137dd3b8-a1fd-4cf1-8899-96ee9fcfd75b" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_131696d9-ab25-4364-9bc8-3d18b2e02e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_82bdb10d-e888-4914-967e-c774371971d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_137dd3b8-a1fd-4cf1-8899-96ee9fcfd75b" xlink:to="loc_us-gaap_DepreciationAndAmortization_82bdb10d-e888-4914-967e-c774371971d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_b94490de-7f6c-4c15-8755-4734c14baf3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_137dd3b8-a1fd-4cf1-8899-96ee9fcfd75b" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_b94490de-7f6c-4c15-8755-4734c14baf3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_be3fc81c-51bf-42b2-a2fa-196401490562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_137dd3b8-a1fd-4cf1-8899-96ee9fcfd75b" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_be3fc81c-51bf-42b2-a2fa-196401490562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8d24fc8-5433-43bb-9a7a-21dfbc942395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1c75fbbf-1a59-4aa8-b9d3-26f53fc0e76c" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8d24fc8-5433-43bb-9a7a-21dfbc942395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c43f3373-e496-4577-b61b-8a8296d608da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8d24fc8-5433-43bb-9a7a-21dfbc942395" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c43f3373-e496-4577-b61b-8a8296d608da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ae5ea3e2-ef6b-498f-bbdf-024a340190ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8d24fc8-5433-43bb-9a7a-21dfbc942395" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ae5ea3e2-ef6b-498f-bbdf-024a340190ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_80f00d1c-922b-4980-b806-042bb6f21965" xlink:href="clbs-20220930.xsd#clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8d24fc8-5433-43bb-9a7a-21dfbc942395" xlink:to="loc_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities_80f00d1c-922b-4980-b806-042bb6f21965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_95e2a9b2-f15c-4d3f-b073-3a8255e1b1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1c75fbbf-1a59-4aa8-b9d3-26f53fc0e76c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_95e2a9b2-f15c-4d3f-b073-3a8255e1b1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_961feb82-2a8a-4851-9752-27c07c267c02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c8ba7d46-729e-4075-aaec-5b3de59fc561" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_961feb82-2a8a-4851-9752-27c07c267c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_8a0ef661-6c8f-4a40-8458-794eec5138ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_961feb82-2a8a-4851-9752-27c07c267c02" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_8a0ef661-6c8f-4a40-8458-794eec5138ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_0e6a39b3-caeb-4c9f-834e-5541892973a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_961feb82-2a8a-4851-9752-27c07c267c02" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_0e6a39b3-caeb-4c9f-834e-5541892973a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_06844a53-02f3-4a03-a540-d7bb7f796070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_961feb82-2a8a-4851-9752-27c07c267c02" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_06844a53-02f3-4a03-a540-d7bb7f796070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3cd4abb9-3c80-4a7a-ba9f-549c786f685e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_961feb82-2a8a-4851-9752-27c07c267c02" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3cd4abb9-3c80-4a7a-ba9f-549c786f685e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_414dff94-721a-4203-8339-be8d2f4fe83d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_961feb82-2a8a-4851-9752-27c07c267c02" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_414dff94-721a-4203-8339-be8d2f4fe83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_56db3f31-3733-428a-b212-8e7d000a508a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c8ba7d46-729e-4075-aaec-5b3de59fc561" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_56db3f31-3733-428a-b212-8e7d000a508a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_a59e00a6-11b3-4b36-b2e3-948ea7d68e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_56db3f31-3733-428a-b212-8e7d000a508a" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_a59e00a6-11b3-4b36-b2e3-948ea7d68e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e203359b-6286-4fe0-ac6d-04248dbe2dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_56db3f31-3733-428a-b212-8e7d000a508a" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e203359b-6286-4fe0-ac6d-04248dbe2dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b4bbb426-59f3-4db7-a9b2-4bffe2fe7858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_56db3f31-3733-428a-b212-8e7d000a508a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b4bbb426-59f3-4db7-a9b2-4bffe2fe7858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_beec1b18-4e6b-4807-b7ed-7451a6315737" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_56db3f31-3733-428a-b212-8e7d000a508a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_beec1b18-4e6b-4807-b7ed-7451a6315737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ed1035e3-1247-482e-84c9-f992c1f3b861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_56db3f31-3733-428a-b212-8e7d000a508a" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ed1035e3-1247-482e-84c9-f992c1f3b861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c7099641-5c05-4fe2-b5cb-7175a22ff5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c8ba7d46-729e-4075-aaec-5b3de59fc561" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c7099641-5c05-4fe2-b5cb-7175a22ff5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fcad9d01-6284-43de-8372-7e33916b22ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c8ba7d46-729e-4075-aaec-5b3de59fc561" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fcad9d01-6284-43de-8372-7e33916b22ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2ced4ec6-1fb5-4a38-8152-f92fd1dac1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c8ba7d46-729e-4075-aaec-5b3de59fc561" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2ced4ec6-1fb5-4a38-8152-f92fd1dac1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_9bc40c58-72bd-45f8-8cfc-07c9e23288b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c8ba7d46-729e-4075-aaec-5b3de59fc561" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_9bc40c58-72bd-45f8-8cfc-07c9e23288b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_e1e87e94-d803-4df2-ad25-823b79c7dba1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_9bc40c58-72bd-45f8-8cfc-07c9e23288b2" xlink:to="loc_us-gaap_StockIssued1_e1e87e94-d803-4df2-ad25-823b79c7dba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1_da0b6311-2bb5-48d5-bc04-ca407d5bea12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_9bc40c58-72bd-45f8-8cfc-07c9e23288b2" xlink:to="loc_us-gaap_LiabilitiesAssumed1_da0b6311-2bb5-48d5-bc04-ca407d5bea12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/TheBusiness" xlink:type="simple" xlink:href="clbs-20220930.xsd#TheBusiness"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/TheBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d5da3e0d-2a3a-49d3-8bb4-c5f2443a8ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_BusinessTextBlock_eea6d709-4a7a-4a62-b8ed-0dcb5dec63a5" xlink:href="clbs-20220930.xsd#clbs_BusinessTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d5da3e0d-2a3a-49d3-8bb4-c5f2443a8ed8" xlink:to="loc_clbs_BusinessTextBlock_eea6d709-4a7a-4a62-b8ed-0dcb5dec63a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="clbs-20220930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_331ee44d-6da7-4376-9a89-bd6133f661bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_23db2ff4-32dc-4fa6-94e6-a2860ad00c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_331ee44d-6da7-4376-9a89-bd6133f661bc" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_23db2ff4-32dc-4fa6-94e6-a2860ad00c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/Merger" xlink:type="simple" xlink:href="clbs-20220930.xsd#Merger"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/Merger" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a84f1119-4a05-4a9a-b5e4-3f851b8c0303" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_751f1234-c488-4746-9035-036a718bd719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a84f1119-4a05-4a9a-b5e4-3f851b8c0303" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_751f1234-c488-4746-9035-036a718bd719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecurities" xlink:type="simple" xlink:href="clbs-20220930.xsd#AvailableforSaleSecurities"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f6bb4814-9e26-4160-9031-2ca6acac301c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_f7a0fd73-d4dc-4390-86e7-8f9154a70932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f6bb4814-9e26-4160-9031-2ca6acac301c" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_f7a0fd73-d4dc-4390-86e7-8f9154a70932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShare" xlink:type="simple" xlink:href="clbs-20220930.xsd#IncomeLossPerShare"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9c840482-902a-42c1-a5bb-7a213dcd5b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_daff97ba-3ece-4985-94f5-3c06caa4af31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9c840482-902a-42c1-a5bb-7a213dcd5b6d" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_daff97ba-3ece-4985-94f5-3c06caa4af31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="clbs-20220930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4ec8d82c-bc4b-446f-98db-6f43ad333367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_04c1e45f-cdc4-414d-9cef-4cf6e35bed83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4ec8d82c-bc4b-446f-98db-6f43ad333367" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_04c1e45f-cdc4-414d-9cef-4cf6e35bed83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilities" xlink:type="simple" xlink:href="clbs-20220930.xsd#AccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_f0c3a3e5-babe-4df8-a9ec-f623b104de24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_9bf613c1-c3a2-4fe2-aa56-367b474deb17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_f0c3a3e5-babe-4df8-a9ec-f623b104de24" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_9bf613c1-c3a2-4fe2-aa56-367b474deb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeases" xlink:type="simple" xlink:href="clbs-20220930.xsd#OperatingLeases"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e8eddd71-3580-4f53-9223-550c7db1d884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_84832ae1-47eb-4593-83de-63100520e446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e8eddd71-3580-4f53-9223-550c7db1d884" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_84832ae1-47eb-4593-83de-63100520e446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquity" xlink:type="simple" xlink:href="clbs-20220930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8971d596-de45-4cbb-bf92-004918e1ebd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4fcf0ed3-8157-4334-9de4-ae240dcc2d17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8971d596-de45-4cbb-bf92-004918e1ebd8" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4fcf0ed3-8157-4334-9de4-ae240dcc2d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="clbs-20220930.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_e33ae39b-dad5-4709-94af-643c3da5f77e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_098d457a-dca7-404f-8c48-7ed8ccad811f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_e33ae39b-dad5-4709-94af-643c3da5f77e" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_098d457a-dca7-404f-8c48-7ed8ccad811f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxes" xlink:type="simple" xlink:href="clbs-20220930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_40bf8406-2024-4d26-b013-a303e94593e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_c3df9934-f7be-4cd5-b167-327aa2e25f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40bf8406-2024-4d26-b013-a303e94593e3" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_c3df9934-f7be-4cd5-b167-327aa2e25f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive" xlink:type="simple" xlink:href="clbs-20220930.xsd#AustraliaResearchandDevelopmentTaxIncentive"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e03d8795-98dc-450f-8b54-5b0ac9afb488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ResearchAndDevelopmentTaxIncentiveTextBlock_ff44ac6e-6ca0-4539-b775-adbd1a5b5d26" xlink:href="clbs-20220930.xsd#clbs_ResearchAndDevelopmentTaxIncentiveTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e03d8795-98dc-450f-8b54-5b0ac9afb488" xlink:to="loc_clbs_ResearchAndDevelopmentTaxIncentiveTextBlock_ff44ac6e-6ca0-4539-b775-adbd1a5b5d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/Contingencies" xlink:type="simple" xlink:href="clbs-20220930.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7cedd09d-0dda-4da2-aef6-1a6e84455c66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_572bf5af-ea28-4e98-803a-61d5bcf0c39f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7cedd09d-0dda-4da2-aef6-1a6e84455c66" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_572bf5af-ea28-4e98-803a-61d5bcf0c39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/LicenseAgreements" xlink:type="simple" xlink:href="clbs-20220930.xsd#LicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/LicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_485afca3-6a20-4c07-8b35-345f5e3c408a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_5d841af7-b3be-4aef-83a7-8a9586ce8c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_485afca3-6a20-4c07-8b35-345f5e3c408a" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_5d841af7-b3be-4aef-83a7-8a9586ce8c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement" xlink:type="simple" xlink:href="clbs-20220930.xsd#ResearchCollaborationandLicenseAgreement"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_add797d3-cf8e-4abb-94da-7abc6fdcb2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_b527311b-f500-4e6a-a517-bb39896f5e51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_add797d3-cf8e-4abb-94da-7abc6fdcb2ca" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_b527311b-f500-4e6a-a517-bb39896f5e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="clbs-20220930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_91c0bab6-1e6c-46c8-a254-8df58100b70b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b826af39-4c26-49fb-849f-c33bdf413f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91c0bab6-1e6c-46c8-a254-8df58100b70b" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b826af39-4c26-49fb-849f-c33bdf413f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_b18ecd94-6b08-44a4-a7af-afe9fca7b494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91c0bab6-1e6c-46c8-a254-8df58100b70b" xlink:to="loc_us-gaap_UseOfEstimates_b18ecd94-6b08-44a4-a7af-afe9fca7b494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_50c13e03-e21f-4ca7-9dfa-b65569f6d9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91c0bab6-1e6c-46c8-a254-8df58100b70b" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_50c13e03-e21f-4ca7-9dfa-b65569f6d9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_e1c3c9e8-adca-48aa-a8ee-e63ac55bf8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91c0bab6-1e6c-46c8-a254-8df58100b70b" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_e1c3c9e8-adca-48aa-a8ee-e63ac55bf8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_b6bc3ea4-ab7c-45fc-be7e-93c72e6c6ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91c0bab6-1e6c-46c8-a254-8df58100b70b" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_b6bc3ea4-ab7c-45fc-be7e-93c72e6c6ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_c2658e13-abdc-4f68-8140-1724df5a3bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91c0bab6-1e6c-46c8-a254-8df58100b70b" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_c2658e13-abdc-4f68-8140-1724df5a3bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_89d48b0d-5cb2-4db7-a58e-4e4fbaaaac14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_91c0bab6-1e6c-46c8-a254-8df58100b70b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_89d48b0d-5cb2-4db7-a58e-4e4fbaaaac14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/MergerTables" xlink:type="simple" xlink:href="clbs-20220930.xsd#MergerTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/MergerTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_04a76a7b-1f67-476c-a232-82d774e1069b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesTables" xlink:type="simple" xlink:href="clbs-20220930.xsd#AvailableforSaleSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_a9c92b31-5e9c-4f2d-b400-27e9817ff476" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_95639859-9ddd-42a7-95f8-286580bc2f60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_a9c92b31-5e9c-4f2d-b400-27e9817ff476" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_95639859-9ddd-42a7-95f8-286580bc2f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_c7eabf59-8fc2-4ef7-b072-e698935eb3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_a9c92b31-5e9c-4f2d-b400-27e9817ff476" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_c7eabf59-8fc2-4ef7-b072-e698935eb3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_893e6cf6-c461-4b7d-89c8-9214e5664fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_a9c92b31-5e9c-4f2d-b400-27e9817ff476" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_893e6cf6-c461-4b7d-89c8-9214e5664fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShareTables" xlink:type="simple" xlink:href="clbs-20220930.xsd#IncomeLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7288e4fc-d09e-461d-93ad-00e681d40b95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4a85a871-053d-4777-8938-cc9533230f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7288e4fc-d09e-461d-93ad-00e681d40b95" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4a85a871-053d-4777-8938-cc9533230f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="clbs-20220930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_25a821dc-a902-4c69-a298-a9100b231a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_d0d980d9-3691-4217-85c5-020358eca7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_25a821dc-a902-4c69-a298-a9100b231a49" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_d0d980d9-3691-4217-85c5-020358eca7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilitiesTables" xlink:type="simple" xlink:href="clbs-20220930.xsd#AccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_e0d124bf-53e1-4f23-9162-ab8d69e32864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_257bf202-ae28-4d82-b400-50fab3e93c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_e0d124bf-53e1-4f23-9162-ab8d69e32864" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_257bf202-ae28-4d82-b400-50fab3e93c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesTables" xlink:type="simple" xlink:href="clbs-20220930.xsd#OperatingLeasesTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3ecc9cde-b18a-4045-9b39-00243c172c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_cbf9e1a2-3698-4cd3-b3c4-09de971c27b4" xlink:href="clbs-20220930.xsd#clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3ecc9cde-b18a-4045-9b39-00243c172c9c" xlink:to="loc_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock_cbf9e1a2-3698-4cd3-b3c4-09de971c27b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0234f99e-2f77-4820-b173-68aa93ff551b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3ecc9cde-b18a-4045-9b39-00243c172c9c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_0234f99e-2f77-4820-b173-68aa93ff551b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="clbs-20220930.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_006dff6a-0f44-4c65-9aa8-9005aa284b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_bfb8554a-1017-4a9f-ab44-fabb02f98584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_006dff6a-0f44-4c65-9aa8-9005aa284b87" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_bfb8554a-1017-4a9f-ab44-fabb02f98584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_aa0d412b-75d0-47e0-85ad-825005a8de57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_006dff6a-0f44-4c65-9aa8-9005aa284b87" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_aa0d412b-75d0-47e0-85ad-825005a8de57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_a660f418-8147-4802-a744-45a19d494ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_006dff6a-0f44-4c65-9aa8-9005aa284b87" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_a660f418-8147-4802-a744-45a19d494ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="clbs-20220930.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_4cdd2a80-105b-41fa-a016-ec535c7dc6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0b4839d3-7135-4f9b-b07a-571909902058" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_4cdd2a80-105b-41fa-a016-ec535c7dc6e2" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0b4839d3-7135-4f9b-b07a-571909902058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_d83e3441-f5ad-4e9b-9201-6c41d611adcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_4cdd2a80-105b-41fa-a016-ec535c7dc6e2" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_d83e3441-f5ad-4e9b-9201-6c41d611adcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_cb49ace6-b67d-486f-ab0e-1c4b45b92fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_4cdd2a80-105b-41fa-a016-ec535c7dc6e2" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_cb49ace6-b67d-486f-ab0e-1c4b45b92fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ac1b4fcb-ca76-4210-854d-25f520dc1bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_15f04cb2-00bd-4deb-b147-be9b6d039b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ac1b4fcb-ca76-4210-854d-25f520dc1bfa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_15f04cb2-00bd-4deb-b147-be9b6d039b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/MergerDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#MergerDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/MergerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b3fed592-396b-49ef-ad4b-55813839e91c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d91ef587-2cbe-4ebf-9c8a-e6d3a49b10ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b3fed592-396b-49ef-ad4b-55813839e91c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d91ef587-2cbe-4ebf-9c8a-e6d3a49b10ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_debf43d4-2598-4aea-b70b-5f169f27f49b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d91ef587-2cbe-4ebf-9c8a-e6d3a49b10ce" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_debf43d4-2598-4aea-b70b-5f169f27f49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_51b9daae-e408-4909-bfe8-16fa60d60c16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_debf43d4-2598-4aea-b70b-5f169f27f49b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_51b9daae-e408-4909-bfe8-16fa60d60c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CENDMember_78425297-31d2-4722-a6d3-02906dc64ca6" xlink:href="clbs-20220930.xsd#clbs_CENDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_51b9daae-e408-4909-bfe8-16fa60d60c16" xlink:to="loc_clbs_CENDMember_78425297-31d2-4722-a6d3-02906dc64ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2a1a9f54-34d4-4d6c-8297-d6424786322b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d91ef587-2cbe-4ebf-9c8a-e6d3a49b10ce" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_2a1a9f54-34d4-4d6c-8297-d6424786322b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_37767f24-3d52-4234-92da-da58999c7ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a1a9f54-34d4-4d6c-8297-d6424786322b" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_37767f24-3d52-4234-92da-da58999c7ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_cbf7262a-13b7-4fae-97f0-561026825050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a1a9f54-34d4-4d6c-8297-d6424786322b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_cbf7262a-13b7-4fae-97f0-561026825050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_6ab575a7-0645-4f13-9813-5c8a2b8cd800" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a1a9f54-34d4-4d6c-8297-d6424786322b" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_6ab575a7-0645-4f13-9813-5c8a2b8cd800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_569608ee-578b-4ac6-b2e5-76aac8364f23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a1a9f54-34d4-4d6c-8297-d6424786322b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_569608ee-578b-4ac6-b2e5-76aac8364f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_f9c31ce4-4819-4c0c-a889-cdc7a9faeb05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a1a9f54-34d4-4d6c-8297-d6424786322b" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_f9c31ce4-4819-4c0c-a889-cdc7a9faeb05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_bba7ed40-7ae9-4126-b376-b1adb9ec792a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a1a9f54-34d4-4d6c-8297-d6424786322b" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_bba7ed40-7ae9-4126-b376-b1adb9ec792a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f5b06c86-e109-4e18-9c86-2ef1a67dd3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a1a9f54-34d4-4d6c-8297-d6424786322b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f5b06c86-e109-4e18-9c86-2ef1a67dd3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_226cd145-314e-4a2b-93bd-9628adc89d67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a1a9f54-34d4-4d6c-8297-d6424786322b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_226cd145-314e-4a2b-93bd-9628adc89d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_77c39d6b-90d7-42c7-96f9-d79ad7d6e9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a1a9f54-34d4-4d6c-8297-d6424786322b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_77c39d6b-90d7-42c7-96f9-d79ad7d6e9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_76db6815-75c1-44fa-942f-26c45b507fec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a1a9f54-34d4-4d6c-8297-d6424786322b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_76db6815-75c1-44fa-942f-26c45b507fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_4e84284f-bf7e-465f-b8c8-3cf4e58932aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a1a9f54-34d4-4d6c-8297-d6424786322b" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_4e84284f-bf7e-465f-b8c8-3cf4e58932aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_5287a92e-5e8c-4c80-8191-d65070df4515" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2a1a9f54-34d4-4d6c-8297-d6424786322b" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_5287a92e-5e8c-4c80-8191-d65070df4515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f6fd3522-8b86-4c72-987d-073759878504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_81077c76-d0a0-4fa6-a4a7-b21747ef94bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_f6fd3522-8b86-4c72-987d-073759878504" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_81077c76-d0a0-4fa6-a4a7-b21747ef94bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ac8cba9f-253e-4c2c-b2ae-14a050ea9c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_81077c76-d0a0-4fa6-a4a7-b21747ef94bb" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ac8cba9f-253e-4c2c-b2ae-14a050ea9c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1578c09-fb89-46a5-8704-7062d0d4d7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ac8cba9f-253e-4c2c-b2ae-14a050ea9c0b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1578c09-fb89-46a5-8704-7062d0d4d7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_7dd45993-1b57-4c01-bb42-a6417f5d5a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1578c09-fb89-46a5-8704-7062d0d4d7d5" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_7dd45993-1b57-4c01-bb42-a6417f5d5a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_03d0e584-eec8-4a1d-8e31-036230403b46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1578c09-fb89-46a5-8704-7062d0d4d7d5" xlink:to="loc_us-gaap_CommercialPaperMember_03d0e584-eec8-4a1d-8e31-036230403b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_1cf3adb6-a387-4035-8696-81369453e1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1578c09-fb89-46a5-8704-7062d0d4d7d5" xlink:to="loc_us-gaap_MoneyMarketFundsMember_1cf3adb6-a387-4035-8696-81369453e1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_d6aaa58a-c5f5-4236-9500-7ad1f736af3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f1578c09-fb89-46a5-8704-7062d0d4d7d5" xlink:to="loc_us-gaap_USStatesAndPoliticalSubdivisionsMember_d6aaa58a-c5f5-4236-9500-7ad1f736af3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09ce94c7-301e-42b1-8cd6-22eaa0de4987" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_81077c76-d0a0-4fa6-a4a7-b21747ef94bb" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09ce94c7-301e-42b1-8cd6-22eaa0de4987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ea0fa003-d171-4fea-81a9-26e238e0bf37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09ce94c7-301e-42b1-8cd6-22eaa0de4987" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ea0fa003-d171-4fea-81a9-26e238e0bf37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_715034bd-d8dc-43cd-bd1c-87cc760cda28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09ce94c7-301e-42b1-8cd6-22eaa0de4987" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_715034bd-d8dc-43cd-bd1c-87cc760cda28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e3c39538-145b-4cd0-af77-b2d17cf0e12e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09ce94c7-301e-42b1-8cd6-22eaa0de4987" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e3c39538-145b-4cd0-af77-b2d17cf0e12e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_eb89e91f-81e7-4500-981c-76e906cd84ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_09ce94c7-301e-42b1-8cd6-22eaa0de4987" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_eb89e91f-81e7-4500-981c-76e906cd84ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_020237cf-2ad9-4fe4-8030-02b8c15601ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_5ca8b814-1aec-4365-9052-b19bad3b29bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_020237cf-2ad9-4fe4-8030-02b8c15601ce" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_5ca8b814-1aec-4365-9052-b19bad3b29bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_7cc18e04-5b25-471d-97a5-27a57d878ded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_020237cf-2ad9-4fe4-8030-02b8c15601ce" xlink:to="loc_us-gaap_MarketableSecurities_7cc18e04-5b25-471d-97a5-27a57d878ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_08084fb3-6e38-4844-8088-9c74ea361b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_020237cf-2ad9-4fe4-8030-02b8c15601ce" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_08084fb3-6e38-4844-8088-9c74ea361b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3e4250c7-11a0-4b4b-b543-a4a4c2fa5edd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_f8cb9f95-f549-4611-acb4-775d2de3b9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3e4250c7-11a0-4b4b-b543-a4a4c2fa5edd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_f8cb9f95-f549-4611-acb4-775d2de3b9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_f28662e5-2bee-4dc5-897e-21f9ca38fca4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_f8cb9f95-f549-4611-acb4-775d2de3b9bb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis_f28662e5-2bee-4dc5-897e-21f9ca38fca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_82d596d6-751c-4677-ad49-56551456e248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_f8cb9f95-f549-4611-acb4-775d2de3b9bb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis_82d596d6-751c-4677-ad49-56551456e248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a09b3d73-4503-4f7a-8790-a751cd6a3876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_f8cb9f95-f549-4611-acb4-775d2de3b9bb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_a09b3d73-4503-4f7a-8790-a751cd6a3876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_42ae49f2-05cf-402f-aa34-1e6b41b2b467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_3e4250c7-11a0-4b4b-b543-a4a4c2fa5edd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_42ae49f2-05cf-402f-aa34-1e6b41b2b467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_1619e443-5a18-4aad-b059-aa32c6b3d0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_42ae49f2-05cf-402f-aa34-1e6b41b2b467" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue_1619e443-5a18-4aad-b059-aa32c6b3d0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_52ce52df-5b00-4798-827f-98f708ada2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_42ae49f2-05cf-402f-aa34-1e6b41b2b467" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue_52ce52df-5b00-4798-827f-98f708ada2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5515496e-54f1-425c-8ce3-5aa1aa2e9b39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_42ae49f2-05cf-402f-aa34-1e6b41b2b467" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5515496e-54f1-425c-8ce3-5aa1aa2e9b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#IncomeLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b437341d-3b18-40eb-9961-2c55b19e641b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_374107f7-7ede-4c8b-9652-7bf3d5351cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b437341d-3b18-40eb-9961-2c55b19e641b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_374107f7-7ede-4c8b-9652-7bf3d5351cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c348ce25-c31c-431e-9707-ce649408872d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_374107f7-7ede-4c8b-9652-7bf3d5351cd6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c348ce25-c31c-431e-9707-ce649408872d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_90ac4a50-ffea-4dfb-bb75-9e0df0355c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c348ce25-c31c-431e-9707-ce649408872d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_90ac4a50-ffea-4dfb-bb75-9e0df0355c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bf9815bf-f6b6-4fe0-8928-195bc945b8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_90ac4a50-ffea-4dfb-bb75-9e0df0355c55" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bf9815bf-f6b6-4fe0-8928-195bc945b8a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_aa78ba37-d046-4899-9bf5-40c28bc1fdc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_90ac4a50-ffea-4dfb-bb75-9e0df0355c55" xlink:to="loc_us-gaap_WarrantMember_aa78ba37-d046-4899-9bf5-40c28bc1fdc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_dd954462-a0ed-4e0b-9302-d59a4b766701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_90ac4a50-ffea-4dfb-bb75-9e0df0355c55" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_dd954462-a0ed-4e0b-9302-d59a4b766701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_72e53427-cf5b-4a91-9847-a4373c66e54e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_374107f7-7ede-4c8b-9652-7bf3d5351cd6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_72e53427-cf5b-4a91-9847-a4373c66e54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6f326294-fc49-451e-917c-00c0316587c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_72e53427-cf5b-4a91-9847-a4373c66e54e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6f326294-fc49-451e-917c-00c0316587c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_54b94f47-14f3-42a9-a421-1a70d7d23e68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e9da809b-565e-4bf0-b760-cf8ea8102b01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_54b94f47-14f3-42a9-a421-1a70d7d23e68" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e9da809b-565e-4bf0-b760-cf8ea8102b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ef0a553f-1ade-423e-935f-657e4d4e8b50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e9da809b-565e-4bf0-b760-cf8ea8102b01" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ef0a553f-1ade-423e-935f-657e4d4e8b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d66cf894-4cf7-421d-9855-180211530892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ef0a553f-1ade-423e-935f-657e4d4e8b50" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d66cf894-4cf7-421d-9855-180211530892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a3a65c4f-f385-46ae-bb04-91a33406ef1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d66cf894-4cf7-421d-9855-180211530892" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a3a65c4f-f385-46ae-bb04-91a33406ef1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e10e1481-5364-4eee-ae8c-699ff20c4eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d66cf894-4cf7-421d-9855-180211530892" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e10e1481-5364-4eee-ae8c-699ff20c4eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ab763314-3da5-4105-a081-c40dc3b8317d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d66cf894-4cf7-421d-9855-180211530892" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ab763314-3da5-4105-a081-c40dc3b8317d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0f616251-fd7d-47c0-9f10-03d0309518a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e9da809b-565e-4bf0-b760-cf8ea8102b01" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0f616251-fd7d-47c0-9f10-03d0309518a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_daad7c68-8185-47e0-82c0-3da9131a68de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0f616251-fd7d-47c0-9f10-03d0309518a7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_daad7c68-8185-47e0-82c0-3da9131a68de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_06be331c-6743-4917-a14e-c5266e663f41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_daad7c68-8185-47e0-82c0-3da9131a68de" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_06be331c-6743-4917-a14e-c5266e663f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e103f22-6caa-41c6-8ca7-2d27d6424559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_e9da809b-565e-4bf0-b760-cf8ea8102b01" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e103f22-6caa-41c6-8ca7-2d27d6424559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_a9477511-483a-4e6e-bbb2-48ed381ca90e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e103f22-6caa-41c6-8ca7-2d27d6424559" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_a9477511-483a-4e6e-bbb2-48ed381ca90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_643064e8-99c2-4dce-a11d-b974e0514f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8e103f22-6caa-41c6-8ca7-2d27d6424559" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_643064e8-99c2-4dce-a11d-b974e0514f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#AccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/AccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_927f7d45-aca2-4125-ad44-a2facf47137d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a2e1d59e-3d19-498a-859e-51e4e06cb85e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_927f7d45-aca2-4125-ad44-a2facf47137d" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a2e1d59e-3d19-498a-859e-51e4e06cb85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_674e000c-171e-467d-9fed-fcb45a3657ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_927f7d45-aca2-4125-ad44-a2facf47137d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_674e000c-171e-467d-9fed-fcb45a3657ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ClinicalAndRDRelatedLiabilities_94eb7863-93e2-475c-8597-da13b68801ba" xlink:href="clbs-20220930.xsd#clbs_ClinicalAndRDRelatedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_927f7d45-aca2-4125-ad44-a2facf47137d" xlink:to="loc_clbs_ClinicalAndRDRelatedLiabilities_94eb7863-93e2-475c-8597-da13b68801ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_144e6d07-8e8f-4098-8e15-2cf37df50b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_927f7d45-aca2-4125-ad44-a2facf47137d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_144e6d07-8e8f-4098-8e15-2cf37df50b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_200cc9ec-a98b-41da-8634-660e5432f432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_927f7d45-aca2-4125-ad44-a2facf47137d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_200cc9ec-a98b-41da-8634-660e5432f432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesNarrativeDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#OperatingLeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9673d7ad-e3a1-48bd-9aae-369e3400f698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_NumberOfOfficesUnderOperatingLeases_02244acc-7dbd-4e61-8088-3b4eb1263d0d" xlink:href="clbs-20220930.xsd#clbs_NumberOfOfficesUnderOperatingLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9673d7ad-e3a1-48bd-9aae-369e3400f698" xlink:to="loc_clbs_NumberOfOfficesUnderOperatingLeases_02244acc-7dbd-4e61-8088-3b4eb1263d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8ffb8bbb-a0cb-418f-8fa6-779ae76141f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9673d7ad-e3a1-48bd-9aae-369e3400f698" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8ffb8bbb-a0cb-418f-8fa6-779ae76141f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_db50e70a-5219-47a0-84a8-38db14564849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9673d7ad-e3a1-48bd-9aae-369e3400f698" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_db50e70a-5219-47a0-84a8-38db14564849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#OperatingLeasesBalanceSheetPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8799168d-fb61-4dd6-82db-0fb062f34cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLeaseRightOfUseAssetAbstract_adbdd415-ce37-4e1f-8e4b-4a7c4e05dd37" xlink:href="clbs-20220930.xsd#clbs_OperatingLeaseRightOfUseAssetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8799168d-fb61-4dd6-82db-0fb062f34cb9" xlink:to="loc_clbs_OperatingLeaseRightOfUseAssetAbstract_adbdd415-ce37-4e1f-8e4b-4a7c4e05dd37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7699c290-fefe-4b8e-8322-b01ae93285c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_OperatingLeaseRightOfUseAssetAbstract_adbdd415-ce37-4e1f-8e4b-4a7c4e05dd37" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7699c290-fefe-4b8e-8322-b01ae93285c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_f3eadd16-a089-4eb9-a7ca-2bed54c790b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_OperatingLeaseRightOfUseAssetAbstract_adbdd415-ce37-4e1f-8e4b-4a7c4e05dd37" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_f3eadd16-a089-4eb9-a7ca-2bed54c790b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_984cffbd-7322-4567-918f-793d07ebf0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8799168d-fb61-4dd6-82db-0fb062f34cb9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_984cffbd-7322-4567-918f-793d07ebf0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_96013778-2ed8-457d-9b63-e6a2d0875007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_984cffbd-7322-4567-918f-793d07ebf0e3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_96013778-2ed8-457d-9b63-e6a2d0875007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1934c8e3-5a6d-459e-b944-edf6d726770e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_984cffbd-7322-4567-918f-793d07ebf0e3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1934c8e3-5a6d-459e-b944-edf6d726770e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d2bed933-6e88-4802-bc16-0cc7150ed843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_984cffbd-7322-4567-918f-793d07ebf0e3" xlink:to="loc_us-gaap_OperatingLeaseLiability_d2bed933-6e88-4802-bc16-0cc7150ed843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_a906fbd8-f45f-4b7d-960d-bd9e6e701545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_984cffbd-7322-4567-918f-793d07ebf0e3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_a906fbd8-f45f-4b7d-960d-bd9e6e701545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_fc5825e4-ff44-4ffa-8bb1-763092d7ea39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_984cffbd-7322-4567-918f-793d07ebf0e3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_fc5825e4-ff44-4ffa-8bb1-763092d7ea39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#OperatingLeasesFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d553ee59-4c7e-47b6-a7b9-4290cfb8c9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d101d5c0-2ce8-4e4d-94e2-22731fc979da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d553ee59-4c7e-47b6-a7b9-4290cfb8c9d3" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d101d5c0-2ce8-4e4d-94e2-22731fc979da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_bff67765-b7fd-47b5-bcdc-1b178fbf3688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d101d5c0-2ce8-4e4d-94e2-22731fc979da" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_bff67765-b7fd-47b5-bcdc-1b178fbf3688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_685e6dd7-66d7-4013-bcf5-80725c412fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d101d5c0-2ce8-4e4d-94e2-22731fc979da" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_685e6dd7-66d7-4013-bcf5-80725c412fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_45516f15-3a8f-4a56-9be6-60b364e5a996" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d101d5c0-2ce8-4e4d-94e2-22731fc979da" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_45516f15-3a8f-4a56-9be6-60b364e5a996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f6082ee5-2a06-4629-9719-370f49b54700" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d101d5c0-2ce8-4e4d-94e2-22731fc979da" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f6082ee5-2a06-4629-9719-370f49b54700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c5aee737-c82c-47d4-81f7-b913797891d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d101d5c0-2ce8-4e4d-94e2-22731fc979da" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c5aee737-c82c-47d4-81f7-b913797891d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_53c2c45a-1ab6-429b-acba-4ac1497f41d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d101d5c0-2ce8-4e4d-94e2-22731fc979da" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_53c2c45a-1ab6-429b-acba-4ac1497f41d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b1c563a5-1237-4f53-b290-e172032aa5db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d101d5c0-2ce8-4e4d-94e2-22731fc979da" xlink:to="loc_us-gaap_OperatingLeaseLiability_b1c563a5-1237-4f53-b290-e172032aa5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="clbs-20220930.xsd#OperatingLeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#StockholdersEquityEquityIssuancesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_90b71352-e8c2-45a8-819c-1b67df0d4b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0672dc72-85b0-4a3d-b0aa-220842c6b546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_90b71352-e8c2-45a8-819c-1b67df0d4b5a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0672dc72-85b0-4a3d-b0aa-220842c6b546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_90322b94-0444-463b-908d-6ec02c21e473" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0672dc72-85b0-4a3d-b0aa-220842c6b546" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_90322b94-0444-463b-908d-6ec02c21e473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8b51b17c-0c79-4a3a-b103-8b3c2199d264" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_90322b94-0444-463b-908d-6ec02c21e473" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8b51b17c-0c79-4a3a-b103-8b3c2199d264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LincolnParkAgreementMember_be2b5dad-03f9-4a2e-b2a0-f8199e25c53a" xlink:href="clbs-20220930.xsd#clbs_LincolnParkAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8b51b17c-0c79-4a3a-b103-8b3c2199d264" xlink:to="loc_clbs_LincolnParkAgreementMember_be2b5dad-03f9-4a2e-b2a0-f8199e25c53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AtTheMarketOfferingAgreementMember_e2d1a89d-e4be-4b17-a88e-f03ad2ab3bdd" xlink:href="clbs-20220930.xsd#clbs_AtTheMarketOfferingAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8b51b17c-0c79-4a3a-b103-8b3c2199d264" xlink:to="loc_clbs_AtTheMarketOfferingAgreementMember_e2d1a89d-e4be-4b17-a88e-f03ad2ab3bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_c0022643-e109-468b-a739-98d96aebcaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0672dc72-85b0-4a3d-b0aa-220842c6b546" xlink:to="loc_us-gaap_ClassOfStockLineItems_c0022643-e109-468b-a739-98d96aebcaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_d210fc94-d7ab-4cd5-bdcb-a840da5b4b77" xlink:href="clbs-20220930.xsd#clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c0022643-e109-468b-a739-98d96aebcaa4" xlink:to="loc_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement_d210fc94-d7ab-4cd5-bdcb-a840da5b4b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration_78db4902-c0b9-4a90-b84f-104ceb27ea54" xlink:href="clbs-20220930.xsd#clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c0022643-e109-468b-a739-98d96aebcaa4" xlink:to="loc_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration_78db4902-c0b9-4a90-b84f-104ceb27ea54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b15920e0-7c94-4d7f-86e5-df001c93b1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c0022643-e109-468b-a739-98d96aebcaa4" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b15920e0-7c94-4d7f-86e5-df001c93b1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_aa5c0307-b708-4901-b3ef-bbfd532400cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c0022643-e109-468b-a739-98d96aebcaa4" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_aa5c0307-b708-4901-b3ef-bbfd532400cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_892d9456-5903-495e-8969-c7a14a764026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c0022643-e109-468b-a739-98d96aebcaa4" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_892d9456-5903-495e-8969-c7a14a764026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_TermOfAgreement_4971d903-3916-449e-a0e8-a777fee612af" xlink:href="clbs-20220930.xsd#clbs_TermOfAgreement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c0022643-e109-468b-a739-98d96aebcaa4" xlink:to="loc_clbs_TermOfAgreement_4971d903-3916-449e-a0e8-a777fee612af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase_6238060b-a551-482f-8ca7-ce2f8c8b0715" xlink:href="clbs-20220930.xsd#clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c0022643-e109-468b-a739-98d96aebcaa4" xlink:to="loc_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase_6238060b-a551-482f-8ca7-ce2f8c8b0715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase_21ab5990-92a0-44c8-ae9a-565eb6097a2b" xlink:href="clbs-20220930.xsd#clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c0022643-e109-468b-a739-98d96aebcaa4" xlink:to="loc_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase_21ab5990-92a0-44c8-ae9a-565eb6097a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase_93853087-4cf5-4f96-9382-80fc03b8bf14" xlink:href="clbs-20220930.xsd#clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c0022643-e109-468b-a739-98d96aebcaa4" xlink:to="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase_93853087-4cf5-4f96-9382-80fc03b8bf14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod_74e7274c-f538-4ddf-b36d-eb9fd5318902" xlink:href="clbs-20220930.xsd#clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c0022643-e109-468b-a739-98d96aebcaa4" xlink:to="loc_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod_74e7274c-f538-4ddf-b36d-eb9fd5318902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty_26f6b112-974f-4712-a27d-1648c06785ed" xlink:href="clbs-20220930.xsd#clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c0022643-e109-468b-a739-98d96aebcaa4" xlink:to="loc_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty_26f6b112-974f-4712-a27d-1648c06785ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8057e362-0842-4e41-86ac-06f870d4be3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c0022643-e109-468b-a739-98d96aebcaa4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8057e362-0842-4e41-86ac-06f870d4be3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#StockholdersEquityStockOptionsandWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9b033561-8efd-4127-903e-adbcd41a8039" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_dbc94aa5-b120-47bf-90c9-ef53bd01d9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9b033561-8efd-4127-903e-adbcd41a8039" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_dbc94aa5-b120-47bf-90c9-ef53bd01d9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_76cf2736-a43a-4ed1-9e59-b8ff1b39cb53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_dbc94aa5-b120-47bf-90c9-ef53bd01d9bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_76cf2736-a43a-4ed1-9e59-b8ff1b39cb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_72d25d2c-5b22-4a5c-9835-b9c64540f7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_76cf2736-a43a-4ed1-9e59-b8ff1b39cb53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_72d25d2c-5b22-4a5c-9835-b9c64540f7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_42811e78-1594-4798-a008-1191d742b9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_76cf2736-a43a-4ed1-9e59-b8ff1b39cb53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_42811e78-1594-4798-a008-1191d742b9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0655e914-6b41-4df3-92d4-d97d122a7775" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_76cf2736-a43a-4ed1-9e59-b8ff1b39cb53" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0655e914-6b41-4df3-92d4-d97d122a7775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d68ac862-e067-4038-8320-3b8e46b835ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_76cf2736-a43a-4ed1-9e59-b8ff1b39cb53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d68ac862-e067-4038-8320-3b8e46b835ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_01846093-121b-4e23-b280-7919366a279e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_76cf2736-a43a-4ed1-9e59-b8ff1b39cb53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_01846093-121b-4e23-b280-7919366a279e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30b2c473-7efe-498a-9e94-0428b2b4fe40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_76cf2736-a43a-4ed1-9e59-b8ff1b39cb53" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30b2c473-7efe-498a-9e94-0428b2b4fe40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0a6f0ddc-e481-4994-b2e1-9fca54240eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_dbc94aa5-b120-47bf-90c9-ef53bd01d9bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0a6f0ddc-e481-4994-b2e1-9fca54240eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_7d6aa746-045f-43a1-af78-25216df18823" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_dbc94aa5-b120-47bf-90c9-ef53bd01d9bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_7d6aa746-045f-43a1-af78-25216df18823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b935f40d-3861-4ae2-af81-c711a3b3eac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_dbc94aa5-b120-47bf-90c9-ef53bd01d9bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b935f40d-3861-4ae2-af81-c711a3b3eac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_366525df-b42a-42da-8539-1eb5182b36eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b935f40d-3861-4ae2-af81-c711a3b3eac5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_366525df-b42a-42da-8539-1eb5182b36eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9488aaa1-ccea-4a5a-840b-c07b9bf35ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b935f40d-3861-4ae2-af81-c711a3b3eac5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9488aaa1-ccea-4a5a-840b-c07b9bf35ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_647ffdbc-a838-4f5c-be1e-03ba1b92bfa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b935f40d-3861-4ae2-af81-c711a3b3eac5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_647ffdbc-a838-4f5c-be1e-03ba1b92bfa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d18358b3-170b-4f0a-ad90-b19336210a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b935f40d-3861-4ae2-af81-c711a3b3eac5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d18358b3-170b-4f0a-ad90-b19336210a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_a4bc9f9a-4de9-4a58-a410-37923e19c499" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b935f40d-3861-4ae2-af81-c711a3b3eac5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_a4bc9f9a-4de9-4a58-a410-37923e19c499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b63d1f05-d2c7-495b-9588-5057527c23d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b935f40d-3861-4ae2-af81-c711a3b3eac5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b63d1f05-d2c7-495b-9588-5057527c23d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b0168df2-e755-4159-903a-10da7cb16b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_dbc94aa5-b120-47bf-90c9-ef53bd01d9bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b0168df2-e755-4159-903a-10da7cb16b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_d22b2893-209a-433e-9d15-d1aaed91787a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_dbc94aa5-b120-47bf-90c9-ef53bd01d9bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_d22b2893-209a-433e-9d15-d1aaed91787a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5e823707-9926-45d3-b616-8243670acbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_dbc94aa5-b120-47bf-90c9-ef53bd01d9bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5e823707-9926-45d3-b616-8243670acbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_33061e26-c8c2-4fa8-8510-8b44b2ccea34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5e823707-9926-45d3-b616-8243670acbdd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_33061e26-c8c2-4fa8-8510-8b44b2ccea34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_2bfcf7a3-7e7d-41ec-a253-2eae3046b3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5e823707-9926-45d3-b616-8243670acbdd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_2bfcf7a3-7e7d-41ec-a253-2eae3046b3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OptionsVestedweightedAverageRemainingContractualTerm_8b2a5620-526b-4e23-bce7-1ef14dee2061" xlink:href="clbs-20220930.xsd#clbs_OptionsVestedweightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5e823707-9926-45d3-b616-8243670acbdd" xlink:to="loc_clbs_OptionsVestedweightedAverageRemainingContractualTerm_8b2a5620-526b-4e23-bce7-1ef14dee2061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0c9880a7-90ae-4cf7-ae9f-c76436be06bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5e823707-9926-45d3-b616-8243670acbdd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0c9880a7-90ae-4cf7-ae9f-c76436be06bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_eb211376-8079-42e1-992d-057125f3132f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5e823707-9926-45d3-b616-8243670acbdd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_eb211376-8079-42e1-992d-057125f3132f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_b5b8b355-0400-4561-a0c0-1e03a0b68b83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_5e823707-9926-45d3-b616-8243670acbdd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_b5b8b355-0400-4561-a0c0-1e03a0b68b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_8ac25861-f576-4a3e-869d-07ba6d5083e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9b033561-8efd-4127-903e-adbcd41a8039" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_8ac25861-f576-4a3e-869d-07ba6d5083e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b1ca13f-0eaa-4fea-9114-ccddfe32d870" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_8ac25861-f576-4a3e-869d-07ba6d5083e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b1ca13f-0eaa-4fea-9114-ccddfe32d870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CommonStockWarrantsShares_a73e5a53-16d9-42c1-9621-9860bd18fe22" xlink:href="clbs-20220930.xsd#clbs_CommonStockWarrantsShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b1ca13f-0eaa-4fea-9114-ccddfe32d870" xlink:to="loc_clbs_CommonStockWarrantsShares_a73e5a53-16d9-42c1-9621-9860bd18fe22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsGranted_572076a9-7f36-4374-8204-ec785989da06" xlink:href="clbs-20220930.xsd#clbs_WarrantsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b1ca13f-0eaa-4fea-9114-ccddfe32d870" xlink:to="loc_clbs_WarrantsGranted_572076a9-7f36-4374-8204-ec785989da06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsExercised_a8637c0f-04bb-4aca-8dd8-027347a1f02e" xlink:href="clbs-20220930.xsd#clbs_WarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b1ca13f-0eaa-4fea-9114-ccddfe32d870" xlink:to="loc_clbs_WarrantsExercised_a8637c0f-04bb-4aca-8dd8-027347a1f02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsCanceled_8e252d40-e157-460a-84d2-afea67a686dd" xlink:href="clbs-20220930.xsd#clbs_WarrantsCanceled"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b1ca13f-0eaa-4fea-9114-ccddfe32d870" xlink:to="loc_clbs_WarrantsCanceled_8e252d40-e157-460a-84d2-afea67a686dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsExpired_56a57000-2950-451c-b1e7-96d101246486" xlink:href="clbs-20220930.xsd#clbs_WarrantsExpired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b1ca13f-0eaa-4fea-9114-ccddfe32d870" xlink:to="loc_clbs_WarrantsExpired_56a57000-2950-451c-b1e7-96d101246486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CommonStockWarrantsShares_0bf89027-1c8e-458b-a677-8f375beea937" xlink:href="clbs-20220930.xsd#clbs_CommonStockWarrantsShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2b1ca13f-0eaa-4fea-9114-ccddfe32d870" xlink:to="loc_clbs_CommonStockWarrantsShares_0bf89027-1c8e-458b-a677-8f375beea937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_Sharesvestedandexpectedtovest_0914ed01-16fe-46af-92d0-49a416968dd4" xlink:href="clbs-20220930.xsd#clbs_Sharesvestedandexpectedtovest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_8ac25861-f576-4a3e-869d-07ba6d5083e5" xlink:to="loc_clbs_Sharesvestedandexpectedtovest_0914ed01-16fe-46af-92d0-49a416968dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsVested_ed18fa10-9a9e-46bf-9376-57ddae2103c7" xlink:href="clbs-20220930.xsd#clbs_WarrantsVested"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_8ac25861-f576-4a3e-869d-07ba6d5083e5" xlink:to="loc_clbs_WarrantsVested_ed18fa10-9a9e-46bf-9376-57ddae2103c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_ed058bcc-4bb4-400f-b2e7-6ccf291e88f0" xlink:href="clbs-20220930.xsd#clbs_WarrantsWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_8ac25861-f576-4a3e-869d-07ba6d5083e5" xlink:to="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_ed058bcc-4bb4-400f-b2e7-6ccf291e88f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding_caf20661-4ed9-4071-b6a1-a3cae803b814" xlink:href="clbs-20220930.xsd#clbs_WeightedAverageExercisePriceWarrantsOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_ed058bcc-4bb4-400f-b2e7-6ccf291e88f0" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding_caf20661-4ed9-4071-b6a1-a3cae803b814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsGranted_0c4124c1-66db-4ae6-9dcd-e53b22fd76b9" xlink:href="clbs-20220930.xsd#clbs_WeightedAverageExercisePriceWarrantsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_ed058bcc-4bb4-400f-b2e7-6ccf291e88f0" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsGranted_0c4124c1-66db-4ae6-9dcd-e53b22fd76b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExercised_0bb58d45-65e0-4ade-b6de-7291673a045f" xlink:href="clbs-20220930.xsd#clbs_WeightedAverageExercisePriceWarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_ed058bcc-4bb4-400f-b2e7-6ccf291e88f0" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsExercised_0bb58d45-65e0-4ade-b6de-7291673a045f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsCanceled_9917a07b-d88b-4dda-8911-383a6fe04b53" xlink:href="clbs-20220930.xsd#clbs_WeightedAverageExercisePriceWarrantsCanceled"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_ed058bcc-4bb4-400f-b2e7-6ccf291e88f0" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsCanceled_9917a07b-d88b-4dda-8911-383a6fe04b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExpired_3730fb5b-d2b7-4b54-abda-56430be3fd68" xlink:href="clbs-20220930.xsd#clbs_WeightedAverageExercisePriceWarrantsExpired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_ed058bcc-4bb4-400f-b2e7-6ccf291e88f0" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsExpired_3730fb5b-d2b7-4b54-abda-56430be3fd68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding_da760414-b0d2-4dc1-9e25-7d343e26cd35" xlink:href="clbs-20220930.xsd#clbs_WeightedAverageExercisePriceWarrantsOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsWeightedAverageExercisePriceRollForward_ed058bcc-4bb4-400f-b2e7-6ccf291e88f0" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsOutstanding_da760414-b0d2-4dc1-9e25-7d343e26cd35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_5bf43e0a-18a4-4bd6-bf33-a169f76d0ccd" xlink:href="clbs-20220930.xsd#clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_8ac25861-f576-4a3e-869d-07ba6d5083e5" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest_5bf43e0a-18a4-4bd6-bf33-a169f76d0ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageExercisePriceWarrantsExercisable_506d572d-8a71-4c47-bb7c-7de982e0ac5c" xlink:href="clbs-20220930.xsd#clbs_WeightedAverageExercisePriceWarrantsExercisable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_8ac25861-f576-4a3e-869d-07ba6d5083e5" xlink:to="loc_clbs_WeightedAverageExercisePriceWarrantsExercisable_506d572d-8a71-4c47-bb7c-7de982e0ac5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WarrantsOtherDisclosuresAbstract_39332301-aec7-4cd2-a817-14cb87838a81" xlink:href="clbs-20220930.xsd#clbs_WarrantsOtherDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_8ac25861-f576-4a3e-869d-07ba6d5083e5" xlink:to="loc_clbs_WarrantsOtherDisclosuresAbstract_39332301-aec7-4cd2-a817-14cb87838a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding_28296711-f287-4ea2-9f49-7399c025d980" xlink:href="clbs-20220930.xsd#clbs_WeightedAverageRemainingContractualTermwarrantoutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsOtherDisclosuresAbstract_39332301-aec7-4cd2-a817-14cb87838a81" xlink:to="loc_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding_28296711-f287-4ea2-9f49-7399c025d980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_ed364606-7956-4e95-a4fb-929502fc5282" xlink:href="clbs-20220930.xsd#clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsOtherDisclosuresAbstract_39332301-aec7-4cd2-a817-14cb87838a81" xlink:to="loc_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest_ed364606-7956-4e95-a4fb-929502fc5282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_WeightedAverageRemainingContractualTermwarrantsvested_c2230121-68a2-48c9-83a3-7b84e782880c" xlink:href="clbs-20220930.xsd#clbs_WeightedAverageRemainingContractualTermwarrantsvested"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsOtherDisclosuresAbstract_39332301-aec7-4cd2-a817-14cb87838a81" xlink:to="loc_clbs_WeightedAverageRemainingContractualTermwarrantsvested_c2230121-68a2-48c9-83a3-7b84e782880c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsOutstanding_6ab035b7-9ab2-4120-bf28-842bccc37977" xlink:href="clbs-20220930.xsd#clbs_AggregateIntrinsicValueWarrantsOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsOtherDisclosuresAbstract_39332301-aec7-4cd2-a817-14cb87838a81" xlink:to="loc_clbs_AggregateIntrinsicValueWarrantsOutstanding_6ab035b7-9ab2-4120-bf28-842bccc37977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_96cc0ff3-82a5-44ec-8c82-65ed1a79cc55" xlink:href="clbs-20220930.xsd#clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsOtherDisclosuresAbstract_39332301-aec7-4cd2-a817-14cb87838a81" xlink:to="loc_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest_96cc0ff3-82a5-44ec-8c82-65ed1a79cc55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_AggregateIntrinsicValueWarrantsvested_9002826a-c204-4b01-aadc-5837d873273d" xlink:href="clbs-20220930.xsd#clbs_AggregateIntrinsicValueWarrantsvested"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_clbs_WarrantsOtherDisclosuresAbstract_39332301-aec7-4cd2-a817-14cb87838a81" xlink:to="loc_clbs_AggregateIntrinsicValueWarrantsvested_9002826a-c204-4b01-aadc-5837d873273d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3cc91ba0-6f97-442b-b0e9-c08f276bfb69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c773da29-cb6c-47ca-9efd-cdd909b6e102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3cc91ba0-6f97-442b-b0e9-c08f276bfb69" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c773da29-cb6c-47ca-9efd-cdd909b6e102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_96fc2e2d-f7d1-4ead-a7cd-2c7fa05f18ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c773da29-cb6c-47ca-9efd-cdd909b6e102" xlink:to="loc_us-gaap_AwardTypeAxis_96fc2e2d-f7d1-4ead-a7cd-2c7fa05f18ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc4f8fbc-b976-4ff4-9eb5-73a18b49af23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_96fc2e2d-f7d1-4ead-a7cd-2c7fa05f18ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc4f8fbc-b976-4ff4-9eb5-73a18b49af23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_92061513-6b48-463b-bf74-4340d1db1026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc4f8fbc-b976-4ff4-9eb5-73a18b49af23" xlink:to="loc_us-gaap_RestrictedStockMember_92061513-6b48-463b-bf74-4340d1db1026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_fc9402fe-8365-4d26-8b49-fadf99150a91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc4f8fbc-b976-4ff4-9eb5-73a18b49af23" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_fc9402fe-8365-4d26-8b49-fadf99150a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f3d7644a-a3f0-43f8-b9b7-8a5e45d0c83c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c773da29-cb6c-47ca-9efd-cdd909b6e102" xlink:to="loc_srt_RangeAxis_f3d7644a-a3f0-43f8-b9b7-8a5e45d0c83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_32828330-a45c-411b-b63d-1c348df29574" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f3d7644a-a3f0-43f8-b9b7-8a5e45d0c83c" xlink:to="loc_srt_RangeMember_32828330-a45c-411b-b63d-1c348df29574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ee53f08a-f113-46cc-9e47-e4e1fc44dc27" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_32828330-a45c-411b-b63d-1c348df29574" xlink:to="loc_srt_MinimumMember_ee53f08a-f113-46cc-9e47-e4e1fc44dc27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7ab21871-ba0c-4d52-9f37-a4c2b1f2d59a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_32828330-a45c-411b-b63d-1c348df29574" xlink:to="loc_srt_MaximumMember_7ab21871-ba0c-4d52-9f37-a4c2b1f2d59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70a2c20e-dbfa-41aa-bad6-3c4406f0dcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c773da29-cb6c-47ca-9efd-cdd909b6e102" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70a2c20e-dbfa-41aa-bad6-3c4406f0dcb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_27e553cf-ffd8-4a0d-9f7a-116fd3d4a861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70a2c20e-dbfa-41aa-bad6-3c4406f0dcb8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_27e553cf-ffd8-4a0d-9f7a-116fd3d4a861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_ab460a68-b398-4edd-a68e-4b557170dda3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70a2c20e-dbfa-41aa-bad6-3c4406f0dcb8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_ab460a68-b398-4edd-a68e-4b557170dda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b44332b9-ced3-4610-8863-c5e3759b848f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70a2c20e-dbfa-41aa-bad6-3c4406f0dcb8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b44332b9-ced3-4610-8863-c5e3759b848f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2dc33fdd-59b9-40a0-9d73-f0a0c5188782" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70a2c20e-dbfa-41aa-bad6-3c4406f0dcb8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2dc33fdd-59b9-40a0-9d73-f0a0c5188782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#ShareBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_d1d3b52f-f7a3-471c-b0fd-c601206d8b29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_466c67a0-000f-4241-a181-ae91c941e70f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_d1d3b52f-f7a3-471c-b0fd-c601206d8b29" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_466c67a0-000f-4241-a181-ae91c941e70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2035eaa8-b79a-4ef9-ae13-1952f37d9b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_466c67a0-000f-4241-a181-ae91c941e70f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2035eaa8-b79a-4ef9-ae13-1952f37d9b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ec8a8101-e36a-4d02-9984-928a65bf1c95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2035eaa8-b79a-4ef9-ae13-1952f37d9b7d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ec8a8101-e36a-4d02-9984-928a65bf1c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b181faf9-c0a6-4390-846e-f2ec027b9ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ec8a8101-e36a-4d02-9984-928a65bf1c95" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b181faf9-c0a6-4390-846e-f2ec027b9ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d4c14366-089e-43f2-b722-438acf3e5915" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ec8a8101-e36a-4d02-9984-928a65bf1c95" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d4c14366-089e-43f2-b722-438acf3e5915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bd03e317-8c2e-422a-b4b2-d57b7ef49d76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ec8a8101-e36a-4d02-9984-928a65bf1c95" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_bd03e317-8c2e-422a-b4b2-d57b7ef49d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e688834-28ae-440c-8300-b49ee857c154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_466c67a0-000f-4241-a181-ae91c941e70f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e688834-28ae-440c-8300-b49ee857c154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d8befb0c-fda0-4065-8780-70a5e15ba703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2e688834-28ae-440c-8300-b49ee857c154" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d8befb0c-fda0-4065-8780-70a5e15ba703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#ShareBasedCompensationCompensationCostNotYetRecognizedDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_6032ccc3-e38a-462c-b516-a8a24eeb16ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ef0e0a93-3b5e-44cc-9175-d51d0c33faeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_6032ccc3-e38a-462c-b516-a8a24eeb16ca" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ef0e0a93-3b5e-44cc-9175-d51d0c33faeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_164f74b1-bfb1-4059-b90b-bf83ad899c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ef0e0a93-3b5e-44cc-9175-d51d0c33faeb" xlink:to="loc_us-gaap_AwardTypeAxis_164f74b1-bfb1-4059-b90b-bf83ad899c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ac21732-c2b3-429b-8bdd-7d4876d61949" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_164f74b1-bfb1-4059-b90b-bf83ad899c4e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ac21732-c2b3-429b-8bdd-7d4876d61949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_012ad819-af63-4502-a3f0-6d2de262a403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ac21732-c2b3-429b-8bdd-7d4876d61949" xlink:to="loc_us-gaap_EmployeeStockOptionMember_012ad819-af63-4502-a3f0-6d2de262a403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c6284346-6df5-422b-8ea5-262b9bfbdaaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ac21732-c2b3-429b-8bdd-7d4876d61949" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c6284346-6df5-422b-8ea5-262b9bfbdaaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_952fbcda-a191-4bd1-96da-a072e4c5a4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ac21732-c2b3-429b-8bdd-7d4876d61949" xlink:to="loc_us-gaap_RestrictedStockMember_952fbcda-a191-4bd1-96da-a072e4c5a4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49b05ba9-3177-47d6-aa63-9d9181b30849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ef0e0a93-3b5e-44cc-9175-d51d0c33faeb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49b05ba9-3177-47d6-aa63-9d9181b30849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_26384413-e9a9-4eae-892e-1a13c43394dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49b05ba9-3177-47d6-aa63-9d9181b30849" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_26384413-e9a9-4eae-892e-1a13c43394dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b4ea9860-89eb-43fd-bbb2-600237c9abcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49b05ba9-3177-47d6-aa63-9d9181b30849" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b4ea9860-89eb-43fd-bbb2-600237c9abcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_990359d8-a2b0-4b34-94b7-bcce8cf8c0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a88a5af-d2a1-49ad-b310-307a49a1a94f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_990359d8-a2b0-4b34-94b7-bcce8cf8c0ec" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a88a5af-d2a1-49ad-b310-307a49a1a94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dd9dfb3f-ea07-4f69-815a-c94e8efe70e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a88a5af-d2a1-49ad-b310-307a49a1a94f" xlink:to="loc_us-gaap_AwardTypeAxis_dd9dfb3f-ea07-4f69-815a-c94e8efe70e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c68c6eae-40e4-41d0-ab9c-d90be692b944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_dd9dfb3f-ea07-4f69-815a-c94e8efe70e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c68c6eae-40e4-41d0-ab9c-d90be692b944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f1ae34c8-34aa-4c6b-97fb-32edd12f46d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c68c6eae-40e4-41d0-ab9c-d90be692b944" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f1ae34c8-34aa-4c6b-97fb-32edd12f46d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_297ece5f-751c-4d49-8a7d-c48e4578ff7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6a88a5af-d2a1-49ad-b310-307a49a1a94f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_297ece5f-751c-4d49-8a7d-c48e4578ff7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_a5ce7637-4d2b-4e90-b551-557face077ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_297ece5f-751c-4d49-8a7d-c48e4578ff7d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_a5ce7637-4d2b-4e90-b551-557face077ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7e18c063-fee7-421a-b545-ac5ed267286f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_297ece5f-751c-4d49-8a7d-c48e4578ff7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7e18c063-fee7-421a-b545-ac5ed267286f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_49916cc1-0b83-4f4f-acb9-8f1acee1c5ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_6fb6d61d-c3b4-462e-bb33-c18f87b3ddfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_49916cc1-0b83-4f4f-acb9-8f1acee1c5ae" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_6fb6d61d-c3b4-462e-bb33-c18f87b3ddfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_229a0d7b-576f-4e4c-9ae2-9139f15ba51c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_6fb6d61d-c3b4-462e-bb33-c18f87b3ddfc" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_229a0d7b-576f-4e4c-9ae2-9139f15ba51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_585a1a7f-78fb-49c8-8aed-7a6da5b044dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_229a0d7b-576f-4e4c-9ae2-9139f15ba51c" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_585a1a7f-78fb-49c8-8aed-7a6da5b044dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_f82bffa0-1b18-434b-8e39-b16539b60d76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_585a1a7f-78fb-49c8-8aed-7a6da5b044dd" xlink:to="loc_us-gaap_DomesticCountryMember_f82bffa0-1b18-434b-8e39-b16539b60d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_e781228e-35b1-46fa-b915-fd008b715c52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_585a1a7f-78fb-49c8-8aed-7a6da5b044dd" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_e781228e-35b1-46fa-b915-fd008b715c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_cb46e1dd-7af3-4373-9920-6332000d099d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_6fb6d61d-c3b4-462e-bb33-c18f87b3ddfc" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_cb46e1dd-7af3-4373-9920-6332000d099d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_e36f3063-8b31-40ca-adc4-0015b52d376f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_cb46e1dd-7af3-4373-9920-6332000d099d" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_e36f3063-8b31-40ca-adc4-0015b52d376f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewJerseyDivisionOfTaxationMember_c1494801-524b-4d05-8d94-7a213ea8217d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewJerseyDivisionOfTaxationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_e36f3063-8b31-40ca-adc4-0015b52d376f" xlink:to="loc_us-gaap_NewJerseyDivisionOfTaxationMember_c1494801-524b-4d05-8d94-7a213ea8217d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_71f6e704-def2-461e-a0d6-38e6cf27a94c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_e36f3063-8b31-40ca-adc4-0015b52d376f" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_71f6e704-def2-461e-a0d6-38e6cf27a94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_bcf603db-3936-4eb3-befc-d975ef098a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_e36f3063-8b31-40ca-adc4-0015b52d376f" xlink:to="loc_us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember_bcf603db-3936-4eb3-befc-d975ef098a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_cffaf573-590b-4560-9183-246833c2c834" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_6fb6d61d-c3b4-462e-bb33-c18f87b3ddfc" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_cffaf573-590b-4560-9183-246833c2c834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsBeforeWriteDown_fa9beb84-b14c-48f0-898f-8e3bb7fa2a87" xlink:href="clbs-20220930.xsd#clbs_OperatingLossCarryforwardsBeforeWriteDown"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cffaf573-590b-4560-9183-246833c2c834" xlink:to="loc_clbs_OperatingLossCarryforwardsBeforeWriteDown_fa9beb84-b14c-48f0-898f-8e3bb7fa2a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_7a34244c-f072-411c-a7ef-49806dbacf82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cffaf573-590b-4560-9183-246833c2c834" xlink:to="loc_us-gaap_OperatingLossCarryforwards_7a34244c-f072-411c-a7ef-49806dbacf82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown_764e3cf5-eff7-4d5c-a538-dfa74ab915a2" xlink:href="clbs-20220930.xsd#clbs_OperatingLossCarryforwardsSetToExpireWrittenDown"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cffaf573-590b-4560-9183-246833c2c834" xlink:to="loc_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown_764e3cf5-eff7-4d5c-a538-dfa74ab915a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain_01508086-0eb5-44e1-a886-6981ef8aab1b" xlink:href="clbs-20220930.xsd#clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cffaf573-590b-4560-9183-246833c2c834" xlink:to="loc_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain_01508086-0eb5-44e1-a886-6981ef8aab1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_df27af04-26cf-4475-8f90-c7b7e2a10ea8" xlink:href="clbs-20220930.xsd#clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cffaf573-590b-4560-9183-246833c2c834" xlink:to="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross_df27af04-26cf-4475-8f90-c7b7e2a10ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram_4486f7c7-10df-4f4b-834b-c42423f3d44b" xlink:href="clbs-20220930.xsd#clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cffaf573-590b-4560-9183-246833c2c834" xlink:to="loc_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram_4486f7c7-10df-4f4b-834b-c42423f3d44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_LossOnSaleOfNetOperatingLosses_d4f573ac-c10c-4a49-92d1-18fe965df6c2" xlink:href="clbs-20220930.xsd#clbs_LossOnSaleOfNetOperatingLosses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_cffaf573-590b-4560-9183-246833c2c834" xlink:to="loc_clbs_LossOnSaleOfNetOperatingLosses_d4f573ac-c10c-4a49-92d1-18fe965df6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/IncomeTaxesDetails_1" xlink:type="simple" xlink:href="clbs-20220930.xsd#IncomeTaxesDetails_1"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/IncomeTaxesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8a3f7cc1-a4d2-4dc1-a3f3-e2351e8085ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_452290e0-fc08-4eef-a9ec-f748007f0202" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8a3f7cc1-a4d2-4dc1-a3f3-e2351e8085ea" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_452290e0-fc08-4eef-a9ec-f748007f0202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_d2279aee-b87f-4ec5-9d01-0d4d9981599f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8a3f7cc1-a4d2-4dc1-a3f3-e2351e8085ea" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_d2279aee-b87f-4ec5-9d01-0d4d9981599f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/LicenseAgreementsDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#LicenseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/LicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1bd92b12-0839-4e07-94ad-ac611cd5c7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a5a8c940-3ea7-40c5-8354-ae690de955b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1bd92b12-0839-4e07-94ad-ac611cd5c7ba" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a5a8c940-3ea7-40c5-8354-ae690de955b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4f6d4dda-fed2-4c76-b86f-11735320244a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a5a8c940-3ea7-40c5-8354-ae690de955b7" xlink:to="loc_srt_CounterpartyNameAxis_4f6d4dda-fed2-4c76-b86f-11735320244a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6fbecc32-00b2-4147-aa9a-6fe9a5ad1fc3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4f6d4dda-fed2-4c76-b86f-11735320244a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6fbecc32-00b2-4147-aa9a-6fe9a5ad1fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SanfordBurnhamPrebysMember_a92da334-bb4f-4714-b81f-bc8a8e68394c" xlink:href="clbs-20220930.xsd#clbs_SanfordBurnhamPrebysMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6fbecc32-00b2-4147-aa9a-6fe9a5ad1fc3" xlink:to="loc_clbs_SanfordBurnhamPrebysMember_a92da334-bb4f-4714-b81f-bc8a8e68394c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_UniversityOfCaliforniaAtSanDiegoMember_843a4bb6-0567-402b-a8ac-49f3be565462" xlink:href="clbs-20220930.xsd#clbs_UniversityOfCaliforniaAtSanDiegoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6fbecc32-00b2-4147-aa9a-6fe9a5ad1fc3" xlink:to="loc_clbs_UniversityOfCaliforniaAtSanDiegoMember_843a4bb6-0567-402b-a8ac-49f3be565462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_MassachusettsInstituteOfTechnologyMember_0c3074c8-5073-47b8-abfc-ebae36dc0ba7" xlink:href="clbs-20220930.xsd#clbs_MassachusettsInstituteOfTechnologyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6fbecc32-00b2-4147-aa9a-6fe9a5ad1fc3" xlink:to="loc_clbs_MassachusettsInstituteOfTechnologyMember_0c3074c8-5073-47b8-abfc-ebae36dc0ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f24c85ee-1a46-43c2-b32c-edb2244d0ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a5a8c940-3ea7-40c5-8354-ae690de955b7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f24c85ee-1a46-43c2-b32c-edb2244d0ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_92f0487d-f98c-4243-af16-44ae4be12dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f24c85ee-1a46-43c2-b32c-edb2244d0ed6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_92f0487d-f98c-4243-af16-44ae4be12dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_cca6b84a-7ce6-4005-ae27-c050eaf9b111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_92f0487d-f98c-4243-af16-44ae4be12dcb" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_cca6b84a-7ce6-4005-ae27-c050eaf9b111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ff9dc1c1-4a6b-43be-8479-91a5d9f015dc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a5a8c940-3ea7-40c5-8354-ae690de955b7" xlink:to="loc_srt_RangeAxis_ff9dc1c1-4a6b-43be-8479-91a5d9f015dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_deecb026-9dd6-4419-8595-860f28462eda" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ff9dc1c1-4a6b-43be-8479-91a5d9f015dc" xlink:to="loc_srt_RangeMember_deecb026-9dd6-4419-8595-860f28462eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4eaabeb9-f8c8-48d2-8591-68b28baf27ea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_deecb026-9dd6-4419-8595-860f28462eda" xlink:to="loc_srt_MinimumMember_4eaabeb9-f8c8-48d2-8591-68b28baf27ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d183e8b8-945d-4245-b851-25cc0c27ef6b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_deecb026-9dd6-4419-8595-860f28462eda" xlink:to="loc_srt_MaximumMember_d183e8b8-945d-4245-b851-25cc0c27ef6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f39c5b1b-7239-40ff-a95f-506bc0e1fe79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a5a8c940-3ea7-40c5-8354-ae690de955b7" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f39c5b1b-7239-40ff-a95f-506bc0e1fe79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SharesIssuedUnderLicenseAgreement_6ca1c98a-4b4e-4adc-bacd-e390fd0c6fdd" xlink:href="clbs-20220930.xsd#clbs_SharesIssuedUnderLicenseAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f39c5b1b-7239-40ff-a95f-506bc0e1fe79" xlink:to="loc_clbs_SharesIssuedUnderLicenseAgreement_6ca1c98a-4b4e-4adc-bacd-e390fd0c6fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_2afdaabb-e677-4bbe-a85c-8cbd3be3f402" xlink:href="clbs-20220930.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f39c5b1b-7239-40ff-a95f-506bc0e1fe79" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee_2afdaabb-e677-4bbe-a85c-8cbd3be3f402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_a18292f0-7b6d-4262-9f2a-8080189d607b" xlink:href="clbs-20220930.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f39c5b1b-7239-40ff-a95f-506bc0e1fe79" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven_a18292f0-7b6d-4262-9f2a-8080189d607b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_f050d5d8-a283-47e7-a2a4-fec47777c205" xlink:href="clbs-20220930.xsd#clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f39c5b1b-7239-40ff-a95f-506bc0e1fe79" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct_f050d5d8-a283-47e7-a2a4-fec47777c205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_d71990b9-1ab6-4899-9f38-29cd5086695a" xlink:href="clbs-20220930.xsd#clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f39c5b1b-7239-40ff-a95f-506bc0e1fe79" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales_d71990b9-1ab6-4899-9f38-29cd5086695a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees_a7ba3c35-8fcf-4232-b673-e3b449d10d97" xlink:href="clbs-20220930.xsd#clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f39c5b1b-7239-40ff-a95f-506bc0e1fe79" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees_a7ba3c35-8fcf-4232-b673-e3b449d10d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour_65864b27-0aac-4218-99e7-a50bd865aa9c" xlink:href="clbs-20220930.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f39c5b1b-7239-40ff-a95f-506bc0e1fe79" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour_65864b27-0aac-4218-99e7-a50bd865aa9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_SharesHeldByThirdParty_25f79673-1740-4924-9965-a2563e2ae531" xlink:href="clbs-20220930.xsd#clbs_SharesHeldByThirdParty"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f39c5b1b-7239-40ff-a95f-506bc0e1fe79" xlink:to="loc_clbs_SharesHeldByThirdParty_25f79673-1740-4924-9965-a2563e2ae531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree_d41483d6-8cec-4b74-98e5-912e8abf8361" xlink:href="clbs-20220930.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f39c5b1b-7239-40ff-a95f-506bc0e1fe79" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree_d41483d6-8cec-4b74-98e5-912e8abf8361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale_753e46f0-6217-4b9d-a5fb-674e6a5b43a3" xlink:href="clbs-20220930.xsd#clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f39c5b1b-7239-40ff-a95f-506bc0e1fe79" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale_753e46f0-6217-4b9d-a5fb-674e6a5b43a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee_32d162e7-e2be-4c38-94ce-26bde92f7979" xlink:href="clbs-20220930.xsd#clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f39c5b1b-7239-40ff-a95f-506bc0e1fe79" xlink:to="loc_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee_32d162e7-e2be-4c38-94ce-26bde92f7979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" xlink:type="simple" xlink:href="clbs-20220930.xsd#ResearchCollaborationandLicenseAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5703d723-b94b-4388-81dc-0698501559c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6d2a1ef7-8882-4869-a31e-e6c2c8b25b69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5703d723-b94b-4388-81dc-0698501559c9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6d2a1ef7-8882-4869-a31e-e6c2c8b25b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2bf5a267-43a9-46e7-9039-792d5051a2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6d2a1ef7-8882-4869-a31e-e6c2c8b25b69" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2bf5a267-43a9-46e7-9039-792d5051a2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3db976c5-a4dd-4e03-bf9c-0d4b388cbc74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2bf5a267-43a9-46e7-9039-792d5051a2bd" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3db976c5-a4dd-4e03-bf9c-0d4b388cbc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_75c54cad-2953-421b-8c7c-9d6dbffbdea4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6d2a1ef7-8882-4869-a31e-e6c2c8b25b69" xlink:to="loc_srt_CounterpartyNameAxis_75c54cad-2953-421b-8c7c-9d6dbffbdea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b76d4eb5-9c91-409c-9225-b3480327cbdd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_75c54cad-2953-421b-8c7c-9d6dbffbdea4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b76d4eb5-9c91-409c-9225-b3480327cbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_QiluMember_23d5b9ff-702f-4cd6-8c5d-7b727983243a" xlink:href="clbs-20220930.xsd#clbs_QiluMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b76d4eb5-9c91-409c-9225-b3480327cbdd" xlink:to="loc_clbs_QiluMember_23d5b9ff-702f-4cd6-8c5d-7b727983243a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cca51727-cf40-4cb0-a205-31e05d8c88cc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6d2a1ef7-8882-4869-a31e-e6c2c8b25b69" xlink:to="loc_srt_ProductOrServiceAxis_cca51727-cf40-4cb0-a205-31e05d8c88cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_830cc939-d62e-4373-879f-7d246183f7b4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_cca51727-cf40-4cb0-a205-31e05d8c88cc" xlink:to="loc_srt_ProductsAndServicesDomain_830cc939-d62e-4373-879f-7d246183f7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_ab035b77-d1da-4104-a287-4eb9e312dd7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_830cc939-d62e-4373-879f-7d246183f7b4" xlink:to="loc_us-gaap_LicenseMember_ab035b77-d1da-4104-a287-4eb9e312dd7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_55f07164-1a80-4192-89dc-65bdf98b3637" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6d2a1ef7-8882-4869-a31e-e6c2c8b25b69" xlink:to="loc_srt_RangeAxis_55f07164-1a80-4192-89dc-65bdf98b3637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_76d6792b-2cf0-4c0c-a4b4-60191d120a22" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_55f07164-1a80-4192-89dc-65bdf98b3637" xlink:to="loc_srt_RangeMember_76d6792b-2cf0-4c0c-a4b4-60191d120a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_70815e9f-382d-4864-80b5-21bf90757938" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_76d6792b-2cf0-4c0c-a4b4-60191d120a22" xlink:to="loc_srt_MinimumMember_70815e9f-382d-4864-80b5-21bf90757938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_351efdde-0b56-48cd-87af-1597d073c697" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_76d6792b-2cf0-4c0c-a4b4-60191d120a22" xlink:to="loc_srt_MaximumMember_351efdde-0b56-48cd-87af-1597d073c697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08d7cf8d-016f-417c-819e-0d852daff2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6d2a1ef7-8882-4869-a31e-e6c2c8b25b69" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08d7cf8d-016f-417c-819e-0d852daff2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_fe4295ee-fd22-453f-a89f-43befb3cf494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08d7cf8d-016f-417c-819e-0d852daff2b8" xlink:to="loc_us-gaap_ContractWithCustomerLiability_fe4295ee-fd22-453f-a89f-43befb3cf494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_18dc9fc9-6db3-4331-b94e-ef1c7d1214e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08d7cf8d-016f-417c-819e-0d852daff2b8" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_18dc9fc9-6db3-4331-b94e-ef1c7d1214e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount_56fcfb4a-0c62-4728-8deb-35faefc238d7" xlink:href="clbs-20220930.xsd#clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08d7cf8d-016f-417c-819e-0d852daff2b8" xlink:to="loc_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount_56fcfb4a-0c62-4728-8deb-35faefc238d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RevenuePerformanceObligationPercentageOfNetSale_434cb8ab-ba4e-4454-86d1-6de2183b9096" xlink:href="clbs-20220930.xsd#clbs_RevenuePerformanceObligationPercentageOfNetSale"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08d7cf8d-016f-417c-819e-0d852daff2b8" xlink:to="loc_clbs_RevenuePerformanceObligationPercentageOfNetSale_434cb8ab-ba4e-4454-86d1-6de2183b9096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues_8ec9d5d6-495b-4063-bb3c-c347a12f1b8d" xlink:href="clbs-20220930.xsd#clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_08d7cf8d-016f-417c-819e-0d852daff2b8" xlink:to="loc_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues_8ec9d5d6-495b-4063-bb3c-c347a12f1b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>clbs-20220930_g1.jpg
<TEXT>
begin 644 clbs-20220930_g1.jpg
M_]C_X  02D9)1@ ! @$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
MQ@#+ -  U0#; .  Y0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%%
M 4P!4@%9 6 !9P%N 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!
M\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+!
M LL"U0+@ NL"]0,  PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H#
MQP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C :=!J\&P ;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X +F NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P S9#/,-#0TF#4 -6@UT#8X-J0W##=X-
M^ X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[! )$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/ 5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$ 891B*&*\8U1CZ&2 9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H< APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D >:AZ4'KX>Z1\3'SX?:1^4'[\?ZB 5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_ D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K BLV*VDKG2O1+ 4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^) (T!D0*9 YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$ T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE
M3FY.MT\ 3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1 9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"
M](-7@[J$'82 A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @;"ALB$1<D*B0<&R D*R@H("0I)24Q+R4I+BHK*SDK*BXO
M-#4U-30O.SL[.SL[.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD@'D'H/$_A%]2FLI8-BQV<F2IRORAHR H"D<!#QP.E '2VMHEHHBB5409PJ
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MQ/&>MOHEI)>1!2\>S <$K\SJIS@@]#ZU=T.]:_MX;A\!I8D8@=,LH)QG/'-
M%ZBN7^(?BB7PW;K<0A2S2A2'!(P58]BO/RUB3:]KL2ES:Q84$G!W'CT F))]
M@,GM0!Z'16#X*\3#Q';+<D ."5<#. P],]B"#WQG&20:WJ "BBB@ HHKE]/\
M42W&ISZ60OE11!@0#OR1&>3G&/G/8=J .HHHHH **** "BN?\%>*_P#A)X6N
M=GE[9"F-V[HJG.<+_>]*Z"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@DDG  ')))Z 4 /HK'\+^*(O$D1N(0P57*D. #D 'L6X^:MB@ HHHH ****
M"BBB@ HKG_%?C6'PQY?GJ[>;NQY84_=QG.67^\*T- UM-;@2\B#!)-V X ;Y
M6*G."1U'K0!H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;X#<\KF+9UZ87 QR!C ) JOX=\=3^%(QI,]LQE0GRP"5+;I.G1LC);#+D'
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MUK_U[M_*>CXU_P#'G'_U\+_Z!)0 >.YWU:]M]$'$<BF1\L0K8W%00HR0NPG
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MT&M",R11Q,I R,'YE^9MI"@^8,>I!% %>'1$T35[*SB+%([>3!<@M\WVACG
M ZGTI^I0-XYU"2P=V%I: _ZM<9<84@E@1NW%@"01M4[1R6JI8>*(O$FLVUQ"
M&"K$ZD. #D)*>Q;CYJE\1-/X.U"35DA#V\R8.W( SLW9(!"L7 .2"&R<?-G
M UM';P)?6R6SLT5Y($8.0<C*+@@*!E2Q*L#WVX !WU-8TE]7UN6U5W1)%42-
M'G/E^2A8''&&("\Y&2.#T-N#5)?'E];S1Q-';6DC-O(SDJ5;!/ !.%&T9*Y)
MRPZ:NC?\AZZ_Z]U_E!0!CWOAE?!=[:&UDD_TF54;<5/R[E#J0%&0VX8Z;2N>
M205]8KS_ .(__'YIO_7Q_P"SPUZ!0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT6KZ*EQ< O);P7)C)9OEVEL=",@;5 !R !CI7=>)X6FM+A$!+-!*  ,DDH0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX7AM]$LE#7;Q=@7 8GYF&XJ "V]LG(7;AD"G*U[KQ#J7A)EFU K/ [*I,>P
M9#$@#8C%N,C/RXR#R05B^(VB)?:C ;@LL,D.W*$;V968E5&#R-ZG&,L,JFY\
M*<+Q-X?TG1XP\<TD\C' 2.:(_4EA&VT>G&2>@QD@ [#XC>++C2FM6LF#"<L<
M!0XDQY>T#@G!W?PD$YX/2L_4];U?PZ!?W6V2%CS''M 3<1\K'86Q@E5(8C=C
M+-]USQ9;&UET>$@J4=%*E@Q&TPC!8  D>H !ZBNB^*7_ "#I_P#MG_Z-2@"E
MXE\62I+IS6[%8KQU+ JI)5C%@'(.#ACT/XUL>/=4DTJREN8&VR)LP< XS(H/
M!!'0GM7%>*(VM[;2;Y=I$'DC:S!,EDC8?,> /W9R2>,@],XT/B3XRM+NQ,$4
MBR//LVA#D@*RN2PZKP,8/.>W!P ;%[XU72+&WNIF!EGB0C(SEC&&9MJXR/88
M&XJ"R [AS]]>ZWI$9U!RK1J6)A8([JO(!8QHF0."2K>Y &X"CXVTSSK#3KIP
MQ@BCC$NS[X61(^1D8'W2,DXW%1WJO>^$]'@B\Y+EG+#Y5$L8/3/S#RRR@ <_
M+N_A"LY"D [Z]UE=:TN6[3@26LIQSP0C!ER0,X((SCG&1Q4/PM_Y!T'_ &T_
M]&O5+2$5-$?8K(IMK@A9#N;#;R#D*F0<Y' X(Z]3=^%O_(.@_P"VG_HUZ .K
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G_$GA3^VIK:Y
MW[/LLF_&W=N^9#C.1C[OH>M=!110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %<)K/PK6ZG-]:SO!([,S$ MRW4J0RE<Y.>3UP,#BN[HH X*S^%"O*+
MB]N)+AD*[0PXPI)*MO,F5/H,=_7CO:** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ*/8>8?ZO_W_ ,/^">X45X?11[#S#_5_^_\ A_P3W"BO#Z*/8>8?ZO\ ]_\
M#_@GN%%>'T4>P\P_U?\ [_X?\$]PHKP^BCV'F'^K_P#?_#_@GN%%>'T4>P\P
M_P!7_P"_^'_!/<**\/HH]AYA_J__ '_P_P"">X45X?11[#S#_5_^_P#A_P $
M]PHKP^BCV'F'^K_]_P##_@GN%%>'T4>P\P_U?_O_ (?\$]PHKP^BCV'F'^K_
M /?_  _X)[A17A]%'L/,/]7_ ._^'_!/<**\/HH]AYA_J_\ W_P_X)[A17A]
M%'L/,/\ 5_\ O_A_P3W"BO#Z*/8>8?ZO_P!_\/\ @GN%%>'T4>P\P_U?_O\
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M7A]%'L/,/]7_ ._^'_!/<**\/HH]AYA_J_\ W_P_X)[A17A]%'L/,/\ 5_\
MO_A_P3W"BO#Z*/8>8?ZO_P!_\/\ @GN%%>'T4>P\P_U?_O\ X?\ !/<**\/H
MH]AYA_J__?\ P_X)[A17A]%'L/,/]7_[_P"'_!/<**\/HH]AYA_J_P#W_P /
M^">X45X?11[#S#_5_P#O_A_P3W"BO#Z*/8>8?ZO_ -_\/^">X45X?11[#S#_
M %?_ +_X?\$]PHKP^BCV'F'^K_\ ?_#_ ()[A17A]%'L/,/]7_[_ .'_  3W
M"BO#Z*/8>8?ZO_W_ ,/^">X45X?11[#S#_5_^_\ A_P3W"BO#Z*/8>8?ZO\
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M?_06KSFNBE\)]5DO^ZKU84445H>F%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!)
M! TY"("S'H%!)]>@K6D\&W48+-'@ 9)+H  ._P!ZNA\)HFD6CZ@X!9MV#SG
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M4T-P[B.,9Y()Z8R><#;UYSU!XHYU:X_KM#V?M.;W=NN_IN96G:7)J3&.%=S
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ML!(!UJ>=J_<Q>.K4U.,DN>/+M>UFTO4XJBMG0O#AU0%V;9&N<OC(&T G.2
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M!2<KTWC@#YN3D@=LY_ KVB,8YG1<7)W4;V3:W.1HK>MO"WVN=H(GWQH5!D4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KN/AG
M_P MO^V?_L]</7<?#/\ Y;?]L_\ V>HJ_"SS\W_W2?R_-'<4445S'R04444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% '*_$;_CW7_KJO\ Z"U><UZ-\1O^/=?^NJ_^@M7G-=%+X3ZK)?\
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MCT*\:STZ>1.&$A //&X(N1C'(SQ[TS5_$\-M$;*Q7"-G<Q!Y##G&[DD]"3T
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M%3C!)ZGTJDKM>NIM2@ISA%)WC/FG==UOU)/"6A&^225I&CA'#;6QNP"3DYP
M 1U!!!/O6MH]U8+<*EM&QDR=K G;RIR?G<'@9[?3/%8_A/Q*FG V\XS$Y/0
MC+;0=P/)&!V]^&R,:%OJNGZ,WFP!I')/.#\H)&0-V.V<=2>06 -$D[LK%0K2
MJ5$U)W7N\ND=OM?\$?\ \Q?_ #_SQK'\:3LMXY!.4V;>3Q\H/'IR<_7FG_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7<?#/_ );?]L__ &>N'KN/AG_R
MV_[9_P#L]15^%GGYO_ND_E^:.XHHHKF/D@HHHH **** "BBB@ HHHH ****
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M_3;_ ,A__9UVGFBCS11[60?VOB_YOP7^1Q?_  K/_IM_Y#_^SH_X5G_TV_\
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MO^;\%_D<7_PK/_IM_P"0_P#[.C_A6?\ TV_\A_\ V==IYHH\T4>UD']KXO\
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M /LZ/^%9_P#3;_R'_P#9UVGFBCS11[60?VOB_P";\%_D<7_PK/\ Z;?^0_\
M[.C_ (5G_P!-O_(?_P!G7:>:*/-%'M9!_:^+_F_!?Y'%_P#"L_\ IM_Y#_\
MLZ/^%9_]-O\ R'_]G7:>:*/-%'M9!_:^+_F_!?Y'%_\ "L_^FW_D/_[.C_A6
M?_3;_P A_P#V==IYHH\T4>UD']KXO^;\%_D<7_PK/_IM_P"0_P#[.C_A6?\
MTV_\A_\ V==IYHH\T4>UD']KXO\ F_!?Y'%_\*S_ .FW_D/_ .SH_P"%9_\
M3;_R'_\ 9UVGFBCS11[60?VOB_YOP7^1Q?\ PK/_ *;?^0__ +.C_A6?_3;_
M ,A__9UVGFBCS11[60?VOB_YOP7^1Q?_  K/_IM_Y#_^SH_X5G_TV_\ (?\
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M\*S_ .FW_D/_ .SH_P"%9_\ 3;_R'_\ 9UVGFBCS11[60?VOB_YOP7^1Q?\
MPK/_ *;?^0__ +.C_A6?_3;_ ,A__9UVGFBCS11[60?VOB_YOP7^1Q?_  K/
M_IM_Y#_^SH_X5G_TV_\ (?\ ]G7:>:*/-%'M9!_:^+_F_!?Y'%_\*S_Z;?\
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M_P#V==IYHH\T4>UD']KXO^;\%_D<7_PK/_IM_P"0_P#[.C_A6?\ TV_\A_\
MV==IYHH\T4>UD']KXO\ F_!?Y'%_\*S_ .FW_D/_ .SH_P"%9_\ 3;_R'_\
M9UVGFBCS11[60?VOB_YOP7^1Q?\ PK/_ *;?^0__ +.NHCM[A0 9$) ZF%LG
MWXD _(5<\T4>:*3FWN95L=7K6YVG;R7^1G7EA<W*[!,J9[I$0>F,9,AQ]1@^
MAKG/^%9_]-O_ "'_ /9UVGFBCS10IM!1Q]>BK1:7HE_D<7_PK/\ Z;?^0_\
M[.C_ (5G_P!-O_(?_P!G7:>:*/-%/VLC7^U\7_-^"_R.+_X5G_TV_P#(?_V=
M'_"L_P#IM_Y#_P#LZ[3S11YHH]K(/[7Q?\WX+_(XO_A6?_3;_P A_P#V='_"
ML_\ IM_Y#_\ LZ[3S11YHH]K(/[7Q?\ -^"_R.+_ .%9_P#3;_R'_P#9T?\
M"L_^FW_D/_[.NT\T4>:*/:R#^U\7_-^"_P CB_\ A6?_ $V_\A__ &='_"L_
M^FW_ )#_ /LZ[3S11YHH]K(/[7Q?\WX+_(XO_A6?_3;_ ,A__9T?\*S_ .FW
M_D/_ .SKM/-%'FBCVL@_M?%_S?@O\CB_^%9_]-O_ "'_ /9T?\*S_P"FW_D/
M_P"SKM/-%'FBCVL@_M?%_P WX+_(XO\ X5G_ --O_(?_ -G1_P *S_Z;?^0_
M_LZ[3S11YHH]K(/[7Q?\WX+_ ".+_P"%9_\ 3;_R'_\ 9T?\*S_Z;?\ D/\
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MV_\ (?\ ]G1_PK/_ *;?^0__ +.NT\T4>:*/:R#^U\7_ #?@O\CB_P#A6?\
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M?^0__LZ[3S11YHH]K(/[7Q?\WX+_ ".+_P"%9_\ 3;_R'_\ 9T?\*S_Z;?\
MD/\ ^SKM/-%'FBCVL@_M?%_S?@O\CB_^%9_]-O\ R'_]G1_PK/\ Z;?^0_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2N,XX!4X'4U-X7A%Y?75S)R\3[5X' RR^G4*H&?0G.<T -M?&MQ:N%O82B$
M[E5AM!QR0=V>64'!!4G&">*W_$.KFPMFNXMK$!2N>5(9@,\$9X/'-86N^,;.
M<O:7$;N$<@\+U4XR#O!'Z<<=ZM>)V1]-)C!"&.':#U"[DP.I[>YH 6YU6_E6
M*6VB1UDA1F).,,PR0,N..GK]:S++Q1J-ZSQ1Q1EHCAQTP<D=Y!GH>E=7X?\
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MH_MN?_GK)_WVW^-'L6']@5/YD>M45Y+_ &W/_P ]9/\ OMO\:/[;G_YZR?\
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MU'4D- $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 1R]*BJ67I45 !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %<C\3?^/9/^NR_^@O7744
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MOR\,8CC-L=N%"[AY@^?: ,9[9Y( />NPHH Y%=7&E7MR\JMY+^4#(%)52J#
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M-=/10!A:=XA;5IL6Z@VZ [Y&!&6(X51QT[Y'3TXW-\)?\O/_ %^3?^RUOT4
M8'@3_CRB_P"!_P#H;5D:)KBZ;;?V<Q*7:;U52N<NQ)3!P5P2PY)QWZ<GMJ*
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M<0J?(MQ(?,8%0Q==N%!&3@CD_7VS8\=_\>4O_ /_ $-:WZ* ([B=;=6E<X5
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^R*0;LL0-H^;Y<D_[. 3ZC.<<WX;:QN9C;Q0,Z @&1&<J"3CGYON_P"UGL<
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MU@O7822!ZX(' [_GTS6?#HKRP/>@C9&VT@D[LG;TXQ_$.]=1X*_T.VFN)O\
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MN0JHO=';AZTI2G"6\7^#U044451TA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!<TW59--;S(CCD9'\)QV([]?P[8->AZ%XFCU48^[)G[A/)[Y'3/
M'7T[]B?,*<CF,AE."#D$<$$=ZB<%(X<;EU/%*^TN_P#F>RT5ROA3Q6;X_9IN
M9#G:P&,XY((' ('X$>_7JJYY1<78^6Q.&GAYN$MPHHHI&(5)#4=20T 2T444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!'+TJ*I9>E14 %%%% !1110 4444 %%%% !1110 4444
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M *[-_P"@I0!UU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>  .?8<#\*[3PKX*$@2ZGY!&Y4Z@@X*DG]=OTR>HKB:NQZS/& JRN !@ .P
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M-)M*3::Y5HFK_P"9TFA^")990+A-L:GYOF'/ ( QG.<C)'N,@BM[P>(A-<B
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_G_O1_FW_P 31_PK^?\ O1_FW_Q->@44>UD']M8KNON//_\ A7\_]Z/\V_\
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M(==_\\__ !]/_BJ/^$.N_P#GG_X^G_Q5>FT4>VD']O8CM'[G_F>9?\(==_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M$<O2HJEEZ5%0 4444 %%%% !1110 4444 %%%% !1110 4444 5[^P2_0PRC
M*-C(R1T((Y!!ZBH-*T&'2=WD+MWXS\S'.,X^\3ZFK]% !1110 4444 %%%%
M!1110 4444 %%%% !5+4=%AU(HTRAC&25R3CG&> <'H.#D5=HH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"GJ>DQ:HHBF
M7<H.0,D<@$=B/6C3-)BTM3%"NU2<D9)Y( [D^E7** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J\U@DSI,P
MR\6[:<GC<,'C.#D>M6** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *DAJ.I(: ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH 0C-&T4V1L5'YAH FVBC:*A\PT>
M8: )MHHVBH?,-'F&@";:*-HJ'S#1YAH FVBC:*A\PT>8: )MHHVBH?,-'F&@
M";:*-HJ'S#1YAH FVBC:*A\PT>8: )MHHVBH?,-'F&@";:*-HJ'S#1YAH FV
MBC:*A\PT>8: )MHHVBH?,-'F&@";:*-HJ'S#1YAH FVBC:*A\PT>8: )MHHV
MBH?,-'F&@";:*-HJ'S#1YAH FVBC:*A\PT>8: )MHHVBH?,-'F&@";:*-HJ'
MS#1YAH FVBC:*A\PT>8: )MHHVBH?,-'F&@";:*-HJ'S#1YAH FVBC:*A\PT
M>8: )MHHVBH?,-'F&@";:*-HJ'S#1YAH FVBC:*A\PT>8: )MHHVBH?,-'F&
M@";:*-HJ'S#1YAH FVBC:*A\PT>8: )MHHVBH?,-'F&@";:*-HJ'S#1YAH F
MVBC:*A\PT>8: )MHHVBH?,-'F&@";:*-HJ'S#1YAH FVBC:*A\PT>8: )MHH
MVBH?,-'F&@";:*-HJ'S#1YAH FVBC:*A\PT>8: )MHHVBH?,-'F&@";:*-HJ
M'S#1YAH FVBC:*A\PT>8: )MHHVBH?,-'F&@";:*-HJ'S#1YAH FVBC:*A\P
MT>8: )MHHVBH?,-'F&@";:*-HJ'S#1YAH FVBC:*A\PT>8: )MHHVBH?,-'F
M&@";:*-HJ'S#1YAH FVBC:*A\PT>8: )MHHVBH?,-'F&@";:*-HJ'S#1YAH
MFVBC:*A\PT>8: )MHHVBH?,-'F&@";:*-HJ'S#1YAH FVBC:*A\PT>8: )MH
MHVBH?,-'F&@";:*-HJ'S#1YAH FVBC:*A\PT>8: )MHHVBH?,-'F&@";:*-H
MJ'S#1YAH FVBC:*A\PT>8: )MHHVBH?,-'F&@";:*-HJ'S#1YAH FVBC:*A\
MPT>8: )MHHVBH?,-'F&@";:*-HJ'S#1YAH FVBC:*A\PT>8: )MHHVBH?,-'
MF&@";:*-HJ'S#1YAH FVBC:*A\PT>8: )MHHVBH?,-'F&@";:*-HJ'S#1YAH
M FVBC:*A\PT>8: )MHHVBH?,-'F&@";:*;(N!4?F&@N30 VBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BHY[A;=2[L%4=2Q  SQU-5/\
MA(+;_GM'_P!_%_QH OT55@U2&? 21&+$@;74Y*C) P>< Y/H*M4 %%%% !11
M10 45'-<+#C>P&X@#) R3T SU)]*DH **C^T+N\K<-^,[<C=C.,XZXSWJ2@
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M7)W^G21O +J[##ST*)Y*@LRG@?*<]\9Z#(SVKK* ./\ '>G?VC+;P#.66XP
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 'VO^-']MP?\]8_^^U_QKR6BCV*#^P*?\S/6O[;@_P">L?\ WVO^-']MP?\
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M4\B7!!Q./M!DW'JQX );G=P,@G&.P!ZG17GNN:NVL:&;E_OLJ!NG)695+<
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MT  !K:+>F^@BN&P&DB1CCIEE!.,YXYJ[67X5_P"/.W_Z]XO_ $ 5J4 %%%%
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M7DDTP M'*Z38.)1YQ?<>K'C!SWZ9R<8H ] HKC=6U)M2THSO]Y@@/N5E"D\
M=<9QVZ5JMX0BGP\Q=Y@/];O8,#DG*@':N"?E &![T ;M%<K!X@DBTP7AYD";
M0???Y88YSD]SGJ?3-3V_@F%E5YMS7&!F7S'W;@.H.1]W^'(Z 9H Z.BN1M]>
MEM+&9W.Z:V=HMV<Y((4-R.<;NXYQSUJ<>!HY8PSLWVG )FWLS!QCD9(R!T'
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M"6XP1U[YXQ0!T.A:RFM0K=Q@A'W8# !OE8J>A(ZCUJ_7!_\ "3W']C?VCO\
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M1"93#;+LQALAH\@YZ8[YQC!SC%=E10!RD7C"XC AELYOM& #Y:@PECT_>[B
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MACI8JI?[*V04445!Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@_O2?FO_ ,31_P *_@_O2?FO_P 37344>TEW#^TL5_.SF?\ A7\']Z3\U_\
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MRS1Y9H ;13O+-'EF@!M%.\LT>6: &T4[RS1Y9H ;13O+-'EF@!M%.\LT>6:
M&T4[RS1Y9H ;13O+-'EF@!M%.\LT>6: &T4[RS1Y9H ;13O+-'EF@!M%.\LT
M>6: &T4[RS1Y9H ;13O+-'EF@!M%.\LT>6: &T4[RS1Y9H ;13O+-'EF@!M%
M.\LT>6: &T4[RS1Y9H ;13O+-'EF@!M%.\LT>6: &T4[RS1Y9H ;13O+-'EF
M@!M%.\LT>6: &T4[RS1Y9H ;13O+-'EF@!M%.\LT>6: &T4[RS1Y9H ;13O+
M-'EF@!M%.\LT>6: &T4[RS1Y9H ;13O+-'EF@!M%.\LT>6: &T4[RS1Y9H ;
M13O+-'EF@!M%.\LT>6: &T4[RS1Y9H ;13O+-'EF@!M%.\LT>6: &T4[RS1Y
M9H ;13O+-'EF@!M%.\LT>6: &T4[RS1Y9H ;13O+-'EF@!M%.\LT>6: &T4[
MRS1Y9H ;13O+-'EF@!M%.\LT>6: &T4[RS1Y9H ;13O+-'EF@!M%.\LT>6:
M&T4[RS1Y9H ;13O+-'EF@!M%.\LT>6: &T4[RS1Y9H ;13O+-'EF@!M%.\LT
M>6: &T4[RS1Y9H ;13O+-'EF@!M%.\LT>6: &T4[RS1Y9H ;13O+-!0B@!M%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!@?\Q+_MS_\ :M&L_P#'[9_]M_\ T 5)KD8M98;\G"QDI(1@
M?+)PI))'RJ^#CG&<]JOW.F+<2QW!)W0[]H&,'>,'/'Y=* ,SQ;_R[?\ 7Y#_
M .S4>._^/*7_ (!_Z&M:>HZ8M_LWDCRI%D&,=5S@'(/'/_UZ-6TQ=4B:W<D*
M^,E< \$'N#Z4 9GCO_CRE_X!_P"AK39/!PD!5KBX((((,N00>HQMK5U;3%U2
M)K=R0KXR5P#P0>X/I5R@#*U6T2SLY88P%18)  /]T_Y)ZD\FIO#_ /Q[0_\
M7&/_ -!%6;RU%VC0MG#JRG'7##!K$C\'",!5N+@    2X  Z#&V@!MS(;[4(
MT0<6J.SGGK*N O3&<8/7D9[BJUV;C4KLR6XC*V@V@R%MNYQ\Y!0=0/E()..N
M,GCH-*TJ/2XQ!$,*/S)[DGN3_P#6&  *-+TQ=-3RD)/))9L%F+'))( R??T
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MEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT
M-HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H
M\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*
M=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+-
M #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 VI(:;
MY9I\:[: )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH 0G%&X4R7I45 %C<*-PJO10!8W"C<*KT
M4 6-PHW"J]% %C<*-PJO10!8W"C<*KT4 6-PHW"J]% %C<*-PJO10!8W"C<*
MKT4 6-PHW"J]% %C<*-PJO10!8W"C<*KT4 6-PHW"J]% %C<*-PJO10!8W"C
M<*KT4 6-PHW"J]% %C<*-PJO10!8W"C<*KT4 6-PHW"J]% %C<*-PJO10!8W
M"C<*KT4 6-PHW"J]% %C<*-PJO10!8W"C<*KT4 6-PHW"J]% %C<*-PJO10!
M8W"C<*KT4 6-PHW"J]% %C<*-PJO10!8W"C<*KT4 6-PHW"J]% %C<*-PJO1
M0!8W"C<*KT4 6-PHW"J]% %C<*-PJO10!8W"C<*KT4 6-PHW"J]% %C<*-PJ
MO10!8W"C<*KT4 6-PHW"J]% %C<*-PJO10!8W"C<*KT4 6-PHW"J]% %C<*-
MPJO10!8W"C<*KT4 6-PHW"J]% %C<*-PJO10!8W"C<*KT4 6-PHW"J]% %C<
M*-PJO10!8W"C<*KT4 6-PHW"J]% %C<*-PJO10!8W"C<*KT4 6-PHW"J]% %
MC<*-PJO10!8W"C<*KT4 6-PHW"J]% %C<*-PJO10!8W"C<*KT4 6-PHW"J]%
M %C<*-PJO10!8W"C<*KT4 6-PHW"J]% %C<*-PJO10!8W"C<*KT4 6-PHW"J
M]% %C<*-PJO10!8W"C<*KT4 6-PHW"J]% %C<*-PJO10!8W"C<*KT4 6-PHW
M"J]% %C<*-PJO10!8W"C<*KT4 6-PILC9%0T4 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 ^(X-2[A5>B@"QN%
M&X57HH L;A1N%5Z* +&X4;A5>B@"QN%&X57HH L;A1N%5Z* +&X4;A5>B@"Q
MN%&X57HH L;A1N%5Z* +&X4;A5>B@"QN%&X57HH L;A1N%5Z* +&X4;A5>B@
M"QN%&X57HH L;A1N%5Z* +&X4;A5>B@"QN%&X57HH L;A1N%5Z* +&X4;A5>
MB@"QN%&X57HH L;A1N%5Z* +&X4;A5>B@"QN%&X57HH L;A1N%5Z* +&X4;A
M5>B@"QN%&X57HH L;A1N%5Z* +&X4;A5>B@"QN%&X57HH L;A1N%5Z* +&X4
M;A5>B@"QN%&X57HH L;A1N%5Z* +&X4;A5>B@"QN%&X57HH L;A1N%5Z* +&
MX4;A5>B@"QN%&X57HH L;A1N%5Z* +&X4;A5>B@"QN% .:KU)#0!+1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% $<O2HJEEZ5%0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1167K?B>WT/;]I?9YF=ORLV=N,_=!]10!J45
MR_\ PLW3O^>W_D.7_P"(KIHI1, ZD%6 ((.00>001U!H =1110 4450U'78=
M.>.&5MKSMM0;6.3D#&0"!RPZXH OT444 %%%% !15#6==AT5!-<-L0L%!VLW
M)!.,*">@-,/B* 31V98B:9-ZJ4<$K@GG*\'Y3P<'CI0!I4450T[78=1>2&)M
MSP-M<;6&#DC&2 #RIZ9H OT444 %%%% !15>RU".^&^%U=0<91@PSUQD$\\U
M8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BL:[\86EHYB>0!E
M." K-@^F0"/KZ'CK6K!<+<*'1@RGH5((...HH DHHHH **** "BBB@ HJ.XG
M6W5I7.%0$D]< #)Z4V.[21!."-A4-N/ VD9SSC''K0!-138Y!( RD$$ @@Y!
M!Z'-.H ***KV%^E^@FB.4;.#@CH2#P0#U% %BBBJ]A?I?H)HCE&S@X(Z$@\$
M ]10!8HHHH **** "BBJ]I?I>;O+.?+<HW!&&7J.1_\ 6H L4444 %%%5[^_
M2P0S2G"+C)P3U( X )ZF@"Q1110 4444 %%%% !1110 457N[]+/;YAQYCA%
MX)RS=!P/_K437Z0ND+'#R[MHP>=HR><8&!ZT 6**C>X5&"%@&?.T$@$XY.!W
MQWJ2@ HHHH **** "BBJ\-^DSO"IR\6W<,'C<,CG&#D>E %BBBJ;:M$IE4MS
M  9.#P"-P[<\#MF@"Y14=O.MPJRH<JX!!Z9!&1UITD@C!9B  "22<  =3F@!
MU%8D'C2SG8()1D_W@RC\V  _.K^IZM%I:B69MJDX!P3R03V!]* +E%8'_"=V
M7_/7_P <?_XFM/3-6BU13+"VY0<$X(Y ![@>M %RBJ<NK112K:%OWKC(7!Y'
M/?&.Q[U<H **AN;M+;!<@;F51GNS'  _STYZ"IJ "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWF*'8)U,3 %CD+[GH.O2NFUSQE8I;">1EFBD( 10KEB,-C:V,%<@G=C'&>2
M<'QI>B^GTJX7(6256&>N&:$C.,\\T 5[_P =:II*)<W5O&L3LH[ACD%L8\QB
MIP#U7@]1VKIO$_C5-+ACEA!DDN0/)4*WS9 ()'!Q\PX^\20!CDAOQ-_Y!TW_
M &S_ /1J5P'C"%D&FRM(8XS;0@,-Q*%=I:0*,<X9>AR=OL* .CO?&6JZ,/M%
MW;1^2#AMC<\].0\F!GN5QVZD5W]K=+=HLR'*.H93@C(89!P>>E>2>(])6TAW
M3:D\R/C"+F0M\Q&=IFQ@%3R> 1C.<"NPU+Q - TN.:,DL8(DB)&#N9!@D?,
M0 6P21QC/- &1?)_PE^J"#&;:QSNR."V>1RO=@%*G@JC%3S5O6/^0Y:_]>[?
MRFK4^'7AO^Q+5=XQ+-\[Y&",_=7D _*.H.<,6QUK+UC_ )#EK_U[M_*:@#O*
MXWPOX@5YK\ND<:6TAW/&A#,%:3+/C)8X7/3J3ZUV5>;>%;I;27599$+HLI+*
M IRN^7=PQ (QG(SR/4\4 16OQ U/4(Y+V""(P1E\DDY 4;B#F122%(Y"\]AV
MKJ[7Q4_]GC5)(CO\LL47//. W/(4CYL\X7GYL<\!I^E6TXDN;"^-J')Q%*WE
ML".@+"3E>>#AL XY8&MO3/&,XTJ:[#;I()/+1W7YBI* ,PR1N ?U(R!G=R2
M/B\3:U-&+E;:(HR!P1R2I&1A1+N)([8SVQFM*S\6W6LV27=E&CS^9LD1CA1@
M$D@LR=?E(Y. <<D$URAM&CMA?/JD@!!(169G/0A<"8?/AEW#HI/)Q\U=#\&O
M^/-_^OAO_0(Z .>^&NH7UK'B")7M?/S(QY<<)OVJ'!)"X( 4DG@9Z5LV?BO6
M-2#2P6L80.R@/E6&TX(.Z1,D="0 ,@C@@@,^$FI);V<RYW2))(_EI@R%0B=%
MSDY/ [9XK)T>:;Q,)+R34#;X/*!BH7D#A?,7"<J QY+$@\C+ '8> ?%TVO\
MG1W"!)(&4':&7[VX8*L2005.>>^,#'/6UYM\(2#)>$.9!OC^<@@MS)\Q!YR>
MO//K7I- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %8WBJ[>&-(HR5:>5(@XZK
MO/+?D,=0><@@BMFL3Q= S1+.HR;:1)=O3(3.1GMP2>_3&* -."PCMXQ;JH$8
M&-N,C!ZYSUSWSU[U2TK2%T;S6#@1.V\*0%"<?-SZ=,=  /J:+I+77H=SE7B4
M[L[B "%[D$$8!Y!Z=Q7-:#;1S_;X;0?(4"H,YR=CKP23P6Y!ST/:@#;_ +0N
M]0_>VJQK"?NF?>&8?WP%Z*>V>2.>XJ]HNK_V@&#H8Y8VVNA()'<'(Z@CH<8/
M.,CFL#P]H::A DB7,_W0"$EP%8 97&.,=AZ8[5=\*1PAYVA>23E TDA#*Q4'
M[K8&<9Y_#'% $&DZY>ZQ$LL*1KUW-+O"L<G[@4DX QDD\DD#H:?9:_=:FICA
MC598B5E:4GR]R\;5VDDGOZ*.,G(-6/ G_'E%_P #_P#0VH\)?\O/_7Y-_P"R
MT 6-!U:2[:2WG4+- 0&V'*$-DJ1DYZ=C_P#6%./6[C56?[&L?EQN5WRL3N(Q
M]T)T ]23D$8[BI-&_P"/V\_[8?\ H!J/P),!;_9CQ) [JXR.#N)[$\<XSW(.
M.E $EIXD::"9G39<6R,70@[<A25(.>5;'K^)&"8=9NKB[LQ-'Y>'MV:7=NSA
MD!^7'X]?:IKW6X]3@NEBR5BC<;\?(3L.=I[X[_4$9!!H_P"8;_VY_P#M*@"/
MPY-<PP(\H0PK I01!C*<*"HP>"2/3OBG1W6H70$J)#&K $)*9"X^NT >^,9'
M0\YJQIE\+>Q2=<,([<' /4HG(SSCD8/H:SK'2VU*/[=+=2#S!O/E/Y<:#'*X
M^;[N""<]N><F@#;T75?[20N5VNCLCKG=M93R,X /&#QQS7*>$;^ZFMTAM43;
M'O#/,3@L6W!0%.>C Y(P>G&.=/P$RM',48LIN9,,WWB,+@G..3U-.^'UVDUH
ML:D%HRP8=QEF(_,'KTZ]P: +VBZVUV\EK,H2:'&0K95@1]Y>^/8],C)R:AT[
M77N;$WS!=XCD; !VY0MCC.>W/-0V<PO-1D=.5A@$;'(QN+[L=?J#Z$$'WJ:)
M_P @EO\ KC/_ #>@"W::G>ZE&DT*1H"!GSB^6X'(5>BYSC))(P>.^EI.LB]C
M:5P(S&SK("V0I0\_-@ \8.1Q[T[P_P#\>T/_ %QC_P#016)I4#7$%]$@RSSW
M( Z9)4 =: +?]H7>H?O;58UA/W3/O#,/[X"]%/;/)'/<5>T75_[0#!T,<L;;
M70D$CN#D=01T.,'G&1S6!X>T--0@21+F?[H!"2X"L ,KC'&.P],=JN^%(X0\
M[0O))R@:20AE8J#]UL#.,\_ACB@#0\1:DUA$3'S+(0D8_P!M^!U!''7G@XQW
MJG?$^&;+]S@F$*/F!P2S ,<9SR23C/'THTS_ (F\[7I_U<)9(<<9.,2/D?>!
MZ*<XP#P#S1X[_P"/*7_@'_H:T .:]O9L311QJF,[)&82D9/H-JDC'!S@]3V$
MG_"0F:WCNH8VD:4J B]B<ALL1P%((W8QG'8YK9KB=*U5M.T^#:0IED,>]NB;
MG?+X/!P!W('KQQ0!IW%]?V"M/*L#H@)98RZM@#G!;(XZ^X&!S1XSG6XL'E0Y
M5Q&0>F074CK5#7="73K=Y);F<G81AI/E9B.%VX)P3VR>,Y. 34FM_P#()7_K
MC!_-* +<.I7UX/M$4<8A."JNQ\QEP".5)4%NV>AZYQDZFA:PNKQ+<)QG@C()
M!'4<?F.F00<#-3P7\=Q&+A6!C(SNS@8'7.>F.^>G>N;\.V']JP22;I(UFN9)
M%,;!6*GC!QGOG(]1Z4 ;/B74VTNW>X0 LFW ;)'+ =B/6JK7M[-B:*.-4QG9
M(S"4C)]!M4D8X.<'J>PSO$VD?V?93_O))-WE_P"M??C#CIP,9SS^%=%8ZM'>
MQ_:$8;,9))'R\9(;!(! //I0!2M?$@N[7[;&C.0/]6OS-NSC''YYQG;SCM4/
MG:C_ *S9!MZ[-S[\==N[[N[MGIGGI6=8:H=.M+F_0!@]Q(\>> 0S*@..O7/!
MP>.V<U8DT,11FYFO)L8+%TDVI@G(PH#=<C !.>PZ"@#5@\01R6POSPFS<1[C
M@J,XR=W Z9/3K66-6OI8Q>)%'Y9 81[F:4KQT(PN2.1QGM@GBLR"!I]'VJ,D
M!C^"REC^0!KK8]9B> 7I8"(J&R>WMQGG/&!DYXZT 8FMZBFI1VEQ'G:]W%C(
MP>"P(_ C'IZ<5JW^IM;W$%N -LWF[B<Y&Q01CG\^M96MWXU".TG4,H>[B(#C
M!QEL'&3UZCU&*LZS_P ?MG_VW_\ 0!0!F:U]K^V08\G.9_*^_C&WG?[[>F._
MM6S<7]S;I''Y:O/(6!*;A"F.C$GGICCJ><'.,U]<D$=Y9EB ,SCDXY*  ?B3
M@>]2>);]U:*RC<1FY+CS.I7:!P!D<L2 #G([<XP 0SZK=Z6/.NEA,.5#&(N&
M4,0-V&!R!Z#GD>]:&O:E)IJK<(N^-3^\ 'S!<?>!R/N]Q@Y'=0":Y;QEI":=
M 2UQ,S,0%223<&P03QCL.<] <=\5TOB?4A:1&-<&6;Y(U./F+?+T((P,Y.>.
MQZT %GK3:A.8X0#!&/FD^\&8@$*I!QP#DGGTP."6W>J37+F&S"$QGYWDW>6#
M_<&WDMW/9>AY/%'PN@T5VTMR"W#QM@*7##YN!GE2#U))'3Y15+2]'%S/<Q--
M+'()W;9%)M!5\%6Q@YSGGTX!Q0!MZ=J\HE^QW2*LA4LKH?W;XZ@;N00#R.3U
M/ QF'1O^/V\_[8?^@&JEM80VMY'%YL\LR!SAV#J@*X^;@8SGC'?&>HS;T;_C
M]O/^V'_H!H T]7U)=,B>X;H@SCU/0#H<9.!GM60NFM86,PDYEDCE>0_[;J2>
MA(XZ<<'&>]2/_P 3FYV=8;0J>.\W;D9R$'49!#'D$5H>(/\ CVF_ZXR?^@F@
M \/_ /'M#_UQC_\ 016;XWB+P*<,T:2HTH4\F,9W=QGM].O&,C2\/_\ 'M#_
M -<8_P#T$5'K>M_V3L=T)B8X=Q_!TVDKC)!/Y>Y(! *<VHV.J0^49(_+((4$
MJI7@J"%;[I';CZ<5JZ99?88D@+%MBA<D 9QQT'Z=\=23S44^GVUP#<.D; C)
M=E4Y '7<1TQW]*S?!#[H7"9\H3R"+((^3.1C/)Y)Y/.>.U #O^8E_P!N?_M6
MM^L#_F)?]N?_ +5JQXJOFM8"L?\ K92L:=1\SG'!&,'&2"2 "* .<ECDO$FU
MA#EDD#0]AY<)*MU.0K L67Y<D>^*[:WG6X594.5< @],@C(ZUSUIX;NK-!#'
M=!448 %NG^/YGJ3R:F\(NT"R6,AR]L^T'G)1AE#U(Y&< '@  T 8VH:7*AM[
MNZ8M,]W%\H/R1J<G:HSCL,GVZGDGN*P/%O\ R[?]?D/_ +-6_0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)_WVW^-']MS_ //63_OMO\:I44[(V]C3_E7W%W^VY_\ GK)_WVW^-']MS_\
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ME_SR_P#'W_\ BJN:9X:M]+8RPIM8C!.YCP2#W)]*TZ* "BBB@ HHHH ****
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M;7.&5E4$IYC#:"$)SM4CD@].:BUCQU/IFJ&V=Q]E0KN4A!A3$&8[MNXD$[@
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M,G.Y.F5/\1ZC\+'Q$_X_-._Z^/\ V>*CXR_\>:?]?"_^@24 =Y1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+R[G,45T_P#PK^?^]'^;?_$T?\*_G_O1_FW_ ,33]I'N;?VEA?YT<Q173_\
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M!Z#T[C/K0^IJG&#T'IW&?6@!^TT;33'U-4XP>@].XSZT-J:K@X/(]O7'K[4
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M;33$U-7(4 \GV_QIO]JKZ']/\: )=IHVFF/J:H2I!X/M_C0^IJA*D'@^W^-
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MKCU]J#J:@;L'DGT[8]_>@!^TT;33#J:@;L'DGT[8]_>@ZFH&[!Y)].V/?WH
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M;-J"Q$J0<CTQ_C2/J:IQ@]!Z=QGUH ?M-&TTQ]35.,'H/3N,^M++J"QXR#R
M>W?\: ';31M-,;4U7!P>1[>N/7VH;4U7!P>1[>N/7VH ?M-&TTU]050&P<-G
MT[?C2'4U W8/)/IVQ[^] #]IHVFF'4U W8/)/IVQ[^]+_:"[=^#C..WIGUH
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M>@].XSZT/J:IQ@]!Z=QGUH ?M-&TTV74%CQD'D ]N_XTC:FJX.#R/;UQZ^U
M#]IJ2(8J!M35<'!Y'MZX]?:K$,HE 8=#ZT /HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ.7
MI45 %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU%
M%FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJ
MU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %
MFBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU
M% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %F
MBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU%
M %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FB
MJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU%
M%FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJ
MU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %
MFBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU
M% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %F
MBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU%
M %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FB
MJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU%
M%FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJ
MU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %
MFBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU20T 2T444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHK(\2:G)8+'Y(4O+,D8WYV_,#SP0>H_\
MK4 :]%<Y/<ZC;*92L#A>2L?F;R.X&>,X^OL">*V=,U%-2C6XCSM<<9&#P<$?
M@1CT].* +5%%% !1110 4444 %%%% !1110 450U[5?[)A:YV[MFWC.,Y8+U
MP?7TJW<;MK>7C?@[=V=N<<9QSC/6@"2BH[?=M7S,;\#=MSMSCG&><9Z5)0 4
M444 %%4M9U0:9&92"QR JCJS,<!1_P#6R<9.#63/>:C"IF\N$J.?+4N9,=US
M]TL!Z=3T!X% '1T55TS44U*-;B/.UQQD8/!P1^!&/3TXJU0 45F>)=3;2[=[
MA "R;<!LD<L!V(]:TZ "BBB@ HHHH **** "BBB@ HHHH **S/#6IMJENEPX
M 9]V0N0.&([D^E:= !17/7GB1H+M;4;?*RBNQ!W!Y Q11SWP.<$#N170T %%
M%% !1110 4444 %%%% !1169H>IM?^=O 'E3R1C&>BXP3DGGG_ZU &G15>P\
MS8//V^9SGR\[>IQC=STQ^-6* "BBB@ HHHH **S-<U-K#R=@!\V>.,YST;.2
M,$<\?_6K3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3%:P2)(?XYT"(HZ%N2<D>F/?!Q@@$FIA=2@CNI9#%!L#R*#]X,HPI88..<8
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M/R@# ]ZI65Y)/8W$<QW20">,MG.[8IYZ#UQSR<9/)J>'Q#/;CR);>1IEPNY
M#&YP,-OPH4$]>/E'7N V/3GLK*X,N!+,LTC@'(#.IX'T '<\YY(H 9I'A6*^
MMXGN=TI,:D99E"@JN%"J0!@ 9/4GD^U>+6Y=&CNHG)D:U9-C.V25E/R@G )V
M]3Z]!@ &G:'KTMA#'%-#(X\M"CPKO!4C(!'RX*C [DXSZ$S+X>DU&*Y:<!);
MHKA0P(41_P"KR0#U(^;&<CH >* ,G[1IDO[R65FG/)EQ*K;NS  ;1C^$8P
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MR1D#H. <=P>:9I.B->::+-P4=@_# J01(67.1G&<9XZ=*>/$=S#&(3;R&Y
MSM!B+''S%U.,=ST Z9'6@!FLZQ)IT<-O<N$:7>))8P3@)_=&.&;(&<?*<D#I
MC&N[K3[5#)92-%.HRI7S3NQSL(;@@D=^,XSD9!Z"]TRY18+G(FN+<MN'"*PD
M&& X R!C!XZ$D$\43Z_/?*8K6"1)#_'.@1%'0MR3DCTQ[X.,$ DU,+J4$=U+
M(8H-@>10?O!E&%+#!QSC 'S9QC.*YF^O[#3T\^Q8K.I4@ R@, PRK;N"I')&
M1T'-=!XBLY%^SRLIG2$GS4"C+%E"A_+Y!P<G';/89(I>)=2FUBW>*&"11\I;
MS4*L?F& BC))SR3T ![D4 :?BW_EV_Z_(?\ V:M^L3Q1;M-]GV*3MNHB< G
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M8'O01LC;:02=V3MZ<8_B'>CW3-?5W%2LK/;3N,_MN?\ YZR?]]M_C1_;<_\
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MH^'I]-423)M4G&=RGG!/8GTH]T<9865K.+OML1?VW/\ \]9/^^V_QH_MN?\
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MSS0!8HHJN^H1I(+<NHD89"%@'(YY"YR1P?R- %BBBB@ HHHH **** "BBB@
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M3R/LG_/5?+W^;]=N[;^./:NJLM0COAOA=74'&48,,]<9!//-<K_PBL/]I?\
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M0%&3\Q(.%R>U5[[7+W1LW-VD)MMZ@^4TF]%9@ YW+\P&<$* 22",#-/\0?\
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M_P!=Y?3=GI[]?RKI9=9ABA-X9%\E03O!#+P<<$9R<\8')/ YKSO_ )E[_/\
MS\T =#?ZYJ,,;7ZQ1"!1O\N0L+C8.N?X V,MCDKTP6&"_P#MO4-43[5911K"
M5RBW.X2OQG("G: >BY/.-V0"*V?%7_'G<?\ 7O+_ .@&CPK_ ,>=O_U[Q?\
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MK"/RA^]A*KCC/R@*1N.,9!#?ACK4'@_0GL6-]<+L2-&(W9#9Z$[1SP,]1W&
M:6G*^YSN5)8:M&7QW>G6]]+?UW(O#FH#3+F33V^:&21D^;GD$J.,8.[@'CT[
M"K7B<KH%O]BAR#,[,3AL;<],D]<;5/7(R2!D9B\/1JC2ZW,-J!G*J,DY8]0>
M >NT=LYSC%6O,'C"V((Q<0DG &!DYP 23PP&#R,$9/ &4_BOTZBJM+$*;3Y$
MXJ;Z<W3[M+E#PF/[0M[BS(!;8"@SACU(&<_=#8/H"QSUKD:ZSX?+Y3RW+'"1
MQ?-USR=V< =@IKDZTC\3/0P^F(K);>Z_FUK^2"BBBJ.T**** "BBB@ HHHH
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MQ?YG]BP>7]WR[?S.GW=@QU_V]O3G\,T 6)_B_%'(0(9#"IVNX*'#'=@ *2K
M[>#O&1DC..>ML/$$-[;K?*2(V'&0=V<[=NT9);=\H SD\+G(SPNE^'=5-ND4
M,\'V=HQM78-I5AGD-!DY!YSR<G/.:Q)[9K'1V6*19$DN@7,08@+M'#;U4J=Z
MKV'5><-R =*WQCA+!EAD,(P&?Y0P8AB!MR0<X[L#UXXYF^#7_'F__7PW_H$=
M=1I=O;V]HB)C[,(1RX 4H5R68$ ?,#EL@=3FN9^#\1AM948$,MRX((P00B @
M@]"* -GQ_?R6%C--$Q5P% 8=1N=5./0X)YZCJ.:X_P ._#*TU:T642EI7526
M0J51BN=A49Z;AN!.XX&"N2*[KQ1KT.BPF6Y!9&.S:%#;MP.1@X&, YR0,#UP
M#R\OPAL[H&2&20!P2A#*Z#=RN/ER5_X%DCOWH 9H-_J'AJT\N>V>9DD58PKA
MFV%6./D#G"%0!G^\ ,!0*R?AKXGG@'D""259KG+S L0I?8&+':<D?>.6'7GU
MK4^'&H36=S/H\KF1802C%@<!"$P.6P""/EW?(01C)-6/@U_QYO\ ]?#?^@1T
M ,O/BY&Q*VD$DP0,6/W %7'S\!SM]2P7'&>O&SH/CF/7();B%&,D"9:(]2=I
M("D Y!(('&>.5'&>7TW5[[624TJ**WMM^0X5!V(PP&X;C@$@)N VY.TAC%\/
M1(NJ7 F97D$3AVC7:I8/&&XVISGJ<<G)YSD@%*S\87*ZC+=_9I&D,(3R<MN1
M?D.?N$@$C/W0,MGZ]KK?Q#AT6-&F5A/)$K^4 <C<#PS$  !AM/\ $.NVL[1_
M^0Y=?]>Z_P H:Q=1L;F[UB?[$Z)*D:MND ( V1J<95\'GKCID9YP0#IO#_Q+
MAU.06DJ-#.21M?&W<#C9NX.X^A4<_+UQEOBWXF1:!(;54,DJ[=PSL4;AG[V"
M2<8/ Q@]<C%<MKFC7L-Q;SWMQ;>:K9C+Y13Y9#$,RQ*,9Z D=3MY)K4OK2X_
MM"XO],>.61%1)(FR",@+MR<*<;-Q(<$$%2.,$ ZGPEXQB\2HS1@J\>W>K=MP
MXP1P1D$#H>.0.*Y%="AT76;:&W78AA9B-S-R5E&<L2>@%7?"7B,_;7L;NWBA
MNF#'?$H!;(5]I(W9)&6)+8X QFGZQ_R'+7_KW;^4U '>4444 %%%% !1110
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M?4UT-% %73=+BTQ!# @1!V48SP!DGJ3@#).2>YJU110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %<QH5A'K9?4IE#^:2(U<;@J*<#Y3D!B02<$
MCTQDUT]8'@S_ $>$V;?ZRW=E8?5BP8=]I!X) SS0 V70VTZX2YM% 1SMF12%
M7'\+A<8^7J<<GH!RQH3Q-+>_O+6W:2+) =G6/)!P<!LDCWXYR, BM#4=9%K)
M%;* TDK?=W8(4 EGZ'ICIQGG'2LFSFNM='VJ&40PMD(OEK(QVD@EMW0G'0$C
M'TR0#8TG5AJ 92I22,A71B,@X!SP>5/8\9QD5FP^*FN6EAAA9Y8I&7 8!<*0
M Q=L ;N< 9/![<U!X45DN;M7D$C P@N %R0K#&!P,=#[CUJSX2_Y>?\ K\F_
M]EH N:5K1NV:"5#%,@!*L0P()."I'WAZG'!.*AOO$#)(UM;Q-+)&%+\A%4,,
MCYF[].,=,\\$5#_S$O\ MS_]JU'X3"I)=(1B3[2Y.1@[6Y3G'(/)'USWY +V
MBZ^-0+0NICGC/S1L<G'9@>,@\<C^1!->3Q!+.2;6 S1@D;_,5 2.NW/4#INZ
M$YQTS3M:GBG$]NF&N?LS\*N7VD<+D#N2/ESGD'%9VB:==3P1/'=@(8UP!"C8
MP,;<YYQT/?(YH W](U=-40R(&&UBK*XPP8=01_G\\BLG2/%;ZL$:&$D$XD.\
M!4YQP2!O.WYB .,@=33O#5N(IK@F832DQA\)LP5# #@D'C@XZ$<\T[P)_P >
M47_ _P#T-J "7Q)+-(\5K 95B.UF+B,;AU4;ASCO_A@G0T36%U6/S0"K*2KJ
MPY5AU7_/XX.0,:ST[[87NK"Y*1RL2R[ XW_Q'#X*YZXQZ=L :.A:G)</+;SA
M?-A*Y,>=A#KD?>.<]<].U &O1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %<S\0/]0O_ %U'_H+5TU8_
MBC1WU:(11D AP?F) P 1V!]:J#M)'3@9QAB(2;LDSS*.0QD,IP0<@C@@CO3I
MYVG)=R68]2Q)/IU-='_PK^?^]'^;?_$T?\*_G_O1_FW_ ,371SQ[GT_]HX6]
M^='-1R&,AE."#D$<$$=Z=/.TY+N2S'J6))].IKH_^%?S_P!Z/\V_^)H_X5_/
M_>C_ #;_ .)HYX]P_M'"WOSHY^6^DF82,[%UQABQ)&#D8).1@UH77BRZNE,3
MR95A@@*HX],@ _X]*T/^%?S_ -Z/\V_^)H_X5_/_ 'H_S;_XFES0(EB\#*UW
M%VVTV]#!;4I682EV+@8#%CN YX!SGN:T)_%]W,"AE.#_ '0JG\U /ZU>_P"%
M?S_WH_S;_P")H_X5_/\ WH_S;_XFCF@$L5@96NXNVVAS]G?/9-YD3%6'<'WS
M@^HXZ'BK>H>(KC4!LE<E?084'H>0H&>G&>G:M7_A7\_]Z/\ -O\ XFC_ (5_
M/_>C_-O_ (FCF@-XS!2DI-QNNO4YBK<&K30 (DCJHZ!78#UZ UN?\*_G_O1_
MFW_Q-'_"OY_[T?YM_P#$T^>)4L?A)*SDF8W]NW'_ #UD_P"_C?XTR+5IH<[9
M'&XDG#L,D]2<'DGUK<_X5_/_ 'H_S;_XFC_A7\_]Z/\ -O\ XFES0)^N8+O$
MR[WQ!/J>(YI/E)YXPO4<D(.<8ST..U:'BC6(I4BL[8YBC&2<8RW(Y!4<]22.
M"6]JD_X5_/\ WH_S;_XFC_A7\_\ >C_-O_B:5X&?M\#S1:DDHW:2VN^NQS4<
MAC(93@@Y!'!!'>KG]NW'_/63_OXW^-;/_"OY_P"]'^;?_$T?\*_G_O1_FW_Q
M-/GB:RQV#EO*+,.?5IIP4>1V4]0SL1Z]":J5T_\ PK^?^]'^;?\ Q-'_  K^
M?^]'^;?_ !-/GB../PD5922(=7UA-5MHM[?OX2000?F!P,YP<G@9R1_%QTK,
MT[6YM-SY+E0>W!';G!R,\=>M;/\ PK^?^]'^;?\ Q-'_  K^?^]'^;?_ !-)
M2@E8RAB<%&#AS)QNW9^?R,/4-5EU$[YF+$=,]!TZ <#IS@<TZ/69XP%65P ,
M !V  ';K6U_PK^?^]'^;?_$T?\*_G_O1_FW_ ,31SP+^NX*RCS1LNAASZM-.
M"CR.RGJ&=B/7H345S=O='=(Q8@8RQ)./3FNA_P"%?S_WH_S;_P")H_X5_/\
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MZ?\ Q5'_  AUW_SS_P#'T_\ BJ.:/</KF'_GC]Z,6BMK_A#KO_GG_P"/I_\
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MT:HS%'C)*L!G&<;@5R,@X'<$$#G&0=*ZT"VNV,LD,;N<99HU9C@8')&>E7Z
M//9_A;->X2XO9)(PP)5@QZ>FZ1@#@D X.,]#6_XH\&+K5M'8HWE)$RE?E+\(
MI4+RP/0]<]JZ.B@"KJMC]OADM\X\V-TSC.-RD9QQG&:P?^$(_P")=_8_F?\
M;39_TU\S[N[\.OO[5U%% &'>^%Q>6(TMG.!%&F\#O'MP<9/&5&1GIQGO6#8_
M#62/$4UW)+!L93$00N"I5< NR@H<,ORG! Q7=44 >>GX6S1J8([V183N CPQ
M7:Q.00) #G// !YXKH;7P-;6UH^F#<8Y"2Q+?.6X(;( &1M&.,<<@\YZ&B@#
MSVU^%LT 6+[;)Y2L#L0,HX;=Q^\(!SR#@X/.*Z3P9X6_X1J%K??YFZ0OG;MZ
MJHQC+?W:WJ* *&N:'%K41MIQE3T(^\I[,#V(_P#K'()%<?'\,I[4>7!?2I&"
M=J@-P"2<?+(HSZD 9/.*[^B@#GO!O@V/PS&R*Q=Y""S$8SC.T!<G &3W)))Y
MQ@#!/PK:UD=[.ZD@1R#M4-QCH"P=<@9.,C('<G)/?T4 < GPNDLR5M;R6*,G
M.T9ZX ))5T!/'H.,#M5_PC\/!X;F-RLI<-%LVE,<DJ2<YZ94X&. <9.,GL**
M .-\1_#LZI<_;X9S!(5 )526) *[MP=<?+@8'I[FHKKX:&98Y%N'6ZCW!IP#
MN<$G&?GSD [0=WW>#D8QV]% '$:7\-##<)>75P\[18*A@0<J<K\Q=C@'G''/
M7C()JGPT,UP]Y:W#P-+DL%!)RQRWS!U."><<\]., =O10!RGAGP$-(F-[-*T
M\Y!&YQT! &>2S;L#&=WW3C%<\NNPZUK-M-;MO00LI.UEY"RG&& /0BO3*H6N
M@6UHPECAC1QG#+&JL,C!Y STH OT444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *DAJ.I(: ):*** "BBB@ HHHH **** "BBB@ HHHH ****
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MU"DDI(RHQGG_ #FF^;-_='^?QH L>31Y-0O)*"<*,9X_SFAY)03A1C/'^<T
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MFH5DEYRHZ<?G]?2A9)><J.G'Y_7TH F\FCR:A627G*CIQ^?U]*$DE/51T/\
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MDEXPHZ<_G]?2AI)>,*.G/Y_7TH F\FCR:A,DN/NC.3_3'>@R2X^Z,Y/],=Z
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M?W1_G\: +'DT>34+R2@G"C&>/\YH>24$X48SQ_G- $WDT>34+R2@G"C&>/\
M.:'DE'11T'\N>_K0!-Y-'DU"\DHZ*.@_ESW]:'DE'11T'\N>_K0!-Y-'DU"T
MDO&%'3G\_KZ4-)+QA1TY_/Z^E $WDT>34+22\84=.?S^OI09)<?=&<G^F.]
M$WDT>34)DEQ]T9R?Z8[T&27'W1G)_ICO0!-Y-'DU"))<?=&<C^N>] DEQ]T9
MR/ZY[T 3>31Y-1))(020,\8_KWI%DEYRHZ<?G]?2@";R:/)J%9)><J.G'Y_7
MTI8I)#G<!T./KV[T 2^31Y-0I)*>JCH?Y<=_6A))3U4=#_+COZT 3>31Y-10
MR2$@, ![?_KI$DE)&5&,\_YS0!-Y-'DU"DDI(RHQGG_.:$DE)&5&,\_YS0!-
MY-'DU"\DH)PHQGC_ #FAY)03A1C/'^<T 3>31Y-0O)*"<*,9X_SFEFDD!(4
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MEDD&-H'09^O?O0!+Y-'DU"TDO&%'3G\_KZ4-)+QA1TY_/Z^E $WDT>343R2
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#=%/.,\G.3C  !@Z3J^IW,/EVMG$+7!"JX(RC#/.^1=X(/+8PQR?6M+X-?\
M'F__ %\-_P"@1U2A^'VH",:>;I5M 7QL!#D-NZ@!<AL\J7(Y[X%='X \,R>'
M8&MYBI9I2WR$D8*J.X'/% &3\&O^/-_^OAO_ $".LK0M:NF!_LBT00#C,DF]
MOO-@9:0;>YV<[2V[HX)M)\/;W1IGETV=$CDS\KYX&XD+@K(#M'1CSUZ9.1/A
M_?Z/OAT^Y ADR2'R&&<C@A6P<8^9=I)[# H I_#TR-JEP9E5)#$Y=8VW*&+Q
MEN=S\YZC/!R.,8'J=<+X)^'TGANY><NKQM$5! *ODE#RO( X/\1[?AW5 !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !16%J.M323?8[159T ,C2;O+4$94<<DGV_7G;':Z]/:S+:WB(IE)V21
MM\A( .,,<]3C/<X '>@#H:*** "BJ6LZH-,C,I!8Y 51U9F. H_^MDXR<&LF
M>\U&%3-Y<)4<^6I<R8[KG[I8#TZGH#P* .CHJKIFHIJ4:W$>=KCC(P>#@C\"
M,>GIQ5J@ HHHH **KVGF?-YNW[YV;,_<_ASG^+UQQ4&D:K_:'F_+M\J9X^N<
M[,<]!C.>GZT 7Z*S+#4VN+B>W(&V'RMI&<G>I)SS^72M.@ HHK,_M-OM?V/
MV>1YF>=V=^W'7&,>WXT :=%%<]-K5Q?2O#9*FV$E7>;<%+#^%=O/'?\ H,%@
M#H:*PM*UZ1IOL-TBI+M+*58%7 8C@$Y' SCDX!) Z52U;4]0TN)KAQ;E4QD+
MYA/) [D>M '545D6'VW>//\ (\OG/E^9NZ'&-W'7'X5)XBU-M/BW1@&5W1$#
M9P68].",<9ZD"@#3HJEHFH_VE!'<<9=1G (&X<,.>>""*-4UF/3 #(3ESA54
M%F8^@ _+TR1D\T 7:*SO#VJ'58%N6 4N6X'8!B!S]!S[]A6C0 4444 %%%%
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MAIFR::N@HK:L=%0VTE[,2 #MC (&YOQ'(SZ'/#>E:FE^&+:2U6]G=U!SG;C
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M'+TJ*I9>E14 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>?,559G7&T8R2  2<]#R." :Z6@ HHHH **** "BBB@ HHHH **** "BBB@
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M7T%W;L"IEN92I8$9Y4J>0?E)'4=LXH GM_!,+*KS;FN,#,OF/NW =0<C[O\
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M( R =KX0?4$,D6H , <I(OEX..",*0<'@KE0>N3T%9.L?\ARU_Z]V_E-6'X
MN!;ZBUK8NTEGL).\D?PKE]IV#=OPN=N=OMS6YK'_ "'+7_KW;^4U '>4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!0U?2O[0\KYMOE3))TSG9GCJ,9SU_2K]%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_37_ ,A__94?\*Y_Z:_^0_\ [*CVL0_M?"?S?@_\CBZ*[3_A7/\ TU_\A_\
MV5'_  KG_IK_ .0__LJ/:Q#^U\)_-^#_ ,CBZ*[3_A7/_37_ ,A__94?\*Y_
MZ:_^0_\ [*CVL0_M?"?S?@_\CBZ*[3_A7/\ TU_\A_\ V5'_  KG_IK_ .0_
M_LJ/:Q#^U\)_-^#_ ,CBZ*[3_A7/_37_ ,A__94?\*Y_Z:_^0_\ [*CVL0_M
M?"?S?@_\C TW7S9Q26K*&CE!X/\ "Q& W0YQ@<>H!!'?*KM/^%<_]-?_ "'_
M /94?\*Y_P"FO_D/_P"RH]I!$QS/ P;:EJ]]'_D<717:?\*Y_P"FO_D/_P"R
MH_X5S_TU_P#(?_V5'M8E?VOA/YOP?^1Q=%=I_P *Y_Z:_P#D/_[*C_A7/_37
M_P A_P#V5'M8A_:^$_F_!_Y'%T5VG_"N?^FO_D/_ .RH_P"%<_\ 37_R'_\
M94>UB']KX3^;\'_D<717:?\ "N?^FO\ Y#_^RH_X5S_TU_\ (?\ ]E1[6(?V
MOA/YOP?^1Q=%=I_PKG_IK_Y#_P#LJ/\ A7/_ $U_\A__ &5'M8A_:^$_F_!_
MY'%T5VG_  KG_IK_ .0__LJ/^%<_]-?_ "'_ /94>UB']KX3^;\'_D<717:?
M\*Y_Z:_^0_\ [*C_ (5S_P!-?_(?_P!E1[6(?VOA/YOP?^1Q=%=I_P *Y_Z:
M_P#D/_[*C_A7/_37_P A_P#V5'M8A_:^$_F_!_Y'+:7>"RD65EW!<\9V]00"
M".00>01R".,4W4;]M0D:>3[S'G P.!@#\!Q_.NK_ .%<_P#37_R'_P#94?\
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M4 %%%% !4D-1U)#0!+1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% $<O2HJEEZ5%0 4444 %%%%
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M""!P15JRT^.Q&R%%12<X10HSTS@ <\58HH *R_\ A%;/_GWA_P"_2?X5J44
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MX4 1>4:/*-2[A1N% $7E&CRC4NX4;A0!%Y1H\HU+N%&X4 1>4:/*-2[A1N%
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M% $7E&CRC4NX4;A0!%Y1H\HU+N%&X4 1>4:/*-2[A1N% $7E&@Q&I=PI"X%
M$7EFCRS3_-%'FB@!GEFCRS3_ #11YHH 9Y9H\LT_S11YHH 9Y9H\LT_S11YH
MH 9Y9H\LT_S11YHH 9Y9H\LT_P T4>:* &>6:/+-/\T4>:* &>6:/+-/\T4>
M:* &>6:/+-/\T4>:* &>6:/+-/\ -%'FB@!GEFCRS3_-%'FB@!GEFCRS3_-%
M'FB@!GEFCRS3_-%'FB@!GEFCRS3_ #11YHH 9Y9H\LT_S11YHH 9Y9H\LT_S
M11YHH 9Y9H\LT_S11YHH 9Y9H\LT_P T4>:* &>6:/+-/\T4>:* &>6:/+-/
M\T4>:* &>6:/+-/\T4>:* &>6:/+-/\ -%'FB@!GEFCRS3_-%'FB@!GEFCRS
M3_-%'FB@!GEFCRS3_-%'FB@!GEFCRS3_ #11YHH 9Y9H\LT_S11YHH 9Y9H\
MLT_S11YHH 9Y9H\LT_S11YHH 9Y9H\LT_P T4>:* &>6:/+-/\T4>:* &>6:
M/+-/\T4>:* &>6:/+-/\T4>:* &>6:/+-/\ -%'FB@!GEFCRS3_-%'FB@!HB
M-'E&GB0&G;A0!%Y1H\HU+N%&X4 1>4:/*-2[A1N% $7E&CRC4NX4;A0!%Y1H
M\HU+N%&X4 1>4:/*-2[A1N% $7E&CRC4NX4;A0!%Y1H\HU+N%&X4 1>4:/*-
M2[A1N% $7E&CRC4NX4;A0!%Y1H\HU+N%&X4 1>4:/*-2[A1N% $7E&CRC4NX
M4;A0!%Y1H\HU+N%&X4 1>4:/*-2[A1N% $7E&CRC4NX4;A0!%Y1H\HU+N%&X
M4 1>4:/*-2[A1N% $7E&CRC4NX4;A0!%Y1H\HU+N%&X4 1>4:/*-2[A1N% $
M7E&CRC4NX4;A0!%Y1H\HU+N%&X4 1>4:/*-2[A1N% $7E&CRC4NX4;A0!%Y1
MH\HU+N%&X4 1>4:/*-2[A1N% $7E&CRC4NX4;A0!%Y1H\HU+N%&X4 1>4:/*
M-2[A1N% $7E&CRC4NX4;A0!%Y1H\HU+N%&X4 1>4:/*-2[A1N% $7E&CRC4N
MX4;A0!%Y1H\HU+N%&X4 1>4:/*-2[A1N% $7E&CRC4NX4;A0!%Y1H\HU+N%&
MX4 1>4:/*-2[A1N% $7E&CRC4NX4;A0!%Y1I\:;:=N% .: %HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@".7I452R]*BH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *DAJ.I(: ):*** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH CEZ5%4LO2HJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$JL_^?B'_OZG^-<?;W!MM8O954NR6NX*.K$)"0HP#R>G0_2MS_A66G?\\?\
MR)+_ /%ULPZ%##.U\JXFD7:S;FY V\8SC^$=!VH \IM-.TK7DENF<VL@W$Q[
MU*#@D% 5!8'&=JX(/R@ ;<Z7ASQ==M87<R;F\@KY32 R. ['>"V &*+\V2.,
M\C;@#LK_ , 6-_(T\D(+N<L0SKD^N%8#)[\<GD\ULQZ?'%']G5%$>"-@4!,-
MG(VXQ@Y.?6@#QVUT/33;B]N[IWEDRQ6,CS-Q&2I5@S$[@?G.U3P>,Y/7?!K_
M (\W_P"OAO\ T".MN/X?V$<GGB!=V2<$L4YSGY"2N.>!C [8P*TM&T*'14,-
MNNQ"Q8C<S<D 9RQ)Z 4 <%\*M<ATV&6TN'$4B3$D2LJ=5"X^8@Y!0Y&.,BL'
M1+>T\1K)=ZE<NLJ=BZ@D99LJ"IXYP$4'!!/\0 ],U+P)9:DYFEA!<]2I9,Y)
M))"$ DD\D\GUIE_X L;^1IY(07<Y8AG7)]<*P&3WXY/)YH X7X6QI'J$HB5U
MC^SDJ)<;]I:,@G  ^8'(QQ@CD]3ZW67I_A>VTZ5KJ&,)(Z[25R%QQQM!VCH.
M@_F:U* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **JZGID>J1M;S+NC?&1DC."".00>HK@M8\"V=O>6=ND6(YO/WC
M>YSL0%>2V1@^F/>@#T>BLO1/#%OH>[[,FSS,;OF9L[<X^\3ZFN,\"^!;/5+.
M*XFBW2/OR=[C.'8#@,!T% 'H]%<?X=MSH5Z^E1L3;-!YR*W)C)DVE0V>5/)Y
M]N^XMAZ))_8TUSJI8^5]MFBF7J I8%) ,CE7;!X8[6.!UR >F45R_CO_ )<_
M^O\ @_\ 9JZB@ HJAK.MQZ0@EES\S!55%+,S$$A0!W..,X&>]</XZ\8QWMG+
M;O'-#(^S8)XBF_:ZEL$9'R@<YQU&,T >CT57O[^/3XVGE8*B#))_SR3T ')/
M YK!B\?0@@3QS6ZL0 ]Q$40L>B[@3@]3S@8!)- '3450N-92WGCLW!#3*Q0X
M!4E.67@Y! YY &.ASQ1K.LII2J[@L9)%C15 W,SG@<D =SDD#CKF@"_161K7
MB6/2BL6V261AGRX$WN%'&\C(PN>,GJ>F<'!HOB>'5BT2[DF09:*52DB@]"0>
MH/!X)P",XS0!KT5R_A__ )"-_P#]NO\ Z*-3W_C:&WD:"))9WC.'%O&9-A[
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MQ0!?HK,O?$45E*+:0D,4##C.<MM"@#+%L]@.G-1V'B9+IQ"R21.^=HEC*[L
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MQP>/U-'-<I8R,U%QZRY7=.^ST.?HKKG\-6NG +>2,LASPASD#C. C$#/3)Y
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M1AT^\F5UD1F(15QC:^.=BG.5H ]$HHHH **** "BBB@ HHHH **** "BBB@
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MQ+*=S*4$@W'JPW'C/?\ PP!)IGAK[%.;LR%W:/:Y8<LQ8$MUP!@ !0,  <T
M0M&'U($@$K:9&1T/F$9'X$CZ&G>+?^7;_K\A_P#9JT/[*_TG[;N_Y8^7MQ_M
M;LYS^&,?C1J^E?VAY7S;?*F23IG.S/'48SGK^E &7I95]0N2QRZI$%!/12H+
M8&>F[!/H3[\ZUQ:0--'*^WS@&"$G#$8^8 9^; /OC.>,U7U30OM3BYBD:*95
MVA@ P*DYP5/![XZ<\\X%1Z7X=^SR&[G<S3$8#%0H5<= HR!GG)_Q.0#"\*?;
M6MU>'R-KER3)YF\G<02Q'4\=?3%:>DVDZ7;33M"&>$ I"6!.&&'*MUQRN?PJ
M:;PY)$[R6LS1>:Q9U*K(NX]P&Z9[]<\=  *M:3H*Z>S3$F2:3&^1L9/3@ ?=
M7C@?09.!@ H^$8P#=-@9-W*"<<X&,#/MD_F:Z&J&D:5_9_F_-N\V9Y.F,;\<
M=3G&.OZ5?H H>(/^/:;_ *XR?^@FCP__ ,>T/_7&/_T$5/J%K]LC>'./,1ES
MC.-P(SBC3[7['&D.<^6BKG&,[0!G% '.ZGIWV_4 F]X\6N<Q-M;_ %A&,X/'
M/\J=J6A2:8ANX9G=X06_TC;(-H!W $KN7(Z[2,]#V(NZGH,MQ.+N&;RF\O8?
MW8?(W%NY_IVJO-X8FO<)<W!DBR"R"-8]V.@+*<XS_D'! !'XKNOMFG--C'F)
M$V,YQN9#C-=/6=K6C#48&LU(0$*!A<@!2"!C(],5GR:'>2 J;LX((X@0'GW!
M!'U'- #;.87FHR.G*PP"-CD8W%]V.OU!]""#[]'573M.33T\M,]222<LS'JS
M'N3W/]*M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7,_$#_4+_P!=
M1_Z"U=-7,_$#_4+_ -=1_P"@M54_B1UY;_O5/U,CX<_\?#?]<F_]"6F:MXON
MH)I(UDPJR. -J= Q ZK6'IVJ2::QDA;:Q&,X!XR#W!]*@GG,[&1CEF))/N3D
M]*Z.2\KGTKP49XB5223322OJ;OA2Z:[ODED.YF+DD_[C?Y]J+:81:B21N'VA
MA@^K,0#WZ$Y_"L6RO7L7$T9PZYP< ]1@\'(Z&F3SF=C(QRS$DGW)R>E'+K\B
MI87FJ2>T7#E_/_,[;Q3>R6DY'V>-U<J%=HMQ8D8QD'KD$ =<"I8II1<6C3^4
MJ$2;!$3@90 #DD=P!M)'IVK!LO'=S;#:2'& !O&2,>X()SWSFLF\U66\?SY&
M)<8P>F,=,8QCUX[\]:E0>QQT\!4LH244DFKJ[;NK?+S-;4=&D-\T0.TM+N#C
MC =LALG'0G'7EOE!SBMKPW9M9W\L3N9&6+EFSDY\L]R>F<=:Q5\>704IN!)/
MWBHW#IP,?+^8/7Z8R['6);%S-&V'8$$D!B<G)^\#W%'+)JQI+#8FK3E"7*O=
MY5YO36]KKT-W3_\ D&3_ /74?SCHU#_D&0?]=3_.2L"/5)(XFM0W[MSDC Y/
M'?&>P[T2:I))$MJ6_=H<@8'!Y[XSW/>GRO\ $T^J3YKW7\3F^5K?>;^G_P#(
M,G_ZZC^<=65N1:V-K*W1+@,<=<!I#7+QZI)'$UJ&_=N<D8')X[XSV'>B35))
M(EM2W[M#D# X//?&>Y[T<GYBE@I2;VLY\WRY;?>=-\0[%WFCD5259 @(&?FW
M,=O'?GCU[=#4^D^'-\T27$GFHL1=5W9 PRJ.,D%".5Z9Q@@8(K%TOQI<:>OE
M AE   <$X [ @@_GG& !BJ?_  D5QYOVK>?,QC/&,>F,8QWQCKSUYI<LK6,H
MX7%*E[)-)132??MTT\SL-$UB6>X-M#"L4*G+9C*L!CC(!4;FQQP<#U J33_^
M0G/_ -<A_*.N:O?'=S<X (3!S\@ZX((SN)]/QY!R*H1^(9XY6N@_[QQ@G:O(
MX[8QV':E[-ZF2RVK+G=HQO'EM=O6ZU;MY&;1116I[04444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !5K3=-?47$,8R3^0'<D^G_ZAS45K:M=,(D&6
M8X '^?\ ]5>F^'=#&D1[,Y=CEB!W]!WP.V?<\9Q43GRHX,QQ\<+#363V7ZEK
M2M-738UA3L.3C&3W/?K^G3H*MT45S-W/DYS<Y.3U;"BBB@D**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "I(:CJ2&@"6BBB@ HHHH **** "BBB@
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MQD'J 6) . 2 2V'PILTA6.9"9MF&=7;[Q') X7 /W<KT R#S4'P:_P"/-_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *B@M4M\[%"[V+-M &6/5CCJ3W/6I:* "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L+QAILFH
MPK'$-S"0'&0.-K#N1ZUNT4T[.YI0K2HU%-;H\R_X0Z[_ .>?_CZ?_%4?\(==
M_P#//_Q]/_BJ]-HK3VTCT_[>Q':/W/\ S/,O^$.N_P#GG_X^G_Q5'_"'7?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+_\ Q='_  MFZ_N1?]\O_P#%T?V;7\OO#V$SU7RA1Y0KRK_A;-U_<B_[Y?\
M^+H_X6S=?W(O^^7_ /BZ/[-K^7WA["9ZKY0H\H5Y5_PMFZ_N1?\ ?+__ !='
M_"V;K^Y%_P!\O_\ %T?V;7\OO#V$SU7RA1Y0KRK_ (6S=?W(O^^7_P#BZ/\
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M%_WR_P#\71_9M?R^\/83/5?*%'E"O*O^%LW7]R+_ +Y?_P"+H_X6S=?W(O\
MOE__ (NC^S:_E]X>PF>J^4*/*%>5?\+9NO[D7_?+_P#Q='_"V;K^Y%_WR_\
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M_OE__BZ/^%LW7]R+_OE__BZ/[-K^7WA["9ZKY0H\H5Y5_P +9NO[D7_?+_\
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M /Q=']FU_+[P]A,]5\H4>4*\J_X6S=?W(O\ OE__ (NC_A;-U_<B_P"^7_\
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M[Y?_ .+H_LVOY?>'L)GJOE"CRA7E7_"V;K^Y%_WR_P#\71_PMFZ_N1?]\O\
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M+H_X6S=?W(O^^7_^+H_LVOY?>'L)GJOE"CRA7E7_  MFZ_N1?]\O_P#%T?\
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M+_OE_P#XNC^S:_E]X>PF>J^4*/*%>5?\+9NO[D7_ 'R__P 71_PMFZ_N1?\
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M_"V;K^Y%_P!\O_\ %T?\+9NO[D7_ 'R__P 71_9M?R^\/83/5?*%'E"O*O\
MA;-U_<B_[Y?_ .+H_P"%LW7]R+_OE_\ XNC^S:_E]X>PF>J^4*/*%>5?\+9N
MO[D7_?+_ /Q='_"V;K^Y%_WR_P#\71_9M?R^\/83/5?*%'E"O*O^%LW7]R+_
M +Y?_P"+H_X6S=?W(O\ OE__ (NC^S:_E]X>PF>J^4*<J;:\H_X6S=?W(O\
MOE__ (NNL\!^+9?$'F^<$'E[,; 1][=G.6/I45<#5I1<G:R%*E**N=;1117*
M9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 <3\6?^/5/^NZ_P#H#UY-7K/Q9_X]4_Z[K_Z ]>35[F6_
MP/FSKH? %%%%=IJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M))R3QQUIUW?27AWRNSL!C+L6./3)SQS4%:8>A&E!*ROU94(**.V^$W_'T_\
MUP;_ -#2K>K_ !.N;.:6!4C*QR.HRK9PK$#/SCGBN9\)>)/^$?E:?9OW(5QN
MV]2ISG!]*S=2O/MLLD^,>8[-C.<;B3C/&<9K*6&4Z\I25U96)=.\VWL;=MXA
MFUN]MY)VSB>/: ,*H,@. /ZG).!DG%=-XRT@:QJ<%JQ*J\(R1UPID8X]SC&>
MW7!Z5Y]IMY]BECGQGRW5L9QG:0<9YQG%;NK^.'O+J/4(D"/$@4 G>#RV<\+P
M0V/7T.:*E"2J)P5DHM+UZ!*#OIV.BUW6K'P[)]B2T20Q_>+A?X@&&&8.S=>^
M,=!Q5CXCOOL(&V>7EXSLQC;^[;Y<8'3IT'TK.E^(EK*PNFM ;@-P25QCC#;M
MN=P*@#Y>!T89(K+\4>.SK\*V[1A65E8L&R"0I!PN. <YZG'OUK"G0J<\'RO3
M=MW_ %(4'=:>IN^-/^05:_\ ;#_T2U9O@/\ X];_ /ZX?^R2U%HOCU+>!;.Z
MA$RQYVEB#V.T88$<$XR#PO0''-#3_%@LA=(L0VW88 !L! =^ !MY W>W2K5&
MHJ<J=NMT]-=1J,N5JW4Z'X41M(ETJ-M8K& V,X)$F#@\'!YQWKCO#?%U"W99
M48GL K!F)]  "2>P&33O#GB!]"F%P@!XPRGNI()&>QX!!]?49!ZT_$BVCQ*E
MHOFL27/RCD,&!W!"6.0&.0,$#KUJYQJ0J3:C=2MVTTL-J2;TO<V-5_Y#-M_U
MP;^4M<9\1Y2]]*"20H0#)Z#8IP/09)/U)JM9^+'CO/[4E4.^3E0=HY0H #@\
M ?4\<G/-5/$6L?VS.]WMV[]ORYW8VJ%ZX'IZ44,/.G4BWLH6OYW"$&I+T.V\
M:?\ (*M?^V'_ *):L_1I3'H]R5)!\X#@XX/E CZ$'!]JR]:\8?VG:Q6'E[?)
MV?-OSG8A7IM&,YSU-5K7Q)]GLY--V9\UPV_=TP4.-N.?N^O>E"A-4TFOM7^5
MP4'RV\S;^$W_ !]/_P!<&_\ 0TKB:V_"7B3_ (1^5I]F_<A7&[;U*G.<'TK$
MKHA!JK.71I?J6D^9L](^#W_+Q_VR_P#9ZS?^%LW7]R+_ +Y?_P"+K-\'^,/^
M$<\S]WO\W9_'MQMW?[)SG-<W6*PJG6G*2NG:WW:D>S3DVT=!9:Q)J]_#<3'+
M&>+ '0#>,*!V _\ KG))-:WQ9_X^D_ZX+_Z&]<EIMY]BECGQGRW5L9QG:0<9
MYQG%:7BWQ)_PD$JS[-FU N-V[H6.<X'K5NDU6BTO=2:*Y?>3Z'6_%#][;VTL
M/_'OSC'RK\R@Q_+Q_"&QQQTXS3/A+*(!<.Y"J0ARQP,)NWG)[+N&?3(SU%9/
MA_Q\;.+['=1B:'*@;L$A0>F""& ZJ#C'3.,8;X@\="[C-K:Q"",Y#%<!F3)(
M7Y0 HRQ) )ZD9P3GG]A5]FZ%M+_%?I>_WF?)+EY+?,W?"=J)=,D6[(6W9LAB
MQ)"AAG"CH=RG;URQY4CAH+/Q%8^%XY#9.99)-N ZL""-W).%&T9Z ;LYR<$;
M=GP_=MI&G136R-<$G+*"P(W$[L ACA6^7"C!Y?U-266OR:TZP7-BRQYR6E!8
M ] =K1C)R<<= 23P":PE)N4VU>/,[JZ6WD]26]7VN<O\/Y3%;7SJ2&6$$$'!
M!"R8(/K6)X,\/C7+CR20%5&8YSSC  XP2-Q&1E3C."#BM?4=13PK+>:?$A9)
MT51E_N[HR?0Y W\<YP.23S7.^'M<?1)EN4YQD%<D!@>H./S'7! .#BNR,9R5
M2<=.9)K[C5)N[778Z_5/$=CHTALXK1)!$2"SXSN!.X9968@'C)/L. "3XI@B
M.T!4(=C_ "#!"\1_*".,#IQQ39?B3;R,)S:(9MV=Q*Y&W&T[MF<_EC P3VQ/
M%?C#_A(DC#Q[7BSR'RIW ;OE*Y'(&/F..G/6LJ-&:J0ERM6O=MWZ>I,8OF3L
M=)\8?^7?_MK_ .R51U"Y:+18%4X$DI5O<!Y&Q^:@UD^,/&'_  D?E_N]GE;_
M ./=G=M_V1C&*K77B3[19QZ;LQY3EM^[KDN<;<<?>]>U52H35*E%K52N_P 1
MQ@U&*[,V_ ?_ !ZW_P#UP_\ 9):L^&?$<NB6H6[A+6CL55L 'YU+$;6QO5NN
M>!UY/ '-Z#XD_LF*X@V;OM*;<[L;>&&<8.?O>W2M#P_X[.FP&RFB6:+/RAB!
MC)W$'*L",\C/(/?IAUJ$I.?NW3:Z^70)0;OH=1::)IWBU)'MU,<F!G *["<A
M?D!V$';R!V[@G->65WEU\2(K0.EC;K$7 P^%4_4HHP2,G&6([D=17!U>$A4C
MS7O;2R;NQTU)7OL%%%%=1H%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Z1\'O^
M7C_ME_[/7F]>D?![_EX_[9?^SURYA_N\OE^:,ZWP,]'HHHKP#C"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M36O]^7_OI/\ XBC_ (5-:_WY?^^D_P#B*['SJ/.H^N5_YF'M9]SCO^%36O\
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M_P"(H_X5-:_WY?\ OI/_ (BNQ\ZCSJ/KE?\ F8>UGW.._P"%36O]^7_OI/\
MXBC_ (5-:_WY?^^D_P#B*['SJ/.H^N5_YF'M9]SCO^%36O\ ?E_[Z3_XBC_A
M4UK_ 'Y?^^D_^(KL?.H\ZCZY7_F8>UGW.._X5-:_WY?^^D_^(H_X5-:_WY?^
M^D_^(KL?.H\ZCZY7_F8>UGW.._X5-:_WY?\ OI/_ (BC_A4UK_?E_P"^D_\
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M_A4UK_?E_P"^D_\ B*/^%36O]^7_ +Z3_P"(KL?.H\ZCZY7_ )F'M9]SCO\
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MYR:M<=1116)(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% $<O2HJEEZ5%0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]G;?^7?S=^?]O9MVX_'.?PK#N/#MWHQ6YLYI;@J</#<2[@RG'W6( 5AUS_\
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MQ;KGJ.OW2H !Z)167X<M+BSB\FZ<2,C$*XSN9!C:6S_%Z]>V23DG4H ****
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M^9A]77<]U_X2.U_Y[Q?]_$_QH_X2.U_Y[Q?]_$_QKPJBC^RH?S,/JZ[GNO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *JZ9J<>J1K<0MNC?.#@C."0>" >HJU7G'@7QU9Z79Q6\T
MNV1-^1L<XR[$<A2.AH [VXU..WDCMW;$DV[8,$YV#+<@8&!ZX]J=?W\>GQM/
M*P5$&23_ )Y)Z #DG@<UQ<OB>WUS4;+[,^_R_M&[Y67&Z+C[P'H:OM:IK^H2
MI.H:.QC0*C ,I:<;B_X !<'(_B&#0!?TWQW9:DXABF!<] P9,Y(  +@ DD\
M<GTK9NKI;1&F<X1%+,<$X"C).!STJAXB\.Q:[$T,JC<58(Y7+(3_ !#H>H&1
MD9Q@\5C0:NVL:0]R_P!]K:8-TY*JREN  ,D9QCC.* .@TG68=7C\^W<.F2,C
M(P1U!!P0?J.F#T(I_P#:<?G?8]W[WR_,VX/W=VW.<8Z]LY]JX_P^XT 6CJ (
M+V*%'QGY9O+^5@ 3S)]UL*.5#,WKI?\ ,7_[</\ VM0!?UGQA:Z*XAN)-CE0
MP&QVX)(SE5(Z@U0_X6;IW_/;_P AR_\ Q%5[W4(['5M\SJBFQQEV"C/G9QDD
M<\5T-KK]M=L(HYHW<YPJR*S' R> <]* *NL^,+717$-Q)L<J& V.W!)&<JI'
M4&C2/&-IK#>5!*&?^Z058\$\!@"< '.,X[U0_P"8O_VX?^UJT?$V@#68608$
MRC,3]&1P0P(;!*@E1G'.* -*ZNEM$:9SA$4LQP3@*,DX'/2N<_X6;IW_ #V_
M\AR__$5%!J[:QI#W+_?:VF#=.2JLI;@ #)&<8XSBI_#7B6UAM8$:>(,L$0(,
MJ @A """>"* -G2=9AU>/S[=PZ9(R,C!'4$'!!^HZ8/0BGZGJ<>EQM<3-MC3
M&3@G&2 . ">IKE/#;QWFHSW5H#]G\K;(Z\1O-N!R.<$[>X'7)_B!:UXI!U6Y
MM],4C9GSY@1G*1D!%() 96;((Y(.&Q@<@'36MTMVBS(<HZAE.",AAD'!YZ5@
MW7B@S%?((V/OVN(I;@MY9"OB.+&%!(&\L,D<*5(:F>")3;B;37)+6<I5=QRW
ME-\T1+="2,C Q@ # JGIMJ]WY5O%(8I;*WDAD(520_[H(=D@)*.$+*0!D#JI
MR* -[2-<%^=A #;=P9'$D3C)!*.,%MIP'RHVDCJ""=2N7\/VC 6\)4K);J[3
M$L&;?(/F0L&;/F,WFGDXVIN4;EQU% %>6^2*1("3OD#%0%8\)C<20, #(ZD9
M) '--_M./SOL>[][Y?F;<'[N[;G.,=>V<^U8V@'[==W=WD,J,D"'&&7RQND7
MH."[>IR1Z!:B_P"8O_VX?^UJ .HK(UKQ9:Z(52XD"LPR!AF..F<*#@>F>N#C
MH:UZX/0M2@T:\NEO3Y=Q+,Q227[K0GE ')( &WIQV7DKA0#K=(UZ#6%\RW<.
M!UQPPY(&5.",X.,@9ZCBL;_A9NG?\]O_ "'+_P#$5+IVF6MS=G4;25"PC*R+
M"8V5M[;@S%<D$D')ZM@<X!#1?$W_ )!TW_;/_P!&I0!:TSQU9ZI(MO#+ND?.
M!L<9P"3R5 Z"M34]3CTN-KB9ML:8R<$XR0!P 3U-6JY3Q2#JMS;Z8I&S/GS
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MT!82EB 3@1R9..PRH&3[D#U-0>&_#\IL;F)D$37C3LD9Z()4"JIP.,>@' [
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M()XQTP<@=A110 4444 %%%% !7&_%3_CU3_KLO\ Z ]=E7&_%3_CU3_KLO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MLO2HJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]?\ /_[+1_S%_P#MP_\ :U6K>S-A?22@$I>1J2P!(5X1MVG"X 96R"6ZJ1W
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MQE@5. ."I(.<^@\UHK)83EY;2::5KZ;$^SM;4[S0X(+K4(UM(5VPEV?+EAC
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^'U?YS)+,VZ21L@M@G'&3ZG)R2222>@',KX"OM'D<Z=<*D+ECL?=A<GIM*R
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M8YF90DB;TRF %VL"P/)3(((.001@<W=(\ 337*ZCJ4PEDC(VJF0ORX*G.%P
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M08 '^>2>I)Y)Y/- %BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_B*/^%5VO]^7_OI/_B*[*BCZY7_F8>UGW.-_X57:_P!^7_OI/_B*/^%5VO\
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MDK.0N3@&/)QVR=PS^0^E>@T4UCJZ^T"JS[GGG_"I/^F__D+_ .SH_P"%2?\
M3?\ \A?_ &=>AT4_[0Q'\WX+_(?MI]SSS_A4G_3?_P A?_9T?\*D_P"F_P#Y
M"_\ LZ]#HH_M#$?S?@O\@]M/N>>?\*D_Z;_^0O\ [.C_ (5)_P!-_P#R%_\
M9UZ'11_:&(_F_!?Y![:?<\\_X5)_TW_\A?\ V='_  J3_IO_ .0O_LZ]#HH_
MM#$?S?@O\@]M/N>>?\*D_P"F_P#Y"_\ LZ/^%2?]-_\ R%_]G7H=%']H8C^;
M\%_D'MI]SSS_ (5)_P!-_P#R%_\ 9T?\*D_Z;_\ D+_[.O0Z*/[0Q'\WX+_(
M/;3[GGG_  J3_IO_ .0O_LZ/^%2?]-__ "%_]G7H=%']H8C^;\%_D'MI]SSS
M_A4G_3?_ ,A?_9T?\*D_Z;_^0O\ [.O0Z*/[0Q'\WX+_ "#VT^YYY_PJ3_IO
M_P"0O_LZ/^%2?]-__(7_ -G7H=%']H8C^;\%_D'MI]SSS_A4G_3?_P A?_9T
M?\*D_P"F_P#Y"_\ LZ]#HH_M#$?S?@O\@]M/N>>?\*D_Z;_^0O\ [.C_ (5)
M_P!-_P#R%_\ 9UZ'11_:&(_F_!?Y![:?<\\_X5)_TW_\A?\ V='_  J3_IO_
M .0O_LZ]#HH_M#$?S?@O\@]M/N>>?\*D_P"F_P#Y"_\ LZ/^%2?]-_\ R%_]
MG7H=%']H8C^;\%_D'MI]SSS_ (5)_P!-_P#R%_\ 9T?\*D_Z;_\ D+_[.O0Z
M*/[0Q'\WX+_(/;3[GGG_  J3_IO_ .0O_LZ/^%2?]-__ "%_]G7H=%']H8C^
M;\%_D'MI]SSS_A4G_3?_ ,A?_9T?\*D_Z;_^0O\ [.O0Z*/[0Q'\WX+_ "#V
MT^YYY_PJ3_IO_P"0O_LZ/^%2?]-__(7_ -G7H=%']H8C^;\%_D'MI]RGI&D1
MZ3&((AA1^9/<D]R?_K#  %7***YI2<G=[F;=PHHHI %20U'4D- $M%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 1R]*BJ67I45 !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 8.I^!;/5)&N)HMTCXR=[C.  . P'05O444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6#IG@6ST
MN1;B&+;(F<'>YQD$'@L1T-;U% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5)#4=20T 2T444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 A&:-HILC8J/S#0!-M%&T5#YAH\PT 3;11M%0^8:/,- $VT
M4;14/F&CS#0!-M%&T5#YAH\PT 3;11M%0^8:/,- $VT4;14/F&CS#0!-M%&T
M5#YAH\PT 3;11M%0^8:/,- $VT4;14/F&CS#0!-M%&T5#YAH\PT 3;11M%0^
M8:/,- $VT4;14/F&CS#0!-M%&T5#YAH\PT 3;11M%0^8:/,- $VT4;14/F&C
MS#0!-M%&T5#YAH\PT 3;11M%0^8:/,- $VT4;14/F&CS#0!-M%&T5#YAH\PT
M 3;11M%0^8:/,- $VT4;14/F&CS#0!-M%&T5#YAH\PT 3;11M%0^8:/,- $V
MT4;14/F&CS#0!-M%&T5#YAH\PT 3;11M%0^8:/,- $VT4;14/F&CS#0!-M%&
MT5#YAH\PT 3;11M%0^8:/,- $VT4;14/F&CS#0!-M%&T5#YAH\PT 3;11M%0
M^8:/,- $VT4;14/F&CS#0!-M%&T5#YAH\PT 3;11M%0^8:/,- $VT4;14/F&
MCS#0!-M%&T5#YAH\PT 3;11M%0^8:/,- $VT4;14/F&CS#0!-M%&T5#YAH\P
MT 3;11M%0^8:/,- $VT4;14/F&CS#0!-M%&T5#YAH\PT 3;11M%0^8:/,- $
MVT4;14/F&CS#0!-M%&T5#YAH\PT 3;11M%0^8:/,- $VT4;14/F&CS#0!-M%
M&T5#YAH\PT 3;11M%0^8:/,- $VT4;14/F&CS#0!-M%&T5#YAH\PT 3;11M%
M0^8:/,- $VT4;14/F&CS#0!-M%&T5#YAH\PT 3;11M%0^8:/,- $VT4;14/F
M&CS#0!-M%&T5#YAH\PT 3;11M%0^8:/,- $VT4;14/F&CS#0!-M%&T5#YAH\
MPT 3;11M%0^8:/,- $VT4;14/F&CS#0!-M%&T5#YAH\PT 3;11M%0^8:/,-
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MY/->IT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%9WB/\ X]9_^N,G_H!IQ7,T@2NS1HKYYHKU/[)_O?A_P3H^K>9]
M#45\\T4?V3_>_#_@A]6\SZ&HKYYHH_LG^]^'_!#ZMYGT-17SS11_9/\ >_#_
M ((?5O,^AJ*^>:*/[)_O?A_P0^K>9]#45\\T4?V3_>_#_@A]6\SZ&HKYYHH_
MLG^]^'_!#ZMYGT-17SS11_9/][\/^"'U;S/H:BOGFBC^R?[WX?\ !#ZMYGT-
M17SS11_9/][\/^"'U;S/H:BOGFBC^R?[WX?\$/JWF?0U%?/-%']D_P![\/\
M@A]6\SZ&HKYYHH_LG^]^'_!#ZMYGT-17SS11_9/][\/^"'U;S/H:BOGFBC^R
M?[WX?\$/JWF?0U%?/-%']D_WOP_X(?5O,^AJ*^>:*/[)_O?A_P $/JWF?0U%
M?/-2V]RULPDC8JPZ%201GCJ*3RG^]^'_  0^K>9] T5X5_PD=U_SWE_[^/\
MXT?\)'=?\]Y?^_C_ .-3_94_YD+ZN^Y[K17A7_"1W7_/>7_OX_\ C1_PD=U_
MSWE_[^/_ (T?V5/^9!]7?<]UHKSKPA\0SE;:[(VX 60]<_[9_3=VZMG)(]%K
MBKT)T96D93@XNS"BBBLB0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "I(:CJ2&@
M"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** (Y>E15++TJ*@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCI@CD O>)=3;2[=[A "R;<!LD<L!V(]:TZX?Q?X5BT^V>6WW1@%=RAF*N-P
MR"3T)R/QX[C1\3VS7-S:1JQ0MY_S+]X#8,X]"1D ]NO:@#IZ*Y/Q#HT6BQ-?
MVX994923O<[LN,JV6.0<Y/<GO5OQ9K7V'RX&8QI,6W2 $LJJ!D* #RV< \[>
MN/0 Z&BO/+NZT^U0R64C13J,J5\T[L<["&X()'?C.,Y&0=R"Z\FXANP-J7\:
MAP3P'5=R?,>Y!V@#&>O)H Z>BL!/]/OR3]VTC  /'SR\Y&.HV#!ST/0=ZWZ
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M,].>*ZJ59RDXM6=KFD9-NS13HJS9Z;+>Y\E'?;C.Q2V,],X!QG%6?^$:NO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .2^(UTMHEK,YPB7L+,
M<$X"AB3@<]*E_P"%FZ=_SV_\AR__ !%=110!REYK\VGRK>G,NGSHI!1#OA^7
M.\@#<4(Y)/(Z<8 >KK/C>#6(9+.QW3S3(4"HCK@.-I=F90 HSU]<9P,D=K10
M!2T6R-C!%;M@M'$BG'3*J <9QQQ6)\,O^0=#_P!M/_1KUU%% '%2:/%XNNY9
M)@6M[4>2J[F ,F=TC<%2"O"G@AN"#Q1K/PSMEA=K-#'<*-T;!W)W*=P W/@$
MXQGMG/:NUHH XW6?B1'96<5Z@S)<*=B'.T,O#Y.!PAXXP6[<'(RM(\3:=#+_
M &A<W'F73+C/ER^6@Y^6-=F0,'&3DGD\;F!]'HH YS68U\3V@GM&RZ,)(6P1
M^\B)QP^T<D%?FX&<X.*J_P#"QHMFSRY/M>W_ (]O+?S-V,XSMQC'S9Z[><9X
MKK:* ,;PEI#:9 !+S-*S22GCF23EN 2..!QP<9 YKD?'7CJSU2SEMX9=TC[,
M#8XSAU)Y*@=!7H]% &#IGCJSU21;>&7=(^<#8XS@$GDJ!T%;U%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'(Z7JC:2TZ/!.V^YE<%(B5() ')(]*G:%_$KJ9(VBMX7W;90 TC # VD'"C)
MSR0P..OW>GHH Q-5MV>[M7"DJGG[B 2!E !D]L]JI7;/IMV]S)"\R2*OEM&N
M]DVC#+@_=W9)X.#[\XZBB@#E3--J-W;7!B9(5\T#>I#\I@EAR%!/"@G)P3W%
M/U7S[6]%W%$9(U@"OC&<%V8[<D988' SZ<9!KIZ* .5U.:7Q(JVJ121QEU,K
M2J$^4<X4'<221U'0@9X)JS=I)I-P]VD;213JN\)@R*R?*N%XR"#SU/4Y &#T
M-% &!%J-SJDB>4C0PJ<NTR@.V/X I)P#_>_(\8)XDBDAE@O40R+ 7#*G+XD
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MHKP*E2523D]SC;;=V%%%%2(**** "BBB@ HHHH **** "BBB@ HHHH ****
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M=Z@J5VHJG@8!SA!U;'].1\%:RFM:M/=Q@A'M^ P ;Y?*4]"1U'K0!Z91110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4-[:B
M\C>%L[9%93CKAA@XJ:BA.SN!QO\ PJNU_OR_]])_\11_PJNU_OR_]])_\179
M45T?7*_\S+]K/N<;_P *KM?[\O\ WTG_ ,11_P *KM?[\O\ WTG_ ,17944?
M7*_\S#VL^YQO_"J[7^_+_P!])_\ $4?\*KM?[\O_ 'TG_P 17944?7*_\S#V
ML^YQO_"J[7^_+_WTG_Q%'_"J[7^_+_WTG_Q%=E11]<K_ ,S#VL^YQO\ PJNU
M_OR_]])_\11_PJNU_OR_]])_\17944?7*_\ ,P]K/N>>?\*D_P"F_P#Y"_\
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M0O\ [.C_ (5)_P!-_P#R%_\ 9UZ'11_:&(_F_!?Y![:?<\\_X5)_TW_\A?\
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MJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU%
M%FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJ
MU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %
MFBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU
M% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %F
MBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU%
M %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FB
MJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU%
M%FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJ
MU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %
MFBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU
M% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU% %FBJU20T
M2T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!'+TJ*I9>E14 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4457?4(TD%N7
M42,,A"P#D<\A<Y(X/Y&@"Q115=-0C>0VX=3(HR4# N!QR5SD#D?F* +%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)':_\]XO^_B?XT?\)':_\]XO^_B?XUX511_94/YF'U==SW7_ (2.U_Y[Q?\
M?Q/\:/\ A([7_GO%_P!_$_QKPJBC^RH?S,/JZ[GNO_"1VO\ SWB_[^)_C1_P
MD=K_ ,]XO^_B?XUX511_94/YF'U==SW7_A([7_GO%_W\3_&C_A([7_GO%_W\
M3_&O"J*/[*A_,P^KKN>Z_P#"1VO_ #WB_P"_B?XT?\)':_\ />+_ +^)_C7A
M5%']E0_F8?5UW/=?^$CM?^>\7_?Q/\:/^$CM?^>\7_?Q/\:\*HH_LJ'\S#ZN
MNY[K_P )':_\]XO^_B?XT?\ "1VO_/>+_OXG^->%44?V5#^9A]77<]U_X2.U
M_P">\7_?Q/\ &C_A([7_ )[Q?]_$_P :\*HH_LJ'\S#ZNNY[K_PD=K_SWB_[
M^)_C1_PD=K_SWB_[^)_C7A5%']E0_F8?5UW/=?\ A([7_GO%_P!_$_QH_P"$
MCM?^>\7_ '\3_&O"J*/[*A_,P^KKN>Z_\)':_P#/>+_OXG^-'_"1VO\ SWB_
M[^)_C7A5%']E0_F8?5UW/=?^$CM?^>\7_?Q/\:/^$CM?^>\7_?Q/\:\*HH_L
MJ'\S#ZNNY[K_ ,)':_\ />+_ +^)_C1_PD=K_P ]XO\ OXG^->%44?V5#^9A
M]77<]U_X2.U_Y[Q?]_$_QH_X2.U_Y[Q?]_$_QKPJBC^RH?S,/JZ[GNO_  D=
MK_SWB_[^)_C1_P )':_\]XO^_B?XUX511_94/YF'U==SW7_A([7_ )[Q?]_$
M_P :/^$CM?\ GO%_W\3_ !KPJBC^RH?S,/JZ[GNO_"1VO_/>+_OXG^-'_"1V
MO_/>+_OXG^->%44?V5#^9A]77<]U_P"$CM?^>\7_ '\3_&C_ (2.U_Y[Q?\
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M4@#J<95T& 2=HQP./<LN/A64+I;7+0PR$Y0)G@C!5F#J74<X#9P">Y8GOZ*
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M'MVK9L-(CLH5LU4&-4VX8 Y&,'(P 2W);CDDT %YK,-G&MP[@1N5 <9*?/\
M=)89 4_WCA>1SS5N640@NQ 50223@ #DDD] *X7P[HWV^QN]*SE8KB>*+><8
MVD,A)4#.'.3Q[8QQ3M0\0/JNGQVZ$_:[HB!E(7<''$Q9!DJH4$D@94,IP,\
M'4/XBMXX1>NX6%AE6<%,\$\*P#$D#( &2.1FJ>F^.[+4G$,4P+GH&#)G)  !
M< $DG@#D^E5_$4=KI2P.8C++ "+:)=S.2%'0<Y"A02Q!VXR/FQGGO'&L7DUJ
MYEM/*",C"43H[(P<88!1G/;(Y&?2@#NM6UF'2(_/N'")D#)R<D]  ,DGZ#ID
M] :JZ+XLM=;+);R!F49(PRG'3.& R/7'3(SU%4/%^C37,EO?6Z+(]J['RGP-
MP? )#'@,N,C/?GJ #5BU19;J%[ZU:&XRRQ2;U>/YE;"F12 6/S (02"<C[U
M'0ZOKT&CKYEPX0'IGECR <*,DXR,X!QU/%,T7Q%;ZV&>V<.$.#P01GIPP!P>
MQQ@X/H:Q-+MQ>:I=3R<M;1PI'P,*)%+,>F<YSSGHQ'3&-F3PY$URNHKE954J
MVTX5P1@!QCG';IT&<X& "U8:G'?[_*;/E2-&W!&&7&1R!G&>HX]Z/[3C\[['
MN_>^7YFW!^[NVYSC'7MG/M6#X$_Y?/\ K_G_ /9:/^8O_P!N'_M:@"70[IY+
MZ^B9B43[-M4DE5W1DG Z#)ZXZU+J7CNRTUS#+, XZA0SXP2""4! ((Y!Y'I5
M7P__ ,A&_P#^W7_T4:I:;JQL@;?2K,RVZ'_6>:(T9B2&VLX.\#&-V3TQTVD@
M'5Z;JD6IH)H'#H>ZG.. <$=0<$9!P1W%9MYXVL[,%Y)0 LK1GY6)WIC<, 9(
M&1D@8Y'/-9/@BXDDNKT2Q^2=T#&(,&569#N;*X!+8!)ZGOR*=X#L(Q)>W.T>
M8;R9-W?:"&Q[#)R<=>,]!@ ["N7\?.^RWB1WC\V[B1FC8HVUPP/(_P#U9KJ*
MY?QW_P N?_7_  ?^S4 '_"%20?/#>7(D'0RN)4]\H0 >.G/!P>U.T+QM'=1@
M7.(YUG$#H/F_>'.,;=V%;!P3QD$9.,GIJX.+31K\NJ1*,K)Y2*S;E7S(D(ZX
M_A<#.,\8Z@\@';W5TMHC3.<(BEF."<!1DG YZ5FZAXLM=/CCN99 J3 %#AB2
M",YV@%L8(SQQD \D5R^HZL?$-I;6!SYUS*L<RD!77R,-.?[JL" 0",X/"^FI
MX@TJX@NX]4MHUG*Q&,QLP1ARS!U=N ><'OCCG<2H!LZ+XBM];#/;.'"'!X((
MSTX8 X/8XP<'T-<1K7CJVU6=8?M,D5JL6[? '1S)NQM)V$[0O/  SU)P,;VC
MZA'+=YGMVM[R2)AN8@HZJ5.U7!P[ 8)PN0!@G I__,7_ .W#_P!K4 ;-K>1V
M[KI^\M*D(;Y\EBH.S<6Q@DGKWSSBI;_4X[#9YK8\V18UX)RS9P. <9QU/'O6
M#_S%_P#MP_\ :U'CO_ES_P"O^#_V:@#;O=9AL72*5PK2!RN<XQ&NYR6Z  <\
MD50LO&UE>R?9HYE+YQ@Y )SC"L0%8DGC!.>HR*R_%UA'?WUA#*H9";@E3T.U
M%89]1D#CH>AXJQ\2_DL9)1P\;1LC#[RL)%&X'J#@GD<\T ;VI:I%IB&:=PB#
MNQQG@G '4G . ,D]A5+1?%EKK99+>0,RC)&&4XZ9PP&1ZXZ9&>HK)O[<7^K1
M1R<I;VS2HN!C>TFPDY&>F"/0@$=\[.I^'(M0EBNVRLL# JZ':Q'=#QRI[CW.
M",G(!SFM_$2&TNX85EQ$C3+<#RV."HP@SMS][/W?QXK936+?4I+::.9_WGG>
M6J[E23:,/N!7^'&1G'/3-5?$'_(1L/\ MZ_]%"CQ!_R$;#_MZ_\ 10H V=7U
MZ#1U\RX<(#TSRQY .%&2<9&< XZGBHM&\46VM9^SR!R,Y'*MQCG:P!QR.<8S
MQG-8VEVXO-4NIY.6MHX4CX&%$BEF/3.<YYST8CIC!XUMQ!/97J<2BY2+( Y2
M7(8'(STSCTW$CDYH WKK7H+20P2.$<1B0[OE4*6V [C\OWN,9S[55TCQC::P
MWE02AG_ND%6/!/ 8 G !SC..]9%U81W>L(9%#>79AUSV82D X]1DX]#SU -6
M/''[MK.5>'%[$H8<-M<,&7/7# <CH>] '44444 %%%% !1110 5QOQ4_X]4_
MZ[+_ .@/795QOQ4_X]4_Z[+_ .@/71@_X\/4NE\:/-](M!>310-D+)(BG'7#
M, <=>>:[/4?#.E:;(8)IY5=<9&,]0".1$1T-<EX:_P"/J#_KO%_Z&*[KQ7X2
MM[^YDFDNXXF;;E&VY&% [N#R!GIWKU<1.U5)R:5NGKZ,Z)OWK7L8FM^!DL9[
M<1L7MKET4,,$C<1_$!M.0<J>_/'&3E^(_#9L+B6"!7>.$*2V-V R!LL5  '7
MTX%=;K6NPM-9:9;,'2&:#+#!^Z0J@,."<$[L#&<8.<BIO%WQ!DTFZ%O$H*1[
M2X8<MD9(!R<#!&#C.X=QP<Z=:O>*M=V>^G7<F,IZ'E]7(](FD3SUC<QX)W!&
M*X'4[L8P,<UW/BVS1=5A/E&7S$0L@/WCEESR<8 4$@X4@?-@$FNB$6IW4HEW
M1Q0EB-G!D"Y(#$X<;\<C#;<@9&,@W/&VC%I)75]7^!3JZ(\8JY=Z1-9C?+&Z
M*3C+HRC/ID@<\5ZE!I\5IJY8  RVY< X^^6VG;QU*J2>YRQZ4.-0TK>KQI=0
M,K817.X >OF;V;<"<KE_0$# *>/NU9+9/5V^X7MCR&K-YILMECSD=-V<;U*Y
MQUQD#.,UZ/\ #[2EV7%U'&%F$KK&LO(CVKPN<;A][#=R!TS6[I6EW4Z/;:B8
MYHW'5<@_3 11CN",$'UXP5<>H2:MHM]=?D$JUF>)5V.B^&[>R@74-0WE9,E$
M4$# !QD\$ECC:%/3YN5W%>3N;9K9VB<89&*D=<$'!'''6K+ZE/>HEH6=U5AL
M3);D@* !UZ< =LG'4YZJL9322=EU]/(TDFSK)_#-IKT+W.G!T>)03&QW9^]Q
MC+-N('!^Z> .=VW'LO#T<^GRZB2WF12!0 1MP2G48SGYCW]*ZC2U'@:V>61E
M:XF(!CSG:54E1@=2-P+\@8/!)V[XO!NI#3-,GN2H;9,2H(R-V(]A(R. V#ZC
M&1S7%[6:B^5MKF5O/NC+F:6FUS@[S39;+'G(Z;LXWJ5SCKC(&<9JM7IG@S7V
M\3+-IUU\P9,J0,D+PI&6R25)4J3ELY)8G%>9UUT:LI.49*S7ZFL9-MIG3:'X
M62:VEU*Y++$@(0+P6;@#DJPVDG;D \YSC;S9\,>&+6\M7OKMW18Y-I*8QC"8
MXV,<Y:K/BPBRTZSM5!(D'F9)Z';N(QCIF3CT []:M^$(H9=,G6Y8I"9_F9>2
M/]5CLW?':N:=6;IN=WK*RMVO;0S<G:_F9=]INDI&[13R&0(VT$'!;'R@_NAP
M3[CZU/I?A:R^QQW]W)(GF,R_+@C(9@!@(QZ+5'6M/TR*)FMII'F&-JL" >1G
M_EFO;/>NBLM)CU32K>*6585$C'<^,$AI!MY9>><]>U%2;C!/FDDY6=]]GY W
M9+5[E2U\&6&LJZ64[F95R!)P/Q&Q21V)&<9!.> <CP9X;@U=)Y;AG58%5LH1
MT(8L3E6)P%[5UNF:9;>#H&U)&,[,NT,GW#EN@VY"C( ))/(XY.TXWPU1'AO5
ME)$9C7<1U"[9-Q'!Y ]C]*CVLO9U&FVDU9O??47,^5ZLA_LK1O\ GXE_[Y/_
M ,:J#PUX8M=4-U([N(;<Y5EP"4^<Y(*$YPH/ 'THOM-TE(W:*>0R!&V@@X+8
M^4']T."?<?6KOPU1'AO5E)$9C7<1U"[9-Q'!Y ]C]*N<G&E*2<NF_JMM!MM1
M;U(?[*T;_GXE_P"^3_\ &J@\->&+75#=2.[B&W.59< E/G.2"A.<*#P!]*+[
M3=)2-VBGD,@1MH(."V/E!_=#@GW'UJ?P'_QZW_\ UP_]DEIR;5*33ET6OJMM
M =^5N[^9);>'=*OF$$-Q)YC\+N&!GMUC4'GMD9Z#DU@:MX2FL+D6 &]WY3;_
M ! YP<=NASGI@G..:QXI3$0ZDAE(((."".A!]:]AOG=[O3VE $A2?<!T#>4-
MP')X!]S]:=2<\/):W33W[I7')N#WN8%YX?TSPV5ANB\DCA,_>  .07^3;\N1
MR,LW3 /?'\4^#X[*%+^T<R0/@$GDC.<'(  &>"" 0W').!D^+;EKB[G9SDB5
MU].$.U1QZ  5T>GW+2Z+.K'(CE"K[ O&V/S8FDHU*:A/F;;:3OMKV"SC9W)W
M^&\<MD+N$N9FA1PI(*DD!F  7.<9"C/7%</INGOJ,B6\8RTC #KCGN< G ')
M/8<UZWIVLFQ&GP$C9/;[3D@?,J1E3R.O50,C);N0*Q?#GAQ=&OKB>0!8K9&9
M?OG"R9*D<?, @93UYZ9/-9TL5.,9\VO6/WV_,F-1I._R,WQQX'AT&%9XF<LT
M@7YRI&"K'LHYXK+\3^&DL8XKVV):WF4<NRE@YR=IV@#H,<9P00>V>H\?3^?I
MMM)@+N:(X4849B8X [ =A6792&XT:4/@^5, F0/ERR$X]_G;GK@D=*JC5J<D
M)-W]ZS^>@XRE9/S.'HHHKT#8**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWO;\6KL<A!)M4C) *J)5^3 &"0&)W;AD99W@C4I[F6ZTAYS)F-S','WD=$#
MAB>0P;&_Y2,=2: .UMO$T=Q=R:8 WF1(&)(&S!VG@YSGYQV]:UZ\=L/"L\NI
M360NI%D2(,9ANWL"(_E/S@X^8?Q'H./31U_5+B>X71Q<B!+:./?,\A1I#M3)
MSG.<-D)NY()+=, 'J-%>4VVM2>&[J%?MHNH)F ?,@.W^'))+[0-P;((W8(.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2[G#95PQ3D?,[,"-PZC((.."*Z.B@#C1H6IP1"PCFA$*JJ"7:ZSA1@'"C*Y
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MWL=QX*UB.>WFTNY=51P=AD(PNX')^9@,*P4@#G<2>F2#P$T4<=Y:S2I&945
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M7;VMJEHHBC4(@SA5 51DY/ XZUP&EZ7J-]J,.H7D*HL:,I*,N,;7QQO8YRU
M'HE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4]5T>+55$4Z[E
M#9 R1R 1GY2/4U<HIQDXNZW!.QSW_"O['_GE_P"/R?\ Q5'_  K^Q_YY?^/R
M?_%5T-%:?6*O\S^]E<\N[.>_X5_8_P#/+_Q^3_XJC_A7]C_SR_\ 'Y/_ (JN
MAHH^L5?YG][#GEW9SW_"O['_ )Y?^/R?_%4?\*_L?^>7_C\G_P 570T4?6*O
M\S^]ASR[LY[_ (5_8_\ /+_Q^3_XJC_A7]C_ ,\O_'Y/_BJZ&BCZQ5_F?WL.
M>7=G/?\ "O['_GE_X_)_\51_PK^Q_P">7_C\G_Q5=#11]8J_S/[V'/+NSGO^
M%?V/_/+_ ,?D_P#BJ/\ A7]C_P \O_'Y/_BJZ&BCZQ5_F?WL.>7=G/?\*_L?
M^>7_ (_)_P#%4?\ "O['_GE_X_)_\570T4?6*O\ ,_O8<\N[.>_X5_8_\\O_
M !^3_P"*H_X5_8_\\O\ Q^3_ .*KH:*/K%7^9_>PYY=V<]_PK^Q_YY?^/R?_
M !5'_"O['_GE_P"/R?\ Q5=#11]8J_S/[V'/+NSGO^%?V/\ SR_\?D_^*H_X
M5_8_\\O_ !^3_P"*KH:*/K%7^9_>PYY=V<]_PK^Q_P">7_C\G_Q5'_"O['_G
ME_X_)_\ %5T-%'UBK_,_O8<\N[.>_P"%?V/_ #R_\?D_^*H_X5_8_P#/+_Q^
M3_XJNAHH^L5?YG][#GEW9RMW\-;.?&T-'C/W')S]=^[I[8JO_P *KM?[\O\
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M5VO]^7_OI/\ XBC_ (57:_WY?^^D_P#B*[*BCZY7_F8>UGW.-_X57:_WY?\
MOI/_ (BC_A5=K_?E_P"^D_\ B*[*BCZY7_F8>UGW.%N_A1$^/*E9>N=X#Y],
M8V8_6JW_  J3_IO_ .0O_LZ]#HJECZZ^U^0_;3[GGG_"I/\ IO\ ^0O_ +.C
M_A4G_3?_ ,A?_9UZ'11_:&(_F_!?Y![:?<\\_P"%2?\ 3?\ \A?_ &='_"I/
M^F__ )"_^SKT.BC^T,1_-^"_R#VT^YYY_P *D_Z;_P#D+_[.MOPUX"BT<F1R
M)9,C:64 +CG@9/.>_7TQSGJ**F>-K37*Y:?(3JR:M<****YR HHHH **** "
MI(:CJ2&@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** (Y>E15-(N:C\LT -HIWEFCRS0 VBG>6
M:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 V
MBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCR
MS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIW
MEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT
M-HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H
M\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*
M=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+-
M #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6
M:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 V
MBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCR
MS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIW
MEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT
M-HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H
M\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*
M=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+-
M #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6
M:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 V
MBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCR
MS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIW
MEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT
M-HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H
M\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*
M=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+-
M #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6
M:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 V
MBG>6:/+- #:*=Y9H\LT -HIWEFCRS0 VBG>6:/+- #:*=Y9H\LT -HIWEFCR
MS0 VBG>6:/+- #:*=Y9H\LT -J2&F^6:?&NV@"2BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BFQR"4!U(
M*D @@Y!!Z$&G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8GBC3
M9=15882REBP9PP"!&&&W(?OY'W1C@\[E[[=% &9X?LVMXE,FX2%5#!B, J,8
M54.Q1Z;0,C&[G-9OAV:;64:Z:61$>5_+"K#]P' SE&.0<CKV_$[FHW?V.)Y\
M9\M&;&<9V@G&>?2L#PE,]E:Q1B&1AMW;@80#O)?C,N>_?!]ATH NQWLFGW"6
MDK&1;@,8V(4.I1065MH4$$<@@9SP01S6A=:K#9G9+(B,1G#NJG'K@FLV.T>X
MF%_<@1I CA%+ D$D[I&88494#C+ =<@BH=#DCM0SVL,KK(VXR':"^[Y@<RNK
M$#. <8ZG)))(!T,<@E =2"I ((.00>A!J.2]CB)1F4,%+$%@"%'5B/3WZ5SO
MA:Y\ZZO  57=$=F5.&*D.?D++DD<X.<]>14.E6@U+4+BZ)+)#LC4$-MW#!8<
M\?(RYQ@C)##G!H Z6TU&*\SY3J^W&=C!L9Z9P3Z4/(&D5!)AE4L4!7+ \9((
M+8!Z$$<]<]*Q]0^?4+<1_>6*4R8X.PX"9/<;^@YP><=ZCT+%W>W5QR0FR)6.
M[ P/WBC/'# $_GWY )$\71/<M")(O)6($N7 .\G[H);!&WDX!P>"<\5NO<K&
MRQE@&?.T$@$XY.!WQWK"\+_OY;NY/WFN#'@=,0@*I^ISSS] *'_TK45!^9;>
MW)&.BO(V.2.Y3H#VY [T ;LURL&-[!=S!1N(&2>@&>I/I0]RL;+&6 9\[02
M3CDX'?'>L+Q'^_N+.V/W6E>3(ZYA7<H^ASSQ]"*J7NFIK6H;9,M%:Q+E2?E$
MCL2 0>N5Y..#@ ^E '1VFHQ7F?*=7VXSL8-C/3."?2B'48IV,2.K.N<JK L,
M'!R <C!XKGM;MQ?7\$ !&V)VE(P T9(VH?[REA@KC&&^N)?% 6%[.*,8<7"[
M0@Y$:C$@&!PN",CICV' !T,URL&-[!=S!1N(&2>@&>I/I1<7*VRF21@JCJ6(
M &>.IK"UW_2;NUM^JJSRLHZ@HO[MCCD#<2!V)XYH\;?O8H[8_=N+B*-CW )W
M9'O\O<'Z4 ;LURL&-[!=S!1N(&2>@&>I/I44.HQ3L8D=6=<Y56!88.#D Y&#
MQ7/>)K%=8NK>R8DHJO)(H.!MX"'WRV1QR 3TSFCQ;;B1[2TB!1VE.UH\(5C5
M<2 -V^4C@<''T! .A_M&+?Y&]?,_N;ANZ9^[G/3GZ<U/)((@78@* 223@ #J
M2:YGQM$EI:>5$H5O,01"-<$/NW?+M'!QNY&/3J:M^(U@N&CBE5I'5MZQ)DYY
MVY8<+M!/5B!P1G&X$ TK758;P[(I$=@,X1U8X]< U7\2ZE_9EM+<#.Y5^4@
MX9OE4X/'!(S[>M87CC4V^RL6B>-@R%'9HN&# Y&V0MG&>@SC/;-7?'A,EN+9
M0-UQ+'&"3@ EMP)X/]W'XY]J -)-32Q5([F6,2[%W;G5<G&"0#C@D'L*T:I6
M.D1V<9@ RK9W;_F+EOO%B>I/?\NG%9O@Z0[)H<DK#<R1H"<X1<;5R>3C/&<\
M<=* -V201 NQ 4 DDG  '4DU6;585*H9$W2 %1O7+!NA SSGMCK67XXD/V5H
M4)$DS)&@!QDLPRN>@R <YP,<5#K6G0Z)I\L*K\@0CH"2S84,<XYW$'/;' X
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M@H*Y4#Z9'.1F@#3\)ZE)J<3W$F=KROY>0H/E@X .WT((YY^HQ6S)((@78@*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH S/$L4L]M+' H:1UV@$@<-PW
M)(' )(YZ^O2KME:BSC2%<[8U51GKA1@9J:B@#,\2:2=6MWME(#.!@GIE6##/
MUQCVZX/2FSW]PPV1PX<Y&Z1U\H<'GY2789Q@;5)'7;6K10!@>#M(ETN.6.;)
M8SNP8D$L"% 8\G&<9P3GUJ3PGITMG$[3@"6:5Y&48PI8XP""<],]>^.U;=%
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M H6PQ!R> %S@9)8%L+H7^GLDR7L0#,J,CJ2060D,-IS@,".,X!R06'!K5HH
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M\<3_ .)KG_M"_P!X?F*/M"_WA^8H]EY?@'U?"?RP^Y'0?\)K=_\ /3_QQ/\
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M\/S%'VA?[P_,4>R\OP#ZOA/Y8?<CH/\ A-;O_GI_XXG_ ,31_P )K=_\]/\
MQQ/_ (FN?^T+_>'YBC[0O]X?F*/9>7X!]7PG\L/N1T'_  FMW_ST_P#'$_\
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M^\/S%'VA?[P_,4>R\OP#ZOA/Y8?<CH/^$UN_^>G_ (XG_P 31_PFMW_ST_\
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M/^$UN_\ GI_XXG_Q-<_]H7^\/S%'VA?[P_,4>R\OP#ZOA/Y8?<CH/^$UN_\
MGI_XXG_Q-'_":W?_ #T_\<3_ .)KG_M"_P!X?F*/M"_WA^8H]EY?@'U?"?RP
M^Y'0?\)K=_\ /3_QQ/\ XFC_ (36[_YZ?^.)_P#$US_VA?[P_,4?:%_O#\Q1
M[+R_ /J^$_EA]R.@_P"$UN_^>G_CB?\ Q-'_  FMW_ST_P#'$_\ B:Y_[0O]
MX?F*/M"_WA^8H]EY?@'U?"?RP^Y'0?\ ":W?_/3_ ,<3_P")H_X36[_YZ?\
MCB?_ !-<_P#:%_O#\Q1]H7^\/S%'LO+\ ^KX3^6'W(Z#_A-;O_GI_P".)_\
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MX36[_P">G_CB?_$T?\)K=_\ /3_QQ/\ XFN?^T+_ 'A^8H^T+_>'YBCV7E^
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M\<3_ .)KG_M"_P!X?F*/M"_WA^8H]EY?@'U?"?RP^Y'0?\)K=_\ /3_QQ/\
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M\/S%'VA?[P_,4>R\OP#ZOA/Y8?<CH/\ A-;O_GI_XXG_ ,31_P )K=_\]/\
MQQ/_ (FN?^T+_>'YBC[0O]X?F*/9>7X!]7PG\L/N1T'_  FMW_ST_P#'$_\
MB:/^$UN_^>G_ (XG_P 37/\ VA?[P_,4?:%_O#\Q1[+R_ /J^$_EA]R.@_X3
M6[_YZ?\ CB?_ !-'_":W?_/3_P <3_XFN?\ M"_WA^8H^T+_ 'A^8H]EY?@'
MU?"?RP^Y'0?\)K=_\]/_ !Q/_B:/^$UN_P#GI_XXG_Q-<_\ :%_O#\Q1]H7^
M\/S%'LO+\ ^KX3^6'W(Z#_A-;O\ YZ?^.)_\31_PFMW_ ,]/_'$_^)KG_M"_
MWA^8H^T+_>'YBCV7E^ ?5\)_+#[D=!_PFMW_ ,]/_'$_^)H_X36[_P">G_CB
M?_$US_VA?[P_,4?:%_O#\Q1[+R_ /J^$_EA]R.@_X36[_P">G_CB?_$T?\)K
M=_\ /3_QQ/\ XFN?^T+_ 'A^8H^T+_>'YBCV7E^ ?5\)_+#[D=!_PFMW_P ]
M/_'$_P#B:/\ A-;O_GI_XXG_ ,37/_:%_O#\Q1]H7^\/S%'LO+\ ^KX3^6'W
M(Z#_ (36[_YZ?^.)_P#$T?\ ":W?_/3_ ,<3_P")KG_M"_WA^8H^T+_>'YBC
MV7E^ ?5\)_+#[D=!_P )K=_\]/\ QQ/_ (FC_A-;O_GI_P".)_\ $US_ -H7
M^\/S%'VA?[P_,4>R\OP#ZOA/Y8?<CH/^$UN_^>G_ (XG_P 31_PFMW_ST_\
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M/^$UN_\ GI_XXG_Q-<_]H7^\/S%'VA?[P_,4>R\OP#ZOA/Y8?<CH/^$UN_\
MGI_XXG_Q-'_":W?_ #T_\<3_ .)KG_M"_P!X?F*/M"_WA^8H]EY?@'U?"?RP
M^Y'0?\)K=_\ /3_QQ/\ XFC_ (36[_YZ?^.)_P#$US_VA?[P_,4?:%_O#\Q1
M[+R_ /J^$_EA]R.@_P"$UN_^>G_CB?\ Q-'_  FMW_ST_P#'$_\ B:Y_[0O]
MX?F*/M"_WA^8H]EY?@'U?"?RP^Y'0?\ ":W?_/3_ ,<3_P")H_X36[_YZ?\
MCB?_ !-<_P#:%_O#\Q1]H7^\/S%'LO+\ ^KX3^6'W(Z#_A-;O_GI_P".)_\
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MX36[_P">G_CB?_$T?\)K=_\ /3_QQ/\ XFN?^T+_ 'A^8H^T+_>'YBCV7E^
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M\<3_ .)KG_M"_P!X?F*/M"_WA^8H]EY?@'U?"?RP^Y'0?\)K=_\ /3_QQ/\
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M\/S%'VA?[P_,4>R\OP#ZOA/Y8?<CH/\ A-;O_GI_XXG_ ,31_P )K=_\]/\
MQQ/_ (FN?^T+_>'YBC[0O]X?F*/9>7X!]7PG\L/N1T'_  FMW_ST_P#'$_\
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MT4450PHKI--^'MY?8.S8K9YD.W&/5>6'M\OOTYJ[<_"ZXMD:5Y(@J*6)RYP
M,D\)GI6+Q5%.W,KD^TCW..HHHK8H**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH TO#7_'U!_P!=XO\ T,5I?$3_ (_YO^V?_HM:S?#7
M_'U!_P!=XO\ T,5I?$3_ (_YO^V?_HM:P?\ O"_PO\T1]OY'-UZ1X+_Y!5U_
MVW_]$K7F]>D>"_\ D%77_;?_ -$K48[^&O5"J[?,Y_X<ZA%8W8:8@ HP5FP
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5M^&_"4OB#?Y)0>7MSO)'WLXQA3Z5B45,U)JR=F)WL>K
MWO@>:?3XM.#)YD4A8DEMN"7Z';G/S#MZUY[XA\.R:#(()2I9E#?(21@DCN!S
MQ652UC1HU*;?O73N]NK^9,8N/4<R8&:93^WXTRKHN33N[ZL<;A1116I04444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !2@XI**&KJP$F\=,?K3"<TE%1"C&#N
2K_>W^;$HI!1115C"BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519624953920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Nov. 10, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LISATA THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-2343568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">110 Allen Road, 2nd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Basking Ridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">842-0100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationFormerLegalOrRegisteredName', window );">Entity Information, Former Legal or Registered Name</a></td>
<td class="text">Caladrius Biosciences, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LSTA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000320017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,859,684<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationFormerLegalOrRegisteredName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Former Legal or Registered Name of an entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationFormerLegalOrRegisteredName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519624566000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 31,478<span></span>
</td>
<td class="nump">$ 24,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">44,052<span></span>
</td>
<td class="nump">70,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">1,760<span></span>
</td>
<td class="nump">1,212<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">77,290<span></span>
</td>
<td class="nump">96,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">299<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">352<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">588<span></span>
</td>
<td class="nump">764<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">78,529<span></span>
</td>
<td class="nump">97,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">974<span></span>
</td>
<td class="nump">1,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">5,417<span></span>
</td>
<td class="nump">2,589<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">6,391<span></span>
</td>
<td class="nump">4,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">6,758<span></span>
</td>
<td class="nump">5,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.000067 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at September 30, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, authorized 33,333,333 shares; issued 7,863,340 and 3,986,719 shares at September 30, 2022 and December 31, 2021, respectively; and outstanding, 7,862,602 and 3,985,981 shares at September 30, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">574,066<span></span>
</td>
<td class="nump">546,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost; 738 shares at September 30, 2022 and December 31, 2021</a></td>
<td class="num">(708)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(501,251)<span></span>
</td>
<td class="num">(453,016)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(90)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Lisata Therapeutics, Inc. stockholders' equity</a></td>
<td class="nump">72,025<span></span>
</td>
<td class="nump">92,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interests</a></td>
<td class="num">(254)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="nump">71,771<span></span>
</td>
<td class="nump">92,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, non-controlling interests and stockholders' equity</a></td>
<td class="nump">$ 78,529<span></span>
</td>
<td class="nump">$ 97,008<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519625946304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_PreferredStockLiquidationPreferenceShare', window );">Preferred stock, liquidation value</a></td>
<td class="nump">0.000067<span></span>
</td>
<td class="nump">0.000067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_PreferredStockSharesDesignated', window );">Preferred stock, shares designated</a></td>
<td class="nump">825,000<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">33,333,333<span></span>
</td>
<td class="nump">33,333,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">7,863,340<span></span>
</td>
<td class="nump">3,986,719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="nump">7,862,602<span></span>
</td>
<td class="nump">3,985,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (shares)</a></td>
<td class="nump">738<span></span>
</td>
<td class="nump">738<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_PreferredStockLiquidationPreferenceShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Liquidation Preference, Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_PreferredStockLiquidationPreferenceShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_PreferredStockSharesDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock, shares designated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_PreferredStockSharesDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519624455392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 3,380<span></span>
</td>
<td class="nump">$ 4,125<span></span>
</td>
<td class="nump">$ 9,898<span></span>
</td>
<td class="nump">$ 13,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="nump">30,393<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,393<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,947<span></span>
</td>
<td class="nump">2,843<span></span>
</td>
<td class="nump">10,770<span></span>
</td>
<td class="nump">8,671<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">37,720<span></span>
</td>
<td class="nump">6,968<span></span>
</td>
<td class="nump">51,061<span></span>
</td>
<td class="nump">22,201<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(37,720)<span></span>
</td>
<td class="num">(6,968)<span></span>
</td>
<td class="num">(51,061)<span></span>
</td>
<td class="num">(22,201)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income, net</a></td>
<td class="nump">337<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">496<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">337<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">347<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before benefit from income taxes and noncontrolling interests</a></td>
<td class="num">(37,383)<span></span>
</td>
<td class="num">(6,927)<span></span>
</td>
<td class="num">(50,714)<span></span>
</td>
<td class="num">(22,180)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,479)<span></span>
</td>
<td class="num">(1,508)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Lisata Therapeutics, Inc. common stockholders</a></td>
<td class="num">$ (37,383)<span></span>
</td>
<td class="num">$ (6,927)<span></span>
</td>
<td class="num">$ (48,235)<span></span>
</td>
<td class="num">$ (20,672)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Basic and diluted loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Caladrius Biosciences, Inc. common stockholders - basic (in usd per share)</a></td>
<td class="num">$ (7.88)<span></span>
</td>
<td class="num">$ (1.74)<span></span>
</td>
<td class="num">$ (11.28)<span></span>
</td>
<td class="num">$ (5.76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Caladrius Biosciences, Inc. common stockholders - diluted (in usd per share)</a></td>
<td class="num">$ (7.88)<span></span>
</td>
<td class="num">$ (1.74)<span></span>
</td>
<td class="num">$ (11.28)<span></span>
</td>
<td class="num">$ (5.76)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic shares</a></td>
<td class="nump">4,747<span></span>
</td>
<td class="nump">3,974<span></span>
</td>
<td class="nump">4,276<span></span>
</td>
<td class="nump">3,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted shares</a></td>
<td class="nump">4,747<span></span>
</td>
<td class="nump">3,974<span></span>
</td>
<td class="nump">4,276<span></span>
</td>
<td class="nump">3,587<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519624926144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (37,383)<span></span>
</td>
<td class="num">$ (6,927)<span></span>
</td>
<td class="num">$ (48,235)<span></span>
</td>
<td class="num">$ (20,672)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Available for sale securities - net unrealized gain (loss)</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</a></td>
<td class="num">(25)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive loss</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Lisata Therapeutics, Inc. common stockholders</a></td>
<td class="num">$ (37,403)<span></span>
</td>
<td class="num">$ (6,974)<span></span>
</td>
<td class="num">$ (48,255)<span></span>
</td>
<td class="num">$ (20,723)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519620362368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Total Lisata Therapeutics, Inc. Stockholders' Equity</div></th>
<th class="th"><div>Series B Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Non- Controlling Interest in Subsidiary</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 32,242<span></span>
</td>
<td class="nump">$ 32,496<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 458,766<span></span>
</td>
<td class="num">$ (13)<span></span>
</td>
<td class="num">$ (425,550)<span></span>
</td>
<td class="num">$ (708)<span></span>
</td>
<td class="num">$ (254)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,292,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(20,672)<span></span>
</td>
<td class="num">(20,672)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,672)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,391<span></span>
</td>
<td class="nump">1,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from issuances of common stock</a></td>
<td class="nump">85,479<span></span>
</td>
<td class="nump">85,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">85,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from issuance of common stock and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,658,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from option exercises</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,986,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">98,413<span></span>
</td>
<td class="nump">98,667<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">545,657<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="num">(446,222)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2021</a></td>
<td class="nump">104,679<span></span>
</td>
<td class="nump">104,933<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">544,949<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(439,295)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, beginning balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,967,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(6,927)<span></span>
</td>
<td class="num">(6,927)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,927)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">708<span></span>
</td>
<td class="nump">708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,986,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 98,413<span></span>
</td>
<td class="nump">98,667<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">545,657<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="num">(446,222)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 92,000<span></span>
</td>
<td class="nump">92,254<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">546,044<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="num">(453,016)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">3,985,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,986,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (48,235)<span></span>
</td>
<td class="num">(48,235)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48,235)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,899<span></span>
</td>
<td class="nump">1,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from issuances of common stock</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock in connection with Merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,773,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock in connection with merger</a></td>
<td class="nump">26,098<span></span>
</td>
<td class="nump">26,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">26,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from issuance of common stock and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">$ (25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">7,862,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,863,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 71,771<span></span>
</td>
<td class="nump">72,025<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">574,066<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="num">(501,251)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2022</a></td>
<td class="nump">82,137<span></span>
</td>
<td class="nump">82,391<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">547,032<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="num">(463,868)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, beginning balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,038,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(37,383)<span></span>
</td>
<td class="num">(37,383)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,383)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">939<span></span>
</td>
<td class="nump">939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock in connection with Merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,773,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock in connection with merger</a></td>
<td class="nump">26,098<span></span>
</td>
<td class="nump">26,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">26,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">$ (25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="nump">7,862,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,863,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 71,771<span></span>
</td>
<td class="nump">$ 72,025<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 574,066<span></span>
</td>
<td class="num">$ (90)<span></span>
</td>
<td class="num">$ (501,251)<span></span>
</td>
<td class="num">$ (708)<span></span>
</td>
<td class="num">$ (254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519625967376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (48,235)<span></span>
</td>
<td class="num">$ (20,672)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Share-based compensation</a></td>
<td class="nump">2,168<span></span>
</td>
<td class="nump">1,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Foreign Currency Transaction Gain (Loss), Unrealized</a></td>
<td class="nump">30,393<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion on marketable securities</a></td>
<td class="nump">893<span></span>
</td>
<td class="nump">1,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other current assets</a></td>
<td class="nump">29<span></span>
</td>
<td class="num">(1,199)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities', window );">Accounts payable, accrued liabilities and other liabilities</a></td>
<td class="num">(150)<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(14,702)<span></span>
</td>
<td class="num">(17,641)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(68,481)<span></span>
</td>
<td class="num">(137,329)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sale of marketable securities</a></td>
<td class="nump">93,865<span></span>
</td>
<td class="nump">66,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Investment in Cend Therapeutics</a></td>
<td class="num">(3,320)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(259)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">21,805<span></span>
</td>
<td class="num">(71,354)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholding payments on net share settlement equity awards</a></td>
<td class="num">(267)<span></span>
</td>
<td class="num">(248)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">85,479<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(238)<span></span>
</td>
<td class="nump">85,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(34)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">6,831<span></span>
</td>
<td class="num">(3,740)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">24,647<span></span>
</td>
<td class="nump">16,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">31,478<span></span>
</td>
<td class="nump">12,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock in connection with merger</a></td>
<td class="nump">23,580<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Incremental fair value of Cend's fully vested stock options assumed</a></td>
<td class="nump">$ 2,136<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519707405056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_BusinessTextBlock', window );">The Business</a></td>
<td class="text">The Business<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lisata Therapeutics, Inc. (together with its subsidiaries, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Lisata&#8221; or the &#8220;Company&#8221;) is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Lisata&#8217;s lead investigational product candidate, LSTA1 (formerly known as CEND-1), is designed to activate a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment (&#8220;TME&#8221;), making tumors more susceptible to immunotherapies. LSTA1 has demonstrated favorable safety, tolerability, and activity to date in completed and ongoing clinical trials to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. Lisata and its collaborators have also amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics. Lisata is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively. In addition, Lisata also has clinical development programs based on its autologous CD34+ cell therapy technology platform.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience across a variety of therapeutic categories and at all stages of development from preclinical through to product registration and launch. Its goal is to develop and commercialize products that address important unmet medical needs based on a broad and versatile portfolio of candidates. The Company&#8217;s current product candidates include: </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">LSTA1, the subject of phase 1b/2a and 2b clinical studies being conducted globally in a variety of solid tumor types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a variety of anti-cancer regimens;</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (LSTA16 formerly CLBS16), the subject of both a completed positive Phase 2a study (ESCaPE-CMD) and follow on Phase 2b study (FREEDOM Trial) in the United States for the treatment of coronary microvascular dysfunction (&#8220;CMD&#8221;); </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (LSTA12 formerly CLBS12), recipient of SAKIGAKE designation, pursuant to which early conditional approval in Japan for the treatment of critical limb ischemia (&#8220;CLI&#8221;) and Buerger&#8217;s disease is being sought based on the current results of a clinical trial executed in Japan. HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was the recipient of orphan drug designation in March 2021 from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for Buerger's disease; and</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">LSTA201 (formerly CLBS201), the subject of a study designed to assess the safety and efficacy of CD34+ cell therapy as a regenerative treatment for patients with chronic kidney disease related to type 2 diabetes (diabetic kidney disease or &#8220;DKD&#8221;).</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Merger with Cend Therapeutics, Inc. and Name Change</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2022, the Company, then operating as Caladrius Biosciences, Inc. (&#8220;Caladrius"), completed its acquisition of Cend Therapeutics, Inc. (&#8220;Cend&#8221;), a Delaware corporation (the &#8220;Merger&#8221;), in accordance with the terms of the Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), dated as of April 26, 2022, by and among Caladrius, Cend and CS Cedar Merger Sub, Inc. (&#8220;Merger Sub&#8221;).</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms set forth in the Merger Agreement and effective September 15, 2022 (the &#8220;Effective Time&#8221;): (i) Merger Sub merged with and into Cend, with Cend surviving as a wholly owned subsidiary of Caladrius, (ii) Caladrius changed its name to Lisata Therapeutics, Inc. in connection with and immediately following to the Effective Time, and (iii) Caladrius effected a 1:15 reverse stock split of its common stock (&#8220;Reverse Stock Split&#8221;) prior to the Effective Time. At the Effective Time, each share of Cend's common stock outstanding immediately prior to the Effective Time was converted into the right to receive shares of Lisata&#8217;s common stock based on an exchange ratio of 0.5338 (the &#8220;Exchange Ratio&#8221;), after taking into account the Reverse Stock Split. In connection with the Merger close, the Company issued an aggregate of 3,772,768 shares of common stock, based on the Exchange Ratio, to holders of Cend, in exchange for all of the Cend capital stock outstanding immediately prior to the closing of the Merger.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Merger Agreement, Lisata assumed all of the outstanding and unexercised options to purchase shares of Cend capital stock under the 2016 Equity Incentive Plan (the &#8220;Cend Plan&#8221;), and, in connection with the Merger, such options were converted into options to purchase shares of Lisata&#8217;s common stock based on the Exchange Ratio. At the closing of the Merger at the Effective Time, the Company assumed Cend's stock options to purchase an aggregate of 1,227,776 shares of the Company's common stock. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caladrius was considered to be the accounting acquirer based on the terms of the Merger Agreement and certain factors including: (i) Caladrius owned approximately 52% of the Company's outstanding shares of common stock immediately following the close of the Merger; (ii) although both entities contributed to the new management team of Lisata, the Caladrius team has more individuals on the management team and will hold the CEO, CMO and other senior management roles; (iii) Caladrius paid a premium to acquire Cend&#8217;s assets; and (iv) Caladrius was significantly larger than Cend regarding total assets, operations, and research and development activities. The Merger was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (&#8220;IPR&amp;D&#8221;). Cend&#8217;s assets (except for cash and working capital) were measured and recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated with IPR&amp;D with no alternative future use being expensed as reported in the consolidated statement of operations. The prior reported operating results prior to the Merger close are those of Caladrius alone.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coronavirus Considerations</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In December 2019, a novel strain of coronavirus (SARS-CoV-2), which causes COVID-19, was reported to have surfaced in China. In March 2020, the World Health Organization declared the outbreak of COVID-19 to be a pandemic, and the world's economies began to experience pronounced effects. Despite the FDA approval of multiple COVID-19 vaccines in late 2020, there remains uncertainty around the extent and duration of disruption and any future related financial impact cannot reasonably be estimated at this time. In response to the COVID-19 pandemic, the Company implemented a universal work from home policy as well as stringent social distancing and other hygiene policies for employees when they must be in the office. The Company's clinical study of HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan experienced significant delays in enrollment due to the States of Emergency in effect in Japan for most of 2020, 2021, and 2022 covering Tokyo and other regions in response to an increased number of COVID-19 infections. With the Company's expectation that COVID-19 in Japan will continue to impact negatively clinical site operations and enrollment of patients in the HONEDRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical trial, it elected to suspend trial enrollment, seek a development partner and consult with the Japanese regulatory authorities regarding the submission of patient data already accrued. Caladrius' phase 2b FREEDOM Trial of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. has also experienced delays in enrolling patients as a result of COVID-19. While early enrollment proceeded to plan with the first patient treated in January 2021, the impact of the COVID-19 pandemic contributed to a general slowing of enrollment, including supply chain disruptions affecting the availability of qualified catheters used in the diagnosis of CMD and/or administration of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as with a contrast agent typically used in many catheter laboratories. In May 2022, the Company announced that enrollment in the FREEDOM Trial had been suspended and that it intended to conduct an interim analysis of the data from not less than the first 20 patients enrolled using the 6-month follow-up data to evaluate the efficacy and safety of XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in subjects with CMD. Following the analysis of results of the FREEDOM Trial subjects completing 6-month follow-up along with Key Opinion Leaders&#8217; input, the Company&#8217;s board of directors determined that execution of a redesigned FREEDOM-like trial would be the appropriate next step, but the cost of such a trial would be prohibitively expensive to undergo without a strategic partner. Accordingly, the Company&#8217;s board of directors concluded that XOWNA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> development will only be continued if a strategic partner that can contribute the necessary capital for a redesigned trial is identified and secured. There can be no assurance that we will be able to identify such a partner and enter into an agreement with such partner on acceptable terms or at all.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 14, 2022, in connection with the Merger, the Company implemented the Reverse Stock Split, as authorized at the annual meeting of stockholders on September 13, 2022. The Reverse Stock Split became effective on September 14, 2022 at 5:00 pm and the Company's common stock began trading on The Nasdaq Capital Market on a post-split basis at the open of business on September 15, 2022. As of September 14, 2022, every fifteen shares of the Company&#8217;s issued and outstanding common stock (and such shares held in treasury) were automatically converted into one share of common stock, without any change in the par value per share. In addition, proportionate adjustments were made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options, stock appreciation rights, convertible notes and warrants to purchase shares of common stock, the number of shares issuable upon the vesting of all restricted stock awards, and the number of shares of common stock reserved for issuance pursuant to the Company&#8217;s equity incentive compensation plans. Any stockholder who would otherwise be entitled to a fractional share of common stock created as a result of the Reverse Stock Split received a cash payment equal to the product of such resulting fractional interest in one share of common stock multiplied by the closing trading price of the common stock on September 15, 2022. The Reverse Stock Split was effectuated in order to </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase the per share trading price of our common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods presented to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from &#8220;common stock&#8221; to &#8220;additional paid-in capital&#8221; in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of September&#160;30, 2022, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2021 and 2020 included in our 2021 Form 10-K. Operating results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values and the valuation of the Merger which was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (&#8220;IPR&amp;D&#8221;). Accordingly, actual results could differ from those estimates and assumptions.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of Lisata and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Remeasurement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is the U.S. Dollar. The functional currency of DrugCendR Australia PTY Ltd. which is a foreign subsidiary of the Company is the Australian Dollar. The assets and liabilities of DrugCendR Australia PTY Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_BusinessTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Business [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_BusinessTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519627377824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and Australia.  Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property and equipment are as follows:</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life of lease</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-lived Assets</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment and intangibles. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company&#8217;s restricted stock and restricted stock units is based on the closing market price of the Company&#8217;s common stock on the date of grant. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (&#8220;R&amp;D&#8221;) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further drive the Company&#8217;s initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company&#8217;s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-process Research and Development Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#8220;business&#8221; as defined under GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Asset</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible asset consists of a single asset, Cend&#8217;s license agreement with Qilu Pharmaceutical, Co., Ltd. (&#8220;Qilu&#8221;) acquired in the Merger, with a value of $0.4&#160;million. The intangible asset is stated at fair value and is amortized using the straight-line method over its estimated useful life of 5 years. Amortization expense was $3 thousand for the three and nine months ended September&#160;30, 2022. The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable.  The projected amortization expense is $71 thousand per year for the next five years. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. There was no revenue recognized for the three and nine months ended September&#160;30, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestones</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company&#8217;s collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company&#8217;s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519627279952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Merger</a></td>
<td class="text">Merger<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger was accounted for as an asset acquisition as substantially all of the fair value was concentrated in IPR&amp;D. Cend&#8217;s assets (except for cash and working capital) were measured and recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated with IPR&amp;D being expensed. The fair value of total consideration was $36.1&#160;million. The following table is a summary of the purchase price calculation (in thousands except per share data).</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:448.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of common shares of the combined company owned by Cend stockholders</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,772,768&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Multiplied by the fair value per share of Lisata common stock on September 15, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.25</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$23,580</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of Lisata's cost method investment in Cend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental fair value of Cend's fully vested stock options</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,136&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lisata transaction costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total purchase price</span></td><td colspan="3" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$36,098</span></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The allocation of the purchase price was as follows (amounts in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:448.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7,062</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net working capital (excluding cash)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,690)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$36,098</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures.  This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519630847728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale-Securities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Available-for-Sale-Securities</a></td>
<td class="text">Available-for-Sale-Securities<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"><tr><td style="width:1.0pt"/><td style="width:94.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,332&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,522&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:360.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.75pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,332&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:361.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,332&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,332&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519627200800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Income (Loss) Per Share</a></td>
<td class="text">Income (Loss) Per Share<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September&#160;30, 2022 and 2021, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive. At September&#160;30, 2022 and 2021, the Company excluded the following potentially dilutive securities (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519627325728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth by level within the fair value hierarchy the Company's financial assets that were accounted for at fair value on a recurring basis as of September&#160;30, 2022 and December&#160;31, 2021 (in thousands).</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:116.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:12.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities - available for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,052&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,052&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519627242176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text">Accrued Liabilities<div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of September&#160;30, 2022 and December&#160;31, 2021 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"><tr><td style="width:1.0pt"/><td style="width:313.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, employee benefits and related taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities &#8212; current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and R&amp;D related liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,417&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519626884752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text">Operating LeasesThe Company has operating leases for two offices with terms that expire in 2023 and 2025, respectively. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. Each of the Company's leases includes options for the Company to extend the lease term and/or sub-lease space in whole or in part.<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:325.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of Use Assets:</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfMi0wLTEtMS0yMjg1OA_188c2eed-0925-44f8-bfd8-8dc48bf41cee"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfMi0wLTEtMS0yMjg1OA_cda64072-7450-44a6-a48d-ee2b330b6907">Other assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Right-of-Use Asset</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNi0wLTEtMS0yMjg1OA_466bdee9-6b20-428a-b677-b820ae3ba607"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNi0wLTEtMS0yMjg1OA_62800bd1-bc30-473e-aedd-b0b3d9f06907">Accrued liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNy0wLTEtMS0yMjg1OA_ceb1d506-32b0-442d-b209-59921ea40600"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNy0wLTEtMS0yMjg1OA_f9192e00-f937-46b7-9c41-0640551a459c">Other long-term liabilities</span></span></span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Lease Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the weighted average remaining lease term for our operating leases was 1.8 years, and the weighted average discount rate for our operating leases was 9.625%. Future minimum lease payments under the lease agreements as of September&#160;30, 2022 were as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:448.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519627279952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 14, 2022, in connection with the merger, we implemented the Reverse Stock Split, as described in Note 1. All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods presented to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from &#8220;common stock&#8221; to &#8220;additional paid-in capital&#8221; in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Issuances</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Purchase Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March&#160;2019, the Company and Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) entered into a purchase agreement (the &#8220;Purchase Agreement&#8221;) and a registration rights agreement (the &#8220;Registration Rights Agreement&#8221;), pursuant to which the Company has the right to sell to Lincoln Park shares of the Company&#8217;s common stock having an aggregate value of up to $26.0 million, subject to certain limitations and conditions set forth in the Purchase Agreement (the &#8220;Offering&#8221;). As consideration for entering into the Purchase Agreement, the Company issued to Lincoln Park an additional 181,510 shares of common stock as commitment shares.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Purchase Agreement, Lincoln Park purchased 250,000 shares of common stock, at a price of $4.00 per share, for a total gross purchase price of $1.0 million (the &#8220;Initial Purchase&#8221;) upon commencement. Thereafter, as often as every business day from and after one business day following the date of the Initial Purchase and over the 36-month term of the Purchase Agreement, the Company has the right, from time to time, at its sole discretion and subject to certain conditions, to direct Lincoln Park to purchase up to 100,000 shares of common stock, with such amount increasing as the closing sale price of the common stock increases; provided Lincoln Park&#8217;s obligation under any single such purchase will not exceed $2.5 million, unless the Company and Lincoln Park mutually agree to increase the maximum amount of such single purchase (each, a &#8220;Regular Purchase&#8221;).&#160;If the Company directs Lincoln Park to purchase the maximum number of shares of common stock it then may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations in the Purchase Agreement, the Company may direct Lincoln Park in an &#8220;accelerated purchase&#8221; to purchase an additional amount </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of common stock that may not exceed the lesser of (i)&#160;300% the number of shares purchased pursuant to the corresponding Regular Purchase or (ii)&#160;30% of the total number of shares of the Company&#8217;s common stock traded during a specified period on the applicable purchase date as set forth in the Purchase Agreement. Under certain circumstances and in accordance with the Purchase Agreement, the Company may direct Lincoln Park to purchase shares in multiple accelerated purchases on the same trading day.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company controls the timing and amount of any sales of its common stock to Lincoln Park.&#160;There is no upper limit on the price per share that Lincoln Park must pay for its common stock under the Purchase Agreement, but in no event will shares be sold to Lincoln Park on a day the closing price is less than the floor price specified in the Purchase Agreement. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the purchase agreement if it would result in Lincoln Park beneficially owning more than 9.99% of its common stock.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Purchase Agreement does not limit the Company&#8217;s ability to raise capital from other sources at the Company&#8217;s sole discretion, except that (subject to certain exceptions) the Company may not enter into any Variable Rate Transaction (as defined in the Purchase Agreement, including the issuance of any floating conversion rate or variable priced equity-like securities) during the 36 months after the date of the Purchase Agreement. The Company has the right to terminate the Purchase Agreement at any time, at no cost to the Company.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company had not made any sales of common stock to Lincoln Park under the Purchase Agreement other than the Initial Purchase. The agreement expired on April 1, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">At The Market Offering Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 4, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;ATM Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC, as sales agent, in connection with an &#8220;at the market offering&#8221; under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $50.0&#160;million.  During the nine months ended September&#160;30, 2022 and since inception, the Company has not issued any shares under the ATM Agreement. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger close, the Company issued an aggregate of 3,772,768 shares of common stock, based on the Exchange Ratio, to holders of Cend, in exchange for all of the Cend capital stock outstanding immediately prior to the closing of the Merger. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options and Warrants</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger and after giving effect to the Reverse Stock Split, the Company assumed 1,227,776 options outstanding from Cend. The options granted from the Cend Plan are exercisable at various dates as determined upon grant and will expire no more than ten years from their original date of grant. The Cend Plan stock options generally vest over a four-year term. The following table summarizes the activity for stock options and warrants for the nine months ended September&#160;30, 2022:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142,041&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.97</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,423,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.37</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assumed through merger</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,227,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,910)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,388)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">352.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,398,977&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,423,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at September 30, 2022<br/>&#160;or expected to vest in the future</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,396,921&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.83&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,423,774&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.57&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.63</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,110,635&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.82&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.97</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,423,774&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.57&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022 and 2021, the Company issued restricted stock for services as follows ($ in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"><tr><td style="width:1.0pt"/><td style="width:322.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:4.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vesting terms of restricted stock issuances are generally between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNDg3Mw_6c617069-871e-4bcc-ac83-10a9da649366">one</span> and four years.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022 and 2021, the Company issued restricted stock units for services as follows ($ in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"><tr><td style="width:1.0pt"/><td style="width:343.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock units issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111,170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock units issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,386&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The weighted average estimated fair value of restricted stock issued for services in the nine months ended September&#160;30, 2022 and 2021 was $12.46 and $23.85 per share, respectively. The fair value of the restricted stock units was determined using the Company&#8217;s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally one year, or upon the achievement of performance-based milestones.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519707444768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Payment Arrangement, Noncash Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize share-based compensation in the form of stock options, restricted stock, and restricted stock units.&#160;The following table summarizes the components of share-based compensation expense for the three and nine months ended September&#160;30, 2022 and 2021 (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:44.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost related to non-vested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at September&#160;30, 2022 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized compensation cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted-average period in years of compensation cost to be recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.66</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.16</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.83</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the nine months ended September&#160;30, 2022 and 2021 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:378.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average estimated fair value of shares granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation Assumptions</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options and warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company&#8217;s common stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519627313808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (&#8220;NOLs&#8221;), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.  Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the Company had approximately $281&#160;million and $264&#160;million, respectively, of federal NOLs available to offset future taxable income expiring from 2030 through 2036.&#160;The Company performed an analysis and determined that it had an ownership change of greater than 50% over a 3-year testing period on January 25, 2021.  As a result, $169&#160;million of the $281&#160;million of federal NOLs will expire unutilized.  The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $112&#160;million of remaining federal NOL.  The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on January 25, 2021 will be subject to an annual limitation of $173 thousand under Internal Revenue Code Section 382, while losses incurred after January 25, 2021 will not be subject to limitations. The Company may be able to utilize additional NOLs of approximately $1.1&#160;million per year for the first five years after this ownership change as a result of the application of the Net Unrealized Built-in Gain rules.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the Company had state NOLs available in New Jersey of $97&#160;million and $99&#160;million, respectively, California of $70&#160;million and $70&#160;million, respectively, and New York City of $13&#160;million and $13&#160;million, respectively, to offset future taxable income expiring from 2031 through 2041. In accordance with Section 382 of the Internal Revenue code, the usage of the Company&#8217;s NOLs would be limited given the change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the FASB&#8217;s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with uncertain tax positions as a component of income tax expense.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For years prior to 2018, the federal statute of limitations is closed for assessing tax. The Company&#8217;s state tax returns remain open to examination for a period of three to four years from date of filing.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company received preliminary approval from the New Jersey Economic Development Authority (&#8220;NJEDA&#8221;) to participate in the Technology Business Tax Certificate Transfer Program (the &#8220;Program&#8221;). The Program permits qualified companies to sell a percentage of their New Jersey net operating losses (&#8220;NJ NOLs&#8221;) to unrelated profitable corporations. On February 22, 2022, the Company received final approval from NJEDA to sell $2.5&#160;million of its NJ NOLs related tax benefits (&#8220;NJ NOL Tax Benefits&#8221;), which was subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $2.3&#160;million. The gross proceeds of $2.5&#160;million have been recorded as a benefit from income taxes and the loss on sale of NJ NOLs of $0.1&#160;million recorded in other income (expense) in the consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519627417136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Australia Research and Development Tax Incentive<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_ResearchAndDevelopmentTaxIncentiveTextBlock', window );">Australia Research and Development Tax Incentive</a></td>
<td class="text">Australia Research and Development Tax IncentiveThe Company&#8217;s Australian subsidiary, which conducts core research and development activities, is eligible to receive a 43.5% refundable tax incentive for qualified research and development activities. As of the nine months ended September&#160;30, 2022, $0.4&#160;million was recorded as an income tax incentive receivable in the consolidated balance sheets, as the Company determined that the expenses met the eligibility criteria and the amounts claimed are expected to be received shortly after the related tax returns are filed.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_ResearchAndDevelopmentTaxIncentiveTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Tax Incentive</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_ResearchAndDevelopmentTaxIncentiveTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519627300400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies</a></td>
<td class="text">Contingencies<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, Cend received a written threat of litigation on behalf of a Chinese entity called Lingmed Limited (&#8220;Lingmed&#8221;) claiming Lingmed was entitled to a success fee based on Cend&#8217;s Collaboration and License Agreement with Qilu Pharmaceuticals. Cend responded by denying that Lingmed is entitled to a success fee under the terms of their agreement. In May 2022, Cend was served with a complaint filed by Lingmed in the San Diego County Superior Court, alleging claims for breach of contract, fraud and declaratory relief. Cend&#8217;s response to the complaint was filed on June 6, 2022. Lingmed filed an </span></div>answer to Cend&#8217;s response on July 11, 2022. The court held a case management conference on October 7, 2022, which resulted in a continuance until December 16, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519630835568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License Agreements</a></td>
<td class="text">License Agreements<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanford Burnham Prebys</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (&#8220;SBP&#8221;) under which Cend was granted an exclusive, worldwide, royalty-bearing license to certain patent rights and know-how controlled by SBP related to the development of CEND-1. At the time the license agreement was entered into, Cend&#8217;s founding shareholder, now a Lisata board member, was an executive at SBP. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 382,030 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $10,000 increasing to $20,000 on year seven of the agreement. The Company could also be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $10.6&#160;million. The Company has also agreed to pay SBP royalties of 4% of net sales of products sold by the Company, or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP 25% of any sublicensing income. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Cend entered into a license agreement with SBP under which Cend was granted an exclusive, royalty-bearing license to certain patent rights and know-how controlled by SBP. The agreement provides Cend with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. The Company is required to pay an annual license maintenance fee of $20,000, increasing to $30,000 on year four of the agreement. Further, the Company could be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $23.2&#160;million. The Company is obligated to pay SBP royalties of 4% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP varying sublicense fees, ranging from 10% to 25%, dependent on when the related milestones are reached. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreements will expire upon the later of (i) the final abandonment of all pending patent applications within the licensed patents or (ii) the expiration of the last to expire patent within the licensed patents. The agreements may be terminated in their entirety by the Company at any time by giving SBP sixty days&#8217; prior written notice. The agreements may be terminated in their entirety by SBP if the Company, at any time, defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice. The agreements may be terminated in their entirety by SBP or the Company (i) in the event of an uncured material breach by the other party, or (ii) in the event the other party (a) files for, or is involuntarily petitioned with, bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation), (b) makes an assignment of all or substantially all of its assets for the benefit of creditors, or (c) has a receiver or trustee is appointed and is unable to secure a dismissal, stay or other suspension of such proceedings within thirty days. Upon termination of the agreements for any reason, all rights and obligations of the Company with respect to the patents and patent applications shall terminate and revert to SBP.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SBP owned 382,030 shares of the Company&#8217;s common stock as of September 30, 2022 and is a related party. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">University of California at San Diego</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, Cend entered into a license agreement with the University of California at San Diego (&#8220;UCSD&#8221;) under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of nano-particles to modulate immune response. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell and otherwise exploit the patent rights. The Company could be required to make milestone payments to UCSD upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $1.2&#160;million. The Company has also agreed to pay UCSD royalties of 1.5% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company agreed to pay UCSD varying sublicense fees, ranging from 10% to 20%, dependent on when the related milestones are reached. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the expiration of the longest-lived patent rights. The agreement may be terminated in its entirety by the Company at any time by giving UCSD ninety days&#8217; prior written notice. The agreement may be terminated in its entirety by UCSD if the Company, at any time, (i) fails to perform or violates any term of the agreement and fails to cure the default within sixty days. Upon termination of the agreement for any reason, UCSD may terminate a sublicensee but will allow </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company to assign any sublicenses to UCSD provided a) that the sublicensee is in good standing upon termination of the agreement with the Company; and b) the sublicensee is not currently involved in litigation as an adverse party to UCSD.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Massachusetts Institute of Technology</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Cend entered into a license agreement with the Massachusetts Institute of Technology ("MIT") under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of tissue specific delivery of interfering RNA. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. The Company is required to pay an annual license maintenance fee of $20,000, increasing to $25,000 for year two and three of the agreement, increasing to $50,000 on year four of the agreement and thereafter until the first commercial sale, and increasing to $150,000 each year of the agreement after the first sale. Further, the Company could be required to make milestone payments to MIT upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $5.0&#160;million. The Company has also agreed to pay MIT royalties of 2% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay MIT varying sublicense fees, ranging from 3% to 20%, dependent on when the related milestones are reached. In connection with the close of the Merger,, the Company was required to pay MIT a change of control fee of $0.3&#160;million, which is included in accrued liabilities within the condensed consolidated balance sheets as of September 30, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the expiration or abandonment of all valid claims. The agreement may be terminated in its entirety by the Company at any time by giving MIT six months prior written notice. The agreement may be terminated in its entirety by MIT if the Company, at any time, (i) defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice, or (ii) commits a material breach of its obligations under the agreement (aside from item (i)) and fails to cure that breach within sixty days after receipt of written notice. Upon termination of the agreement for any reason, the rights and licenses granted to the Company shall terminate and revert to MIT. Upon termination of the agreement for any reason, MIT may terminate a sublicensee but will allow the Company to assign any sublicenses to MIT provided that the sublicensee is in good standing upon termination of the agreement with the Company.</span></div>Research Collaboration and License Agreement<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusive License and Collaboration Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Cend entered into an Exclusive License and Collaboration Agreement (the &#8220;Qilu Agreement&#8221;) in which Cend granted an exclusive license to Qilu for the development and commercialization of CEND-1 in the Territory (defined as the Greater Area of China including China, Macau, Hong Kong, and Taiwan). Under the terms of the agreement, Qilu is solely responsible for the development of CEND-1 in its Territory. In consideration for the license, Qilu made an upfront payment of $10&#160;million to Cend, which was recognized as revenue by Cend prior to the Merger. In addition, Cend received and recognized as revenue a $5&#160;million development milestone prior to the Merger. The Company is eligible to receive additional developmental and commercial milestone payments up to $100&#160;million and $125&#160;million, respectively, tiered royalties on net sales ranging from 10% to 15%, and tiered sublicensing revenues ranging from 12% to 35%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated early, the Qilu Agreement will continue in effect until the expiration of all Qilu payment obligations. Either party may terminate the Qilu Agreement if an undisputed material breach by the other party is not cured within a defined period of time, or upon notice for insolvency-related events of the other party that are not discharged within a defined time period. Qilu may terminate the Qilu Agreement in its entirety, at any time with at least sixty days written notice. All right and obligations of Qilu with respect to such licensed patents and patent applications would terminate.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519627209472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreement<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Research Collaboration and License Agreement</a></td>
<td class="text">License Agreements<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanford Burnham Prebys</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (&#8220;SBP&#8221;) under which Cend was granted an exclusive, worldwide, royalty-bearing license to certain patent rights and know-how controlled by SBP related to the development of CEND-1. At the time the license agreement was entered into, Cend&#8217;s founding shareholder, now a Lisata board member, was an executive at SBP. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 382,030 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $10,000 increasing to $20,000 on year seven of the agreement. The Company could also be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $10.6&#160;million. The Company has also agreed to pay SBP royalties of 4% of net sales of products sold by the Company, or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP 25% of any sublicensing income. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Cend entered into a license agreement with SBP under which Cend was granted an exclusive, royalty-bearing license to certain patent rights and know-how controlled by SBP. The agreement provides Cend with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. The Company is required to pay an annual license maintenance fee of $20,000, increasing to $30,000 on year four of the agreement. Further, the Company could be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $23.2&#160;million. The Company is obligated to pay SBP royalties of 4% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP varying sublicense fees, ranging from 10% to 25%, dependent on when the related milestones are reached. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreements will expire upon the later of (i) the final abandonment of all pending patent applications within the licensed patents or (ii) the expiration of the last to expire patent within the licensed patents. The agreements may be terminated in their entirety by the Company at any time by giving SBP sixty days&#8217; prior written notice. The agreements may be terminated in their entirety by SBP if the Company, at any time, defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice. The agreements may be terminated in their entirety by SBP or the Company (i) in the event of an uncured material breach by the other party, or (ii) in the event the other party (a) files for, or is involuntarily petitioned with, bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation), (b) makes an assignment of all or substantially all of its assets for the benefit of creditors, or (c) has a receiver or trustee is appointed and is unable to secure a dismissal, stay or other suspension of such proceedings within thirty days. Upon termination of the agreements for any reason, all rights and obligations of the Company with respect to the patents and patent applications shall terminate and revert to SBP.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SBP owned 382,030 shares of the Company&#8217;s common stock as of September 30, 2022 and is a related party. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">University of California at San Diego</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, Cend entered into a license agreement with the University of California at San Diego (&#8220;UCSD&#8221;) under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of nano-particles to modulate immune response. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell and otherwise exploit the patent rights. The Company could be required to make milestone payments to UCSD upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $1.2&#160;million. The Company has also agreed to pay UCSD royalties of 1.5% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company agreed to pay UCSD varying sublicense fees, ranging from 10% to 20%, dependent on when the related milestones are reached. </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the expiration of the longest-lived patent rights. The agreement may be terminated in its entirety by the Company at any time by giving UCSD ninety days&#8217; prior written notice. The agreement may be terminated in its entirety by UCSD if the Company, at any time, (i) fails to perform or violates any term of the agreement and fails to cure the default within sixty days. Upon termination of the agreement for any reason, UCSD may terminate a sublicensee but will allow </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company to assign any sublicenses to UCSD provided a) that the sublicensee is in good standing upon termination of the agreement with the Company; and b) the sublicensee is not currently involved in litigation as an adverse party to UCSD.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Massachusetts Institute of Technology</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Cend entered into a license agreement with the Massachusetts Institute of Technology ("MIT") under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of tissue specific delivery of interfering RNA. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. The Company is required to pay an annual license maintenance fee of $20,000, increasing to $25,000 for year two and three of the agreement, increasing to $50,000 on year four of the agreement and thereafter until the first commercial sale, and increasing to $150,000 each year of the agreement after the first sale. Further, the Company could be required to make milestone payments to MIT upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $5.0&#160;million. The Company has also agreed to pay MIT royalties of 2% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay MIT varying sublicense fees, ranging from 3% to 20%, dependent on when the related milestones are reached. In connection with the close of the Merger,, the Company was required to pay MIT a change of control fee of $0.3&#160;million, which is included in accrued liabilities within the condensed consolidated balance sheets as of September 30, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement will expire upon the expiration or abandonment of all valid claims. The agreement may be terminated in its entirety by the Company at any time by giving MIT six months prior written notice. The agreement may be terminated in its entirety by MIT if the Company, at any time, (i) defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice, or (ii) commits a material breach of its obligations under the agreement (aside from item (i)) and fails to cure that breach within sixty days after receipt of written notice. Upon termination of the agreement for any reason, the rights and licenses granted to the Company shall terminate and revert to MIT. Upon termination of the agreement for any reason, MIT may terminate a sublicensee but will allow the Company to assign any sublicenses to MIT provided that the sublicensee is in good standing upon termination of the agreement with the Company.</span></div>Research Collaboration and License Agreement<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exclusive License and Collaboration Agreement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Cend entered into an Exclusive License and Collaboration Agreement (the &#8220;Qilu Agreement&#8221;) in which Cend granted an exclusive license to Qilu for the development and commercialization of CEND-1 in the Territory (defined as the Greater Area of China including China, Macau, Hong Kong, and Taiwan). Under the terms of the agreement, Qilu is solely responsible for the development of CEND-1 in its Territory. In consideration for the license, Qilu made an upfront payment of $10&#160;million to Cend, which was recognized as revenue by Cend prior to the Merger. In addition, Cend received and recognized as revenue a $5&#160;million development milestone prior to the Merger. The Company is eligible to receive additional developmental and commercial milestone payments up to $100&#160;million and $125&#160;million, respectively, tiered royalties on net sales ranging from 10% to 15%, and tiered sublicensing revenues ranging from 12% to 35%.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless terminated early, the Qilu Agreement will continue in effect until the expiration of all Qilu payment obligations. Either party may terminate the Qilu Agreement if an undisputed material breach by the other party is not cured within a defined period of time, or upon notice for insolvency-related events of the other party that are not discharged within a defined time period. Qilu may terminate the Qilu Agreement in its entirety, at any time with at least sixty days written notice. All right and obligations of Qilu with respect to such licensed patents and patent applications would terminate.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519624835264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of September&#160;30, 2022, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2021 and 2020 included in our 2021 Form 10-K. Operating results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values and the valuation of the Merger which was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (&#8220;IPR&amp;D&#8221;). Accordingly, actual results could differ from those estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">Principles of ConsolidationThe Consolidated Financial Statements include the accounts of Lisata and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Remeasurement</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Remeasurement</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is the U.S. Dollar. The functional currency of DrugCendR Australia PTY Ltd. which is a foreign subsidiary of the Company is the Australian Dollar. The assets and liabilities of DrugCendR Australia PTY Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risks</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and Australia.  Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation </span></div>of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-process Research and Development Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#8220;business&#8221; as defined under GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Asset</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intangible asset consists of a single asset, Cend&#8217;s license agreement with Qilu Pharmaceutical, Co., Ltd. (&#8220;Qilu&#8221;) acquired in the Merger, with a value of $0.4&#160;million. The intangible asset is stated at fair value and is amortized using the straight-line method over its estimated useful life of 5 years. Amortization expense was $3 thousand for the three and nine months ended September&#160;30, 2022. The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable.  The projected amortization expense is $71 thousand per year for the next five years. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. There was no revenue recognized for the three and nine months ended September&#160;30, 2022.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Milestones</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company&#8217;s collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company&#8217;s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalties</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. There was no revenue recognized for the three and nine months ended September&#160;30, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519626856544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Available-for-Sale-Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Available-for-sale Securities Reconciliation</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"><tr><td style="width:1.0pt"/><td style="width:94.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,332&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,522&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:360.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.75pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,332&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Investments Classified by Contractual Maturity Date</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:361.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:70.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,332&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,332&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519627418272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text">At September&#160;30, 2022 and 2021, the Company excluded the following potentially dilutive securities (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519627356672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth by level within the fair value hierarchy the Company's financial assets that were accounted for at fair value on a recurring basis as of September&#160;30, 2022 and December&#160;31, 2021 (in thousands).</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:116.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:12.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:42.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities - available for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,052&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,052&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,323&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519627411680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities as of September&#160;30, 2022 and December&#160;31, 2021 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"><tr><td style="width:1.0pt"/><td style="width:313.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries, employee benefits and related taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,034&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities &#8212; current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical and R&amp;D related liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,417&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519707697712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock', window );">Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"/><td style="width:325.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of Use Assets:</span></td><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfMi0wLTEtMS0yMjg1OA_188c2eed-0925-44f8-bfd8-8dc48bf41cee"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfMi0wLTEtMS0yMjg1OA_cda64072-7450-44a6-a48d-ee2b330b6907">Other assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Right-of-Use Asset</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Lease Liabilities:</span></td><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNi0wLTEtMS0yMjg1OA_466bdee9-6b20-428a-b677-b820ae3ba607"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNi0wLTEtMS0yMjg1OA_62800bd1-bc30-473e-aedd-b0b3d9f06907">Accrued liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNy0wLTEtMS0yMjg1OA_ceb1d506-32b0-442d-b209-59921ea40600"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNy0wLTEtMS0yMjg1OA_f9192e00-f937-46b7-9c41-0640551a459c">Other long-term liabilities</span></span></span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Lease Liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments Under Lease Agreements</a></td>
<td class="text">Future minimum lease payments under the lease agreements as of September&#160;30, 2022 were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"/><td style="width:448.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amounts representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519627035664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option and Warrants Activity</a></td>
<td class="text">The following table summarizes the activity for stock options and warrants for the nine months ended September&#160;30, 2022:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.127%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Weighted Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Aggregate Intrinsic Value (In Thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142,041&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84.60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.97</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,423,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.37</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes during the period:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assumed through merger</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,227,776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,910)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,388)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">352.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,398,977&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.30</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,423,774&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at September 30, 2022<br/>&#160;or expected to vest in the future</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,396,921&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.83&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,423,774&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.57&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.63</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,110,635&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.82&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.97</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,423,774&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.57&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of Restricted Stock Activity</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022 and 2021, the Company issued restricted stock for services as follows ($ in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"><tr><td style="width:1.0pt"/><td style="width:322.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:4.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,863&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">973&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022 and 2021, the Company issued restricted stock units for services as follows ($ in thousands, except share data):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"><tr><td style="width:1.0pt"/><td style="width:343.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of restricted stock units issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111,170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of restricted stock units issued </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,386&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519624919232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Payment Arrangement, Noncash Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule Share-based Compensation Expense</a></td>
<td class="text">The following table summarizes the components of share-based compensation expense for the three and nine months ended September&#160;30, 2022 and 2021 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:44.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,639&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Total Compensation Cost Related to Nonvested Awards</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation cost related to non-vested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at September&#160;30, 2022 were as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized compensation cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected weighted-average period in years of compensation cost to be recognized</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.66</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.16</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.83</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Share-based Compensation Awards</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total fair value of shares vested and the weighted average estimated fair values of shares granted for the nine months ended September&#160;30, 2022 and 2021 were as follows (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"/><td style="width:378.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.75pt"/><td style="width:1.0pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of shares vested</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average estimated fair value of shares granted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519627369296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">$ 352<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519625884304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 14, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="nump">7,862,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,985,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 31,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=clbs_CENDMember', window );">CEND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,772,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</a></td>
<td class="nump">$ 2,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business Acquisition, Share Price</a></td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</a></td>
<td class="nump">$ 23,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Business Combination, Acquisition Related Costs</a></td>
<td class="nump">382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Business Combination, Consideration Transferred</a></td>
<td class="nump">36,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">7,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</a></td>
<td class="num">(1,690)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</a></td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="nump">30,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived Intangible Assets Acquired</a></td>
<td class="nump">$ 355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=clbs_CENDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=clbs_CENDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519620654560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 67,397<span></span>
</td>
<td class="nump">$ 91,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(65)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">67,332<span></span>
</td>
<td class="nump">91,452<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">39,311<span></span>
</td>
<td class="nump">53,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(65)<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">39,246<span></span>
</td>
<td class="nump">53,070<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">14,459<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">14,459<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">13,457<span></span>
</td>
<td class="nump">18,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">13,457<span></span>
</td>
<td class="nump">18,124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Municipal debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">20,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 170<span></span>
</td>
<td class="nump">$ 20,258<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519627566400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 23,280<span></span>
</td>
<td class="nump">$ 21,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">44,052<span></span>
</td>
<td class="nump">70,323<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Total</a></td>
<td class="nump">$ 67,332<span></span>
</td>
<td class="nump">$ 91,452<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519625121104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis', window );">Less than one year</a></td>
<td class="nump">$ 67,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis', window );">Greater than one year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">67,397<span></span>
</td>
<td class="nump">$ 91,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue', window );">Less than one year</a></td>
<td class="nump">67,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue', window );">Greater than one year</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total estimated fair value</a></td>
<td class="nump">$ 67,332<span></span>
</td>
<td class="nump">$ 91,452<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519624863760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">1,399<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">1,424<span></span>
</td>
<td class="nump">1,424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519624971136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available for sale</a></td>
<td class="nump">$ 44,052<span></span>
</td>
<td class="nump">$ 70,323<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">44,052<span></span>
</td>
<td class="nump">70,323<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available for sale</a></td>
<td class="nump">44,052<span></span>
</td>
<td class="nump">70,323<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">44,052<span></span>
</td>
<td class="nump">70,323<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable securities - available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519625949632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Salaries, employee benefits and related taxes</a></td>
<td class="nump">$ 2,147<span></span>
</td>
<td class="nump">$ 2,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities &#8212; current</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_ClinicalAndRDRelatedLiabilities', window );">Clinical and R&amp;D related liabilities</a></td>
<td class="nump">2,338<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">729<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 5,417<span></span>
</td>
<td class="nump">$ 2,589<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_ClinicalAndRDRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical and R&amp;D Related Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_ClinicalAndRDRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519624881808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>office</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_NumberOfOfficesUnderOperatingLeases', window );">Number of offices under operating leases</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term for operating leases (in years)</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate for operating leases (percent)</a></td>
<td class="nump">9.625%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_NumberOfOfficesUnderOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Offices Under Operating Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_NumberOfOfficesUnderOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519624864656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Balance Sheet Presentation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_OperatingLeaseRightOfUseAssetAbstract', window );"><strong>Right-of Use Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 548<span></span>
</td>
<td class="nump">$ 724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Right-of-use assets, balance sheet line item</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 548<span></span>
</td>
<td class="nump">$ 714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease liabilities, current, balance sheet line item</a></td>
<td class="text">Accrued liabilities<span></span>
</td>
<td class="text">Accrued liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating lease liabilities, noncurrent, balance sheet line item</a></td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">Other long-term liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_OperatingLeaseRightOfUseAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_OperatingLeaseRightOfUseAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519626019872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Future Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Minimum Lease Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Amounts representing interest</a></td>
<td class="num">(77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 548<span></span>
</td>
<td class="nump">$ 714<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519620707520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Equity Issuances (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 04, 2021</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_LincolnParkAgreementMember', window );">Lincoln Park Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement', window );">Aggregate offering amount authorized per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration', window );">Commitment shares issued as consideration per agreement (in shares)</a></td>
<td class="nump">181,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares sold (in shares)</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price of shares sold (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross price for stock transaction</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_TermOfAgreement', window );">Term of agreement (in months)</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase', window );">Number of shares allowable to direct for Regular Purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase', window );">Maximum obligation per directed purchase transaction for Regular Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase', window );">Maximum shares allowed in Accelerated Purchase as percent of shares In Regular Purchase (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod', window );">Maximum shares allowed in Accelerated Purchase as percent of shares traded during specified period (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty', window );">Maximum beneficial ownership allowable per agreement (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_AtTheMarketOfferingAgreementMember', window );">ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement', window );">Aggregate offering amount authorized per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Registration Rights Agreement, Maximum Beneficial Ownership Allowable For Counterparty</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Amount Per Agreement, Allowable To Direct Counterparty To Purchase, Regular Purchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Amount Per Agreement Per Transaction For Direct Counterparty Purchase, Regular Purchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares In Regular Purchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares Of Stock Traded During Specified Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Issued As Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_TermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term Of Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_TermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_LincolnParkAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=clbs_LincolnParkAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=clbs_AtTheMarketOfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=clbs_AtTheMarketOfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519620592576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock Options and Warrants (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options, Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Outstanding, Beginning of Period (in shares)</a></td>
<td class="nump">142,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options, Granted (in shares)</a></td>
<td class="nump">37,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, Forfeited (in shares)</a></td>
<td class="num">(2,910)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options, Expired (in shares)</a></td>
<td class="num">(5,388)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Outstanding, End of Period (in shares)</a></td>
<td class="nump">1,398,977<span></span>
</td>
<td class="nump">142,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options, Vested and expected to vest (in shares)</a></td>
<td class="nump">1,396,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options, Vested (in shares)</a></td>
<td class="nump">1,110,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Stock Options, Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options, Outstanding. Beginning of Period (in dollars per share)</a></td>
<td class="nump">$ 84.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options, Granted (in dollars per share)</a></td>
<td class="nump">13.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options, Exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options, Forfeited (in dollars per share)</a></td>
<td class="nump">19.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options, Expired (in dollars per share)</a></td>
<td class="nump">352.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options, Outstanding, End of Period (in dollars per share)</a></td>
<td class="nump">10.83<span></span>
</td>
<td class="nump">$ 84.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options, Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">10.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Options, Vested (in dollars per share)</a></td>
<td class="nump">$ 11.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options, Weighted Average Contractual Term and Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">7 years 11 months 19 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options, Vested and expected to vest, Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_OptionsVestedweightedAverageRemainingContractualTerm', window );">Options, Vested, Weighted Average Remaining Contractual Term</a></td>
<td class="text">6 years 11 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options, Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options, Vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options, Vested, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Warrants, Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CommonStockWarrantsShares', window );">Warrants, Outstanding, Beginning of Period (in shares)</a></td>
<td class="nump">1,423,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WarrantsGranted', window );">Warrants, Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WarrantsExercised', window );">Warrants, Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WarrantsCanceled', window );">Warrants, Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WarrantsExpired', window );">Warrants, Expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CommonStockWarrantsShares', window );">Warrants, Outstanding, End of Period (in shares)</a></td>
<td class="nump">1,423,774<span></span>
</td>
<td class="nump">1,423,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_Sharesvestedandexpectedtovest', window );">Warrants, Vested and expected to vest (in shares)</a></td>
<td class="nump">1,423,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WarrantsVested', window );">Warrants, Vested (in shares)</a></td>
<td class="nump">1,423,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WarrantsWeightedAverageExercisePriceRollForward', window );"><strong>Warrants, Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsOutstanding', window );">Warrants Outstanding, Beginning of Period (in dollars per share)</a></td>
<td class="nump">$ 42.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsGranted', window );">Warrants, Granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsExercised', window );">Warrants, Exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsCanceled', window );">Warrants, Forfeited (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsExpired', window );">Warrants, Expired (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsOutstanding', window );">Warrants Outstanding, End of Period (in dollars per share)</a></td>
<td class="nump">42.57<span></span>
</td>
<td class="nump">$ 42.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest', window );">Weighted Average Exercise Price, Warrants Vested And Expected To Vest</a></td>
<td class="nump">42.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WeightedAverageExercisePriceWarrantsExercisable', window );">Warrants, Vested, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 42.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WarrantsOtherDisclosuresAbstract', window );"><strong>Warrants, Weighted Average Contractual Term and Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding', window );">Warrants, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">3 years 7 months 17 days<span></span>
</td>
<td class="text">4 years 4 months 13 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest', window );">Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term</a></td>
<td class="text">3 years 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_WeightedAverageRemainingContractualTermwarrantsvested', window );">Warrants, Vested, Weighted Average Remaining Contractual Term</a></td>
<td class="text">3 years 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_AggregateIntrinsicValueWarrantsOutstanding', window );">Warrants Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest', window );">Warrants, Vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_AggregateIntrinsicValueWarrantsvested', window );">Warrants, Vested, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_AggregateIntrinsicValueWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Warrants Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_AggregateIntrinsicValueWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_AggregateIntrinsicValueWarrantsvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Warrants vested</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_AggregateIntrinsicValueWarrantsvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value, Warrants vested and expected to vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_CommonStockWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Warrants, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_CommonStockWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_OptionsVestedweightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options, Vested, weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_OptionsVestedweightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_Sharesvestedandexpectedtovest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>shares, vested and expected to vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_Sharesvestedandexpectedtovest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Canceled</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Expired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Other Disclosures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, Vested</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WarrantsWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Weighted Average Exercise Price [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WarrantsWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Canceled</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Exercisable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Expired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants Vested And Expected To Vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageRemainingContractualTermwarrantoutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Term warrant outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageRemainingContractualTermwarrantoutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_WeightedAverageRemainingContractualTermwarrantsvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>weighted Average Remaining Contractual Term, warrants vested</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_WeightedAverageRemainingContractualTermwarrantsvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519620510160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of shares issued</a></td>
<td class="nump">70,740<span></span>
</td>
<td class="nump">40,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Value of shares issued</a></td>
<td class="nump">$ 973<span></span>
</td>
<td class="nump">$ 878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value</a></td>
<td class="nump">$ 12.46<span></span>
</td>
<td class="nump">$ 23.85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms (years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms (years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of shares issued</a></td>
<td class="nump">111,170<span></span>
</td>
<td class="nump">30,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Value of shares issued</a></td>
<td class="nump">$ 1,386<span></span>
</td>
<td class="nump">$ 729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms (years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519624463104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 1,040<span></span>
</td>
<td class="nump">$ 773<span></span>
</td>
<td class="nump">$ 2,168<span></span>
</td>
<td class="nump">$ 1,639<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">523<span></span>
</td>
<td class="nump">631<span></span>
</td>
<td class="nump">643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,537<span></span>
</td>
<td class="nump">$ 996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 769<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519626020832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 1,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted-average period in years of compensation cost to be recognized</a></td>
<td class="text">1 year 7 months 28 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted-average period in years of compensation cost to be recognized</a></td>
<td class="text">2 years 1 month 28 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted-average period in years of compensation cost to be recognized</a></td>
<td class="text">1 year 9 months 29 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519624808384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details) - Stock Options - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of shares vested</a></td>
<td class="nump">$ 853<span></span>
</td>
<td class="nump">$ 757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average estimated fair value of shares granted</a></td>
<td class="nump">$ 1.23<span></span>
</td>
<td class="nump">$ 13.59<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519618853232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Feb. 22, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain', window );">Possible additional NOLs for five years resulting from Net Unrealized Built-in Gain rules</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross', window );">Proceeds from sale of NOLs, gross</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram', window );">Net proceeds from sale of NOLs</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_LossOnSaleOfNetOperatingLosses', window );">Loss on sale of NOLs</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_OperatingLossCarryforwardsBeforeWriteDown', window );">Net operating loss carryforwards, prior to write down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,000<span></span>
</td>
<td class="nump">$ 264,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown', window );">Write down of NOLs set to expire unutilized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,000<span></span>
</td>
<td class="nump">99,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | New York</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_LossOnSaleOfNetOperatingLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss On Sale Of Net Operating Losses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_LossOnSaleOfNetOperatingLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Annual Available, Five Years, Net Unrealized Built In Gain</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_OperatingLossCarryforwardsBeforeWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Before Write Down</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_OperatingLossCarryforwardsBeforeWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_OperatingLossCarryforwardsSetToExpireWrittenDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Set To Expire, Written Down</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_OperatingLossCarryforwardsSetToExpireWrittenDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Net Operating Losses, NJEDA Program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewJerseyDivisionOfTaxationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewJerseyDivisionOfTaxationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519631685392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research tax credit rate</a></td>
<td class="nump">43.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Research tax credit</a></td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519621697472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>License Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale', window );">Annual license maintenance fee, after first sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=clbs_SanfordBurnhamPrebysMember', window );">Sanford Burnham Prebys | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_SharesIssuedUnderLicenseAgreement', window );">Shares issued under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">382,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee', window );">Annual license maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven', window );">Annual license maintenance fee, year seven</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales', window );">Royalties, net of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees', window );">Sublicensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour', window );">Annual license maintenance fee, year four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_SharesHeldByThirdParty', window );">Shares held by third party</a></td>
<td class="nump">382,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=clbs_SanfordBurnhamPrebysMember', window );">Sanford Burnham Prebys | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees', window );">Sublicensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=clbs_SanfordBurnhamPrebysMember', window );">Sanford Burnham Prebys | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees', window );">Sublicensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=clbs_UniversityOfCaliforniaAtSanDiegoMember', window );">University of California at San Diego | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales', window );">Royalties, net of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=clbs_UniversityOfCaliforniaAtSanDiegoMember', window );">University of California at San Diego | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees', window );">Sublicensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=clbs_UniversityOfCaliforniaAtSanDiegoMember', window );">University of California at San Diego | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees', window );">Sublicensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=clbs_MassachusettsInstituteOfTechnologyMember', window );">Massachusetts Institute of Technology | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee', window );">Annual license maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales', window );">Royalties, net of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour', window );">Annual license maintenance fee, year four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree', window );">Annual license maintenance fee, years two and three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee', window );">Change of control fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=clbs_MassachusettsInstituteOfTechnologyMember', window );">Massachusetts Institute of Technology | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees', window );">Sublicensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=clbs_MassachusettsInstituteOfTechnologyMember', window );">Massachusetts Institute of Technology | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees', window );">Sublicensing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee After First Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Two and Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Change of Control Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Sublicensing Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SharesHeldByThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Held by Third Party</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SharesHeldByThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_SharesIssuedUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Issued Under License Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_SharesIssuedUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=clbs_SanfordBurnhamPrebysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=clbs_SanfordBurnhamPrebysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=clbs_UniversityOfCaliforniaAtSanDiegoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=clbs_UniversityOfCaliforniaAtSanDiegoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=clbs_MassachusettsInstituteOfTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=clbs_MassachusettsInstituteOfTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140519618819392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Research Collaboration and License Agreement (Details) - Qilu - License - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 14, 2022</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from contract</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=clbs_QiluMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Variable consideration amounts, milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_RevenuePerformanceObligationPercentageOfNetSale', window );">Percentage of net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues', window );">Percentage of sublicensing revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=clbs_QiluMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Variable consideration amounts, milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_RevenuePerformanceObligationPercentageOfNetSale', window );">Percentage of net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues', window );">Percentage of sublicensing revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_RevenuePerformanceObligationPercentageOfNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Percentage of Net Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_RevenuePerformanceObligationPercentageOfNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Percentage of Sublicensing Revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>clbs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123385629&amp;loc=SL5834089-161433<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=clbs_QiluMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=clbs_QiluMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>clbs-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:clbs="http://www.caladrius.com/20220930"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="clbs-20220930.xsd" xlink:type="simple"/>
    <context id="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic3f379b9aca34c4c99fad8b18e07b126_I20221110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2022-11-10</instant>
        </period>
    </context>
    <context id="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib97be91eba48467897085df19e17a272_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia5c2e6f4066b47fbb0c62e47d1a34e30_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i86d263da61bd426cb7086a17123228f7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i17ae6b2b209f4867bbb33069c004b3aa_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id86020b0b46045dc893b03e2966eb75c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i029fe570e6734389a205caae3c3445a0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i03285eb13bc340e3a8a2ff34047b4093_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i07070a35a7c74213a020599cb2deffb7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2c69daf49eff4222a69cd10c77c98604_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia9d9e85847ab4fcf9aac296f60571be8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i69110a58290f48db984963c9b07024c0_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7b905b12169646dea54aa6e1e067b6f0_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6d228b1f84b744de88a126fa2a54dd15_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iebd096734b704a05b20e0d2a7a46f6f4_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1cec8b5ec5914024a14b5f754a3d6ddf_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id9801b9ed9e24c90b66bf7dc589a24f2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i944ba198ef814601b1dc3e189a2d15b9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5163c19edf884a309a10703ede9fbc6c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i853118dfc75844fb9a23dfa0374528cd_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5c936e2b28ea43c7b0b9af4a69e00249_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6b81c7260bd84f378acc80251b158b2a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1ec4c587d4a3466ab448abb94ba9f29d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id3c09e4703ba40298dd79e85417cdb61_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8d30a645527f4337a60c7da8f18e85ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7eef7cc26c004a4c908e6fe160d201d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i686c5d52741f40f5a71ed6e2545ec05b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4050b9a1a6ec412b8853f688ad35a4fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7fa893b6dc4a4a698cf4f78caf023478_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if7779b193bfe449bbd568049e6084cc7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0d1ccf571c4245369c9de32e62b102ee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i63f9702a0ee94ee3a2adeeac786c1860_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie19069eadb3a4525bd0e3c209f26c6fc_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i29f228f551d04b7d9d199959a37d10b2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie1e85bf072d8481caf42f6d9beb8f4e6_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9485a0db274745a69f25443e8b178239_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iab2f266a4d614842a787f8e85ec8abfd_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie8fa07dd822c4c8db0ca288934287b7d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i16004a445bd449db8e2738b544722065_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i038ee7bc9a294a179161a5703da8dba9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i57d6d03e551b49a8a244e5310fc9c806_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0bd86cb6ffe24ae9af1b0bf46c620e7f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iec685200531f473bab6967cb468862fb_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0251e8a199d84ca68ff8b0e1aa8255ce_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iedd0d04163e74945bb220b2e853c3e5e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia59e32a50e1444c697ba1a65e5e48334_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib0d534735e7c4b63b3bf26d250ca8b2b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iadddb49f7b264fa48f4b8133ef8e3991_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i81f77055e79c4a769aa1eeb70f3e5de2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifc9fdc2eadc94b589888a37676c11ae9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9f9539108c6c4e1ba0d051b1aabb567a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8d2b62b865bd4041b0251301f7f51424_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i872ef751a6a241769e47a7626414f412_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iee65085e733d41a19e4143446eff7b7c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i33afa975dd374f46b8ea96b4c0471c87_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id2242481d947422a87b50a693e117608_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i57e94f040b084f7b9def7834d945a4c7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id9d73cec2ab1421e98d1f86d5a3b506a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic87a4ec489bc4ec0bf3f93cc71f5e063_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i74b1319645614dceb3e4fce1f773ff25_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i848e51e03eed447c935cb2899345a1ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i26cf58fb84e74ac694d839db83461838_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib450656958d64dd7809ab86b82185cce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie3e5d05a52e7442a8b64eb445899cdf0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85b4ca140e7d4f318fdd15f0a5cfb26c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib8a27c130df24312b50441271af5f833_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8fad62fd3c3b4c7083f34c136706b9ab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if5443afa6b3c4665b9c1eae0dbd038e1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i83e78453949e4f5fb203beb11be8a1dc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0a6f0161fc68498fb65a78febe096c25_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if0a6fa60498746079ad9eb4134e0a7c0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i07a0bb3234e14e0fbc6b7bce9f23f88a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i86917d398d3247a6b5578480b5333d60_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3698298d7aba49a9af19841d1ba110c1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i59aeca5b7a5446ed90ba736d79d9d4f4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">clbs:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iac286da95e1c493abbddee71f1aac890_I20220914">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">clbs:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-14</instant>
        </period>
    </context>
    <context id="ia46e584dcd2741798d67f30f0cfd9c15_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">clbs:CENDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2d567e0b72224eb89e01194dfcc635c5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i098bf094035d44e2af451fa66daf6448_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i57b538ea7c44400bad5071a7a6c98c1d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie90154aebcd24967a0f809ea3f40f699_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd0667d730324d439adcd5260c8be67a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2502dcdd9a7b46ccb98d0960950fb9ae_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie80e4088fafa43969d532971e7a875dc_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i09c4e12405dd4187a733724a3dd4b1c8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i33f0a817fe2049da85aa3551a5c905e4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5e0d719ce9044ab281734908fb138fe4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i422414ad4ec143fe9c83f80484b18850_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i972cd99d76534d3cb8f6e561e629dc10_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i161cdf72d862420686200bfdd753f6d7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifccd968d78a3473898c3258429a71f76_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i48063441de8a46dc974334dbf9a3a293_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7348558529cf46d2959b0b4229242404_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9a76766f174f4c3b84f09f885f2170c6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib35c54c2e1b14397ae34101068f8d0a3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8f89ef4342fe4c27b982bc991aff78d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie2404060e56d462683781d6a6eb5e03e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i03006f5a9605427eb1a8f9b1e13d1902_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8aa7a96703004d078dc7feb5458b2718_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7128331c98ad445b8fb23487460be1ba_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:LincolnParkAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ic92d752f756145678f3d08b54d87d88e_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:LincolnParkAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i5748a0eb61f64415a43f6fd83aab5103_I20210604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-04</instant>
        </period>
    </context>
    <context id="i4f7b301665c749bf9b60eccd141f1949_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">clbs:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iafd0678032f1403699288c6ead8540b2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib889d615bc824253bdc29e6be132de5e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i307650e93d90403dbe9bbce2cef38283_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i961120305be6447cb05c316b019232b0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id9c9001c970d4ccd8a77b7e8f997ca0c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i85d58dcae34e4ef8875042573be0b9be_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib0800b6bb894400cb3122c7e867ed365_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i34bf47839bf14111b1a9f241df421e60_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i01ce7704d3fe44b2b990f2b244335218_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i837f26cb6fd94ea2be192be38846f7d4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8cdf12952bfe4ee58d1c62f6fc6b922f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iddf5f8d32bb9415e8e2d387027b79ab6_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia363623f86d0452f826ddd27e9bd14ef_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i750cd69f59fa41ab8d1716b4af6483aa_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie55321c2f35248728ece5383ad81d1ab_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i018aef0ebc684655bb91626b836264c8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9bdf4a4104384257bd274663a65297cc_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="icb6073bf55444dc9adf45d6bd29a32bd_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ifb50bb2a566f4b72a4ec8baa84a38a44_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i83d716d023604513b9d5e44c712a5656_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if68b9c4980394919b2d4601761b01f4d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i31c432312f38454b845861eb8d0891a5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1b434d8601de4e05b998640da3d91bcc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i02b1d9ded41146128c64adca8ae00256_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewJerseyDivisionOfTaxationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i93a7f18008c44e9997baaba9c4bcc603_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic221f3b9f147476abbbaa83788e46406_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i68d905e37c484eff8d11dc6b86a7e0f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i579b018c55b04e3c984da0273c1ef442_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if463b298d932482a86bb1787b18f2ed0_D20220222-20220222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <startDate>2022-02-22</startDate>
            <endDate>2022-02-22</endDate>
        </period>
    </context>
    <context id="i54c1f41cac654131b84226d73d9d67db_I20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:SanfordBurnhamPrebysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="i155f1b104580445ca4ca140a0f0d9e28_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:SanfordBurnhamPrebysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="i3fd21aa0eb7e469692c04143d4a0aaa5_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:SanfordBurnhamPrebysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="i568bd639252d47638984e18f0836cd66_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:SanfordBurnhamPrebysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="ie7a582d9c51846c999a8aae8d00b9b3f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:SanfordBurnhamPrebysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie0f3bab25f7348bdbffea94e657798a0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:UniversityOfCaliforniaAtSanDiegoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if1424658bffc4343bd5497ca9d561930_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:UniversityOfCaliforniaAtSanDiegoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifa3e87e793164479a26fb0338f9209f6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:UniversityOfCaliforniaAtSanDiegoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ieb7b6c7937914fcea021631924808998_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="i0050d762a7e64fa192ac048bca1f9775_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="ib023bcf774d145f5834f6ee5051da753_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="i2362238e05b541a487b62ee42291726f_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="ic23e1c2433b54fffa2ed10e25463b457_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:QiluMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="iab8db93a425c431683da42085f6e40e9_D20220914-20220914">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:QiluMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-14</startDate>
            <endDate>2022-09-14</endDate>
        </period>
    </context>
    <context id="i00de76018f10443a96daffcfc7a36a9f_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:QiluMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="i51afcddd58ef4d74a4eecfadef3991a2_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000320017</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">clbs:QiluMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="office">
        <measure>clbs:office</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80L2ZyYWc6OTY1NDY4YTZjODkyNDE5OGIxNjgwZWU5MWM4MjJhNGIvdGFibGU6YmY0ZDVjMGJhZGRjNDI2ODlhYjI2MWU4OGJiODZjZmIvdGFibGVyYW5nZTpiZjRkNWMwYmFkZGM0MjY4OWFiMjYxZTg4YmI4NmNmYl8zLTEtMS0xLTIyODU4_0b15f89b-1bf2-45b4-b62d-5e61066db333">0000320017</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80L2ZyYWc6OTY1NDY4YTZjODkyNDE5OGIxNjgwZWU5MWM4MjJhNGIvdGFibGU6YmY0ZDVjMGJhZGRjNDI2ODlhYjI2MWU4OGJiODZjZmIvdGFibGVyYW5nZTpiZjRkNWMwYmFkZGM0MjY4OWFiMjYxZTg4YmI4NmNmYl80LTEtMS0xLTIyODU4_b9f937d4-8b02-43bf-b454-a5429e614d5e">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80L2ZyYWc6OTY1NDY4YTZjODkyNDE5OGIxNjgwZWU5MWM4MjJhNGIvdGFibGU6YmY0ZDVjMGJhZGRjNDI2ODlhYjI2MWU4OGJiODZjZmIvdGFibGVyYW5nZTpiZjRkNWMwYmFkZGM0MjY4OWFiMjYxZTg4YmI4NmNmYl81LTEtMS0xLTIyODU4_6f725780-8d1a-4fdf-8908-a02de0567e5b">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80L2ZyYWc6OTY1NDY4YTZjODkyNDE5OGIxNjgwZWU5MWM4MjJhNGIvdGFibGU6YmY0ZDVjMGJhZGRjNDI2ODlhYjI2MWU4OGJiODZjZmIvdGFibGVyYW5nZTpiZjRkNWMwYmFkZGM0MjY4OWFiMjYxZTg4YmI4NmNmYl82LTEtMS0xLTIyODU4_4c608d57-6d1a-4662-bdb1-c1615a88afb4">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80L2ZyYWc6OTY1NDY4YTZjODkyNDE5OGIxNjgwZWU5MWM4MjJhNGIvdGFibGU6YmY0ZDVjMGJhZGRjNDI2ODlhYjI2MWU4OGJiODZjZmIvdGFibGVyYW5nZTpiZjRkNWMwYmFkZGM0MjY4OWFiMjYxZTg4YmI4NmNmYl83LTEtMS0xLTIyODU4_7559117f-7be9-41ad-9bd0-7cf772163a86">false</dei:AmendmentFlag>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfMi0wLTEtMS0yMjg1OA_188c2eed-0925-44f8-bfd8-8dc48bf41cee">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfMi0wLTEtMS0yMjg1OA_cda64072-7450-44a6-a48d-ee2b330b6907">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNi0wLTEtMS0yMjg1OA_466bdee9-6b20-428a-b677-b820ae3ba607">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNi0wLTEtMS0yMjg1OA_62800bd1-bc30-473e-aedd-b0b3d9f06907">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNy0wLTEtMS0yMjg1OA_ceb1d506-32b0-442d-b209-59921ea40600">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNy0wLTEtMS0yMjg1OA_f9192e00-f937-46b7-9c41-0640551a459c">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i961120305be6447cb05c316b019232b0_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNDg3Mw_6c617069-871e-4bcc-ac83-10a9da649366">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGV4dHJlZ2lvbjoxNmJjYTZmMGFlZTQ0MmY2YTMyMWQ3MDAzNmQ0YmRjN18yMDI0_01e078f8-76b4-43ee-b765-c3770199fc9d">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6MGFkODEzZDI1NWVhNGZiZjljMTYxYzk1ZjVlNmI5NjcvdGFibGVyYW5nZTowYWQ4MTNkMjU1ZWE0ZmJmOWMxNjFjOTVmNWU2Yjk2N18wLTAtMS0xLTIyODU4_f55f067e-c78a-42e6-9970-54140eda70d0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGV4dHJlZ2lvbjoxNmJjYTZmMGFlZTQ0MmY2YTMyMWQ3MDAzNmQ0YmRjN181NDk3NTU4MTQxMTc0_eabc1e54-e77d-4123-8ea7-da3484ac54eb">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6MjM4YjJkZGE3Njc1NGUzODhiN2ZmYTJhZTA5NTEzZDkvdGFibGVyYW5nZToyMzhiMmRkYTc2NzU0ZTM4OGI3ZmZhMmFlMDk1MTNkOV8wLTAtMS0xLTIyODU4_b8c58660-e962-4a48-ae24-8bd27c119447">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGV4dHJlZ2lvbjoxNmJjYTZmMGFlZTQ0MmY2YTMyMWQ3MDAzNmQ0YmRjN18yMDI1_276b6a86-70c1-4028-9205-36d776179463">001-33650</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGV4dHJlZ2lvbjoxNmJjYTZmMGFlZTQ0MmY2YTMyMWQ3MDAzNmQ0YmRjN18yMDI2_fc1e5521-ba54-4ef0-80f7-2ee5bb79dd2a">LISATA THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6NTkxMzVlZWVhYmUxNDM1MjkzOTM0ZmYwZDU3YmU0YzYvdGFibGVyYW5nZTo1OTEzNWVlZWFiZTE0MzUyOTM5MzRmZjBkNTdiZTRjNl8wLTAtMS0xLTIyODU4_5af43b55-c3d8-45f1-a82b-6caebbd9e052">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6NTkxMzVlZWVhYmUxNDM1MjkzOTM0ZmYwZDU3YmU0YzYvdGFibGVyYW5nZTo1OTEzNWVlZWFiZTE0MzUyOTM5MzRmZjBkNTdiZTRjNl8wLTEtMS0xLTIyODU4_b7a90460-89d7-4a96-b4fc-ebde1208a87a">22-2343568</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6NTkxMzVlZWVhYmUxNDM1MjkzOTM0ZmYwZDU3YmU0YzYvdGFibGVyYW5nZTo1OTEzNWVlZWFiZTE0MzUyOTM5MzRmZjBkNTdiZTRjNl8zLTAtMS0xLTIyODU4L3RleHRyZWdpb246ZDg4OTlkMDc4NGFjNGM0YWIxMjc4ZmNkMGU1ZGRjZDlfNA_64d55451-d388-4b7a-9c25-ca0ea3845d86">110 Allen Road, 2nd Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6NTkxMzVlZWVhYmUxNDM1MjkzOTM0ZmYwZDU3YmU0YzYvdGFibGVyYW5nZTo1OTEzNWVlZWFiZTE0MzUyOTM5MzRmZjBkNTdiZTRjNl8zLTAtMS0xLTIyODU4L3RleHRyZWdpb246ZDg4OTlkMDc4NGFjNGM0YWIxMjc4ZmNkMGU1ZGRjZDlfOA_b228ba69-7690-4413-b31d-3e8d6fed453c">Basking Ridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6NTkxMzVlZWVhYmUxNDM1MjkzOTM0ZmYwZDU3YmU0YzYvdGFibGVyYW5nZTo1OTEzNWVlZWFiZTE0MzUyOTM5MzRmZjBkNTdiZTRjNl8zLTAtMS0xLTIyODU4L3RleHRyZWdpb246ZDg4OTlkMDc4NGFjNGM0YWIxMjc4ZmNkMGU1ZGRjZDlfMTI_4560da38-2fe6-4dce-aac0-3c34b6373122">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6NTkxMzVlZWVhYmUxNDM1MjkzOTM0ZmYwZDU3YmU0YzYvdGFibGVyYW5nZTo1OTEzNWVlZWFiZTE0MzUyOTM5MzRmZjBkNTdiZTRjNl8zLTEtMS0xLTIyODU4_829933df-3355-40d1-b96c-00926129aaef">07920</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGV4dHJlZ2lvbjoxNmJjYTZmMGFlZTQ0MmY2YTMyMWQ3MDAzNmQ0YmRjN18yMDI3_4197accc-9f19-4412-9a40-0fd962179d87">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGV4dHJlZ2lvbjoxNmJjYTZmMGFlZTQ0MmY2YTMyMWQ3MDAzNmQ0YmRjN18yMDMy_1127eb25-a27c-433c-8631-c4690ec64f83">842-0100</dei:LocalPhoneNumber>
    <dei:EntityInformationFormerLegalOrRegisteredName
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGV4dHJlZ2lvbjoxNmJjYTZmMGFlZTQ0MmY2YTMyMWQ3MDAzNmQ0YmRjN18yNzQ4Nzc5MDcxNzEz_b0c1a4b3-12df-4f6a-b88d-c59759ddaf43">Caladrius Biosciences, Inc.</dei:EntityInformationFormerLegalOrRegisteredName>
    <dei:Security12bTitle
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6ZDQyNDZiZjU4ZWMyNDM1NDlhYjBhOTU0YzBjNjRhNjcvdGFibGVyYW5nZTpkNDI0NmJmNThlYzI0MzU0OWFiMGE5NTRjMGM2NGE2N18yLTAtMS0xLTIyODU4_68eeda75-6045-4b3d-9afe-a5467a71c58d">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6ZDQyNDZiZjU4ZWMyNDM1NDlhYjBhOTU0YzBjNjRhNjcvdGFibGVyYW5nZTpkNDI0NmJmNThlYzI0MzU0OWFiMGE5NTRjMGM2NGE2N18yLTEtMS0xLTIyODU4_d5b811f2-0294-446d-90a0-bd3a54d33d2d">LSTA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6ZDQyNDZiZjU4ZWMyNDM1NDlhYjBhOTU0YzBjNjRhNjcvdGFibGVyYW5nZTpkNDI0NmJmNThlYzI0MzU0OWFiMGE5NTRjMGM2NGE2N18yLTItMS0xLTIyODU4L3RleHRyZWdpb246OWVkOTI2ZTQwYTE4NDQ1YWE0OTQ3NDk5YzgwZTdmNTFfOA_816653f5-16c9-4523-b29d-6e6bee61e15a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGV4dHJlZ2lvbjoxNmJjYTZmMGFlZTQ0MmY2YTMyMWQ3MDAzNmQ0YmRjN18yMDI4_8cffe7f6-5cc1-4792-8ccc-41a3237cb0de">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGV4dHJlZ2lvbjoxNmJjYTZmMGFlZTQ0MmY2YTMyMWQ3MDAzNmQ0YmRjN18yMDI5_1a504af2-65b5-4331-87f2-4b419c31173d">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6NDE3OGJkOTJlNDg1NDhmNmJhMTE2MmQzZTY3OWM0ZWEvdGFibGVyYW5nZTo0MTc4YmQ5MmU0ODU0OGY2YmExMTYyZDNlNjc5YzRlYV8xLTAtMS0xLTIyODU4_ec1a82f4-7ffb-4731-af80-e36cf0e861ce">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6NDE3OGJkOTJlNDg1NDhmNmJhMTE2MmQzZTY3OWM0ZWEvdGFibGVyYW5nZTo0MTc4YmQ5MmU0ODU0OGY2YmExMTYyZDNlNjc5YzRlYV8xLTQtMS0xLTIyODU4_7bbee5da-850e-4a33-9e46-9ddd49e31172">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6NDE3OGJkOTJlNDg1NDhmNmJhMTE2MmQzZTY3OWM0ZWEvdGFibGVyYW5nZTo0MTc4YmQ5MmU0ODU0OGY2YmExMTYyZDNlNjc5YzRlYV8yLTQtMS0xLTIyODU4_7bfba1eb-148f-4905-996b-25b0ee7dc00a">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGV4dHJlZ2lvbjoxNmJjYTZmMGFlZTQ0MmY2YTMyMWQ3MDAzNmQ0YmRjN18yMDMx_3219b9e6-c6ec-4a01-aea8-89e8a80739eb">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ic3f379b9aca34c4c99fad8b18e07b126_I20221110"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xL2ZyYWc6MTZiY2E2ZjBhZWU0NDJmNmEzMjFkNzAwMzZkNGJkYzcvdGFibGU6YjczY2RmZTBjNDc4NDljNGE0NzhmN2Q3MDZmNjkyNTMvdGFibGVyYW5nZTpiNzNjZGZlMGM0Nzg0OWM0YTQ3OGY3ZDcwNmY2OTI1M18xLTEtMS0xLTIyODU4_8b515f62-2391-4ae6-b796-635fe59ddc9c"
      unitRef="shares">7859684</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMi0xLTEtMS0yMjg1OA_fcbd2f33-975f-486a-9d90-4f51e1e70150"
      unitRef="usd">31478000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMi0zLTEtMS0yMjg1OA_3c05dd56-01f8-40c8-81d6-488e94253f06"
      unitRef="usd">24647000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMy0xLTEtMS0yMjg1OA_8976e59f-ba0b-4345-80cd-99af97db261f"
      unitRef="usd">44052000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMy0zLTEtMS0yMjg1OA_c64479fc-7512-46bd-85fb-4879a9e03745"
      unitRef="usd">70323000</us-gaap:MarketableSecurities>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfNC0xLTEtMS0yMjg1OA_38fe226a-caaf-4cb0-b961-56122eb25dd5"
      unitRef="usd">1760000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfNC0zLTEtMS0yMjg1OA_0be02dc8-6ae7-4369-affc-e30c5037b495"
      unitRef="usd">1212000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfNS0xLTEtMS0yMjg1OA_1e4130eb-e060-4857-b848-c47743dd3595"
      unitRef="usd">77290000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfNS0zLTEtMS0yMjg1OA_09655d58-05fe-405e-9ccf-586807651ad9"
      unitRef="usd">96182000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfNi0xLTEtMS0yMjg1OA_46cd8623-5951-4d7c-a530-7397ba5c9cf9"
      unitRef="usd">299000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfNi0zLTEtMS0yMjg1OA_e27bb1f1-08dd-421d-98eb-ece6fb290c7d"
      unitRef="usd">62000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfOC0xLTEtMS0yNTY3Mg_a4ee7f66-6276-46c7-9e18-768827138ae3"
      unitRef="usd">352000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfOC0zLTEtMS0yNTY3Mg_4bea6d7b-62af-45a2-93e6-4f89b4766b0c"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfOC0xLTEtMS0yMjg1OA_892a7f75-0548-4a56-81b8-75d9e0412d87"
      unitRef="usd">588000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfOC0zLTEtMS0yMjg1OA_af16f550-079b-4ed0-86e7-096e59b4d262"
      unitRef="usd">764000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfOS0xLTEtMS0yMjg1OA_c214d88f-ddf3-4104-979a-e74bf084f6e4"
      unitRef="usd">78529000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfOS0zLTEtMS0yMjg1OA_5ea6d810-e12d-4d3c-ad8c-2b7b6beca541"
      unitRef="usd">97008000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMTMtMS0xLTEtMjI4NTg_8381d992-9f44-4153-a559-79dc3eca57c3"
      unitRef="usd">974000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMTMtMy0xLTEtMjI4NTg_ad8c4c85-eb6f-4f07-92ec-98aa71aee6bd"
      unitRef="usd">1934000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMTQtMS0xLTEtMjI4NTg_595f4bf2-6e24-4dbf-8f6c-f5e3b8db3c69"
      unitRef="usd">5417000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMTQtMy0xLTEtMjI4NTg_59c0659d-17ec-4380-a530-b10124209ad7"
      unitRef="usd">2589000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMTUtMS0xLTEtMjI4NTg_9d76990e-bb6f-4490-bb6c-e9ba9e24ba24"
      unitRef="usd">6391000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMTUtMy0xLTEtMjI4NTg_86831fec-30f8-4493-8263-87cca941b4c1"
      unitRef="usd">4523000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMTYtMS0xLTEtMjI4NTg_cb9655e0-5964-4fd5-8c6b-6e41189eb8d8"
      unitRef="usd">367000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMTYtMy0xLTEtMjI4NTg_2bebce60-95a9-4af7-8270-23a65c784385"
      unitRef="usd">485000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMTctMS0xLTEtMjI4NTg_65ce0363-954b-403b-b54d-bc35304fba7f"
      unitRef="usd">6758000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMTctMy0xLTEtMjI4NTg_3ed9d16c-be4f-439e-a507-f73173296ae5"
      unitRef="usd">5008000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMTgtMS0xLTEtMjI4NTg_d72fb535-c0e7-4559-b62c-15683e90c43e"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMTgtMy0xLTEtMjI4NTg_651aa9b2-0e1b-4163-bcac-4d1fb2ea8b9d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjEtMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjoyYTE5MjcxNjFmNWY0N2JlODQ4YmIxY2RkZjMwYjBkNl8zNA_5ec8f056-984e-4957-ab98-e42540316f9e"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjEtMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjoyYTE5MjcxNjFmNWY0N2JlODQ4YmIxY2RkZjMwYjBkNl8zNA_d1fc4e60-8f3e-4875-8347-7691e38fe504"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <clbs:PreferredStockLiquidationPreferenceShare
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjEtMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjoyYTE5MjcxNjFmNWY0N2JlODQ4YmIxY2RkZjMwYjBkNl8xMTE_63d232f6-8022-48a2-8ab6-52b7a2a4187e"
      unitRef="shares">0.000067</clbs:PreferredStockLiquidationPreferenceShare>
    <clbs:PreferredStockLiquidationPreferenceShare
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjEtMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjoyYTE5MjcxNjFmNWY0N2JlODQ4YmIxY2RkZjMwYjBkNl8xMTE_f959406c-06f8-41cd-a63d-2af99b1d728c"
      unitRef="shares">0.000067</clbs:PreferredStockLiquidationPreferenceShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjEtMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjoyYTE5MjcxNjFmNWY0N2JlODQ4YmIxY2RkZjMwYjBkNl8xMzc_a729fead-d39f-4d26-baab-7455eef9750d"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjEtMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjoyYTE5MjcxNjFmNWY0N2JlODQ4YmIxY2RkZjMwYjBkNl8xMzc_cf298571-b826-44c2-b789-33202e59b5a9"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <clbs:PreferredStockSharesDesignated
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjEtMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjoyYTE5MjcxNjFmNWY0N2JlODQ4YmIxY2RkZjMwYjBkNl8xNTE_6b741403-bef2-4f27-89ce-456588d48b61"
      unitRef="shares">825000</clbs:PreferredStockSharesDesignated>
    <clbs:PreferredStockSharesDesignated
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjEtMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjoyYTE5MjcxNjFmNWY0N2JlODQ4YmIxY2RkZjMwYjBkNl8xNTE_c25a3df1-16f2-401c-b12a-5eb2023efe45"
      unitRef="shares">825000</clbs:PreferredStockSharesDesignated>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjEtMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjoyYTE5MjcxNjFmNWY0N2JlODQ4YmIxY2RkZjMwYjBkNl8xOTc_678624b7-6cf4-4ab8-b7d9-dbd59ce42a9f"
      unitRef="shares">10000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjEtMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjoyYTE5MjcxNjFmNWY0N2JlODQ4YmIxY2RkZjMwYjBkNl8xOTc_776d44ad-a154-46bf-8791-50cb314cd389"
      unitRef="shares">10000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjEtMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjoyYTE5MjcxNjFmNWY0N2JlODQ4YmIxY2RkZjMwYjBkNl8xOTc_bf6125ad-f3fa-4d3c-ac0a-d68194e8fc6b"
      unitRef="shares">10000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjEtMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjoyYTE5MjcxNjFmNWY0N2JlODQ4YmIxY2RkZjMwYjBkNl8xOTc_ef55544b-3169-4431-ae0f-b31849c371da"
      unitRef="shares">10000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjEtMS0xLTEtMjI4NTg_903fec47-f670-4bc0-a2af-5fa28e6e4c5d"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjEtMy0xLTEtMjI4NTg_8daca816-520d-4237-a0e6-bf5f7fe9dd6c"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjItMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjpmOTBiNTkzYmFmNGE0MjU3Yjg3NzEwYmM4OTg4NTI4OV8xOA_24dd4b41-f4a9-49a5-9e64-dbe7c48bac65"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjItMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjpmOTBiNTkzYmFmNGE0MjU3Yjg3NzEwYmM4OTg4NTI4OV8xOA_4248d274-5ed8-4049-8163-9683ccab88bb"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjItMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjpmOTBiNTkzYmFmNGE0MjU3Yjg3NzEwYmM4OTg4NTI4OV80Mw_6e124651-ec79-4468-a72c-ba973f8ab0e6"
      unitRef="shares">33333333</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjItMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjpmOTBiNTkzYmFmNGE0MjU3Yjg3NzEwYmM4OTg4NTI4OV80Mw_72aa93b3-19d5-494b-a342-a8ea67ae4394"
      unitRef="shares">33333333</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjItMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjpmOTBiNTkzYmFmNGE0MjU3Yjg3NzEwYmM4OTg4NTI4OV82MQ_1cad9fdc-a295-4518-aca7-49385ecade87"
      unitRef="shares">7863340</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjItMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjpmOTBiNTkzYmFmNGE0MjU3Yjg3NzEwYmM4OTg4NTI4OV82OA_1bf1eeca-0cbc-426e-9f85-6195c97afb15"
      unitRef="shares">3986719</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjItMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjpmOTBiNTkzYmFmNGE0MjU3Yjg3NzEwYmM4OTg4NTI4OV8xNTA_ec6c3696-3c34-4b8f-a486-54d70495fa9c"
      unitRef="shares">7862602</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjItMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjpmOTBiNTkzYmFmNGE0MjU3Yjg3NzEwYmM4OTg4NTI4OV8xNTc_763ed42e-5c9a-486c-92c8-c4bddd6d2924"
      unitRef="shares">3985981</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjItMS0xLTEtMjI4NTg_d67e402c-d43e-4792-86d2-83fbf36b7fe1"
      unitRef="usd">8000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjItMy0xLTEtMjI4NTg_60fbf5fc-c878-4a53-8cc1-aec66e3dcfb0"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjMtMS0xLTEtMjI4NTg_316bf048-45b2-4f5c-8be6-4f5cf39eafc4"
      unitRef="usd">574066000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjMtMy0xLTEtMjI4NTg_efce5a8b-c24f-4c4c-b460-2c591306a9ed"
      unitRef="usd">546044000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjQtMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjpkNjFlZGE5ZGU4MDQ0MTA3YWFkZDQ4ZjRmZTc2Yjc4Nl8yOQ_3e222d38-9a30-4b3b-8c81-b2fba11cd13e"
      unitRef="shares">738</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjQtMC0xLTEtMjI4NTgvdGV4dHJlZ2lvbjpkNjFlZGE5ZGU4MDQ0MTA3YWFkZDQ4ZjRmZTc2Yjc4Nl8yOQ_6c46ddad-bff4-42c3-bba2-cca610365d12"
      unitRef="shares">738</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjQtMS0xLTEtMjI4NTg_851f1614-b38f-4d8a-8dee-a8351b5096e4"
      unitRef="usd">708000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjQtMy0xLTEtMjI4NTg_435038cd-df69-4169-a4d6-6bb5a8d0b27e"
      unitRef="usd">708000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjUtMS0xLTEtMjI4NTg_a36b5c32-582b-4fea-a1d2-cdef07d4b694"
      unitRef="usd">-501251000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjUtMy0xLTEtMjI4NTg_2e996b12-2308-4539-ad13-113b1bdeddb8"
      unitRef="usd">-453016000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjYtMS0xLTEtMjI4NTg_6a413d38-85b9-4d3a-8068-3e8c6f8526a0"
      unitRef="usd">-90000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjYtMy0xLTEtMjI4NTg_bc8ef4fa-e189-4890-9158-59b9a34fc398"
      unitRef="usd">-70000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjctMS0xLTEtMjI4NTg_6328a608-34fb-474a-abf6-a86974206e03"
      unitRef="usd">72025000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjctMy0xLTEtMjI4NTg_05d84807-ea83-4148-b48c-af08b7310a60"
      unitRef="usd">92254000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjgtMS0xLTEtMjI4NTg_0773bbc8-5bbc-4da7-b44b-dd5cc8491aa8"
      unitRef="usd">-254000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjgtMy0xLTEtMjI4NTg_5a3978b2-8e16-4eb1-b878-44f89d2c6a12"
      unitRef="usd">-254000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjktMS0xLTEtMjI4NTg_838ff811-8ea7-4d6b-9d4c-757a87a76437"
      unitRef="usd">71771000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMjktMy0xLTEtMjI4NTg_38dd1a13-4528-4c5d-88f4-95fc4b5ecc32"
      unitRef="usd">92000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMzAtMS0xLTEtMjI4NTg_913868ee-a901-40c5-beae-a5cbc174634c"
      unitRef="usd">78529000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xNi9mcmFnOjgyYjc4MWQxZjhjYTQwZDZhMDNkYjk3MmM0NzZmYjcxL3RhYmxlOjdkNjQ0ZjdlMjdhMTQzZjViYmU2NzIyYjU0Zjk1ZTE2L3RhYmxlcmFuZ2U6N2Q2NDRmN2UyN2ExNDNmNWJiZTY3MjJiNTRmOTVlMTZfMzAtMy0xLTEtMjI4NTg_4f135996-9823-4cac-b00c-6372b6789277"
      unitRef="usd">97008000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMy0xLTEtMS0yMjg1OA_83d04f7b-df16-42d0-b061-11d7c41543b1"
      unitRef="usd">3380000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMy0zLTEtMS0yMjg1OA_3e4e121e-ae67-40bd-91fe-6e0e0bdfa6c1"
      unitRef="usd">4125000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMy01LTEtMS0yMjg1OA_8f8b3e4e-1591-427d-977f-65aa4059640c"
      unitRef="usd">9898000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMy03LTEtMS0yMjg1OA_4a86c6ac-9ec0-4a9e-9672-11dec8481096"
      unitRef="usd">13530000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNC0xLTEtMS0yNTcxNw_39fc7f31-cbdd-490d-bfe4-af538f100cd7"
      unitRef="usd">30393000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNC0zLTEtMS0yNTcxNw_bf15ad9b-7632-4241-8825-4f4bce6224a3"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNC01LTEtMS0yNTcxNw_b3bcbebb-c70b-46a5-aaa1-814d7d584daf"
      unitRef="usd">30393000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNC03LTEtMS0yNTcxNw_0b6c6cd2-b27a-4e8d-826b-c1bb202bb1bb"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNC0xLTEtMS0yMjg1OA_aa82c80d-d834-410c-a05e-f84c236e1db7"
      unitRef="usd">3947000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNC0zLTEtMS0yMjg1OA_1318c6da-391f-4ba9-9e16-3939e88f1203"
      unitRef="usd">2843000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNC01LTEtMS0yMjg1OA_5c4906f3-80d5-41dd-9f72-ea4ec4a7140c"
      unitRef="usd">10770000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNC03LTEtMS0yMjg1OA_f7d555bc-1c81-4b6a-a1fb-e651a0ef9d68"
      unitRef="usd">8671000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNS0xLTEtMS0yMjg1OA_4ad99122-6669-44d7-bd4a-f33b361c5316"
      unitRef="usd">37720000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNS0zLTEtMS0yMjg1OA_6a3f028c-9fa3-4f86-8ca3-61cc36aebb6d"
      unitRef="usd">6968000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNS01LTEtMS0yMjg1OA_f02b791a-fef9-4ec4-91c0-2f0dc4c53b3f"
      unitRef="usd">51061000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNS03LTEtMS0yMjg1OA_1f967702-ef53-4dc5-8091-38e55e1c3bd7"
      unitRef="usd">22201000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNy0xLTEtMS0yMjg1OA_852b5f2e-87b1-4cf6-9aec-dcf687ddfe13"
      unitRef="usd">-37720000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNy0zLTEtMS0yMjg1OA_4069e2b6-1d9d-4bd4-a184-1c169a5582cf"
      unitRef="usd">-6968000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNy01LTEtMS0yMjg1OA_807fed68-2de6-49a7-a577-c3ebb0e293b3"
      unitRef="usd">-51061000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfNy03LTEtMS0yMjg1OA_7401306d-1a3d-4cfb-b94d-9252d112221e"
      unitRef="usd">-22201000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTAtMS0xLTEtMjI4NTg_a08f3ffd-4d54-44a5-8f88-3ab5b113b40f"
      unitRef="usd">337000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTAtMy0xLTEtMjI4NTg_77bc159e-10b1-4fee-ba7b-46b0729ee523"
      unitRef="usd">41000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTAtNS0xLTEtMjI4NTg_3457b61d-0882-4ee5-8d8b-53088a6923db"
      unitRef="usd">496000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTAtNy0xLTEtMjI4NTg_1b670033-c78e-4cd0-9913-cdd493eeae15"
      unitRef="usd">111000</us-gaap:InvestmentIncomeNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTEtMS0xLTEtMjI4NTg_b7f84ee1-657a-4c05-bc5d-e41bb93d9d21"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTEtMy0xLTEtMjI4NTg_80bee637-7fe8-45a8-859f-98a75c43d5fa"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTEtNS0xLTEtMjI4NTg_8867e619-3b81-450b-ba64-7e295a1e0946"
      unitRef="usd">-149000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTEtNy0xLTEtMjI4NTg_14ac4da1-2835-45c5-9a49-ae7204417815"
      unitRef="usd">-90000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTItMS0xLTEtMjI4NTg_8dc9db37-5def-421b-b51d-718e26d41365"
      unitRef="usd">337000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTItMy0xLTEtMjI4NTg_b8615b8d-c1d2-4ea7-8037-655dbd313072"
      unitRef="usd">41000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTItNS0xLTEtMjI4NTg_3e1ae8ef-bf3a-425c-bd8b-50c8245d4b20"
      unitRef="usd">347000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTItNy0xLTEtMjI4NTg_4aef3511-5815-4089-a507-ee5a5027a40e"
      unitRef="usd">21000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTQtMS0xLTEtMjI4NTg_cd390cda-a1f5-4600-9f44-f515b5a6e332"
      unitRef="usd">-37383000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTQtMy0xLTEtMjI4NTg_17146ed3-1bd4-4e63-a9b1-1f2b7c617f9a"
      unitRef="usd">-6927000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTQtNS0xLTEtMjI4NTg_c11507ff-84ae-4d89-8470-34c29ed0df3c"
      unitRef="usd">-50714000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTQtNy0xLTEtMjI4NTg_b585ff59-2f54-425d-b93a-7d0440e88614"
      unitRef="usd">-22180000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTUtMS0xLTEtMjI4NTg_83cb84bb-f2d2-4de4-8e47-184f61ff80c2"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTUtMy0xLTEtMjI4NTg_a55d9400-59ce-49c5-9810-e4a40252a8be"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTUtNS0xLTEtMjI4NTg_ac0025f1-4ca1-454b-afde-d58cd1972d6b"
      unitRef="usd">-2479000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTUtNy0xLTEtMjI4NTg_21b21305-0585-48f2-bba3-2ebca2690477"
      unitRef="usd">-1508000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTgtMS0xLTEtMjI4NTg_99664396-70b1-46f7-b61c-13512fdf5f5a"
      unitRef="usd">-37383000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTgtMy0xLTEtMjI4NTg_9fb460b4-3e96-451b-b479-7109c2288e76"
      unitRef="usd">-6927000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTgtNS0xLTEtMjI4NTg_544efbd5-bb74-4116-bce0-683bcbaee335"
      unitRef="usd">-48235000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMTgtNy0xLTEtMjI4NTg_9a560e89-dcf4-4cd4-a3f4-18beb24fe5e7"
      unitRef="usd">-20672000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjItMS0xLTEtMjI4NTg_3c00c754-a4aa-4693-a74c-abf43d2a1cbb"
      unitRef="usdPerShare">-7.88</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjItMS0xLTEtMjI4NTg_9f66202f-9cea-4939-8c15-b460e5ec47a3"
      unitRef="usdPerShare">-7.88</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjItMy0xLTEtMjI4NTg_327bbc0c-8d60-4e53-82fc-6d7d1b0e96e5"
      unitRef="usdPerShare">-1.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjItMy0xLTEtMjI4NTg_40748671-82ec-4684-af0b-66beda6a0f0d"
      unitRef="usdPerShare">-1.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjItNS0xLTEtMjI4NTg_3db279b4-3208-4435-8f1b-dec6cf0cedfc"
      unitRef="usdPerShare">-11.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjItNS0xLTEtMjI4NTg_7cc146e9-09d9-46a6-8c7a-dc69e8cc024d"
      unitRef="usdPerShare">-11.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjItNy0xLTEtMjI4NTg_15235622-9d54-4071-beda-d92e807929d6"
      unitRef="usdPerShare">-5.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjItNy0xLTEtMjI4NTg_475ee68b-45fb-4562-b6de-9e0c97acc405"
      unitRef="usdPerShare">-5.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjUtMS0xLTEtMjI4NTg_916137b8-937b-4e1e-9b57-3905217ea913"
      unitRef="shares">4747000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjUtMS0xLTEtMjI4NTg_b4012e4e-8705-4c69-ae39-e11bfeb4af09"
      unitRef="shares">4747000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjUtMy0xLTEtMjI4NTg_8ba6df43-736c-4be4-a879-de3fc25f1bb2"
      unitRef="shares">3974000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjUtMy0xLTEtMjI4NTg_c8790877-1dbf-422b-beb4-21921901617a"
      unitRef="shares">3974000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjUtNS0xLTEtMjI4NTg_7fdf6efc-5004-4f5b-8ca8-b8ad8a42eacc"
      unitRef="shares">4276000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjUtNS0xLTEtMjI4NTg_ccbb88a2-31e7-4cd0-b9eb-e46585b05519"
      unitRef="shares">4276000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjUtNy0xLTEtMjI4NTg_4f167adb-6dd4-44c8-8deb-78870e0ad8ab"
      unitRef="shares">3587000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xOS9mcmFnOjY1Mzg5Y2VhMDVmMzQ0ZjE5NTAyNWVkYTIxYjE1ODhmL3RhYmxlOjUyYzg5NTNlNzA1NzRjOGI5MjRhZDM4YThmNjYwZTlmL3RhYmxlcmFuZ2U6NTJjODk1M2U3MDU3NGM4YjkyNGFkMzhhOGY2NjBlOWZfMjUtNy0xLTEtMjI4NTg_adf36ad4-d258-41bd-850c-06bc66eab2a2"
      unitRef="shares">3587000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProfitLoss
      contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfMi0xLTEtMS0yMjg1OA_658f2293-3478-496a-829b-1050e71b4456"
      unitRef="usd">-37383000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfMi0zLTEtMS0yMjg1OA_8b41def3-04f4-4ab3-ac39-dd0b269c4c47"
      unitRef="usd">-6927000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfMi01LTEtMS0yMjg1OA_f2318eb9-4a70-4705-91e4-c97ce551822a"
      unitRef="usd">-48235000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfMi03LTEtMS0yMjg1OA_8112ca4a-6c62-4f13-8043-86d0ff8eb543"
      unitRef="usd">-20672000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfNS0xLTEtMS0yMjg1OA_f0397538-58cb-4e98-bc17-18d208e320f5"
      unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfNS0zLTEtMS0yMjg1OA_96db2c0c-92de-42e5-b5bb-5f8b3a978954"
      unitRef="usd">-47000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfNS01LTEtMS0yMjg1OA_e1998432-5b38-4a11-b185-586aaf02aaf6"
      unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfNS03LTEtMS0yMjg1OA_944a5136-db96-4b7e-b87b-3007f7625be4"
      unitRef="usd">-51000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfNi0xLTEtMS0yNTc1Nw_624eb1e8-fd56-45a7-859f-d2d529d66a25"
      unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfNi0zLTEtMS0yNTc1Nw_397e5d59-7571-4463-9197-c4e408d02719"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfNi01LTEtMS0yNTc1Nw_f0e83d22-6c35-4327-9eb8-090e23cd3e2c"
      unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfNi03LTEtMS0yNTk3NA_183d1cba-1007-45a4-b183-4dda241aa129"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfNi0xLTEtMS0yMjg1OA_c3aedb94-b0fc-4e93-9ec5-7b6dd045f4b6"
      unitRef="usd">-20000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfNi0zLTEtMS0yMjg1OA_9d9b0e65-a989-4ea0-98ff-1e63d9e18f5b"
      unitRef="usd">-47000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfNi01LTEtMS0yMjg1OA_f61f24e0-97df-49dd-a132-2f67368089fc"
      unitRef="usd">-20000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfNi03LTEtMS0yMjg1OA_5041678b-5757-4f40-b626-b74c1aeaf182"
      unitRef="usd">-51000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfMTItMS0xLTEtMjI4NTg_2cfeeb8f-e9fb-4f7c-b41f-778188badcfd"
      unitRef="usd">-37403000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfMTItMy0xLTEtMjI4NTg_52eb00f3-0fae-4534-a359-3b23d0bcfd66"
      unitRef="usd">-6974000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfMTItNS0xLTEtMjI4NTg_bcd194a2-dfd9-41e2-a810-9c1ef2cbb1d5"
      unitRef="usd">-48255000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yMi9mcmFnOmQzNDk4ZGI2N2Y0NTRkNGM4MTk1ZmFiOWExZGVkZmE2L3RhYmxlOmRjZjM3ZmU4NWU0YjQ0NjU5NjY1MjUxODFjZWI2MDNkL3RhYmxlcmFuZ2U6ZGNmMzdmZTg1ZTRiNDQ2NTk2NjUyNTE4MWNlYjYwM2RfMTItNy0xLTEtMjI4NTg_0bc13504-2dd8-4d2e-a4bd-4d5b6be21631"
      unitRef="usd">-20723000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia5c2e6f4066b47fbb0c62e47d1a34e30_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMi0xLTEtMS0yMjg1OA_1fd54ff4-5489-412d-9b90-ff2a9c3a51ca"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia5c2e6f4066b47fbb0c62e47d1a34e30_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMi0xLTEtMS0yMjg1OA_585fe28b-52c9-42f3-aaec-aaaaa25f043e"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia5c2e6f4066b47fbb0c62e47d1a34e30_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMi0xLTEtMS0yMjg1OA_a9629bf9-0a8b-45db-be18-87e9b84fdc18"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia5c2e6f4066b47fbb0c62e47d1a34e30_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMi0zLTEtMS0yMjg1OA_976ab462-ec6c-48d0-8d77-06a65f579a3b"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i86d263da61bd426cb7086a17123228f7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMi01LTEtMS0yMjg1OA_0d97ad07-d0f8-46bf-a870-a8accc628647"
      unitRef="shares">4038000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i86d263da61bd426cb7086a17123228f7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMi03LTEtMS0yMjg1OA_ce04d74d-1e95-4b81-91ee-fd15dbd917a9"
      unitRef="usd">4000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i17ae6b2b209f4867bbb33069c004b3aa_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMi05LTEtMS0yMjg1OA_220a777c-9c1a-49f5-8faa-e3ed5e7db7be"
      unitRef="usd">547032000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id86020b0b46045dc893b03e2966eb75c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMi0xMS0xLTEtMjI4NTg_07752db1-a296-460b-b89d-e7a119ee9de1"
      unitRef="usd">-70000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i029fe570e6734389a205caae3c3445a0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMi0xMy0xLTEtMjI4NTg_f9d84907-6b7a-436b-b17d-b15e82ca83e9"
      unitRef="usd">-463868000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i03285eb13bc340e3a8a2ff34047b4093_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMi0xNS0xLTEtMjI4NTg_2da00b92-de90-4231-b032-85fde0dc7e01"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i07070a35a7c74213a020599cb2deffb7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMi0xNy0xLTEtMjI4NTg_d517e113-d607-4a83-963c-3c9086f7dcf8"
      unitRef="usd">82391000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2c69daf49eff4222a69cd10c77c98604_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMi0xOS0xLTEtMjI4NTg_33e199bb-9985-44a5-8c4a-08fdd23be4c3"
      unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia9d9e85847ab4fcf9aac296f60571be8_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMi0yMS0xLTEtMjI4NTg_408ade25-6a72-47e0-b650-7052346cc03d"
      unitRef="usd">82137000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i69110a58290f48db984963c9b07024c0_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMy0xMy0xLTEtMjI4NTg_3993ceb3-4cde-46e9-8cd8-244a9b82f19c"
      unitRef="usd">-37383000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7b905b12169646dea54aa6e1e067b6f0_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMy0xNy0xLTEtMjI4NTg_8090696a-657e-4125-a5ca-1054483553a8"
      unitRef="usd">-37383000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMy0yMS0xLTEtMjI4NTg_c4c258a3-f324-460d-9f71-40ee0b37e52c"
      unitRef="usd">-37383000</us-gaap:ProfitLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i6d228b1f84b744de88a126fa2a54dd15_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfNS01LTEtMS0yMjg1OA_0823e33d-db6b-4c16-b53f-52ec8c985614"
      unitRef="shares">52000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iebd096734b704a05b20e0d2a7a46f6f4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfNS05LTEtMS0yMjg1OA_f7484aa3-4340-44bf-b02a-52b1b63f048f"
      unitRef="usd">940000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7b905b12169646dea54aa6e1e067b6f0_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfNS0xNy0xLTEtMjI4NTg_2efac6ec-0f20-46cb-8279-544475309619"
      unitRef="usd">939000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfNS0yMS0xLTEtMjI4NTg_01b0449f-4e8b-4332-818b-fc5caaabc8b0"
      unitRef="usd">939000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i6d228b1f84b744de88a126fa2a54dd15_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfOS01LTEtMS0yNjE3Ng_fe7368b1-a874-4e9b-b391-4506a438e779"
      unitRef="shares">3773000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i6d228b1f84b744de88a126fa2a54dd15_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfOS03LTEtMS0yNjE3Ng_1bd66d3f-91dd-4594-9335-747d1a09824e"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="iebd096734b704a05b20e0d2a7a46f6f4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTAtOS0xLTEtMjU1NDE_65d97fca-9413-4d19-9439-b1866d803184"
      unitRef="usd">26094000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i7b905b12169646dea54aa6e1e067b6f0_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTAtMTctMS0xLTI1NTM2_e51ed6f0-f4bd-4f4d-b688-c056b09b4945"
      unitRef="usd">26098000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTAtMjEtMS0xLTI1NTM2_33087518-7ab9-4a05-bef3-efdfcd3cd557"
      unitRef="usd">26098000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i1cec8b5ec5914024a14b5f754a3d6ddf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTItMTEtMS0xLTI1NTQx_5b47337e-5730-49bc-a485-3ae47a2650d3"
      unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i7b905b12169646dea54aa6e1e067b6f0_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTItMTctMS0xLTI1NTM2_cbe2691b-2d00-43b5-92dd-04086e74b3a1"
      unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTItMjEtMS0xLTI1NTM2_20c40406-2e46-45fc-a171-e1415c66d4fe"
      unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i1cec8b5ec5914024a14b5f754a3d6ddf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTEtMTEtMS0xLTI3NTU5_e511d19b-417c-4601-ae0d-8f732dc0771f"
      unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTEtMTctMS0xLTI3NTU5_5eaf2722-4520-410c-9bab-13d6f8d7e009"
      unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTEtMjEtMS0xLTI3NTU5_036d7c63-87a5-42ee-b117-6931ca3f9387"
      unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id9801b9ed9e24c90b66bf7dc589a24f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfOS0xLTEtMS0yMjg1OA_dd8a8779-c5a9-473f-83b5-e5a5cb2eaf36"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id9801b9ed9e24c90b66bf7dc589a24f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfOS0zLTEtMS0yMjg1OA_5d6e864e-b02b-4594-adb1-3956e1eaeb31"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i944ba198ef814601b1dc3e189a2d15b9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfOS01LTEtMS0yMjg1OA_2bc0981c-aec1-481f-9c07-ae1140d56cb2"
      unitRef="shares">7863000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i944ba198ef814601b1dc3e189a2d15b9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfOS03LTEtMS0yMjg1OA_ec05452c-994e-4126-ae16-cf81feff68b0"
      unitRef="usd">8000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5163c19edf884a309a10703ede9fbc6c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfOS05LTEtMS0yMjg1OA_d7e388ee-f017-46d7-a698-86e12b866a9d"
      unitRef="usd">574066000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i853118dfc75844fb9a23dfa0374528cd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfOS0xMS0xLTEtMjI4NTg_a921c7b0-124d-4a95-91f5-1bc0cd138cd6"
      unitRef="usd">-90000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5c936e2b28ea43c7b0b9af4a69e00249_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfOS0xMy0xLTEtMjI4NTg_1b36074e-c8a3-43bc-85c4-6dcd577bdbb5"
      unitRef="usd">-501251000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6b81c7260bd84f378acc80251b158b2a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfOS0xNS0xLTEtMjI4NTg_2217b371-04f4-4ca0-83ae-e5a64733bb71"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1ec4c587d4a3466ab448abb94ba9f29d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfOS0xNy0xLTEtMjI4NTg_9b325ab8-a08d-4dfb-9061-b0326cdeb407"
      unitRef="usd">72025000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id3c09e4703ba40298dd79e85417cdb61_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfOS0xOS0xLTEtMjI4NTg_684d9c54-5913-437f-9f70-b74767efcaf5"
      unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfOS0yMS0xLTEtMjI4NTg_372a5efb-5cf7-459c-99cd-8441ad3ebe33"
      unitRef="usd">71771000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i8d30a645527f4337a60c7da8f18e85ae_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTMtMS0xLTEtMjI4NTg_aa878e7e-fbc5-4cb9-bc29-5541973de815"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8d30a645527f4337a60c7da8f18e85ae_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTMtMy0xLTEtMjI4NTg_6397f74f-82f9-472a-83d4-aadc40bc15e7"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7eef7cc26c004a4c908e6fe160d201d1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTMtNS0xLTEtMjI4NTg_0358b2ce-b039-49cc-82ed-f96a4f27ba76"
      unitRef="shares">3986000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7eef7cc26c004a4c908e6fe160d201d1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTMtNy0xLTEtMjI4NTg_fc960858-e938-4d26-8999-032c53592c9f"
      unitRef="usd">4000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i686c5d52741f40f5a71ed6e2545ec05b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTMtOS0xLTEtMjI4NTg_079ab309-cc51-4c76-9b1d-e80d099fa11e"
      unitRef="usd">546044000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4050b9a1a6ec412b8853f688ad35a4fd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTMtMTEtMS0xLTIyODU4_8833e898-df4d-4f8a-9519-a964868b18ca"
      unitRef="usd">-70000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7fa893b6dc4a4a698cf4f78caf023478_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTMtMTMtMS0xLTIyODU4_7eb7efe3-21b2-46fc-9402-79345e0fc9a0"
      unitRef="usd">-453016000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if7779b193bfe449bbd568049e6084cc7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTMtMTUtMS0xLTIyODU4_e5a397f3-2093-488a-af34-892edc0e7f32"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0d1ccf571c4245369c9de32e62b102ee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTMtMTctMS0xLTIyODU4_6eed1f10-0c4b-4103-b374-f5deff793c3c"
      unitRef="usd">92254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i63f9702a0ee94ee3a2adeeac786c1860_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTMtMTktMS0xLTIyODU4_5ec14768-ff6f-48c3-a408-a8a24c48ecc1"
      unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTMtMjEtMS0xLTIyODU4_8ca926cd-ba60-4858-8d6c-a2789d9932f3"
      unitRef="usd">92000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ie19069eadb3a4525bd0e3c209f26c6fc_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTUtMTMtMS0xLTIyODU4_2b62ec51-9635-4c02-9a7a-fdc200b3b506"
      unitRef="usd">-48235000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i29f228f551d04b7d9d199959a37d10b2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTUtMTctMS0xLTIyODU4_2f0ed9e2-525f-4f4b-b145-f365744d1f4c"
      unitRef="usd">-48235000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTUtMjEtMS0xLTIyODU4_e18fd70a-2683-4f32-96ee-d7f8a5339aad"
      unitRef="usd">-48235000</us-gaap:ProfitLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ie1e85bf072d8481caf42f6d9beb8f4e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTctNS0xLTEtMjI4NTg_ffd00571-aa19-407c-9856-6264ea799026"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie1e85bf072d8481caf42f6d9beb8f4e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTctNy0xLTEtMjI4NTg_f5aef239-bf32-45fc-b890-bd62587616c4"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9485a0db274745a69f25443e8b178239_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTctOS0xLTEtMjI4NTg_d5359c2b-aa84-4550-82e1-81ba3b5a21fe"
      unitRef="usd">1899000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i29f228f551d04b7d9d199959a37d10b2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTctMTctMS0xLTIyODU4_72c7ecdf-02a3-4b26-8ba9-3f323068ddf0"
      unitRef="usd">1899000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTctMjEtMS0xLTIyODU4_b0800809-d062-4502-8dc5-fd9f4117e5ec"
      unitRef="usd">1899000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ie1e85bf072d8481caf42f6d9beb8f4e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTgtNS0xLTEtMjI4NTg_07e69ff1-ff3f-40b7-bff1-ff35973f7cfc"
      unitRef="shares">4000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9485a0db274745a69f25443e8b178239_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTgtOS0xLTEtMjI4NTg_d5e94e8c-cdce-4d58-ad96-44a5e8bf6f31"
      unitRef="usd">29000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i29f228f551d04b7d9d199959a37d10b2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTgtMTctMS0xLTIyODU4_3bf496a2-c658-43f3-968e-8005ac7e803d"
      unitRef="usd">29000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMTgtMjEtMS0xLTIyODU4_da440d21-b349-432e-9320-e92675efb04b"
      unitRef="usd">29000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="ie1e85bf072d8481caf42f6d9beb8f4e6_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjMtNS0xLTEtMjYyMDU_3102fabe-b22a-43a8-a0b9-55a8eb9b6e05"
      unitRef="shares">3773000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="ie1e85bf072d8481caf42f6d9beb8f4e6_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjMtNy0xLTEtMjYyMDU_0fcff799-d7c1-4e99-b864-7a92fafe0008"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i9485a0db274745a69f25443e8b178239_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjMtOS0xLTEtMjYyMDU_07f13f86-c164-4afe-888d-c25d1f33b88f"
      unitRef="usd">26094000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i29f228f551d04b7d9d199959a37d10b2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjYtMTctMS0xLTI1NTYz_0484f77f-19b1-4b5f-a507-e6220d0a0486"
      unitRef="usd">26098000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i29f228f551d04b7d9d199959a37d10b2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjYtMTctMS0xLTI1NTYz_52a3741c-9a9f-44e8-b6a8-ff4ae71f78fe"
      unitRef="usd">26098000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjYtMjEtMS0xLTI1NTcy_48dbfb0d-4906-4ffb-beb6-3b4a1076b4f1"
      unitRef="usd">26098000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="iab2f266a4d614842a787f8e85ec8abfd_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjgtMTEtMS0xLTI1NTYz_ce2ac3d5-2024-4017-b6b3-683d6275d9bb"
      unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i29f228f551d04b7d9d199959a37d10b2_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjgtMTctMS0xLTI1NTYz_a2342957-0274-4262-a9b7-457526dbbba0"
      unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjgtMjEtMS0xLTI1NTcy_fb31a95d-7e0a-4a27-a200-96803806c371"
      unitRef="usd">5000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="iab2f266a4d614842a787f8e85ec8abfd_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjUtMTEtMS0xLTI3NTg1_00e2631e-37bc-4f91-9589-1d79504e22c6"
      unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjUtMTctMS0xLTI3NTg1_5c63aec5-76e6-4bd2-b240-fe8bb178ad48"
      unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjUtMjEtMS0xLTI3NTg1_44bd9fec-2d07-44b8-99b1-be4639eb4d9b"
      unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id9801b9ed9e24c90b66bf7dc589a24f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjEtMS0xLTEtMjI4NTg_cdb5378a-6a18-4707-b2eb-aafb08f15e14"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id9801b9ed9e24c90b66bf7dc589a24f2_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjEtMy0xLTEtMjI4NTg_e9347d2c-1161-4f88-bafe-3ef03fa27fa2"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i944ba198ef814601b1dc3e189a2d15b9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjEtNS0xLTEtMjI4NTg_737eebdb-0e3f-4c8d-a7b4-a3874a0ef1c8"
      unitRef="shares">7863000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i944ba198ef814601b1dc3e189a2d15b9_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjEtNy0xLTEtMjI4NTg_1cf1f71e-c597-451f-89ce-b61321334a3f"
      unitRef="usd">8000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5163c19edf884a309a10703ede9fbc6c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjEtOS0xLTEtMjI4NTg_3138934d-a075-44ce-832b-9456e9424227"
      unitRef="usd">574066000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i853118dfc75844fb9a23dfa0374528cd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjEtMTEtMS0xLTIyODU4_e9e53df6-0497-41bb-b861-97149d91a9c7"
      unitRef="usd">-90000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5c936e2b28ea43c7b0b9af4a69e00249_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjEtMTMtMS0xLTIyODU4_7f2d0d43-aa8b-43ef-8504-b6b923e78b21"
      unitRef="usd">-501251000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6b81c7260bd84f378acc80251b158b2a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjEtMTUtMS0xLTIyODU4_7676f774-6fb0-420f-8031-c15b6b68191c"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1ec4c587d4a3466ab448abb94ba9f29d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjEtMTctMS0xLTIyODU4_ef398382-21fa-47c8-bf22-e56f351cc7da"
      unitRef="usd">72025000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id3c09e4703ba40298dd79e85417cdb61_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjEtMTktMS0xLTIyODU4_6bd2cc61-7fa0-4cc7-9405-eea116a00bfe"
      unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjg4MTEzMjljMDAxODQzNTI5YmFjNzM0NDMwOTEzYzNkL3RhYmxlcmFuZ2U6ODgxMTMyOWMwMDE4NDM1MjliYWM3MzQ0MzA5MTNjM2RfMjEtMjEtMS0xLTIyODU4_f2416230-4551-4b6d-984b-a44d20cd71df"
      unitRef="usd">71771000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ie8fa07dd822c4c8db0ca288934287b7d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMi0xLTEtMS0yMjg1OA_94f9e7df-45db-40da-a5cf-49ca8229bea1"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie8fa07dd822c4c8db0ca288934287b7d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMi0zLTEtMS0yMjg1OA_9b15572d-19c2-4130-8053-e5259caf6e4b"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i16004a445bd449db8e2738b544722065_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMi01LTEtMS0yMjg1OA_3c88c480-ddf9-4e6a-b08b-e7ddb82f2744"
      unitRef="shares">3967000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i16004a445bd449db8e2738b544722065_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMi03LTEtMS0yMjg1OA_dc7c914b-d210-4bf3-9b06-0cf6cf7d70f8"
      unitRef="usd">4000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i038ee7bc9a294a179161a5703da8dba9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMi05LTEtMS0yMjg1OA_f2704af1-02e7-436a-85a6-9ea26e9f8a0e"
      unitRef="usd">544949000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i57d6d03e551b49a8a244e5310fc9c806_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMi0xMS0xLTEtMjI4NTg_5f2bb70f-08ca-4bb0-be60-f8c0f4b68055"
      unitRef="usd">-17000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0bd86cb6ffe24ae9af1b0bf46c620e7f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMi0xMy0xLTEtMjI4NTg_976a123f-af21-419d-ac31-3b27c64a6812"
      unitRef="usd">-439295000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iec685200531f473bab6967cb468862fb_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMi0xNS0xLTEtMjI4NTg_4ee8a726-c49d-45d9-8620-b0475f2b360f"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0251e8a199d84ca68ff8b0e1aa8255ce_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMi0xNy0xLTEtMjI4NTg_5b9a40ad-264b-4b49-8058-bdfffdcaf470"
      unitRef="usd">104933000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iedd0d04163e74945bb220b2e853c3e5e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMi0xOS0xLTEtMjI4NTg_f6acf282-d556-4a91-a92b-f087fa4cfba7"
      unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia59e32a50e1444c697ba1a65e5e48334_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMi0yMS0xLTEtMjI4NTg_f9ac0724-9b9e-4fb4-985b-c4bf7b30b31e"
      unitRef="usd">104679000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ib0d534735e7c4b63b3bf26d250ca8b2b_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMy0xMy0xLTEtMjI4NTg_73f7b72a-6c16-4bd4-8526-2da80cb4b53e"
      unitRef="usd">-6927000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iadddb49f7b264fa48f4b8133ef8e3991_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMy0xNy0xLTEtMjI4NTg_ff31e612-aa55-4ceb-95be-ed33a84b8c35"
      unitRef="usd">-6927000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMy0yMS0xLTEtMjI4NTg_e6a6e65d-ae2b-42d5-9dfd-cc50382ddaf4"
      unitRef="usd">-6927000</us-gaap:ProfitLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i81f77055e79c4a769aa1eeb70f3e5de2_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfNS01LTEtMS0yMjg1OA_bec44a67-5212-4b00-8ab4-d3736d0252f4"
      unitRef="shares">19000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ifc9fdc2eadc94b589888a37676c11ae9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfNS05LTEtMS0yMjg1OA_b85b2cb2-1cb5-4ae9-9d29-ad12bca1efa9"
      unitRef="usd">708000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iadddb49f7b264fa48f4b8133ef8e3991_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfNS0xNy0xLTEtMjI4NTg_2ff58c40-a53d-4736-95e9-ddc8356c7a2b"
      unitRef="usd">708000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfNS0yMS0xLTEtMjI4NTg_a7881ff7-ef44-47e5-b94c-383b078c06bf"
      unitRef="usd">708000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i9f9539108c6c4e1ba0d051b1aabb567a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS0xMS0xLTEtMjc2MTM_95cdb4b4-6fe2-4930-831f-10ee63400fcb"
      unitRef="usd">-47000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="iadddb49f7b264fa48f4b8133ef8e3991_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS0xNy0xLTEtMjc2MTM_4bac063e-db3e-43ea-96b4-4196f271cea4"
      unitRef="usd">-47000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS0yMS0xLTEtMjc2MTM_25d70de0-9c36-4700-b285-c3f909435503"
      unitRef="usd">-47000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i8d2b62b865bd4041b0251301f7f51424_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS0xLTEtMS0yMjg1OA_52f8eef2-8f8f-47af-8fbf-87ff1e4deaf0"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8d2b62b865bd4041b0251301f7f51424_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS0zLTEtMS0yMjg1OA_0e6b1bf1-142d-423c-bebc-9ec00ecc1260"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i872ef751a6a241769e47a7626414f412_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS01LTEtMS0yMjg1OA_7ec64f7a-c926-4d16-b543-3c29efa82529"
      unitRef="shares">3986000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i872ef751a6a241769e47a7626414f412_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS03LTEtMS0yMjg1OA_b20aa0a0-3a58-429b-ab32-d4c193794afb"
      unitRef="usd">4000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iee65085e733d41a19e4143446eff7b7c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS05LTEtMS0yMjg1OA_fcbd2d8c-9d90-4761-bf3e-53870b1492bf"
      unitRef="usd">545657000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i33afa975dd374f46b8ea96b4c0471c87_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS0xMS0xLTEtMjI4NTg_978d45f7-9e96-40d3-a06a-16984997881c"
      unitRef="usd">-64000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id2242481d947422a87b50a693e117608_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS0xMy0xLTEtMjI4NTg_468b22a4-9989-4dbd-9d08-332401fa62e8"
      unitRef="usd">-446222000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i57e94f040b084f7b9def7834d945a4c7_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS0xNS0xLTEtMjI4NTg_21141e7a-731f-4cce-a627-337dd4f784d7"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i57e94f040b084f7b9def7834d945a4c7_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS0xNS0xLTEtMjI4NTg_8808068a-7fef-4b55-bbc1-4063497d5d49"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id9d73cec2ab1421e98d1f86d5a3b506a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS0xNy0xLTEtMjI4NTg_b7089ac1-1a09-499f-b9a3-9c7bdf467a45"
      unitRef="usd">98667000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic87a4ec489bc4ec0bf3f93cc71f5e063_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS0xOS0xLTEtMjI4NTg_30ae9603-3d1f-4a3b-8d63-355e758deaa6"
      unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i74b1319645614dceb3e4fce1f773ff25_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfOS0yMS0xLTEtMjI4NTg_19e6a4b1-82b4-4d4b-94d3-3f838d916aa9"
      unitRef="usd">98413000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i848e51e03eed447c935cb2899345a1ff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTMtMS0xLTEtMjI4NTg_999525f4-1ff7-43cd-8c16-c3bf0e99fa48"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i848e51e03eed447c935cb2899345a1ff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTMtMy0xLTEtMjI4NTg_c6fd1bae-cd03-4d2a-823f-fa96acdc35b0"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i26cf58fb84e74ac694d839db83461838_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTMtNS0xLTEtMjI4NTg_fa002cc7-6adc-4b9d-81b7-3bce15dc0572"
      unitRef="shares">1292000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i26cf58fb84e74ac694d839db83461838_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTMtNy0xLTEtMjI4NTg_73fa3bd2-7d0e-460b-a300-18d1e6313368"
      unitRef="usd">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib450656958d64dd7809ab86b82185cce_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTMtOS0xLTEtMjI4NTg_0f1c1cbb-dbf7-4684-8f5f-29d81c548d2b"
      unitRef="usd">458766000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie3e5d05a52e7442a8b64eb445899cdf0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTMtMTEtMS0xLTIyODU4_8dd0f77f-1bf9-4313-9a76-bf7671dacbdf"
      unitRef="usd">-13000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i85b4ca140e7d4f318fdd15f0a5cfb26c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTMtMTMtMS0xLTIyODU4_1db113de-ae55-4aeb-9b57-cc34e1cc9612"
      unitRef="usd">-425550000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib8a27c130df24312b50441271af5f833_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTMtMTUtMS0xLTIyODU4_29d1eae2-1a8b-4645-bbbb-eb70637f7a77"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8fad62fd3c3b4c7083f34c136706b9ab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTMtMTctMS0xLTIyODU4_a4acc085-9694-4b96-a104-b346db0d8d9b"
      unitRef="usd">32496000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if5443afa6b3c4665b9c1eae0dbd038e1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTMtMTktMS0xLTIyODU4_c9405939-1e5f-4e13-9ab1-331230b617a3"
      unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i83e78453949e4f5fb203beb11be8a1dc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTMtMjEtMS0xLTIyODU4_9ec94b5b-64ff-42c7-bb92-41d716fd70c5"
      unitRef="usd">32242000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i0a6f0161fc68498fb65a78febe096c25_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTUtMTMtMS0xLTIyODU4_2efab64e-5758-4b77-9747-32665d59be63"
      unitRef="usd">-20672000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if0a6fa60498746079ad9eb4134e0a7c0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTUtMTctMS0xLTIyODU4_05d33702-601b-4de3-a7c2-e43a932b2c1c"
      unitRef="usd">-20672000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTUtMjEtMS0xLTIyODU4_e85d5f30-950d-46a4-916b-c57a9eb93ce8"
      unitRef="usd">-20672000</us-gaap:ProfitLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i07a0bb3234e14e0fbc6b7bce9f23f88a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTctNS0xLTEtMjI4NTg_17d146f9-7145-4ba0-9b92-52f541b3c491"
      unitRef="shares">36000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i86917d398d3247a6b5578480b5333d60_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTctOS0xLTEtMjI4NTg_f4891042-b4d9-4dd6-88cf-f8540372516b"
      unitRef="usd">1391000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if0a6fa60498746079ad9eb4134e0a7c0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTctMTctMS0xLTIyODU4_84bab397-7784-407d-a061-fee20a39d19f"
      unitRef="usd">1391000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTctMjEtMS0xLTIyODU4_35a9e0d8-a1b9-4ced-a852-0dcc51d4cbd6"
      unitRef="usd">1391000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i07a0bb3234e14e0fbc6b7bce9f23f88a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTgtNS0xLTEtMjI4NTg_78975ee3-ab08-4651-b602-24883b1e43a4"
      unitRef="shares">2658000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i07a0bb3234e14e0fbc6b7bce9f23f88a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTgtNy0xLTEtMjI4NTg_0e761f3a-6f40-478a-bf2d-c54964855b63"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i86917d398d3247a6b5578480b5333d60_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTgtOS0xLTEtMjI4NTg_8accac95-d149-4f0a-9691-0e3efdaff72b"
      unitRef="usd">85476000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if0a6fa60498746079ad9eb4134e0a7c0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTgtMTctMS0xLTIyODU4_e9643d95-5e84-41df-a988-5489f45b8156"
      unitRef="usd">85479000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTgtMjEtMS0xLTIyODU4_c0c82757-dfa0-409c-933b-3f2a6e1f3d21"
      unitRef="usd">85479000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i86917d398d3247a6b5578480b5333d60_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTktOS0xLTEtMjI4NTg_d3bc8ff2-dbc0-4e2a-99d6-44b15b8ae6b0"
      unitRef="usd">24000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if0a6fa60498746079ad9eb4134e0a7c0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTktMTctMS0xLTIyODU4_c6ab49d4-4d48-4d25-9303-f3ee4b635060"
      unitRef="usd">24000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMTktMjEtMS0xLTIyODU4_fad0402f-771e-42a9-8a22-67e69514ee2c"
      unitRef="usd">24000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i3698298d7aba49a9af19841d1ba110c1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMjEtMTEtMS0xLTI3NjIz_427197bd-a714-474b-9847-7f42d816c282"
      unitRef="usd">-51000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="if0a6fa60498746079ad9eb4134e0a7c0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMjEtMTctMS0xLTI3NjIz_dea36293-4bdd-44ec-9172-4c4311248726"
      unitRef="usd">-51000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMjEtMjEtMS0xLTI3NjIz_ecd72f3f-7954-4cdc-ad8d-04c7d03e5d54"
      unitRef="usd">-51000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i8d2b62b865bd4041b0251301f7f51424_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMjEtMS0xLTEtMjI4NTg_2c59fcc1-a89d-43ee-8bff-3d7a7dd90b50"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8d2b62b865bd4041b0251301f7f51424_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMjEtMy0xLTEtMjI4NTg_153a63d4-3f31-4fe9-9598-97a1af0a2a22"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i872ef751a6a241769e47a7626414f412_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMjEtNS0xLTEtMjI4NTg_8cf55cf2-f7a3-4d48-a186-28cc96dc61ca"
      unitRef="shares">3986000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i872ef751a6a241769e47a7626414f412_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMjEtNy0xLTEtMjI4NTg_a894efd8-b458-4fe3-980e-9bdaa072ebad"
      unitRef="usd">4000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iee65085e733d41a19e4143446eff7b7c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMjEtOS0xLTEtMjI4NTg_1d5d7225-7f81-425c-b0a1-664a63efb05c"
      unitRef="usd">545657000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i33afa975dd374f46b8ea96b4c0471c87_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMjEtMTEtMS0xLTIyODU4_e93aaeaf-0867-47af-a97a-7b4a9e263f85"
      unitRef="usd">-64000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id2242481d947422a87b50a693e117608_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMjEtMTMtMS0xLTIyODU4_ce3df694-b5b1-4bbe-aadb-0d4111403273"
      unitRef="usd">-446222000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i57e94f040b084f7b9def7834d945a4c7_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMjEtMTUtMS0xLTIyODU4_f1787862-8598-4b30-9503-e3f335f8d448"
      unitRef="usd">-708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id9d73cec2ab1421e98d1f86d5a3b506a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMjEtMTctMS0xLTIyODU4_43b8fcc6-ff63-490e-8be5-0aac115e1d9c"
      unitRef="usd">98667000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic87a4ec489bc4ec0bf3f93cc71f5e063_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMjEtMTktMS0xLTIyODU4_eae0e136-3fdb-4c9e-b1a7-e068e8d2d43d"
      unitRef="usd">-254000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i74b1319645614dceb3e4fce1f773ff25_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yNS9mcmFnOjBkMDAzMGFjM2ExODQ2OGJiMTRiOTgwY2ZlNDY4MmU0L3RhYmxlOjNlNjNjOGI2OGQzYTQ1OGQ5MzdiMmYxODI5MGUwYzM3L3RhYmxlcmFuZ2U6M2U2M2M4YjY4ZDNhNDU4ZDkzN2IyZjE4MjkwZTBjMzdfMjEtMjEtMS0xLTIyODU4_36986143-4f86-415d-9060-b37b120e2163"
      unitRef="usd">98413000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMy0xLTEtMS0yMjg1OA_4faa62ac-0c13-49a1-95d1-1bda6fbb3ddd"
      unitRef="usd">-48235000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMy0zLTEtMS0yMjg1OA_5cfaa974-115d-4be7-a398-61e7d577761a"
      unitRef="usd">-20672000</us-gaap:ProfitLoss>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfNS0xLTEtMS0yMjg1OA_4c5f89d1-e73d-4b23-8dfc-12698ac5564f"
      unitRef="usd">2168000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfNS0zLTEtMS0yMjg1OA_c3de061b-3a1f-4b3b-b76e-304e6137307f"
      unitRef="usd">1639000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:DepreciationAndAmortization
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfNi0xLTEtMS0yMjg1OA_f728d8d9-ba6f-480e-affd-5c1478ac1473"
      unitRef="usd">22000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfNi0zLTEtMS0yMjg1OA_195f14aa-e758-43e1-acae-9bcc9abf3ba2"
      unitRef="usd">47000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfOS0xLTEtMS0yNTQwNg_9180f76a-3429-495f-8936-0d68e23a494a"
      unitRef="usd">-30393000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfOS0zLTEtMS0yNTQxNA_5ece3386-c0da-4dcc-95c5-e4e371c313b3"
      unitRef="usd">0</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfOS0xLTEtMS0yMjg1OA_539cf581-b792-4fbf-9f89-9608248190bd"
      unitRef="usd">-893000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfOS0zLTEtMS0yMjg1OA_d1d11fdd-5aae-4a12-b77d-2bf473f6dba6"
      unitRef="usd">-1925000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTEtMS0xLTEtMjI4NTg_8539d966-8b68-462f-a7c6-fc04b63fc9a4"
      unitRef="usd">-29000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTEtMy0xLTEtMjI4NTg_3e96fc3d-b7b9-4550-a620-f0ecfb55ed33"
      unitRef="usd">1199000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTItMS0xLTEtMjI4NTg_4191adfe-9919-4f9e-ab20-cd5a6e1d80d5"
      unitRef="usd">-178000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTItMy0xLTEtMjI4NTg_7cb45f32-557e-40c3-bdae-ef803ad920f4"
      unitRef="usd">-252000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTMtMS0xLTEtMjI4NTg_d43c8c51-a341-4040-ab92-c9854ed45888"
      unitRef="usd">-150000</clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities>
    <clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTMtMy0xLTEtMjI4NTg_68af70c2-f985-4ebc-b55b-da140f869ddf"
      unitRef="usd">367000</clbs:IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTQtMS0xLTEtMjI4NTg_264d2c83-bc15-4bbd-b21b-a8126f3933d9"
      unitRef="usd">-14702000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTQtMy0xLTEtMjI4NTg_594c9e47-5025-45d1-a02e-109426af8ebb"
      unitRef="usd">-17641000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTYtMS0xLTEtMjI4NTg_ec6625a1-771e-4661-ae91-d831f6a3a483"
      unitRef="usd">68481000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTYtMy0xLTEtMjI4NTg_6961ea4f-83b2-439b-a5d5-93ea6d1f6b25"
      unitRef="usd">137329000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTctMS0xLTEtMjI4NTg_3eb5dab2-0ba2-4a35-a410-0f83584b0095"
      unitRef="usd">93865000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTctMy0xLTEtMjI4NTg_0f238869-4c67-497f-9590-ca1b5831ed81"
      unitRef="usd">66035000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTktMS0xLTEtMjU0MzQ_a69a96d9-27df-4460-880d-c544b94960c1"
      unitRef="usd">3320000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTktMy0xLTEtMjU0NTE_b8225435-5fd5-47c4-845d-c0add9e7f0e2"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTgtMS0xLTEtMjI4NTg_999177c2-9871-4253-b3d6-80997a7eca70"
      unitRef="usd">259000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMTgtMy0xLTEtMjI4NTg_9f4a4b38-afd2-403f-8987-2f55f276a5a3"
      unitRef="usd">60000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjAtMS0xLTEtMjI4NTg_bd86958c-21fe-4f3e-83d4-789d7479322b"
      unitRef="usd">21805000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjAtMy0xLTEtMjI4NTg_b6119e2c-d608-45ab-a89d-a38a29ce2b21"
      unitRef="usd">-71354000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjItMS0xLTEtMjI4NTg_76363b53-d4ab-468f-bf96-e10a798bf745"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjItMy0xLTEtMjI4NTg_33cef3e9-3922-46f7-a1f3-30c2188dd59e"
      unitRef="usd">24000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjMtMS0xLTEtMjI4NTg_bb2a09a1-780a-4948-9579-e2a4781fff03"
      unitRef="usd">267000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjMtMy0xLTEtMjI4NTg_084f9568-ceb7-47a7-a187-35fb525717b4"
      unitRef="usd">248000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjQtMS0xLTEtMjI4NTg_af58d4ea-da5a-4b1c-9145-2efcab3c9e75"
      unitRef="usd">29000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjQtMy0xLTEtMjI4NTg_0fcc2e66-3007-4bdd-996b-aba088a8f674"
      unitRef="usd">85479000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjYtMS0xLTEtMjI4NTg_d1334bcd-49cf-4672-8f85-ef9a7e547378"
      unitRef="usd">-238000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjYtMy0xLTEtMjI4NTg_2979077e-fe51-425f-a41b-615b25368fc4"
      unitRef="usd">85255000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMzAtMS0xLTEtMjYxMzA_b2605385-cdac-4874-9714-90d6d8722dfe"
      unitRef="usd">-34000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMzAtMy0xLTEtMjYxMzA_34260be4-fc4d-4559-89a1-afaf03d2c6f3"
      unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjctMS0xLTEtMjI4NTg_b6247137-cf8b-4652-8f12-7c920e30c67b"
      unitRef="usd">6831000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjctMy0xLTEtMjI4NTg_2b3bc528-8557-49c5-96b7-d6d147f27a3e"
      unitRef="usd">-3740000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjgtMS0xLTEtMjI4NTg_defe284b-8a72-468e-855f-f5864a37a874"
      unitRef="usd">24647000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i83e78453949e4f5fb203beb11be8a1dc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjgtMy0xLTEtMjI4NTg_f1850d41-2e46-40ce-8e12-dc0c47dbc1ab"
      unitRef="usd">16512000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjktMS0xLTEtMjI4NTg_dfa08e33-f91e-4d87-abcc-3b4b85ced83f"
      unitRef="usd">31478000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i74b1319645614dceb3e4fce1f773ff25_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMjktMy0xLTEtMjI4NTg_45279e3f-62e0-4684-a2bc-192f9922da4f"
      unitRef="usd">12772000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:StockIssued1
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMzYtMS0xLTEtMjc2NDY_67b84b9d-54b5-4380-93ec-e80e9249a0d7"
      unitRef="usd">23580000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMzYtMy0xLTEtMjc2NDY_c2e60fe4-53f4-445b-801f-890cefaa638b"
      unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMzctMS0xLTEtMjc2NDY_8f858d62-6301-41b1-9b58-f62608bba82f"
      unitRef="usd">2136000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8yOC9mcmFnOmFmNTNiNWI0N2IzYjRmZWU4M2I4YzE1N2Q4MGUwODliL3RhYmxlOmZjNmVjYmRhNzA0ZDQ5ZmQ4NTRhZWQ1ZWI5MWFiMGE0L3RhYmxlcmFuZ2U6ZmM2ZWNiZGE3MDRkNDlmZDg1NGFlZDVlYjkxYWIwYTRfMzctMy0xLTEtMjc2NDY_6e567bf3-327c-44be-a5c0-bcb1e85ce085"
      unitRef="usd">0</us-gaap:LiabilitiesAssumed1>
    <clbs:BusinessTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8zNC9mcmFnOjBkYzk4ZTljODdlZDQ0OTNhNTk1NjVkNjc2YjJlZmQ3L3RleHRyZWdpb246MGRjOThlOWM4N2VkNDQ5M2E1OTU2NWQ2NzZiMmVmZDdfMTk4MTQ_be48859e-7e1e-4b9b-b386-fc226fe9231d">The Business&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lisata Therapeutics, Inc. (together with its subsidiaries, &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; &#x201c;Lisata&#x201d; or the &#x201c;Company&#x201d;) is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Lisata&#x2019;s lead investigational product candidate, LSTA1 (formerly known as CEND-1), is designed to activate a novel uptake pathway that allows anti-cancer drugs to penetrate solid tumors more effectively. LSTA1 actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are not affected. LSTA1 also has the potential to modify the tumor microenvironment (&#x201c;TME&#x201d;), making tumors more susceptible to immunotherapies. LSTA1 has demonstrated favorable safety, tolerability, and activity to date in completed and ongoing clinical trials to enhance delivery of standard-of-care chemotherapy for pancreatic cancer. Lisata and its collaborators have also amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anti-cancer therapies, including immunotherapies and RNA-based therapeutics. Lisata is exploring the potential of LSTA1 to enable a variety of treatment modalities to treat a range of solid tumors more effectively. In addition, Lisata also has clinical development programs based on its autologous CD34+ cell therapy technology platform.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's leadership team has decades of collective biopharmaceutical and pharmaceutical product development experience across a variety of therapeutic categories and at all stages of development from preclinical through to product registration and launch. Its goal is to develop and commercialize products that address important unmet medical needs based on a broad and versatile portfolio of candidates. The Company&#x2019;s current product candidates include: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;LSTA1, the subject of phase 1b/2a and 2b clinical studies being conducted globally in a variety of solid tumor types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a variety of anti-cancer regimens;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;XOWNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (LSTA16 formerly CLBS16), the subject of both a completed positive Phase 2a study (ESCaPE-CMD) and follow on Phase 2b study (FREEDOM Trial) in the United States for the treatment of coronary microvascular dysfunction (&#x201c;CMD&#x201d;); &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;HONEDRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (LSTA12 formerly CLBS12), recipient of SAKIGAKE designation, pursuant to which early conditional approval in Japan for the treatment of critical limb ischemia (&#x201c;CLI&#x201d;) and Buerger&#x2019;s disease is being sought based on the current results of a clinical trial executed in Japan. HONEDRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was the recipient of orphan drug designation in March 2021 from the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) for Buerger's disease; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;LSTA201 (formerly CLBS201), the subject of a study designed to assess the safety and efficacy of CD34+ cell therapy as a regenerative treatment for patients with chronic kidney disease related to type 2 diabetes (diabetic kidney disease or &#x201c;DKD&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Merger with Cend Therapeutics, Inc. and Name Change&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 15, 2022, the Company, then operating as Caladrius Biosciences, Inc. (&#x201c;Caladrius"), completed its acquisition of Cend Therapeutics, Inc. (&#x201c;Cend&#x201d;), a Delaware corporation (the &#x201c;Merger&#x201d;), in accordance with the terms of the Agreement and Plan of Merger and Reorganization (the &#x201c;Merger Agreement&#x201d;), dated as of April 26, 2022, by and among Caladrius, Cend and CS Cedar Merger Sub, Inc. (&#x201c;Merger Sub&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms set forth in the Merger Agreement and effective September 15, 2022 (the &#x201c;Effective Time&#x201d;): (i) Merger Sub merged with and into Cend, with Cend surviving as a wholly owned subsidiary of Caladrius, (ii) Caladrius changed its name to Lisata Therapeutics, Inc. in connection with and immediately following to the Effective Time, and (iii) Caladrius effected a 1:15 reverse stock split of its common stock (&#x201c;Reverse Stock Split&#x201d;) prior to the Effective Time. At the Effective Time, each share of Cend's common stock outstanding immediately prior to the Effective Time was converted into the right to receive shares of Lisata&#x2019;s common stock based on an exchange ratio of 0.5338 (the &#x201c;Exchange Ratio&#x201d;), after taking into account the Reverse Stock Split. In connection with the Merger close, the Company issued an aggregate of 3,772,768 shares of common stock, based on the Exchange Ratio, to holders of Cend, in exchange for all of the Cend capital stock outstanding immediately prior to the closing of the Merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Merger Agreement, Lisata assumed all of the outstanding and unexercised options to purchase shares of Cend capital stock under the 2016 Equity Incentive Plan (the &#x201c;Cend Plan&#x201d;), and, in connection with the Merger, such options were converted into options to purchase shares of Lisata&#x2019;s common stock based on the Exchange Ratio. At the closing of the Merger at the Effective Time, the Company assumed Cend's stock options to purchase an aggregate of 1,227,776 shares of the Company's common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Caladrius was considered to be the accounting acquirer based on the terms of the Merger Agreement and certain factors including: (i) Caladrius owned approximately 52% of the Company's outstanding shares of common stock immediately following the close of the Merger; (ii) although both entities contributed to the new management team of Lisata, the Caladrius team has more individuals on the management team and will hold the CEO, CMO and other senior management roles; (iii) Caladrius paid a premium to acquire Cend&#x2019;s assets; and (iv) Caladrius was significantly larger than Cend regarding total assets, operations, and research and development activities. The Merger was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;). Cend&#x2019;s assets (except for cash and working capital) were measured and recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated with IPR&amp;amp;D with no alternative future use being expensed as reported in the consolidated statement of operations. The prior reported operating results prior to the Merger close are those of Caladrius alone.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Coronavirus Considerations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In December 2019, a novel strain of coronavirus (SARS-CoV-2), which causes COVID-19, was reported to have surfaced in China. In March 2020, the World Health Organization declared the outbreak of COVID-19 to be a pandemic, and the world's economies began to experience pronounced effects. Despite the FDA approval of multiple COVID-19 vaccines in late 2020, there remains uncertainty around the extent and duration of disruption and any future related financial impact cannot reasonably be estimated at this time. In response to the COVID-19 pandemic, the Company implemented a universal work from home policy as well as stringent social distancing and other hygiene policies for employees when they must be in the office. The Company's clinical study of HONEDRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in Japan experienced significant delays in enrollment due to the States of Emergency in effect in Japan for most of 2020, 2021, and 2022 covering Tokyo and other regions in response to an increased number of COVID-19 infections. With the Company's expectation that COVID-19 in Japan will continue to impact negatively clinical site operations and enrollment of patients in the HONEDRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; clinical trial, it elected to suspend trial enrollment, seek a development partner and consult with the Japanese regulatory authorities regarding the submission of patient data already accrued. Caladrius' phase 2b FREEDOM Trial of XOWNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the U.S. has also experienced delays in enrolling patients as a result of COVID-19. While early enrollment proceeded to plan with the first patient treated in January 2021, the impact of the COVID-19 pandemic contributed to a general slowing of enrollment, including supply chain disruptions affecting the availability of qualified catheters used in the diagnosis of CMD and/or administration of XOWNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as well as with a contrast agent typically used in many catheter laboratories. In May 2022, the Company announced that enrollment in the FREEDOM Trial had been suspended and that it intended to conduct an interim analysis of the data from not less than the first 20 patients enrolled using the 6-month follow-up data to evaluate the efficacy and safety of XOWNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in subjects with CMD. Following the analysis of results of the FREEDOM Trial subjects completing 6-month follow-up along with Key Opinion Leaders&#x2019; input, the Company&#x2019;s board of directors determined that execution of a redesigned FREEDOM-like trial would be the appropriate next step, but the cost of such a trial would be prohibitively expensive to undergo without a strategic partner. Accordingly, the Company&#x2019;s board of directors concluded that XOWNA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; development will only be continued if a strategic partner that can contribute the necessary capital for a redesigned trial is identified and secured. There can be no assurance that we will be able to identify such a partner and enter into an agreement with such partner on acceptable terms or at all.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 14, 2022, in connection with the Merger, the Company implemented the Reverse Stock Split, as authorized at the annual meeting of stockholders on September 13, 2022. The Reverse Stock Split became effective on September 14, 2022 at 5:00 pm and the Company's common stock began trading on The Nasdaq Capital Market on a post-split basis at the open of business on September 15, 2022. As of September 14, 2022, every fifteen shares of the Company&#x2019;s issued and outstanding common stock (and such shares held in treasury) were automatically converted into one share of common stock, without any change in the par value per share. In addition, proportionate adjustments were made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options, stock appreciation rights, convertible notes and warrants to purchase shares of common stock, the number of shares issuable upon the vesting of all restricted stock awards, and the number of shares of common stock reserved for issuance pursuant to the Company&#x2019;s equity incentive compensation plans. Any stockholder who would otherwise be entitled to a fractional share of common stock created as a result of the Reverse Stock Split received a cash payment equal to the product of such resulting fractional interest in one share of common stock multiplied by the closing trading price of the common stock on September 15, 2022. The Reverse Stock Split was effectuated in order to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;increase the per share trading price of our common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods presented to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from &#x201c;common stock&#x201d; to &#x201c;additional paid-in capital&#x201d; in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#x2019;s financial position as of September&#160;30, 2022, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2021 and 2020 included in our 2021 Form 10-K. Operating results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values and the valuation of the Merger which was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;). Accordingly, actual results could differ from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements include the accounts of Lisata and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Remeasurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s reporting currency is the U.S. Dollar. The functional currency of DrugCendR Australia PTY Ltd. which is a foreign subsidiary of the Company is the Australian Dollar. The assets and liabilities of DrugCendR Australia PTY Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.&lt;/span&gt;&lt;/div&gt;</clbs:BusinessTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8zNC9mcmFnOjBkYzk4ZTljODdlZDQ0OTNhNTk1NjVkNjc2YjJlZmQ3L3RleHRyZWdpb246MGRjOThlOWM4N2VkNDQ5M2E1OTU2NWQ2NzZiMmVmZDdfMTk4MjQ_3c02d9e3-0f73-4e32-aaff-20fc67fb422f">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company&#x2019;s financial position as of September&#160;30, 2022, and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December&#160;31, 2021 and 2020 included in our 2021 Form 10-K. Operating results for the three and nine months ended September&#160;30, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8zNC9mcmFnOjBkYzk4ZTljODdlZDQ0OTNhNTk1NjVkNjc2YjJlZmQ3L3RleHRyZWdpb246MGRjOThlOWM4N2VkNDQ5M2E1OTU2NWQ2NzZiMmVmZDdfMTk4MjU_0d0aa015-3f18-485a-8ad9-cf1f703b9935">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of expenses during the reporting period. The Company bases its estimates on historical experience and other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The Company makes critical estimates and assumptions in determining stock-based awards values and the valuation of the Merger which was accounted for as an asset acquisition as substantially all of the fair value is concentrated in in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;). Accordingly, actual results could differ from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8zNC9mcmFnOjBkYzk4ZTljODdlZDQ0OTNhNTk1NjVkNjc2YjJlZmQ3L3RleHRyZWdpb246MGRjOThlOWM4N2VkNDQ5M2E1OTU2NWQ2NzZiMmVmZDdfMTk4MTg_b155d972-7f1c-4683-8516-a13836ab3d99">Principles of ConsolidationThe Consolidated Financial Statements include the accounts of Lisata and its wholly owned and majority owned subsidiaries and affiliates. All intercompany activities have been eliminated in consolidation</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8zNC9mcmFnOjBkYzk4ZTljODdlZDQ0OTNhNTk1NjVkNjc2YjJlZmQ3L3RleHRyZWdpb246MGRjOThlOWM4N2VkNDQ5M2E1OTU2NWQ2NzZiMmVmZDdfNTQ5NzU1ODIzMTExMg_640b54c7-f05a-4eb3-9cdc-93e4d8107aee">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Remeasurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s reporting currency is the U.S. Dollar. The functional currency of DrugCendR Australia PTY Ltd. which is a foreign subsidiary of the Company is the Australian Dollar. The assets and liabilities of DrugCendR Australia PTY Ltd. are translated into U.S. Dollars at the exchange rates in effect at each balance sheet date, and the results of operations are translated using the average exchange rates prevailing throughout the reporting period. Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in stockholders' equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8zNy9mcmFnOjIyMTc1Zjg5MDIwMjQwZTU5NTQxNGY2MjAxMTgyNzg5L3RleHRyZWdpb246MjIxNzVmODkwMjAyNDBlNTk1NDE0ZjYyMDExODI3ODlfMzE4OQ_93612445-82c8-4d07-b092-b7efacccadab">Summary of Significant Accounting Policies&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and Australia.  Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company's marketable securities are considered as available-for-sale and carried at estimated fair values and reported in cash equivalents and marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. The Company regularly reviews all of its investments for other-than-temporary declines in fair value. The Company's review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities and whether it is more likely than not that it will be required to sell the securities before the recovery of their amortized cost basis. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss for the amount of such decline.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cost of property and equipment is depreciated over the estimated useful lives of the related assets. Depreciation is computed on the straight-line method. Repairs and maintenance expenditures that do not extend original asset lives are charged to expense as incurred. The estimated useful lives of property and equipment are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Life of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist of property and equipment and intangibles. The assets are amortized on a straight line basis over their respective useful lives. The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset exceeds the fair value of the asset. If other events or changes in circumstances indicate that the carrying amount of an asset that the Company expects to hold and use may not be recoverable, the Company will estimate the undiscounted future cash flows expected to result from the use of the asset and/or its eventual disposition, and recognize an impairment loss, if any. The impairment loss, if determined to be necessary, would be measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses all share-based payment awards to employees, directors, and consultants, including grants of stock options, warrants, and restricted stock, over the requisite service period based on the grant date fair value of the awards. Consultant awards are remeasured each reporting period through vesting. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. The Company determines the fair value of option awards using the Black-Scholes option-pricing model which uses both historical and current market data to estimate the fair value. This method incorporates various assumptions such as the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options or warrants. Stock based compensation expense also includes an estimate, which is made at the time of the grant, of the number of awards that are expected to be forfeited. The fair value of the Company&#x2019;s restricted stock and restricted stock units is based on the closing market price of the Company&#x2019;s common stock on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share is based on the weighted effect of all common shares issued and outstanding and is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period. Diluted loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus the number of common shares that would be issued assuming conversion of all potentially dilutive securities outstanding. Diluted loss per share is not presented as such potentially dilutive securities are anti-dilutive to losses incurred in all periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Gains or losses on the subsequent reissuance of shares are credited or charged to additional paid in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) expenses include salaries, benefits, and other headcount related costs, clinical trial and related clinical manufacturing costs, contract and other outside service fees including sponsored research agreements, and facilities and overhead costs. The Company expenses the costs associated with research and development activities when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To further drive the Company&#x2019;s initiatives, the Company will continue targeting key governmental agencies, congressional committees and not-for-profit organizations to contribute funds for the Company&#x2019;s research and development programs. The Company accounts for such grants as a deduction to the related expense in research and development operating expenses when earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;In-process Research and Development Expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#x201c;business&#x201d; as defined under GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Asset&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s intangible asset consists of a single asset, Cend&#x2019;s license agreement with Qilu Pharmaceutical, Co., Ltd. (&#x201c;Qilu&#x201d;) acquired in the Merger, with a value of $0.4&#160;million. The intangible asset is stated at fair value and is amortized using the straight-line method over its estimated useful life of 5 years. Amortization expense was $3 thousand for the three and nine months ended September&#160;30, 2022. The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable.  The projected amortization expense is $71 thousand per year for the next five years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. There was no revenue recognized for the three and nine months ended September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Milestones&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company&#x2019;s collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company&#x2019;s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8zNy9mcmFnOjIyMTc1Zjg5MDIwMjQwZTU5NTQxNGY2MjAxMTgyNzg5L3RleHRyZWdpb246MjIxNzVmODkwMjAyNDBlNTk1NDE0ZjYyMDExODI3ODlfNTQ5NzU1ODE2OTk2MA_405f593e-08b7-4bb3-998b-688f3a8bda69">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States and Australia.  Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation &lt;/span&gt;&lt;/div&gt;of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8zNy9mcmFnOjIyMTc1Zjg5MDIwMjQwZTU5NTQxNGY2MjAxMTgyNzg5L3RleHRyZWdpb246MjIxNzVmODkwMjAyNDBlNTk1NDE0ZjYyMDExODI3ODlfMzE5Mw_3052cc8d-b8fd-4ae5-8532-2975832f2e6f">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;In-process Research and Development Expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments, are immediately expensed as IPR&amp;amp;D in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#x201c;business&#x201d; as defined under GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. The Company accounts for contingent consideration payable upon achievement of certain regulatory, development or sales milestones in such asset acquisitions when the underlying contingency is probable and estimable. Milestone payments made to third parties subsequent to regulatory approval will be capitalized as intangible assets and amortized over the estimated remaining useful life of the related product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Asset&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s intangible asset consists of a single asset, Cend&#x2019;s license agreement with Qilu Pharmaceutical, Co., Ltd. (&#x201c;Qilu&#x201d;) acquired in the Merger, with a value of $0.4&#160;million. The intangible asset is stated at fair value and is amortized using the straight-line method over its estimated useful life of 5 years. Amortization expense was $3 thousand for the three and nine months ended September&#160;30, 2022. The intangible asset is reviewed for potential impairment when events or circumstances indicate that carrying amounts may not be recoverable.  The projected amortization expense is $71 thousand per year for the next five years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. There was no revenue recognized for the three and nine months ended September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Milestones&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company or the Company&#x2019;s collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts the Company&#x2019;s estimate of the overall transaction price. Any such adjustments are allocated on a cumulative catch-up basis to satisfied and partially satisfied performance obligations, with the consideration allocated to an ongoing performance obligation being recognized over the period of performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue from any collaborative arrangement.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8zNy9mcmFnOjIyMTc1Zjg5MDIwMjQwZTU5NTQxNGY2MjAxMTgyNzg5L3RleHRyZWdpb246MjIxNzVmODkwMjAyNDBlNTk1NDE0ZjYyMDExODI3ODlfNTQ5NzU1ODE2OTk1OA_1803c03d-2c2c-4890-98f7-f59b4de49359">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates license and collaboration arrangements to determine whether units of account within the arrangement exhibit the characteristics of a vendor and customer relationship. For arrangements and units of account where a customer relationship exists, the Company applies the revenue recognition guidance. The Company recognizes revenue upon the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies the performance obligations. At contract inception, the Company assesses the goods or services promised within each contract and assesses whether each promised good or service is distinct and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Taxes imposed by governmental authorities on the Company's revenue, such as sales taxes and withholding taxes, are excluded from net revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. If licenses are bundled with other performance obligations, the Company would utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. There was no revenue recognized for the three and nine months ended September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90ZXh0cmVnaW9uOjk4MmNjYWFmYjM2YzQ3NzNhN2VkZmMwZmY5OGFmODMwXzU0OTc1NTgxNDg4OA_b47298c4-1400-40a1-8631-b07879810521">Merger&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Merger was accounted for as an asset acquisition as substantially all of the fair value was concentrated in IPR&amp;amp;D. Cend&#x2019;s assets (except for cash and working capital) were measured and recognized as an allocation of the transaction price based on their relative fair values as of the transaction date with any value associated with IPR&amp;amp;D being expensed. The fair value of total consideration was $36.1&#160;million. The following table is a summary of the purchase price calculation (in thousands except per share data).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:448.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of common shares of the combined company owned by Cend stockholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,772,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Multiplied by the fair value per share of Lisata common stock on September 15, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$23,580&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of Lisata's cost method investment in Cend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incremental fair value of Cend's fully vested stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lisata transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total purchase price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$36,098&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The allocation of the purchase price was as follows (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:448.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$7,062&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net working capital (excluding cash)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,690)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired in-process research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$36,098&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i59aeca5b7a5446ed90ba736d79d9d4f4_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90ZXh0cmVnaW9uOjk4MmNjYWFmYjM2YzQ3NzNhN2VkZmMwZmY5OGFmODMwXzU0OTc1NTgxNDAwNzE_24f5955e-4161-49fc-9c11-fd413ed30282"
      unitRef="usd">36100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iac286da95e1c493abbddee71f1aac890_I20220914"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90YWJsZTplYjE5N2UzMDIwYzY0MjQ1OTY5YzM5NjFjYzdkNjc1OS90YWJsZXJhbmdlOmViMTk3ZTMwMjBjNjQyNDU5NjljMzk2MWNjN2Q2NzU5XzMtMS0xLTEtMjc0Mzk_a3a5ee75-71e2-4b51-acf5-253444d56d98"
      unitRef="shares">3772768</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i59aeca5b7a5446ed90ba736d79d9d4f4_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90YWJsZTplYjE5N2UzMDIwYzY0MjQ1OTY5YzM5NjFjYzdkNjc1OS90YWJsZXJhbmdlOmViMTk3ZTMwMjBjNjQyNDU5NjljMzk2MWNjN2Q2NzU5XzQtMS0xLTEtMjc0Mzk_15e7a7e9-7597-4899-a329-28ab5e6e00cf"
      unitRef="usdPerShare">6.25</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i59aeca5b7a5446ed90ba736d79d9d4f4_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90YWJsZTplYjE5N2UzMDIwYzY0MjQ1OTY5YzM5NjFjYzdkNjc1OS90YWJsZXJhbmdlOmViMTk3ZTMwMjBjNjQyNDU5NjljMzk2MWNjN2Q2NzU5XzUtMS0xLTEtMjc0Mzk_2a2ab5d1-8cca-4df6-bdba-0d1a099c9d25"
      unitRef="usd">23580000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i59aeca5b7a5446ed90ba736d79d9d4f4_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90YWJsZTplYjE5N2UzMDIwYzY0MjQ1OTY5YzM5NjFjYzdkNjc1OS90YWJsZXJhbmdlOmViMTk3ZTMwMjBjNjQyNDU5NjljMzk2MWNjN2Q2NzU5XzYtMS0xLTEtMjc0Mzk_7a886845-af74-48ef-ac53-d7273a65dbf2"
      unitRef="usd">10000000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="ia46e584dcd2741798d67f30f0cfd9c15_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90YWJsZTplYjE5N2UzMDIwYzY0MjQ1OTY5YzM5NjFjYzdkNjc1OS90YWJsZXJhbmdlOmViMTk3ZTMwMjBjNjQyNDU5NjljMzk2MWNjN2Q2NzU5XzgtMS0xLTEtMjc0NjQ_9cead5d8-48f8-481b-8767-e2709c8b27bb"
      unitRef="usd">2136000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="ia46e584dcd2741798d67f30f0cfd9c15_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90YWJsZTplYjE5N2UzMDIwYzY0MjQ1OTY5YzM5NjFjYzdkNjc1OS90YWJsZXJhbmdlOmViMTk3ZTMwMjBjNjQyNDU5NjljMzk2MWNjN2Q2NzU5XzktMS0xLTEtMjc0NjQ_9c85344e-44f1-43de-b174-087781a8de46"
      unitRef="usd">382000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i59aeca5b7a5446ed90ba736d79d9d4f4_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90YWJsZTplYjE5N2UzMDIwYzY0MjQ1OTY5YzM5NjFjYzdkNjc1OS90YWJsZXJhbmdlOmViMTk3ZTMwMjBjNjQyNDU5NjljMzk2MWNjN2Q2NzU5XzEwLTEtMS0xLTI3NDY0_1230beba-7f21-4045-937d-b237bd7c62ea"
      unitRef="usd">36098000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i59aeca5b7a5446ed90ba736d79d9d4f4_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90YWJsZTplYjE5N2UzMDIwYzY0MjQ1OTY5YzM5NjFjYzdkNjc1OS90YWJsZXJhbmdlOmViMTk3ZTMwMjBjNjQyNDU5NjljMzk2MWNjN2Q2NzU5XzEwLTEtMS0xLTI3NDY0_1778e641-0bff-4e2e-af78-0e709a7f374e"
      unitRef="usd">36098000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i59aeca5b7a5446ed90ba736d79d9d4f4_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90YWJsZTozZTA4MDNjYzlkNTA0ODIzOGQ3YmIyM2I3ZWE3ZGI2ZS90YWJsZXJhbmdlOjNlMDgwM2NjOWQ1MDQ4MjM4ZDdiYjIzYjdlYTdkYjZlXzQtMS0xLTEtMjc1MTc_72155266-1df6-4bed-870a-0c30b8cca54d"
      unitRef="usd">7062000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i59aeca5b7a5446ed90ba736d79d9d4f4_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90YWJsZTozZTA4MDNjYzlkNTA0ODIzOGQ3YmIyM2I3ZWE3ZGI2ZS90YWJsZXJhbmdlOjNlMDgwM2NjOWQ1MDQ4MjM4ZDdiYjIzYjdlYTdkYjZlXzUtMS0xLTEtMjc1MTc_035112c0-13d2-4b1a-a354-e5215791c996"
      unitRef="usd">1690000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="i59aeca5b7a5446ed90ba736d79d9d4f4_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90YWJsZTozZTA4MDNjYzlkNTA0ODIzOGQ3YmIyM2I3ZWE3ZGI2ZS90YWJsZXJhbmdlOjNlMDgwM2NjOWQ1MDQ4MjM4ZDdiYjIzYjdlYTdkYjZlXzYtMS0xLTEtMjc1MTc_b065ff63-0d33-4614-b3bb-f1e202748cf6"
      unitRef="usd">22000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i59aeca5b7a5446ed90ba736d79d9d4f4_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90YWJsZTozZTA4MDNjYzlkNTA0ODIzOGQ3YmIyM2I3ZWE3ZGI2ZS90YWJsZXJhbmdlOjNlMDgwM2NjOWQ1MDQ4MjM4ZDdiYjIzYjdlYTdkYjZlXzctMS0xLTEtMjc1MTc_4f91341f-abd2-4074-9564-06e6ee9ac85b"
      unitRef="usd">30393000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="ia46e584dcd2741798d67f30f0cfd9c15_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90YWJsZTozZTA4MDNjYzlkNTA0ODIzOGQ3YmIyM2I3ZWE3ZGI2ZS90YWJsZXJhbmdlOjNlMDgwM2NjOWQ1MDQ4MjM4ZDdiYjIzYjdlYTdkYjZlXzgtMS0xLTEtMjc1MTc_b6f3881a-3ec6-4384-8a0c-16d0d0eb5f96"
      unitRef="usd">355000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i59aeca5b7a5446ed90ba736d79d9d4f4_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV85ODEvZnJhZzo5ODJjY2FhZmIzNmM0NzczYTdlZGZjMGZmOThhZjgzMC90YWJsZTozZTA4MDNjYzlkNTA0ODIzOGQ3YmIyM2I3ZWE3ZGI2ZS90YWJsZXJhbmdlOjNlMDgwM2NjOWQ1MDQ4MjM4ZDdiYjIzYjdlYTdkYjZlXzEwLTEtMS0xLTI3NTE3_815f70ec-d9b7-40ec-80df-8b918d383564"
      unitRef="usd">36098000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RleHRyZWdpb246Zjc3NmYzODJlZDFlNDJiMGFlMDFkZmQxMzk2OWExNDFfNjI3_b9310997-34d5-4069-9b4e-8000afb27bd5">Available-for-Sale-Securities&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:32pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:360.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:361.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater than one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RleHRyZWdpb246Zjc3NmYzODJlZDFlNDJiMGFlMDFkZmQxMzk2OWExNDFfNjIy_2326b578-26ff-4681-ad03-f84d4575b756">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:32pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2d567e0b72224eb89e01194dfcc635c5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfMy0xLTEtMS0yMjg1OA_fb2d3c18-c5f0-4764-b2ec-9c5a3d7c452d"
      unitRef="usd">39311000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2d567e0b72224eb89e01194dfcc635c5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfMy0zLTEtMS0yMjg1OA_8a11404a-3651-47f1-a3b0-5c264eddf081"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2d567e0b72224eb89e01194dfcc635c5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfMy01LTEtMS0yMjg1OA_691b78ba-8a4d-4cba-a50e-1983ae42118c"
      unitRef="usd">65000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2d567e0b72224eb89e01194dfcc635c5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfMy03LTEtMS0yMjg1OA_b88c15c4-51ab-4a5e-8777-153d3da0782a"
      unitRef="usd">39246000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i098bf094035d44e2af451fa66daf6448_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfMy05LTEtMS0yMjg1OA_b72d7775-92cb-4331-92be-f1a6f8e2ea34"
      unitRef="usd">53135000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i098bf094035d44e2af451fa66daf6448_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfMy0xMS0xLTEtMjI4NTg_da9b98e5-9a65-402b-abd5-08a55f91563e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i098bf094035d44e2af451fa66daf6448_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfMy0xMy0xLTEtMjI4NTg_8a232ffe-49dc-436d-a6de-c6a9341e084c"
      unitRef="usd">65000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i098bf094035d44e2af451fa66daf6448_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfMy0xNS0xLTEtMjI4NTg_6ab77659-2bc4-4192-9b38-1d39bf9ef65b"
      unitRef="usd">53070000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i57b538ea7c44400bad5071a7a6c98c1d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNC0xLTEtMS0yMjg1OA_fdc01db1-a8c2-432d-9290-8624d6031bc3"
      unitRef="usd">14459000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i57b538ea7c44400bad5071a7a6c98c1d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNC0zLTEtMS0yMjg1OA_adb045d1-0b1b-43af-ad4c-38595ca4a9e2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i57b538ea7c44400bad5071a7a6c98c1d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNC01LTEtMS0yMjg1OA_29b2eab7-1443-4ce4-b6f2-0b2369f3f76b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i57b538ea7c44400bad5071a7a6c98c1d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNC03LTEtMS0yMjg1OA_fbd79627-f2a9-461c-a715-f59be6251204"
      unitRef="usd">14459000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie90154aebcd24967a0f809ea3f40f699_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNC05LTEtMS0yMjg1OA_2227036a-f80e-409b-adbe-8a454c5c4ef8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie90154aebcd24967a0f809ea3f40f699_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNC0xMS0xLTEtMjI4NTg_50b3188b-109b-4779-a429-36bb53b63613"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie90154aebcd24967a0f809ea3f40f699_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNC0xMy0xLTEtMjI4NTg_194a19e3-cdc9-4b40-a23e-56f8a0367650"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie90154aebcd24967a0f809ea3f40f699_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNC0xNS0xLTEtMjI4NTg_c34b6e32-8378-48eb-8331-2692cc760fee"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icd0667d730324d439adcd5260c8be67a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNS0xLTEtMS0yMjg1OA_83272426-4dd2-4bcc-a820-797f25c6df74"
      unitRef="usd">13457000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icd0667d730324d439adcd5260c8be67a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNS0zLTEtMS0yMjg1OA_2957e992-7848-4bac-944d-1624beab8038"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icd0667d730324d439adcd5260c8be67a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNS01LTEtMS0yMjg1OA_0414a021-41a4-4eae-9a6d-2904f0cdffb8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icd0667d730324d439adcd5260c8be67a_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNS03LTEtMS0yMjg1OA_72d16e6c-dd93-483f-9eae-5892b24f6f7a"
      unitRef="usd">13457000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2502dcdd9a7b46ccb98d0960950fb9ae_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNS05LTEtMS0yMjg1OA_fa9651fb-3d62-40ed-962a-496fceabc068"
      unitRef="usd">18124000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2502dcdd9a7b46ccb98d0960950fb9ae_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNS0xMS0xLTEtMjI4NTg_658c507d-6fa9-453b-9939-0d71843c54f7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2502dcdd9a7b46ccb98d0960950fb9ae_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNS0xMy0xLTEtMjI4NTg_b307b1aa-cf0a-4656-9d50-cf254cd7b2f2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2502dcdd9a7b46ccb98d0960950fb9ae_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNS0xNS0xLTEtMjI4NTg_6d032aa5-0fc9-437e-b77f-f55e1b6f78ca"
      unitRef="usd">18124000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie80e4088fafa43969d532971e7a875dc_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNi0xLTEtMS0yMjg1OA_47ecdde0-a70a-4e2c-b339-2aaeb5860b41"
      unitRef="usd">170000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie80e4088fafa43969d532971e7a875dc_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNi0zLTEtMS0yMjg1OA_8a3b70bb-b456-40a6-82a6-3571cb5f7b19"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie80e4088fafa43969d532971e7a875dc_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNi01LTEtMS0yMjg1OA_c7c67a1e-0eca-47bd-83b4-89d2899b37b7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie80e4088fafa43969d532971e7a875dc_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNi03LTEtMS0yMjg1OA_d84f2667-dfb7-4222-858a-020140d63636"
      unitRef="usd">170000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i09c4e12405dd4187a733724a3dd4b1c8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNi05LTEtMS0yMjg1OA_1f8a490e-5a00-4304-8696-d7db0a060b0f"
      unitRef="usd">20263000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i09c4e12405dd4187a733724a3dd4b1c8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNi0xMS0xLTEtMjI4NTg_68ff3676-23f9-4178-950f-b43d39474026"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i09c4e12405dd4187a733724a3dd4b1c8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNi0xMy0xLTEtMjI4NTg_fcafe892-9632-40aa-b88c-9a92f43c26af"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i09c4e12405dd4187a733724a3dd4b1c8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfNi0xNS0xLTEtMjI4NTg_164daa83-9331-4d9f-a393-e23d2dff55ad"
      unitRef="usd">20258000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfOC0xLTEtMS0yMjg1OA_73d6b041-66e0-4d85-b7ac-357563a4d868"
      unitRef="usd">67397000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfOC0zLTEtMS0yMjg1OA_cb7948da-97b0-4e6e-aca3-8b16a09ab398"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfOC01LTEtMS0yMjg1OA_fae0bf85-e1b8-4e3b-84b3-9c139434c7d5"
      unitRef="usd">65000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfOC03LTEtMS0yMjg1OA_daceb9cf-fe6a-405e-af18-0e2582422aa7"
      unitRef="usd">67332000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfOC05LTEtMS0yMjg1OA_88b10d43-1818-4ceb-a92c-0f1fbb5e4a63"
      unitRef="usd">91522000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfOC0xMS0xLTEtMjI4NTg_d5a0622a-2682-4205-9bbc-97a56779ee69"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfOC0xMy0xLTEtMjI4NTg_32f3a154-2243-4e40-a2f4-bd1c9b126411"
      unitRef="usd">70000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOmM4MGEzMDEwOWI4OTQ5NTk5YzUyZGQ3YjU0MmExYTIyL3RhYmxlcmFuZ2U6YzgwYTMwMTA5Yjg5NDk1OTljNTJkZDdiNTQyYTFhMjJfOC0xNS0xLTEtMjI4NTg_3149e09f-812a-45ca-a982-8f5a02a04ee4"
      unitRef="usd">91452000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RleHRyZWdpb246Zjc3NmYzODJlZDFlNDJiMGFlMDFkZmQxMzk2OWExNDFfNjM1_9b79947a-dfc1-489d-86cb-baebf4ffcd55">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale securities in our Consolidated Balance Sheets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:360.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOjA0NDMwN2VhNTc4MTRkMGE5MzBhYTVlODg3ZWMzNDYwL3RhYmxlcmFuZ2U6MDQ0MzA3ZWE1NzgxNGQwYTkzMGFhNWU4ODdlYzM0NjBfMS0xLTEtMS0yMjg1OA_a00ae2c6-19e6-4f11-8baa-10b5935c6f0b"
      unitRef="usd">23280000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOjA0NDMwN2VhNTc4MTRkMGE5MzBhYTVlODg3ZWMzNDYwL3RhYmxlcmFuZ2U6MDQ0MzA3ZWE1NzgxNGQwYTkzMGFhNWU4ODdlYzM0NjBfMS0zLTEtMS0yMjg1OA_5828d859-d03f-440f-9f65-f56be3740316"
      unitRef="usd">21129000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecurities
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOjA0NDMwN2VhNTc4MTRkMGE5MzBhYTVlODg3ZWMzNDYwL3RhYmxlcmFuZ2U6MDQ0MzA3ZWE1NzgxNGQwYTkzMGFhNWU4ODdlYzM0NjBfMi0xLTEtMS0yMjg1OA_7930ccde-a133-42d2-b3e4-ca71474301bc"
      unitRef="usd">44052000</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOjA0NDMwN2VhNTc4MTRkMGE5MzBhYTVlODg3ZWMzNDYwL3RhYmxlcmFuZ2U6MDQ0MzA3ZWE1NzgxNGQwYTkzMGFhNWU4ODdlYzM0NjBfMi0zLTEtMS0yMjg1OA_63ac805b-34b5-4179-ae96-653b1c32d134"
      unitRef="usd">70323000</us-gaap:MarketableSecurities>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOjA0NDMwN2VhNTc4MTRkMGE5MzBhYTVlODg3ZWMzNDYwL3RhYmxlcmFuZ2U6MDQ0MzA3ZWE1NzgxNGQwYTkzMGFhNWU4ODdlYzM0NjBfMy0xLTEtMS0yMjg1OA_62e36d16-daf4-4c24-ab0b-acde4b44c730"
      unitRef="usd">67332000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOjA0NDMwN2VhNTc4MTRkMGE5MzBhYTVlODg3ZWMzNDYwL3RhYmxlcmFuZ2U6MDQ0MzA3ZWE1NzgxNGQwYTkzMGFhNWU4ODdlYzM0NjBfMy0zLTEtMS0yMjg1OA_6eea9530-c081-43ea-95dd-d6300ac4aaad"
      unitRef="usd">91452000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RleHRyZWdpb246Zjc3NmYzODJlZDFlNDJiMGFlMDFkZmQxMzk2OWExNDFfNjM4_bc682c15-af83-4dfd-9357-2c6c6ce68e69">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our portfolio of available-for-sale securities by contractual maturity (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:361.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:70.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Greater than one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOjg4NGUxZmNmYTkzNjRmZTc5MmViZDg4NDdhOWMyZTdjL3RhYmxlcmFuZ2U6ODg0ZTFmY2ZhOTM2NGZlNzkyZWJkODg0N2E5YzJlN2NfMi0xLTEtMS0yMjg1OA_3ff8b98a-baa9-467f-b380-b6f80a3cc6df"
      unitRef="usd">67397000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOjg4NGUxZmNmYTkzNjRmZTc5MmViZDg4NDdhOWMyZTdjL3RhYmxlcmFuZ2U6ODg0ZTFmY2ZhOTM2NGZlNzkyZWJkODg0N2E5YzJlN2NfMi0zLTEtMS0yMjg1OA_64cccf75-87fb-47c2-8e35-a1018b68b235"
      unitRef="usd">67332000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOjg4NGUxZmNmYTkzNjRmZTc5MmViZDg4NDdhOWMyZTdjL3RhYmxlcmFuZ2U6ODg0ZTFmY2ZhOTM2NGZlNzkyZWJkODg0N2E5YzJlN2NfMy0xLTEtMS0yMjg1OA_d4755ce3-c136-4e7d-9c9f-78f5a4a6fa3e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOjg4NGUxZmNmYTkzNjRmZTc5MmViZDg4NDdhOWMyZTdjL3RhYmxlcmFuZ2U6ODg0ZTFmY2ZhOTM2NGZlNzkyZWJkODg0N2E5YzJlN2NfMy0zLTEtMS0yMjg1OA_1cc9ec1e-1da0-4798-b2da-b1c0be805d32"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOjg4NGUxZmNmYTkzNjRmZTc5MmViZDg4NDdhOWMyZTdjL3RhYmxlcmFuZ2U6ODg0ZTFmY2ZhOTM2NGZlNzkyZWJkODg0N2E5YzJlN2NfNC0xLTEtMS0yMjg1OA_ad02eddc-e693-41b0-a73b-3a4a5bca3278"
      unitRef="usd">67397000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80MC9mcmFnOmY3NzZmMzgyZWQxZTQyYjBhZTAxZGZkMTM5NjlhMTQxL3RhYmxlOjg4NGUxZmNmYTkzNjRmZTc5MmViZDg4NDdhOWMyZTdjL3RhYmxlcmFuZ2U6ODg0ZTFmY2ZhOTM2NGZlNzkyZWJkODg0N2E5YzJlN2NfNC0zLTEtMS0yMjg1OA_570128eb-7470-45a6-80ee-91a9ede7438e"
      unitRef="usd">67332000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80Ni9mcmFnOmNhYTNmODFmNDZmZTQ1MzNhNGQyM2Y4MjNhM2VjMjAwL3RleHRyZWdpb246Y2FhM2Y4MWY0NmZlNDUzM2E0ZDIzZjgyM2EzZWMyMDBfMzE5_1658d64b-c3fe-4f71-b624-73f3c09011c7">Income (Loss) Per Share&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the nine months ended September&#160;30, 2022 and 2021, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of diluted loss per share as they are anti-dilutive. At September&#160;30, 2022 and 2021, the Company excluded the following potentially dilutive securities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.713%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80Ni9mcmFnOmNhYTNmODFmNDZmZTQ1MzNhNGQyM2Y4MjNhM2VjMjAwL3RleHRyZWdpb246Y2FhM2Y4MWY0NmZlNDUzM2E0ZDIzZjgyM2EzZWMyMDBfMzM2_d66f018f-fa7b-435f-87d8-d92439ff7419">At September&#160;30, 2022 and 2021, the Company excluded the following potentially dilutive securities (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.713%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i33f0a817fe2049da85aa3551a5c905e4_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80Ni9mcmFnOmNhYTNmODFmNDZmZTQ1MzNhNGQyM2Y4MjNhM2VjMjAwL3RhYmxlOmQzY2NmNjg3YzVkNDRlYWNhY2QwOTAxMzBmMmM2ZWRlL3RhYmxlcmFuZ2U6ZDNjY2Y2ODdjNWQ0NGVhY2FjZDA5MDEzMGYyYzZlZGVfMi0xLTEtMS0yMjg1OA_96458680-f7e2-4469-8d99-80741c257f8b"
      unitRef="shares">1399000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5e0d719ce9044ab281734908fb138fe4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80Ni9mcmFnOmNhYTNmODFmNDZmZTQ1MzNhNGQyM2Y4MjNhM2VjMjAwL3RhYmxlOmQzY2NmNjg3YzVkNDRlYWNhY2QwOTAxMzBmMmM2ZWRlL3RhYmxlcmFuZ2U6ZDNjY2Y2ODdjNWQ0NGVhY2FjZDA5MDEzMGYyYzZlZGVfMi0zLTEtMS0yMjg1OA_266c3528-a23f-4fbc-afa7-a89c0b07f31a"
      unitRef="shares">142000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i422414ad4ec143fe9c83f80484b18850_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80Ni9mcmFnOmNhYTNmODFmNDZmZTQ1MzNhNGQyM2Y4MjNhM2VjMjAwL3RhYmxlOmQzY2NmNjg3YzVkNDRlYWNhY2QwOTAxMzBmMmM2ZWRlL3RhYmxlcmFuZ2U6ZDNjY2Y2ODdjNWQ0NGVhY2FjZDA5MDEzMGYyYzZlZGVfMy0xLTEtMS0yMjg1OA_d9198294-c5d2-47f7-bca2-fc47c0060c64"
      unitRef="shares">1424000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i972cd99d76534d3cb8f6e561e629dc10_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80Ni9mcmFnOmNhYTNmODFmNDZmZTQ1MzNhNGQyM2Y4MjNhM2VjMjAwL3RhYmxlOmQzY2NmNjg3YzVkNDRlYWNhY2QwOTAxMzBmMmM2ZWRlL3RhYmxlcmFuZ2U6ZDNjY2Y2ODdjNWQ0NGVhY2FjZDA5MDEzMGYyYzZlZGVfMy0zLTEtMS0yMjg1OA_e3840494-4af1-41d4-84e2-47db2954202e"
      unitRef="shares">1424000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i161cdf72d862420686200bfdd753f6d7_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80Ni9mcmFnOmNhYTNmODFmNDZmZTQ1MzNhNGQyM2Y4MjNhM2VjMjAwL3RhYmxlOmQzY2NmNjg3YzVkNDRlYWNhY2QwOTAxMzBmMmM2ZWRlL3RhYmxlcmFuZ2U6ZDNjY2Y2ODdjNWQ0NGVhY2FjZDA5MDEzMGYyYzZlZGVfNS0xLTEtMS0yMjg1OA_ac7a416e-5325-41c3-926e-456a2deb5c23"
      unitRef="shares">48000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifccd968d78a3473898c3258429a71f76_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80Ni9mcmFnOmNhYTNmODFmNDZmZTQ1MzNhNGQyM2Y4MjNhM2VjMjAwL3RhYmxlOmQzY2NmNjg3YzVkNDRlYWNhY2QwOTAxMzBmMmM2ZWRlL3RhYmxlcmFuZ2U6ZDNjY2Y2ODdjNWQ0NGVhY2FjZDA5MDEzMGYyYzZlZGVfNS0zLTEtMS0yMjg1OA_facb7368-f9d5-4124-9fbd-30cfa686efb0"
      unitRef="shares">53000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RleHRyZWdpb246NTM0ZWJlNjRlOTk0NDBkMTg5YmU5ZjNjOWY3YmYyMjVfMTQ3MA_34fd32b0-baf4-40e5-a59d-a2acff74627b">Fair Value Measurements&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth by level within the fair value hierarchy the Company's financial assets that were accounted for at fair value on a recurring basis as of September&#160;30, 2022 and December&#160;31, 2021 (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:116.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:12.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities - available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RleHRyZWdpb246NTM0ZWJlNjRlOTk0NDBkMTg5YmU5ZjNjOWY3YmYyMjVfMTQ3Mw_ee024a13-6685-4c41-bef5-a525fb20b0a0">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth by level within the fair value hierarchy the Company's financial assets that were accounted for at fair value on a recurring basis as of September&#160;30, 2022 and December&#160;31, 2021 (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:116.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:12.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:42.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities - available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i48063441de8a46dc974334dbf9a3a293_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfMy0yLTEtMS0yMjg1OA_321471fc-bad3-4cd6-8d4f-493b5564d258"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i7348558529cf46d2959b0b4229242404_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfMy00LTEtMS0yMjg1OA_0b2de1b0-e477-46a2-bb95-7c8cf630c168"
      unitRef="usd">44052000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i9a76766f174f4c3b84f09f885f2170c6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfMy02LTEtMS0yMjg1OA_c8edbe3a-6aa8-4f1e-8846-998c8f1227e7"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib35c54c2e1b14397ae34101068f8d0a3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfMy04LTEtMS0yMjg1OA_8110c7ad-222f-4f8c-b567-07a2e7561c56"
      unitRef="usd">44052000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i8f89ef4342fe4c27b982bc991aff78d8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfMy0xMC0xLTEtMjI4NTg_b450b90e-b9d8-43c7-af42-ec51d4056e7b"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ie2404060e56d462683781d6a6eb5e03e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfMy0xMi0xLTEtMjI4NTg_4411763e-cd00-4d8e-ba60-cbe4428bbc34"
      unitRef="usd">70323000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i03006f5a9605427eb1a8f9b1e13d1902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfMy0xNC0xLTEtMjI4NTg_26187e07-cf87-42d9-a17b-2cadde6bac7d"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i8aa7a96703004d078dc7feb5458b2718_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfMy0xNi0xLTEtMjI4NTg_b686d104-b0e4-478c-8dca-5bd4f5351bad"
      unitRef="usd">70323000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i48063441de8a46dc974334dbf9a3a293_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfNS0yLTEtMS0yMjg1OA_c3c9b8ad-902d-40af-9f0a-60541a04660e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7348558529cf46d2959b0b4229242404_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfNS00LTEtMS0yMjg1OA_d593f6db-5fd4-4353-b508-673212ecd7b3"
      unitRef="usd">44052000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9a76766f174f4c3b84f09f885f2170c6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfNS02LTEtMS0yMjg1OA_54980177-d5f6-4956-afe0-2117ef9f5247"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib35c54c2e1b14397ae34101068f8d0a3_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfNS04LTEtMS0yMjg1OA_92aba935-71fa-436a-85c4-b6da7ad73bbc"
      unitRef="usd">44052000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8f89ef4342fe4c27b982bc991aff78d8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfNS0xMC0xLTEtMjI4NTg_f8407896-c207-453f-b297-c98bbb1000c4"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie2404060e56d462683781d6a6eb5e03e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfNS0xMi0xLTEtMjI4NTg_0e159fbb-b961-45d0-b84a-33c9e48dea68"
      unitRef="usd">70323000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i03006f5a9605427eb1a8f9b1e13d1902_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfNS0xNC0xLTEtMjI4NTg_71b295f0-759a-45b5-bf50-c6cf5b896f6f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8aa7a96703004d078dc7feb5458b2718_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV80OS9mcmFnOjUzNGViZTY0ZTk5NDQwZDE4OWJlOWYzYzlmN2JmMjI1L3RhYmxlOmI1ZjFjMTgxNmIwNjQwMThhZTQwMGExYjQ5NjE0NTFhL3RhYmxlcmFuZ2U6YjVmMWMxODE2YjA2NDAxOGFlNDAwYTFiNDk2MTQ1MWFfNS0xNi0xLTEtMjI4NTg_a96cf3d8-fbb2-4e0b-b321-04e17b1b0012"
      unitRef="usd">70323000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81Mi9mcmFnOjc3NWQ4YzBmOTE4OTRlYWRhYjlhYWM1YjY1YzJjM2I2L3RleHRyZWdpb246Nzc1ZDhjMGY5MTg5NGVhZGFiOWFhYzViNjVjMmMzYjZfMTA4_0990548a-c4f1-4f65-8f60-7995cb087f8e">Accrued Liabilities&lt;div style="margin-bottom:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities as of September&#160;30, 2022 and December&#160;31, 2021 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:313.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salaries, employee benefits and related taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities &#x2014; current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical and R&amp;amp;D related liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81Mi9mcmFnOjc3NWQ4YzBmOTE4OTRlYWRhYjlhYWM1YjY1YzJjM2I2L3RleHRyZWdpb246Nzc1ZDhjMGY5MTg5NGVhZGFiOWFhYzViNjVjMmMzYjZfMTA2_0c0b8d26-6d15-439c-85e1-3e902535816a">&lt;div style="margin-bottom:8pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities as of September&#160;30, 2022 and December&#160;31, 2021 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:507.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:313.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salaries, employee benefits and related taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities &#x2014; current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical and R&amp;amp;D related liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81Mi9mcmFnOjc3NWQ4YzBmOTE4OTRlYWRhYjlhYWM1YjY1YzJjM2I2L3RhYmxlOjAwM2IzNjkwNTNjYjQzOGI5NmZjOWQ4MGJlYzNkMmIxL3RhYmxlcmFuZ2U6MDAzYjM2OTA1M2NiNDM4Yjk2ZmM5ZDgwYmVjM2QyYjFfMS0xLTEtMS0yMjg1OA_b3cc5ce4-6e7f-403f-822d-5cc3095d87c1"
      unitRef="usd">2147000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81Mi9mcmFnOjc3NWQ4YzBmOTE4OTRlYWRhYjlhYWM1YjY1YzJjM2I2L3RhYmxlOjAwM2IzNjkwNTNjYjQzOGI5NmZjOWQ4MGJlYzNkMmIxL3RhYmxlcmFuZ2U6MDAzYjM2OTA1M2NiNDM4Yjk2ZmM5ZDgwYmVjM2QyYjFfMS0zLTEtMS0yMjg1OA_8a66de97-22d5-4e5f-9f88-49b3872a9a8b"
      unitRef="usd">2034000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81Mi9mcmFnOjc3NWQ4YzBmOTE4OTRlYWRhYjlhYWM1YjY1YzJjM2I2L3RhYmxlOjAwM2IzNjkwNTNjYjQzOGI5NmZjOWQ4MGJlYzNkMmIxL3RhYmxlcmFuZ2U6MDAzYjM2OTA1M2NiNDM4Yjk2ZmM5ZDgwYmVjM2QyYjFfMi0xLTEtMS0yMjg1OA_74764e98-7adb-43c5-b82e-4e07588f1229"
      unitRef="usd">203000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81Mi9mcmFnOjc3NWQ4YzBmOTE4OTRlYWRhYjlhYWM1YjY1YzJjM2I2L3RhYmxlOjAwM2IzNjkwNTNjYjQzOGI5NmZjOWQ4MGJlYzNkMmIxL3RhYmxlcmFuZ2U6MDAzYjM2OTA1M2NiNDM4Yjk2ZmM5ZDgwYmVjM2QyYjFfMi0zLTEtMS0yMjg1OA_de35edb9-cca5-4b32-9601-91507ca71ff9"
      unitRef="usd">229000</us-gaap:OperatingLeaseLiabilityCurrent>
    <clbs:ClinicalAndRDRelatedLiabilities
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81Mi9mcmFnOjc3NWQ4YzBmOTE4OTRlYWRhYjlhYWM1YjY1YzJjM2I2L3RhYmxlOjAwM2IzNjkwNTNjYjQzOGI5NmZjOWQ4MGJlYzNkMmIxL3RhYmxlcmFuZ2U6MDAzYjM2OTA1M2NiNDM4Yjk2ZmM5ZDgwYmVjM2QyYjFfNC0xLTEtMS0yOTI0Nw_caf584c2-fb8a-419d-a98a-946ef5807a5f"
      unitRef="usd">2338000</clbs:ClinicalAndRDRelatedLiabilities>
    <clbs:ClinicalAndRDRelatedLiabilities
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81Mi9mcmFnOjc3NWQ4YzBmOTE4OTRlYWRhYjlhYWM1YjY1YzJjM2I2L3RhYmxlOjAwM2IzNjkwNTNjYjQzOGI5NmZjOWQ4MGJlYzNkMmIxL3RhYmxlcmFuZ2U6MDAzYjM2OTA1M2NiNDM4Yjk2ZmM5ZDgwYmVjM2QyYjFfNC0zLTEtMS0yOTI0Nw_cb1bbea9-f563-4211-b1a2-bc563865cb5f"
      unitRef="usd">0</clbs:ClinicalAndRDRelatedLiabilities>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81Mi9mcmFnOjc3NWQ4YzBmOTE4OTRlYWRhYjlhYWM1YjY1YzJjM2I2L3RhYmxlOjAwM2IzNjkwNTNjYjQzOGI5NmZjOWQ4MGJlYzNkMmIxL3RhYmxlcmFuZ2U6MDAzYjM2OTA1M2NiNDM4Yjk2ZmM5ZDgwYmVjM2QyYjFfNC0xLTEtMS0yMjg1OA_5f4246ee-c14f-4263-a246-e641db45fd7b"
      unitRef="usd">729000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81Mi9mcmFnOjc3NWQ4YzBmOTE4OTRlYWRhYjlhYWM1YjY1YzJjM2I2L3RhYmxlOjAwM2IzNjkwNTNjYjQzOGI5NmZjOWQ4MGJlYzNkMmIxL3RhYmxlcmFuZ2U6MDAzYjM2OTA1M2NiNDM4Yjk2ZmM5ZDgwYmVjM2QyYjFfNC0zLTEtMS0yMjg1OA_7fb49a96-04b9-43d0-8c47-a5a864e00b17"
      unitRef="usd">326000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81Mi9mcmFnOjc3NWQ4YzBmOTE4OTRlYWRhYjlhYWM1YjY1YzJjM2I2L3RhYmxlOjAwM2IzNjkwNTNjYjQzOGI5NmZjOWQ4MGJlYzNkMmIxL3RhYmxlcmFuZ2U6MDAzYjM2OTA1M2NiNDM4Yjk2ZmM5ZDgwYmVjM2QyYjFfNS0xLTEtMS0yMjg1OA_e4617342-2362-4eb9-93b1-7b9ea2a5ff61"
      unitRef="usd">5417000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81Mi9mcmFnOjc3NWQ4YzBmOTE4OTRlYWRhYjlhYWM1YjY1YzJjM2I2L3RhYmxlOjAwM2IzNjkwNTNjYjQzOGI5NmZjOWQ4MGJlYzNkMmIxL3RhYmxlcmFuZ2U6MDAzYjM2OTA1M2NiNDM4Yjk2ZmM5ZDgwYmVjM2QyYjFfNS0zLTEtMS0yMjg1OA_7eea2ee0-81ef-4f58-a51a-d1b9e0ba9f5c"
      unitRef="usd">2589000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RleHRyZWdpb246NmY4MzE5YmExYjIwNGI3YWIzNWY5NWJhYjE1ODQ5MTZfMTE3Mw_44214626-81cb-4c81-ad82-b5459fb0996b">Operating LeasesThe Company has operating leases for two offices with terms that expire in 2023 and 2025, respectively. The Company estimates its incremental borrowing rate at lease commencement to determine the present value of lease payments as most of the Company's leases do not provide an implicit rate of return. The Company recognizes lease expense on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company elected to account for non-lease components associated with its leases and lease components as a single lease component. Each of the Company's leases includes options for the Company to extend the lease term and/or sub-lease space in whole or in part.&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:325.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of Use Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfMi0wLTEtMS0yMjg1OA_188c2eed-0925-44f8-bfd8-8dc48bf41cee"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfMi0wLTEtMS0yMjg1OA_cda64072-7450-44a6-a48d-ee2b330b6907"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Right-of-Use Asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating Lease Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNi0wLTEtMS0yMjg1OA_466bdee9-6b20-428a-b677-b820ae3ba607"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNi0wLTEtMS0yMjg1OA_62800bd1-bc30-473e-aedd-b0b3d9f06907"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNy0wLTEtMS0yMjg1OA_ceb1d506-32b0-442d-b209-59921ea40600"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNy0wLTEtMS0yMjg1OA_f9192e00-f937-46b7-9c41-0640551a459c"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Operating Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the weighted average remaining lease term for our operating leases was 1.8 years, and the weighted average discount rate for our operating leases was 9.625%. Future minimum lease payments under the lease agreements as of September&#160;30, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:448.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <clbs:NumberOfOfficesUnderOperatingLeases
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RleHRyZWdpb246NmY4MzE5YmExYjIwNGI3YWIzNWY5NWJhYjE1ODQ5MTZfNjg_f6e666ca-34fe-4ae9-900f-4360c658944c"
      unitRef="office">2</clbs:NumberOfOfficesUnderOperatingLeases>
    <clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RleHRyZWdpb246NmY4MzE5YmExYjIwNGI3YWIzNWY5NWJhYjE1ODQ5MTZfMTE2OQ_3885cd80-9893-41e0-b6a3-0cbc8685ffab">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities and right-of-use assets were recorded in the following captions of our balance sheet were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:325.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of Use Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfMi0wLTEtMS0yMjg1OA_188c2eed-0925-44f8-bfd8-8dc48bf41cee"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfMi0wLTEtMS0yMjg1OA_cda64072-7450-44a6-a48d-ee2b330b6907"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Right-of-Use Asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating Lease Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNi0wLTEtMS0yMjg1OA_466bdee9-6b20-428a-b677-b820ae3ba607"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNi0wLTEtMS0yMjg1OA_62800bd1-bc30-473e-aedd-b0b3d9f06907"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNy0wLTEtMS0yMjg1OA_ceb1d506-32b0-442d-b209-59921ea40600"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNy0wLTEtMS0yMjg1OA_f9192e00-f937-46b7-9c41-0640551a459c"&gt;Other long-term liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Operating Lease Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfMi0xLTEtMS0yMjg1OA_8618a7ce-3cb2-40ff-a9df-c38536c62579"
      unitRef="usd">548000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfMi0zLTEtMS0yMjg1OA_1477247d-293d-4143-bf2f-7a77e3a3d68a"
      unitRef="usd">724000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfMy0xLTEtMS0yMjg1OA_e071524f-012d-4a79-8d61-7125155a838a"
      unitRef="usd">548000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfMy0zLTEtMS0yMjg1OA_59f48ac5-92f6-4d26-a785-dae4a7de2d9c"
      unitRef="usd">724000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNi0xLTEtMS0yMjg1OA_c1b7d532-7036-4e80-8487-bd6d37a95244"
      unitRef="usd">203000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNi0zLTEtMS0yMjg1OA_05fd999a-67e5-42be-ae59-b76b211cf417"
      unitRef="usd">229000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNy0xLTEtMS0yMjg1OA_e847a94a-8491-4808-ad49-71a5f522ed83"
      unitRef="usd">345000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfNy0zLTEtMS0yMjg1OA_921fae82-f15a-41b1-bd08-f9d223d896ec"
      unitRef="usd">485000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfOC0xLTEtMS0yMjg1OA_010f4aa7-cc81-43d7-8053-babdf63e4755"
      unitRef="usd">548000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjI0ZTgxY2Q0ZTczOTQ0NzJiOTRlMTVjZDRlZmIxZjFjL3RhYmxlcmFuZ2U6MjRlODFjZDRlNzM5NDQ3MmI5NGUxNWNkNGVmYjFmMWNfOC0zLTEtMS0yMjg1OA_931ad48c-cb4e-48df-ac62-70c580ef43c2"
      unitRef="usd">714000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RleHRyZWdpb246NmY4MzE5YmExYjIwNGI3YWIzNWY5NWJhYjE1ODQ5MTZfOTky_86c53463-7ab3-4c28-83d0-ed860f873e84">P1Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RleHRyZWdpb246NmY4MzE5YmExYjIwNGI3YWIzNWY5NWJhYjE1ODQ5MTZfMTA2NA_aaddf0f0-0da5-46c9-b64d-fae4879bba45"
      unitRef="number">0.09625</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RleHRyZWdpb246NmY4MzE5YmExYjIwNGI3YWIzNWY5NWJhYjE1ODQ5MTZfMTE3MA_ebbf77ec-375e-4c3a-886d-8087463b7184">Future minimum lease payments under the lease agreements as of September&#160;30, 2022 were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:448.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Amounts representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#bfe4ff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjQwY2I5MDA2NWFmYjRhNjg4OTdiYTdmMGFjYWRlNjJjL3RhYmxlcmFuZ2U6NDBjYjkwMDY1YWZiNGE2ODg5N2JhN2YwYWNhZGU2MmNfMy0xLTEtMS0yMjg1OA_a32edbd6-e1fc-473a-906b-f3d5a015e1d6"
      unitRef="usd">75000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjQwY2I5MDA2NWFmYjRhNjg4OTdiYTdmMGFjYWRlNjJjL3RhYmxlcmFuZ2U6NDBjYjkwMDY1YWZiNGE2ODg5N2JhN2YwYWNhZGU2MmNfNC0xLTEtMS0yMjg1OA_a815a78d-4f3d-4694-926f-73b1a2d9723a"
      unitRef="usd">217000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjQwY2I5MDA2NWFmYjRhNjg4OTdiYTdmMGFjYWRlNjJjL3RhYmxlcmFuZ2U6NDBjYjkwMDY1YWZiNGE2ODg5N2JhN2YwYWNhZGU2MmNfNS0xLTEtMS0yMjg1OA_b1fffc04-419a-4e9e-ae96-6388c49831ae"
      unitRef="usd">190000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjQwY2I5MDA2NWFmYjRhNjg4OTdiYTdmMGFjYWRlNjJjL3RhYmxlcmFuZ2U6NDBjYjkwMDY1YWZiNGE2ODg5N2JhN2YwYWNhZGU2MmNfNi0xLTEtMS0yMjg1OA_a188f76e-f727-4922-8f3c-f30f2dccb268"
      unitRef="usd">143000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjQwY2I5MDA2NWFmYjRhNjg4OTdiYTdmMGFjYWRlNjJjL3RhYmxlcmFuZ2U6NDBjYjkwMDY1YWZiNGE2ODg5N2JhN2YwYWNhZGU2MmNfNy0xLTEtMS0yMjg1OA_3fc95408-4c14-40bd-967b-730cd604143e"
      unitRef="usd">625000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjQwY2I5MDA2NWFmYjRhNjg4OTdiYTdmMGFjYWRlNjJjL3RhYmxlcmFuZ2U6NDBjYjkwMDY1YWZiNGE2ODg5N2JhN2YwYWNhZGU2MmNfOC0xLTEtMS0yMjg1OA_0c390648-2246-48e3-95f1-1f50094705b4"
      unitRef="usd">77000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81NS9mcmFnOjZmODMxOWJhMWIyMDRiN2FiMzVmOTViYWIxNTg0OTE2L3RhYmxlOjQwY2I5MDA2NWFmYjRhNjg4OTdiYTdmMGFjYWRlNjJjL3RhYmxlcmFuZ2U6NDBjYjkwMDY1YWZiNGE2ODg5N2JhN2YwYWNhZGU2MmNfOS0xLTEtMS0yMjg1OA_964416bc-0a8e-46e2-9f33-b16420bc1c2e"
      unitRef="usd">548000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNTQ1NQ_5fc84d0c-8e88-4872-90f2-fc40c9ad57a8">Stockholders' Equity&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reverse Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 14, 2022, in connection with the merger, we implemented the Reverse Stock Split, as described in Note 1. All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods presented to give retroactive effect to the Reverse Stock Split. Accordingly, the consolidated statements of equity reflect the impact of the Reverse Stock Split by reclassifying from &#x201c;common stock&#x201d; to &#x201c;additional paid-in capital&#x201d; in an amount equal to the par value of the decreased shares resulting from the Reverse Stock Split.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Issuances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March&#160;2019, the Company and Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;) entered into a purchase agreement (the &#x201c;Purchase Agreement&#x201d;) and a registration rights agreement (the &#x201c;Registration Rights Agreement&#x201d;), pursuant to which the Company has the right to sell to Lincoln Park shares of the Company&#x2019;s common stock having an aggregate value of up to $26.0 million, subject to certain limitations and conditions set forth in the Purchase Agreement (the &#x201c;Offering&#x201d;). As consideration for entering into the Purchase Agreement, the Company issued to Lincoln Park an additional 181,510 shares of common stock as commitment shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Purchase Agreement, Lincoln Park purchased 250,000 shares of common stock, at a price of $4.00 per share, for a total gross purchase price of $1.0 million (the &#x201c;Initial Purchase&#x201d;) upon commencement. Thereafter, as often as every business day from and after one business day following the date of the Initial Purchase and over the 36-month term of the Purchase Agreement, the Company has the right, from time to time, at its sole discretion and subject to certain conditions, to direct Lincoln Park to purchase up to 100,000 shares of common stock, with such amount increasing as the closing sale price of the common stock increases; provided Lincoln Park&#x2019;s obligation under any single such purchase will not exceed $2.5 million, unless the Company and Lincoln Park mutually agree to increase the maximum amount of such single purchase (each, a &#x201c;Regular Purchase&#x201d;).&#160;If the Company directs Lincoln Park to purchase the maximum number of shares of common stock it then may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations in the Purchase Agreement, the Company may direct Lincoln Park in an &#x201c;accelerated purchase&#x201d; to purchase an additional amount &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of common stock that may not exceed the lesser of (i)&#160;300% the number of shares purchased pursuant to the corresponding Regular Purchase or (ii)&#160;30% of the total number of shares of the Company&#x2019;s common stock traded during a specified period on the applicable purchase date as set forth in the Purchase Agreement. Under certain circumstances and in accordance with the Purchase Agreement, the Company may direct Lincoln Park to purchase shares in multiple accelerated purchases on the same trading day.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company controls the timing and amount of any sales of its common stock to Lincoln Park.&#160;There is no upper limit on the price per share that Lincoln Park must pay for its common stock under the Purchase Agreement, but in no event will shares be sold to Lincoln Park on a day the closing price is less than the floor price specified in the Purchase Agreement. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the purchase agreement if it would result in Lincoln Park beneficially owning more than 9.99% of its common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Purchase Agreement does not limit the Company&#x2019;s ability to raise capital from other sources at the Company&#x2019;s sole discretion, except that (subject to certain exceptions) the Company may not enter into any Variable Rate Transaction (as defined in the Purchase Agreement, including the issuance of any floating conversion rate or variable priced equity-like securities) during the 36 months after the date of the Purchase Agreement. The Company has the right to terminate the Purchase Agreement at any time, at no cost to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the Company had not made any sales of common stock to Lincoln Park under the Purchase Agreement other than the Initial Purchase. The agreement expired on April 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;At The Market Offering Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 4, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;ATM Agreement&#x201d;) with H.C. Wainwright &amp;amp; Co., LLC, as sales agent, in connection with an &#x201c;at the market offering&#x201d; under which the Company from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $50.0&#160;million.  During the nine months ended September&#160;30, 2022 and since inception, the Company has not issued any shares under the ATM Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Merger close, the Company issued an aggregate of 3,772,768 shares of common stock, based on the Exchange Ratio, to holders of Cend, in exchange for all of the Cend capital stock outstanding immediately prior to the closing of the Merger. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options and Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Merger and after giving effect to the Reverse Stock Split, the Company assumed 1,227,776 options outstanding from Cend. The options granted from the Cend Plan are exercisable at various dates as determined upon grant and will expire no more than ten years from their original date of grant. The Cend Plan stock options generally vest over a four-year term. The following table summarizes the activity for stock options and warrants for the nine months ended September&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,423,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes during the period:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assumed through merger&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,227,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;352.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,398,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,423,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at September 30, 2022&lt;br/&gt;&#160;or expected to vest in the future&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,396,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,423,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,110,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,423,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2022 and 2021, the Company issued restricted stock for services as follows ($ in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:322.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:4.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number of restricted stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of restricted stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The vesting terms of restricted stock issuances are generally between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNDg3Mw_6c617069-871e-4bcc-ac83-10a9da649366"&gt;one&lt;/span&gt; and four years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2022 and 2021, the Company issued restricted stock units for services as follows ($ in thousands, except share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:343.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number of restricted stock units issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;111,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of restricted stock units issued &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The weighted average estimated fair value of restricted stock issued for services in the nine months ended September&#160;30, 2022 and 2021 was $12.46 and $23.85 per share, respectively. The fair value of the restricted stock units was determined using the Company&#x2019;s closing stock price on the date of issuance. The vesting terms of restricted stock unit issuances are generally one year, or upon the achievement of performance-based milestones.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement
      contextRef="i7128331c98ad445b8fb23487460be1ba_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNDI2_dcc91888-8956-4189-910c-ec546458b139"
      unitRef="usd">26000000</clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement>
    <clbs:StockIssuedDuringPeriodSharesIssuedAsConsideration
      contextRef="ic92d752f756145678f3d08b54d87d88e_D20190301-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNjM4_bd30dc61-5002-4f60-8f69-eba860b3d32b"
      unitRef="shares">181510</clbs:StockIssuedDuringPeriodSharesIssuedAsConsideration>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ic92d752f756145678f3d08b54d87d88e_D20190301-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNzQ1_1c1b3646-1993-40cf-a97e-035b5bd15216"
      unitRef="shares">250000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i7128331c98ad445b8fb23487460be1ba_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNzg2_cb92ed88-408f-4940-b9d7-2c3870c29a48"
      unitRef="usdPerShare">4.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ic92d752f756145678f3d08b54d87d88e_D20190301-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfODM2_050c50dd-ac7f-46dd-9209-d54e560b22c2"
      unitRef="usd">1000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <clbs:TermOfAgreement
      contextRef="ic92d752f756145678f3d08b54d87d88e_D20190301-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfMTAxNA_d5b504a0-4c53-425e-8318-d46233e10c78">P36M</clbs:TermOfAgreement>
    <clbs:SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase
      contextRef="i7128331c98ad445b8fb23487460be1ba_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfMTE5OQ_0bacc891-7cf6-4a71-81a6-c820d66deab9"
      unitRef="shares">100000</clbs:SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase>
    <clbs:SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase
      contextRef="i7128331c98ad445b8fb23487460be1ba_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfMTM5Mw_d020bb79-c52d-4965-ab11-5b08373eca26"
      unitRef="usd">2500000</clbs:SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase>
    <clbs:SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase
      contextRef="i7128331c98ad445b8fb23487460be1ba_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfMTkzOA_a646cc86-0459-40ac-8beb-46d270bdd977"
      unitRef="number">3</clbs:SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase>
    <clbs:SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod
      contextRef="i7128331c98ad445b8fb23487460be1ba_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfMjAyNw_1990c02f-50f3-4b2a-bcd4-e9a830283c1e"
      unitRef="number">0.30</clbs:SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod>
    <clbs:RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty
      contextRef="i7128331c98ad445b8fb23487460be1ba_I20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfMjkyNw_f4cd5ac6-c9b5-4f31-af45-9c5f315b0b2a"
      unitRef="number">0.0999</clbs:RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty>
    <clbs:TermOfAgreement
      contextRef="ic92d752f756145678f3d08b54d87d88e_D20190301-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfMzMzNA_d5b504a0-4c53-425e-8318-d46233e10c78">P36M</clbs:TermOfAgreement>
    <clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement
      contextRef="i5748a0eb61f64415a43f6fd83aab5103_I20210604"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNDAwNg_35ef4269-f791-40d5-a663-b669bd9bd749"
      unitRef="usd">50000000</clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i4f7b301665c749bf9b60eccd141f1949_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNDA2NA_e9f40945-f113-44ec-9da6-845fb84f0af7"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNTQzNw_f3adf315-7fac-45d2-9673-92d5f2c0d3ab">The following table summarizes the activity for stock options and warrants for the nine months ended September&#160;30, 2022:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.952%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.127%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Aggregate Intrinsic Value (In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,423,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes during the period:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assumed through merger&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,227,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;352.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,398,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,423,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at September 30, 2022&lt;br/&gt;&#160;or expected to vest in the future&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,396,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,423,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,110,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,423,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMi0yLTEtMS0yMjg1OA_4b15dbee-c2c8-41e2-bd99-35d2e4ac7d39"
      unitRef="shares">142041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMi00LTEtMS0yMjg1OA_b07c9239-b388-43f4-8204-5f04b4e29722"
      unitRef="usdPerShare">84.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="iafd0678032f1403699288c6ead8540b2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMi02LTEtMS0yMjg1OA_ce3e0407-63c6-4d21-8a04-a2c07e871e6e">P7Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMi04LTEtMS0yMjg1OA_0981da9a-2767-40cb-b7b1-a42a0f9bbb8a"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <clbs:CommonStockWarrantsShares
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMi0xMC0xLTEtMjI4NTg_121e8515-42be-405b-85cc-750ab76dd772"
      unitRef="shares">1423774</clbs:CommonStockWarrantsShares>
    <clbs:WeightedAverageExercisePriceWarrantsOutstanding
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMi0xMi0xLTEtMjI4NTg_d5ac3e1e-dd4f-454f-a692-0d07318bca53"
      unitRef="usdPerShare">42.57</clbs:WeightedAverageExercisePriceWarrantsOutstanding>
    <clbs:WeightedAverageRemainingContractualTermwarrantoutstanding
      contextRef="iafd0678032f1403699288c6ead8540b2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMi0xNC0xLTEtMjI4NTg_e32beeb9-bd61-48c5-8f1d-6105f29de027">P4Y4M13D</clbs:WeightedAverageRemainingContractualTermwarrantoutstanding>
    <clbs:AggregateIntrinsicValueWarrantsOutstanding
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMi0xNi0xLTEtMjI4NTg_8385816a-eb3e-4ed7-8302-b9ff1d4596f6"
      unitRef="usd">0</clbs:AggregateIntrinsicValueWarrantsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfNS0yLTEtMS0yMjg1OA_58848d4f-3466-4978-b6ed-c4c78f8299d7"
      unitRef="shares">37458</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfNS00LTEtMS0yMjg1OA_b0195f7e-2a00-482c-8e8a-8833a764eaa6"
      unitRef="usdPerShare">13.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <clbs:WarrantsGranted
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfNS0xMC0xLTEtMjI4NTg_8f601099-4dbc-44c5-9583-e7ff87d461e1"
      unitRef="shares">0</clbs:WarrantsGranted>
    <clbs:WeightedAverageExercisePriceWarrantsGranted
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfNS0xMi0xLTEtMjI4NTg_2ae7184d-e557-4661-81d1-0de3b093eddb"
      unitRef="usdPerShare">0</clbs:WeightedAverageExercisePriceWarrantsGranted>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfNi0yLTEtMS0yMjg1OA_577e9608-b394-454e-9f89-17a40db1f1e2"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfNi00LTEtMS0yMjg1OA_8c4cd91d-1f0c-4f9e-bb03-b57d8009f76c"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <clbs:WarrantsExercised
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfNi0xMC0xLTEtMjI4NTg_539597f6-6990-4de3-991c-2c28c8d78065"
      unitRef="shares">0</clbs:WarrantsExercised>
    <clbs:WeightedAverageExercisePriceWarrantsExercised
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfNi0xMi0xLTEtMjI4NTg_2c527801-a2c3-4ce4-bda4-f22072099fa2"
      unitRef="usdPerShare">0</clbs:WeightedAverageExercisePriceWarrantsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfNy0yLTEtMS0yMjg1OA_22d344ea-a5db-44db-be8c-144715d2adb4"
      unitRef="shares">2910</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfNy00LTEtMS0yMjg1OA_de210cef-5da0-4418-b907-1aed42c497aa"
      unitRef="usdPerShare">19.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <clbs:WarrantsCanceled
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfNy0xMC0xLTEtMjI4NTg_1ec9d46a-404a-4941-87a0-f9e746ea8158"
      unitRef="shares">0</clbs:WarrantsCanceled>
    <clbs:WeightedAverageExercisePriceWarrantsCanceled
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfNy0xMi0xLTEtMjI4NTg_05ddfcb6-4049-4d10-8299-2129ddf11976"
      unitRef="usdPerShare">0</clbs:WeightedAverageExercisePriceWarrantsCanceled>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfOC0yLTEtMS0yMjg1OA_bf513154-00c9-4268-bcac-f2d8bb542fe6"
      unitRef="shares">5388</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfOC00LTEtMS0yMjg1OA_465bcc78-c099-4d32-86a2-f424d442bbd9"
      unitRef="usdPerShare">352.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <clbs:WarrantsExpired
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfOC0xMC0xLTEtMjI4NTg_1a0548ee-2462-4522-a7ad-eb3000da929c"
      unitRef="shares">0</clbs:WarrantsExpired>
    <clbs:WeightedAverageExercisePriceWarrantsExpired
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfOC0xMi0xLTEtMjI4NTg_499070e7-3bf7-4d76-89b8-4c9360ae2a86"
      unitRef="usdPerShare">0</clbs:WeightedAverageExercisePriceWarrantsExpired>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfOS0yLTEtMS0yMjg1OA_5561c9c1-1300-4cfc-b72a-5ca0845e7fec"
      unitRef="shares">1398977</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfOS00LTEtMS0yMjg1OA_e0d20a29-2432-43f4-9c6a-42f28d5bf9a4"
      unitRef="usdPerShare">10.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfOS02LTEtMS0yMjg1OA_69a16e6f-7760-4e8f-9e1d-c4fe02d0f534">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfOS04LTEtMS0yMjg1OA_8d352182-538c-458b-a2e1-fbbcb09c0946"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <clbs:CommonStockWarrantsShares
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfOS0xMC0xLTEtMjI4NTg_f59fab96-2497-4fd5-8722-e6bc7e528f35"
      unitRef="shares">1423774</clbs:CommonStockWarrantsShares>
    <clbs:WeightedAverageExercisePriceWarrantsOutstanding
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfOS0xMi0xLTEtMjI4NTg_ec8504f1-c191-4c63-8763-f66d85dbe029"
      unitRef="usdPerShare">42.57</clbs:WeightedAverageExercisePriceWarrantsOutstanding>
    <clbs:WeightedAverageRemainingContractualTermwarrantoutstanding
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfOS0xNC0xLTEtMjI4NTg_6bb5772a-96ba-4514-868e-5bcb3518a190">P3Y7M17D</clbs:WeightedAverageRemainingContractualTermwarrantoutstanding>
    <clbs:AggregateIntrinsicValueWarrantsOutstanding
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfOS0xNi0xLTEtMjI4NTg_32a06bf1-0098-4ae9-aa24-4bfb0764b465"
      unitRef="usd">0</clbs:AggregateIntrinsicValueWarrantsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTAtMi0xLTEtMjI4NTg_7e2ea44e-9c56-4b79-a3ed-92e2780d9caa"
      unitRef="shares">1396921</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTAtNC0xLTEtMjI4NTg_16329620-82eb-4afa-b899-d75ee91e84f2"
      unitRef="usdPerShare">10.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTAtNi0xLTEtMjI4NTg_17156f2e-bc3d-4844-b088-9d5f1bd133a1">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTAtOC0xLTEtMjI4NTg_95a69dd8-f3f9-4cbb-905a-f241148b711f"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <clbs:Sharesvestedandexpectedtovest
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTAtMTAtMS0xLTIyODU4_0ba70e5d-2a84-4e94-9730-06cf5000b69d"
      unitRef="shares">1423774</clbs:Sharesvestedandexpectedtovest>
    <clbs:WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTAtMTItMS0xLTIyODU4_a6a8f7f0-3f08-48da-a203-793ce071beb6"
      unitRef="usdPerShare">42.57</clbs:WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest>
    <clbs:WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTAtMTQtMS0xLTIyODU4_22ba8c14-f52e-45e9-bcfe-46091d7db16e">P3Y7M17D</clbs:WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest>
    <clbs:AggregateIntrinsicValueWarrantsvestedandexpectedtovest
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTAtMTYtMS0xLTIyODU4_4d5861c8-4467-4cb5-ab6c-4ca26ec3a545"
      unitRef="usd">0</clbs:AggregateIntrinsicValueWarrantsvestedandexpectedtovest>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTEtMi0xLTEtMjI4NTg_da2811a2-b36c-48ec-8bfb-99e81652b849"
      unitRef="shares">1110635</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTEtNC0xLTEtMjI4NTg_de0d6e59-f097-4fcb-b72a-f305fa5a72fd"
      unitRef="usdPerShare">11.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <clbs:OptionsVestedweightedAverageRemainingContractualTerm
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTEtNi0xLTEtMjI4NTg_a942b037-acd9-42ea-9982-5ac5ce66313c">P6Y11M19D</clbs:OptionsVestedweightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTEtOC0xLTEtMjI4NTg_2485c9a8-fdf9-4462-96e7-927475850270"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <clbs:WarrantsVested
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTEtMTAtMS0xLTIyODU4_faa8189a-a0f4-47ae-94f3-d49ff20a1fb4"
      unitRef="shares">1423774</clbs:WarrantsVested>
    <clbs:WeightedAverageExercisePriceWarrantsExercisable
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTEtMTItMS0xLTIyODU4_527cd8ac-6047-481a-bcea-50b76e4e25f8"
      unitRef="usdPerShare">42.57</clbs:WeightedAverageExercisePriceWarrantsExercisable>
    <clbs:WeightedAverageRemainingContractualTermwarrantsvested
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTEtMTQtMS0xLTIyODU4_df3d396b-fda3-48c6-9c00-5729a0cca3da">P3Y7M17D</clbs:WeightedAverageRemainingContractualTermwarrantsvested>
    <clbs:AggregateIntrinsicValueWarrantsvested
      contextRef="ib12d6f63cd104608b5d9da1ad7e0125b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmYzMzQ4OTNhNDJhYTQzNmY4ZjNmYmFjYzg0NTk4YzVhL3RhYmxlcmFuZ2U6ZjMzNDg5M2E0MmFhNDM2ZjhmM2ZiYWNjODQ1OThjNWFfMTEtMTYtMS0xLTIyODU4_edd693d8-6a60-42de-ab51-fec7c957d137"
      unitRef="usd">0</clbs:AggregateIntrinsicValueWarrantsvested>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNTQ0Mw_038141bf-9894-4687-bf18-874a6f61e0c0">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2022 and 2021, the Company issued restricted stock for services as follows ($ in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:483.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:322.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:4.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number of restricted stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of restricted stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ib889d615bc824253bdc29e6be132de5e_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmFlMjRhMTIyOTBlYzRlNDdiMGY0Zjg0YjUzOGRjOGExL3RhYmxlcmFuZ2U6YWUyNGExMjI5MGVjNGU0N2IwZjRmODRiNTM4ZGM4YTFfMi0yLTEtMS0yMjg1OA_b11f6cd4-52f7-40f6-bb7a-abb2729abdc7"
      unitRef="shares">70740</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i307650e93d90403dbe9bbce2cef38283_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmFlMjRhMTIyOTBlYzRlNDdiMGY0Zjg0YjUzOGRjOGExL3RhYmxlcmFuZ2U6YWUyNGExMjI5MGVjNGU0N2IwZjRmODRiNTM4ZGM4YTFfMi00LTEtMS0yMjg1OA_bd2681f5-b8e1-4035-a8fd-e56b504d6010"
      unitRef="shares">40863</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ib889d615bc824253bdc29e6be132de5e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmFlMjRhMTIyOTBlYzRlNDdiMGY0Zjg0YjUzOGRjOGExL3RhYmxlcmFuZ2U6YWUyNGExMjI5MGVjNGU0N2IwZjRmODRiNTM4ZGM4YTFfMy0yLTEtMS0yMjg1OA_141ccde7-2756-4f6c-bc6e-14a939997363"
      unitRef="usd">973000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i307650e93d90403dbe9bbce2cef38283_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOmFlMjRhMTIyOTBlYzRlNDdiMGY0Zjg0YjUzOGRjOGExL3RhYmxlcmFuZ2U6YWUyNGExMjI5MGVjNGU0N2IwZjRmODRiNTM4ZGM4YTFfMy00LTEtMS0yMjg1OA_9c376dae-b569-4048-9da8-f4be40890d3e"
      unitRef="usd">878000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id9c9001c970d4ccd8a77b7e8f997ca0c_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNDg3OQ_b5b5178b-dced-4384-89e6-c2720bce1e27">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNTQ0Ng_bc0c5bad-c81d-451d-b7cf-234350d57585">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2022 and 2021, the Company issued restricted stock units for services as follows ($ in thousands, except share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:498.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:343.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Number of restricted stock units issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;111,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Value of restricted stock units issued &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i85d58dcae34e4ef8875042573be0b9be_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOjc5ZDg1YTE3ZjZhNDRmYzFhYjIzZGJiOWVlOTUxYzU2L3RhYmxlcmFuZ2U6NzlkODVhMTdmNmE0NGZjMWFiMjNkYmI5ZWU5NTFjNTZfMi0xLTEtMS0yMjg1OA_814af3af-41d8-454e-8c66-fc08c9907c94"
      unitRef="shares">111170</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ib0800b6bb894400cb3122c7e867ed365_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOjc5ZDg1YTE3ZjZhNDRmYzFhYjIzZGJiOWVlOTUxYzU2L3RhYmxlcmFuZ2U6NzlkODVhMTdmNmE0NGZjMWFiMjNkYmI5ZWU5NTFjNTZfMi0zLTEtMS0yMjg1OA_77e3914d-e3a6-45f0-abdb-10427e0aad5b"
      unitRef="shares">30549</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i85d58dcae34e4ef8875042573be0b9be_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOjc5ZDg1YTE3ZjZhNDRmYzFhYjIzZGJiOWVlOTUxYzU2L3RhYmxlcmFuZ2U6NzlkODVhMTdmNmE0NGZjMWFiMjNkYmI5ZWU5NTFjNTZfMy0xLTEtMS0yMjg1OA_cf44c526-41b5-4821-9e0e-f153e3826719"
      unitRef="usd">1386000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ib0800b6bb894400cb3122c7e867ed365_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RhYmxlOjc5ZDg1YTE3ZjZhNDRmYzFhYjIzZGJiOWVlOTUxYzU2L3RhYmxlcmFuZ2U6NzlkODVhMTdmNmE0NGZjMWFiMjNkYmI5ZWU5NTFjNTZfMy0zLTEtMS0yMjg1OA_04d28f48-def0-44d0-8f33-453c11f8bd32"
      unitRef="usd">729000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib889d615bc824253bdc29e6be132de5e_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNTE0Mw_c7a9c3ea-7796-4042-b73c-1913098a5d3d"
      unitRef="usdPerShare">12.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i307650e93d90403dbe9bbce2cef38283_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNTE1MA_d16a1307-957f-437e-adff-01e884c8ce29"
      unitRef="usdPerShare">23.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i85d58dcae34e4ef8875042573be0b9be_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV81OC9mcmFnOjI2YjRiNGIyNzhkMDRiMTliMjRiZTM3NzNkNWUxOGRjL3RleHRyZWdpb246MjZiNGI0YjI3OGQwNGIxOWIyNGJlMzc3M2Q1ZTE4ZGNfNTM3MA_147986da-179b-4876-9be3-2e37ec92fa89">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RleHRyZWdpb246OGMyNTFlYzUyMmIxNGI5NmJiZTRmMDVlMDkxNTU5YzVfMTEzMw_bf029629-c732-41fb-8723-910091ba97ce">Share-Based Compensation&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We utilize share-based compensation in the form of stock options, restricted stock, and restricted stock units.&#160;The following table summarizes the components of share-based compensation expense for the three and nine months ended September&#160;30, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.149%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation cost related to non-vested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at September&#160;30, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized compensation cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected weighted-average period in years of compensation cost to be recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.83&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total fair value of shares vested and the weighted average estimated fair values of shares granted for the nine months ended September&#160;30, 2022 and 2021 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:378.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of shares vested&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average estimated fair value of shares granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Valuation Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options and warrants at the date of grant was estimated using the Black-Scholes option pricing model. The expected volatility is based upon historical volatility of the Company&#x2019;s common stock. The expected term for the options is based upon observation of actual time elapsed between date of grant and exercise of options for all employees. The expected term for the warrants is based upon the contractual term of the warrants.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RleHRyZWdpb246OGMyNTFlYzUyMmIxNGI5NmJiZTRmMDVlMDkxNTU5YzVfMTEzNg_799a332c-d66a-43c9-8a1e-86825c4e4cb0">The following table summarizes the components of share-based compensation expense for the three and nine months ended September&#160;30, 2022 and 2021 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.149%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i34bf47839bf14111b1a9f241df421e60_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjM3NjA4YmYwODIyZDQ1MGU4ZTM4MWQxODBkYmNhM2FhL3RhYmxlcmFuZ2U6Mzc2MDhiZjA4MjJkNDUwZThlMzgxZDE4MGRiY2EzYWFfMi0xLTEtMS0yMjg1OA_d28989e1-1665-4cc2-ae1c-2069b4f6db60"
      unitRef="usd">271000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i01ce7704d3fe44b2b990f2b244335218_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjM3NjA4YmYwODIyZDQ1MGU4ZTM4MWQxODBkYmNhM2FhL3RhYmxlcmFuZ2U6Mzc2MDhiZjA4MjJkNDUwZThlMzgxZDE4MGRiY2EzYWFfMi0zLTEtMS0yMjg1OA_46b257be-a0b9-4fd5-b7ea-aa9d57a81501"
      unitRef="usd">523000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i837f26cb6fd94ea2be192be38846f7d4_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjM3NjA4YmYwODIyZDQ1MGU4ZTM4MWQxODBkYmNhM2FhL3RhYmxlcmFuZ2U6Mzc2MDhiZjA4MjJkNDUwZThlMzgxZDE4MGRiY2EzYWFfMi01LTEtMS0yMjg1OA_5ce95f9d-9997-4eaa-9e93-ffcafb0a5318"
      unitRef="usd">631000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8cdf12952bfe4ee58d1c62f6fc6b922f_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjM3NjA4YmYwODIyZDQ1MGU4ZTM4MWQxODBkYmNhM2FhL3RhYmxlcmFuZ2U6Mzc2MDhiZjA4MjJkNDUwZThlMzgxZDE4MGRiY2EzYWFfMi03LTEtMS0yMjg1OA_c7185105-cb60-4244-83b1-9c1153f40f15"
      unitRef="usd">643000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iddf5f8d32bb9415e8e2d387027b79ab6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjM3NjA4YmYwODIyZDQ1MGU4ZTM4MWQxODBkYmNhM2FhL3RhYmxlcmFuZ2U6Mzc2MDhiZjA4MjJkNDUwZThlMzgxZDE4MGRiY2EzYWFfMy0xLTEtMS0yMjg1OA_410620fe-dd34-4f26-afe4-6c71d47d5ce5"
      unitRef="usd">769000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia363623f86d0452f826ddd27e9bd14ef_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjM3NjA4YmYwODIyZDQ1MGU4ZTM4MWQxODBkYmNhM2FhL3RhYmxlcmFuZ2U6Mzc2MDhiZjA4MjJkNDUwZThlMzgxZDE4MGRiY2EzYWFfMy0zLTEtMS0yMjg1OA_2d097404-beaa-49f2-a95d-360e00545308"
      unitRef="usd">250000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i750cd69f59fa41ab8d1716b4af6483aa_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjM3NjA4YmYwODIyZDQ1MGU4ZTM4MWQxODBkYmNhM2FhL3RhYmxlcmFuZ2U6Mzc2MDhiZjA4MjJkNDUwZThlMzgxZDE4MGRiY2EzYWFfMy01LTEtMS0yMjg1OA_74d4ab29-8844-492c-be75-4755a3c3268f"
      unitRef="usd">1537000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie55321c2f35248728ece5383ad81d1ab_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjM3NjA4YmYwODIyZDQ1MGU4ZTM4MWQxODBkYmNhM2FhL3RhYmxlcmFuZ2U6Mzc2MDhiZjA4MjJkNDUwZThlMzgxZDE4MGRiY2EzYWFfMy03LTEtMS0yMjg1OA_236e67ba-6f1e-418c-9e87-76758524c712"
      unitRef="usd">996000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjM3NjA4YmYwODIyZDQ1MGU4ZTM4MWQxODBkYmNhM2FhL3RhYmxlcmFuZ2U6Mzc2MDhiZjA4MjJkNDUwZThlMzgxZDE4MGRiY2EzYWFfNC0xLTEtMS0yMjg1OA_2ac51f51-b004-45d0-bff7-bbe5bd45f70d"
      unitRef="usd">1040000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i16f1415b407b4131be13205925c1ef6a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjM3NjA4YmYwODIyZDQ1MGU4ZTM4MWQxODBkYmNhM2FhL3RhYmxlcmFuZ2U6Mzc2MDhiZjA4MjJkNDUwZThlMzgxZDE4MGRiY2EzYWFfNC0zLTEtMS0yMjg1OA_79817a8a-2901-44d8-aca1-513866bb9a38"
      unitRef="usd">773000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjM3NjA4YmYwODIyZDQ1MGU4ZTM4MWQxODBkYmNhM2FhL3RhYmxlcmFuZ2U6Mzc2MDhiZjA4MjJkNDUwZThlMzgxZDE4MGRiY2EzYWFfNC01LTEtMS0yMjg1OA_0ec64807-fcd1-41a9-bf33-920513d3e2ba"
      unitRef="usd">2168000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i844ddbae8d6846769b286aad72ab6856_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjM3NjA4YmYwODIyZDQ1MGU4ZTM4MWQxODBkYmNhM2FhL3RhYmxlcmFuZ2U6Mzc2MDhiZjA4MjJkNDUwZThlMzgxZDE4MGRiY2EzYWFfNC03LTEtMS0yMjg1OA_d90e31ae-d8d9-44ad-a7e9-302d9fdc8532"
      unitRef="usd">1639000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RleHRyZWdpb246OGMyNTFlYzUyMmIxNGI5NmJiZTRmMDVlMDkxNTU5YzVfMTE0Mw_b0810825-a773-4879-a06b-beb3a7190ecb">&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation cost related to non-vested awards not yet recognized and the weighted-average periods over which the awards were expected to be recognized at September&#160;30, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.856%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized compensation cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected weighted-average period in years of compensation cost to be recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.83&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i018aef0ebc684655bb91626b836264c8_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOmYxMjJjOThhMGRhMTRhYjA4MGJkZjJkYzI3NmZhYjQ2L3RhYmxlcmFuZ2U6ZjEyMmM5OGEwZGExNGFiMDgwYmRmMmRjMjc2ZmFiNDZfMS0xLTEtMS0yMjg1OA_5aecbf00-25c2-447f-ab58-db4ca33f82c4"
      unitRef="usd">1577000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i9bdf4a4104384257bd274663a65297cc_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOmYxMjJjOThhMGRhMTRhYjA4MGJkZjJkYzI3NmZhYjQ2L3RhYmxlcmFuZ2U6ZjEyMmM5OGEwZGExNGFiMDgwYmRmMmRjMjc2ZmFiNDZfMS0zLTEtMS0yMjg1OA_f206298a-ea05-4aac-8db7-b5705a011299"
      unitRef="usd">168000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="icb6073bf55444dc9adf45d6bd29a32bd_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOmYxMjJjOThhMGRhMTRhYjA4MGJkZjJkYzI3NmZhYjQ2L3RhYmxlcmFuZ2U6ZjEyMmM5OGEwZGExNGFiMDgwYmRmMmRjMjc2ZmFiNDZfMS01LTEtMS0yMjg1OA_1d845f6f-a4cb-46c2-bc7e-bf4601f70daa"
      unitRef="usd">722000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ifb50bb2a566f4b72a4ec8baa84a38a44_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOmYxMjJjOThhMGRhMTRhYjA4MGJkZjJkYzI3NmZhYjQ2L3RhYmxlcmFuZ2U6ZjEyMmM5OGEwZGExNGFiMDgwYmRmMmRjMjc2ZmFiNDZfMi0xLTEtMS0yMjg1OA_c9509799-d45e-4416-b268-9bbc5fcbaed1">P1Y7M28D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i85d58dcae34e4ef8875042573be0b9be_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOmYxMjJjOThhMGRhMTRhYjA4MGJkZjJkYzI3NmZhYjQ2L3RhYmxlcmFuZ2U6ZjEyMmM5OGEwZGExNGFiMDgwYmRmMmRjMjc2ZmFiNDZfMi0zLTEtMS0yMjg1OA_9ae274e4-a134-43e9-bee6-e0594701b653">P2Y1M28D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ib889d615bc824253bdc29e6be132de5e_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOmYxMjJjOThhMGRhMTRhYjA4MGJkZjJkYzI3NmZhYjQ2L3RhYmxlcmFuZ2U6ZjEyMmM5OGEwZGExNGFiMDgwYmRmMmRjMjc2ZmFiNDZfMi01LTEtMS0yMjg1OA_798d9c9e-7cc7-49da-b1cf-035c19d72609">P1Y9M29D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RleHRyZWdpb246OGMyNTFlYzUyMmIxNGI5NmJiZTRmMDVlMDkxNTU5YzVfMTE0NQ_2dca7413-c43d-4cf5-8f86-2d002c360499">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total fair value of shares vested and the weighted average estimated fair values of shares granted for the nine months ended September&#160;30, 2022 and 2021 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:378.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of shares vested&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average estimated fair value of shares granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="ifb50bb2a566f4b72a4ec8baa84a38a44_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjZkZWIwYzc2ZjMwNzQ1NzQ5NjBjOGNiZjFjZDQ2YWMyL3RhYmxlcmFuZ2U6NmRlYjBjNzZmMzA3NDU3NDk2MGM4Y2JmMWNkNDZhYzJfMy0xLTEtMS0yMjg1OA_928e9b9e-0fe3-4149-84a5-8d1fa8dcd9df"
      unitRef="usd">853000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i83d716d023604513b9d5e44c712a5656_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjZkZWIwYzc2ZjMwNzQ1NzQ5NjBjOGNiZjFjZDQ2YWMyL3RhYmxlcmFuZ2U6NmRlYjBjNzZmMzA3NDU3NDk2MGM4Y2JmMWNkNDZhYzJfMy0zLTEtMS0yMjg1OA_69f3a100-d366-4689-a780-97a6c3eba375"
      unitRef="usd">757000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ifb50bb2a566f4b72a4ec8baa84a38a44_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjZkZWIwYzc2ZjMwNzQ1NzQ5NjBjOGNiZjFjZDQ2YWMyL3RhYmxlcmFuZ2U6NmRlYjBjNzZmMzA3NDU3NDk2MGM4Y2JmMWNkNDZhYzJfNC0xLTEtMS0yMjg1OA_76396df9-a13e-477a-8459-6db6f87a5777"
      unitRef="usdPerShare">1.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i83d716d023604513b9d5e44c712a5656_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82NC9mcmFnOjhjMjUxZWM1MjJiMTRiOTZiYmU0ZjA1ZTA5MTU1OWM1L3RhYmxlOjZkZWIwYzc2ZjMwNzQ1NzQ5NjBjOGNiZjFjZDQ2YWMyL3RhYmxlcmFuZ2U6NmRlYjBjNzZmMzA3NDU3NDk2MGM4Y2JmMWNkNDZhYzJfNC0zLTEtMS0yMjg1OA_92bf0cb0-fb51-4bd4-873a-1de34121a7e2"
      unitRef="usdPerShare">13.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfNDI2OA_c4e71926-bc9a-49c1-9c91-2e6ea3093c8c">Income Taxes&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In assessing the realizability of deferred tax assets, including the net operating loss carryforwards (&#x201c;NOLs&#x201d;), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets.  Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020, the Company had approximately $281&#160;million and $264&#160;million, respectively, of federal NOLs available to offset future taxable income expiring from 2030 through 2036.&#160;The Company performed an analysis and determined that it had an ownership change of greater than 50% over a 3-year testing period on January 25, 2021.  As a result, $169&#160;million of the $281&#160;million of federal NOLs will expire unutilized.  The Company wrote off that portion of the deferred tax asset and reduced the corresponding valuation allowance resulting in $112&#160;million of remaining federal NOL.  The write off of the deferred tax asset and the corresponding reduction in valuation allowance has no impact to the balance sheet or income statement. Losses incurred before the ownership change on January 25, 2021 will be subject to an annual limitation of $173 thousand under Internal Revenue Code Section 382, while losses incurred after January 25, 2021 will not be subject to limitations. The Company may be able to utilize additional NOLs of approximately $1.1&#160;million per year for the first five years after this ownership change as a result of the application of the Net Unrealized Built-in Gain rules.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020, the Company had state NOLs available in New Jersey of $97&#160;million and $99&#160;million, respectively, California of $70&#160;million and $70&#160;million, respectively, and New York City of $13&#160;million and $13&#160;million, respectively, to offset future taxable income expiring from 2031 through 2041. In accordance with Section 382 of the Internal Revenue code, the usage of the Company&#x2019;s NOLs would be limited given the change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the FASB&#x2019;s provisions for uncertain tax positions. The Company utilizes the two-step process to determine the amount of recognized tax benefit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties associated with uncertain tax positions as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For years prior to 2018, the federal statute of limitations is closed for assessing tax. The Company&#x2019;s state tax returns remain open to examination for a period of three to four years from date of filing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, the Company received preliminary approval from the New Jersey Economic Development Authority (&#x201c;NJEDA&#x201d;) to participate in the Technology Business Tax Certificate Transfer Program (the &#x201c;Program&#x201d;). The Program permits qualified companies to sell a percentage of their New Jersey net operating losses (&#x201c;NJ NOLs&#x201d;) to unrelated profitable corporations. On February 22, 2022, the Company received final approval from NJEDA to sell $2.5&#160;million of its NJ NOLs related tax benefits (&#x201c;NJ NOL Tax Benefits&#x201d;), which was subsequently sold to a qualifying and approved buyer pursuant to the Program for net proceeds of $2.3&#160;million. The gross proceeds of $2.5&#160;million have been recorded as a benefit from income taxes and the loss on sale of NJ NOLs of $0.1&#160;million recorded in other income (expense) in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <clbs:OperatingLossCarryforwardsBeforeWriteDown
      contextRef="if68b9c4980394919b2d4601761b01f4d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfNTQw_4dc79b93-2130-419f-a227-b34d66dab4d3"
      unitRef="usd">281000000</clbs:OperatingLossCarryforwardsBeforeWriteDown>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i31c432312f38454b845861eb8d0891a5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfNTQ3_62244b91-bff7-4005-a27b-c3a95a60e3da"
      unitRef="usd">264000000</us-gaap:OperatingLossCarryforwards>
    <clbs:OperatingLossCarryforwardsSetToExpireWrittenDown
      contextRef="if68b9c4980394919b2d4601761b01f4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfODIy_b293a518-9e51-478b-8bef-2919c9e0ff9a"
      unitRef="usd">169000000</clbs:OperatingLossCarryforwardsSetToExpireWrittenDown>
    <clbs:OperatingLossCarryforwardsBeforeWriteDown
      contextRef="if68b9c4980394919b2d4601761b01f4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfODMy_f49e955b-c6d2-4896-8590-98028bc0409a"
      unitRef="usd">281000000</clbs:OperatingLossCarryforwardsBeforeWriteDown>
    <us-gaap:OperatingLossCarryforwards
      contextRef="if68b9c4980394919b2d4601761b01f4d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfMTAwMA_ea156777-c158-4352-a361-b18751790a82"
      unitRef="usd">112000000</us-gaap:OperatingLossCarryforwards>
    <clbs:OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain
      contextRef="ib97be91eba48467897085df19e17a272_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfMTQ4NA_5bf07f1c-65e5-449a-8a66-72f523d3dc4b"
      unitRef="usd">1100000</clbs:OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i1b434d8601de4e05b998640da3d91bcc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfMTY5NQ_c0a47c9c-85c3-4a9b-ae73-cb403806776c"
      unitRef="usd">97000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i02b1d9ded41146128c64adca8ae00256_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfMTcwMg_90d14897-e168-43a3-ba34-da499bd2b8a1"
      unitRef="usd">99000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i93a7f18008c44e9997baaba9c4bcc603_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfMTczNA_62788509-81ed-4e69-9e9a-4ec930554f9e"
      unitRef="usd">70000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ic221f3b9f147476abbbaa83788e46406_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfMTc0MQ_c9b7f507-08f7-4722-a167-c7c56cf6c29d"
      unitRef="usd">70000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i68d905e37c484eff8d11dc6b86a7e0f6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfMTc4MA_1abcb5ce-5a76-4da1-a779-11362b006c3a"
      unitRef="usd">13000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i579b018c55b04e3c984da0273c1ef442_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfMTc4Nw_9737ae57-9cff-485d-b657-1ca58fb94d01"
      unitRef="usd">13000000</us-gaap:OperatingLossCarryforwards>
    <clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross
      contextRef="if463b298d932482a86bb1787b18f2ed0_D20220222-20220222"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfMzg5OQ_251bab9a-c782-4b3d-997c-14b66ccf5a7c"
      unitRef="usd">2500000</clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross>
    <clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgram
      contextRef="if463b298d932482a86bb1787b18f2ed0_D20220222-20220222"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfNDA3MA_56bafe88-386b-492f-9dcf-7bf60890e7a8"
      unitRef="usd">2300000</clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgram>
    <clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross
      contextRef="if463b298d932482a86bb1787b18f2ed0_D20220222-20220222"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfNDA5Ng_5282f25a-5f71-454b-8f26-1730b261c001"
      unitRef="usd">2500000</clbs:ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross>
    <clbs:LossOnSaleOfNetOperatingLosses
      contextRef="if463b298d932482a86bb1787b18f2ed0_D20220222-20220222"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV82Ny9mcmFnOjJjNmE2ODMxYTM2NDQ1ZThhYTRhOTQyZGI1MzI5ZDllL3RleHRyZWdpb246MmM2YTY4MzFhMzY0NDVlOGFhNGE5NDJkYjUzMjlkOWVfNDE4NA_fde4034e-2013-4603-a33e-3bfa0e38a2ab"
      unitRef="usd">100000</clbs:LossOnSaleOfNetOperatingLosses>
    <clbs:ResearchAndDevelopmentTaxIncentiveTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDYyL2ZyYWc6ZmM4MGE5Mjk4ODYxNGEwNmIyYTJkMjEyYjM2YzRhNGEvdGV4dHJlZ2lvbjpmYzgwYTkyOTg4NjE0YTA2YjJhMmQyMTJiMzZjNGE0YV81NDk3NTU4MTM5NzM0_0ad0953f-6a2d-44c1-9f35-c9cd99850311">Australia Research and Development Tax IncentiveThe Company&#x2019;s Australian subsidiary, which conducts core research and development activities, is eligible to receive a 43.5% refundable tax incentive for qualified research and development activities. As of the nine months ended September&#160;30, 2022, $0.4&#160;million was recorded as an income tax incentive receivable in the consolidated balance sheets, as the Company determined that the expenses met the eligibility criteria and the amounts claimed are expected to be received shortly after the related tax returns are filed.</clbs:ResearchAndDevelopmentTaxIncentiveTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDYyL2ZyYWc6ZmM4MGE5Mjk4ODYxNGEwNmIyYTJkMjEyYjM2YzRhNGEvdGV4dHJlZ2lvbjpmYzgwYTkyOTg4NjE0YTA2YjJhMmQyMTJiMzZjNGE0YV81NDk3NTU4MTM5NzM2_c7ea679a-62e7-4ca2-b8d4-0a463fb27518"
      unitRef="number">0.435</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDYyL2ZyYWc6ZmM4MGE5Mjk4ODYxNGEwNmIyYTJkMjEyYjM2YzRhNGEvdGV4dHJlZ2lvbjpmYzgwYTkyOTg4NjE0YTA2YjJhMmQyMTJiMzZjNGE0YV81NDk3NTU4MTM5NzQz_1e329347-26f4-499b-93a2-db3b96ec35c5"
      unitRef="usd">400000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV83MC9mcmFnOjljNjBkMTM0Nzg4MTQ1ZjNhNzNkY2M1MmZjM2U5OTg2L3RleHRyZWdpb246OWM2MGQxMzQ3ODgxNDVmM2E3M2RjYzUyZmMzZTk5ODZfNDM3_e5153877-baaa-4f98-9b7b-fa8e83ef7497">Contingencies&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on the Company's financial condition or operating results. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, Cend received a written threat of litigation on behalf of a Chinese entity called Lingmed Limited (&#x201c;Lingmed&#x201d;) claiming Lingmed was entitled to a success fee based on Cend&#x2019;s Collaboration and License Agreement with Qilu Pharmaceuticals. Cend responded by denying that Lingmed is entitled to a success fee under the terms of their agreement. In May 2022, Cend was served with a complaint filed by Lingmed in the San Diego County Superior Court, alleging claims for breach of contract, fraud and declaratory relief. Cend&#x2019;s response to the complaint was filed on June 6, 2022. Lingmed filed an &lt;/span&gt;&lt;/div&gt;answer to Cend&#x2019;s response on July 11, 2022. The court held a case management conference on October 7, 2022, which resulted in a continuance until December 16, 2022.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5NTE3_7a66f858-fc06-42c5-be40-cf44de2d5123">License Agreements&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sanford Burnham Prebys&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2015, Cend entered into a license agreement with Sanford Burnham Prebys (&#x201c;SBP&#x201d;) under which Cend was granted an exclusive, worldwide, royalty-bearing license to certain patent rights and know-how controlled by SBP related to the development of CEND-1. At the time the license agreement was entered into, Cend&#x2019;s founding shareholder, now a Lisata board member, was an executive at SBP. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. As consideration for the license, Cend issued a total of 382,030 shares of common stock, as adjusted for the Reverse Stock Split and Exchange Ratio. The Company is required to pay an annual license maintenance fee of $10,000 increasing to $20,000 on year seven of the agreement. The Company could also be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $10.6&#160;million. The Company has also agreed to pay SBP royalties of 4% of net sales of products sold by the Company, or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP 25% of any sublicensing income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, Cend entered into a license agreement with SBP under which Cend was granted an exclusive, royalty-bearing license to certain patent rights and know-how controlled by SBP. The agreement provides Cend with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. The Company is required to pay an annual license maintenance fee of $20,000, increasing to $30,000 on year four of the agreement. Further, the Company could be required to make milestone payments to SBP upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $23.2&#160;million. The Company is obligated to pay SBP royalties of 4% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay SBP varying sublicense fees, ranging from 10% to 25%, dependent on when the related milestones are reached. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreements will expire upon the later of (i) the final abandonment of all pending patent applications within the licensed patents or (ii) the expiration of the last to expire patent within the licensed patents. The agreements may be terminated in their entirety by the Company at any time by giving SBP sixty days&#x2019; prior written notice. The agreements may be terminated in their entirety by SBP if the Company, at any time, defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice. The agreements may be terminated in their entirety by SBP or the Company (i) in the event of an uncured material breach by the other party, or (ii) in the event the other party (a) files for, or is involuntarily petitioned with, bankruptcy (other than dissolution or winding up for the purposes of reconstruction or amalgamation), (b) makes an assignment of all or substantially all of its assets for the benefit of creditors, or (c) has a receiver or trustee is appointed and is unable to secure a dismissal, stay or other suspension of such proceedings within thirty days. Upon termination of the agreements for any reason, all rights and obligations of the Company with respect to the patents and patent applications shall terminate and revert to SBP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SBP owned 382,030 shares of the Company&#x2019;s common stock as of September 30, 2022 and is a related party. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;University of California at San Diego&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, Cend entered into a license agreement with the University of California at San Diego (&#x201c;UCSD&#x201d;) under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of nano-particles to modulate immune response. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell and otherwise exploit the patent rights. The Company could be required to make milestone payments to UCSD upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $1.2&#160;million. The Company has also agreed to pay UCSD royalties of 1.5% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company agreed to pay UCSD varying sublicense fees, ranging from 10% to 20%, dependent on when the related milestones are reached. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement will expire upon the expiration of the longest-lived patent rights. The agreement may be terminated in its entirety by the Company at any time by giving UCSD ninety days&#x2019; prior written notice. The agreement may be terminated in its entirety by UCSD if the Company, at any time, (i) fails to perform or violates any term of the agreement and fails to cure the default within sixty days. Upon termination of the agreement for any reason, UCSD may terminate a sublicensee but will allow &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company to assign any sublicenses to UCSD provided a) that the sublicensee is in good standing upon termination of the agreement with the Company; and b) the sublicensee is not currently involved in litigation as an adverse party to UCSD.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Massachusetts Institute of Technology&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, Cend entered into a license agreement with the Massachusetts Institute of Technology ("MIT") under which Cend was granted an exclusive, royalty-bearing license to certain patent rights related to the development of tissue specific delivery of interfering RNA. The agreement provides the Company with the rights to grant and authorize sublicenses to use, sell, and otherwise exploit the patent rights. The Company is required to pay an annual license maintenance fee of $20,000, increasing to $25,000 for year two and three of the agreement, increasing to $50,000 on year four of the agreement and thereafter until the first commercial sale, and increasing to $150,000 each year of the agreement after the first sale. Further, the Company could be required to make milestone payments to MIT upon completion of certain regulatory and commercial milestones. The aggregate potential milestone payments are approximately $5.0&#160;million. The Company has also agreed to pay MIT royalties of 2% of net sales of products sold by the Company or through a sublicense, subject to certain reductions. Additionally, the Company is obligated to pay MIT varying sublicense fees, ranging from 3% to 20%, dependent on when the related milestones are reached. In connection with the close of the Merger,, the Company was required to pay MIT a change of control fee of $0.3&#160;million, which is included in accrued liabilities within the condensed consolidated balance sheets as of September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement will expire upon the expiration or abandonment of all valid claims. The agreement may be terminated in its entirety by the Company at any time by giving MIT six months prior written notice. The agreement may be terminated in its entirety by MIT if the Company, at any time, (i) defaults in the payment of any sum when due and fails to make such payment within thirty days after receipt of written notice, or (ii) commits a material breach of its obligations under the agreement (aside from item (i)) and fails to cure that breach within sixty days after receipt of written notice. Upon termination of the agreement for any reason, the rights and licenses granted to the Company shall terminate and revert to MIT. Upon termination of the agreement for any reason, MIT may terminate a sublicensee but will allow the Company to assign any sublicenses to MIT provided that the sublicensee is in good standing upon termination of the agreement with the Company.&lt;/span&gt;&lt;/div&gt;Research Collaboration and License Agreement&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Exclusive License and Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, Cend entered into an Exclusive License and Collaboration Agreement (the &#x201c;Qilu Agreement&#x201d;) in which Cend granted an exclusive license to Qilu for the development and commercialization of CEND-1 in the Territory (defined as the Greater Area of China including China, Macau, Hong Kong, and Taiwan). Under the terms of the agreement, Qilu is solely responsible for the development of CEND-1 in its Territory. In consideration for the license, Qilu made an upfront payment of $10&#160;million to Cend, which was recognized as revenue by Cend prior to the Merger. In addition, Cend received and recognized as revenue a $5&#160;million development milestone prior to the Merger. The Company is eligible to receive additional developmental and commercial milestone payments up to $100&#160;million and $125&#160;million, respectively, tiered royalties on net sales ranging from 10% to 15%, and tiered sublicensing revenues ranging from 12% to 35%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless terminated early, the Qilu Agreement will continue in effect until the expiration of all Qilu payment obligations. Either party may terminate the Qilu Agreement if an undisputed material breach by the other party is not cured within a defined period of time, or upon notice for insolvency-related events of the other party that are not discharged within a defined time period. Qilu may terminate the Qilu Agreement in its entirety, at any time with at least sixty days written notice. All right and obligations of Qilu with respect to such licensed patents and patent applications would terminate.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <clbs:SharesIssuedUnderLicenseAgreement
      contextRef="i54c1f41cac654131b84226d73d9d67db_I20151231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5MjY4_99350bf7-8db6-4d9b-a961-ffc239b97f5f"
      unitRef="shares">382030</clbs:SharesIssuedUnderLicenseAgreement>
    <clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee
      contextRef="i54c1f41cac654131b84226d73d9d67db_I20151231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5Mjc3_83e74a55-ca27-4459-b0b4-e1c9ebbda608"
      unitRef="usd">10000000</clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee>
    <clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven
      contextRef="i54c1f41cac654131b84226d73d9d67db_I20151231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5Mjg5_589db692-3496-4a2c-afdf-09233bf08976"
      unitRef="usd">20000000</clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven>
    <clbs:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct
      contextRef="i54c1f41cac654131b84226d73d9d67db_I20151231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5MzAx_a38a8596-88fd-4019-8d0e-49772cc84de8"
      unitRef="usd">10600000</clbs:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct>
    <clbs:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales
      contextRef="i54c1f41cac654131b84226d73d9d67db_I20151231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5MzE2_781c8402-2c77-459f-9f00-e2290e2d4383"
      unitRef="number">0.04</clbs:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales>
    <clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees
      contextRef="i54c1f41cac654131b84226d73d9d67db_I20151231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5MzIw_ef1fce96-2845-433c-a275-6e43d915ee35"
      unitRef="usd">0.25</clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees>
    <clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee
      contextRef="i155f1b104580445ca4ca140a0f0d9e28_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5MzI1_f832a56b-0ced-4126-a343-723df6820865"
      unitRef="usd">20000000</clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee>
    <clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour
      contextRef="i155f1b104580445ca4ca140a0f0d9e28_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5MzM3_f93597fa-a1ce-4595-8754-ee5424eb3c8c"
      unitRef="usd">30000000</clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour>
    <clbs:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct
      contextRef="i155f1b104580445ca4ca140a0f0d9e28_I20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5MzQ5_abe0b9d0-6469-4e1f-b90c-179aa2a0699a"
      unitRef="usd">23200000</clbs:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct>
    <clbs:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales
      contextRef="i155f1b104580445ca4ca140a0f0d9e28_I20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5MzY0_0d9aa64f-940e-4bf2-a9ec-9164e86c4e7f"
      unitRef="number">0.04</clbs:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales>
    <clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees
      contextRef="i3fd21aa0eb7e469692c04143d4a0aaa5_I20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5MzY4_dd1c7096-0295-4815-bc8d-a827442090f4"
      unitRef="usd">0.10</clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees>
    <clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees
      contextRef="i568bd639252d47638984e18f0836cd66_I20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5Mzcz_69e68bc9-7f7e-47dd-b771-a23afabfcb5a"
      unitRef="usd">0.25</clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees>
    <clbs:SharesHeldByThirdParty
      contextRef="ie7a582d9c51846c999a8aae8d00b9b3f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5Mzc4_a4fbb587-6c41-45ff-a44d-9d3a8831ff32"
      unitRef="shares">382030</clbs:SharesHeldByThirdParty>
    <clbs:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct
      contextRef="ie0f3bab25f7348bdbffea94e657798a0_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5Mzk2_19a7bd05-6f9b-4de5-90dd-487b90c0b22f"
      unitRef="usd">1200000</clbs:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct>
    <clbs:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales
      contextRef="ie0f3bab25f7348bdbffea94e657798a0_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5NDEw_4f85a8bf-7159-4c6a-9cb3-8f7b1499e4eb"
      unitRef="number">0.015</clbs:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales>
    <clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees
      contextRef="if1424658bffc4343bd5497ca9d561930_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5NDE2_63c0d9c6-0473-4174-a272-eec7f1937c05"
      unitRef="usd">0.10</clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees>
    <clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees
      contextRef="ifa3e87e793164479a26fb0338f9209f6_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5NDIx_975761c4-4a3c-4c51-80b9-641c83e2daa5"
      unitRef="usd">0.20</clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees>
    <clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee
      contextRef="ieb7b6c7937914fcea021631924808998_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5NDI2_c2062c96-6337-4d2f-85da-7358e6aa8145"
      unitRef="usd">20000000</clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee>
    <clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree
      contextRef="ieb7b6c7937914fcea021631924808998_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5NDM1_24495cfd-b731-443c-b048-ed2475f15482"
      unitRef="usd">25000000</clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree>
    <clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour
      contextRef="ieb7b6c7937914fcea021631924808998_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5NTM2_ffba508d-558e-4a12-8331-006fa9eca697"
      unitRef="usd">50000000</clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour>
    <clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale
      contextRef="i0050d762a7e64fa192ac048bca1f9775_I20211031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5NDYy_2c047468-3818-4bad-a95d-e910f60b75d7"
      unitRef="usd">150000000</clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale>
    <clbs:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct
      contextRef="ieb7b6c7937914fcea021631924808998_I20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5NDc1_9c5fd571-afd9-4c87-bf4d-598671d617f3"
      unitRef="usd">5000000</clbs:CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct>
    <clbs:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales
      contextRef="ieb7b6c7937914fcea021631924808998_I20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5NDg5_8168a6e4-ece2-40ee-aa86-f73dd392eec4"
      unitRef="number">0.02</clbs:CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales>
    <clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees
      contextRef="ib023bcf774d145f5834f6ee5051da753_I20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5NDkz_3f2ba4c1-36c5-4c1b-b90d-fc28dfe35497"
      unitRef="usd">0.03</clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees>
    <clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees
      contextRef="i2362238e05b541a487b62ee42291726f_I20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5NTIz_263ebaf1-d3e1-46b2-a4bb-517fb9470a8b"
      unitRef="usd">0.20</clbs:CollaborativeArrangementRightsAndObligationsSublicensingFees>
    <clbs:CollaborativeArrangementRightsAndObligationsChangeOfControlFee
      contextRef="ieb7b6c7937914fcea021631924808998_I20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDE0L2ZyYWc6ZTkyYzk1ODUzZjNmNGJlYjk5NzQwMmY2ZDBjOWMxMzIvdGV4dHJlZ2lvbjplOTJjOTU4NTNmM2Y0YmViOTk3NDAyZjZkMGM5YzEzMl81NDk3NTU4MTU5NTAy_3da26bb5-07d5-4e33-bb7a-3dc5feaa52c5"
      unitRef="usd">300000</clbs:CollaborativeArrangementRightsAndObligationsChangeOfControlFee>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ic23e1c2433b54fffa2ed10e25463b457_I20210228"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDM4L2ZyYWc6MTg4OGEwOGI5Nzg4NGU4OTk4MzQxN2FmYzIyMjA4YWMvdGV4dHJlZ2lvbjoxODg4YTA4Yjk3ODg0ZTg5OTgzNDE3YWZjMjIyMDhhY181NDk3NTU4MTUwOTMy_17d81b93-7f32-4b28-b904-f2d566781a1e"
      unitRef="usd">10000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="iab8db93a425c431683da42085f6e40e9_D20220914-20220914"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDM4L2ZyYWc6MTg4OGEwOGI5Nzg4NGU4OTk4MzQxN2FmYzIyMjA4YWMvdGV4dHJlZ2lvbjoxODg4YTA4Yjk3ODg0ZTg5OTgzNDE3YWZjMjIyMDhhY181NDk3NTU4MTUwOTkz_68476783-a538-417a-bfa7-896b4f732367"
      unitRef="usd">5000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <clbs:RevenueRemainingPerformanceObligationVariableConsiderationAmount
      contextRef="i00de76018f10443a96daffcfc7a36a9f_I20210228"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDM4L2ZyYWc6MTg4OGEwOGI5Nzg4NGU4OTk4MzQxN2FmYzIyMjA4YWMvdGV4dHJlZ2lvbjoxODg4YTA4Yjk3ODg0ZTg5OTgzNDE3YWZjMjIyMDhhY181NDk3NTU4MTUwOTQ1_b2a2f9be-fd5b-4da5-b9ef-ca623a5164d4"
      unitRef="usd">100000000</clbs:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <clbs:RevenueRemainingPerformanceObligationVariableConsiderationAmount
      contextRef="i51afcddd58ef4d74a4eecfadef3991a2_I20210228"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDM4L2ZyYWc6MTg4OGEwOGI5Nzg4NGU4OTk4MzQxN2FmYzIyMjA4YWMvdGV4dHJlZ2lvbjoxODg4YTA4Yjk3ODg0ZTg5OTgzNDE3YWZjMjIyMDhhY181NDk3NTU4MTUwOTU5_367ffe3f-ea87-4576-a690-fa8bf01d6e14"
      unitRef="usd">125000000</clbs:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <clbs:RevenuePerformanceObligationPercentageOfNetSale
      contextRef="i00de76018f10443a96daffcfc7a36a9f_I20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDM4L2ZyYWc6MTg4OGEwOGI5Nzg4NGU4OTk4MzQxN2FmYzIyMjA4YWMvdGV4dHJlZ2lvbjoxODg4YTA4Yjk3ODg0ZTg5OTgzNDE3YWZjMjIyMDhhY181NDk3NTU4MTUwOTgz_4401b3b1-0c77-4353-9634-31a4909fd9a2"
      unitRef="number">0.10</clbs:RevenuePerformanceObligationPercentageOfNetSale>
    <clbs:RevenuePerformanceObligationPercentageOfNetSale
      contextRef="i51afcddd58ef4d74a4eecfadef3991a2_I20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDM4L2ZyYWc6MTg4OGEwOGI5Nzg4NGU4OTk4MzQxN2FmYzIyMjA4YWMvdGV4dHJlZ2lvbjoxODg4YTA4Yjk3ODg0ZTg5OTgzNDE3YWZjMjIyMDhhY181NDk3NTU4MTUwOTg4_c5eec827-54d1-42d2-9d8b-c31f68edbc99"
      unitRef="number">0.15</clbs:RevenuePerformanceObligationPercentageOfNetSale>
    <clbs:RevenuePerformanceObligationPercentageOfSublicensingRevenues
      contextRef="i00de76018f10443a96daffcfc7a36a9f_I20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDM4L2ZyYWc6MTg4OGEwOGI5Nzg4NGU4OTk4MzQxN2FmYzIyMjA4YWMvdGV4dHJlZ2lvbjoxODg4YTA4Yjk3ODg0ZTg5OTgzNDE3YWZjMjIyMDhhY181NDk3NTU4MTUwOTcz_271c4c48-ed1a-42e7-ad09-826eec0589ac"
      unitRef="number">0.12</clbs:RevenuePerformanceObligationPercentageOfSublicensingRevenues>
    <clbs:RevenuePerformanceObligationPercentageOfSublicensingRevenues
      contextRef="i51afcddd58ef4d74a4eecfadef3991a2_I20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmUxMDg0ZTNmMWZjNzRlMjFiMDZkZGNjMTZjZjRlYzY5L3NlYzplMTA4NGUzZjFmYzc0ZTIxYjA2ZGRjYzE2Y2Y0ZWM2OV8xMDM4L2ZyYWc6MTg4OGEwOGI5Nzg4NGU4OTk4MzQxN2FmYzIyMjA4YWMvdGV4dHJlZ2lvbjoxODg4YTA4Yjk3ODg0ZTg5OTgzNDE3YWZjMjIyMDhhY181NDk3NTU4MTUwOTc4_0d422acf-0445-4a68-b757-5f28aa0138c1"
      unitRef="number">0.35</clbs:RevenuePerformanceObligationPercentageOfSublicensingRevenues>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>62
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
MF8%J5;)XF-@4!@  Z!\  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6RU
MF6MSXC84AO^*AG8Z[4R(;1D(V1)FB)-T:;,L&]AVVDX_"%N )[;E2C(D_[Y'
M-M@DE07C6;XDOIT7/;J^.AIL&7\6:THE>HFC1-RTUE*F'RQ+^&L:$W')4IK
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M2Z3N:4A?,L(EY=$K>J(IXU*'9Y:2/--5BF>,:HC7*_%ZI^%-*0]9H$8A@GE
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M[OKX7675I%83+=9E%[80&GNZ<IAB7P_2&.#[I1!Z-S$.FG\*X[\!4$L#!!0
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M%$K+H#0"I5$HC:%H<N/I'#O7;MF]<(ZDG3JXE4 ].U?WV;2.%)DPA=(R*(U
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M)%!541#Y=$%SL3V;P,GSC;_9W4;;&[/E:4GNZ#757\LK:3[-=EXR5E"NF.!
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M33 ^JS 9"*?E.7J9Y^5!_IE2E5F$+O_F^%:8N)06Z;U7>A_6O?V>QR:)POD
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M:)-:H1%JUL@;,PEBRT64I9NJ?9$G4/1RB3HY/OAO?NP,::1 Q#\YIG,_"9I
M>UP?_"LIX/KR_.N'WC?(C2H==V3Q<M\8U=^F=NE<)YDL>CJ'LQT2VRU:"0ER
M>V6G1W+6E^I(NB,"/O/X97;?K;]N"M."*-\LGKZA(- R19IL9;.)/.(=\#A
MZ#UC9^,R9#39&WH%OA;*-LV3@FJS,VL.@I K@3)IF11]Z=67(8./&E)B9PL,
MXUL1E->6?(L_79:[%]0DBPR>-8E-NT,F6*3F>9UZ/\*EU/0-$#IJC7CO?'SC
MXFN;;NDHD;LQVA,00$U>GAL\/A$P,V&9QTE/DNEZ+[\F]_GY$)WV]F@C7QY<
MHVOBC1K4X*J6EY;DP/O"SS?_DX(MWU;EUTBXLUA.-,--7:T%#V?\,Z:7Q!H=
M1%1MLX;<_HN4GI<11@]Q8D.A+ -(.R4I'1HY+242U@8%I>2N83((=?2*P0#6
MQPO0-!E/@W"^@!QS'+,6QRRC?!S'<7S3V0I2ENY2TQLUJ'+Z5 ]Q/."QPP-K
MNH03C0JAK]C.X4A(\FK E\F-P[- 8X\$],AS'*O802:P/L_^ GO4("AH8&3@
MX]OF&4@?RW%A4/G=YJ%_GI68T3V-POJBKWE$01%IR\<E0)%>^1?I)!GEESLZ
MO_?E2BQ +US";% /<9#,:?H!N8N:HW&3/Y-AHZ/1/E]ZCP-QN%>Q=6V<;2@,
M5V\?MB8"6B->E?NH^,Z$]"=YDAICG(!ZH\%LFEBS,/X?S*TGJ99?@ZJR4@L.
MH*6%N?I4(-%(]4'Y':(^RIF4T.7)6XNBD:\EPY324AY-7K'UVLWDVB!]R:^J
M,00^O4F8WYI8+F%,\DH!U?!<@J0W[89[!Z.Z#!Y1TP5\D7,QYH5P6"295:/.
M^:YUL4'!$V?X+/'/.Y+HX,-%6F3#,/"XH!>)O!ANNN).J2D]"QG0!6JZ:/!)
MG?4$#((?=?7Y?]2[#@%!3(Y?+UQ&XJ;7*2?8EQR<MVDFQS_@A%^C(/9I3:AT
M!EM&K.7H.;[W)[/AV*00/$QW&!>ZXA)87NZ6=PAW5!7CBF)Z] #(0YN>7K'<
M.A.)BL8F\A2_()-"TOU(>S:JH;8;AG@D?Q&%ODMW#R3">_+AFT%#J<#>'[?-
M>^4S*6QDTF;QQ0WT]S)>S.\,FA3NZ6=OUA'XQCDTE=Y']@O\7L88POP^]GF'
MN][T/1J]L\T37GHSG:-%T\GKV_G;_/+[F;SS/3PN;\ZCJ5[1%8#*++'T^/#Y
MTSV!IM*'SK7\!OC"=9VK^<\U3R/H ?Q.U7[Z0 ?D_R7 ZW\#4$L#!!0    (
M )F!:E72+-S[-!,  !HW   8    >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
MM5MK<QRW<OTK4[PN6ZI:+BE*OG;TJJ)D^T955H41[=P/J7S SF!W(<X,Y@(8
M4NM?G].-!@:S#\I);KY(N[-X-+I/GWY@^/K!NCN_U3I47[JV]V_.MB$,+R\N
M?+W5G?)+.^@>OZRMZU3 5[>Y\(/3JN%)77MQ=7GYUXM.F?[L[6M^=N/>OK9C
M:$VO;USEQZY3;O=.M_;AS=FSL_3@D]EL SVX>/MZ4!M]J\/OPXW#MXN\2F,Z
MW7MC^\KI]9NSZV<OW[V@\3S@/XQ^\,7GBDZRLO:.OGQHWIQ=DD"ZU76@%13^
MN]?O==O20A#C'[+F6=Z2)I:?T^J_\-EQEI7R^KUM_VZ:L'US]N-9U>BU&MOP
MR3[\JY;S?$_KU;;U_&_U$,>^>'Y6U:,/MI/)D* S??Q??1$]%!-^O#PQX4HF
M7+'<<2.6\B<5U-O7SCY4CD9C-?K 1^79$,[T9)3;X/"KP;SP]C8:H[+KZM9L
M>K,VM>I#=5W7=NR#Z3?5C6U-;;1_?1&P'\VZJ&7M=W'MJQ-K_TOUT?9AZZN?
M^T8W\_D7D#,+>Y6$?7?UZ(*W>EA6SR\7U=7EU=4CZSW/AW_.ZST_L=Z14U;_
M>;WRP0$L_W7LP'&]%\?7(P=ZZ0=5ZS=G\!"OW;T^>_OM7Y[]]?+5(]*^R-*^
M>&SU_Z.I_EEK5^^5WU:J;^*'G_\QFGO5ZCX4O]3T01>_F+YNQT97?FM=. _:
M=8MJ"W]I=U5K,*Y98,B]]J'CX0\F; 'R,#H3:$M(U4/@L*L:M<-75[7:8]A6
M]]4PNGH+MVR6U7O;UYCO%/L[)GTR_LY7OVTU?NH&U>\JXT$_J\^@A"K8JG:Z
M,:%R&%:MG>TJ@\T'B+C&82VM0"=9')Z'#@E]W>F@5BV.I6L1=5G]#JP[7F@Z
M$=:$\G:+*A2BM*:C4:HC#:?1NL$'B%AOBT6KU2Z+JL@8BZ2<'>FM 4O =!MG
MQZ'48Q5V@V91C?>C=HM*?ZGU$"I0>;DZ_]K0)B3>[\O;9;6Q]]KUM,@R6A5Z
MV^JVJ53 UI\M,6%_1T+'.;TAR6^#"CHJYYID4JU12U(_B-8Z/3\^5NQM@$B#
MA?'(&O34%^"K2W,R" [LA06]KM:F5WUM5 MYL.W((.*-<1#5\M1BZ^^.F@9'
ML8Y,A\&#,S9J5SEHT$-C+:*7?UEYM288TA'%PS/8, E"#)""?FT0:YSGHZ0!
M)/9"\([%Z5$)>C^NU^1A/4.SHX#,N%NW1!.$/J=YY((W4-!/-^A@**I5:@VG
M.@_J"R%$\VX:".F7U<<)IK>3S4N?:#0Y)/S+LY;4,#B+P] Z=:O\_! $V:/(
M)VC0]("0S>H0OV1AG=9PG9'AP>!N-%DZKHJ)6N'92K4P(Y$$G;W!X&5UW;:'
MUCNQ/TP%R'@#(P)0L)JZ5Z:E8>> W[F'[PH[.6<T8QG*-W E?%DKXRJ240#L
M-/% =,?_F?LC-6K-'YBY04H4Q[;6>Z*Q_IA(>T> CQ)5-A'@(#TB3]OI ZE4
M78_=V++T%@IR# BGMY0Q 1(R[0EM_I35@:T&Q?B@D;8GJ$&YR#'JNZUMH3?_
M'9\S[);5O_&2:1&X*9;53Q=)(I*1_ C0@1(7A'<HOF\(G1UD-'],CI&0 .$Z
M,W9>',1S;,&$1S5&.F(/+O74RY'/PU;UB"<XC:/PU>BZ92 +,4U6G:\ =U\3
MWT22J*T/>SMXJ(,HBA*^AL2@U?R@:W*&BDX:)K?H=-C:9CES*J<WL(UKZ=,]
MI9*5BE">1P;/9/S5LTSGF.T"7XBK3Q8)V\D+L@7XH1J]3E\,IAM' BQD*H5X
M'L84BTPZ;&GSS)VBFYW$$A_)O!^[5:3,,IX FWTU3HY Q@3/>D/R+&0YT*,1
M)FW&N:A[4\E<"/6,QS*" %/Q, !A)$TD^VTI;<)*FHW8 9L"GAHT?*=;BG@0
ME>(0/@3Z_<%@B95.A-N<6G;%(8V?.EU3N-R)^+"4> !F,[0 (@-J^#NE*^$4
M\0I]BM7G1J>5(6<1M0B:5% QG-24I?%6?&;8ST^K^:,86]")<<BQ3L@!->YH
MG;SMW/:A(IY(#%DC8!*ML'T)QQP^.)]A2$2B9PF6U0V"BG9B<<H:!SY(Z7]#
M.43G(7P.<$=M(M?="PXF\@:RUV,+F][K#%BG(S4B@&G*!GY*2Q#0L"11X!@*
MYT:B017<.2LLN?0G38Z2&)^1QC&*^1".,KIDO,9*/H,A6-29#;*2-FXODG&$
MVBJWB; 23B5JA@^.SFGAD-,'.Z&A_2SE%T1^EHW'K<V7*.>SRVJG%4[S/I[=
M%4L\EY]N[3H\T'KIP:\:%+AE.D1T@?(C;?UJUHR/EGZN?K7]YIRD1.;'^BZ?
M1 M$5GK4T)RJ]D'U&X,(*1F<S.8C9K>B2)HM5K'%(O(3.. Y./&@N>:?J7&?
MIB,YMP?B$IXGFN1:@SBKPC]T?OP*4_:;R'>U<0C&/A VZ$%#H4%/7IW]:O(.
M^'/$!B7ENO%'XE5(QU]6']82X__IV^=!224$RQI; *%L=K(*A8Y.[1CAJ\QX
ME,?,DWIFSP1?X?(4Z"FE&1F4.:WULEGT!QAL;$-.[*LB7D51(<F%C;45JV&$
M?V'U*;(D6D(-\8=FQIP,2"0U#_O'?LR4S!+AJ+V&2CUSY8,=H8X5D8/RH^28
M!>6A@'K8&G#>"96'"<U_PN8 ZBVX0I^_XQ2$- RVB/3UVYZY>LJ5*+_P/",F
M+8/:1:^".S=L3M!^:W>:XFF#V%8'ZZ28(-^$[A6G8U-"L'&*P28Y8F4'+L6@
M"IQ.Y5*$,D!GV(P\;C%Q-(=1F(>"B+LW8$XXOK'-/+'B?3CC/Z8-EI^K>Y$Q
M'8DX@6HBL087$3%#)N%EH[!%7;S95A0Z\7A9_0((R0+<9\ X[FW"=T1S,A2Y
M$ 1'(33'>()WM!ZH;*56II6"#B(8'3DRR5^LGU><(S4&HVS=%!=2!(/E$(Q\
MTL3,9TC4Y6/5W%R?T8!IH=&GK.]=J^J[\]L:#D^!AD>=HP:L:4!G&]T*M$="
MV@I45"&] 'Y -+'>Y?C5!RF+R):*(5=RP3R+I4R,HRP7&8XR$E+JO8+91D].
M,'81;S&3$&>C*OI\C8(R%Q]<\BXFM=Q;Z(TM4CQ,]4FU,UI(+?_62BRCY07B
M1+ )Y'!$1G\$QU%3J=;;*0<'\:1S+T1O=%C5Z/TB.8-_D;Y-&77R6^+G6!A.
M9@<) 5-K36V7:/Y#OQ% ?/N7'Z^>_?#*'WCI4=<%7W.!LE?YU"!(AD*T+B'C
MY#Y04$=U6V2,.+^1I@2?=8GD  GC#8[)#%>!X5!4Q2H!#YG$#D1XX/XZN?EZ
M3>T[TA 8+^U&<W(KB^O#,5! 9!Z+/3!P<EM+P0RN9D30KU31\N8J0!>K,1;U
MU!XL3B+U<>J296D4Q<&-3@*4NZ*L2?X5N0A)J&DYYSP\Z_^G;!.FYMH:?>PD
MT*35,1LDH0CJ0SOZ/83.5V.@YAB9+$%>S%QJ>VZ(Q2J/+#=8*ML,/M)YH1?*
MU(H*JU#E8XJCE(1;<7W,]B-9?&UQ3B<QX#S_")U*TR$EXUS(DJ!L/#_M H]S
M''1VP@SY:P1]:GC(-G5.?T J([>'0ZIZA $?J$<JYB.YW504<0BLI1B-ZQLO
MQ9>D(+/=E]7?N(M"3?+<1.$"9UQY1&,B::?)/!R1*+9'^['!N?HGIW-EI:*:
MAC,L<#U2)NF)#2:HEBHDCSJACHW_GQ#[6ANS^?<X@)__W!0_/R'"N+I\]>E;
MU0VO?N)OSUX]G?*9?&>@6H0$2EI62,'7)F4=,1_>:M6P?G.X),5A")6=')W@
M-Q*C\HCT$X+RN%9UB(Z:)MJ>[W^*30B*IIERF+7.\M%$9*"]MV0?ET^[080J
MNK78A2)2;E[!%TCRN.?R>$*70,*QT$KURRF+.Z54ON.,V_#E2%%76F3?CD_3
M.,;[$>J&6@)5R/?:'\GK23&F1X )! S.D.[TKK@K(#5O=%^SL3 :.O ^PH:H
MPH2@Y?QP6FZ (GN"08&VC>JE8^@CN_61[J!K>,S473@2U(YK BLCV'1[NA5?
MC.LQ44B*R^W1ACHA3':<<DT96 KSIC^](56T?#DS&9!-@-$]&> #)526BHG3
M+O.S[//[@"*(#A%3>.'6*$V2C3DA%C[,J @5#S#MN(G-76AM0:=ZH-Z58O(Z
M)R-HQQ<EG4&B%RSJYK1'O.LP&-$0TMH,1.:8#S?BIRE>2':-;[GFV<45!'(+
M,@'E7,U48AZ("&YF,,P2J$KTI)G$"D@7$88*EF " 415PB0KRF<Q3ZB$Q&[
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M_HM9_H:M/R>,EQGEPB\LH^QHG$#6.&^J5ID85%+'?_'<QF%+X6RP1R%M%=+
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M"=O9/F2G*WD'WYM\$4[8VTJL0!0%13CHLIH(K=A5^XM)LR],M"=ADJP53;$
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MC98%Z+XP-/G:#1M8/\UG_P)02P,$%     @ F8%J5;JGS;2D @  $ 8  !D
M  !X;"]W;W)K<VAE971S+W-H965T,30N>&ULC95M3]LP$,>_RBE#:),JDC@M
ME-)6*K!IDX9 = \OIKUPDTMCX=B9[5+X]CL[;5:T4O&FML]WO_N?G7/':VT>
M;(7HX*F6RDZBRKEF%,<VK[#F]D0WJ&BGU*;FCI9F&=O&("]"4"UCEB2G<<V%
MBJ;C8+LST[%>.2D4WAFPJ[KFYOD2I5Y/HC3:&N[%LG+>$$_'#5_B'-WWYL[0
M*NXHA:A16:$5&"PGT2P=7?:]?W#X(7!M=^;@*UEH_> 77XI)E'A!*#%WGL!I
M>,0KE-*#2,:?#3/J4OK W?F6_BG43K4LN,4K+7^*PE63:!A!@25?27>OUY]Q
M4\_ \W(M;?B%=>N;4<9\99VN-\&TKH5J1_ZT.8>=@&'R2@#;!+"@NTT45%YS
MQZ=CH]=@O#?1_"24&J))G%#^4N;.T*Z@.#>=Y;E980%?!5\(*9Q .XX=@?UV
MG&\@ERV$O0(YAQNM7&7AHRJP>!D?DZ!.%=NJNF0'@7-L3B!+>L 2Q@[PLJ[*
M+/"RMU<)OV8+ZPQ]%;_W%=SR^OMYOE-&MN$Y3B)J!8OF$:/I\;OT-+DXH+;?
MJ>T?HK_U3@Y"]DO<=PY;F]RQ<0NZ!+H%A_4"37<5P%4!UYAOK&FPIK!&@SZF
MU)*:W,)[H<!5>F7)W7X8[0/]#YESR0TE[P'6C=3/B+! A:5P-J0U*+DCG8X_
MD<(C8+VT?Q;&).O#;8.&.Z&6()&:]$4UQ^^&+&47U$[&H'*4+@/&SN&*SDSD
M7 ;\_3&OFXOK+LTN@/6R;-AA;EU%NL\(D+%3^*8=$8Y@T.NGK9S!\!SV?07Q
M3I?6:);A+;*0ZY5R;<-VUNZYF[5=_L^]?2MON%D*9:G6DD*3D[-!!*9]?]J%
MTTWH^85V](*$:45/-AKO0/NEUFZ[\ FZ/X'I7U!+ P04    " "9@6I5ECC^
MU94$  #L"@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6R-5FUOVS80
M_BL'K=M:(+%L68X=SS:0I!TVH$6"I-TP#/M 2V>+*$5J)!4E_?6]HV3'<1QO
M'RSSY>[A<Z_DK#'VJRL0/3R42KMY5'A?3>/89066PO5,A9IV5L:6PM/4KF-7
M611Y4"I5G/3[9W$II(X6L[!V8Q<S4WLE-=Y8<'59"OMXB<HT\V@0;19NY;KP
MO! O9I58XQWZ+]6-I5F\1<EEB=I)H\'B:AY=#*:7*<L'@3\D-FYG#&S)TIBO
M//D]GT=])H0*,\\(@O[N\0J58B"B\6^'&6V/9,7=\0;]UV [V;(4#J^,^E/F
MOIA'DPAR7(E:^5O3_(:=/2/&RXQRX0M-*SL@X:QVWI2=,C$HI6[_Q4/GAQV%
M2?\5A:132 +O]J# \KWP8C&SI@'+TH3&@V!JT"9R4G-0[KRE74EZ?G%=H15>
MZC5\1#+.S6)/J+P79QW"98N0O()P#I^,]H6##SK'_+E^3&RVE)(-I<OD*. =
M5CT8]D\@Z2?)$;SAUL1AP!N^@M<:!G]?+)VWE 7_'+*QA4@/0W!E3%TE,IQ'
ME/H.[3U&BY]^&)SU?SE",-T23(^A_Z\8'$4XS&\?]G.!<&7*2NA'*(0#L]U7
MK8>HQ,$W!LQJ)3.:-](7X-&6#GPA/.!#)2V"U!R9(0B=\V!T0L7I*@SEI1Y[
ML'L..B^I= A,>OKIS")5M!<*EL:2F_AT(H% \($%9*8DB2R(@3=48<R ["4.
M",$ZVK@7JD8BVBE5XI'E'9!9I7&>=_P3C9_=QL3<@#:>8,R]S.E4#;*LE,RD
M;VF0GD5?6_W<#(N966OY#3L@=@4U)I*GO@*<5ES\IQP6[A&2G'N/-E!HY=F&
M'E ?Z>9B;1%;RO1!BSDYAZPE 6JMCJ@Z6A(KWZ&(W%2ABQ'!SZ:2&4S2Y&37
M1@B-CI0(1629J<E+'%!M].G6LY71G9N<R:1@\1!D#D[G(8[J 7DVDX*E<'^S
M!Q]$5KSJ< JYJG/D;&/^79+MT":Z^."13GWN+282&[X^EAW_D."<?4UAB ?M
MT;@2EBA</T]E4%(LI9)>=@;9$!ZS.JW9]^1;LJDAKX? VCQX/YR_,DJU69F)
MCC!99FIN_4I06D)[509EX3IY!V^#OJD=G>;>38%ZF,=R2=';-#)XCUFW,@@K
M [CM6,$78G416$WAFFC8#<<W,$HG]!TG*86=RV:C<[K5>2:T5_/P\<D14[C(
M,EN3K;O>>4-4AOQ-SKNCE='KTQ"!7;EA.H)T,NI8'#GFB<X@)8+LOI?.:#.W
M"5<FYSD5"[T *!K\C'@*8V#!"<,!>-&N&O+_H#>!1Q36G80X'T3-I6O+(53X
M4;CSWEDR^I$*M:8>@'S?RK(N]YM,31?=;G'O%+-XQ>#_3)B_V CJ!9R+^XV[
M11B/VK:;#,8\2&%PW@_]%P;IL(O+'E$RAB <A[YD#SCR<-=!&5V&SD/=\NUX
M_ YN#K=6]2*TAVZ\>.<%4J)=AW>6@^#W]C&R7=T^Y2[:%\R3>/L._"3L6FIN
M("M2[??&HZBMW\W$FRJ\9Y;&T^LH# MZCJ)E =I?&>,W$SY@^\!=? =02P,$
M%     @ F8%J51O3(BB."P  GB$  !D   !X;"]W;W)K<VAE971S+W-H965T
M,38N>&ULS5IM;]M&$OXK"Y_;<P"&%B79DN/$@..V5Q^:)G#2!(?#?5B1*VDO
M))?EDI9]O_Z>F5U2I$3907$%[HLDDKOS/L_,+/5Z8\JO=JU4)1ZR-+=OCM95
M5;PZ/;7Q6F72AJ90.9XL39G)"I?EZM06I9();\K2T_%H='Z:29T?7;WF>Q_*
MJ]>FKE*=JP^EL'66R?+QK4K-YLU1=-3<N-.K=44W3J]>%W*E/JKJM^)#B:O3
MEDJB,Y5;;7)1JN6;H^OHU=LIK><%G[7:V,YO09HLC/E*%[?)FZ,1":12%5=$
M0>+K7MVH-"5"$.-W3_.H94D;N[\;ZC^Q[M!E(:VZ,>D7G53K-T?S(Y&HI:S3
MZLYL?E9>GS.B%YO4\J?8N+5C<(QK6YG,;\9UIG/W+1^\'3H;YJ,#&\9^PYCE
M=HQ8RA]D):]>EV8C2EH-:O2#5>7=$$[GY)2/58FG&ONJJX^5B;^N39JHTOY5
M_/A[K:O'UZ<5*-/ST]A3>>NHC ]0N1#O3%ZMK?@Q3U32WW\*B5JQQHU8;\=/
M$ORHBE!,1H$8C\;C)^A-6C4G3&]R@)Y33/SS>F&K$I'PKR$='8GI, G*CE>V
MD+%Z<X3PMZJ\5T=7W_\E.A]=/B'@M!5P^A3U;_;#DU2&91PB+>[4/2Z5X(?B
M8Y'J2KS/!>Q>J6RA2A%-G?$#H7,1FSSW:;31U5I4:R4R5:Y4&8B-$CHK4H5,
MK53"CP:(!T):9(N-2[W *M#\U51*1*&X3E-AU[)40N:)*,#:7V6FSBLKS!+L
MLPRL+9$+A"E($,O+-[(L):T"0>(L8ZPM9/ZH\Y58ZESFL9:@7\F*!;1B+>^5
M6"A%D,*W$P%H$Q)2@+<VB15L.J>,$2N !I96I7$ (M1R"5/0HP.J0B5(4280
M(7T,>!7L9TVJ$V;7$0:Z*></8%'*9-=L3O"BAP<XB 5MB%-IK5XZ54N3B>__
M,A^/1Y==:_&MZ)*D]4]EDFBR'ZQ22)V\)._*0E<R;=;BCLR]^4D\K/3*%K(4
M]S*M52-;HF)4 DM*D<\LV11PV$ITT$(^"F^MK>$B;/Q0E_$:E,3UJE1L'7&;
MBW<2=Q&&T86SXXUS+KO^%YT#_'+Q099?Q8U30?Q4YTD@?OGE1IQX?;O+O(8O
M!'FWY#"$9E(4#7/9,C\A=I[$OFPM(1)$0NN5)ESA!"FI#M@#I.ZZ*^_<RCVJ
M 0E$AN$HVZQUO.YI#UGXFCG1$A0Y]E'/)-XCWE-^+[&(9I>VEU*4$^0R\OH*
MPJP0GUL_UP61/AZ?AR,4H#2%Y %J^.+?/@MB558H_B+5&5RP34W$O(LT"_DJ
M2C( AT_3 6]WK?0>*59"HL8@R"C+.:2!8<YVE+/L11*<W3A,MQ\W&O'FTKIG
M*E)\FQ;1/ K.HE''@#UC26<\7;'8;E%(G%N/'9*DQ[.)N42,ST;!:'2('X"S
MHA M=<SN.)Z&6-O"9.#0"VPI_%>EL78;SMM-T=9Y/4O?YM :&QMQV\"N"Y.S
M' KI2>*'XM,:.2.7%8&^)#DK@"A^4'X_BD5M48S /9&/+ODY-VBY,+G:>6Y2
M=(/D.D81BC<?I[L",14##OQT<OXRHT9#@&K6;'G.Z;UT"3PPH;%D5^&;+:R1
MB(!H"*-1HY3K&,%Z(-"W@1W0[427M*#G7-QNG>#R)QH][60NJ[9&IGO@!3F"
M5LY+)W^<&KZT,NVXUI673GSZC<I>8I&Y1\KTL;*% +-(]<IE$U 3%B9C$0>0
M9TE:%3:(')$;5(.'6('<\3@\VV)!G:?DUR?Q.:LKU)'TT<$B&:01T_42\D%G
M==;H#K58 "],*\>)DO$:[NJ@:9VB)NU&;RAN>ZCG?60/.ZDK1%YS T1"#".
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MCL+9V9&;A9J+RA3\!GYAJLID_'.M,*R4M #/E\94S04Q:/^2<?5?4$L#!!0
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MH-Z@-WO_KA=T/YP)97 (97 ._4U5^W](\.K&-X32IEGZ+X)I9#1JRJ02;(+
M/0/4"HC%T0.H@O=,B\XRI36-+&FYG18(&;]8A5*FU&_@LP/*J'ND<@U6+#.L
M6PBY8)P=MJTDU= X:Z]YA75=R2VG9A.-Z&Q+R@KD%7V1Z0M$/HOY$O6!@4Z0
M!CWXR86G2D,KYN<K\I!QFNQ_IOZ)X<_L.W@'_32Z)](('27.;(P;:I^%H^P%
M^&&/OD._3]^@S^-@T(??4*(6F9,7,;6*E,G+/0_"8 S^L N]UK ?PG@<P&=E
M2?2[F;H@E>Z@2_\P9&M^JQ>,W&K0']<@1XJ1,I8JF0DNHU4@E;S<4&%I)K9"
MQX96+.R0A2*UEE3"V'G,]=BZ%HKQI=A0)&N$ G6J2$?1'+9)2ME@N1IIBQJ=
MIU%M;(E'J/94EIV2,#6CS(M:+ASU_JRHRD78<[+:^,*</+7<,/PR(9RP81CR
MWZ4O)$=N]XZ_$C6?H1TQP%'Z)>2+<'OM( "_W0MH-.K7M5F)5,-&9"4>#H:!
M?3V>91WV]FD[S5T!G]1-0W]-+=/MUL?H;8?G;07X\9/S_8 O8#1D$H?#D)K8
M#P1](F:J8-N=NUZ_/1S#5Q*KBG)MJ"?53KN.=8S2;( N%T1AAC1,4TYB3+99
MTAFB7=/PJ#2N\Y'4/!/1P^4B2E3&)7%X4! 562!7,695OSR<BHVBHTC-VNX@
M-5"=]))Z)234'10I4LX:,N0 F^%^+^3N_;N1WPL_&*8?U;>*XID!B]3B]TS8
M!WAL2BWY^JO21 ;H/BW)*@5',)DH6&Z)=HLHGV6!\X2/J*/4N-4]/)L360:8
M%YG:(9IS/AT2?>Q4=6U(=[T[=["ZJIHJ[5,W=:?QULI1K]V+DE-42EL]NPZK
MAT?K=?56>Q*O7KP?A5ZG%$^&*U+MML.A![IZ1583JPKW<ELJ2^] -TSHX8V:
M!6A_I93=3]C X2D_^P]02P,$%     @ F8%J5<4?ZAKK"   -Q8  !D   !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&ULG5CO<]NX$?U7,#KW)C=CZZ?M.(GM
M&=M)VF3N<IDDUTZGTP\0"8IH0( !0,NZO[YO%R1%R7+NVB^V1 &+M[MOWRYX
MN7;^:RB5BN*A,C9<C<H8ZY>32<A*5<DP=K6R^*5POI(17_UJ$FJO9,Z;*C.9
M3Z?GDTIJ.[J^Y&<?_?6E:Z+15GWT(C15)?WF5AFWOAK-1MV#3WI51GHPN;ZL
MY4I]5O&W^J/'MTEO)=>5LD$[*[PJKD8WLY>WI[2>%_Q=JW48?!;DR=*YK_3E
M77XUFA(@9506R8+$OWMUIXPA0X#QK;4YZH^DC<//G?6W[#M\6<J@[ISYA\YC
M>36Z&(E<%;(Q\9-;_TVU_IR1O<R9P'_%.JU=+$8B:T)T5;L9""IMTW_YT,9A
ML.%B^L2&>;MASKC308SRM8SR^M*[M?"T&M;H [O*NP%.6TK*Y^CQJ\:^>/W.
M9JY2XHM\4.%R$F&1GD^R=O=MVCU_8O<+\8NSL0SBC<U5OKM_ B0]G'D'YW;^
M78.?53T6B^FQF$_G\^_86_3N+=C>X@_=$Z]UR(P+C5?B7S?+$#T(\>]#+B>+
MIX<M4I&\#+7,U-4(51"4OU>CZQ]_F)U/7WT'[VF/]_1[UO\P'7]^MW@'RH>@
M0M!V)6*I4$+2Z-_E4AL=-\(51%[EO<I%1'AH;0S'0MO,-'FWQT(6( !>1GJ"
M\ 612>\W4(.U]'D0SW[\X6(^G[[Z\.O/@3_.7OUTS%OO7%5+NVE! ! ]E/=2
M&[DT2M0N:"I((6V.8U:2OZA[G2N;*1&=4"%JE)T2NH!F%(7.M+)1%$VD' (S
MV]')Y[4V1BR56"E+:,DI)YH(7W_'FAB$>M"!G3C@]5C<HK!S 96@I0DQE"?N
M>E+*(&KO"&(N)(#@R'MI&IGTQ4#@)&&7*XAAB&R+ GC@1/PCT]IW[B2HR9)7
MI*9!-##F(SX*&;%:8POT<"QN F7OM<I4M51>+&9<+C..)#Y,]U$#; W<#QQ-
MLQ%'\XL9M,08AHU-1_/ST^[!,8X/M6*Q-)MC.JE0.6)J!.5XD$$$V!4%O'DB
M)>JAUIXB7GA7 =AB"ES>-:N2OIR/Q9<!2G",.@P%EC!)LPGPE\#E*BH/Y:/X
ME9*BFERRPJV1ZU#J6F2EM"M%6%=@.=;34BO.IG\1[A[?I%B<;)3$8Y5(@..T
MXX2_E[9!-Q+SLQ1%#J^D($#7C\71[/Q%'RO8I\CNQ&\_/DQ$=AU)M2T#\UUG
MU]Y%0ELDCVKGX\#\8[IP'/"DR3@(2F3.4Y:<Y4(]Q,&$GWX%?8YFL_D0<"(8
MIV8+/4%<>]U"^SZ:QR@8'Z/ B8<@4?E8)S1BD$5B#]E82L,_I@G$^8X\(2*-
M5()C\;-C^< /#0-9*C!%\>['#'B<T%X:0K/\CTHG,\>PS BC*QUE%_ZCV?,%
M#+LFD(\-FIJ'CH)/(*3XI.Z5;2B+N1*?VZEB<3$_%NM2@_9F#Z<LB(B'X5@7
M]R!M@81=LE1R0TN[DNLT3>:YIM4=[X!^K\IGXRU+P7?!!8#0<>0*[:%0!6DN
M/0\M6E:91U&5VXKH:(&SC,[DD+<?D,#?;.HR</^VT2:>@ M_)07SC5'A_Y$N
M)L*^],#@!PQ\[P%3<2L[>O%\5]%>O'A*T.Z #U&P6O+&Y]/=C=OO^QOI9SKU
MGQ@SQ5W;0X]FB]W]V^_[^_]GO9P-]/(4PD0=/4/1Y5PQ:QW+(0V[-#SB:P:^
MIKB"UDDE!T&FICU[_BJTZN4:0Q66Z(@LK@#>IFI/7- #W4U$)9WA/MT.&!TG
M#K4]L"M7N%#DU,D;2 >;;IMV)Z<'HY,WOAM*6O%>EXS,!:Q5%424RBS7!4ZE
M$2+ C;0S"1-L[1864[B=2][>?+[M(\$]GFX=@<MEVX;)D32W/*K2MBR3M;AV
M)R&JFBP!2*#4]VTLE4_E&AN3%F=N9;EBR/P2H2@T5.\M%>KP/%%!(;L05%#
M$Z._@E@GU.I.2%# %A5*9_+CX1F# W2;25AS1N<\)A7:@DX:?.DEE]-$"XWT
M*S3,#E3J5B6KP:,^RV!TZ:BK%MB16D*K!9SIGB=@0C1\4B)Q&DZ-NI=XPF1I
MD%8THLUNC'M/2&1Q.$&CF@.?)&PKGMP<?"&_V/(3J4N"!G( EDII:%E&RU"'
MN'3V<Q:N)+%5J_9><@Q-MJ@D]B!W*K1R#C;=JT<38])PP*48/P6((YN*SZMO
M#0T/FMM"I21?6=($4!CN%E0#F"!L))-&9E\)9\!E$88'\[WL#Z"^*#'51Z(
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MZ># ]@X<S<=GP\&?'&YAB0[)H.OL8^=PW[:_;6_W&'>S4JRA;9A? ^0*$<+
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MMP,&1@/5Z?C-64$^/YEY$UV?GJF5BWCTTF>+?QGL10#WC7-QMQ$#^_\MR_\
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MID1;YI(DC]A2B_TA\O MF<[A'!*?,=)9=*5!5JW2SC7"E3SNFR+&2CI,T).
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MHZA>\R78BM\47-@0;,$?UPJUS-$-^'UI,0NE+\2@?77T^+]02P,$%     @
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MD'A2*ETSBTN]"DVC@17>J18AC:+SL&9<!NG4[]WK=*I:*[B$>TU,6]=,ORY
MJ/4LB(/MQ@-?5=9MA.FT82M8@OW6W&M<A3VEX#5(PY4D&LI9,(\GBZ&S]P;?
M.:S-SIRX3#*EGMSB2S$+(B<(!.36$1@.SW -0C@0ROB]809]2.>X.]_2/_G<
M,9>,&;A6X@<O;#4+Q@$IH&2ML ]J_1DV^8P<+U?"^%^R[FP3&I"\-5;5&V=4
M4'/9C>QE<P\[#N/H'0>Z<:!>=Q?(J[QAEJ53K=9$.VNDN8E/U7NC."[=HRRM
MQE..?C:=Y[ENH2!?.<NXX):#(1\>62; G$Y#BQ&<79AO:(N.1M^A79);)6UE
MR$=90/'6/T1EO3RZE;>@!X%+:,Y($@T(C2@]P$OZ=!//2_XCW9_SS%B-G\>O
M?0EWO.%^GBN9B6E8#K, :\* ?H8@/3F*SZ.K VJ'O=KA(7JZQ!(L6@%$E62/
M\GUR#P+WR]V2Q<Z=,.-BXNU;J#/0_1,0)@MR _EF-_:[,5F#!N=3*H%5CE\0
ME\16JC5H;DXG^T#_0I9,,(W!!P3J1JA7 )*!A));X\-J$,RB3LM>4.$QH8-X
M>.''*!F2NP8TLURNB "LTC?9G!R-:4ROL)ZT!FDQ7$(HO237>#\\9\+C'TY8
MW5S=]&%V 720).,><V<KU'V!@(2>DT=ED7!,1H-AW,D9C2_)OM</=\JT!KWR
MS<B07+72=A7;[_;];MZ5^5_SKEG>,KWBTF"N);I&9Q>C@.BN 74+JQI?])FR
MV$+\M,*>#=H9X'FIE-TN7(#^7R#] U!+ P04    " "9@6I5/.$LJED#  !<
M"   &0   'AL+W=O<FMS:&5E=',O<VAE970R."YX;6R-5FUOVS80_BL'K1@:
M8(E>+,>)9QNPVQ4MD*!&W708AGV@I;--E")5DHK;?[\C12LO5=5^L<CCW7//
MO9&>'97^; Z(%KY60IIY=+"VGL:Q*0Y8,7.A:I1TLE.Z8I:V>A^;6B,KO5$E
MXBQ)+N.*<1DM9EZVUHN9:JS@$M<:3%-53'];H5#'>91&)\$'OC]8)X@7LYKM
M<8/VKEYKVL4=2LDKE(8K"1IW\VB93E=CI^\5/G$\FD=K<)%LE?KL-N_*>90X
M0BBPL Z!T><>7Z$0#HAH? F84>?2&3Y>G]#?^-@IEBTS^$J)OWEI#_/H*H(2
M=ZP1]H,ZOL40CR=8*&'\+QR#;A)!T1BKJF!,#"HNVR_[&O+P*P99,,@\[]:1
M9_F:6;:8:74$[;0)S2U\J-Z:R''IBK*QFDXYV=G%^QHULUSNX08I. ,O/[*M
M0',VBRW!.Z6X"%"K%BK[ =0UW"II#P;^DB663^UCHM5QRT[<5MD@X ;K"Q@E
M?T"69-D WJB+=>3Q1C_ "Q'^N]P:JZD=_NN+L87(^R'<B$Q-S0J<1S0#!O4]
M1HO??TLODS\'".8=P7P(?;&AD2L;@:!V\*PP<,/9E@MN.47 9 E^?,[5[OR.
M#I?&H#5 7;YB@LD"8>,ZHB^^00;]\3U0$9Z*>$9%GZ@T=,A:*D?42$-;*$V]
M %R"/2#LE*!+P $5K'9#:5RDJG&#U=)N+R)OS$S0IY[T]JHQY,V<38$:PV*U
M1=UU![S&(DA2+TF[!,%#@J;PGFCH$\<7,,ZOZ'>2Y?!1629ZDOI$:: F4U@6
MA6XHUL?9>4%41NXWNPZNA9+[<XNZ>J(WRL>07XT#BZ'2=W32' 8Z;MQUW/B7
M.^Y-8QO*^RV7O&JJX'O-OM$53,FZHZ'60;C<:T0O[NNP08_]'19<5\%UVV;U
MR77C7;L&:@]8Y]XU"3'OZ8>?M= _R+0!=#?5\WR;%F$R=M\19.G$+7)(KQ.W
M&$.:CT*EGA&]I,,;-*X9*M4XB48?I/3H7%+AT5AX.9F<P;H]@'LF&I__[X>K
M+79?F>-'-WZ%>N_?-0.%\]I>_IVT>SJ7[8OQH-Z^N[=,[SE-HL =F287$ZJ?
M;M^R=F-5[=^/K;+T&OGE@9Y_U$Z!SG=*V=/&.>C^4"S^!U!+ P04    " "9
M@6I5X5/J_E<$  !S#   &0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6S-
M5VUOXD80_BLC+KHFDF7\AFTX0"(O;?/A[J*02U15_;#8 [9B>[G==4CZZSN[
M-H0$PD55J_8+^S;SS#,[.^-AN.+B7F:("A[+HI*C3J;4<M#MRB3#DDF;+[&B
MDSD7)5.T%(NN7 IDJ5$JBZ[G.&&W9'G5&0_-WI48#WFMBKS"*P&R+DLFGDZQ
MX*M1Q^VL-Z[S1:;T1G<\7+(%3E%]6UX)6G4W*&E>8B5S7H' ^:@S<0>GH98W
M K<YKN36'+0G,\[O]>(R'74<30@+3)1&8#0\X!D6A08B&M];S,[&I%;<GJ_1
M?S:^DR\S)O&,%W=YJK)1)^Y BG-6%^J:KW[%UI^>QDMX(<TOK!K9(.I 4DO%
MRU:9&)1YU8SLL;V'+878>4/!:Q4\P[LQ9%B>,\7&0\%7(+0TH>F)<=5H$[F\
MTD&9*D&G.>FI\53QY#[C18I"_@07W^M</<'Q#9L5*$^&744FM& W:>%.&SCO
M#;@^?.:5RB1<5"FF+_6[1&W#SUOS._4. DYQ:8/O6. YGG< S]_XZQL\_PV\
MUL/?)S.I!#V)/_;YV$ $^R%TF@SDDB4XZE >2!0/V!E__."&SJ<#!(,-P> 0
M^GA*:9?6!0*?@PD.?%TV[[=*X8X)P2HE8:(?,SFRC_U!_/WL;S*$.2\H0_-J
M 4I'OTW3_$^4H.B8M19)CG+:$..&F#3,5FMF^EC+5V07RN8QH'X,0*%46,Y0
M;.(Y>.&A?'9OFC'B!G<FITAU\H""2@1</*)(<HEP)?($=\^O4=<A[<,96=;Q
MK5D!-RA*./X-F9 G,%DL!"Z80K@DB9RJ2P*WK*@1CB\KN,EX+<D?$OP_</A:
M*ZEHJM&8@G-,V@MTS06ZX :>Y00N'$$<V*$#D=V/:/'Q0^RYWB=PK<#SK2@*
M:"_P[%X$@>UO"YQEK%J0EVDM3.0I<$L4.4\'\(L.!?GE1U;0B\'U[:"_T5N/
M$TG/A(14)GB]R*!$L2!^KN5Y$=D-P;>C:$=K?87ISLGKD2KO''--X]BS^JYS
M F[?[H=[$)>YT%(]RX_C$_![GNV[.V*O[G/W11)SOQ];_4A?DNO8L4]7ZCL'
MK]2W0W]+X!:EYOLV?&CU/???@G==QPK]GH9W[=B#\$</XA7\@0K6VU2PWKLK
MV#6QI331C)M4/U2X#L+N+USGS^_V/07'E"J=.)91.>/EDE5/D-,K)GGQ3+8I
M<*;4D2'*<ZIRLBV1$HZ/(*\(89VG _BBC6]_^O89-QG[I3:;=#<[YEH:D6-%
M@0.!8\44FJ8N'! _@GZD(QA'\:'HA9OHA7\_>M^J_ <?GX/@_T4,:T/YG9&T
M !\3L@A2%W](J:/ZIX+;\&A9NBYE:N1H[1Y5U;=C_$+K2)>/.*0Q\OI[8]W=
M:@1-*=;MKH2$UY5J>L+-[J:CGC2-Y+-XTXY_9F)!7R8H<$ZJCAU1=HJFQ6T6
MBB]-6SGCBII4,\WH7P$*+4#G<\[5>J$-;/YGC/\"4$L#!!0    ( )F!:E6)
M\""B!@0  /H*   9    >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;)56;7/:
M1A#^*SNJIY/,V$A((($+S-BND_9#4H]QD@^=?CBD!=U8NE/O#K#[Z[MW$C+$
MH#A?T+WL/OMRSRX[V4KUJ'-$ T]E(?34RXVI+GU?ISF63/=DA8)NEE*5S-!6
MK7Q=*6294RH+/PR"V"\9%]YLXL[NU&PBUZ;@ N\4Z'59,O5\C87<3KV^MSNX
MYZO<V -_-JG8"N=HOE1WBG9^BY+Q$H7F4H#"Y=2[ZE]>QU;>"7SEN-5[:["1
M+*1\M)L_LZD76(>PP-18!$:?#=Y@45@@<N/?!M-K35K%_?4._8.+G6)9,(TW
MLOC&,Y-/O9$'&2[9NC#W<OL'-O$,+5XJ"^U^85O+Q@,/TK4VLFR4R8.2B_K+
MGIH\["F,@A,*8:,0.K]K0\[+WYEALXF26U!6FM#LPH7JM,DY+NRCS(VB6TYZ
M9C;/F<*+:XHK@QM9TEMKYM+U[H$M"M3O)[XA,U;83QO(ZQHR/ $YAD]2F%S#
MK<@P.]3WR;W6QW#GXW78"3C'J@=1< YA$(8=>%$;<^3PHLZ8%R[F._9,%#-P
MI103*[3K<_@L1<IT#K=/-A\(?U\MM%%$H'^.9:,V-CANS!;5I:Y8BE./JD:C
MVJ W^_67?AS\UA'*H UET(4^FU.19NL"83^F@W=L8CCF>"?T<<<?<H2E+*B4
MN5B!L11IZIG_AQH,7:=D70K*HP:Y!+WG5[KO%S:YI;[BU$RN$(&)# 0Y F5-
M(;04 B* P7*!JF6!$Z1%']YQ0;IRK>E$O[^$!X>SS\#OU#];^(Y[!^^@7U;W
M%#]3:>[,9KBA7E8YVIQ!F/3I=QA&]!M'=AT/(OB( A4KG#S+J&ZY)9!M0)#$
M8PB' ?3/AU$"XW$,#]*0Z \S=48JP2"@;Y)8:^%Y/QZYTS@:0P>9ABV9AF\C
M$[U;[=,!DVZD-I2)@AGRT$A;)1O4=G.U92K3QRC6;; V<A!L:HVH%R-"BHO&
M"G-6Z,3 ,UJA5*X$T2YS6;8<VKH>C-D%VU#V5P@5*BY)1](>MCFG%[1R#=(6
M%;KLIHVQ!1Z@FF/,<$I,-U6@7_%O;F3Z"']5-AIMB6,4=_CUQ1?!S='C/<.O
M$V(?>9@D]NN>/"%';G>.GX@:R+%G8JTKP]>0K\+M]^(8PEX_IM4HZJ!3W-(I
M?C.=/C"NX"LKUFYWLEF=)E*GJ1.]RK%K:2UO=I9=D6G8,>H[WL N@W3-2T?!
M%W6]I[^B/PMWVS2OGVM9/T>AM_>K'P=\!J.A;1W),(%O;PGZ2,S$P9[K=OVH
M-SS>=_R]>:1$M7)3ER;>K86I1Y/VM!WLKNIYYD6\G@H_,;7BE(4"EZ0:]!+J
M**J>M.J-D96;;A;2T*SDECD-IZBL -TOI32[C370CKNS_P%02P,$%     @
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M-3-\6$'9 )Q?2FE>.O;N;I[JY#=02P,$%     @ F8%J58Z#J4]; @  D@4
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MOF< MN(W@;7<N$;&RI3S>[/X,1LXGE$$%%)E*+#^6L$0*#5,6L??BM2IWVF
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MZXL4"-- ?U]RKMX*YJQNKF;I7U!+ P04    " "9@6I5B)6W?E$%  ";'P
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M UMLI<S.P>9D0L5:[PH7'V2A]9;[E/75>N?Y5N^W.OO'RVWK.1%KEDH4TQ5
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M!P[$;K/Q^>L-#=GSU0 .]A>^!*NUC"^,9I=;?T4?J?RV?>#J;)1'600;&HF
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M:DU&>NR!348T$S%)X8$AGB4)9KM;B.EV;+G6Z\ C645"#=B3T1JO8 ;B:?W
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M*\(YR=1C##@"*@7$^PTA_#B0!NH&K_\_4$L#!!0    ( )F!:E48*?X^. ,
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M4Z&I3]IA0B\92N- ZS,A]&9B M1O8_@'4$L#!!0    ( )F!:E7UQKFW= 0
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MA8:G7FUF6^M/G39X?*49,OL7G>>:_ 92P4,K&J\NWZM:XDO-!K@U^K3S>JL
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M._Q3;IU64+L#E$:A:&[RK=V!3VYW8%"[ Y06@](H%,W-I;4[\,OM#C^B=3)
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M!]RLWV@QKY[@,A):B[QZF7 VX;+\@/G[5 C]]*9\*,SF,4/#_P!02P,$%
M  @ F8%J56T6R3)] P  F@\  !D   !X;"]W;W)K<VAE971S+W-H965T-3$N
M>&ULQ5=K;],P%/TK5D!H2*-Y]+$';:6Q"8$$8FPP/B ^N.EM8^'8Q7;:\>^Y
M3M(L!==:H!+]T,2)S_$]Q_;-]7@CU7>= 1ARGW.A)T%FS.H\#'6:04YU3ZY
MX)N%5#DUV%3+4*\4T'D)RGF81-$HS"D3P71</KM6T[$L#&<"KA7119Y3]?,5
M<+F9!'&P?7##EIFQ#\+I>$67< OF\^I:82ML6.8L!Z&9%$3!8A)<Q.>7\< "
MRAYW##:Z=4^LE)F4WVWC[7P21#8BX) :2T'QLH9+X-PR81P_:M*@&=,"V_=;
M]M>E>!0SHQHN)?_"YB:;!*<!F<."%MS<R,T;J 4-+5\JN2[_R:;N&P4D+;21
M>0W&"'(FJBN]KXUH 5"H&Y#4@.2Q@'X-Z)="J\A*65?4T.E8R0U1MC>RV9O2
MFQ*-:IBPTWAK%+YEB#/3&]! 59H1]('3F52T<E?,R3N6XG0!N5@J )PY0XZN
MP%#&]7/R@GQDO,#+MM,+\OGVBAP]?4Z>$B;(ITP6&DGT.#08I1TK3.N(7E41
M)7LBNH55C\2#8Y)$2>* 7_KAKV'6(\EI"8]WX2%ZTQB4- 8E)5]_#U_+ES5Z
MH105R\H-ZU&[_<%DH(C)J""[H*_OD).\-9#K;RX_J@ &[@#L/C[7*YK"),"-
MJD&M(9@^>Q*/HI<N=PY$MN-5O_&J[V-'KX11N#%Q#9NL7KV@C@EG=,8X,S]=
MZKV47=579*.2S&:P]32.\#<.UPY9@T;6P"OK!M8@"B +)7.2UAI=4@9_C#YL
M#UZ%Z!WK+R=HV"@9>I6\9X+E1>Z*W0OL.@T'(MO1.&HTCO[WAAT=TJL#D>UX
M==)X=>)=#W=4X=;D8%>U9G/89O]<%L+H8_S@<,!-+,"9Q[W<76TX<>_</5OW
MM!%XZA5X#0J_3P8+$B(71&!9I"D'EQ@O3U<Q%5F<M-1$O=@MY:R1<M9!BBYF
MO/ST,K'$<JI,4,Y)\I)VU77FU)6XA<710PT2^=,2O=^7EOS(KO$?BFU79ZO6
MBO]W:JHC.)1?!V+;]>NA](J]U<H_IB<_>6<KDC\35#+<FZ#BAYHI]A=-CT]1
M?J+.@OK.S3S<H^>A6(K]U=)?YBD_:V=Q Y>X_N_BPM;!R9Y:WU.U9$(3#@N$
M1;T3+&14=1"L&D:NRK/43!JL;<O;# _/H&P'?+^0TFP;]GC6',>GOP!02P,$
M%     @ F8%J5>5*?GQ4 P  N!4   T   !X;"]S='EL97,N>&ULW5AM;]HP
M$/XK4;I.K3010D8@*R!M2)4F;5.E]L.^588X8,EQ,L=TL%\_GQW"2WV(]L,*
M"VKCN\?WW'/VA;@=5&K%Z?V<4N4M<RZJH3]7JOP4!-5T3G-2M8J2"HUDA<R)
MTJ:<!54I*4DK",IYT&FWXR G3/BC@5CDM[FJO&FQ$&KH]QN79V]?TZ$?QA]]
MS]*-BY0._<>K][\6A;IYY]G[Q8>+B_;C]<V^_\H UW[@).WNDIJYK;:Y--?5
MMHU1Q$?H:K5Q:2V<NG<<]4%NE+R/E'ZY4_@E%IX<I>V ,H2XUW;HVFC"]/1"
M=SD[U=C@H.ZWT2 KQ*;M(M\Z-#O)J?=$^- ?$\XFDD%41G+&5];= <>TX(7T
ME.YWG2X$3_7'PJ&UX%&H>7(F"FERVPSV]Z2>O@>L+1#(.&\$=GSK& U*HA25
MXE8;9K)Q/H.\>ORP*K7"F22KL-/U-P'FII-,"IE2V:0)_;5K-. T SF2S>9P
M5T49 *A4D>M!RLBL$,1H6$?4 TT[I9S?P_?$SVR'>YEM[9O9;-$,M:!Z:&FL
M ?S;;)9[F[;[*EZO9$^%^K+0Y0AC0W_2.TDSMC3V,FL$8.PASD[*DJ\^<S83
M.;7%'YUP-"#K.&]>2/9'9X-6F6H'E;[W1*5BTVW/;TG*![I4ZW9:9KCFSAEJ
M_K?K/*."2L*W1>O>/^55?K7BJ/=6DLVWRKY@I\;ZY7_J(KOG(#(^!Y%GT9/]
M<Q"9G('(WIM]:[Y$9'CZ(J/3W.V@/JYMG0EW3H2-UX.3]]#_ >=XODGJ31:,
M*R9J:\[2E(IG!T--K\A$_UFZPZ_GIS0C"ZX>&G#H;\;?:<H6>=+,NH.%J&=M
MQM^@O#!NCOTZ%Q,I7=)T7)MR-C%#3P]TUOJ"@'WDUEQN!(NQF!L!#,N#*<!B
M;!26YW^JIX_68S%,6]^)]-&8/AICHUS(V'RP/.Z81%_N2I,DBN(86]'QV*E@
MC*U;',./FPW3!A%8'LCTLK7&=QOOD,-]@.WIH0[!*L4[$:L47VM W.L&$4GB
MWFTL#T1@NX#U#N1WYX&><L=$$>PJI@U[@G$D23 $>M'=HW&,K$X,'_?^8$])
M%"6)&P',K2"*, 2>1AS!%( &#(DB\Q[<>Q\%Z_=4L/E?[>@O4$L#!!0    (
M )F!:E67BKL<P    !,"   +    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP
M!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T0
M4FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7
MG:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B
M6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!0
M2P,$%     @ F8%J5<=YQP9#!   X"$   \   !X;"]W;W)K8F]O:RYX;6S%
MFDMOVS@0@/\*H<NZ!Z^MA],VJ ODL=D-X#1!'>2ZH*6Q140BO23E-/WU):5Z
MEXKEP5ZF/EFB9.G3\/$-*7UZ4?IYI=0S^U97TLRCTMKM^61B\A)J;GY76Y#N
MR%KIFENWJS<3L]7 "U,"V+J:)-/IV:3F0D:?/^VO]: GX8ZRD%NAI"OT!4\"
M7LQ_Q_TNVPDC5J(2]G4>M=L51*P64M3B.Q3S:!HQ4ZJ7OY06WY6TO%KF6E75
M/(J[ T^@K<@/BI<>\I&O3%MB^>HK=R#SZ&SJ+K@6VMCVC/;ZW#'NP)W<[356
MW8C*@K[F%O[4JMD*N?&7<4\Q"1ZCC</^MPOBN?X_853KM<CA6N5-#=)V<=10
M>4!I2K$U$9.\AGETI7:@_?.X&]P6W;-9!Q5$2I\+=T#?%BT>)8HTJA*%NWO!
M+GG%90ZL#:$) !,$,#D9(!L]\  R12#37PBY]!#^#X:I-;O?]JHZ0R"SDT%>
MJ7H;0,X0R-G)(/_XIQ$!Y!D">7:Z2')3!I#O$<CWM)"/);#+Q@@))NS*'Q"B
M#[1$RZ:NN7[U85J*C13N;UQ:=I'GJI$VK-N/".1'6L@[T)O^X#S%1N<I+<W%
MCHN*NWN.W=_'2^XVEI W6E@!8:W&J$*('7(K<U4#&RV4,>_8 V@W/G,-(1XF
MD)C8(#=<:/;$JP;8'7#3Z*ZWAGB8.F)B=[CFKQLWCBP$;_.E-Q6+"2,F-H9W
MERN5&[9P@>MS88Z(B26QM"I_+E55@#:_M5ZPKR$;IH:8V UMTQ]?NG 5K59!
MFO:DD ^S0DRLA9^=]9%_Z]<GYH686 P7C;&:5X*SKV" Z[QD7!;L&G90J6T=
M8F)FB(G5X+3O.P/(O-]'$\P0";$A%NXT:8!=;#0<#&P)IH6$6 O_UN65F\#Q
ME=+M*6W->N@0$YU?$.L!S4K^3D),3!,)M2:P3("-0DQ,&0FQ,H[D FSTZ-E[
M;1,S2$)LD",YP1 F)I.$6"8#N<$>\5W(B DE(1;*VR1A$!"S2T(][1C(%@8A
M,;<DQ&XYEC;\! V7.3#;I,2VP0?+-,3$U),2JZ>;Q+'1-5@W:O9J.<5<DQ*[
M!A_$QR$FNIIU2M?TE)ABKDF)78-C]AHCYIJ4V#5'E=BUSA 3<TU*[)JC2CS$
MQ'23$NMF4(E#_1Q33DJLG ,GCMD7KGW1SM=[B(E))R66S@!FN,(>+EMCTLF(
MI3. >=-8UT#9G7^?%&)BTLF(I3.89XSW&[<A)N:@C'J^,XS9%K/[\#5 ACDH
M(W;0$4PWJ;1:Y#;$1-^I$#OH:-XV;D?Y$!-S4$:]8G8<\\V[GPQS4':BQ3/?
MXYV>0DS,0=DO7$,;E$^&R2<CEL\P72]MRS#K9,36.5RQ&HSA#%/.C%@YZ-I5
M+Y0S3#FS[N."_1<%!:R%A.*+NX5QY3FO\@?-_$_WDB2;^?7-=5-55Z[L7BX4
M+_8?*.P_KOC\ U!+ P04    " "9@6I5H9?JE,D!  "@'@  &@   'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QSS=FY;L) %(7A5T%^ (:[F"R"5&G21KR
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MLBH4616*K$,468?_*>N[,:N__CG:W--*%_4QG[5_H*>?4$L! A0#%     @
MF8%J50=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " "9@6I5-=ZFANT    K @  $0
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M965T-"YX;6Q02P$"% ,4    " "9@6I52(R0\K0#   U#   &
M    @($J'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @
MF8%J57D_^'KK#@  +;(  !@              ("!%"(  'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;%!+ 0(4 Q0    ( )F!:E41B;#8KP8  *(;   8
M          " @34Q  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M    " "9@6I5@\^LV747   >0   &               @($:.   >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ F8%J5=(LW/LT$P  &C<
M !@              ("!Q4\  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+
M 0(4 Q0    ( )F!:E7V_GWS2P0  #()   9              " @2]C  !X
M;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ F8%J56MRPO$!
M!   B H  !D              ("!L6<  'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q02P$"% ,4    " "9@6I5\OSWV=T"  !R!@  &0
M@('I:P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( )F!
M:E6,ZB=]AP0  *8+   9              " @?UN  !X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L! A0#%     @ F8%J5;JGS;2D @  $ 8  !D
M         ("!NW,  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M    " "9@6I5ECC^U94$  #L"@  &0              @(&6=@  >&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( )F!:E4;TR(HC@L  )XA
M   9              " @6)[  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L! A0#%     @ F8%J531J/4B<!   U@L  !D              ("!)X<
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " "9@6I5Q1_J
M&NL(   W%@  &0              @('ZBP  >&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+ 0(4 Q0    ( )F!:E5E&I(#& ,  !@'   9
M  " @1R5  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @
MF8%J5;V=<U#] P  PP@  !D              ("!:Y@  'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"% ,4    " "9@6I5< >ZO,L+   2*@  &0
M            @(&?G   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4
M Q0    ( )F!:E7#^[C>T@L  $8J   9              " @:&H  !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ F8%J5?E?9<DN$
MG3<  !D              ("!JK0  'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6Q02P$"% ,4    " "9@6I5Y1T8XED$  #V"P  &0              @($/
MQ0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( )F!:E7(
MK-WAG0(  ,@%   9              " @9_)  !X;"]W;W)K<VAE971S+W-H
M965T,C4N>&UL4$L! A0#%     @ F8%J5;"Y^;_K @  [08  !D
M     ("!<\P  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )F!:E4/WFR4/ (  "$%   9              "
M@=K>  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ F8%J
M59@Z"G4(!0  IAD  !D              ("!3>$  'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"% ,4    " "9@6I5%\>/P:,$   X&0  &0
M        @(&,Y@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0
M   ( )F!:E5@DWRPA0(  ($&   9              " @6;K  !X;"]W;W)K
M<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ F8%J51@TVY[7 @  VPD
M !D              ("!(NX  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q0
M2P$"% ,4    " "9@6I57W2G^QP#  #D#   &0              @($P\0
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( )F!:E76U:<=
M8P,  )00   9              " @8/T  !X;"]W;W)K<VAE971S+W-H965T
M,S<N>&UL4$L! A0#%     @ F8%J5:AV/+C$ @  M@<  !D
M ("!'?@  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " "9
M@6I5CH.I3UL"  "2!0  &0              @($8^P  >&PO=V]R:W-H965T
M<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( )F!:E6]\9A4]P(  ",+   9
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M970T-"YX;6Q02P$"% ,4    " "9@6I5@1=AS.4#  #L%0  &0
M    @('B% $ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (
M )F!:E48*?X^. ,  %<,   9              " @?X8 0!X;"]W;W)K<VAE
M971S+W-H965T-#8N>&UL4$L! A0#%     @ F8%J55F2.<;; @  )P<  !D
M             ("!;1P! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"
M% ,4    " "9@6I5]<:YMW0$  "3&@  &0              @(%_'P$ >&PO
M=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( )F!:E5@E;[=/@(
M "(%   9              " @2HD 0!X;"]W;W)K<VAE971S+W-H965T-#DN
M>&UL4$L! A0#%     @ F8%J5<;1=TE.!P  <D@  !D              ("!
MGR8! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " "9@6I5
M;1;),GT#  ":#P  &0              @($D+@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4Q+GAM;%!+ 0(4 Q0    ( )F!:E7E2GY\5 ,  +@5   -
M      "  =@Q 0!X;"]S='EL97,N>&UL4$L! A0#%     @ F8%J59>*NQS
M    $P(   L              ( !5S4! %]R96QS+RYR96QS4$L! A0#%
M  @ F8%J5<=YQP9#!   X"$   \              ( !0#8! 'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( )F!:E6AE^J4R0$  * >   :
M  "  ; Z 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M )F!:E4HM&@3PP$  (D>   3              "  ;$\ 0!;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     [ #L %!   *4^ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>153</ContextCount>
  <ElementCount>278</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>41</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedStatementsofEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - The Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/TheBusiness</Role>
      <ShortName>The Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Merger</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/Merger</Role>
      <ShortName>Merger</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Available-for-Sale-Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecurities</Role>
      <ShortName>Available-for-Sale-Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Income (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeLossPerShare</Role>
      <ShortName>Income (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Australia Research and Development Tax Incentive</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive</Role>
      <ShortName>Australia Research and Development Tax Incentive</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/LicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Research Collaboration and License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement</Role>
      <ShortName>Research Collaboration and License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Available-for-Sale-Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesTables</Role>
      <ShortName>Available-for-Sale-Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/AvailableforSaleSecurities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Income (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeLossPerShareTables</Role>
      <ShortName>Income (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/IncomeLossPerShare</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/FairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/AccruedLiabilities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/OperatingLeases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/StockholdersEquity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/ShareBasedCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Merger (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/MergerDetails</Role>
      <ShortName>Merger (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/Merger</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails</Role>
      <ShortName>Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails</Role>
      <ShortName>Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails</Role>
      <ShortName>Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Income (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeLossPerShareDetails</Role>
      <ShortName>Income (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/IncomeLossPerShareTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/AccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/AccruedLiabilitiesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Operating Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesNarrativeDetails</Role>
      <ShortName>Operating Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Operating Leases - Balance Sheet Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails</Role>
      <ShortName>Operating Leases - Balance Sheet Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Operating Leases - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Stockholders' Equity - Equity Issuances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails</Role>
      <ShortName>Stockholders' Equity - Equity Issuances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Stockholders' Equity - Stock Options and Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Stock Options and Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails</Role>
      <ShortName>Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails</Role>
      <ShortName>Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails</Role>
      <ShortName>Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/IncomeTaxes</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/IncomeTaxesDetails_1</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/IncomeTaxes</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/LicenseAgreementsDetails</Role>
      <ShortName>License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/LicenseAgreements</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="clbs-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Research Collaboration and License Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails</Role>
      <ShortName>Research Collaboration and License Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement</ParentRole>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  clbs-20220930.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="clbs-20220930.htm">clbs-20220930.htm</File>
    <File>clbs-20220930.xsd</File>
    <File>clbs-20220930_cal.xml</File>
    <File>clbs-20220930_def.xml</File>
    <File>clbs-20220930_lab.xml</File>
    <File>clbs-20220930_pre.xml</File>
    <File>clbs-ex311_20220930xq3.htm</File>
    <File>clbs-ex32_20220930q3.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>clbs-20220930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="581">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>68
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "clbs-20220930.htm": {
   "axisCustom": 0,
   "axisStandard": 15,
   "contextCount": 153,
   "dts": {
    "calculationLink": {
     "local": [
      "clbs-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "clbs-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "clbs-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "clbs-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "clbs-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "clbs-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 412,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 7,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 12
   },
   "keyCustom": 57,
   "keyStandard": 221,
   "memberCustom": 7,
   "memberStandard": 32,
   "nsprefix": "clbs",
   "nsuri": "http://www.caladrius.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "role": "http://www.caladrius.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Merger",
     "role": "http://www.caladrius.com/role/Merger",
     "shortName": "Merger",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Available-for-Sale-Securities",
     "role": "http://www.caladrius.com/role/AvailableforSaleSecurities",
     "shortName": "Available-for-Sale-Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Income (Loss) Per Share",
     "role": "http://www.caladrius.com/role/IncomeLossPerShare",
     "shortName": "Income (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Fair Value Measurements",
     "role": "http://www.caladrius.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Accrued Liabilities",
     "role": "http://www.caladrius.com/role/AccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Operating Leases",
     "role": "http://www.caladrius.com/role/OperatingLeases",
     "shortName": "Operating Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Stockholders' Equity",
     "role": "http://www.caladrius.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Share-Based Compensation",
     "role": "http://www.caladrius.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Income Taxes",
     "role": "http://www.caladrius.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clbs:ResearchAndDevelopmentTaxIncentiveTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Australia Research and Development Tax Incentive",
     "role": "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive",
     "shortName": "Australia Research and Development Tax Incentive",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clbs:ResearchAndDevelopmentTaxIncentiveTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ib12d6f63cd104608b5d9da1ad7e0125b_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.caladrius.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ib12d6f63cd104608b5d9da1ad7e0125b_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Contingencies",
     "role": "http://www.caladrius.com/role/Contingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - License Agreements",
     "role": "http://www.caladrius.com/role/LicenseAgreements",
     "shortName": "License Agreements",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Research Collaboration and License Agreement",
     "role": "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement",
     "shortName": "Research Collaboration and License Agreement",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Available-for-Sale-Securities (Tables)",
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables",
     "shortName": "Available-for-Sale-Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Income (Loss) Per Share (Tables)",
     "role": "http://www.caladrius.com/role/IncomeLossPerShareTables",
     "shortName": "Income (Loss) Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.caladrius.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Accrued Liabilities (Tables)",
     "role": "http://www.caladrius.com/role/AccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Operating Leases (Tables)",
     "role": "http://www.caladrius.com/role/OperatingLeasesTables",
     "shortName": "Operating Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.caladrius.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ib12d6f63cd104608b5d9da1ad7e0125b_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "role": "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ib12d6f63cd104608b5d9da1ad7e0125b_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://www.caladrius.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ib12d6f63cd104608b5d9da1ad7e0125b_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ib12d6f63cd104608b5d9da1ad7e0125b_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Merger (Details)",
     "role": "http://www.caladrius.com/role/MergerDetails",
     "shortName": "Merger (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "iac286da95e1c493abbddee71f1aac890_I20220914",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ib12d6f63cd104608b5d9da1ad7e0125b_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)",
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails",
     "shortName": "Available-for-Sale-Securities - Schedule of Available-for-Sale Securities Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ib12d6f63cd104608b5d9da1ad7e0125b_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ib12d6f63cd104608b5d9da1ad7e0125b_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)",
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails",
     "shortName": "Available-for-Sale-Securities - Classification of Available-for-Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ib12d6f63cd104608b5d9da1ad7e0125b_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ib12d6f63cd104608b5d9da1ad7e0125b_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)",
     "role": "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails",
     "shortName": "Available-for-Sale-Securities - Available-for-Sale Securities by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ib12d6f63cd104608b5d9da1ad7e0125b_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i33f0a817fe2049da85aa3551a5c905e4_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Income (Loss) Per Share (Details)",
     "role": "http://www.caladrius.com/role/IncomeLossPerShareDetails",
     "shortName": "Income (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i33f0a817fe2049da85aa3551a5c905e4_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ib35c54c2e1b14397ae34101068f8d0a3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.caladrius.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ib35c54c2e1b14397ae34101068f8d0a3_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ib12d6f63cd104608b5d9da1ad7e0125b_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Accrued Liabilities (Details)",
     "role": "http://www.caladrius.com/role/AccruedLiabilitiesDetails",
     "shortName": "Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ib12d6f63cd104608b5d9da1ad7e0125b_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ib12d6f63cd104608b5d9da1ad7e0125b_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "clbs:NumberOfOfficesUnderOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "office",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Operating Leases - Narrative (Details)",
     "role": "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails",
     "shortName": "Operating Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ib12d6f63cd104608b5d9da1ad7e0125b_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "clbs:NumberOfOfficesUnderOperatingLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "office",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Statements of Operations",
     "role": "http://www.caladrius.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ib12d6f63cd104608b5d9da1ad7e0125b_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Operating Leases - Balance Sheet Presentation (Details)",
     "role": "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails",
     "shortName": "Operating Leases - Balance Sheet Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "clbs:LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ib12d6f63cd104608b5d9da1ad7e0125b_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ib12d6f63cd104608b5d9da1ad7e0125b_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Operating Leases - Future Minimum Lease Payments (Details)",
     "role": "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails",
     "shortName": "Operating Leases - Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ib12d6f63cd104608b5d9da1ad7e0125b_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i7128331c98ad445b8fb23487460be1ba_I20190930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Stockholders' Equity - Equity Issuances (Details)",
     "role": "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails",
     "shortName": "Stockholders' Equity - Equity Issuances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i7128331c98ad445b8fb23487460be1ba_I20190930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "clbs:SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ib97be91eba48467897085df19e17a272_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Stockholders' Equity - Stock Options and Warrants (Details)",
     "role": "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails",
     "shortName": "Stockholders' Equity - Stock Options and Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ib889d615bc824253bdc29e6be132de5e_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)",
     "role": "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails",
     "shortName": "Stockholders' Equity - Restricted Stock and Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ib889d615bc824253bdc29e6be132de5e_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Details)",
     "role": "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails",
     "shortName": "Share-Based Compensation - Share-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i018aef0ebc684655bb91626b836264c8_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)",
     "role": "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
     "shortName": "Share-Based Compensation - Compensation Cost Not Yet Recognized (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i018aef0ebc684655bb91626b836264c8_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ifb50bb2a566f4b72a4ec8baa84a38a44_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)",
     "role": "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
     "shortName": "Share-Based Compensation - Fair Value of Shares Vested and Weighted Average Estimated Fair Value of Shares Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ifb50bb2a566f4b72a4ec8baa84a38a44_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ib97be91eba48467897085df19e17a272_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "clbs:OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Income Taxes (Details)",
     "role": "http://www.caladrius.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ib97be91eba48467897085df19e17a272_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "clbs:OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Income Taxes (Details)",
     "role": "http://www.caladrius.com/role/IncomeTaxesDetails_1",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ifab8e1ed99814befae83b3f9f40d2157_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i0050d762a7e64fa192ac048bca1f9775_I20211031",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - License Agreements (Details)",
     "role": "http://www.caladrius.com/role/LicenseAgreementsDetails",
     "shortName": "License Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i0050d762a7e64fa192ac048bca1f9775_I20211031",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "clbs:CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ic23e1c2433b54fffa2ed10e25463b457_I20210228",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Research Collaboration and License Agreement (Details)",
     "role": "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
     "shortName": "Research Collaboration and License Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "ic23e1c2433b54fffa2ed10e25463b457_I20210228",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i848e51e03eed447c935cb2899345a1ff_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Equity",
     "role": "http://www.caladrius.com/role/ConsolidatedStatementsofEquity",
     "shortName": "Consolidated Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i848e51e03eed447c935cb2899345a1ff_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clbs:BusinessTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - The Business",
     "role": "http://www.caladrius.com/role/TheBusiness",
     "shortName": "The Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "clbs:BusinessTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "clbs-20220930.htm",
      "contextRef": "i608d0b6add234b58ad5c39d84784ba87_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 41,
   "tag": {
    "clbs_AggregateIntrinsicValueWarrantsOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Intrinsic Value, Warrants Outstanding",
        "label": "Aggregate Intrinsic Value, Warrants Outstanding",
        "terseLabel": "Warrants Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "AggregateIntrinsicValueWarrantsOutstanding",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_AggregateIntrinsicValueWarrantsvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Intrinsic Value, Warrants vested",
        "label": "Aggregate Intrinsic Value, Warrants vested",
        "terseLabel": "Warrants, Vested, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "AggregateIntrinsicValueWarrantsvested",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_AggregateIntrinsicValueWarrantsvestedandexpectedtovest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Intrinsic Value, Warrants vested and expected to vest",
        "label": "Aggregate Intrinsic Value, Warrants vested and expected to vest",
        "terseLabel": "Warrants, Vested and expected to vest, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "AggregateIntrinsicValueWarrantsvestedandexpectedtovest",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_AtTheMarketOfferingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering Agreement",
        "label": "At The Market Offering Agreement [Member]",
        "terseLabel": "ATM Agreement"
       }
      }
     },
     "localname": "AtTheMarketOfferingAgreementMember",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_BusinessTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Business [Text Block]",
        "label": "The Business [Text Block]",
        "terseLabel": "The Business"
       }
      }
     },
     "localname": "BusinessTextBlock",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/TheBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clbs_CENDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CEND",
        "label": "CEND [Member]",
        "terseLabel": "CEND"
       }
      }
     },
     "localname": "CENDMember",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_ClinicalAndRDRelatedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical and R&amp;D Related Liabilities",
        "label": "Clinical and R&amp;D Related Liabilities",
        "terseLabel": "Clinical and R&amp;D related liabilities"
       }
      }
     },
     "localname": "ClinicalAndRDRelatedLiabilities",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee",
        "label": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee",
        "terseLabel": "Annual license maintenance fee"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFee",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee After First Sale",
        "label": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee After First Sale",
        "terseLabel": "Annual license maintenance fee, after first sale"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeAfterFirstSale",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven",
        "label": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Starting at Year Seven",
        "terseLabel": "Annual license maintenance fee, year seven"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeStartingAtYearSeven",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Four",
        "label": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Four",
        "terseLabel": "Annual license maintenance fee, year four"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearFour",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Two and Three",
        "label": "Collaborative Arrangement, Rights and Obligations, Annual License Maintenance Fee Year Two and Three",
        "terseLabel": "Annual license maintenance fee, years two and three"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsAnnualLicenseMaintenanceFeeYearTwoAndThree",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_CollaborativeArrangementRightsAndObligationsChangeOfControlFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Change of Control Fee",
        "label": "Collaborative Arrangement, Rights and Obligations, Change of Control Fee",
        "terseLabel": "Change of control fee"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsChangeOfControlFee",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product",
        "label": "Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments, Per Product",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePaymentsPerProduct",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales",
        "label": "Collaborative Arrangement, Rights and Obligations, Royalties Net of Sales",
        "terseLabel": "Royalties, net of sales"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsRoyaltiesNetOfSales",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clbs_CollaborativeArrangementRightsAndObligationsSublicensingFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Sublicensing Fees",
        "label": "Collaborative Arrangement, Rights and Obligations, Sublicensing Fees",
        "terseLabel": "Sublicensing fee"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsSublicensingFees",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_CommonStockWarrantsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants, Shares",
        "label": "Common Stock Warrants, Shares",
        "periodEndLabel": "Warrants, Outstanding, End of Period (in shares)",
        "periodStartLabel": "Warrants, Outstanding, Beginning of Period (in shares)"
       }
      }
     },
     "localname": "CommonStockWarrantsShares",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities",
        "label": "Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities",
        "terseLabel": "Accounts payable, accrued liabilities and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]",
        "label": "Lessee, Operating Lease, Balance Sheet Presentation [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease Liabilities and Right-of-Use Assets on Balance Sheet"
       }
      }
     },
     "localname": "LesseeOperatingLeaseBalanceSheetPresentationTableTextBlock",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clbs_LincolnParkAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lincoln Park Agreement [Member]",
        "label": "Lincoln Park Agreement [Member]",
        "terseLabel": "Lincoln Park Agreement"
       }
      }
     },
     "localname": "LincolnParkAgreementMember",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_LossOnSaleOfNetOperatingLosses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss On Sale Of Net Operating Losses",
        "label": "Loss On Sale Of Net Operating Losses",
        "terseLabel": "Loss on sale of NOLs"
       }
      }
     },
     "localname": "LossOnSaleOfNetOperatingLosses",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_MassachusettsInstituteOfTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Massachusetts Institute of Technology",
        "label": "Massachusetts Institute of Technology [Member]",
        "terseLabel": "Massachusetts Institute of Technology"
       }
      }
     },
     "localname": "MassachusettsInstituteOfTechnologyMember",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_NumberOfOfficesUnderOperatingLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Offices Under Operating Leases",
        "label": "Number Of Offices Under Operating Leases",
        "terseLabel": "Number of offices under operating leases"
       }
      }
     },
     "localname": "NumberOfOfficesUnderOperatingLeases",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "clbs_OperatingLeaseRightOfUseAssetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Right-Of-Use Asset",
        "label": "Operating Lease, Right-Of-Use Asset [Abstract]",
        "terseLabel": "Right-of Use Assets:"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAbstract",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clbs_OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Annual Available, Five Years, Net Unrealized Built In Gain",
        "label": "Operating Loss Carryforwards, Annual Available, Five Years, Net Unrealized Built In Gain",
        "terseLabel": "Possible additional NOLs for five years resulting from Net Unrealized Built-in Gain rules"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsAnnualAvailableFiveYearsNetUnrealizedBuiltInGain",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_OperatingLossCarryforwardsBeforeWriteDown": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Before Write Down",
        "label": "Operating Loss Carryforwards, Before Write Down",
        "terseLabel": "Net operating loss carryforwards, prior to write down"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsBeforeWriteDown",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_OperatingLossCarryforwardsSetToExpireWrittenDown": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Set To Expire, Written Down",
        "label": "Operating Loss Carryforwards, Set To Expire, Written Down",
        "terseLabel": "Write down of NOLs set to expire unutilized"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsSetToExpireWrittenDown",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_OptionsVestedweightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options, Vested, weighted Average Remaining Contractual Term",
        "label": "Options, Vested, weighted Average Remaining Contractual Term",
        "terseLabel": "Options, Vested, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "OptionsVestedweightedAverageRemainingContractualTerm",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "clbs_PreferredStockLiquidationPreferenceShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Liquidation Preference, Share",
        "label": "Preferred Stock, Liquidation Preference, Share",
        "terseLabel": "Preferred stock, liquidation value"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreferenceShare",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_PreferredStockSharesDesignated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock, shares designated",
        "label": "Preferred stock, shares designated",
        "terseLabel": "Preferred stock, shares designated"
       }
      }
     },
     "localname": "PreferredStockSharesDesignated",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgram": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Sale Of Net Operating Losses, NJEDA Program",
        "label": "Proceeds From Sale Of Net Operating Losses, NJEDA Program",
        "terseLabel": "Net proceeds from sale of NOLs"
       }
      }
     },
     "localname": "ProceedsFromSaleOfNetOperatingLossesNJEDAProgram",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross",
        "label": "Proceeds From Sale Of Net Operating Losses, NJEDA Program, Gross",
        "terseLabel": "Proceeds from sale of NOLs, gross"
       }
      }
     },
     "localname": "ProceedsFromSaleOfNetOperatingLossesNJEDAProgramGross",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_QiluMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Qilu",
        "label": "Qilu [Member]",
        "terseLabel": "Qilu"
       }
      }
     },
     "localname": "QiluMember",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Registration Rights Agreement, Maximum Beneficial Ownership Allowable For Counterparty",
        "label": "Registration Rights Agreement, Maximum Beneficial Ownership Allowable For Counterparty",
        "terseLabel": "Maximum beneficial ownership allowable per agreement (percent)"
       }
      }
     },
     "localname": "RegistrationRightsAgreementMaximumBeneficialOwnershipAllowableForCounterparty",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clbs_ResearchAndDevelopmentTaxIncentiveTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Tax Incentive",
        "label": "Research and Development Tax Incentive [Text Block]",
        "terseLabel": "Australia Research and Development Tax Incentive"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxIncentiveTextBlock",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/AustraliaResearchandDevelopmentTaxIncentive"
     ],
     "xbrltype": "textBlockItemType"
    },
    "clbs_RevenuePerformanceObligationPercentageOfNetSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Percentage of Net Sale",
        "label": "Revenue, Performance Obligation, Percentage of Net Sale",
        "terseLabel": "Percentage of net sale"
       }
      }
     },
     "localname": "RevenuePerformanceObligationPercentageOfNetSale",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clbs_RevenuePerformanceObligationPercentageOfSublicensingRevenues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Percentage of Sublicensing Revenues",
        "label": "Revenue, Performance Obligation, Percentage of Sublicensing Revenues",
        "terseLabel": "Percentage of sublicensing revenues"
       }
      }
     },
     "localname": "RevenuePerformanceObligationPercentageOfSublicensingRevenues",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clbs_RevenueRemainingPerformanceObligationVariableConsiderationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "terseLabel": "Variable consideration amounts, milestones"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement",
        "label": "Sale Of Stock, Aggregate Offering Amount Authorized Per Agreement",
        "terseLabel": "Aggregate offering amount authorized per agreement"
       }
      }
     },
     "localname": "SaleOfStockAggregateOfferingAmountAuthorizedPerAgreement",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Amount Per Agreement, Allowable To Direct Counterparty To Purchase, Regular Purchase",
        "label": "Sale Of Stock, Amount Per Agreement, Allowable To Direct Counterparty To Purchase, Regular Purchase",
        "terseLabel": "Number of shares allowable to direct for Regular Purchase (in shares)"
       }
      }
     },
     "localname": "SaleOfStockAmountPerAgreementAllowableToDirectCounterpartyToPurchaseRegularPurchase",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Amount Per Agreement Per Transaction For Direct Counterparty Purchase, Regular Purchase",
        "label": "Sale Of Stock, Maximum Amount Per Agreement Per Transaction For Direct Counterparty Purchase, Regular Purchase",
        "terseLabel": "Maximum obligation per directed purchase transaction for Regular Purchase"
       }
      }
     },
     "localname": "SaleOfStockMaximumAmountPerAgreementPerTransactionForDirectCounterpartyPurchaseRegularPurchase",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares In Regular Purchase",
        "label": "Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares In Regular Purchase",
        "terseLabel": "Maximum shares allowed in Accelerated Purchase as percent of shares In Regular Purchase (percent)"
       }
      }
     },
     "localname": "SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesInRegularPurchase",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clbs_SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares Of Stock Traded During Specified Period",
        "label": "Sale Of Stock, Maximum Shares Allowed In Accelerated Purchase As Percent Of Shares Of Stock Traded During Specified Period",
        "terseLabel": "Maximum shares allowed in Accelerated Purchase as percent of shares traded during specified period (percent)"
       }
      }
     },
     "localname": "SaleOfStockMaximumSharesAllowedInAcceleratedPurchaseAsPercentOfSharesOfStockTradedDuringSpecifiedPeriod",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "clbs_SanfordBurnhamPrebysMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanford Burnham Prebys",
        "label": "Sanford Burnham Prebys [Member]",
        "terseLabel": "Sanford Burnham Prebys"
       }
      }
     },
     "localname": "SanfordBurnhamPrebysMember",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_SharesHeldByThirdParty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Held by Third Party",
        "label": "Shares Held by Third Party",
        "terseLabel": "Shares held by third party"
       }
      }
     },
     "localname": "SharesHeldByThirdParty",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_SharesIssuedUnderLicenseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Issued Under License Agreement",
        "label": "Shares Issued Under License Agreement",
        "terseLabel": "Shares issued under license agreement"
       }
      }
     },
     "localname": "SharesIssuedUnderLicenseAgreement",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_Sharesvestedandexpectedtovest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "shares, vested and expected to vest",
        "label": "shares, vested and expected to vest",
        "terseLabel": "Warrants, Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "Sharesvestedandexpectedtovest",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_StockIssuedDuringPeriodSharesIssuedAsConsideration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Issued As Consideration",
        "label": "Stock Issued During Period, Shares, Issued As Consideration",
        "terseLabel": "Commitment shares issued as consideration per agreement (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedAsConsideration",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_TermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Of Agreement",
        "label": "Term Of Agreement",
        "terseLabel": "Term of agreement (in months)"
       }
      }
     },
     "localname": "TermOfAgreement",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "clbs_UniversityOfCaliforniaAtSanDiegoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of California at San Diego",
        "label": "University of California at San Diego [Member]",
        "terseLabel": "University of California at San Diego"
       }
      }
     },
     "localname": "UniversityOfCaliforniaAtSanDiegoMember",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "clbs_WarrantsCanceled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Canceled",
        "label": "Warrants Canceled",
        "negatedLabel": "Warrants, Forfeited (in shares)"
       }
      }
     },
     "localname": "WarrantsCanceled",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_WarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Exercised",
        "label": "Warrants Exercised",
        "negatedTerseLabel": "Warrants, Exercised (in shares)"
       }
      }
     },
     "localname": "WarrantsExercised",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_WarrantsExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Expired",
        "label": "Warrants Expired",
        "negatedTerseLabel": "Warrants, Expired (in shares)"
       }
      }
     },
     "localname": "WarrantsExpired",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_WarrantsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Granted",
        "label": "Warrants Granted",
        "terseLabel": "Warrants, Granted (in shares)"
       }
      }
     },
     "localname": "WarrantsGranted",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_WarrantsOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Other Disclosures",
        "label": "Warrants Other Disclosures [Abstract]",
        "terseLabel": "Warrants, Weighted Average Contractual Term and Intrinsic Value"
       }
      }
     },
     "localname": "WarrantsOtherDisclosuresAbstract",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clbs_WarrantsVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Vested",
        "label": "Warrants, Vested",
        "terseLabel": "Warrants, Vested (in shares)"
       }
      }
     },
     "localname": "WarrantsVested",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "clbs_WarrantsWeightedAverageExercisePriceRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Weighted Average Exercise Price [Roll Forward]",
        "label": "Warrants Weighted Average Exercise Price [Roll Forward]",
        "terseLabel": "Warrants, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "WarrantsWeightedAverageExercisePriceRollForward",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsCanceled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Canceled",
        "label": "Weighted Average Exercise Price, Warrants Canceled",
        "terseLabel": "Warrants, Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsCanceled",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Exercisable",
        "label": "Weighted Average Exercise Price, Warrants Exercisable",
        "terseLabel": "Warrants, Vested, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsExercisable",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Exercised",
        "label": "Weighted Average Exercise Price, Warrants Exercised",
        "terseLabel": "Warrants, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsExercised",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Expired",
        "label": "Weighted Average Exercise Price, Warrants Expired",
        "terseLabel": "Warrants, Expired (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsExpired",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Granted",
        "label": "Weighted Average Exercise Price, Warrants Granted",
        "terseLabel": "Warrants, Granted (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsGranted",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Outstanding",
        "label": "Weighted Average Exercise Price, Warrants Outstanding",
        "periodEndLabel": "Warrants Outstanding, End of Period (in dollars per share)",
        "periodStartLabel": "Warrants Outstanding, Beginning of Period (in dollars per share)"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsOutstanding",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants Vested And Expected To Vest",
        "label": "Weighted Average Exercise Price, Warrants Vested And Expected To Vest",
        "terseLabel": "Weighted Average Exercise Price, Warrants Vested And Expected To Vest"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "clbs_WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest",
        "label": "Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest",
        "terseLabel": "Warrants, Vested and expected to vest, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "clbs_WeightedAverageRemainingContractualTermwarrantoutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Contractual Term warrant outstanding",
        "label": "Weighted Average Remaining Contractual Term warrant outstanding",
        "terseLabel": "Warrants, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualTermwarrantoutstanding",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "clbs_WeightedAverageRemainingContractualTermwarrantsvested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "weighted Average Remaining Contractual Term, warrants vested",
        "label": "weighted Average Remaining Contractual Term, warrants vested",
        "terseLabel": "Warrants, Vested, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualTermwarrantsvested",
     "nsuri": "http://www.caladrius.com/20220930",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Legal or Registered Name of an entity",
        "label": "Entity Information, Former Legal or Registered Name",
        "terseLabel": "Entity Information, Former Legal or Registered Name"
       }
      }
     },
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.caladrius.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r37",
      "r39",
      "r92",
      "r93",
      "r197",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r196",
      "r207",
      "r256",
      "r258",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r408",
      "r442",
      "r444",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r196",
      "r207",
      "r256",
      "r258",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r408",
      "r442",
      "r444",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r141",
      "r242",
      "r244",
      "r409",
      "r441",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r141",
      "r242",
      "r244",
      "r409",
      "r441",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r196",
      "r207",
      "r246",
      "r256",
      "r258",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r408",
      "r442",
      "r444",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r196",
      "r207",
      "r246",
      "r256",
      "r258",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r408",
      "r442",
      "r444",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r38",
      "r39",
      "r92",
      "r93",
      "r197",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r25",
      "r377"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Accretion on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails",
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities [Abstract]",
        "terseLabel": "Accrued Liabilities [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r16",
      "r44",
      "r45",
      "r46",
      "r429",
      "r449",
      "r450"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r43",
      "r46",
      "r53",
      "r54",
      "r55",
      "r95",
      "r96",
      "r97",
      "r337",
      "r445",
      "r446",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r14",
      "r291",
      "r377"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r288",
      "r289",
      "r290",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r260",
      "r284",
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r89",
      "r133",
      "r135",
      "r139",
      "r161",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r331",
      "r338",
      "r355",
      "r375",
      "r377",
      "r412",
      "r428"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r36",
      "r89",
      "r161",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r331",
      "r338",
      "r355",
      "r375",
      "r377"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.caladrius.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Assets, fair value disclosure"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r148"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r145",
      "r168"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails",
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year",
        "verboseLabel": "Less than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Remainder of Fiscal Year",
        "terseLabel": "Less than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Amortized Cost",
        "verboseLabel": "Greater than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year through fifth year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling after One Through Five Years, Fair Value",
        "terseLabel": "Greater than one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r143",
      "r146",
      "r168",
      "r415"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "totalLabel": "Total estimated fair value",
        "verboseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesAvailableforSaleSecuritiesbyContractualMaturityDetails",
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r262",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r255",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r255",
      "r257",
      "r314",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Business Acquisition, Share Price"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Business Combination, Acquisition Related Costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r318",
      "r319"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r316",
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r316",
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Business Combination, Consideration Transferred"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CaliforniaFranchiseTaxBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of California.",
        "label": "California Franchise Tax Board [Member]",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CaliforniaFranchiseTaxBoardMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r22",
      "r79"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets",
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Available-for-Sale-Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r74",
      "r79",
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r74",
      "r358"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r322",
      "r323",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License Agreements",
        "verboseLabel": "Research Collaboration and License Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreements",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r31",
      "r182",
      "r416",
      "r434"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 13)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r183",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r13",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common stock, ending balance (in shares)",
        "periodStartLabel": "Common stock, beginning balance (in shares)",
        "terseLabel": "Common stock, shares, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals",
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity",
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r13",
      "r377"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value, authorized 33,333,333 shares; issued 7,863,340 and 3,986,719 shares at September 30, 2022 and December 31, 2021, respectively; and outstanding, 7,862,602 and 3,985,981 shares at September 30, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r49",
      "r51",
      "r52",
      "r60",
      "r421",
      "r437"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Lisata Therapeutics, Inc. common stockholders"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r126",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Risks"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r85",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r232",
      "r233",
      "r243"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Contract with customer, liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r247",
      "r254",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r77",
      "r175"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r262",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "terseLabel": "Schedule of Total Compensation Cost Related to Nonvested Awards"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r61",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r108",
      "r110",
      "r112",
      "r113",
      "r114",
      "r118",
      "r119",
      "r345",
      "r346",
      "r422",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Caladrius Biosciences, Inc. common stockholders - basic (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Basic and diluted loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r61",
      "r100",
      "r101",
      "r102",
      "r103",
      "r104",
      "r110",
      "r112",
      "r113",
      "r114",
      "r118",
      "r119",
      "r345",
      "r346",
      "r422",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Caladrius Biosciences, Inc. common stockholders - diluted (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Income (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r358"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r296",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research tax credit rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails_1"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Salaries, employee benefits and related taxes"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Expected weighted-average period in years of compensation cost to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r53",
      "r54",
      "r55",
      "r95",
      "r96",
      "r97",
      "r99",
      "r105",
      "r107",
      "r121",
      "r162",
      "r221",
      "r228",
      "r288",
      "r289",
      "r290",
      "r303",
      "r304",
      "r344",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r445",
      "r446",
      "r447",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Assets Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r198",
      "r200",
      "r201",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r348",
      "r381",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r347",
      "r348",
      "r349",
      "r350",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r198",
      "r247",
      "r248",
      "r253",
      "r254",
      "r348",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r198",
      "r200",
      "r201",
      "r247",
      "r248",
      "r253",
      "r254",
      "r348",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r198",
      "r200",
      "r201",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r348",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r351",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r198",
      "r200",
      "r201",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r381",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r352",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Finance Minimum Lease Payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r151",
      "r152",
      "r158",
      "r159",
      "r160",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r169",
      "r170",
      "r171",
      "r172",
      "r199",
      "r219",
      "r343",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r174",
      "r410"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Finite-Lived Intangible Assets, Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets",
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-lived Intangible Assets Acquired",
        "terseLabel": "Finite-lived Intangible Assets Acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r78",
      "r356",
      "r357"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedTerseLabel": "Foreign Currency Transaction Gain (Loss), Unrealized"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Remeasurement"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r57",
      "r133",
      "r134",
      "r137",
      "r138",
      "r140",
      "r411",
      "r418",
      "r423",
      "r439"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before benefit from income taxes and noncontrolling interests"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r177",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Total share-based compensation expense"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r297",
      "r299",
      "r300",
      "r305",
      "r308",
      "r310",
      "r311",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r91",
      "r106",
      "r107",
      "r132",
      "r295",
      "r306",
      "r309",
      "r440"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Benefit from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "auth_ref": [
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "terseLabel": "Research tax credit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails_1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r64",
      "r66"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Investment income, net"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Investments Classified by Contractual Maturity Date"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://www.caladrius.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Marketable securities - available for sale"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r23"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments Under Lease Agreements"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r372"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: Amounts representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r27",
      "r89",
      "r136",
      "r161",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r332",
      "r338",
      "r339",
      "r355",
      "r375",
      "r376"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r19",
      "r89",
      "r161",
      "r355",
      "r377",
      "r414",
      "r432"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, non-controlling interests and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAssumed1": {
     "auth_ref": [
      "r80",
      "r81",
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.",
        "label": "Liabilities Assumed",
        "terseLabel": "Incremental fair value of Cend's fully vested stock options assumed"
       }
      }
     },
     "localname": "LiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r29",
      "r89",
      "r161",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r332",
      "r338",
      "r339",
      "r355",
      "r375",
      "r376",
      "r377"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0
      },
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesClassificationofAvailableforSaleSecuritiesDetails",
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Schedule of Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "auth_ref": [
      "r3",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures.  This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "terseLabel": "Merger"
       }
      }
     },
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/Merger"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r35",
      "r89",
      "r161",
      "r185",
      "r189",
      "r190",
      "r191",
      "r194",
      "r195",
      "r355",
      "r413",
      "r431"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r74",
      "r75",
      "r78"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r47",
      "r50",
      "r55",
      "r58",
      "r78",
      "r89",
      "r98",
      "r100",
      "r101",
      "r102",
      "r103",
      "r106",
      "r107",
      "r111",
      "r133",
      "r134",
      "r137",
      "r138",
      "r140",
      "r161",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r346",
      "r355",
      "r419",
      "r435"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss attributable to Lisata Therapeutics, Inc. common stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewJerseyDivisionOfTaxationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of New Jersey.",
        "label": "New Jersey Division of Taxation [Member]",
        "terseLabel": "New Jersey"
       }
      }
     },
     "localname": "NewJerseyDivisionOfTaxationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of New York.",
        "label": "New York State Division of Taxation and Finance [Member]",
        "terseLabel": "New York"
       }
      }
     },
     "localname": "NewYorkStateDivisionOfTaxationAndFinanceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash investing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r228",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- Controlling Interest in Subsidiary"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Activity"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating Expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r133",
      "r134",
      "r137",
      "r138",
      "r140"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r368"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Operating lease liabilities",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails",
      "http://www.caladrius.com/role/OperatingLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]",
        "terseLabel": "Operating Lease Liabilities:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r368"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities \u2014 current",
        "verboseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails",
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating lease liabilities, current, balance sheet line item"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r368"
     ],
     "calculation": {
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating lease liabilities, noncurrent, balance sheet line item"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Right-of-use assets, balance sheet line item"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesBalanceSheetPresentationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r371",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate for operating leases (percent)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r370",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term for operating leases (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r28"
     ],
     "calculation": {
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r329",
      "r330",
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r41",
      "r42",
      "r44"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized loss on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r48",
      "r51",
      "r53",
      "r54",
      "r56",
      "r59",
      "r221",
      "r359",
      "r364",
      "r365",
      "r420",
      "r436"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Total other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r41",
      "r44"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Available for sale securities - net unrealized gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Total Lisata Therapeutics, Inc. Stockholders' Equity"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r68",
      "r70"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Investment in Cend Therapeutics"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Tax withholding payments on net share settlement equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r12",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r12",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred stock, ending balance (in shares)",
        "periodStartLabel": "Preferred stock, beginning balance (in shares)",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals",
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r12",
      "r377"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.000067 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at September 30, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r20",
      "r21"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r71",
      "r287"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "verboseLabel": "Proceeds from exercise of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r47",
      "r50",
      "r55",
      "r73",
      "r89",
      "r98",
      "r106",
      "r107",
      "r133",
      "r134",
      "r137",
      "r138",
      "r140",
      "r161",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r329",
      "r334",
      "r335",
      "r341",
      "r342",
      "r346",
      "r355",
      "r423"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.caladrius.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r176",
      "r377",
      "r426",
      "r433"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r15",
      "r228",
      "r291",
      "r377",
      "r430",
      "r448",
      "r450"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r95",
      "r96",
      "r97",
      "r99",
      "r105",
      "r107",
      "r162",
      "r288",
      "r289",
      "r290",
      "r303",
      "r304",
      "r344",
      "r445",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "auth_ref": [
      "r321",
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "terseLabel": "Revenue from contract"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r86",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Gross price for stock transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock, Name of Transaction [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price of shares sold (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Available-for-sale Securities Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r149",
      "r150",
      "r153",
      "r154",
      "r155",
      "r156",
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r314",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/MergerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r260",
      "r283",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule Share-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r262",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r267",
      "r276",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option and Warrants Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Share-based Compensation Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r32",
      "r87",
      "r122",
      "r123",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r210",
      "r214",
      "r219",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Noncash Expense [Abstract]",
        "terseLabel": "Share-based Payment Arrangement, Noncash Expense [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting terms (years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average estimated fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Warrants, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Stock Options, Weighted Average Contractual Term and Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Options, Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options, Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Options, Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average estimated fair value of shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options, Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r269",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options, Outstanding, End of Period (in shares)",
        "periodStartLabel": "Options, Outstanding, Beginning of Period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Stock Options, Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options, Outstanding, End of Period (in dollars per share)",
        "periodStartLabel": "Options, Outstanding. Beginning of Period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Stock Options, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r280"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Options, Vested, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Options, Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Options, Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Options, Vested and expected to vest, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options, Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options, Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r259",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationCompensationCostNotYetRecognizedDetails",
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails",
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r262",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options, Vested and expected to vest, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ShareBasedCompensationFairValueofSharesVestedandWeightedAverageEstimatedFairValueofSharesGrantedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r84",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r33",
      "r53",
      "r54",
      "r55",
      "r95",
      "r96",
      "r97",
      "r99",
      "r105",
      "r107",
      "r121",
      "r162",
      "r221",
      "r228",
      "r288",
      "r289",
      "r290",
      "r303",
      "r304",
      "r344",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r445",
      "r446",
      "r447",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Statement, Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r121",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r80",
      "r81",
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Issuance of common stock in connection with merger"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r12",
      "r13",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Issuance of common stock in connection with Merger (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r12",
      "r13",
      "r221",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Stock issued (shares)",
        "verboseLabel": "Net proceeds from issuance of common stock and warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity",
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r221",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r12",
      "r13",
      "r221",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r12",
      "r13",
      "r221",
      "r228",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options, Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityStockOptionsandWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r33",
      "r221",
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Issuance of common stock in connection with merger"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r12",
      "r13",
      "r221",
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Net proceeds from issuances of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r12",
      "r13",
      "r221",
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Value of shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityRestrictedStockandRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r12",
      "r13",
      "r228",
      "r261",
      "r277"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r33",
      "r221",
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Proceeds from option exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r13",
      "r17",
      "r18",
      "r89",
      "r142",
      "r161",
      "r355",
      "r377"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Lisata Therapeutics, Inc. stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r54",
      "r89",
      "r95",
      "r96",
      "r97",
      "r99",
      "r105",
      "r161",
      "r162",
      "r228",
      "r288",
      "r289",
      "r290",
      "r303",
      "r304",
      "r327",
      "r328",
      "r340",
      "r344",
      "r355",
      "r359",
      "r360",
      "r365",
      "r446",
      "r447",
      "r468"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets",
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r88",
      "r206",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r228",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/StockholdersEquityEquityIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r151",
      "r152",
      "r158",
      "r159",
      "r160",
      "r199",
      "r219",
      "r343",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Treasury stock (shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockCommonValue": {
     "auth_ref": [
      "r34",
      "r229",
      "r230"
     ],
     "calculation": {
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Value",
        "negatedTerseLabel": "Treasury stock, at cost; 738 shares at September 30, 2022 and December 31, 2021"
       }
      }
     },
     "localname": "TreasuryStockCommonValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/LicenseAgreementsDetails",
      "http://www.caladrius.com/role/ResearchCollaborationandLicenseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USStatesAndPoliticalSubdivisionsMember": {
     "auth_ref": [
      "r247",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments.",
        "label": "US States and Political Subdivisions Debt Securities [Member]",
        "terseLabel": "Municipal debt securities"
       }
      }
     },
     "localname": "USStatesAndPoliticalSubdivisionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/AvailableforSaleSecuritiesScheduleofAvailableforSaleSecuritiesReconciliationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r124",
      "r125",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/IncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r109",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted shares"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted average common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r108",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic shares"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.caladrius.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=123385629&loc=SL5834089-161433"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r455": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r456": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r457": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r458": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r459": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r460": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r461": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r462": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r463": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r464": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r465": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r466": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r467": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>69
<FILENAME>0000320017-22-000102-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000320017-22-000102-xbrl.zip
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MIG5P[>#9G<N#DPUR^';WY.!ZFQR0 W3XJ4KJ'Q5Z1PZO#CXY46\<X-K6 3N
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MBT?0B845ID]<[()3E@?'-69@00UFED<)^I=ZX7U<0.).(Q@Q?4)[K1"V.@"
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M'9K^-EP"Y",J<HX]8E9Z[5.=7ZX-E1XC2Q:/JI-*KID\+0,.BMN()/&**0S
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M.I/R"<='&LO N'*AN?*">2\5TL8J\#D(5MP-U[ 7@333\ G'1Z:05AP0-YR
M!#%P,*Q@P3+&0<4Y']'BD&G*/N'X2*8XN.P&,Q2D9Y%B%5-UTX@,=]&285VP
M12#91'W",6H^98ATF"(?":.8@)?!&"82F\BCHG1AZ#-IGW",(A2-%R1ZZBC(
MDD2*1LJ 9$(B8<%.+0R))N 3CH\J,6U ,M$(2QT3@EOM<# !>>M3NC9>&*I,
MP2<<H^S0(!7C5#,-SB 'DX.H#1:G8P ,]A,T/].: 61$1%C@Z(1B&MP/P8U4
M,=B M'"$3^%8O;FWQ ]7?R=_Z%],9#4" 44E$TAJXW5(QTVR@(P<'O"P4%2=
M5(+5Y&F)I$'64@*TPT"^5"[72NN"CH1&I<SBT7*B"5:3)Z@2&DM/M?*4, D(
M@7,P0@I93BGU8@&%<VH)5I,G+A5:I5J5TEC#M$D[AK1BV&-K,$8.+R!Q9R'!
M:O*$YMH$9[B5AJ?D$*^1-9(*+[77GL7165\S3-^_!SW 0;W>A@/Z]@H!+2GK
MFK;W>G.[MO6B*'Y\-4B-(TIXHWG CFEJK/4^!(DC-L8I/3I/4F.V),6728'9
M.$@!HL 5\\ZGPI82%*&0D:*(7/3@ ?,Y*M8P#9I,OP@#\5S(@*PDA+!@E0X(
M8\U\=$Y0[OCLJ[4W>=NT76Z:.\#&W4%Z^B&\[)YUNC _6\'V]X(;=(&X85[J
MR2.M;$2:(<H]8X&8R#@&7P\48!2,S4%URYDDT/CJOW$)0%X%<+,98PA0@>=(
M8@- WVGE\!Q4DW\&@5JMT$UWO#<P,W,B.4$CS)D)%HP3TP+<ZJB0#H:F^LM"
MZX60G,D19GP2XSP20GI)8<J89U0;P ^<".24#6E3ROQ+3!4\IZNJZ9Z&_IM!
MV\^+L2$<$:"%UT9:)IRS .B0%DASE X'FH,ZL+-%F3%6&54H,*14--& Q CM
M.25:XB"-DMS/P8%:WZ3,_EX1@>AMM/W[3A,@@#/-O8'U^7F>6IH7&4(Z[;0C
M#''O&5;22$HE24=#>F:Q6P3 -E5*C4^F*(W(*"QC((AI;Q0WAG*.#7<:\<#F
MR'G=@!9\WAST\_-PBZ"W+UUSX(-_T^VT4IAN %2#Q^IQM!;V/G3WCDTW_'WU
M= /WR;[=.FMVKD(H(O7UL]34(KK$/" OL7: 'QDSE@"'4*:1BA93%8=L,1\A
MW05EBZD$@!DA##/C67"8T1BT4Q0<"J9 JRO%T5);W&>+3Z;;-8M94%I+XKS6
M7@I.F:?.JB@"%S@(HKW#\[2BMT"L,!6M@ 5V/J;*XH(P@@3\0<A&[V4Z-\C+
MI59XF(T#D#)W_>%>C?UVWN_M[NTOHI:(#I2$4%XJDTI:*:T<)5PQ MXUCE(L
MM<0LL,9TL(1"@C*&?5"&">^T9!0LB8W:4$,TG0-OWN3=CZ8Y -K>?/P7M&BZ
M[OCJ73@/S?O$O;EIIPU\TBONP-\@[8]TIEJD=1=I#&^ZX=^#T'977^C)G5M[
MNXDGN\"S<Q)D (]$<:XXT2X" Q'-M446(*I.>^[1'&0CC(.!R)*!?I2!P 8)
M*43$J9J&HU:QB'0$/R82+)$3<\5 +TRSB?(TG1,&LBD[@#D2L 5W6$L3*$M@
M1JBH/#+S9<)^$:$'TN@0&64D!B"=M%H1Z[3&)D:I_#R$II>P8ZJK4 E;(($"
M%YX)(A25"GMA1+ \U1GX-1CHEX,=8SQHE"(D(C=:(,Z(#!8;%;7% 5./-2)S
MQ4!+V#%Y!E+&2. >F1B)>016R\D(VH=Q98G$\V7"%E?H!^V\)%@GQMR%&UJT
MRF&4.;7E;Z,61C^-OJ<F'C77'J2A/6INV"7X^)S6[GO2F"A*L=/*^'3:E8J6
M@'.=MM'95# W,11HIAG&L7L#V\M];KI7>Z89ZK&(GMU)77Z7MUVGV7YONJ<;
M1]U0\-!+<@[6XZNTI8F7G$29:CAQ(56D'J5#R+R27JF00JA '%J$4-.'V17[
MV:#2W=!GHA-]7NBSO/56&?S,ZKIDRJ!@!4[IRY@;1J.(7E%C+,=H5#Q-H)G=
MO/$M2F[T&\>AS#"KQQB2HIZ(W)7'<*!Q;.M(Y2!!J(3@3C)M :$!YG?.8X8C
MUFRN#EB=*6I-?U7*1(] D<),1\P0%5H3I9P(QBO.1@=;WZY*S4@MA!]?LKD'
M8GYBWJQ2V@O,K5.$$4ZM=T0' 1B!$I].4)H?D=BX,%W?N#H+7UU_6T3FIT@*
MCH*F7B-@?F^#MM8%XD*D"G#@/"W)S@(1I[)XJ@5H)<!\W :1REI:Q!W%P@)*
M(938N4K$&@<1O_FV7K?_>M>TCX9O25^K>3MO#5J+*.->.PUT<EHBSP"S*".E
ME4%%K:4SR"W9XQGL82X7E3T4]UQYEY:K @M1*<D1V'-);4!6V\6SXXN<8F61
M0L@*:Y5.>R^=I9@0!\(N9/!4S%,UJYDBYG1*J3 ;F504_$WP,W$ZI4I'PK"/
MJ?2]&-EU.0>2699!N2FH\J[CS&T]@3ND#2E$OP%3ED+PG;-T[_;E&;3VTB54
MR///J!J?M()1#E(BYFD,C%EBM4:16,(8I9Q@-4>'D<T\@:=S"!F5D13GIWO-
M@B'@'&OXARK%1)1^GC94S3R!IP.>G(^8:$XL2' ( *2P$R2*Z(35A,0YLK<S
M3^"IV&#O4YUG#VZTU0SSH +Q5$E$P(72QHI%L\%[H2AC^S:T0]<T@<P;O@6N
M,6 NDU+5AY1^Z9JA4['&A@HJ4DE)X1'C)"HBO/=$!FT]!L]HT:SQ;)!Z*G89
M7%SGA8Y<1\.PL:"V)1:6I0I":>%MT>SR-VB\B)8Y<$X)=B0"DF9*$A5<X!2(
MZQ7V0/)%L\S3)?%T"@-C94)$P:;2W8)S,-%8$&$530?)#@M+S+3P?B'&,9$-
MY"^SB\+ZR$"E(D95"B+:5 91"&H$)UJZ.:C*,NVPTXN0!3Q0)*F-G#/&O-,&
MJ,2] .IH ]!V#DJR36MU[T7($2U'UA+#A8C,2I(.3U36&,4,58;-4UA@FAIL
M^B!#40^XT2-"!;@,F%KM>6#,29R(R^=J1_.L$'(ZYT4(9;5C6J%T% K6EG@F
M8(8%M@A'YF<_B[H$B0USN3'H'W>ZT+7[A-R"7WO]W&UV!NU^]VIV,Z7O+X%@
MQRC,.L!XQ3BS\(\2.(##AI3&AL_^*4*S1)?QG9J#+:/,*Q 1'UA W&JM!$/>
M4*^Q'>*\N9:7PMT";RIY6\U_!MV\YP%G?%O]_40':J;U0/O6PL4_H=L+5UO#
M2G+U" ^8%W<(QKB_B5CLM0^>8<P$)LH)9KPSX+DA1+B8?P'^I1EE?!I%4R,C
M5@@IQUC06DL Q-: 409U(D9I\$M&^4E&V33-/':Z[=R\Z9JV.\Y[Z8&_.P#^
MYD2C.$)P!*0=,9-,"F-M\IRH5"HP,$%+C3+?C#(^C2*43U5+J71,L1"C\AA[
M)ZP21@84Q5*CC,OT''2ZIT5?'EL?Z%U9/?=E#V0>Y^D%&EP^Y3BWB 7JM&+>
M("*IPR$R1I;J97&X9HRGW3)!;3KV3%/"%#%*6(NEDA:K2((?I>H10K+1AUG;
M1$0R!)TCSPR@W;WU9S8_,H<CP\XXP1FF&!Q\0H27X$9Z(7UQ=C/FLRQM*616
MCQNIGN=1L3SW\$"*9M/83KD6=^>N!GSJF4+L/N7]X_<PV5>-SI?N'D=&>Q%@
M"-VS]*9;>2RV_.V9-IAZ__>@VSXVK??=8*]>M&0YYN,+1' >L<6(<848X\XP
M9S!#!D7D=2"C\@=HR4"+Q$#)WJ,Q11BC)]BD#=@2_ <M-'&(848],\B8881Q
MR4!3VW+U"[,F%\IZ037AQ(.GFPKFL@"  BDJG!=BR9HOQIK/VN[U"[-FD(8K
MXK7C6#'AM-9&&1.41VG/&(VS[UO/#6O.& .-JW >BM0:2WA,E7NMMS$&HUD0
M7$JM#!I6/9G!^C7?H,E^&UB@VX.>UN-M#&VC#[3:RL-19UQ.]BSP[\\RT[T2
M.C_C?6-&F. *F,@QRJCUG*6]S=IS@35=,M,\,-/+0<B985-#@Y)!:HI3G09M
MB(@6N%)%39 >!:27;+IX;/I2U0->A$W!$[;" 9=*C5ETP4#C@F)-F$)*ZV5(
M92+8KFIZT)?C02_T^[UT[F#>'_1A5(W@CMN=9N?HQ5.XQN0J(,21EX(8&02+
M!OC(. 20SQD<M903#+!,:P8L(M2Z*"7SF/'(%651A, 1Q]Y(3I<"-1<"-;L
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M)N7*ND:/XF#9"Q*EJ*[_/O'%',<Y?X8PU:O/&!,9+/ANADB7,4I=I@3%F6.
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MGZK,Y,;FS?OE#<9;;GP>"#U;QXS/PXS]<DDG#@;3[U7.S)5Y(L_DIU>L9VW
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MSAD);$D5#_!C4')E7:XJ ;S(G@I\/F?E?+9\FQ1;G14@L!21V181P*781AQ
M%#+DK,L8$2'34?%,8,W_'WO?VM36L:S]5U3L4^_9IXHF<^FY.;NH(K:3PZD
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M7V$\LN8,T\ILZ$LYX;3$8P;7>N"'/@M1!_EP@UQJF RW+HN2C7_O]A+U1D^
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MU92:9X%4E-VD#.A2 E]@&T361FK+K,NQ[O95[5M0IU'5?@GAB:G:*X9<&QM
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M6%D]U:T NPI2:FOJK0+LC0%V-J&6/")+@D.0Z K "@(G!0-R0AM%.93MLF4
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M!,YB (^8!(O)\)2+B<@WC9D/(+;61)R>/OL\E,^:H,;@=SEV?K<J^0+,?GD
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M64(YAHUM7,*!FZKA%8>KE*J45DI*[: 9J+OE ^V67XJ0)KLEEJ7-M"1(H?Q
M21Z<+ILG<J>S,#R2Q[I;KI2&5QQ>!2FU@PB@XO##X/#9K-<B5#(L$0,7I08T
MC$$05D&4V3&'4BDFVX/#:\4#8"[5SY_\L>]%ZOA1YY ^C.@DT* CV6:GT;#;
MD %<I&GXBJ1A!4%LP:/-200M@M4J)&3(0],-2S*>358<Q>?6!M^MGGPQH$R#
M :5Q&>7D(//!Z6@X\KUF_KZF-,G=CY3@$PWZ%:,6M!5G3MHI4<Q^R@)LMKE
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M4S2+9*+2^(J#<SVL!*['7:J_;AY0_=AAM'RU-Z4 7;=*W2H]?!U /Q9^EK$
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M0&Z]2)->%'7NP X/'PT>WD8)E$DLN)8\23,)__6SG.4IDS*F>:C]B'5*X*:
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MX%&2DRQ/(Z*I+^(TR?*8A^L8HNMB\.L>@[]>I#O1O9WHSE>N95+G3*>$I4$
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M,!F.FMU7CP0'H?0 K$&S2F +BB]P8N./*I'K,>SP\:@//S*^5?B7G0;#<KS
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M:H#=#:/4)X65&UASO&-?3(;R%/80K/_)"'Y4F"WH[KMP1NKZ3I4[3)0""*]
M<!#Q45@G@'NPH<T9W/>&IG5.L\N$EY4C84$'!!6;2/518DK83OUB9":X/O]
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MDZ==%E5UWB_,:6:=_*T$_'I+OG77FWQ%[PBO;W04$ #4A9<-YIFW/5XZ1BU
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MRB&]6W%+HQ=]V*H 6'"@E!/,=VC4J[\[1F>0>3-\,+S%??+Z'OL6J=ETR.!
M"]+0]-LH-X]LN(J-E+K OMD-+5@!+#'I+)9KU))P8P5I9???>5^T_$)Y45;C
M9C<8?D#-\1E.,!)ED1 O=0A3&^WSY_:\.2T\2SP _'%&.J9@M+;[E,M;8;'N
M"XQKP8.G.DCE,G#J'2R^B*+O4EKP9O\%6QM. HV^-/A^C#&%234U2U0A3H:P
M1:S/;7\'I>@WM#1G23+WO)4?-X^II7$Y-K79!@(VE3#:U_CBW&5RU4LS0+VN
M7C&OR?XQ'@*CI%\L<@L\U#*MMFP.Q-;F=HL]"T^G0H&V!LJ;0UMGAIO?%OB;
ML?W0UM0P"03FS(81%>BG$?T+MV_,1D*0-,HFJKI]R\01PY8 !?Y4.NW8X.:3
MJMZY$1G K)PZAQ69G-M;HD6 QKEP.G_#Y\&Q.IY/MSOO!K..6.6V)Z  4N;:
M;L/V8K<(D(M[JKF3XZC@#187%OT1)_9A_PMVP^$Y0 V S%\VG<CYDV!@YY/Q
MS YO/$W9" YM:XR5VCI6%4H*8%:S^PT7TV$7G@0-5<R-F/2+S]II&%]'D[YJ
MO+YH49Z7Z 8"5?$;&$=C?=[S +2=(\<JP29*(.9O #\]+;+"J9?6(61892,;
MOC@9F?<&<]EPV- /=V+2,XP.\\S;-M0:F+;^Q8U?'7UZF,SCWKP3A1\5A;96
M:8R'T=#:ZDVHSROR9>MF)Q[,K=8![WSEZ%I%':$.91DW;GL[V@T$LE6@[\F>
MU0;;8/^6J&@>&V<%WCS3Q@5959/2D*_,4[]J.U;TM-09L?9.%_4>;6O()G;N
MZ! 8!JJ#%48:S?7UU2-#]-+G8WM;&^HH75[=(_$F+F&!/ HWXBP3D=<LN6L"
MGU<YE:[@R_2,DFV-J<O:CX6'!6C%?6^@+?R;)&CX3<-HF1D:LT.S7J(ESX!M
M+9&^-26BC9:]&CX[?.Z#AC%H?(S+HY>UH[$41JV&C_')!Z)2XK]@TUDAW1?E
M9SVV69B 9C#W=BP"ST#WFJ-S;<Z6S)4$F1M86+_8MCDJEZV&-OG7>9&/C1:V
M+/3:P'Y#-%(S <!9UIB!C4E-\:J\4]VWBGYIXBP7+NJ"N<L#,6Z*!\S&MH=Z
MRA";Y2PU!]?PPO'K:L42(,-%4,XQ.H<_GTNUQB-U5)JT#JRYH%!>!I98;0)!
M</+7#JGF%E[-%7"QGGIAI\XB]YXX.0:D)N<NJMC\$@]_!/)VT+0=%^^Y?^*A
MKS'T@X)AF&M5KYX:4VC UI<SH2Q1 OR.KPK_S\[9#<=;=UERPRV;AG'U\."A
MJNI=/07S(6 ,YI5?7-BPJ!O]G,]1.>9WF;:4BJ*A5* :!QJ,G1:TBL'^V(;E
M;TDT\C.=_F/\?5\+$P^S(>1^;>?FKD0JZHC+=I<GG5D]9[=? 3TUIQ =WB;&
M>"XN;+XX&KS-3G)YS[6V-JV@T1J.,6A@OG$O7[GYZ] "'L[9Q0Q-HT82NT?=
MD&<YE<N!X2K$PV"-A;M)[6@PE4CQK3IRWO?)>4%'SEN+H=PW.6_E9+L'VK!U
M!&3NX%O E-&DG,44=)+#A%2NHL[?Z#-0?M!E-Y@,O*Q0[J>E-FR7)IUI:LCT
M"W?B?$<!>ASY#]O]^LPQ-4>:218#9-8L.;.;[B;MP]YI.C,U9Y=5E[6Q=>-7
MPU-%--0=&(7MU(X$#CB=A\X'?(+G;*G'Y<@5A7*1-W>&+>6I+W@)EK-+S+NY
M,QWDL6]NN^"E7JIUXP]D'TQ-6$A[8(X&-:VR/5MU13(8K?NVUOFPH(LH%$&;
MP^ZJ^MK"</OM],\=V*+5?L9X%74=(71Z3OL(=RF>RV9HH1[?/11@K,OS_X%6
MP6&^W9 %7YM N_WS21=F/'OSB4D_4*EFQ,]C1N D"(@0>0Z3F<LHSC,>!/E\
MH<7UP>Y;>A/,3L"M^]H*N#FQ'@6&'L]#WV0H)LJ4N7C9AIY7#2(>+4-$ +YS
M0QE:DD38(MO"V04W.>_#^%U\K'_A?%'3R-5LE0U,"33B/4W[_W-[^_5,1G<=
MNFCQ<X:VC49-YFD\(@563)O(ACK]"B[SJ$_>F,NVT84)YAOU\;EO;609[W%$
M_E,CU]'NR^L?NHCD%YX:F0B**]#49G+.CS8?C<;6+'7'O+%-ELS8\JFU^H!-
M)5U>*!U->.OJL YZI%@UE-O>XGEX_5:8]6XT%>YF*V5:$AL>T<TNZ\W,AZM%
MZ$BCD]+03MH^A1:;>^J!-:6]C%P:=FC_8JD)/)V(VOQQ_-'&A+/5?9E?NW%J
MF[P5&,%WFB.3F!P_M%1S4U*RKF.QH!)8NW J7M>6L_?0/8Q!G-,Z!H%$!6^V
M'"D^ZA0TOE'IRG]>=].YA:J'>Z%%B=$[##;4-$4W']0R@FI"D%^OF#5@)Z7]
MMA:D_WWF'2X06YOB'F ]6&UM"$CDF?!1_=0KEJ$I2%FO=V&*99GJIL9KF,^L
MD?&<#X0EXADFD5/3ZI?$I^'0&BZF>[]@27Y<NP[P_:H:[RI]F.\ZXF#U)%6*
M=Y]\Y0OATY" 59D0GH2"P%RF1(*1&?LL2U,6/AJ5XIWU839K_FBT":L*-.R2
MI2!DPQ5XZ*$%8X ,#_7ZN*MFDD=&6"IV2JMU12 Q):K.@#)%&)UQ9;# $:);
MAJ!+83#5'J==MRP'N*C0Y3>IG8/F/#4$X2M^,ZYY$2VOX'6M2:8+[4J\?G^X
M+N&@0H)R':NWUYFSWIPM,P1<DR]1F<-H.E&P JVSH5UQL^%PMN<QT_U"?VD2
MI1I6LVXEZ,FBE).!(1/CB3YW/-H#'M?5?&/#*H9@:I.USR;JQ.X D8WJL#L8
MXD;):.S#*^;=+K,[#? HQ)- G*/>61?^=$E$<"C)N=*99@]5TX)25^\F9&$Y
MRD$35'"U;ZVSOLD^<>J!);&TDEGJ+!\S&1N0ZS.CJIIRUOUF4:71/50!V[6L
M+7-,0[ER_JXY1C<5KN_Y_)\JV#"'G8-A__CD4T;#4*5Q0.*<2L*CA)$DI!$1
ME"4L$AE3:3J?JRW2+! ZC](,9E_Q(*5)EC"F))<BR=-H7GMX/36:D"797H3O
M-X+8T/-YN=/]VEESU:&OLP%K2ZXV'^O#;*[J^4S9%_S0= HPM-;92C!-P><\
MAS/ 5D-&GZ^QO.M&!],4RY8[ @ZR =:YM? H%]9U)K;V4WV*8";!@@Q?FJ*#
M(.33O,5J>ZC,/ZW+H7K:*'!P_"8\N'Q'#W?V+O>/=[_MGWR*N)^%7,8D]\$R
MX#IC))5*DI1IKA+JQT+K1V,>N'WBU1O%>ZM=3BW*VJ, H^,E3IJICBOK%R^J
M:;; #C9,**UB5]?31:]'?2V #5:"Q.3EM][V!.E\ !S>Z^,/WE]C4)BM2F;:
MJ.1N@F?K3LT0I>R#F]L,9QY_A9)ZW0A<$-!(><W,:;U:8UVT"R39+$<7/4(&
M+!9[RD3?N%BK4ZU-)HM>ZK!J.ZMF'STE: -LEMA*9NZ98,AASH&]RA31KU7V
M14MDN^6CFX_DU)B&'[A)7[9V5QB*"_-CJ@U,'5!&.W:W;>XUGN)HRWW8<U6B
M1T.7^=7T1M&U.81?E_K4<7OA.9A?^0M8AY4I MWFN_W=!>"N47B_2^6XB[C>
ML0];O,%]V +OGENPU:?UT33=<BX*"+*^-D?S17TT[UWL'TOZ\>PDW-_9^[I_
M]N;KQ^-W(1REWP[^_!#LGVU_ \7ZXN#R)%PXFL_VOAU<_GMPN/,9?K=]<;#S
M1]\<Z3N[_L>S#Q?[.[O?X"AFASO]?/]REQ^^^92RB :<AR0)9$*X\F.2^6E
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M3$>#B> V.A\H-U)9G#0VT;+$<9+&/ U?I-;5]Q7K2:H(I51A)BV":8R(8^/
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M8M0H$I752@3_>/O]-3#='IA:4UOZ7$70,1$CJ[*U$:E'CH%O 5@5G= 2.TX
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MD#)AHA,L;^409R(AK8)&P5#.3$J*$S,)!#[J2(R,RC+-"776:BE)DDD$E6C
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MMSW)4[C1#?!)_RB&_YR7A3S'CP6IJ$@:K3%">-;\\H'OGO[1V=X!9-B!-K^
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MB5NKD,^YKC@+"FDL&'+6!9BUR%7.M#8_\O_S9ZU[HI!M#98U6"Z:'5R#Y=W
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M:NUEM$$+CATMB1QD3.08P<<,Q' W(X:[,V*<N8(7/,'L"-*9I]<R=:4&D]N
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M>M6HEUK^["KT>%S$6#2 KHLKW;[*X[W0\N[QP=MC91T6G!](3H8%(PX46VK
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M/J^[PB2RN&D$#K=3,XU]AUMF9'A)$L>F%Z=@:'CAF>>_N.=]>?3KL>[BBWF
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M6=$:[U>3(R<?K\Z<)/;#*+1UR[0-W3'#5&? :?7(=A+/2UCD))@P%)C7&(U
MC".Z;T D=R$ VXP=&X[72NW <9T(_@@\DT>@* 2AR5PB &.% +QEO>!Z&N@.
M_9I#M\\\RW*<"'0%ZF@$+,&%0_<C/;99Z#+/X':"A>\]Y^9#[P%O+%&/!V$Q
M6O20A:0\H4;I*($:\@78?YZFP&JO$1A@#F0%RH.TR,? ;&P#>$V1S\^'^ ^O
M+X8]:; ?.'8\7DHQ@/]GHT69"6LMX6@? (O#S .&?%_P*C!HKD <E<-LJL5#
M=&()ZX4#]T+S W[@&G\7]4^99NN8,P6FAI!3,I,;:/H/!BI.L= L5[!'$%?
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M?*1>"2%>!+[TZXQ<_\^#LI%!BD#&% ZHP/,!O2X0O$]%/G'?YR*1H1&!PS-
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MU 8C,<DE8%!0+@#+^L[1F*K2=F3F@CP>468)2X0*OS:13>LU2[_27K)7E(%
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MT&U"MPG=)G2;T&U"MPG=)G2;T&U"MPG=)G2;T&U"MPG=)G2;T&W" VW"/ZA
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M]\1Z^]JU7!KV" 3B4,-NL7E2-K;J+FV+6I+!7]\$ZGL$Z2Z\*2JRZ^C!W%"
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M?:DTWXKA;*Y(AS^*1X;P:2)NU*-F#LF0D(J)KA[#;%1*AL4<FK$+9_ O\35
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MS$XF>L6RU>< CY"X0'ERL;H'K-*I&FT8P>.XP)$ \T^F/:)]8]FX^00HB8
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M3BJ<1XG(INPQW; L-^1-_.Y=4+"E.Z,%JT-GS&D@M4MJ1MQC!S0-Z6F:R=)
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M]>]5#$,K%DE(KG#P+9NA+9QF12E?5_G;-OVRM*<'EZNZ5DE[LS!BYV1HR>#
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M8$I4(<?->!XP$SH0<(44VL\E9#%M+MI=;+:AS8'1)'GI)$ \-Q*!B42<L(F
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M11VQ;(OT"+=L5>/72O%:3:U5R#B^ ^^/4KR_-:/Q^(]A WY0!O W%/N+LCA
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MB7$];VELM 01LR*0<SDY5PA6"4M2]D;B3HSF(-]SQ;CYS8^'$O4%WV&;W#O
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ML[.:Q6N?N &VNPHZS&V^!+'8H#> T?U)[P\ AS_+W5$%RTK<0WY=']%>@9,
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M @^X: 3\$_G^'@#]_O]64%,/#@?^WPFUHQ\F$ ! >A=<W,DYP/&"QUQPKY!
MO]_ENQ><SL'S-P=#?W/,A8(7G/$W=_TK%_A+F[]R]&_NY.WC=,%_Z^SGY.WT
MF_=<\/C@(.<+#KE^P>."W9U#+OC4!4=Z!7F[7_#CWWV]G>T#  !*]KL\T-G1
M[8*+7' RC)&!R@67 P B,M>_XPY_QP.=0P-_&Z7BZQ>&<7=U"X3S./+"1:6E
M47!-YQ OY\! 03U[1T][C!-<Q=?;S]XG# #^:O-?A.:W;^$73I84E9:4%!03
M$OT[1_V;E?].^1W;O[(#_;_$#,3PYA_+_J5VOD4 @#J\\$W*/Y8Y/ * IE@
M8)SYQS)D(0!07L2M<>SO[&'X/5_< @/]9(2%0T)"A-R='85^._1O\G]L\.^0
MO_L^H=_#_<T]<%5G%_L@KT#X;[\Y^GKY!F'@ 7[VCLYPP7\^B?_#'?]E/00,
MG%V<,<X^%SU,+F:9NX_K1;A]G-P#W7U]X.X^_UH0_X/=_IG\=5Y?".V3,X#.
M5@B@&J,#(-MO "@M*0"QRK^H ?TM;M>)38#?*\^48^VO\_XO OK?1P4G__X(
M<'?]2S\5 R.X8Q F^*]UOY<E0 "0 )0 '< $L ,(@ <0!,0 *4 60 -JP#5
M%S "S $;P!%P [P!#! "A .10!QP'T@!,H!LH !X I0#5< +H EH!SJ!/F 8
M& ?> ;/ (K *; *[P'?@)P@$(@21@VA!3" .$!>('R0&0H$40&J@ZR #D#G(
M#N0*\@$%@<)!T:#[H#10-N@QJ!Q4"VH!=8(&01.@CZ ET#IH'_0## &3@>G
M;. K8&$P"JP$U@8;@:W!KF!_\$UP##@)_!!<!'X.;@1W@H?![\"+X$WP(02
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M($T@K2P=(=TN?2(C*1,H\T+FJZR@K*?L,]DO<MQRSG)/Y/#RE^7MY1_++RK
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M"!@*(2" 7B1)H-L7]0"4FH"&4U0)1JMO3WC9GTXL,O4Q$4*YMI/>8&(7*>Z
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M*,F,Y4LTOF_<.J2&1G"<#I\"70_7+2T:CKZ'BUGA0S)87HGCM@W\<UE=V1^
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M:V5=2HDSC(Z.0FT:ZH'4Z/X'P'7SQXQ;BOS*XP2-)DY \$!$'Y<B4V#1/Z'
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MIJ:IQ<ENK55M:@<MZQ.P2N<L+CRZ]NOUW8RW-AZ[U\>?DVQ\OJK9)=1-NXT
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MMP$Q4Q1DF]K\%<LMHBMKM'D_\LS!W^B(1G-3"_\(>*\-#R]RUB[^K-RP'CR
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MG\6+V1-=,I4[@;U'?+OPYK_5ZA[X=U&&>NDO(>S9+\8N912=:^ZZ;)V_-=O
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MW8Q1U'A:F'(PX"HIJFA%V63IIEQ>INVZZ\Z.Q'^3ZB,A!=LI(-(XDYTK3!1
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M9L?] ;KAM FR3,(022"#*VC[:8,'8TDB^2@_#(5P.I8%M1'[F(.AP4'8!%V
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M5Y&^C -%O*_C*_7DM'2CX!MFJS.HD+\8^+IA!?NR;P*;U4%FU<52'?F2/?Z
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M9"2%EH<20993+D3W#+9"T1JSZT'J<+2R<*_9^MX:Y D'>Q _7"<T3=><-:
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M!U^F/N?@@$>2FV?XOF*7<4"[WJM/2E5Q#M)MERM,\69$RH+I]\?&.*!?YB1
MYK!(9H;R9_RUH,,?05LZRQ5W]S^S[N]S5@0NGMFD!'U@]L8!^/%L[>+Y4/#O
MD(T-<C:74MH(6O!]?L(^$K2#_T%8U<]X8P[E?S^,\7.D];>#_D'TOR/1DN5
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M1,LL>B3L3BVCE7? \BUWBVF.CE?<@-[<38(8(3=9DC7GQT\[Y,I&GL^&#D%
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MW9*V!A2!5=6K.19HYW^W3^28G<XSF01?@KI_KGBH2IWZQ4-#590&!73!<@!
M,L$ 7_RR9TZ/=_XX<8< ?]*WFTI'<CY#5H;(74R'$KP+++K\\+XKFV"[C<28
MH.P.+;$\95/C!$BSCXJQ!LQ04A()+'C>N8%5>*<3U_8\GOK2.8)0V*/U3D:7
MW"%@W+=%K#1[F2RWA?F%&Z>13:;*?!HDW3+>-5,DN%W!]47 BQ6ID0=OA-[>
M[!#L;[T^[=M]4L,6C4T=RJ9T-ZKTO?;&2N?R^76I9 (=;T6@:TG8SZ:8E9K?
M9*/#-E=KXV$#;TBO*T="\^)+#P\-*.NL[5QY0^1ICD/$!8Y@"U,A;(+7%IO\
MQ#1%<W1Z)NTEOV\YKB6-Y4K.'/)T$Y?1!3=3(#L5-L2YKUGR4)*7-O'S0K5#
M_$#&KJ*VXNE'VX>SS;&OPXGSG&" ,C>SGPT$K+.7X88U#5LK=ER(FF>\MW%.
M,?+13)_*@W0F,_+I> 3=V"=9NMUC=HM+AB6W.B)SI5VR0>D6F7SQ6RTISE<-
M)L <:2&TL1*$.E=3V%#WY#3\SV=*CCC<\PM_LM_SU/_CZ+%$VC96JJ&=; 1I
ML>2^+LNTAP,B!#R7#/K([FFI)#A4K+Z#Z3(:A<,N<"(!D(P_E%'U1#.W,G6,
M%CUA.&9E(L"<3$N=N]9!7\J=?[>#2!D_4:FDM\)+74O'N@@;*[J;V-U%K?1/
M5L,4($F(N<S([ ..ZA/CEW=$Y/SM)>XXL$M)\(8K 9+SP4"LY%9PO+"K,3,M
MJ'/")W+S'I^C#7G5?+2)0T15F&9,75YLKY\%#BCI\5XK/2U<=+QN.EJUT3)>
MW]<WL=N'Z#324U( W%.97W<&!/!=(<8;46-MYXJKA"FIY$-'F'D?'= <!N[[
M)X6HF-?I1R9?]+_RQ"O1"LO0YYYUVR:C$3_7/W1Y<V7YC#VJ^MS]G/JF^166
M(_.Q&MONK!JU637*Z_E>+$X"8@ZKJKG@3@+?:6<M&$,,83KY(\@T&S<W9)?C
MY^1[GMJR=]PTI73VQ*&&Q\7U*AJXJAE.F@V[TFFB$P$CLC7PB.L4?^K"V*U]
MGS8[:?+\!OU5/5L/*#T6?=\+G8F7:*Q'8V  *>Q=;65*YF722U^1HU_UYG7[
MY"#!&.1!<Q]1_^/K(]PI8@L7_1_&"5 EY7(^9_6IOCOJU>$5E<H#3C_TMM]/
M$FSG>.:Z8*5/=S^%/II*FB\7O[[GO%XV'6/1^UC=G0);3E_K9U84R6QZ:8K/
MX8NXE+94/>)6V; -^Z;X)9QC=5LIM$]VQ=^FT6L7/Y\=9TW7W??5.598Q?1]
MHRXF79Q';G2U[,)7(U]:O9E< J^-N*JZT,XBLN_,/PL*\+;2MV&0\<^LN3H9
M1@OJ,E"XWNA-=]QQ/^2KJ=DS<ST[HB_=H=O!T2)=T^CP(T>?S\,;UWO*5!\T
M!J?9<I-*6$5+@B9V2Z+Q_2TU;7Q$<X>& :9SI*-==M6'B8 $2$]W1W\Q"9UV
M<"#F#-?/C5<P34FA>V+1-5< (W 1Z1/Z*3C=QK:Y"O7AVV-L-++W$\W5@J/G
M$T@!0+"U#"D@**+I\[QMP7:QW- AOC>^@U[^&2PD)QB:*.T>G?'Z[8N?+Z$I
M?-);F2XX.KHQ:/'TT+N@4+1EL.^Y):Z#E5Y_R\LU\X",I@KD9+[-5]=ZJ-/#
M7JRT2/1P-7[KV3-9OESM[ Z[)JS\>K["H3'!ME6 :G(RW@=^_01;\ *%N"LZ
M%C59V?(DGFY']EN>S)40?3?:\Q]"W%S47?7.^J;&6)P&R]=J)D.KKUN[9J9T
MVH^_0 DA-9T& [+,$ZI6.%Q(FAFZ\*JV6*\ATIAK?E/SDK*U @VO68W5C+()
M"?T:E9NZW$_^A.6;3MB[^Z89,'I '.-<.<M8'F^$[3$';-^HOU5M65_GEL=W
MQ*@" 3]BFS[H],,W(ECI[\O/?><&3!C$$*T <1K/:'GF&D_ITX\$I"*LAS<\
M;RLX,K9BIF!+1)_.NN.]S\>TCB.8\2W]1R.>>657R5CO$'H>QK<0W*@<>!?R
M=HZ'.PPR-YTY6U?$ S[?GA1_YY(JS:8MEXKX(F&(#9N+[^*)L L%A=II91"W
MI<BUYYXDURVM?([>^7 '3^QC2HHB@>8OQ9>K:F(TPE3#;L1SQ-7D?R.48XKU
M;48@04.#]X<%Q%0TS97"8>QY=@GD4VL\B-6)/98)HB7;;(+:?AHIPPE#(^)O
M"C%]$YQ:;4X:A#\U.T+BR>5ZECL-YZ_&Q%[2'GT:&V@>^ !;(M2OUD"S^.$%
MWX6W$?,1?2X@:XA$P2J:/),( ?\IO,V/V\Y/A-*,U_4*7W_HRYEN$\2(6@UC
MD&ZT?Y7P0FPA]>H$K1=5*T$>-;M5GZ)KNDUT!E\17@*"9Z62+<ZE^5)@ !M;
MH0OPHZ>%'5*9* _,JJZ8(Y=_#U>5-14"2$!EQ[:\A8.SFY$VA>T_@\\$%A?V
MO%$LJMH.981%QPL,>\KO*%)MN;F!F(+3;0A>#8GY7C/S=_#WO7CP0,:?I9V4
M-H26P&TR4<D]$S6B@U_Q?[2G=;TBUM%O2B0>HTW"7(F+;K!(7>'YDWR-K"3=
MRG_0)_$62OHD'+D3#@>Y$2.'^P^5UIL6T4$'ZT$?2O%=,-X(AED;VM*BE:L%
MWP(\][??T2A.'5QD%JJ9K1AO<^^)L*B*O:5&$FM^&8Z0ZO & H1J/!8)ZB[A
M;;+!73O+MV$ZRIDDR':]([<>SG/$<&1HIYHKABY0G:9WNI.YXKT7,>,0<2AE
M4P,&0MD9-6'!4!*.7_P;Y*VD1D4%;I>?JQUM5$^F BA;QV-%@HWY:36@?'E+
M4;ZOGDH0,H=^;RZ$*-]SCTNW8<#FW\J<:G._\9J\:D=T&KA5E-QC$=K G,V2
MC[[&6?GS%Q>C"AM31?#G62STW4:K 31,XG"(V3E0AWL7_311#/5$*_VC<8R3
M+%A*+J*LL]=836AB%_Q*R6!Y*9M23[\L4ZPZZ?Y^,+6S&)W2QP:S<\FM#_J9
MP%/H>+[#YUII^M4^.2$*K%><Q4C+CL()>+JXD0D#@'^<,7[I>3+[U"MM[9@V
MHUKS/$H-Z%/IE)6V7VA\%60ONW_4XMJRC$$8???!,.R_QNMD0:22.[GY>6?V
M6H!\G8BCDU7($][I/D"9PFPW5OQL04HG-@6FFISR50]M]00.1HF@I_W2K>L,
M\--*I]JFOM(EK\CW. (2_ RPW.^W1]HYC5R(Y[AB+25(2Z/&K"YGZ*%!Q!VQ
M>V1E6U+<L<SFYC5'T7T"[Z+OD]IGV(S,#RKJ>9-3$<Z0*VPFTAVLHQ%+OQUH
M$3I@ML>V92Q-"^IW2+6+XK^/%B$N85N/IP,Q1D,7_+2_B58[/%6AIBUG3B8E
MX:;,SRZNXR%(JF6(_V:EH2*D#(!A\?E@NB<%H[?V-0AO=+"3(6U"NI_N< FZ
M]YM+>7 3U.$WYXG_D2!_V7C,$/V-SDR.6I&8$W(NEY/.ZR\WN'R_OI:LLU\(
M9 LJ,/VQ(K-[H2A_B[.4'P?XY:^X2MZ>)<F-BZ:SO*'^UDS]5N7LTZ'WM;ZY
M",7QT!#\WC8T=$A7AV[0T2G N2RF4D=R;"JJQ^]OJ$)K:/CXSQ7Z^G! FXO8
MKMZMKU'G[=C5(9O,Q-"HYJU#RRVM?HIT$6:5Q1V05"+T6CV#9DL?$1S"PT00
MX./'ZTMINK;TFJ?KM5+B>M%4V;B]Y-[+^1:;5L6!!^283@<GB\'0@3VFW1:F
MH1]W,DH>?73=?U/BHV/FA@"[:*E:(,W(/7^X:&NN[5:V;0]W8?(O,]XK9L8O
M=Y2=BB/3-1(7!D_*)I1[\Z+3^A!(E!*$R>R<BO25+D>K'*=G=1,7*"H%&6N:
M,9>5:CFS9L 0"08%IC#D>V3?9_MK'G7C6Z3#[P:+7\E^-GK@GE[Z[&.TSQP3
M4[0#;V15=%VLF^Z=4M7 PHR8B(6*+Y;G W*=S@D@\YT>I2_&&#B%%1F,RUU^
MUI\8KP<\DO&V;<5"F:(E8UT[_>9X"N<^=U[;?QB0FO^1C[_J\Q1G75722"L9
M+*[[<F++*!$CX $IW$-8Q*6["/-&J*^I4DQM?UD+'K+DHG)R[QR(.MDF="NK
M^DS" .PB6O:G0X\N#7S96Q8+I^(B^H2Z"%^-=U&9._A!:I2:<JIXRWXS13P]
M;=4QL9YVG>[>D+)+6/BL9'"FNOSX6/VJHU/'9]9W[5=DE;[I.!Y)J]UB42^!
MKZ/)?2=IYUDL'NI2PM.,*YXK. 1>R: L<[0HRPNW\7T"@4+CE;M@V>L)7VI7
M>%XE1ME^WG>M',?;UN%R"K1WQ?[K[^M>_Q"('7L30HM%Q_N#AK!-)ED8=WDO
M#G<TQ]QD_-5#[];BUU7JU(5':3^H@N:']J&#FA S7C0@"$P#4CH!$G?N("!"
M:-!1PD3"*@Y88=(I6D@_2MF^%RZI7_3\F,^25E-!KNWO>:I&!Q-C5J$ 5/\!
MSQ2(VVY!T3T_;>W_,E!JR\E-'!#S4>KLO<R^3Y'ITTL6_4[/-0J%#;OJW>(9
MM&-2:J0C[F;F,DQ;OSA\#OGFF=$FA'Q_$SW'4;;T*98$P,)+JF\,F6J&V<2+
MG*]:R[5Q:3TG&88,SLQ8 HNW=NH^/U?<@RF;EZ!S#Y]^V"('U$#HND-(()2*
M?!$-6Y ?&UD!KNQ<S-\C6HC%LX3N#<[/A76C.C<I72AEUUX>.N9WJR8KZB>T
M8G*S9.D!:53SNL&! ?E%P30N67;XT<4Y$T;O[UBFG79 [SOZ!I\4?O\VI^A#
M/_^,)C O7KUPH<:4( C#L?/;56ABZ>W*2L.;^AKWJ6\4=,%)!8G4I7G#'H?S
MK['[PQ.H5>O=-BPRNFFW53C9O$1!+4&]C6=!BPOU4Z0XH#.CZ=2__:?/GLP,
M??6QS+Y7_T20NWN0?]"WOLW&?M//I6-CQ2^N\@A&Y&A;IA/2@[DSGX'F,ZF&
M\SZ+^J<EOV6V:8;9,#Y23?=#S]F@]R"NVFFR9?Y>[^OKA2<<NW02)2X /&HW
MT5."S:[;B:V@ZH05/]/'CKLU8V.T!!*P=_%&S,U7^F9]V"R8^02NA8\]O E_
M9*6,;$##]P@C.$?1++N@A.\.9\BIL_>,.$ V.N9QT-817EN/=)[U\SNK6&?2
M5KE;D3P4=.:_EY)<IL/-[3OM/EB-U9>A8$OK:ZA)Y7[:'V<$U64VN"$+(\>*
M@K[]JZ-M_3=,(*8#,J>7DR$%*_HH(I\5^UL=PT831G(/!+4O)#8_.'>>Y1X;
M=5Q#M*";4K;HNG.;:EZ#YKLDFLWCABIM<J!FKHR-4@%P^&2$/2Q>TP]X=Y[<
M,98)'FOI'D+KFCG5P\"6UJXU-GMO_2L;C&(^5!":8PGFK%+T6>YJ9F/<F>"O
M>^Y%FEMH#C!@"XNROL<:!O7;XH#-61P097/X.X"Q7M[W^0I483CRG!)Q]LX&
MP+F"R";;5N8D3$8!L'@7@%G-_OD)[,+4SIC,\6$3UF@_47R5L:#UHC)ZZ5%L
MH(+Z\[B14I9)>+O=DA]S0]+W<@4&+IXN+C%8?"XW/)MB[$$\<8LU&T "2P>@
M=U,7KVHO>:M:UAXC5SJ$1AQX>M!)W!#W/4[FC_I; :U'-[Y<]7W./Q]C)1-0
M%N("A>Q#14'EA!\F>#S,NOWHV$*C)2,]_H+>A^^+/R#QRU.MU%0L/D>P.105
MC,_R0E>7=)VVMX9 M9=9K#6?;%[A4C];]YP;:1A+)RQ:#D_2H4C>RZN3 P&&
MZ^G"]YK%1"9X!6\TBRS:P@A<NYHWH_?"2GSNWR(IIK.HB9@G!5+V[G90*I4R
M3*>?3VFX^9G1N:)HUM9+^:+WC::'-,28,7U6S<%*P/&3YGA?->F[G.X:"$L*
MQ-*S\+]VO5!4%Y[&\N(%0G$>"N]BFHYN\QLNXF&RXJG/MS;' 1^8[?Z$^'3P
M9\2GP=\0GW[ZF>L.TQE]WG#>ZU7:Z=FTOG;"_B7K-\"GH-]0I(IE?H)(X8 3
M'4=-)='ZQR-"K/W7&I.;OC\V"/H)"H8#?D,%J_@-%>P8WX).I0+3YPU6H[8@
MY/O]_[1I6G?5F@!WZI/MXZ]/<0"Q9_[)#EX%3N& R-RS<ZOJ1XOXY:()!] 9
M:FM^%)CY^_HHP4)<]>R^=JFT3G1@EOB,SD_XMY;391FQGS!MKUY$^WKS(L*Y
M>"<V-Q%9AWK?@_S4/P;]!N;V2Z$8.P'LV>?V(*G_L,C,Z<O(,R]WF>^ETV>[
M6:GXP?X$C@L]_ASH\!,X[HX"RV?CUF-5NI.UA:#?Z_Z&0 <]R#L9P0%/2E(C
MI?/J'^\G\1U][?T)9_?GVK_!V5%MJAR5XH#SQF*T_BK>5.M7]7;*4WZM_A/N
MC?5;PH[I&5>=/<]^_ ;KF'[IHHW(KY653O@.91JY%YI.[G@,::Y?GI"I*#/M
MZ[/YO6K,[V-<+L@=4ZT)LC-ORDCO_[TBZ^]#%!O45*IX[O)_ W>*1E@I/\5L
MS+%9'#X3ZA^B.],9^:0^IEJKV;NEZ;T8%-SQ*Y DGI7]I_@>8().$[T\--<M
M]?;?7SMJ(CQ38L WMGB&'\"<S%EWS"] E#I?/_V$!G3 :\FT[Z9SKEG?2X*6
M2\_D<<!:P5_ 4!IG_ ;7]P_0>YW[R4/[\]T>-97C7K^$,Y;0ZA'8DJ9*W^WN
M]S+4)LAWB2-=@7C+53L]YU_D=OPJSEWSR!K%J"#5(^K[Q_>/[S_Q2\N!__[7
M]BY$T#\'T/WT!K_"K&>=5N.  4*5$D5^J_"3]*N6>8_,'KYSR8M7ZBX-C79-
MWW]](&D^H<K<PNTAM1^,9L9"D8'&/&"17^)\#_T2T,' +SJY^E@B'EEX00[M
M:33-%-HI<^HG]C\[1S\#I6";#K>?GX%P0$ZQN#J4!*1;4\,60BP\=\X/[5AL
M;'C;6(NKVNW&>V$]X+O<!M5+HVSR8MU/5]?FPP7I+I  X-/!,Y45=:Y7W_'+
MG3]>(1A9X(>A<*^A\J+M0)7+2K?K"+F@ XT,E+A9IZ8&  "::4"2W#&;: +C
M7$G\"7JA8&TQ\UT)P6Z':^A(7.;L:^.TJ%MK74Z<?+;BH>R.]>D/YVB998^4
M8=@289\ET6)>:0$AB#RIC+!_O'\"#OA"#Y"*-@IY#&W')G1=3B-,+NN"H80#
M3H%L2J\-U7J2%XTUY];ZDQ;X6^=CH^^E,_&^A1;,81M-RW& _/L4TS,3+7'Y
MT2,+AVLR[5-@I)NKP<$^7Q"C+ [P;('F+XAD*FDNV5<NA#*OP+2<N-C$W\_"
M(.1.$U('NS ")5H05_EKKL3S:G,N< C6W4MSI'0PN%].8Y6RWXX//M8!O>R>
M3O.8D[-$VKXQ_Q$V7"'CF\H]D>J^@!F53C8S]\Z]%1#EEOJ/F^8?5:A<6A2)
M,1K>B Y%60WWU5BI <)2O.KOK)#9ZY YA>C\^*]>GFO4OMS^"(A'>B?9_O']
M^[]YX6GSJ0\=JE"P?^"5#8BDG3%,^&<T%OT)G@G>1EJ0A4NN2]&N!F'4AZ@/
MKS_)7I @E2 M5?@C^X_L_S@[C=-26_1?CP?S%\!\<#&!&9VE;#+&,,8PO1>H
MJTZT3G0FD4!9C6:-CA\/0<>,XA_9_UZV+*)H[_\$YO#_FNB>%Q]F3LF/[S__
MNF#CW/TQHZ9_$CJD0?22K@>_D_DXV+18?2;_' =$E*1>N=DL&:N#8@N-E9L[
MIZ1A"_I35$YM,68O9@0V7'=LIVJ(47]NCMR2 'I5<A9U[=^"5FF+97@QTT%&
M*,K("*$.$K#S:![N;-'661[(IZ])''8)?H5*D!*21;Z6(W4H-/H9Z*4"G;S:
MR/TA$V5SQWZPHVME.*5RAS*PG?_*EN#TSV.F,^G1B#YT#AL>8K*B%^PWLCS?
M+V;^SXOV]3/Q7=KLN) 4;>X+6,'9^,2I7LERKB[YK!J\->+_\%B1/#]'BQB.
M+<@F^4M<RPUN0T\[HQD-&G4C0-COKD6]RCDUXE%M<6SSF*)[GU!G,7!'01P!
M00G'R@$AE'+0G(^2^.:*]B\N!X;81FN6AX9(TE!!P$,:A)%_Y;]_[F+1_O-E
MW_H>Q/9$KHLB@U^T$@XP0%W]TSF=7E.3*D3DELM3=/KY(10<R'SUYYQ?DL[&
MYN=^YV37!;C"='JY!Q/56>5YTSR!V++6GGK;ED7;KD5Z>I8*D'EDU 8=/;L9
MPTX%#0@^-^W=Z1?_"Z>*OD_E]7TO[&FO=FG!NF 6Z1$LS_!U>-/L/UU)5'4'
MB-2H@*C6:B3EUVRR9]I>.\4?WA2XE8"@K^08F.T^_WHLAY<I71B+:'E&"(FB
M^D$HS\DH("/95+CRR<[^<DI5(1P*V9;[&6^)[)DN](3;RW0'OR5E"CKCJMC]
M:,"O>?MMU3P4,ATM"ZW!=]HM,E^@F%:K.,?Y6PW&B$5)>BNZL]$(;P:%+ZSS
MOS4*KDU4]"]G F3ZU?Q(4_^Y<O/_:_I7/4+F0QTF\D0N-->"D"-4-3->0F@X
M FNG)6\3(DQ%-S62>:)6:5B?1FQDQ6*MR\#)GLJFJ"3- WHOU/#9K"J.^KX=
M,SUW;(&^8 ?EW'$V#4D7 X!F41!I-5@]-+QEF-*Q_IGU,N)N99^+VB!Z)OU\
MK**@+T'VUF8H^T".X2J,YU,-U<X%K6C2]-=)F"Y2I1OTX1 /[[;Z^2'^=3'"
MHW5TBNU!(G\- >TZ!D)HQ8W04F9>(KAW<O_U:'9MZC"RA,R1HD9 @@FU=C>X
MR^I#9FZE\^IUR>@O;?8N)]^L(?=;6(5@YUQ/)VA\6SK ;A0LE[<4WE0)8][E
MT+1RO&)<N-H55>\WY\1 W[W('VSB7SS61?3<@H]J\DV\D^)5L+.U)9P>:XN<
M8Y+H]OT(>$ADB@U[8+YLS(X)4>K!(>*,9:=86NY7]WS@$)M(F[8[^LH_/%?(
M0[Z9/S;+N'T;9!'[?C%[]7.=HWN'[I4'W'%)MGEL$(T2?;2X>)6@'EO&:"?#
M',KEH9W?M?S/)1?9+1/U;4H8<CCA_<@!0G\<P&R?>NORQ^$&A_/OHF>BY1Y8
M])KG WLF5)IC=<[G#X=%:RR2SEG&SU%=OE'],988YN*Z0WE]"P:*5G9NFSJ"
MWL$!#W# KKT>"$M\CRB-3]D"/7X#3-&68_PRCU2HC\&/*>/]!Y2DU!2#?9W@
ML<)D1: RW#&J7QI!Q47DG]CIE*<7]+^XP.K%^\2H&"I[WRE$8@X_"%CR[U!G
MO'I@1H?,!-'WN?"]'6J0%:400.3"RD)@$7&AM;%F<3N +.%;%28+Y "1PG;0
M!],B8J$T!Z8-S'25+U.I%^A6)FDN'7*XT>),/JEI;V.JVW[HT'.F:4U5YYO0
MU2FI.3/TZ? <>#LZ>Y'<D-GAFCX.B)TO/?6OWDY%275C'UZ;)?0M[<ES?5GQ
MV+WCD0BAG7 _.@ENM+NB7NREL_"-KLY0Q?.>Y8VE=_'=!.G_@[WW#(MJV=9&
M9]-(@R 9R4%I! &1(-B$)DI221(EB9(DT^2D-%'!IH%&0#*2LR)90$"@ 9$D
M4;+2Y)PS7-SKK+7<^VS/^>YWPCWGN>M'_:F>LVJ,M]XQNFI6U1A%^^Z.37@"
MB:@-N!HUB.9-TP4U=?2=(;;G#?0^&%5IC<J .&H,-5IV<\BMJ&BP6>TX65CY
MLOC1NV9:B4WDZ 9U>(+$-\_]XBY0]KQ.;PB?[?6P'"<$=>'T6_947NBTY^2W
MMZ2B)C8.=]=14[?CET3FV:+:%5WW0S%((9+(2L@V.YNE.Q0I>9W*1E.!3V?X
M,LJO@0F38?;P5G4(>[G0"'TAC]3%,1L197=S!HD3BS8*-+4)I1)OV^ T>Q02
MT88_R&7'(/[0YR #2:XD;V$))S0D>M85;-28%M76TF%$UO!F;]/W8,_A&$\,
MF/W L$ [4/R=,'K9YZBU)9;IRG$>$Z7L))(:XT$_;R#RE&= F.U+@PV=]%*J
MI'9PKS_I/!74!0H($D[Z@R4IK94=+ 5G74*@X=-9)$&RG/*=JFK@<H^")!:K
MFKO0FBAUD3V)U$>O/<%!F[1$GY MF*: UG; C06T[C)\"B0Q?\3'$*B[!3^H
MK33)IY0YI^JYBB)Q'AA,\+G$UN8A%T>P=^)$>.USB@ D,;EF<]$XZC\G7)VI
M1][RM[#+J&BK::4 ='[-QD1$B[IG*UOHUP(U6ND.RL[T*\.W8AWN!G8J>#LJ
MK_;2I5Z \;)7H SR_.CH1E HEJHNP]TNX^T[M[_0*FSJP2C$'<Y+JR?ZC!ZX
MM$@#!_%\F$'C9\[1'B]7.K\#E[PC9.@@$5[N-!V/17JZ=O;L(*WJW"2SG*9O
M\*,:[&6ZY(:1(J= *=\VV?AP@0W18=:3;Z]\?<[-99=[LB=_?_/X?=T.TF3.
M-$9D>$X)Z@YASV%_C26#M<Z\E8"_SGJ-IQ0K=-Q-J.Q(@Z0W-$6YL;Q:UO6Y
MRG1I]K&QLJCT%R4Y'AK(2CD!(MF7!"%-;B4VO5),V7Y>H=;]1O7'XK9#/V48
MF!ZZH0Q^G?W59E<__M6W,!V]D/OZ]WQJV[']P\J<=6EH0:<+>FN<1Y[RIP#X
M%.@>#B?R;>\Z?GKF-=YUGPN#Z&"6,RJ29#M H'*FUQ?.:#J;;7H*#%!/#:P(
MZ_@6%SPUM-?U*5#]+K KZP+NBXI0$ ^-4O@1D;;K\.$ID,H07A\%<M@Q;8H0
MST>A2;][4[7 NIQ(Q=3Q8Y*A5JEQ22*&!NRTLJ2C01Q*HM,&+'4A=%>8+1:^
MKWQ688U]5F$1Z[;T+8(UEC7\@77\KD&XIO_\HS:]=$0=ZR5Q4K?DO=5M?#/R
MQZ? *X>_1??E!L(;HPP;\21>D_#@O:0@$$SDXN;W@(:K[F4KNN88@;BA OF
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M1*7(E"G33<Y"<I>$:E0R?"V_JAVV0<>F3X'")WN-Z$022XD3FAZ]A9[QEIW
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MQ"X3I1E9.'A^CDA\0XR<<)(J,7[HQS$>Q(\DGZM9/PXGV7.YVCR\>B?&,/>
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MF1P(N/.;>%'T,E$-%5E62>DEW$Z/<@OMC<NJ&53TW2-[_7E.#)_OW?C=D=3
MMX#Y'1-'3W;ZUOI.99CD+N]RH8_B>SK3C0QI?L]I$'8%-DI$WZD\7YW4[BTG
M:>BN$]-1;A8O&^#O2 A>=70.JX(+18U<ZPU^+7#%TR=:O>4: ^M[1V\ XH,1
M%*6GOU2^+9RO[_1RNL.BL-UM(.:!.:?W-NS\\)<:Q>-8(K0PBY63^UL(V+XG
M'!$UZ!?5T%;@R>K)ZQ65#(!3'M8?\:BV?]R]V7HE3# LD?F3&!,+$22GT-S&
MVFLO2+G!6P&SZ:;PILEA;^_! :[N@$KG6:!=>N6[:(M30(>#=ZCK%F%+-KS:
M>;[C>I@$7#)3L.V\O08=_6AZTF?OR,6[W:6-UU [GTF_\>#18LX';G5*LR>:
M12:E)NKH&C[?@!=P^&?37-,,6]K6#[PH\O2R#OJK1!6[3-@H54.+@N@LXRM_
M1T2?O^@U'C4Q5*Y]K>&49$ N7%$F"KT]Y"$G$Z5@Q5=$T*S7NL"(6N&<YLP:
M?S4KV:_6R'W#QDKXRF&G");LJ>\X?3NIHCIUY$!\]!O3QX_@L64HCL^U_<P.
M^74/F@*P7FG[(99TGW4F+U3!H*2!P6WU4R7@ZOC/ZP0?AMMYWHZ4 ?50U"P'
M<CD9[D6JHA[&L/PQ/ YGZ^3)$9Z[+5DVQ\ 9&(P.=M>X,;6"5" @H[N&]HY9
M$ ,MC*7&.NMC7OL%7B^(&;=;.04FWZ%3L>TJY)U*D>ME!CF@!O @2/%I7 O3
M^>^3R,Z/PO06;* 558C^Q#ISV-+DZ!@?!9R>OSI<&L29"Y9(CI/0X4MPNF:.
MUIE#%R &@0!51B%#:L_'G<JY(B-N_0\J<"Z24J_86ZQ??24Q!9@BD_D]MS30
M1[.UKN]=6M=D;#B/RBN8+.E!U/R+B=^JW?!WBJZW#(RK]-C.?I9WR)(T])VJ
M.K)1TZD[Z3(@.N1V1A(UZ#62/E&0E]-%:<SVO5YVW//@S%<Y6IJ8T5Q[BJ:<
M48AEM',WP]F-$@&;(_XR4_C@9N/UBJ.[)VTEX>+B[HC='5-8UQNXC6+S8.10
M_2K+S3$3,Y,5.B#9]YD#DPN4)5LXZ'L5B>-]P42*BS),Y+(M'415ROSIHM\%
MJ!=KKWN\>6ET"E ^>'Y34AG=1D"A< H89R AJ<:.("PI/T"]"HPGI A^5(L7
M#$2J2:O2D1ZM;$\MJ!BN*Z!]I".-#2Y\5B!L9;W:AHNIYW8B9,(=:AFSE)W]
M=UF+VML3L )<,-R&6S!]IT<G"(Q6)J%^CZM0U[[:#EX:7+]>86QS]M^&7YCZ
M%;Z3=$, 57V;7Q"BQINL"I&YMW?GXZ"(4 B.D48&WQ[_+=OZ!L[1T;.E3/<+
MY^,;7Y.(="A1-%"68G1:YIK]N]T/YHD=-4J!;U[-1J%HNC@CG%ON4D+T[7<B
M76LK2IJ<1F+C)CY\VAD8N5@#=XIE".R@':6PH\/R!]&B$&C83IYEHZZ5VR!7
M)8O-6[OVUC98O<G3AUA!H41* B5W_Z6PL*6W+#EH005!<!$IO$4XK&!1J$4B
M[UTEGBX ,0%(/!9EU1)4&X-$WV^$B12VT12./]/PA$5IA<A,L[,=,A=-M(:^
MSO4X[YUK%GV??^6SH $,FK(RH.A?-[4BM<=Z@NQ7/!N \)"ZQ8*4 XJLM-YW
M2U9J%^XEN:I2EJ666>_V[R>1H0O#"G2*;VJ=K2;C0.<</.H:,3:2#V*T;,>2
MFL)K*YA!6T7.S:? ^JKE*6!8MZ.WZ-PB!AU.B<85+2=L?D)7(_K";Z=,[R?F
M5AX;;7)5]_4OU^6VV"0S12F,S-"(;X9EI%2CML$#[Z5"4C9:3H9]EZ([C?>,
M9YI)OERA0$15J6GZU4.WA0<\\M5\R5LN-+\=Y6]A1$J)P%5A[)!DLBFM\6)W
ML3SMT,)G"?$85>4V_4$;U8+6M6='WN.^@]>/8VX/^M,=J5C1Y"F7?2>NI(C9
MI[6:8@](KGMF? YF^T#ZW:O6UV:QQ.W@B F^<;)QL#-B"%W))I/C 3-LIMYA
M>_MPD\"\2R)@R,PI SR$Z/OB9G]B(<RAFGE?+2%F<]<\75?#8&N+/46UNOLR
MAEP;H[%IU]8"@8T"T!SQMT3G!1WYK<;/7=[L+'YZ[U:7<2"Y( C?,L)YY/'1
MS:.;#O"73O#U3[DD-U/XPQ)CIB21?LGI;*1[K*3L5]QM'2^S)7_EK61%DTW+
MK[RZ70$_OUN"*)D)U^U=*6[KD:?)7?EGYS-(%04B/CG*M++[$ZX:1WZ#^RRT
MRH4G2YBAGXDV[$@XC_1V.^I+Q@PG^I^;@JL2 :391_ U(>/76?.YV6S! L@?
M5U2>^![+A7XJT:G0;.JR[L&I6V^.>5[?X\CC2GLKZ?*_X?,(N'/+3E.C?]42
M+?I2QLXY6$<;/_M5X^-+1)W][!@R5>MKIBV:\_&OR]U9S66K7P;2:9);B)>O
M0*DJ :<F.V;I_#K24V!J4^,4>!-^G*P_<Z3Y.LE4_4,8@=D=%Q>F6>Y+K8 K
MAQ/0<D\R%3S$\]D'/C42]D#SXK>&<LN7W(%@[IQF5:6Q**0:W!O4K/]AW>,)
M4ZN2X#M>"/3#_9=F,:Q-IN+[4CP^A3'X.HK/7'R7DF0_7N:?^9JT46W@')*
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M]NY$KM@=9P:=N#A3ZZK]B+?CNZJX7_%;0*$_R,+R!=YX>(?X:&Z&JRCE%QC
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M+DR5(T9W\MV]2,14REHBJMT_[N^_FCT_=-AT$%_V/4ETF]&*+9QQB 0/D53
M2+_;PEPR2*-@9%ZFQ_&B-8ZI_A1X0GC/;>HQ7+EMRB\>\-_94.*UFPI<QB#P
M'Y:$5?<Y=Q^8HA6<1&FN#?J;RLR,"'%\2OJH8/'(X,,2SF=L30I/D,@S0]G=
M_'Q+=#)-2!\361RUHPRK\1D$'AVTQFR55:R6_D24%K!KET_F?6M&@N5,*^C@
MCD_G@3F[7;L'0HQK-^TZ1Z<2+1,M,Y6U/GS=D;M0DQ"'PW<XC[<B/ZH\&S8$
M!26?1+LA^87KDE=ZR+COMD"RM$&:X1I#.\L&V]'?F457(LV?L?CP,@LB4E8O
MP1T;_05!L+9FC91FRF6NF%[/,8+IXR'[%!\6+:\UPA4Q),%BMZ^9#$X?Q&C8
MF4<(/6<EEKSW#8$5Z'.Z.LA"%*2=S-R." CQ:1FK1&?@CE>_U\^I<O.\(6XM
MK];PJ[KOL]P(W(AKFT2Y3#J"V*C\XF.FFISO%I+H;/+BR(FYGS>:1M4D99"F
MHVZ":_\?]MX[*JID71_>#4ALR2@-35!:&PE*IDF2)+0H0:)D)(N$;G*2I*#8
MI"8HV"0!09 H&21+3A)$DH)D$) <)'PX<\:9<0;ON?>>^]W[6^O\46OMZF=7
M[=KOKC?4[MK/"ZCV%YWO*TP1VY\FIBB[*1-9PX3"N<SIWCV?@#0D8W^2GO#Y
M9G1QGDZ-!3 VEM T3.1_N[@H^2FWR,M/(U,RZQ!8+#XST<2"W\A&5A5;[U3T
ML_(2QE2_EN%P8<XO$S!3Q/)[RRIVO,#<<:OUYH3I+EXE^M'P1?_3TQS27,2L
M3DTP\$I<F+9%OWF^N2DD^IR(H0YA"!+8G6"%H@;H) ZR+A8$]M!;8%I\NSA.
M:,I(F;;LA%)(!_0%O+GN^/S)1:YH?-K[YC?>=Q+%T*&E:CHE"JSPTA\X617J
MQ!V,\+5B4N.77,T;-0N:6&?@91(++U^J,.@5O4E]<.2?VT\01 :I=VN- F9N
MH6\M5%=;3?W%8VE1E52^:7Z=8L:6+J@!PC+&XXT9/#@[/@ZR]XI+C=\]PJ\T
MOM[*]A[EL/O63%X+Y,.YON?ON#^P&T<HM.IUR+R\:^(;S(?L@JT#S)/?OKAB
M2!&MR7#)+W] V.B@> ?*7+J>L>%#5F]+^_BJO@KTSI4JT^767$<<FI"""4&?
ME<!>8EW5E8\<=J9"$(R!)W%.^.]R;2)BN:<U"2)I?0$^)(<#KQ1$M#C_3.']
M2#R]7&Y0"^A:5GP]1-QE?:&3QP#NSPH4FO?<@5YE>K0DH;,6D+#/'XG1<(V[
M\MA%]:7[S7&=>.F:G0@% JJ-L:-9CND+^20RU< [K'@.3M#,2XV#QD^(^5Y^
M,B+JZ"=%_D=B_>(_IS/24O!?'/K0(^#,47]7%H^X+7_6:D6NPBCS)D?\*\2'
M&BC'>?JU3OJQ$\VL:U+TIRZ<F,)EP?)3!^3B7YT%"RTVBX57DI,KMLS>WGH@
MR++(S3.">JRSYBLUPB1+[C[FS^EZ0/75?F>"9?^KT9<<I893EDJ!\X,:.\HW
M-(RKV;G/<IX1!_D3=A.-SEOA>U>>H=UV?U19XY/]H=:O1425O+]6DAT?_\.+
MFX9(B9 &1Z8>*3BFV+'B5H('A;YC2Z/*^?2@!O[AL+-Z[@SF=4M28#L'GN$O
MR=(2;CL*AF-"$B*?7^: 2ZG;7RF.07T[T_W6 5?Q&2P[*$[A_JVJDH=+KE>O
MW9:_&<7.4:J:*44/F&W (Q<-N>T,&,0R<+$,_9&F8F;147M).#R7C<NO"0'"
M^.2%GO>R4'59MC!N4G'.2CHV5JK5L8R:)67^V6MMXW."]#FZ#M1ZSTI5:^Y3
M'0)9+< &VW0C6A1P2P(G%EIC#U9OWDP7CT5Q%"^U XSRDO=, 4 DFUM,77B3
M9NK1CA(?D?AI$#H[H'DLM$S<#!=7PO+00HH-.V0D!C %@^7"5#Z8^5(X=GYP
MQ&D$D@6]>J)/V=,"O<=!45&F3&F:(TD3B4E(Q7L>,:Z3F_W),[XGDB$BQIR4
M-(>6(YP0@$@@)[\JV.1<CK=&G6D/''(-4<(B&7U/A'G9+882(A;T=J$68FZ:
M?@1R]*P82AD,1HNN^,% M\%P'H=Y6=0+8WGW&^GA=V\HJ TCDD@6]VC(."J'
MXR;P^7;"*AR8I)N_5M='=(-[O4Z2^,%#GN3KQ8),^\)I:?HV%MX]J%00)\Y[
M79B-("4'5ELF$GG,P*$J]$2A@R\J6>QAG,*X4I>R<!P>[>0ESH2KD=W=A!:1
M+X2>II'T+K,[2#RZJL$L/8>;J+Y:+'X2FA_H8E\X1B.T:4'.V]P"P4\:@[H2
MQ5E$/A.<CN,:H76AJ,=+I3ICWBF/PEF&QE^8:'#E:3PCM,H8#G1VW^)"K9U6
MQ[A* ',1[WPA+Q>HK=_6VZ/'&0P^(4T)QN!;\@B+9DA3*UIJ#F-3D7VY'QQS
M0T ]HS5Z3?FS8U[@F+_"77[,I!FS_]:U,CG_F;,VC]##0<0O8?3&"'Q64Z+0
M>^$JM"JY75[/.75@2(J53C\J!9F12*P$[W( AI)$D*<\BFI4Z4SP2;])U;M?
MS.EOU!-!)P"OP4;^X&G[W,\"ZVN?=5[.:_B"DWC ?-D5_JEH>07I#B?FLZ\B
M[G9Q7H@_ ^^02N&Z*1.TND-$!&=Z]=XLV/!G!HLP\9'/U/!!]9E#8##K[M]&
MDK9_?J.DOQQZ,6'HA-7[%VM *Y9<J 2J+:??U4"Q078(&"@<^/>K;D<,/(:M
M"/0NH7R.XZ ]D99?[OS0H^($9 Z+,H#O<3X-6U8XB@2$O^7+/OG&SEOB]I/;
MW!?063O'\]@*?@RR*(SF3J7GXR%UC!9!=!YU\)+\6=9\G*-U@6!%^$U4?%D3
M*_.81Z_^RU)O0]MSK4LYQ>]=C^>#9E/YE[.I_HGV5>-=<;9+'7OCM*DOT<[1
MPEK-#'X5JVWMW9SX]PT2LZUR4Q'!,B0<C%,P#+6"@P1[D)R[L6>W?/.P-4'\
MH)@'*NP3T^S6M8'^$8V7+S=[2[M^PF0M7_63P=\X!$P0)5]1')0X0*5]9,(O
M+-=KC :CN2]9,W ZXQRC!@^!G2F6F( EBL5P[^L-._8Z9X>\ZU4:N79/8X]]
MR*9Z7_K*+X.?<(Q"T/+>(OB),\/)C9J"%M;* AP*<1<$9X]GU;ZT2?/(IX0Z
MF:2&8*^C$T&_N]4)0KQ12MW6]58EDJNCEI]&0.^F]_JZ[S(8SE'',/"BO5[
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M<#%SVSR&/_$)*B "EXN + 0VLH05+MA>/.'&%G*Q\GT[L[ZQB#.JFWW2-)_
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ME*8)LAJX'4-!;R>4+C*/:FF9$6&E?;EG@B['E/A81*3RW%M%#T?<E4TL523
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MG:P1>4B4,;0 Y]RH@0F[MM[2I"X7=F_Q#MB"O>X)652M'3@ K*S2K@AX#=8
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M.I/#.S<,6,WJXAY3<%>.>[V_.MD4?T]TTGL"M]&EW ?*_:\N?/[\.E=+,EC
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M)Z3=8.M; ^^F(-L-G81/S>/A^%-[#>LM!-1-J!D"KW1Z_"SM<U +&3IY) )
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M_SN>^U\/M?%G4?UQ5+)-RKXRO?P<Y3K@;A&=!1DT^EXR_%]?L_\HH>J[E,
MJLW'HP%KG 9/U<:>N/Z(E;G/B ]:9J1%R#GZ66=NC0AQNYDJ-#XZ>7Y@S3X4
ML&#4>K4N_O3_PY0#G69?CF. \**F0I7,ZZFOIP%.JZ,OTO_ .PN^^.YO@P&^
MC;KXBKX)(I\1,)G6\9<@796K>LNQ2>3W<\91\X45!B!<O4[& $OBUSTQ9R_$
MCVZ4W<< )YI7A8K7XU\#!.8Q0->OM>*1:ZK!JYNO=@5<)3#L%0>LEUQ+8X"M
MO),RTFU?YD-_TLMHKHAM\05]##!B=!EV$Q;5_D:U#=E_I3;D;0$C?B>X=0^U
MH.3-2T3DB%D2I\#./%SRGVP-*G]N=L#7.@SPJ?F<% .49TU)WJ$=Q,&?2BSQ
M8SBG-:":^IM?__15^K&' 38+XA_W I:<7/^.47UTPDZ^W#EO!EW+W9-Q3_M3
M76_ZT@4#* 4<,&  \YL>^K]+'6?.'!'K76V#5I<.]V-<;((E,B]<9X)%REG9
MJZI;U%YBA_2.W# PSAYM@- &!OC+;K<BFDG;%KDG+LY?73WH4/MWNY[]PNC6
MY<]@#, 4F5F?_X6^[Q;!VHLRNYX 1M+#3W\&5CR)V[&LX& WHA:,8,_]*V"^
M&"OZA:N<D&M7%\H7*G_&#Y3[$[8A_7?1M@M%HLNU%9;BM+\ 313-]@D[2;QW
M/MRG9B#^+^,B^LB?DFYS/#[,^I!9'_!7&)DWM6:8TC%:E>.1<<4 _S(>X3;3
MC'AE:?- M$G$^HU5_PJ-<DJN-L#J54 J;3O57P,ORE7&.%Y_OTD]A/[3S%3Y
MQ C[ T-?+5NK-]M2D-\!"&>DV1_&.AKQZ)-5Z!N]E684VYG*UP#+]K[%I8V"
M@,B9"V\2#*#<](-2FR(^7LSB7B3ZD>_W<ZY6&4K-E-:_6O^K2ZN-QOY!D?MO
MG[7E'BM$Y+S/D?E7D=G2>Q18>4=%9_%G6!#6=T6D-W#Q5/%U' OVC >X6;^W
M-HF3SNC00IC#!&GIA48K5?%M#:FKWH3I/"#.)GLF3\ 4*XD3Q/;C?Z):M6ZG
M!"9-[F CL;1QR60E04$$HI(%-WZC>A[P^F"DYWJE?7+<8[9#Z'"DY _T[,BM
M_(KN*9&F!O=YNVFD7>=S4Z1KNU;5$&<16)&6)PNYD/A4&P(6"40G^$< _>_;
MM"LHMG%E/J#@X;>@!W"HLY*E#-D;7%7L/ #@!F@!8 U/Z*9<9)MV:>PFKN2[
M(()PK!N_9G24>5D^LEA&<U]&AADF0\@W @-<VG4R$82]&."-]N"UWP(&:(9?
M4^7+ #(VUHD1#Z*D& >H)+0@@B(D0C_TBK"GMI%_L(1VZ&9IFP8&=D/67ZRE
M$T_Z/K7AX1IZIAL._1"+4H&BY* _(OW8:%X?FD91G83,Y&54(P#]P!0 'Z0,
MRGF9B6 U7"LUHCN4H2D%]V:6=>J;!7<^$8O$Z>#L4_LPNG1?AH54)*0#:^GZ
M=?&P!&5AI0Z'\IE)%!AI3JZY6,P++$8\=M5Y''V>&35!;#ZL<_-(<C&Y00;0
M*ON>43H83RW7 )F(J.M\/D^\^/3KNK=AEE]>6YZA5%Y9%BM++]+.UZDIVOG'
MVKM_<Y;Z#_F_0/X#9INGXVYRR]3O4M1J57$-U;)ZGG(MR"Y(D'O)QK",-H30
MA  RR]0B6>H[E/:46/?>61Y$*=;^H^@_BOX_6)18-F>&E2CPYNGK&(Z1RV&Y
M9!8LM&Y6[Q,,\$1M)0*P2+0\Z!?OI_3*1$"6DT4J5 YEZ"W3\?]1^C^_-/6#
M)UZR:"A^ZO_)X^<?1?^YJ-7^IRGW!0G!=+Q_QZ$R;$%O32V.)C:V?]/UI7_(
M/^1_)6SRUD(H:B#QWW'W@6!Y74VS_"@O[]]\=+(P,NV.G(,'_0=I+U2&L00-
MMP"]LDM:[,E1D??\<<PYR4L,,-X0P)J'TU@8Z7!'SLGCT0<<KSA&$WD:;G<T
MB4M:BOMQD?=2Y:R[597NEFX%L6.HUE0CQ8-5V. ^?6X3X%;YXL/49G+N6R;4
M]7>99^H8H)X ')5U'XNE;T"..?.R-QC5DTI7$EZ<7>I37>-0=9]]^=R^[B&"
M^%XB&PZVG_RKN#&$4#W[P&*P04/,]@/Y$4>.!VP9G>KW5I#SO^UM8WXQKA19
M";6?AG.<ONRF5J%<II82D]/2WR'L<E1>Z!@>.AH8POJQ-K4E]!U2-.V-SZ8\
M9B@!^@,WFNW*B[F-2'A=%>[ QEE:2V_"31.-?;=UPKL8. \32[4QG#.P><DI
M\KQZ386\YP-37F<_N8DC%O-.ZHPS81XH4TW?(; 1[N3&4>^V3N_+5LB=H[.Z
M:X%HYEH&$%@;1*3)#6S_Y>/K_QTINU0K%(LG2^2^Q07JNP5F1'_SUE#8Z7AG
MI5 X>G=K(K,1 US?Q<4 LS$'#G^0'.C<P0#NXMW-9P7-YDS-%_>H)OU6T]4,
M S  $7; 3N>YP#_Q%G#<P@ -#$L_+[7H>R2O(B.VOAP.L92(8X"00/%3T\N/
M_T0Y\2>UYHS7[>WN1EYKE"_2,,#7EK2+LFNE_TY$\">UY;$!)K\:'C<>$;(/
M8H %8Y6K"0SPZ \N@[]1/"DO7N9D\'[.&X]J%0/LE3)?;P7$_Q/_P3_KW<IF
MF*@M[MT5Q8XXQ !_:I7XG]6>J)-NZ;\P/T4'RGAA@#^UBN&?M?JP@DZXV,LO
M!B7^CJU$WP7_OV,J)[++9\: 9Z#]LD[>Y5OQ@>R;3T9A@.?-!\P8P%1Q4C[L
MG<GNWC7[Y<! Q*+X@FG R./+< PP,7S3 IKKI( EE>N.&//[ 68F&.#]OM&*
MNZN6@8"ZD@SN<$KP>? ,^>8?! !:!<&A:DYVHM2$+)F!_YH-N?\M^2^[8/GG
M/XE6O]RO5U2RGM(%/R!R232ADGW6XNRY:1BB,S48O.V6>T=?KNEK",BG!(A'
MLF.-)@/OKRD^BY^?A5U?YYZ-,S@XVE5%3FHIEK_<(10JNW6+D)N4.5?ZJ&CP
M3/NEQ^4^!NA"88!]MPJ2$&*^JH/B1W'N%?;V$M,=?#$+="!KX."CDK#".$KO
MDXL-X\QSG]'T^5A5*KS #O=B G$6P&[@?9B(@?O8/9='*P>$YTJ,O#"23D].
M!#CS<I()>< _3]*# 5KN"AP\.9 BJNLE&Z@3J]7&86ZF1:L\K:!/HU6[2E5[
MYLEDK'KG=DI4;0>)LI\E3J>=J^B3Z<CIAEPOLUXJ9 R?$X1-*YA'./!\X(<(
M/5_\N"\U!HBY&=TEH1A@B*FH]IIA0HX9S6@PR8Q;]D?@1=6N!B)))EJ*.&FD
MPF2D;]=O2;6_G>GO!BPXX&MX@*,18567ZX1Y9:T393@/5*$G59-+S(1$4CHN
MFI<=]*RF<I^ZVR-?O[XG-3(/:OZ1C1 MV"(#PKUS*4'Z?+3QEGF^8+*.I,MH
MOMD '!K[!ALN$M]]_,GH#+OC6A8M+^DA: (99QXG;#$[78SO7D' C$+*LKW?
M9#YTB]E:RGM/<Y*(#'($S@.[.L%,\:._9\W7K^]5C^38Y)G>8BK^_N*^4R>-
MY)002?!Y\NA_^#7/OY7/^>MQ&W%5C;WU AVR\@-_[#%OL >-B1!9.'A9V,>9
M"#9>+?JD;$F\0$V"Q3Z<II/*998?J1#KK?E\Z?LHTF=_GE11 [OX]CMY481H
M7D]4?8 ]/'.6:;=[;A'FCH-H<:7$6CMZP; P[9)A^"6!YH[MD%=743<RB3_A
M-EKSP.MDM[::/ISYY,FX4+[ILE^UY2?#=%9C=0E>P1>V].!MT\!Q1OHD&>=K
MX1O?%_^- 8(QP.OB3 0A6VA%46<V8Z+^91^5%F4%'YF\*L@EFB\0?=QVMMG!
M,S?9:[_?3QQ388Q^\/&D/K$5PL!"NTHGRR=!'_,O7_)MC>P<"L+=[[<OE"!U
M(G_&X<TUKTRJ,8"/!1T"*<FHUHZISWENS9"-L%/"\.#*NIZ"N"1>@&G&(*6-
M4(^50O%\&4HFBDIBIF\UL!OP$(22"*T@'@_K4H^'FWZ/:*^&F[U*X\*=6Y"C
MZ>KZNHI$YWYR=+3\PARFS4FQ X\USTQ0D$\_@M*G[WDR \C%)U@E-TUFP "Q
M-_/D53T&6,O2^'DV1>-%38#2G>,+N[N?Q$_?DA(8/RCE* G"505)R[Q>^\(8
MIDMLPNQ,*\3-MO9SUER48,D#@HOM: ,[.\ VB[HKE\A*1^STZ9SD:T$?-@I[
MN9;C!8S1F4>"CHXJ+O,,3:=3J5CW2#(Q0HOU0?!0K'=PZWP*-A_RQRT1/X+'
M%-!R.&UQ*"Q6^'H7^(*UP"N!.Q\_'8P@28Y8,3T+MN/P&94WG]/HNO4QJC?E
M>E<4P(U/(4F:;3<8:M2Z6SI(&!:MLU\O^-[L R/91/=B6AOR& ),9I8_+:'H
MS*&*M$5UM8GIWVKZ&BT0%Q<R"!%5>3X_/^RK0E+X\N%,/&.O#-N[.,DU>5')
M^3UE+$B')8YA1&O]?O;=[]V6TDDFTV^TY@9TB1:HG)6!I5@ UKV2,]RH19^W
M<ALEPZ(^_0B9185[NRVO0UEHE7%?@N;)"U#)6>M"4XU,Q!+4#F:N"7M/A-"T
M;PL1YU>1<#%(3 HX.1NSBZ'?NBPO'@=#G7F=4LQ\3!"<:KKUXV_O#P<EP6=6
M"2*(A&M.M>34/>E"Y7&1$;G9GCV<LD;EO'#B!@\VY8^0,$'V[@&>R_T46L!!
M3<>[)G)A)/N"6_?A!^"YX_VX'RK[] B2U,,N6&N_N.R^IG?6!WXX98:B;3(O
M4I-,@"0+ MM,"6X';(=UIF(BC4=R[SJC:#MHR1H"9RZP$74FWTX(/5>K9#YY
M=@A/WIU=3(8P"./N4_ZLI)A@8EK&25G,NS&1=T3OV*4,?5R5OG#W(W<YBGON
MTU$3.-%8W=VT%E1=9Y'M:ALQ5OC=#]X9MOQW$T7]#Q/1A\B86L=+O-?.?Q#/
MYS6G05I?*]DLSKT!HV7XFO.72BFQ\F6\=M_^8?F36%L4J\S6[7++'AY5^1DA
MI-EBL3,IU8CUW.,PY?BM5K-$8RR>EE Y+?%OWH"0QR#C(N@)5IV,J>4<6XRF
MRQ^58K6+EU6+",)?&#5EIG.)]2QV,=H/;O.QCZ3JDI]R[,ESXKH'Y,V&$?K;
MHA$K".$>=GY1;_&*JWK5H73<.-YMIR Y]D'F4@@S$VUR[]_UZW_OWC[5"\UZ
M_MANWD56FM+!YP4H%NP?5%WKAG>"M=\8*#\O[Q.X-R-["]P";)][&P=W=?"T
M3.Y=99\$_DJ*+.CRK7X]TZ[")$*"OCH  &*$];#.N#];]#T>V7*%+L=?E(\K
M?]]I.5Y'WWBX5O]CW1@-W YEU86$0&V--<G+)EX24DHL]XCE2^ZN9$M>;%4Y
M_GFAA)ES.CD')SUW#[4V^PHN[8?A.A;0$**X#4\&HPX$U[ .PU[2MV9A.=YV
M#"#ZDFEY_DAP::&VDZZ=_F8]&</2/!_PFT85_XI*6FOHU8_J\\V&UTZ'W!U.
M:?5RZ<6F2GNIE>,"W.7F#P[<HP8[EJ"'#<S,8PAA:W:>G$A)^0RM^_22U($#
M1"AG1=I%P>/?6M.]&991?!8$A9UTCEF/$(\R*XJK1JMK[O71O-*T!01>[4?S
M15\>:EKLIZBBIJ$\.#%/-7C<6H4KND#1(-&*=L!A6.>%/W<$\3OXPV<,?%\;
M%FG-@B9Q KNWQ(5^!%T+OVW_6LH3ESK9TK*9<M3I>[0K<9>ED/3L^2^'5-.D
M3 R _DQ^L">4LN?8N!K=46*PN:_7>C*OV(YP3HE'W<M@RA )#A+<E:!^HNT6
M6OM^QS1*OR XG/]ZO53BOEZS>!B(5CL*H'SQY.3G7IS*@SJ'"@EW6V)-X6B=
M%./+7( D:8D^O=TCDX&T?%:7W:Y+UT3_R_+@')"R0U?V^_8DL)%7:--,)4?T
M(4OWH1G,B?#>E-^M>>^C0<;@(+:QA*)'.76:O/6FSO(YNAX6$#I!')$[[7^@
M53WVE:%ZESDE)4U)#!MPGI9"\+973)"DC+K3/U+,)2N'W_GB'F[*W@#$!W?-
MNPT(10#CF1552MZBL+?3+O)M[+36NEUTRJ!?7DP9'4Y*WWTEZ;/[R8A1CWA1
M7..M'22\GJN7WDB$U;#NRYBWJ/[+!/A#1ZQ7A [3Z(]UX,%7X[2_7W>\+^S,
M#S)E9G'L:?G,>L1X;9@$ D4 #3*OQ)$/\+(TXV:A9JS4.P[Q-T'@H@[V3T%
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MGT=)A;C7_*)!+S2: T4>9];*S(Q7*G&RFI*"LCZ)3R]&]_,\@F=WG-- 1&&
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MF^_@Q-[\FK&.<B!:2*G<+Q+2*O=DOY*)17F7-$XJ%Z2%)0ZL(%DYM%K[:_O
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M'O"\0[$&O^O\MN:>)GN:E?R#2BL,*0Q<B+1XJ_6%T9POM-I5(^>?_[?W_Y"
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M(K"-.L03-O&97HP7_0;"JB8OLTF.]JQ[5E*N_MQ9P';3;7"P8H8K7(JU/<]
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M35F(6DZ,2.O7K# X">.=,!>"(!U#>&$]%$=)+%SXSCY#ASP_5-S<K%@11T>
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M"DNS"]=^'#SFYA>ETQ3"8!W\P^ ['^,;U_KQ1IM[/!=MDI2KS6&W(<_>'*:
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M<H^#; 1E!KK8-4)7^'W$UF@287*U0<H-^FS/#>-J;"G /%3BXIZ<I&0[TCX
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M&)R:*#P>R^\2C_:1<C3S9XP EH5?C7XY"'JBV)5!<N,QU4E[>!M%J:N<Z9M
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M4BB)=^;@V*D-1G/$FYH-@G+I4%55B>V48 #RE/1KYM<-6'42/4[P:B!*  8
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M%&#!E =CJ.;3OEEQ-CQ 59&2ON*=?Y'C1!/&!Y=UXD*RUA>@=*MYTN93U?Z
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M(EY8A[/KP:NK:E&-E#[*2</2;V" V:=B-IV/&.GXM0X)^VP-S6U;)8K34Z*
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M>0(G:6Z"71Q#I,Q#\1+:.WS'22_)B4[>8X-O13XR,+R.^HRV@F'X4=]/KPB
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M+#WGEDUE\CF,HTITI#@@O>UR[TU&=.BD0O=M!YVPY;$AJXU\&D)[,J)KH)4
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MT8UDMQMM.KF/4I30R(NBEA0\9VI-!P(,(5Z/S[27'&N_E*@OS !AZD2*=E!
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MCR1RV3M?BC/.>,CD6!P>E,  :W_TL.E;X>DK%P1TJ0AT])VGL<"E0$MU2E%
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M(4Y@.BU6&]E8R:)T'53'D\\4LU@08=7)=3/7D9@!ZX<N%W0B(LY;TN U4/.
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M7!VG0IC+&Z5 &HZJ(!2+]W+IN1,_(9LJQ2[K6E%%J]DP+&Z71W4+T^9S,5P
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M<=_,C* H,')<[S9DT:^R54(@/7[^W+?D[\&J>T'U@_$7<2 N@%$(I6VY6%;
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M8<H1]R_U9XU#\T?013;SJ?@'40R2IC>!TCMY&5)I=(>^T_5A=J26SXES3<!
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M!G@XI9-SXPU*) :*[U.(R5?LR(/-:#5M'*&OHE*TI&9A\?U),/7C<J$_FJ*
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M R7$(Y#*#5ML0O?K/U3U[/ L2&D[.5C;S(SY?5K",ZT?9$5LK-**#S;R-U<
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M>W>N!VAN_3L; 89U^'I <^ !]KF'PQJS=W/^2K=D$KQ.R-RN4[?^AZ2*ZI)
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M&"+!TR@(C5H8F@TW-AK9"P.R#)*Z *T99;@#S#-K-(+JQ+Q=S#R%R)KAXI1
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M)RA+L.ZKB4+E<J>Y;+)P&(TE5220IZ&1RVTVW-B<Z,Y[K\7M)N. __-?<T6
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MS"I?X#IQQO:6UY+"6E30RKH3#]JW?_.51C-;Y UG"M\;Y==;P7K!YP8\IXO
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M<F79/$E3&.5A1DF :)ZE3M<)?24=&\MNG+Z.Q!-P=W]?UC'#_2H ^[>WH[7
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M*TZOR\4W+0#K(=M2&;JPEU N%LVP8F"J/*Y<, :ES!,1XDA&L56IC+.CC8V
MU\*"CK3M$O]"^'4/I,UV19SAYYEZ^T-GO3=B!(G3[9'S(PZZ0V*D_/XFB=F7
M7$5L;++>TX0E)"4$ID12B-2_,"<Q5DLXCE,9DS#!5J613P\U-B(Y%HEP;82&
M93$!-V#Y=MC,(S:\% NX#)+G(([;)/]?5OMR4(>C9/[W2F)2/6R[<,WYIG+
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M5O^(2#W##VIR6PPB#4*D<5'C:#!\5RSR/T-^BT_[$V_<RM7>83TI>^U_!-?
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MGNA\V419";9Z7,[_+?@[KM[?N9SKX,][-?JF2:%>"_ZWU8K_.5\LU,+X?G]
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ML#]$C\$^ZTSYZG[)'^AB_ECS6_5Y]4P6^F!.+9!*#+5!KV89S*@L\A(D68$
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M:KD,#?PR)5T,H+A8V<7DWA?J%5'W1FR<ND8] 7C!BC@A&8BS,@$HSR' )48
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M,_""/NY46F\$ X#N=??G4[Y1MWP!@#W>YX48XL9:/N]W%1(+GK)2,@18DG"
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M<U'HQKKNQ]C7!)B:I:D%N^W@^BKD;@?8/H%\^8-L];M.@V@0\IL/MDUQ"WK
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MWS.>G71!V@-;Z-(UCJ<7U[I87&IB\7Z^%'5UWEF*(,T2$0,68Z+K!U! .*0
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MKXPY;JBU&0 G,=:&MSG2"-'5 ^M2@755EXZD9H@*$4ME@:"T((I$XAR4!:%
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MYZW_N1;B]>J)S)<S#&6:9&J62\QUPT="E<5+8_V?/$$\1;E==OS5$:=&S9W
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MHYRN'2@>M9'"7;65[AWH,(AZ(#255WKOQ!Z'.E9'IUHJ+.ZB%HVH#X?NP]
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MJQ4)]Y)700&T#JE>CA%8&2X08@F0BHXNF%AB>,S5',[K33K&Z7[0#!475F<
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M"1/9U^(E%.'K;9]8(&97UTFA', QI_AC]<Y'E6[<)F;LPL1A]'RW;.,HH7>
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M;K3QO> A*LE3YF RQ?<J6 KRHTG (OK@(^/8R#_=1\VX:#E<MX_V2SY T!V
MY5K+P0L&K'69&PU)%5%/21Q$1]EAD%S:*I,LV_3_ND/*N-OZ@\'D.!$?C)'/
MN(R+MO/MS]DQG)EL4H22*CN.3&[$8"!H[TK=KU*FS3661\D:=_-[,/0,)_H.
MK,T.,XC/&<.H8J[WLUFLX[ U,Q!Y\#5CX.B"3"RW.2/?F<1QMZJ'PU<3E72
MM=OCUL^YL,)'RV6!E!4CV\L5V=YZN$/1H \D,:[;''[?3\^X6]"#H6@ 87<
MF7OZY)XSPK(2SM4==V$5,2(S>.DRH$G:E: 45R?K6;P'<)I=OQL,.,.(O /L
MW']3^9R77+2/HG:&5X76@1$!G'$&A"AUXS21SVYS^/4852/?1AD\9Q], QV@
MZ7(#[%>RJIN;\),@(E?<%M"LQ'K\Y\ ;)@"SM5(D[K1O?$AQ24LG]58#;BL?
M)N8.@$(16K6@^#-N_WXYOWMX\X96Q"^+Y9]AF2=DJ7.0+D'A9*%5+N21A?7
M$V>HG"B!M7%D>Q+:R?[S@;BXVX6@F9(ZP."WYH9IIHSW68%UF=CAA8,+9'NK
M 48,+ ?69G]@B'%N+;NMMP/%GI/=]M%0!X"[*R@2YK9Y]^O%<J/ ]7HYC6?K
MZB'>+1[H(L.PEE?1DC:%4A0EBP07=:)O@RG",HH_62./.@3]H[<1/1E\1]!W
MC_,+[ZY;[HL15E(8&PP)52L!OHZ'L3SRR+C6Q;<Y^SMZ2E/+;J0GP^5@NND&
M;==NRR#:Y%.2P PM&94HN Z&7(23V7NEDBZNS17V/6\IM6R*=D('?9#<>_'%
MVP%XUR^6;-?#19\)W!2VXGRU4=Y$HB^6R3H NW8G9Y92-DOKPQ7O"F7Z&!J5
M+!Q [.@]T4[K91MJLE^P;L;-/L"A<SQH+AP(1 4*=8"HC05TW B3C*"(XI18
M?836T3NRC0W5H?38.5)_QS\W/ZF#&2A+(UZ \ZA!>5]'OH< 2$PBFL+IAR<'
MYR5YH[=JZP*/AVFK7PB>#U&N0[*V(RJ),6\]RN0!=4VL1,C@@F50@O6>%X5.
MM3G>V)G$T=L<C0W%([76+QPW:^P&7R2C8+5/$!*WH(K-$+VMYXB1.UIFH>A6
M5U=VHW#<\=@=@/$XG?6+Q>TBNV;P?7+99DTK+"90@7OP)G)0$:TSQA>6VJ30
MN]$W\CCM#H!XC,*Z*,Q\-!"N/WOU:;/ 7GS!99I23#S)QKDB$0'1UM:>AD,,
MGH/F)7CB6 G5<--['U)'GLK= 3P'4F,'!O.QV^[//H?IK&[<DR3?AAE>:UAR
MMR.#B5D*R0*4(BF-,YR!HU4)#KE5M10VN#8=XX;B8#=4?Q?'-J,HO6.P']Z(
MY-Y3KFT-WH0$D:UD&BQSD2P!V00?K "GO1;H,K)&'3Y/RN9NR^:[.%7J%SX=
MK*UO53(DPY$5E.!DJG.WBH9 D@>A:V&ACZFP-N'-(+4FW\E9UG J.O)@],4\
MMS^$-]8%Y>JHKU1K5G/=UO,\@[4R^HR4-Y0V5RN//H3GW\6YU6#*Z01L U6[
M%)D9CU9"DHDR6,,84/YJ"41%*<<,D_CDJYOX]W.:=5J%#PKUDW5C#JL/O\P6
M?P[;A?GRH8V[+]]/_/!-G2Y?=-FS)[D8;%8&;*T_4LR2PPV80$>94?N2=*/[
MN8]1-<!(M/K,U\O%YRG)[Z>O?ZPPOYQ?3B)_1I'QYVU">3G()%E=8BS @_:@
M0G! /D"",$7+DAA:T^8&Q?ZT=E+^?BR:[IFPUE)I7>0GEX5<0L3 O))@F,AU
M;DZ"D N"*%X[R:WCV*@Q2R=MOEMK^^$:NGU$WP%HKC+VU;O%&R3GGJ8SO#&.
M\-UB;U%*F[.LMZ%X(1FD6M/O?#W00*156K+5L0G\6G S\B3QTP)Y=#ATL"3J
M84B8)SQO1OALGO\>ELM (JD;QKC\/$V4Z"V?S\+TXXJ8X\:;[.M&@@8EC0(?
MDP.9N8L"F<!&E_KW(G-<:SP^JF[?BFNFX@[P^S/2F],TG&_//OM8$[G_/"]%
M%#%'SC*@<PZ4Y\2*L0C)6B4M]Y;G-FA]A*AQ#6QWV!Q*?1T@\>%C@XL9$5?#
M(R;1*^591K#%;/;,-#BK=6V_0-^H&(IL$[/N0^6X%XRZPVHS!>\/7K\%[QS?
MU^V/=T/VC5KB1L'7%F(=2K9*B[/:%G2>7R_QX_3LX^KE_#.>JV<2D4(MQRDW
MY;%6.$8!090 W!O%.,E!-SH:/8S><:\[=8?K$RB]'X3?W6^^%.MYQ[=+F1:7
MA2(60:MZ\4;&6$]L PB>2TQ>">G;E,#L3N.X%OK$Z5HCU740.MSEC!;<IS#-
M/Y_3\^)+O6!3!U=LBA:>K59(*S#5J]722D#EZ\U7:R$:'FM+ 4$AO&$NMRE[
M/8S>WMI #(.>;X)T<%5V;4PK3U<&8,M<0(U!H@ L)E(@7\>DQER "14D^0K/
M\%0XO8^^WOH[G B71ZMJ?!S6T\=[.*. 9A.XO Y?ZT%NC6_.+A?>ZF+E_3H-
M<3K;N*>)8X6Q3+&,%V+#-H/HF %&84TT15!,<\O5WSWX'(J8WMHZ# K'4336
M@8??/52:>(TB>(JF"Z_E-%G6J0OD&22Y JV11Q[:] 7?G<9Q$Z@3AYV-5-?!
M&+D'.-LF>?<+TAM>,#H!(KC-H#P.WFKZUB9FDS#T5YM,?W]:.VF>>**C_:&4
MUH&M)"=POCNRN;JXQ-_"\A^XJ<FZNKTP<8%1C&(XF%2'3 ?%P"GMP'J%F#27
M+K0Y=MV)O"X+ @;#R)TA+D,K;/S0\EJQ0T+,JU](R/7^#,4BOX5UY>GKJW(O
MGPQ-D#Y*2 $I,DF^@),*06O%G1?>RM!FOM3>I'9YV-\,I$T5V9'9_&6QO,[K
M)G*^1Z@39IQ204O*[0J%[X%)")H69;8QVF*]8;;1#8[]".URC[.U*6VAQ&.-
M:AOG3FQ2)+W^^GH6YFM:E+4P^U/]E8E,6848/<A$V9VJJ64,M BU\LDZ4XS3
M;9KN[$YCEXG0R=S\,*KKQ]?O+L^)XBJ7XA5%\#S4@?7UEI7T$-%E451!U^C\
M?G<:QVVH=V)L-E)=OTGZ+]-YF*?[!:E-CK)(PHZM&W."I!D%%^#09L98T*Q1
M1]']:1W7N9\Z21]*:3U$F]?#Z7L[9P3MD>@VM0L;,12E(890@E<.2;#&H6YS
M?/Y-TKI,S@?#QF-YS]&*ZJ(9ST4@\@8WX]3>+=Z%+W^?KC_4JWTDP%K5>G]O
M2B1C+[6/8(0S0*:>04@FUT,#Y7)$D9N-\#V,XBXS]&9(/85:^XDVKR_,JQ+M
M:Y>L)U'%&)4P0-Z&A)FCA<WI@HJEH"AH7:,&>]\DK<N<_!06]'A%=>"[=Y??
M)"(F'KD#A;4>P#$+T6(&JS0/1G)M99NNS+O3V&4.W@J+C53709[S@I9*HD#\
MQ9?T(<S?XQNRMJ_FE=GZ?]U:^!QF6_= <IPFLL7U!\_F^>8'UWYS@IDSJ2F4
MX4)9$H% <"IY*-Z+Q(N,KM&%[ ;,=)G.MX+YV&#HP$@?Q>RVK>'=.IOS;A?7
MQ;H5]219YKU1''1BNL90 J).$2RW.@A1BL8V!_NGY7-<9]%LOZ%CL'3@6HZS
M&R6%[#,!E[(+!8J4 4Y: 1:E]-Q$(1JU%WC"[J)/H.^ERFY&11W'LDB8%28#
MO-19"$$Z<%P+\GJB9)Y#XJE--6%[]#;K2=4I>O=192<MUFH'+>+BZAAFGB]#
MQLVXUZO#GY@42[4<2,1<FQ42<ZDD8#9Y%%(X%QL5%NY*XKA35MH=531140<!
M]+5>WWR"')U%KR [5G=HBH"0A08G9+0^V1Q#J]9<5U2,?.[01M$/=UC?3^H=
M(.;:_8)GQ,''RD(.+!K).8A8C:[+&F)B"E*@999UQ,#;V*5[B!GY-. D^#E6
M!X/!:.AFB^\^X$]GJ^D<5P>U5;S^SX=IH/@@00.U2GRU?!_FY[?)KYHU;OM\
MO+Y&]JMR#J,PN^KC>(FEK'.0R#*(( .H>FG#Q4BZUT4H)8/#W.8,9!#RC[K8
M=J&==Z20GV;UG $QF$RY][:B2@5#>3<) %A.46<*#678[9K:G4>/ZYI.#Y4;
M]]&.$W2W%N?MV<>/8?EU4=Y.W\^G99IJE=[VHMVFX^ULFNKQR0'&:,<G#V.G
M#F%C(!-V]S678).2(RJ5P>1@04EKP ?G(6;#I:SW'&*;'J</TW1TP/R8?*_6
MAI YBE(42)$3J!*(<X4&@G"&A<Q8$FTBHMWH&[GYVS"(N1-5#Z^:;LW6;[A\
MC\M#S-+YOQS&[-Q'QD!FY<+?/%]\C.3/+GJ?U1OXUX;U70(G.%4XY]49U=WV
MX.M$720E%Z=Y=(E)UJ:-W7YT'FM^M@*_,3J3WO;S=/5I<?YM[4@T6ZS.EM<Q
M;S4O7$AR\ZIVB;.*,,^D!B9-L-S%;'F;F:B'T3NN>6J(O-LFZP3J[-:$70[=
M*K>';AUBUAYYVC"F;E=RAXJJ'AY)=ME:PE#@[FK#1Q0&%#>LHH"#2,&$%))D
MO%%T]4W:&ASG;*XBWKV >+4HB@VL9"LAJ^K7I6?@#%IPQ7--*0I!Y62'\]\B
M=N3X:UAL[7" ,ZCRNK5H5[T)7^.V#/<02W;/4X:Q8-\B;R#+]2(LYQ1X7[[D
M:L<S.<64$X0D4>\4)0Y!QP@V""YSRCJ:-C4"#U%T=#7>K>=>P3F'4KR- 20F
MK(UW-.4818-,S*005"BR44W=0R2-:W$&P<2=^K=!Q-^M-?DE3)>;F;N_8:CQ
MW[8KZP$&Y?X'#6-3=B!R(+-R^:9K$?$EC!0FEYU($).*H)0IX%V.8(J2(4OZ
MS[2IP'Z,JJ-[9=_S["N,,Y4X*ET@Y:2@WM<$G[#4MK8&I8Z879N$]U&RQC4S
M@V'D3E?KP531K;DY;R=WO<?>(6G8W:<,E'Y]@[SA-K-OO6;;R;S>W*]GN^??
M7(;)+,D@44.D1]6S>P?!8X)BA(R<J8RB3>'8?G0.T/'\1N?!>;[[_JN5<;4P
M?"R&U_E_)"6Q+8$-01N@E1:5)>E$WL8L'TCPZ-OBK;!W3S?SY@KMUM)=-B7\
MM99P'V3F;C]B&!OW*&$#&;CMHR]!A YSSI86D*X]2(J6M5>H!*U9K3SBV;DV
M!NPF'4<7)>%JA7A+?E>P=<I)$9"#LK5)E?:UFT5&,)(SI@5#B@8:<?D87>.:
MFR.0<*<>:3CQ=VLU[L[%/:@HX.Y3!BH ^ 9Y0VWN;!Y]"1I7YPMI;R!3_$OQ
M+F7NL7@!C"G/'7*,C0J/;M(Q_)#KWQ=KO,\!JI(*PUHTPW4]GY8*//$.@9PM
MRRF)W"BBV9G$D3=Z#L?'MP=1#Z&4?NW+_;TM#K$QCW3).-[.[$#F4&.D[WW5
ME<.2,J#T$7+(=604\^!5*&"43#('7:QMT_GN<;J.GM5W"?!-^X3+YY\W_'B^
M6*U75Q1<MIN[VHSP+BMM ^14*VB8*N"2<F QNY1"=IR7)F(YDO"1ATP/A[4[
MT_M.J-!NK=OV[.E=^')8OG7]GP]Y&'8/00,9K\OG7ZG_:B>2Q>(4,Y5'19F[
M,! 9EQ DD^AK?(R-!L0^3-0 4VYN/_H*PK1&BO?DEHNM6Q6IWDW@QH(4-@2!
M0I=&L^X?HVKT24N#X..>$3;#Z*%;4_+LK(II-@UOZ(%$WX<PSS_C9YPM-FU5
MB762 7TQ_7S0\?L^CQ]H:_M0ADY@JI#)[*S7]:@D4>K.R/E$K4!'%I(/)2K7
M)L%K8*HVUQ@N9/SL01E?*THI2H5D$$P*C)BO_4]MO3::8^9!1TTK<Z>;)'N\
MM%^KM \4;MP<:27R;BW4\\6F]!SGAUX=N?F 8:S,(T0-9$=JL[?I=NXIJ?K&
M^^Z!DTV8,_/UNE .Y.2"H'R]&.#!H%-*ZV3:[,GN1>;1A8R[O.P*_MJ*6#0E
M%AA$[4GF'3@F QB>=4SUQ,>W2=[VHW-<(]4.9W<J&=MIKUOC]>LT;49OOE_B
MX25'=Q\RC!'[!G%=7<I5CJ"0@@03!+FRQ"SY2ZE!*ETTRJ1:-1@?]5+NU=*9
MT:>+>B#T&9\ME[4Y5GW!O>LF.\5#L1!E34MH>8*3@<05O'8FH4NJS92J/8C\
M'N[^[H/(NZ:PC3Z[M8,74>LUQA<DVGS;!!UB'G=^]C!6\S!6NC*F(6?K;9:0
MBJN0JF-4R9>##3&9DE,4Z?\WIIO%%[6PDO,(13-6V]H&")K36HS2.V]HH>LV
MI>?_Q8SI/H@\QICNH\\!!P^,TV>A?;^%4?HNC-5_P?/$8HB4[*!)H$QR$(16
MX'+1CC,6+6L36+7KO_!36$U7K\JM%WS=_GEMU3AA0I&>HIQZ?\V7"([^A"1E
MS$5Q642;NT:[T3=ZH>D0B+EMU1JHIH-^9W^L\%5YL5I//Y(+6$TB=YBR5V B
MHQQ?!07!4LH?"GJ*K6U4ODW!Y$TZQNURU@A 1XBZ Z#<""5N@UZSQ"4R"2AX
MO1A"V9#/)4 T6AM?3/:AS1S1QZ@:=T!)(Q -IH8.(/7+8HD45VRO 1 ?%"BN
M2#[G;2(VW\XV?*YN,XH\R>21Y)93'1,8*&ITB(!&AJ1UI)BU#=X.)GG<IO.-
MP'@:!7: 5%IU]2QON[7P9KKZQW.B8;JN7TVBB4EBM=[1UH/#DB"B1? R64$R
M-5C:S+A[A*AQ.[^W,WV#**$#/-U?C[>=RD<KY_+DN$[5/5\[$PHGM<-:)Q,W
MC;U,;?VM&' K%$DO4'C9QN8=0.RXO=L;X:^UTCK Y1O\C/,SK%/.ZG%@%5F=
MOO?\;+5>?,3E;2ON?%8NL@PZU4EGFYEGNFX7H2HQT'^)M\D6]J-SW*[MC=#8
M4%7='EIL^XF]JW<Z#]I#N_'OAVP1>!])XS0*9"I80\DC\&(L*$NX"D(*<");
MJY SX]OLB1W2*/!T/=<.Q\PWG]FZ_UI#;.W0*2OXY$64'#3ZZL!$AJ@8 V'1
M.VY+(8BUV6-MWH7M;?J ^6R&K\K#[WJ#B:+.Z6RZT>E&%=>NBVLCO=.>DNR<
M08F:;M=&]\*1TV<QB6(:161'4MY]?[9]4'<G3#NE6CN(V1[O/)<LAEB(&5<2
M^7VL90O,"DJTO?-28Y2AS66,XQL$MMO?;0O X132 ;JVHSXV9\//9V&UFI9I
M'?UY$7*>A=EO85V9_/IS6..ME40,46!;#"1E.*AH,SA/0:X77*$V1A5LTY?W
M&*I'WC9NB\V3J;/;'.)NF\C#8\,'G]6JHV7#6/#!'H96.$=)8H+,ZF QPS-X
M&3(PAL;QK%CT;?8W6_6UO!8@4%J>I[.SNFMSM=!>?*E33S%O4^N/G\XNZF4>
M[LBH@M/!6>)"2PH9K+6T,J2#E+R64DA6;)O"]N%YZ;23YCXH?"0B'$/AW9K"
M>[M;'FX-'WM<PW:<#6WBHPT7!0% \)P@>$:!7#(>@O"U2UG=N1.2!]4FN#E)
M4\[-QLWJ7,[YU?Q-72U+6@R;,IAKO6A9]H[^!VD\Q02"TT+020,33&J'*=C2
MZ"1V3TH[;MVY#Y(>;-W90F'=6JZ[[?R.V.![Z%FM.GNVW-#;K\<BLLR%B@6T
MK.W+BI#@N1$0HLO&HQ3.? _]/:_Y__N5<6UZDK:Q$-&UN9(#E9W8YE::E1 E
M>IED\T#N&S2.7ES9"F&/A&U#JJU;HW:[P>#!%NW^!S5IXMG0EMUJX"B18NN4
M$2)WH?8)TN"C])0 ""43MX)^VF1E#M/*<],JX+Y&DC^1C.<)WWY 7%^_GG$+
MX2D6CSR(ZK9=[6TB(<JD@/F,WO(D;%3?PL61-'35SW,?.-QHUW B'72P=7L?
MIQ<F].O%-M\M%IF0JGC*L$6AE%8YP4C 5H)Q(7A9BM:\S?'Q <2.>X@P !Y/
MI:AN/=[='IB'.[T'G]6J 6W+O=B;;489,[D4$X 5I6I^2-@*P8%G3(<@G(JN
M35?6@=O07L9S]U?2;42\+:=;/4OKZ>>[J(\E.JU5 ,XH;U7!%XHD2284Y44F
MBG>Z43_OXVGOJG'M/HAZ."P_B1H[<*24U]13,\QOZ,_E--%7&R8W_#_$8P@L
M*RXB6)U9;0W.P.F0P0E=A>PRZC:+]A!JQW6E X*SN:HZ@./5 GR(VS_FT_6#
MS!I#<N6;.N0:.-2DV58YZ\!]5EZ%U.8X[RBRQSV4;V(]6RNOWZCO7K=Q1.3W
MV/-:M@5O& %^HV$SY9Y9!,?(@>H(BI< @7$#F+34R>9DL,TPV+;-P:\6QPM2
M_.(KXEM<?I[6S/S>U\XVC]P<U=:*OO?SZ7]B?HW+Z6+;=_I:NA25DYX2=LNE
M!LJ<8JVZ"J M]\Q[)IANT^BS&4M=-Q3?!Y\/6\@Q0="!G[_>6?T!WJ]ZJZQ^
M^GJGR_JS/\,R7SOY<Q*E4AQ*#6X4$OM>$&)-4CP;SD-.;?9V!F9DW&"U(?+'
M5'@'>+\OL;S.V/7$LAYY;R6R6IU]W'YV9[=6^9#00#26N'>F)ID,@2<5E8Y>
ME$:5S\/R,6[D>Q([?W)U]QL:[]1OZ6=<A^FL81>IBQ><LHG4O4RU[R$5$H^J
MI @I6%/+86KNKS((7;1@F7Y:VG3>:]=#ZI<I99#XZ_0SYI>DL?G[:9V!N2D/
M^AW7$ZX+4_42*&.1%DI&BH)J-AG)/YC,I(^-2AP>IVOTLH8A$'*G.FLX571K
ML[8W8(^P23<?,.2UW)8V9<][N:1)S-H+D-Z0I_1([BFK"%H[+BDK0<_;E"\<
M<B]WB!CNXKW77D(AZ[7O-OY[DCW'HIT%D6HS78P%?'(!T&09E(^<I49CSO:D
M=%S[U!!M#\=E#53809IQ#U?/ODQ7$[*^1<FLR+#7ZHZ  6K_!="%&U^$+:KQ
MS?E;!(V\P=,4!;=;*PZ@DDZ15;]<(OZ\^!BF\XGFT><0$%#5GG^>>8@%'7!3
M@F'9L,3;W*;_)FE]F+>C + #J [7QHCPVI2M/7_Q^\^_X<>(RXEU2FCA+>DX
M"U!6" BTR( )SPREW"J%W>8V73VS/^T?H:G%\6+KTYA0#(POU_AQ-1&!!U^T
M JER':%G$KC*6C9**.N,%.)DONJ2JI'W94=V6(<IIP.@U2E YU4[VRJ)5V?K
M%>6JF9+AB;36V"*(EZQIT8@Z>UKD #EHY[U/%E.;3=3'J.K.6AVH^WO&,0VB
MB Y =4^^4CO73C-NVS=N>H-N*=L65[R<T\MQM5Z]7*W.,-=^>O3%9J&F6*PP
M(@"7T8(JY :\+0RTX4R86J2CVUPQ')")<6UC,\B.I>:.$'Y-IIM5^WHY33@Q
M(6JK@P5F5#UJYA(\I=Z@R<.(Z%)VK"UF[R5KW+.DYB@\7A4=X>K:DKHJ:WB9
M:XO1,@V7V\CG@7+^VV*1_YS.9L_FUZ_);8[+,->]9FV\8;7%LK8N0IU""E&@
M!FM"2$Z:>C?O5%9T"(;&;:A]2HMZ<O5WL JN]2EZ.7]6RJ95&Z[>GD5R+M.P
MW#*W2)M/B>G_N9C.U_].OUXOUD^*3Y(G)-D[7@=QL 3!.0\I)TN:"1A9FQK7
MH\@>MVEW,T2?3I4=X/:^??HK@;[!&3&Y+4N;Q!@L9L7 !B3.N* 5*2W]P4..
M'I/UHLW)\^XTCMO&^Y0V=@@E]0F_7;S'@UZCZ,A,<@:0,V(?N:M[) 8$%AZ,
MS5EBFTLL S,R;@?PWH*%0=3= =J?A]6'.KB:_JK9Y><PJT[FV?IY6"Z_3N?O
M-WUQ)D*8E#F%_I*K.LE01/ R9O!&N)"3\]FTP?!.Y.V$3/?DD#F\:CK VY#+
M[=HG$VN3)%:)>98M*)$L2:!XR-:';+-!'T[6LWT(AG;"M']RF.Y!_?NO K]=
M!7-\7Z.:=UTNAJO&0==^]FK]H9[:F1R-XY2HZL1!J1+ *U& +(?243-;\&1U
M4PWXV^TH@_V77BL#H>/[7#I79:6KB4*GA%,%8K&U1ZJFKUQR(%-1J)V7(IPL
MHQR"H=T6Q],[Z.M!_QV$4]OBZ-E]Q=$7+/.)%LX&+Q TN@0J.0:.>TYRIM7-
M<E&:M]G*VX6ZW0#Z]([U!M=,M\7K#X_=N:@G692'?^?F&)$C2N!;D-%Z+M%
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M9&@)LS)RS/$H_4\C_CX2;$/&WH=I_BGA_:' ZHIS+1)JD0OHR,B^6._ "5O
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MMDP!)NNT=SX'9CIA;.N+3_3&Y8F1=8PVQEZW;FC_VOLU."-M8B0&%2-M$"F
MR]D!$U8J&WAAXKLC;A[^ZA.]OA@)38=I9/SFB/>8>!YF=>I>GC@46F3% +FV
MH RKM<ZY9L9C,#889[8SO+Z#JIMO/M%P_TB@.D@?H[:IW;*)7Z>+NL*:H"UC
M#(37-2["$T2.=/ TF3,NE%%NO_UN\\4G&JX>;87:7QN-K$^[G4$62QWA:8$G
MA\1,G91GK 57I-41,7AIG\!=;R_,VHR[OH^&1JY=NIY,NR;[6C1AEG$3!%[-
MZUL3YKG"S#@=/FH35Q-*;;5/9N2#XL8;VND[#L-^[#'GZLCW'^OH666M^/?7
M=Q 3K,?9P!GXX"OI-6F[7@9JFW- P9E,W5:W^]][KI[]0/ Z0BFMX.E[Q; W
MZS_9"2W0*0$=710H1J>8*,@W,"D5X3DZ5]A>@.OXX',]%@R,R"'4.CID'^'I
MAN\[B1.3%(I@II9N8PT',LLAFMI?5J: CLGH>+<=><\'CQ/&'5[]\R?212.A
MV0X<W@0*65)T/$H<C,DUL(,&?$X94,LH1,G6;#>I/P)IHX9TVT/9(3HXA97L
MSA"O&+7+2H/12,YIR$BV0_]8DIVQ,M3.V;VA:^0@;WOX.DP/IX"PVQBB]]P&
M<BT@.SJ#JUR[R]+A'J23@4Y&3'TSC_D(@(T;[VT/7P=IX13@=1-5E%:R$C7Q
M):(E$6H%(1)SVBC)(LJ2C>MQ^1HQ_ML>N [1P2E@ZZYKF8,U3'$%D65!=E-O
M_5%HL%DJB<*D+/5H;G[OX=_V,':H+EH(Z7;A;T?6[T3'0CRQ -P%$FK,!F*1
M$@(WOEB364H=;T(/)^)<[[F&BHX\D;I/80F]D[4^T8S$9D4&%^A@KI*R$*--
M9+;HG2"FDTY]GS#J@\_U!FU$^!ZJUM$A>[.;5%$^)#7II122<0A8.QVFFN/@
MN 6N4G3624<_[16 WO6D$^WV,W;$N1?%C8[";F7GOUWS/+_C^0@GO+%T7"O"
M$9<8!/BB/%CI?6)"9^\ZWH\<2D(#8>=^,/#(DC>00DX$=O==E'#CHJRN'13,
MTBC##%BOR8+1:PBJ1/ UFT>4I$DB?2+P46H:B$Z/!L;^U'0BN-Q8WR;/8I)$
ME:[@8!P9G7+)@Y.UE4QT"JT3SK&#O,ENCV\@;CWV,GB((L:&VH[*V8>"#"9$
M)G6TX$,4M5"1T4E,.'!*Q)22M-YVRWWI_LP&@M7]@VH@D3>.I%W)8-ZDQ$J1
MX$30H!0F<,F)>MF3>; ^)=TMC'C8\QN(6#\YPOI0Q4F@;>(9HVW=!$BU?DC%
M*LN0$V@G;796"BN[Q0H[/:Z!R/1(6-I+T+U!Y[_^\HV@?Z(WUA^M/ZE_]0[+
MO]?___+NU;WO3^$BY,7T:OF?:7YY_?WK9.E/\PO2T_+Z6/^.N%M,JXFL/R.3
MV7KGE]ETM7R!JS"]6-[G;SF]_/7BNX5>QS[R+U^9W1;#YLG?8&QHQO'W%=+2
MDO_CN)K]K2X),B7/8V!@BB?\TOX'D:&'Q%P1UL02S3 SF.[3<70G@O0)\]4%
MOBF'CP_ZL XR)DLF%01)()H$RJ8 OC:02#E[YJ-!S@8:[]@7"^.671^!KV_*
M^D=1:@-]-:XIIU]^]OMT2>Y#20)%AF)S33@,&8)-&42R)3!=N,-AFM#?(V/D
M8OYQH##O2R\-@.IPP7UE>Y;?7H39ZW")+^;UR#XI21578H+H:YB]%$72C!JL
M#-Q%Y4,1(S4C.X";<2%^!+AZFZ#7DZ8;0/N66_4S7D9<3'SMGZNY!!.5 V4D
M[4;%DF,M%<L\1[)],PA<'R2G\?XH@Z-DWK?*VL/=VIU_]_Z7#3,E><5$07#2
M:%!9F#IAP$,)N7C/-0M^F&;YCY+5>!'FR#@\0H4CXG&Y6$W>50FN=Y,BLS5*
M!0BR,#*=XD@PT8(+&I7.+#G9J9LV?>L=S-%/VWB[]]B1<36JRWBX_%L S0;K
M4CCAI&00E";&.:>UU\@,/$E59_QY;3M-X^D.FS$WQB-4MJWT ^0WLMI_GLZF
MEU>7&\(1-7'M A1..Z\R*1'BE054R&EI53D)VYOB[SUZ9-4?HKAY'U(<6_WA
M]SN$VQ %=[6F,3!B/^N::R(M22.)R(O(VG>:2ME-_7<?/<Z6T9OZ#Y9B Y[K
MP9EZ/TUG^&J%E\N)94$DP1!R+('D%@+QG@U( CLSA>44W2#N[?&TC]PIHHGP
MUA,CH 7,5P?_U7)YA?G%U6(Z^_CVNN1ZW69EZQRPYO2OB_ER.1$6M9:I0"F9
MSJ2!9;)L&X!S4[+,*KCM84M]X?P@>AN/,_2,JFU0#Z_B=H&\OE+>S62(M<&>
M(<]6>E=;&62@G[ 6U&G++<LY#!2]/83<QL,4H\"X1P6W@.+!B@767166KV;7
M4MM*/UQ_^"*L\&68+C8#+I224D3:1C%7U[V. G5&0M(HK?;1*=?81*2^17"B
MK;-ZLK96M+ 7$$_9@M?_U(3RVZ6-3T1.4A9:LXC/VF0G,/#92BCT*FGNG-VN
M !C;"!_@XD0;?HUL1\?"H=U<N <E\O"[M<YBML1CTN .?UI/&7 ]L=M3\ML.
M/-XD*V6>9=2"G/XZ*EC9VC"8U<.S85PPDUT4PR3#/4Y7.\EQRIAD+!D>JST7
ME% < G<U^=7SY!5'RP9RB\XC.:Y'_ V7++>/DAMP.5[-:+7!]Z3$-7,_U3^H
M_-9+',&DQA#H_&,][5U8/''!)7!/4I8V^VB'29U[A*AS2:3;"R;S8736+OPV
M>0B8:@$ X0.E(68R$^"]4^"%"T;'0I(:9@+@HV2-"\'>E-\-5 =HH@%8O2.=
M$ &?GLWR"_R,%_-?*T\;%VESP13)W$HH-9DZU'D^GLZ&RB 4@8D)&SWF8:Y;
M.A#7),0.@<*WR4&]ZJ4!J/T59[@(%\31LWPYG4VK,[*:?L;[3&65N)+& '.U
M&;@L@FQ4"'KE0BH2M>?#K&2=R!LW-CP<W/K730. >X\7]-''[_"VO+&FS"1*
M;L$E0<P)$2"J*"!K&RT6Y;,=)F=W+S+'#9<.!\#A=-4"$(^/C@DTSCFI@&1)
M'"N6P$G&B&V/Z+1-7'=*D6LUY>$$TC./.8@\,0(:P/RSB_7O8'XT"#?)+F*)
MQ$O))%G%C 9G'0/+@D:N8[!LF*OA;O0U&<89##7;96C]J_#$XN7W7R]7K^>K
M?^#J':;YQ]GTGYA[#YEW?>"04?.#F'Z:P+EA4M2^*>1A./(PC$@0-3<07! *
M,7*3.B6,GFW@' M#%KP$&74U]YH*S*TFQXAG5J^U L8_ ^<'!\[WP=]P@?-]
ME-R")W"OX)0;5:R*'&*A?Q33'J)GM=C.R9"=]TGA,!O^.5:9[P6%1ZO,]]%+
M Z :I)J/A22XE0*2B)(\?!_!Q9S!9N6LR89[]:3WLF=39;X7N)ZBRGP?33>
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M6CK()5@5:KPOB"-7JH>?W.JV-^B"U8,2VD78L]GL*EP\^QRF%]5U>#G]C/_
ML%B^QM4OLP72$>B?F'^XFEZL7LW^NFZ_PC5SS!E@&#4HA1R"HQ^-=QR+"R'R
M>"3V]J5IW,F#(Z%R4,6-C=>WBWE"S,N7).WWH69P$UOW9('+UW_[\<4S^L6/
MBW!Y/00XUR-WH>.XH-,W<6@UN.(9I-J37P3.,+A.T#SH\9U0J$\2A<.KX]0
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MF"G >Q(Z[E&Q!VAL-R<>4$\-P'"70=_A[._3U:>W=1/Y,-_UVS<%8BF8Z%0
MFY X9DR3/0L+B6F&H?C(.1\$HWUR,7*[XB'AMEV--9;NQPZ"5-*O%X;B<^*)
M@R+B:6&("$Y9#YX'G7UA7.=.]5C=@APWCQUY@F ;F_GABF@!/1O09\04F3#@
M<ZXVQSTX[8E[PXIPM4HH]Q>8O?/@$6,=AZEL6^D'R&]DM?\\G4TOKRXWA"L,
M]''T4!R=<Y3+HA+.P;@H7 Q%V&[9,)T4?^_1(ZO^$,7-^Y#BV.H/O]\A/',G
MT=&YUBN=ZZZK(3K-0>B46"*RB^GDC'=3_]U'CQBKZD/]!TNQ85=YC^WRI]N<
MS")]TI%'L*+>D+)2\Y!T <U,3 QY03O,N-@^N1BW2J011V9T>(P=CKV>^?9J
MN;S"_,N,=+Z=D#,Q*?#D70 5%9*_D!/$D#*@]*QDEDS9;JFXZ_;G>X\:]_ V
M'@3F@^EC;'3MDNF[VCZ["O9-O)A^7*MX4\"U8??G,)VM<-W0X27B1(22R=N(
M@*9.Z8SDK@:G$[@4,_FNLJCMI-T=&.R)H'$CNFT@=0S=G@F>WZ_"HI9B/%O5
M$L7W^!EGD\"=J/$@L-%4?\H(\$4$<,PQ[GPVS'8KH!J.QG%#'V>%^F,1<$J&
ML#DW//M(6QB]A3]/+W"YFL_P9C#F6UR\7<SS55I-"M,LZ_5HS-HIW:*E5T%!
MP:0L_9<$T[U;P1X$CNLTGYX)#*7[4\+_N_F7<+&:8BU%?U-J0=YRDBWWGD4/
M/$0Z@SOOR=:E ^%3ULP9XW7H'></$#)ND?;IX?E879X2;M]?T>NZ=]$^15O6
M<A)L##+)6K9>"]B%%!"-E73RB$KYS%GVW3)RCJ%BW'KOTT/L45H\);@^XFU5
M'^OE_&HQ,=H9%84%%FIZG. .O*_[C&8Q.Z-#\-TR67LF;-PR]-,#==^Z'AOG
MUU&?_\&+_,.7#Y^FB[R^MI\(7:ROMLFM8J"\4,2"T>06:2-1!-22=X+KP]_?
M"77NO%'7@^3'!D^/AO/AMSG]_@?"$DZRXLK);, E)/N)ED3@4(/G EV(Q4G3
M#7S#T-<)O/Z\P=N YL\$_,\*T?-RNEBNJD\_L5JB,H6!$;S&)'VF;:-$,%:A
M"3HJ&>138O\^>=WN2=B?V!]6\:<$_>>?ZJ?ULG6V(AIJW%V*S(T@APA%1%!)
MUJO\A"!,S.@%[7_;E]@]8/Q;.KJ!^<QO_9Y0E<TVK;CI\G)'%G.RTKQ] 7I$
M+XM]']%/BXNC&&NJ\X6V3&;"-D1?9XA(Y\#QG( 9[S3C6OLT3-[+N7:^,%D$
MCL6"<TZ <L9#D!P!36WL%H6.9AB!_MGYXEA\/T'GBWW0T4"*W</E.R(6'40M
M2Y6!]D1#NY1GM#M:+[)FF@<1AQD%=7@IWBGUPM@+(YU*\?916 .HV[?F1N;H
MK4FZM@_+M;L-67OQJ3;XBF3P*28[S!25,RC%VPL:1Y;B[:.G%MO^6)VT2B&#
M\%K6\',$EVP"GTV.I9!C'CKA;-BV/Z=4=7S(4M>+>L:N6>K<'2!:DU7M9D]^
M2IVO1>;BA= 0I7),"IMBM^GG9]WV9R_-']3V9Q\UC!U$^M_IQ=5FQ14RZ^A+
M <M$ 976 6"=P48KK'=2T*K?*2#T]3M/H:W/7MJ:'R^ZD5>33;;5F\5[7'R>
MILUDVQ0TM[7@M]3KKA09!,$TF3LRG5VB_;:_4MJ'*#B[JMI#-ZNCU=,&O*J\
M-APL-W;F)$O)D[>8Z_R]]?1D9SV93!;*<">+C?TY1#O)&&]%.EZSW\+D2#$W
M<'R[N939M$.+3.IH+62> RC.5$T&M75^IT?)1<YVF'[8]\@8'2/'JG7>EXS'
M]GQOZ]6U+LQRHX '1W;"O0#G<P*C8R[>16EDIQ;! _1Z.*42R4-WI<,4T0)Z
M;B93FVRL%Q%$*G6=90F"B@H,XYYG+E@0G:8^G&*OA[U4MJ/7PS[R&[O8_UZ7
M LL<UT@+I70B5\0K<(R<?3KV%<^LMEZZWA3?8*^'O12WL]?#/E(<6_WWNA34
MD1 E9P2BMN;FITS;9BC M;>969G,=LKZ>?5Z.%C]!TNQ 9^RUYP.YK)-Q672
MM:&C/;<)'/<DBNRTR*$4$3LM(.WW>ABLS*<11V9T>#1A&K/U57=M#??\:KF:
M7]8. R%.+Z:K+Y."2OC::K%D05+5LD!PM.K7_E E2CJC^F'NQAXEZXS:0NR%
MEF]@VY?J&L#ANUKQ?(5ULN4N ?_X>[JXRM/9QWN_^ZT,)MSEY$OR8'*4Q+#D
M-7^#UH+"DZ4]CBL<IMEOCTR<44.)8S ^%BS&OH79\/(.:ZR'>'N+BS)?7-8<
MY:^9G_\7%M.Z^=7\IFG&ZSS"9Y?U5F.B34DEJ@ L&3)_*QRXC!&D+@%+$I*4
MTNGNYEA*SJA'Q"% ?GIM-@+=!WFD-U-5_\?K$;3K#'LE58HN1(BAMB]2FHZ2
M)G.R4A3<R>B9-_L@M>N#SZASP[' '$17IX+#N_70F[]93APFGW7MANAU!,6,
MA$A.$R2I;."B\.BZ]3@[AHHSZL4P.$*/UN+P91";#^H_,2SQO__M7U!+ P04
M    " "9@6I5X#E-54<'  ! )0  &@   &-L8G,M97@S,3%?,C R,C Y,S!X
M<3,N:'1M[5IM;]LV$/Z^7\&Y6)L \HOL9,G<+$ 6NUB&+NTR#\4^#;1XLKA0
MHDI2=MQ?OSM2?DGL8@ZV;&F0?% B\8Y\J'OXW)'1R=>#=^>CW]\/6>9RQ=[_
M]L/;BW/6:+;;'WKG[?9@-& _CGY^RPY:G9B-#"^L=%(77+7;P\L&:V3.E?UV
M>S:;M6:]EC:3]NBJ35T=M)76%EK"B<;I"3W!*W!Q^M7)U\TF&^BDRJ%P+#'
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MWUFY\+'5JG*;+G_S-4]]#=\6^:^<3O\"4$L#!!0    ( )F!:E6>/; WG 4
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M+3(P,C(P.3,P7VQA8BYX;6Q02P$"% ,4    " "9@6I5 5Y_!4=K   9ZP0
M%0              @ $!2P4 8VQB<RTR,#(R,#DS,%]P<F4N>&UL4$L! A0#
M%     @ F8%J5> Y355'!P  0"4  !H              ( !>[8% &-L8G,M
M97@S,3%?,C R,C Y,S!X<3,N:'1M4$L! A0#%     @ F8%J59X]L#><!0
MSQH  !@              ( !^KT% &-L8G,M97@S,E\R,#(R,#DS,'$S+FAT
7;5!+!08     "0 ) %H"  #,PP4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
